,ID,pubmed_id,cpd_key,accession,protein,organism,IUPAC,smiles,CHEMBLID,Agonist_assay,Antagonist_assay,Binding_assay,Binding_assay_value,profile,activity,type_activity_test,ref_activity,ref_activity_conc,ref_competitive_bdg,ref_competitive_bdg_concentration,ref_competitive_bdg_Kd,other_RBA_ref_cpd,other_RBA_ref_IC50,ag_type,ag_eq,ag_val,ag_unit,antag_type,antag_eq,antag_val,antag_unit,binding_eq,p_binding_value,p_binding_type,binder_nonbinder,binding_assay_type,canonical_smile,activity_val,HAMW,MW,numHdon,numHacc,rotabonds,ArRings,logP,TPSA,BM,IEC50_based_annotation,perc_based_annotation,transfered_IEC50_annot,transfered_perc_annot,Bmcluster
1,0,17681466,42,P04150,GR,Homo sapiens,"(+)-4-(1-(allyloxy)ethyl)-6-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-1,2-dihydroquinoline",Br.COc1ccc(F)cc1c2ccc3NC(C)(C)C=C(C(C)OCC=C)c3c2,CHEMBL541908,IL-6 inhibition ,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,partial agonist,28.00%,agonist,,,,,,,,IC50,=,170,nM,,,,,=,7.397940009,pIC50,B,FPA,Br.C=CCOC(C)C1=CC(C)(C)Nc2ccc(-c3cc(F)ccc3OC)cc21,28,421.16,447.1209194,1,3,6,2,6.2578,30.49,C1CCC(C2CCC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,119
6,10,17890084,11,P03372,ERA,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-17-ethynyl-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@]2(O)C#C,CHEMBL398841,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 150nM,agonist,82.00%,agonist,E2,,E2,,,,,EC50,=,130,nM,,,,,=,6.823908741,pIC50,,radiometric,C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C=C)[C@H]3CC[C@@]21C,82,296.24,326.2245802,2,2,1,0,3.8405,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
8,10,17890084,11,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-17-ethynyl-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@]2(O)C#C,CHEMBL398841,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,agonist,78.00%,agonist,E2,,E2,,,,,EC50,=,24,nM,,,,,=,7.853871964,pIC50,B,radiometric,C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C=C)[C@H]3CC[C@@]21C,78,296.24,326.2245802,2,2,1,0,3.8405,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
28,1011,16125384,11,P55055,LXRB,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-adamantan-1-yl-ethyl)-amide",CC(NC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C45CC6CC(CC(C6)C4)C5,CHEMBL371990,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 180nM,partial agonist,49.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.744727495,pIC50,,radiometric,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,49,394.324,435.3137296,2,2,3,1,6.1236,49.33,CC(CCC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1082
29,1011,16125384,11,Q13133,LXRA,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-adamantan-1-yl-ethyl)-amide",CC(NC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C45CC6CC(CC(C6)C4)C5,CHEMBL371990,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 90nM,agonist,136.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,7.045757491,pIC50,B,radiometric,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,136,394.324,435.3137296,2,2,3,1,6.1236,49.33,CC(CCC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,1082
34,1014,16112571,4,P04150,GR,Homo sapiens,"2-Hydroxy-2,4-dimethyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(C)(O)C(=O)Nc1ccc2C(=O)OCc2c1)c3ccccc3,CHEMBL195021,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 370nM,partial antagonist,70.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,2370,nM,=,6.431798276,pIC50,,FPA,CC(O)(CC(C)(C)c1ccccc1)C(=O)Nc1ccc2c(c1)COC2=O,70,330.234,353.1627082,2,4,5,2,3.4144,75.63,CC(CCCC1CCCCC1)CC1CCC2C(C)CCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,1218
40,1015,9484511,3,P10275,AR,Homo sapiens,N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,luciferase reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 117nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,157,nM,=,6.931814138,pKi,,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
41,1015,9871534,3,P10275,AR,Homo sapiens,N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,,,Ki = 82nM,antagonist,78.00%,antagonist,DHT,,,,,,,,,,,IC50,=,157,nM,=,7.086186148,pKi,B,other,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,78,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,"antagonist,agonist",antagonist,1304
42,1015,10230628,Bicalutamide,P10275,AR,Homo sapiens,N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 117nM,antagonist,78.00%,antagonist,DHT,,,,,,,EC50,=,6,nM,,,inactive,,=,6.931814138,pIC50,,other,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,78,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,agonist,antagonist,"antagonist,agonist",antagonist,1304
43,1015,10743937,2 (Bicalutamide),P10275,AR,Homo sapiens,N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,cotransfection,hAR transfected into COS-1 cells,Ki = 117nM,antagonist,98.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,338,nM,=,6.931814138,pKi,,other,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,98,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,"antagonist,agonist",antagonist,1304
44,1015,15546739,1,P10275,AR,Homo sapiens,N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,Functional antagonist activity determined through a transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP)reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 65nM,antagonist,no detail about the percentage act,,,,DHT,,,,,,,,,IC50,=,170,nM,=,7.187086643,pKi,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
45,1015,16420057,33a,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled mibolerone from the ligand-binding domain (LBD) ,Ki = 4.6nM,,,,,,,,,,,,,,,,,,,=,8.337242168,pKi,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,,,"antagonist,agonist",antagonist,1304
46,1015,17257838,bicalutamide,P10275,AR,Homo sapiens,N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,-,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 151nM,antagonist,85.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,162,nM,=,6.821023053,pIC50,,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,85,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,"antagonist,agonist",antagonist,1304
47,1015,17804229,3,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,antagonist,no detail about the percentage act,,,,mibolerone,,,,,FI5,=,770,nM,IC50,=,140,nM,=,6.698970004,pIC50,,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,"antagonist,agonist",,"antagonist,agonist",antagonist,1304
48,1015,18291644,"4, bicalutamide",P10275,AR,Homo sapiens,N-(4-cyano-3-trifluoromethyl-phenyl)-3-(4-fluoro-benzenesulfonyl)-2-hydroxy-2-methyl-propionamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,"transiently transfected reporter assay system utilizing the secreted alkaline phosphatase reporter gene driven by the AR-dependent, PSA promoter",radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 64nM,antagonist,no detail about the percentage act,,,,DHT,,,,,,,,,IC50,=,173,nM,=,7.193820026,pKi,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
49,1015,18442912,Bicalutamide,P10275,AR,Homo sapiens,N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 151nM,antagonist,85.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,162,nM,=,6.821023053,pKi,,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,85,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,"antagonist,agonist",antagonist,1304
50,1015,20381361,3,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,Stable reporter gene assay,Stable reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled mibolerone",IC50 = 200nM,antagonist,no detail about the percentage act,,,,mibolerone,0.34nM,,,,EC50,=,200,nM,sIC50,=,100,nM,=,6.698970004,pIC50,,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,"antagonist,agonist",,"antagonist,agonist",antagonist,1304
51,1015,20584610,5,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 64nM,antagonist,no detail about the percentage act,,DHT,1nM,DHT,,,,,,,,,IC50,=,173,nM,=,7.193820026,pKi,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
52,1015,22094279,Bicalutamide,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,Luciferase reporter gene assay,luciferase reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 54nM,antagonist,no detail about the percentage act,,,,mibolerone,3nM,,,,EC50,>,10000,nM,IC50,=,330,nM,=,7.26760624,pIC50,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
53,1015,22391033,Bicalutamide,P10275,AR,Homo sapiens,Bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,luciferase reporter gene assay,luciferase reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 54nM,antagonist,no detail about the percentage act,,,,DHT,100nM,,,,EC50,>,10000,nM,IC50,=,330,nM,=,7.26760624,pIC50,B,radiometric,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
54,1015,26046313,2,P10275,AR,Homo sapiens,bicalutamide,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL409,,androgen-sensitive human PCa LNCaP cells,androgen-sensitive human PCa LNCaP cells,Ki = 160.2nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,732.7,nM,=,6.795337488,pKi,,other,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,"antagonist,agonist",antagonist,1304
59,1019,19376703,4,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-methyl-1H-pyrazol-5-yl)ethyl)amino)-2-chlorobenzonitrile,CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3ccnn3C,CHEMBL564782,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 25nM,agonist,102.00%,agonist,progesterone,,,,,,,EC50,=,6,nM,,,,,=,7.602059991,pIC50,B,FPA,CC(c1ccnn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,102,367.154,384.0908519,0,4,5,3,5.36638,44.85,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
62,1020,19376703,5,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(1-methyl-1H-1,2,3-triazol-4-yl)ethyl)amino)-2-chlorobenzonitrile",CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3cn(C)nn3,CHEMBL551784,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,partial agonist,32.00%,agonist,progesterone,,,,,,,EC50,=,606,nM,,,,,=,7.397940009,pIC50,B,FPA,CC(c1cn(C)nn1)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,32,369.15,385.0861009,0,5,5,3,4.76138,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
63,1021,19376703,7,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-methyl-1H-imidazol-2-yl)ethyl)amino)-2-chlorobenzonitrile,CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nccn3C,CHEMBL559580,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 20nM,agonist,99.00%,agonist,progesterone,,,,,,,EC50,=,0.6,nM,,,,,=,7.698970004,pIC50,B,FPA,CC(c1nccn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,99,367.154,384.0908519,0,4,5,3,5.36638,44.85,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
64,1022,19376703,31,P06401,PR,Homo sapiens,"2-chloro-4-((cyclohexylmethyl)(1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)amino)benzonitrile",CC(N(CC1CCCCC1)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL552108,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,agonist,140.00%,agonist,progesterone,,,,,,,EC50,=,3,nM,,,,,=,7.397940009,pIC50,B,FPA,CC(c1nncn1C)N(CC1CCCCC1)c1ccc(C#N)c(Cl)c1,140,333.697,357.1720234,0,5,5,2,4.48808,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
65,1023,19376703,10,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)amino)-2-chlorobenzonitrile",CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL559974,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,agonist,107.00%,agonist,progesterone,,,,,,,EC50,=,0.5,nM,,,,,=,7.886056648,pIC50,B,FPA,CC(c1nncn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,107,369.15,385.0861009,0,5,5,3,4.76138,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
66,1024,19376703,17,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-isopropyl-1H-tetrazol-5-yl)ethyl)amino)-2-chlorobenzonitrile,CC(C)n1nnnc1C(C)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL564015,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 32nM,agonist,116.00%,agonist,progesterone,,,,,,,EC50,=,35,nM,,,,,=,7.494850022,pIC50,B,FPA,CC(c1nnnn1C(C)C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,116,395.168,414.11265,0,6,6,3,5.20028,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
67,1025,19376703,9,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-methyl-1H-tetrazol-5-yl)ethyl)amino)-2-chlorobenzonitrile,CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL556891,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,agonist,92.00%,agonist,progesterone,,,,,,,EC50,=,0.02,nM,,,,,=,7.886056648,pIC50,B,FPA,CC(c1nnnn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,92,371.146,386.0813499,0,6,5,3,4.15638,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
81,103,12781197,12,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-(3-methyl-2-methylene-butylidene)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC(C)C(=C)\C=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL65410,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 26nM,agonist,122.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,29,nM,,,,,=,7.585026652,pKi,B,radiometric,C=C(/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3)C(C)C,122,349.279,375.1998427,1,2,2,2,7.0456,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
124,1036,12781197,16,P06401,PR,Homo sapiens,"5-sec-Butylidene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC\C(=C/1\Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13)\C,CHEMBL63015,co-transaction assay,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.1nM,partial agonist,64.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,27,nM,IC50,=,980,nM,=,8.508638306,pKi,B,radiometric,CC/C(C)=C1/Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,64,325.257,349.1841926,1,2,1,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,515
125,1036,16821785,72,P06401,PR,Homo sapiens,"(E)-5-(butan-2-ylidene)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC\C(=C/1\Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13)\C,CHEMBL63015,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.78,,,,progesterone,,,,,,,,,,,,,,,=,7.78,pKi,B,radiometric,CC/C(C)=C1/Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,,325.257,349.1841926,1,2,1,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,"antagonist,agonist",partial agonist,515
126,1037,12781197,15,P06401,PR,Homo sapiens,"5-sec-Butylidene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC\C(=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13)\C,CHEMBL62981,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 26nM,agonist,112.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,11,nM,,,,,=,7.585026652,pKi,B,radiometric,CC/C(C)=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,112,325.257,349.1841926,1,2,1,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
127,1037,16821785,71,P06401,PR,Homo sapiens,"(Z)-5-(butan-2-ylidene)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC\C(=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13)\C,CHEMBL62981,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.1,,,,progesterone,,,,,,,,,,,,,,,=,8.1,pKi,B,radiometric,CC/C(C)=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,,325.257,349.1841926,1,2,1,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,agonist,agonist,515
134,104,15026058,6,P04150,GR,Homo sapiens,"5-(2-Bromo-allyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC(=C)Br)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL296624,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 16nM,partial agonist,54.00%,agonist,dexamethasone,,,,,,,IC50,=,240,nM,,,,,=,7.795880017,pIC50,B,radiometric,C=C(Br)CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,54,402.162,425.0990411,1,3,3,2,6.7018,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
145,1044,15911262,8,P55055,LXRB,Homo sapiens,"1-((9R,10S)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-3-((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-propane-1,3-dione",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)CC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(O)cc56,CHEMBL192837,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 163nM,partial agonist,51.00%,agonist,,,Methyl-AA,,,,,,,,,,,,,=,6.787812396,pIC50,,radiometric,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,51,484.381,528.3239599,2,4,4,2,7.3469,74.6,CC(CCC1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1115
146,1044,15911262,8,Q13133,LXRA,Homo sapiens,"1-((9R,10S)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-3-((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-propane-1,3-dione",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)CC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(O)cc56,CHEMBL192837,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 67nM,partial agonist,33.00%,agonist,,,Methyl-AA,,,,,,,,,,,,,=,7.173925197,pIC50,B,radiometric,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,33,484.381,528.3239599,2,4,4,2,7.3469,74.6,CC(CCC1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1115
147,1045,15911262,5,P55055,LXRB,Homo sapiens,"(4aR,9S)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid ((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carbonyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(O)cc56,CHEMBL365544,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,partial agonist,30.00%,agonist,,,Methyl-AA,,,,,EC50,<,3,nM,,,,,=,9,pIC50,B,radiometric,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,30,486.377,529.3192089,3,4,2,2,6.4614,86.63,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1195
148,1045,16125384,2,P55055,LXRB,Homo sapiens,"(4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid ((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carbonyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(O)cc56,CHEMBL365544,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,agonist,no detail about the percentage act,,maximal inhibition (no details),,,,,,,EC50,<,3,nM,,,,,=,9,pIC50,B,radiometric,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,,486.377,529.3192089,3,4,2,2,6.4614,86.63,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,,,,partial agonist,1195
153,1048,19321341,15,P04150,GR,Homo sapiens,"8-bromo-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(Br)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474188,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.7nM,agonist,82.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,118.8,nM,,,,,=,8.769551079,pKi,B,FPA,CC1(C(=O)Nc2nccs2)CC2(Br)c3ccccc3C1c1ccccc12,82,408.215,424.0244963,1,3,2,3,5.2756,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,agonist,agonist,agonist,951
154,1049,19321341,13,P04150,GR,Homo sapiens,"8-cyano-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C#N)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL515127,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 2.5nM,partial agonist,52.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,330.6,nM,,,,,=,8.602059991,pKi,B,FPA,CC1(C(=O)Nc2nccs2)CC2(C#N)c3ccccc3C1c1ccccc12,52,354.329,371.1092332,1,4,2,3,4.44678,65.78,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
156,1050,19321341,16,P04150,GR,Homo sapiens,"8-chloro-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(Cl)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL514636,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.7nM,partial agonist,71.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,229.4,nM,,,,,=,8.769551079,pKi,B,FPA,CC1(C(=O)Nc2nccs2)CC2(Cl)c3ccccc3C1c1ccccc12,71,363.764,380.0750118,1,3,2,3,5.1195,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
157,1051,19321341,11,P04150,GR,Homo sapiens,"15-methyl-8-nitro-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(c3ccccc3C1c4ccccc24)[N+](=O)[O-])C(=O)Nc5nccs5,CHEMBL516386,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 3.0nM,partial agonist,54.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,1067.3,nM,,,,,=,8.522878745,pKi,B,FPA,CC1(C(=O)Nc2nccs2)CC2([N+](=O)[O-])c3ccccc3C1c1ccccc12,54,374.316,391.0990624,1,5,3,3,4.1574,85.13,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
158,1052,19321341,14,P04150,GR,Homo sapiens,"1-cyano-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2c3ccccc3C1(C#N)c4ccccc24)C(=O)Nc5nccs5,CHEMBL474966,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 343nM,agonist,87.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,874.2,nM,,,,,=,6.46470588,pKi,,FPA,CC1(C(=O)Nc2nccs2)CC2c3ccccc3C1(C#N)c1ccccc12,87,354.329,371.1092332,1,4,2,3,4.44678,65.78,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,agonist,agonist,agonist,951
159,1053,19321341,12,P04150,GR,Homo sapiens,"15-methyl-1-nitro-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2c3ccccc3C1(c4ccccc24)[N+](=O)[O-])C(=O)Nc5nccs5,CHEMBL514481,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 369.6nM,partial agonist,48.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,1159.6,nM,,,,,=,6.432268037,pKi,,FPA,CC1(C(=O)Nc2nccs2)CC2c3ccccc3C1([N+](=O)[O-])c1ccccc12,48,374.316,391.0990624,1,5,3,3,4.1574,85.13,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
160,1054,19321341,2,P04150,GR,Homo sapiens,"15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL475159,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 2.9nM,partial agonist,43.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,268,nM,,,,,=,8.537602002,pKi,B,FPA,CC1(C(=O)Nc2nccs2)CC2c3ccccc3C1c1ccccc12,43,328.311,346.1139842,1,3,2,3,4.769,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
161,1055,19321341,10,P04150,GR,Homo sapiens,"15-methyl-N-(1,3,4-thiadiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2c3ccccc3C1c4ccccc24)C(=O)Nc5nncs5,CHEMBL515738,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 5.4nM,partial agonist,40.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,294.9,nM,,,,,=,8.26760624,pKi,B,FPA,CC1(C(=O)Nc2nncs2)CC2c3ccccc3C1c1ccccc12,40,330.307,347.1092332,1,4,2,3,4.164,54.88,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
170,1059,15911262,3,P55055,LXRB,Homo sapiens,"13-hydroxy-2,6-dimethyl-(2S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 13-hydroxy-2,6-dimethyltricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic anhydride",CC1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)OC(=O)C4(C)CCCC5(C)C4CCc6ccc(O)cc56,CHEMBL555373,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,agonist,85.00%,agonist,,,Methyl-AA,,,,,EC50,=,1,nM,,,,,=,9,pIC50,B,radiometric,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,85,488.369,530.3032244,2,5,2,2,6.8884,83.83,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,agonist,agonist,agonist,1195
171,1059,15911262,3,Q13133,LXRA,Homo sapiens,"13-hydroxy-2,6-dimethyl-(2S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 13-hydroxy-2,6-dimethyltricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic anhydride",CC1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)OC(=O)C4(C)CCCC5(C)C4CCc6ccc(O)cc56,CHEMBL555373,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,50.00%,agonist,,,Methyl-AA,,,,,EC50,=,1,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,50,488.369,530.3032244,2,5,2,2,6.8884,83.83,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,partial agonist,agonist,partial agonist,1195
172,106,15026058,7,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-(2-methyl-allyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC(=C)C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL48283,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.1nM,agonist,81.00%,agonist,dexamethasone,,,,,,,IC50,=,66,nM,,,,,=,8.508638306,pIC50,B,radiometric,C=C(C)CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,81,334.269,361.2041791,1,3,3,2,6.3693,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
211,1081,21324689,16,P04150,GR,Homo sapiens,"6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2-dimethyl-2,3-dihydroquinolin-4(1H)-one O-tert-butyl oxime",CC(C)(C)O\N=C\1/CC(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4c(Cl)c[nH]c34,CHEMBL1762203,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.0nM,agonist,98.00%,agonist,dexamethasone,,,,,,,EC50,=,3.4,nM,,,,,=,8.698970004,pKi,B,radiometric,CC1(C)C/C(=N\OC(C)(C)C)c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)N1,98,407.722,431.1575965,2,3,2,3,6.8799,49.41,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,agonist,agonist,agonist,700
215,1082,21324689,14,P04150,GR,Homo sapiens,"5,7-difluoro-6-(1H-indol-7-yl)-2,2-dimethyl-2,3-dihydroquinolin-4(1H)-one O-tert-butyl oxime",CC(C)(C)O\N=C\1/CC(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1762201,IL-6 repression,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7.0nM,agonist,99.00%,agonist,dexamethasone,,,,,,,IC50,=,40,nM,,,,,=,8.15490196,pKi,B,radiometric,CC1(C)C/C(=N\OC(C)(C)C)c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)N1,99,372.269,397.1965689,2,3,2,3,6.2265,49.41,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,agonist,agonist,agonist,700
217,1083,16125384,12,Q13133,LXRA,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-amide",CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@@]4(C)[C@H]3CCc5ccc(O)cc45)C1C2,CHEMBL197522,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 350nM,partial agonist,63.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.455931956,pIC50,,radiometric,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,63,358.291,395.2824294,2,2,2,1,5.3434,49.33,CC(CC1CCC2CC1C2)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,928
230,1088,10212133,11,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2-dimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1(C)Nc2ccc3c4ccccc4OC(c5ccc(Cl)cc5)c3c2C=C1,CHEMBL33909,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10.5nM,partial antagonist,50.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,1300,nM,IC50,=,140,nM,=,7.978810701,pKi,B,radiometric,CC1(C)C=Cc2c(ccc3c2C(c2ccc(Cl)cc2)Oc2ccccc2-3)N1,50,353.723,373.1233419,1,2,1,3,6.7061,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,61
231,1089,9484511,36,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-8,9-dihydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)Nc2cc3nc(O)cc(c3cc2C=C1)C(F)(F)F,CHEMBL350877,,luciferase reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 86nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,58,nM,=,7.065501549,pKi,B,radiometric,CC1(C)C=Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,,281.172,294.0979977,2,3,0,2,4.1765,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,,antagonist,partial antagonist,586
232,1089,17257838,1,P10275,AR,Homo sapiens,"8,8-dimethyl-4-trifluoromethyl-4a,8,9,10a-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)Nc2cc3nc(O)cc(c3cc2C=C1)C(F)(F)F,CHEMBL350877,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 73nM,partial antagonist,74.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,14,nM,=,7.13667714,pIC50,B,radiometric,CC1(C)C=Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,74,281.172,294.0979977,2,3,0,2,4.1765,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
235,1090,10212133,10,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2-dimethyl-2,3-dihydro-1H,5H-6-oxa-1-aza-chrysen-4-one",CC1(C)CC(=O)c2c(N1)ccc3c4ccccc4OC(c5ccc(Cl)cc5)c23,CHEMBL286662,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 24.6nM,antagonist,84.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,376,nM,=,7.609064893,pKi,B,radiometric,CC1(C)CC(=O)c2c(ccc3c2C(c2ccc(Cl)cc2)Oc2ccccc2-3)N1,84,369.722,389.1182566,1,3,1,3,6.2657,38.33,CC1CCCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C12,antagonist,antagonist,antagonist,antagonist,693
282,1104,11277515,3,P10276,RARA,Homo sapiens,"4-{(E)-4-[2-(4-tert-Butyl-phenyl)-6,6-dimethyl-cyclohex-1-enyl]-but-3-en-1-ynyl}-benzoic acid",CC(C)(C)c1ccc(cc1)C2=C(\C=C\C#Cc3ccc(cc3)C(=O)O)C(C)(C)CCC2,CHEMBL424190,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 875nM,antagonist,94.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,350,nM,=,6.057991947,pIC50,,radiometric,CC1(C)CCCC(c2ccc(C(C)(C)C)cc2)=C1/C=C/C#Cc1ccc(C(=O)O)cc1,94,380.317,412.2402303,1,1,3,2,7.2539,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,440
283,1104,11277515,3,P10826,RARB,Homo sapiens,"4-{(E)-4-[2-(4-tert-Butyl-phenyl)-6,6-dimethyl-cyclohex-1-enyl]-but-3-en-1-ynyl}-benzoic acid",CC(C)(C)c1ccc(cc1)C2=C(\C=C\C#Cc3ccc(cc3)C(=O)O)C(C)(C)CCC2,CHEMBL424190,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 25nM,partial antagonist,27.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,27,nM,=,7.602059991,pIC50,B,radiometric,CC1(C)CCCC(c2ccc(C(C)(C)C)cc2)=C1/C=C/C#Cc1ccc(C(=O)O)cc1,27,380.317,412.2402303,1,1,3,2,7.2539,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,440
288,1107,9871534,28,P10275,AR,Homo sapiens,"(5bR,9aS)-9,9-Dimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CC1(C)CCC[C@H]2[C@@H]1Nc3cc4nc(O)cc(c4cc23)C(F)(F)F,CHEMBL162368,,,,Ki = 79nM,partial antagonist,67.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,26,nM,=,7.102372909,pKi,B,other,CC1(C)CCC[C@@H]2c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@@H]21,67,317.205,336.1449479,2,3,0,2,5.047,45.15,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,573
289,1108,9871534,27,P10275,AR,Homo sapiens,"(5bR,9aR)-5b,9,9-Trimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CC1(C)CCC[C@@]2(C)[C@@H]1Nc3cc4nc(O)cc(c4cc23)C(F)(F)F,CHEMBL423620,,,,Ki = 77nM,antagonist,76.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,51,nM,=,7.113509275,pKi,B,other,CC1(C)CCC[C@]2(C)c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@H]12,76,329.216,350.160598,2,3,0,2,5.2211,45.15,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,573
295,1111,10340624,6g,P10275,AR,Homo sapiens,"6,6-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL281028,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12nM,partial agonist,36.00%,agonist,DHT,,DHT,,,,,EC50,=,68,nM,IC50,=,16,nM,=,7.920818754,pKi,B,radiometric,CC1(C)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,36,281.172,296.1136478,2,3,0,2,4.0524,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
299,1113,10230628,10,P10275,AR,Homo sapiens,"7,7-Dimethyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CC1(C)CCc2cc3C(=CC(=O)Oc3cc2N1)C(F)(F)F,CHEMBL7289,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 1nM,partial agonist,64.00%,agonist,DHT,,,,,,,EC50,=,6,nM,,,inactive,,=,9,pIC50,B,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,64,283.164,297.0976633,1,3,0,2,3.9485,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
300,1114,10743937,7b,P10275,AR,Homo sapiens,"8-Bromo-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(Br)nc3cc2N1)C(F)(F)F,CHEMBL134140,,cotransfection,hAR transfected into COS-1 cells,Ki = 159nM,partial antagonist,72.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,72,nM,=,6.798602876,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(Br)nc3cc2N1,72,345.077,358.0292452,1,2,0,2,5.1528,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
301,1115,10743937,9,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-pyrido[3,2-g]quinoline-2-carbonitrile",CC1(C)CCc2cc3c(cc(nc3cc2N1)C#N)C(F)(F)F,CHEMBL335316,,cotransfection,hAR transfected into COS-1 cells,Ki = 22nM,antagonist,83.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,9,nM,=,7.657577319,pKi,B,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(C#N)nc3cc2N1,83,291.191,305.1139821,1,3,0,2,4.26198,48.71,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
302,1116,10743937,20,P10275,AR,Homo sapiens,"2,2-Dimethyl-6,8-bis-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(nc3cc2N1)C(F)(F)F)C(F)(F)F,CHEMBL132205,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,95.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,467,nM,>,6,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(C(F)(F)F)nc3cc2N1,95,334.178,348.1061178,1,2,0,2,5.4091,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
303,1117,10743937,5c,P10275,AR,Homo sapiens,"8-Chloro-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(Cl)nc3cc2N1)C(F)(F)F,CHEMBL133792,,cotransfection,hAR transfected into COS-1 cells,Ki = 84nM,antagonist,75.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,30,nM,=,7.075720714,pKi,B,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(Cl)nc3cc2N1,75,300.626,314.0797608,1,2,0,2,5.0437,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
304,1118,10743937,6c,P10275,AR,Homo sapiens,"8-Fluoro-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(F)nc3cc2N1)C(F)(F)F,CHEMBL133503,,cotransfection,hAR transfected into COS-1 cells,Ki = 11nM,partial antagonist,66.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,22,nM,=,7.958607315,pKi,B,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(F)nc3cc2N1,66,284.171,298.1093113,1,2,0,2,4.5294,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
305,1119,10743937,16b,P10275,AR,Homo sapiens,"N-[8,8-dimethyl-4-(trifluoromethyl)-6,7,8,9-tetrahydropyrido[3,2-g]quinolin-2-yl]-N-(methylsulfonyl)methanesulfonamide",CC1(C)CCc2cc3c(cc(nc3cc2N1)N(S(=O)(=O)C)S(=O)(=O)C)C(F)(F)F,CHEMBL134303,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,84.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,636,nM,>,6,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(N(S(C)(=O)=O)S(C)(=O)=O)nc3cc2N1,84,431.332,451.0847328,1,6,3,2,3.1159,96.44,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
306,112,15026058,16,P04150,GR,Homo sapiens,"2-(10-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysen-5-ylmethyl)-prop-2-en-1-ol",COc1cccc2OC(CC(=C)CO)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL416465,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,partial agonist,50.00%,agonist,dexamethasone,,,,,,,IC50,=,310,nM,,,,,=,7.920818754,pIC50,B,radiometric,C=C(CO)CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,50,350.268,377.1990937,2,4,4,2,5.3417,50.72,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
308,1120,10743937,15,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-pyrido[3,2-g]quinolin-2-ylamine",CC1(C)CCc2cc3c(cc(N)nc3cc2N1)C(F)(F)F,CHEMBL133329,,cotransfection,hAR transfected into COS-1 cells,Ki = 1000nM,partial antagonist,70.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,3217,nM,=,6,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(N)nc3cc2N1,70,279.18,295.1296322,2,3,0,2,3.9725,50.94,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
309,1121,10743937,16a,P10275,AR,Homo sapiens,"N-(8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-pyrido[3,2-g]quinolin-2-yl)-methanesulfonamide",CC1(C)CCc2cc3c(cc(NS(=O)(=O)C)nc3cc2N1)C(F)(F)F,CHEMBL134180,,cotransfection,hAR transfected into COS-1 cells,Ki = 572nM,antagonist,80.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,503,nM,=,6.242603971,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(NS(C)(=O)=O)nc3cc2N1,80,355.256,373.1071825,2,4,2,2,3.7618,71.09,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
310,1122,9484511,9e,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL6874,,luciferase reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 26nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,27,nM,=,7.585026652,pKi,B,radiometric,CC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,,281.172,296.1136478,2,3,0,2,4.0959,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,,antagonist,partial antagonist,586
311,1122,10230629,7,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL6874,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 26nM,partial antagonist,74.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,27,nM,=,7.585026652,pKi,B,radiometric,CC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,74,281.172,296.1136478,2,3,0,2,4.0959,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
312,1122,10743937,3,P10275,AR,Homo sapiens,"8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1(C)CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL6874,,cotransfection,hAR transfected into COS-1 cells,Ki = 26nM,partial antagonist,74.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,27,nM,=,7.585026652,pKi,B,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,74,281.172,296.1136478,2,3,0,2,4.0959,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
313,1123,10743937,13,P10275,AR,Homo sapiens,"8-Methanesulfonyl-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(nc3cc2N1)S(=O)(=O)C)C(F)(F)F,CHEMBL132635,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,94.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,479,nM,>,6,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(S(C)(=O)=O)nc3cc2N1,94,341.249,358.0962834,1,4,1,2,3.7938,59.06,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
314,1124,10743937,11c,P10275,AR,Homo sapiens,"2,2-Dimethyl-8-(2,2,2-trifluoro-ethylsulfanyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(cc(SCC(F)(F)F)nc3cc2N1)C(F)(F)F,CHEMBL132354,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,80.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,889,nM,>,6,pKi,,other,CC1(C)CCc2cc3c(C(F)(F)F)cc(SCC(F)(F)F)nc3cc2N1,80,378.256,394.0938388,1,3,2,2,6.0447,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
315,1125,10743937,8b,P10275,AR,Homo sapiens,"2,2-Dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1(C)CCc2cc3c(ccnc3cc2N1)C(F)(F)F,CHEMBL338922,,cotransfection,hAR transfected into COS-1 cells,Ki = 5nM,antagonist,95.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,212,nM,=,8.301029996,pKi,B,other,CC1(C)CCc2cc3c(C(F)(F)F)ccnc3cc2N1,95,265.173,280.1187331,1,2,0,2,4.3903,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
320,113,15026058,15,P04150,GR,Homo sapiens,"Acetic acid 2-(10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysen-5-ylmethyl)-allyl ester",COc1cccc2OC(CC(=C)COC(=O)C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL296623,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,partial agonist,48.00%,agonist,dexamethasone,,,,,,,IC50,=,390,nM,,,,,=,7.886056648,pIC50,B,radiometric,C=C(COC(C)=O)CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,48,390.289,419.2096584,1,5,5,2,5.9125,56.79,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
342,114,9435893,LGD1069,P19793,RXRA,Homo sapiens,"4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid",Cc1cc2c(cc1C(=C)c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL1023,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16nM,synergist/agonist,,,,,,,,,,,,,,,,,,=,7.795880017,pKi,B,radiometric,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,,320.262,348.2089301,1,1,3,2,6.10372,37.3,CC(C1CCCCC1)C1CCC2CCCCC2C1,,,agonist,agonist,847
343,114,9703470,LGD-1069,P19793,RXRA,Homo sapiens,"4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid",Cc1cc2c(cc1C(=C)c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL1023,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 3.0,agonist,132.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,0.61,nM,,,,,=,3,RBA,,radiometric,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,132,320.262,348.2089301,1,1,3,2,6.10372,37.3,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,847
344,114,19791803,"1, Bexarotene",P19793,RXRA,Homo sapiens,"4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid",Cc1cc2c(cc1C(=C)c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL1023,RAR/RARE-agonist activity assay (Caco-2 human colon cancer cells),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 21nM,partial agonist,25.00%,agonist,All-trans RA,1000nM,9cRA,10nM,,,,EC50,=,52,nM,,,,,=,7.677780705,pKi,B,radiometric,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,25,320.262,348.2089301,1,1,3,2,6.10372,37.3,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,,agonist,agonist,847
350,1143,9871534,12,P10275,AR,Homo sapiens,"3,3-Dimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",CC1(C)CNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL351022,,,,Ki = 28nM,partial agonist,38.00%,agonist,DHT,,,,,,,EC50,=,42,nM,IC50,=,10,nM,=,7.552841969,pKi,B,other,CC1(C)CNc2cc3nc(O)cc(C(F)(F)F)c3cc21,38,269.161,282.0979977,2,3,0,2,3.6623,45.15,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,578
354,1147,15911283,37,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a,5',5'-trimethyl-(4aS)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",CC1(C)COC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)OC1,CHEMBL364511,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,partial agonist,73.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,12,nM,,,,,=,7.552841969,pIC50,B,radiometric,CC1(C)COC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)OC1,73,343.252,368.1900063,0,4,1,2,4.5203,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
368,1152,25978072,12e,P04150,GR,Homo sapiens,"6-(Imidazo[1,2-a]pyridin-5-yl)-2,2,4,4-tetramethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",CC1(C)Nc2c3CCCc3c(cc2C(C)(C)C1=O)c4cccc5nccn45,CHEMBL3582119,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 11nM,antagonist,92.00%,antagonist,,,,,,,,,,,,IC50,=,21,nM,=,7.958607315,pKi,B,radiometric,CC1(C)Nc2c(cc(-c3cccc4nccn34)c3c2CCC3)C(C)(C)C1=O,92,334.273,359.1997624,1,4,1,3,4.5408,46.4,CC1CCC2C(C1)CC(C1CCCC3CCCC31)C1CCCC21,antagonist,antagonist,antagonist,antagonist,560
371,1153,25978072,12h,P04150,GR,Homo sapiens,"6-([1,2,4]triazolo[4,3-a]pyridin-5-yl)-2,2,4,4-tetramethyl-4,7,8,9-tetrahydro-1H-cyclopenta[h]quinolin-3(2H)-one",CC1(C)Nc2c3CCCc3c(cc2C(C)(C)C1=O)c4cccc5nncn45,CHEMBL3582122,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 53nM,antagonist,87.00%,antagonist,,,,,,,,,,,,IC50,=,91,nM,=,7.27572413,pKi,B,radiometric,CC1(C)Nc2c(cc(-c3cccc4nncn34)c3c2CCC3)C(C)(C)C1=O,87,336.269,360.1950114,1,5,1,3,3.9358,59.29,CC1CCC2C(C1)CC(C1CCCC3CCCC31)C1CCCC21,antagonist,antagonist,antagonist,antagonist,560
375,1155,25978072,12f,P04150,GR,Homo sapiens,"2,2,4,4-Tetramethyl-6-(pyrazolo[1,5-a]pyridin-4-yl)-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",CC1(C)Nc2c3CCCc3c(cc2C(C)(C)C1=O)c4cccn5nccc45,CHEMBL3582120,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 35nM,antagonist,103.00%,antagonist,,,,,,,,,,,,IC50,=,84,nM,=,7.455931956,pKi,B,radiometric,CC1(C)Nc2c(cc(-c3cccn4nccc34)c3c2CCC3)C(C)(C)C1=O,103,334.273,359.1997624,1,4,1,3,4.5408,46.4,CC1CCC2C(C1)CC(C1CCCC3CCCC31)C1CCCC21,antagonist,antagonist,antagonist,antagonist,560
378,1157,25978072,12k,P04150,GR,Homo sapiens,"2,2,4,4-Tetramethyl-6-([1,8]naphthyridin-4-yl)-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",CC1(C)Nc2c3CCCc3c(cc2C(C)(C)C1=O)c4ccnc5ncccc45,CHEMBL3582125,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 35nM,antagonist,93.00%,antagonist,,,,,,,,,,,,IC50,=,53,nM,=,7.455931956,pKi,B,radiometric,CC1(C)Nc2c(cc(-c3ccnc4ncccc34)c3c2CCC3)C(C)(C)C1=O,93,346.284,371.1997624,1,4,1,3,4.8363,54.88,CC1CCC2C(C1)CC(C1CCCC3CCCCC31)C1CCCC21,antagonist,antagonist,antagonist,antagonist,561
381,1158,25978072,12g,P04150,GR,Homo sapiens,"6-(Imidazo[1,2-a]pyrazin-5-yl)-2,2,4,4-tetramethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",CC1(C)Nc2c3CCCc3c(cc2C(C)(C)C1=O)c4cncc5nccn45,CHEMBL3582121,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 46nM,antagonist,89.00%,antagonist,,,,,,,,,,,,IC50,=,93,nM,=,7.337242168,pKi,B,radiometric,CC1(C)Nc2c(cc(-c3cncc4nccn34)c3c2CCC3)C(C)(C)C1=O,89,336.269,360.1950114,1,5,1,3,3.9358,59.29,CC1CCC2C(C1)CC(C1CCCC3CCCC31)C1CCCC21,antagonist,antagonist,antagonist,antagonist,560
387,1161,10743938,11,P06401,PR,Homo sapiens,"4-(2,2,4,4-Tetramethyl-3-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1(C)Nc2ccc(cc2C(C)(C)C1=O)c3csc(c3)C#N,CHEMBL131681,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 12.4nM,antagonist,79.00%,antagonist,progesterone,,,,,,,EC50,=,1190,nM,IC50,=,14,nM,=,7.906578315,pIC50,B,other,CC1(C)Nc2ccc(-c3csc(C#N)c3)cc2C(C)(C)C1=O,79,292.278,310.1139842,1,4,1,2,4.33758,52.89,CC1CCC2CCC(C3CCCC3)CC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,643
388,1161,16821785,48,P06401,PR,Homo sapiens,"4-(2,2,4,4-tetramethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carbonitrile",CC1(C)Nc2ccc(cc2C(C)(C)C1=O)c3csc(c3)C#N,CHEMBL131681,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.91,,,,progesterone,,,,,,,,,,,,,,,=,7.91,pKi,B,radiometric,CC1(C)Nc2ccc(-c3csc(C#N)c3)cc2C(C)(C)C1=O,,292.278,310.1139842,1,4,1,2,4.33758,52.89,CC1CCC2CCC(C3CCCC3)CC2C1,,,"antagonist,agonist",antagonist,643
389,1162,10212133,25,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2,4,4-tetramethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",CC1(C)Nc2ccc3c4ccccc4OC(c5ccc(Cl)cc5)c3c2C(C)(C)C1=O,CHEMBL34589,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,partial agonist,36.00%,agonist,progesterone,,progesterone,,,,,EC50,=,9.8,nM,,,,,=,8.27572413,pKi,B,radiometric,CC1(C)Nc2ccc3c(c2C(C)(C)C1=O)C(c1ccc(Cl)cc1)Oc1ccccc1-3,36,393.744,417.1495567,1,3,1,3,6.5396,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,partial agonist,agonist,partial agonist,601
410,1175,19863083,4,P06401,PR,Homo sapiens,Lecanindole D,CC1(C)[C@H](O)CC[C@@]2(C)[C@@]1(O)CC[C@H]3Cc4c([nH]c5ccccc45)[C@]23C,CHEMBL1076438,PRE luciferase reporter assay in T47D breast cancer cells,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 57.3nM,agonist,97.00%,agonist,progesterone,,progesterone,3nM,,,,EC50,=,1.1,nM,,,,,=,7.241845378,pIC50,B,radiometric,CC1(C)[C@H](O)CC[C@]2(C)[C@@]3(C)c4[nH]c5ccccc5c4C[C@@H]3CC[C@@]12O,97,322.258,353.2354792,3,2,0,2,4.31,56.25,C1CCC2C(C1)CC1C2CC2CCC3CCCCC3C21,agonist,agonist,agonist,agonist,7
411,1176,17616395,19D1E1,P04150,GR,Homo sapiens,"5-amino-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-carboxamide",CC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccccc3)C(F)(F)F)CCCc4ccccc14,CHEMBL236947,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.24,agonist,76.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.74,,,,,,=,8.24,pIC50,B,FPA,CC1(CC(O)(CNC(=O)c2cnn(-c3ccccc3)c2N)C(F)(F)F)CCCc2ccccc21,76,445.295,472.2086108,3,5,6,3,4.162,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
412,1176,17616395,19D1E2,P04150,GR,Homo sapiens,"5-amino-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-carboxamide",CC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccccc3)C(F)(F)F)CCCc4ccccc14,CHEMBL236947,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.29,agonist,93.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.74,,,,,,=,8.29,pIC50,B,FPA,CC1(CC(O)(CNC(=O)c2cnn(-c3ccccc3)c2N)C(F)(F)F)CCCc2ccccc21,93,445.295,472.2086108,3,5,6,3,4.162,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
413,1177,18038970,54D2E1,P04150,GR,Homo sapiens,"1,1,1-trifluoro-3-(5-isoquinolinylamino)-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol",CC1(CC(O)(CNc2cccc3cnccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL393349,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.13,partial agonist,26.70%,agonist,dexamethasone,,,,,,,PEC50,=,6.59,,,,,,=,7.13,pIC50,B,FPA,CC1(CC(O)(CNc2cccc3cnccc23)C(F)(F)F)CCCc2ccccc21,26.7,389.271,414.1918981,2,3,5,3,5.6244,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,partial agonist,"agonist,antagonist","partial agonist,partial antagonist",989
414,1177,18038970,54D1E2,P04150,GR,Homo sapiens,"1,1,1-trifluoro-3-(5-isoquinolinylamino)-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol",CC1(CC(O)(CNc2cccc3cnccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL393349,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.06,partial antagonist,69.20%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,6.99,,=,8.06,pIC50,B,FPA,CC1(CC(O)(CNc2cccc3cnccc23)C(F)(F)F)CCCc2ccccc21,69.2,389.271,414.1918981,2,3,5,3,5.6244,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,antagonist,partial antagonist,"agonist,antagonist","partial agonist,partial antagonist",989
416,1179,18038970,19D1,P04150,GR,Homo sapiens,"3-(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-indol-2-ylmethyl)-2-propanol",CC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL235799,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.46,partial antagonist,67.70%,antagonist,dexamethasone,,,,,,,PEC50,=,7.38,,PIC50,=,6.35,,=,7.46,pIC50,B,FPA,CC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc2ccccc21,67.7,363.253,387.180999,2,1,4,3,5.6881,36.02,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,43
420,1181,18038970,17D1,P04150,GR,Homo sapiens,"1-{3,3,3-trifluoro-2-hydroxy-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]propyl}-4(1H)-quinolinone",CC1(CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL235591,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.85,antagonist,92.70%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,6.65,,=,7.85,pIC50,B,FPA,CC1(CC(O)(Cn2ccc(=O)c3ccccc32)C(F)(F)F)CCCc2ccccc21,92.7,391.263,415.1759137,1,3,4,3,4.9792,42.23,CC1CCC(CCCC2CCCC3CCCCC32)C2CCCCC12,antagonist,antagonist,antagonist,"antagonist,partial antagonist",801
421,1181,18038970,17D2,P04150,GR,Homo sapiens,"1-{3,3,3-trifluoro-2-hydroxy-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]propyl}-4(1H)-quinolinone",CC1(CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL235591,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.46,partial antagonist,70.00%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,6.15,,=,7.46,pIC50,B,FPA,CC1(CC(O)(Cn2ccc(=O)c3ccccc32)C(F)(F)F)CCCc2ccccc21,70,391.263,415.1759137,1,3,4,3,4.9792,42.23,CC1CCC(CCCC2CCCC3CCCCC32)C2CCCCC12,antagonist,partial antagonist,antagonist,"antagonist,partial antagonist",801
422,1182,15911262,6,P55055,LXRB,Homo sapiens,"(1S,4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (4aR,9S)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-ylmethyl ester",CC1(COC(=O)[C@@]2(C)CCC[C@@]3(C)[C@H]2CCc4ccc(O)cc34)CCC[C@@]5(C)[C@H]1CCc6ccc(O)cc56,CHEMBL195184,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,agonist,76.00%,agonist,,,Methyl-AA,,,,,EC50,=,100,nM,,,,,=,7.920818754,pIC50,B,radiometric,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,76,472.37,516.3239599,2,4,3,2,7.3618,66.76,CC(CCC1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,agonist,agonist,agonist,1115
423,1182,15911262,6,Q13133,LXRA,Homo sapiens,"(1S,4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (4aR,9S)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-ylmethyl ester",CC1(COC(=O)[C@@]2(C)CCC[C@@]3(C)[C@H]2CCc4ccc(O)cc34)CCC[C@@]5(C)[C@H]1CCc6ccc(O)cc56,CHEMBL195184,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,agonist,88.00%,agonist,,,Methyl-AA,,,,,EC50,=,100,nM,,,,,=,7.853871964,pIC50,B,radiometric,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,88,472.37,516.3239599,2,4,3,2,7.3618,66.76,CC(CCC1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,agonist,agonist,agonist,1115
473,1204,19321341,17,P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474189,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.8nM,agonist,79.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,14.7,nM,,,,,=,8.744727495,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nccs3)C(c3ccccc31)c1ccccc12,79,340.322,360.1296343,1,3,2,3,4.9431,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,agonist,agonist,"agonist,partial agonist",951
474,1204,19321341,"17a, isomer A",P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474189,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.0nM,partial agonist,73.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,5.3,nM,,,,,=,9,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nccs3)C(c3ccccc31)c1ccccc12,73,340.322,360.1296343,1,3,2,3,4.9431,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",951
475,1204,19321341,"17b, isomer B",P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474189,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 67.8nM,partial agonist,61.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,800.4,nM,,,,,=,7.168770306,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nccs3)C(c3ccccc31)c1ccccc12,61,340.322,360.1296343,1,3,2,3,4.9431,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",951
476,1204,21899328,4,P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474189,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,Ki =1.0 nM,partial agonist,31.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,117,nM,,,,,=,9,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nccs3)C(c3ccccc31)c1ccccc12,31,340.322,360.1296343,1,3,2,3,4.9431,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",951
480,1205,19321341,18,P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3,4-thiadiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nncs5,CHEMBL514630,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.3nM,partial agonist,59.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,16.9,nM,,,,,=,8.886056648,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nncs3)C(c3ccccc31)c1ccccc12,59,342.318,361.1248832,1,4,2,3,4.3381,54.88,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
481,1205,19321341,"18a, isomer A",P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3,4-thiadiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nncs5,CHEMBL514630,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.3nM,partial agonist,69.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,11.4,nM,,,,,=,8.886056648,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nncs3)C(c3ccccc31)c1ccccc12,69,342.318,361.1248832,1,4,2,3,4.3381,54.88,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
482,1205,19321341,"18b, isomer B",P04150,GR,Homo sapiens,"8,15-dimethyl-N-(1,3,4-thiadiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CC1(CC2(C)c3ccccc3C1c4ccccc24)C(=O)Nc5nncs5,CHEMBL514630,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 49.7nM,partial agonist,51.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,3835,nM,,,,,=,7.303643611,pKi,B,FPA,CC12CC(C)(C(=O)Nc3nncs3)C(c3ccccc31)c1ccccc12,51,342.318,361.1248832,1,4,2,3,4.3381,54.88,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
633,1275,10743937,22a,P10275,AR,Homo sapiens,"8-Chloro-1,2,2,4-tetramethyl-6-trifluoromethyl-1,2-dihydro-pyrido[3,2-g]quinoline",CN1c2cc3nc(Cl)cc(c3cc2C(=CC1(C)C)C)C(F)(F)F,CHEMBL132516,,cotransfection,hAR transfected into COS-1 cells,Ki = 1000nM,antagonist,86.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,336,nM,=,6,pKi,,other,CC1=CC(C)(C)N(C)c2cc3nc(Cl)cc(C(F)(F)F)c3cc21,86,324.648,340.0954109,0,2,0,2,5.5387,16.13,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
643,1281,9873612,7a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,10-dihydro-1H-pyrido[2,3-b]carbazole",CC1=CC(C)(C)Nc2cc3[nH]c4ccccc4c3cc12,CHEMBL329339,,cotransfection,-,Ki = 113nM,antagonist,80.00%,antagonist,,,,,,,,,,,,IC50,=,59,nM,=,6.946921557,pKi,,other,CC1=CC(C)(C)Nc2cc3[nH]c4ccccc4c3cc21,80,244.212,262.1469986,2,1,0,3,4.9285,27.82,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
644,1281,16821785,14,P06401,PR,Homo sapiens,"2,2,4-trimethyl-2,10-dihydro-1H-pyrido[2,3-b]carbazole",CC1=CC(C)(C)Nc2cc3[nH]c4ccccc4c3cc12,CHEMBL329339,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.95,,,,progesterone,,,,,,,,,,,,,,,=,6.95,pKi,,radiometric,CC1=CC(C)(C)Nc2cc3[nH]c4ccccc4c3cc21,,244.212,262.1469986,2,1,0,3,4.9285,27.82,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,antagonist,28
645,1282,9873612,16n,P06401,PR,Homo sapiens,"5-Chloro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4ccccc4c3c(Cl)c12,CHEMBL330702,,cotransfection,-,Ki = 53.1nM,partial antagonist,73.00%,antagonist,,,,,,,,,,,,IC50,=,163,nM,=,7.274905479,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(c(Cl)c21)-c1ccccc1C3O,73,293.668,311.1076919,2,2,0,2,5.0095,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
646,1283,9873612,5m,P06401,PR,Homo sapiens,"5,8-Difluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(F)ccc4c3c(F)c12,CHEMBL433403,,cotransfection,-,Ki = 1.5nM,antagonist,96.00%,antagonist,,,,,,,,,,,,IC50,=,650,nM,=,8.823908741,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(c(F)c21)-c1ccc(F)cc1C3,96,280.212,297.132906,1,1,0,2,5.1434,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
647,1283,16821785,12,P06401,PR,Homo sapiens,"5,8-difluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(F)ccc4c3c(F)c12,CHEMBL433403,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.82,,,,progesterone,,,,,,,,,,,,,,,=,8.82,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(c(F)c21)-c1ccc(F)cc1C3,,280.212,297.132906,1,1,0,2,5.1434,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,antagonist,28
649,1285,9873612,8m,P06401,PR,Homo sapiens,"5,8-Difluoro-2,2,4-trimethyl-1,2-dihydro-indeno[1,2-g]quinolin-10-one",CC1=CC(C)(C)Nc2cc3C(=O)c4cc(F)ccc4c3c(F)c12,CHEMBL91227,,cotransfection,-,Ki > 10000nM,partial antagonist,59.00%,antagonist,,,,,,,,,,,,IC50,=,365,nM,>,5,pKi,NB,other,CC1=CC(C)(C)Nc2cc3c(c(F)c21)-c1ccc(F)cc1C3=O,59,296.211,311.1121705,1,2,0,2,4.7836,29.1,CC1C2CCCCC2C2CC3CCCCC3CC12,antagonist,partial antagonist,antagonist,partial antagonist,478
650,1286,9873612,17m,P06401,PR,Homo sapiens,"Trifluoro-acetic acid 5,8-difluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-yl ester",CC1=CC(C)(C)Nc2cc3C(OC(=O)C(F)(F)F)c4cc(F)ccc4c3c(F)c12,CHEMBL327934,,cotransfection,-,Ki = 62.5nM,partial antagonist,72.00%,antagonist,,,,,,,,,,,,IC50,=,46,nM,=,7.204119983,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(c(F)c21)-c1ccc(F)cc1C3OC(=O)C(F)(F)F,72,393.226,409.1101199,1,3,1,2,5.7475,38.33,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
651,1287,9873612,16m,P06401,PR,Homo sapiens,"6,8-Difluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4cc(F)cc(F)c4c3cc12,CHEMBL316348,,cotransfection,-,Ki = 25.5nM,partial antagonist,74.00%,antagonist,,,,,,,,,,,,IC50,=,80,nM,=,7.59345982,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cc(F)cc1C3O,74,296.211,313.1278206,2,2,0,2,4.6343,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
654,1289,9873612,5i,P06401,PR,Homo sapiens,"6-Fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cccc(F)c4c3cc12,CHEMBL313418,,cotransfection,-,Ki = 11.2nM,partial antagonist,58.00%,antagonist,,,,,,,,,,,,IC50,=,146,nM,=,7.950781977,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cccc1C3,58,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
655,1289,16821785,9,P06401,PR,Homo sapiens,"6-fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cccc(F)c4c3cc12,CHEMBL313418,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.95,,,,progesterone,,,,,,,,,,,,,,,=,7.95,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cccc1C3,,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
657,129,8627601,12,P06401,PR,Homo sapiens,"Acetic acid 5-bromo-4-methoxy-2-(4,6,6-trimethyl-2-methylene-cyclohex-3-enylmethyl)-phenyl ester",COc1cc(CC2C(=C)C=C(C)CC2(C)C)c(OC(=O)C)cc1Br,CHEMBL54270,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 59.6nM,partial antagonist,42.00%,antagonist,,,,,,,,EC50,=,1457,nM,IC50,=,710,nM,=,7.22475374,pKi,B,radiometric,C=C1C=C(C)CC(C)(C)C1Cc1cc(OC)c(Br)cc1OC(C)=O,42,368.121,392.0987068,0,3,4,1,5.4741,35.53,CC1CCCCC1CC1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,730
659,1290,9873612,8i,P06401,PR,Homo sapiens,"6-Fluoro-2,2,4-trimethyl-1,2-dihydro-indeno[1,2-g]quinolin-10-one",CC1=CC(C)(C)Nc2cc3C(=O)c4cccc(F)c4c3cc12,CHEMBL90766,,cotransfection,-,Ki = 29.1nM,antagonist,78.00%,antagonist,,,,,,,,,,,,IC50,=,158,nM,=,7.536107011,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cccc1C3=O,78,277.213,293.1215924,1,2,0,2,4.6445,29.1,CC1C2CCCCC2C2CC3CCCCC3CC12,antagonist,antagonist,antagonist,antagonist,478
660,1290,16821785,16,P06401,PR,Homo sapiens,"6-fluoro-2,2,4-trimethyl-1,2-dihydroindeno[1,2-g]quinolin-10-one",CC1=CC(C)(C)Nc2cc3C(=O)c4cccc(F)c4c3cc12,CHEMBL90766,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.54,,,,progesterone,,,,,,,,,,,,,,,=,7.54,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cccc1C3=O,,277.213,293.1215924,1,2,0,2,4.6445,29.1,CC1C2CCCCC2C2CC3CCCCC3CC12,,,antagonist,antagonist,478
661,1291,9873612,16i,P06401,PR,Homo sapiens,"6-Fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4cccc(F)c4c3cc12,CHEMBL328261,,cotransfection,-,Ki = 449nM,antagonist,85.00%,antagonist,,,,,,,,,,,,IC50,=,99,nM,=,6.347753659,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1c(F)cccc1C3O,85,277.213,295.1372424,2,2,0,2,4.4952,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
662,1292,9873612,5k,P06401,PR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-8-nitro-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(c(F)cc4c3cc12)[N+](=O)[O-],CHEMBL330527,,cotransfection,-,Ki = 1.9nM,partial antagonist,40.00%,antagonist,,,,,,,,,,,,IC50,=,100,nM,=,8.721246399,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1cc(F)c([N+](=O)[O-])cc1C3,40,307.219,324.127406,1,3,1,2,4.9125,55.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
663,1292,16821785,11,P06401,PR,Homo sapiens,"7-fluoro-2,2,4-trimethyl-8-nitro-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(c(F)cc4c3cc12)[N+](=O)[O-],CHEMBL330527,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.72,,,,progesterone,,,,,,,,,,,,,,,=,8.72,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1cc(F)c([N+](=O)[O-])cc1C3,,307.219,324.127406,1,3,1,2,4.9125,55.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
664,1293,9873612,16p,P06401,PR,Homo sapiens,"7,9-Difluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4c(F)cc(F)cc4c3cc12,CHEMBL328787,,cotransfection,-,Ki = 202nM,antagonist,80.00%,antagonist,,,,,,,,,,,,IC50,=,74,nM,=,6.694648631,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1cc(F)cc(F)c1C3O,80,296.211,313.1278206,2,2,0,2,4.6343,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
665,1294,9873612,5e,P06401,PR,Homo sapiens,"8-Bromo-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(Br)ccc4c3cc12,CHEMBL446418,,cotransfection,-,Ki = 24nM,partial antagonist,66.00%,antagonist,,,,,,,,,,,,IC50,=,434,nM,=,7.619788758,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(Br)cc1C3,66,322.12,339.0622617,1,1,0,2,5.6277,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
666,1294,16821785,5,P06401,PR,Homo sapiens,"8-bromo-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(Br)ccc4c3cc12,CHEMBL446418,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.62,,,,progesterone,,,,,,,,,,,,,,,=,7.62,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(Br)cc1C3,,322.12,339.0622617,1,1,0,2,5.6277,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
669,1297,9873612,16e,P06401,PR,Homo sapiens,"8-Bromo-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4cc(Br)ccc4c3cc12,CHEMBL91708,,cotransfection,-,Ki = 1858nM,partial antagonist,73.00%,antagonist,,,,,,,,,,,,IC50,=,3443,nM,=,5.73095429,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(Br)cc1C3O,73,338.119,355.0571763,2,2,0,2,5.1186,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
670,1298,9873612,5f,P06401,PR,Homo sapiens,"8-Chloro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(Cl)ccc4c3cc12,CHEMBL328523,,cotransfection,-,Ki = 29nM,partial antagonist,58.00%,antagonist,,,,,,,,,,,,IC50,=,248,nM,=,7.537602002,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(Cl)cc1C3,58,277.669,295.1127773,1,1,0,2,5.5186,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
671,1298,16821785,6,P06401,PR,Homo sapiens,"8-chloro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(Cl)ccc4c3cc12,CHEMBL328523,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.54,,,,progesterone,,,,,,,,,,,,,,,=,7.54,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(Cl)cc1C3,,277.669,295.1127773,1,1,0,2,5.5186,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
672,1299,9873612,5g,P06401,PR,Homo sapiens,"8-Fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(F)ccc4c3cc12,CHEMBL92750,,cotransfection,-,Ki = 3.5nM,partial antagonist,36.00%,antagonist,,,,,,,,,,,,IC50,=,10,nM,=,8.455931956,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(F)cc1C3,36,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
673,1299,16821785,7,P06401,PR,Homo sapiens,"8-fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(F)ccc4c3cc12,CHEMBL92750,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.46,,,,progesterone,,,,,,,,,,,,,,,=,8.46,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(F)cc1C3,,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
685,1300,9873612,16g,P06401,PR,Homo sapiens,"8-Fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4cc(F)ccc4c3cc12,CHEMBL93451,,cotransfection,-,Ki = 101nM,partial antagonist,72.00%,antagonist,,,,,,,,,,,,IC50,=,122,nM,=,6.995678626,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc(F)cc1C3O,72,277.213,295.1372424,2,2,0,2,4.4952,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
686,1301,9873612,5d,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-8-nitro-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(ccc4c3cc12)[N+](=O)[O-],CHEMBL328506,,cotransfection,-,Ki = 3.6nM,partial antagonist,30.00%,antagonist,,,,,,,,,,,,IC50,=,90,nM,=,8.443697499,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc([N+](=O)[O-])cc1C3,30,288.221,306.1368278,1,3,1,2,4.7734,55.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
687,1301,16821785,4,P06401,PR,Homo sapiens,"2,2,4-trimethyl-8-nitro-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4cc(ccc4c3cc12)[N+](=O)[O-],CHEMBL328506,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.44,,,,progesterone,,,,,,,,,,,,,,,=,8.44,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccc([N+](=O)[O-])cc1C3,,288.221,306.1368278,1,3,1,2,4.7734,55.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
690,1303,9873612,5h,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4c(F)cccc4c3cc12,CHEMBL93690,,cotransfection,-,Ki = 2.3nM,partial antagonist,65.00%,antagonist,,,,,,,,,,,,IC50,=,1772,nM,=,8.638272164,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1cccc(F)c1C3,65,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
691,1303,16821785,8,P06401,PR,Homo sapiens,"9-fluoro-2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4c(F)cccc4c3cc12,CHEMBL93690,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.64,,,,progesterone,,,,,,,,,,,,,,,=,8.64,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1cccc(F)c1C3,,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,partial antagonist,28
692,1304,9873612,5a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4ccccc4c3cc12,CHEMBL329198,,cotransfection,-,Ki = 14nM,antagonist,78.00%,antagonist,,,,,,,,,,,,IC50,=,220,nM,=,7.853871964,pKi,B,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3,78,242.216,261.1517496,1,1,0,2,4.8652,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
693,1304,16821785,1,P06401,PR,Homo sapiens,"2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinoline",CC1=CC(C)(C)Nc2cc3Cc4ccccc4c3cc12,CHEMBL329198,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.85,,,,progesterone,,,,,,,,,,,,,,,=,7.85,pKi,B,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3,,242.216,261.1517496,1,1,0,2,4.8652,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,antagonist,28
694,1305,9873612,8a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-1,2-dihydro-indeno[1,2-g]quinolin-10-one",CC1=CC(C)(C)Nc2cc3C(=O)c4ccccc4c3cc12,CHEMBL94286,,cotransfection,-,Ki = 3553nM,antagonist,91.00%,antagonist,,,,,,,,,,,,IC50,=,353,nM,=,5.449404793,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3=O,91,258.215,275.1310142,1,2,0,2,4.5054,29.1,CC1C2CCCCC2C2CC3CCCCC3CC12,antagonist,antagonist,antagonist,antagonist,478
695,1305,16821785,15,P06401,PR,Homo sapiens,"2,2,4-trimethyl-1,2-dihydroindeno[1,2-g]quinolin-10-one",CC1=CC(C)(C)Nc2cc3C(=O)c4ccccc4c3cc12,CHEMBL94286,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 5.45,,,,progesterone,,,,,,,,,,,,,,,=,5.45,pKi,,radiometric,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3=O,,258.215,275.1310142,1,2,0,2,4.5054,29.1,CC1C2CCCCC2C2CC3CCCCC3CC12,,,antagonist,antagonist,478
696,1306,9873612,16a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-10-ol",CC1=CC(C)(C)Nc2cc3C(O)c4ccccc4c3cc12,CHEMBL93407,,cotransfection,-,Ki = 483nM,antagonist,93.00%,antagonist,,,,,,,,,,,,IC50,=,609,nM,=,6.316052869,pKi,,other,CC1=CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3O,93,258.215,277.1466642,2,2,0,2,4.3561,32.26,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
698,1308,10743937,5a,P10275,AR,Homo sapiens,"8-Chloro-2,2,4-trimethyl-6-trifluoromethyl-1,2-dihydro-pyrido[3,2-g]quinoline",CC1=CC(C)(C)Nc2cc3nc(Cl)cc(c3cc12)C(F)(F)F,CHEMBL133331,,cotransfection,hAR transfected into COS-1 cells,Ki = 320nM,partial antagonist,70.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,30,nM,=,6.494850022,pKi,,other,CC1=CC(C)(C)Nc2cc3nc(Cl)cc(C(F)(F)F)c3cc21,70,312.637,326.0797608,1,2,0,2,5.5144,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
699,1309,10743937,6a,P10275,AR,Homo sapiens,"8-Fluoro-2,2,4-trimethyl-6-trifluoromethyl-1,2-dihydro-pyrido[3,2-g]quinoline",CC1=CC(C)(C)Nc2cc3nc(F)cc(c3cc12)C(F)(F)F,CHEMBL132803,,cotransfection,hAR transfected into COS-1 cells,Ki = 57nM,partial antagonist,56.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,31,nM,=,7.244125144,pKi,B,other,CC1=CC(C)(C)Nc2cc3nc(F)cc(C(F)(F)F)c3cc21,56,296.182,310.1093113,1,2,0,2,5.0001,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
706,1312,9873612,6a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-1,2-dihydro-benzo[4,5]furo[3,2-g]quinoline",CC1=CC(C)(C)Nc2cc3oc4ccccc4c3cc12,CHEMBL328058,,cotransfection,-,Ki = 184nM,antagonist,84.00%,antagonist,,,,,,,,,,,,IC50,=,1847,nM,=,6.735182177,pKi,,other,CC1=CC(C)(C)Nc2cc3oc4ccccc4c3cc21,84,246.204,263.1310142,1,2,0,3,5.1934,25.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
707,1312,16821785,13,P06401,PR,Homo sapiens,"2,2,4-trimethyl-1,2-dihydrobenzofuro[3,2-g]quinoline",CC1=CC(C)(C)Nc2cc3oc4ccccc4c3cc12,CHEMBL328058,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.74,,,,progesterone,,,,,,,,,,,,,,,=,6.74,pKi,,radiometric,CC1=CC(C)(C)Nc2cc3oc4ccccc4c3cc21,,246.204,263.1310142,1,2,0,3,5.1934,25.17,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,antagonist,28
708,1313,10743938,5e,P06401,PR,Homo sapiens,"3,5-Dimethyl-4-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3c(C)sc(C#N)c3C,CHEMBL334890,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 36nM,partial antagonist,74.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,124,nM,=,7.443697499,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3c(C)sc(C#N)c3C)cc21,74,288.29,308.1347196,1,3,1,2,5.51102,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,36
709,1313,16821785,36,P06401,PR,Homo sapiens,"3,5-dimethyl-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3c(C)sc(C#N)c3C,CHEMBL334890,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.44,,,,progesterone,,,,,,,,,,,,,,,=,7.44,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3c(C)sc(C#N)c3C)cc21,,288.29,308.1347196,1,3,1,2,5.51102,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,partial antagonist,36
710,1314,10743938,6j,P06401,PR,Homo sapiens,"3-Bromo-5-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(Br)c(C#N)s3,CHEMBL132950,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 249nM,antagonist,95.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,242,nM,=,6.603800653,pIC50,,other,CC1=CC(C)(C)Nc2ccc(-c3cc(Br)c(C#N)s3)cc21,95,344.172,358.0139316,1,3,1,2,5.65668,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
711,1314,16821785,46,P06401,PR,Homo sapiens,"3-bromo-5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(Br)c(C#N)s3,CHEMBL132950,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.6,,,,progesterone,,,,,,,,,,,,,,,=,6.6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(Br)c(C#N)s3)cc21,,344.172,358.0139316,1,3,1,2,5.65668,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
712,1315,10743938,6c,P06401,PR,Homo sapiens,"6-(4-Bromo-thiophen-2-yl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(Br)cs3,CHEMBL538158,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 32nM,antagonist,91.00%,antagonist,progesterone,,,,,,,EC50,=,29,nM,IC50,=,105,nM,=,7.494850022,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(Br)cs3)cc21,91,318.154,333.0186826,1,2,1,2,5.785,12.03,C1CCC2CC(C3CCCC3)CCC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,36
713,1315,16821785,39,P06401,PR,Homo sapiens,"6-(4-bromothiophen-2-yl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(Br)cs3,CHEMBL538158,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.49,,,,progesterone,,,,,,,,,,,,,,,=,7.49,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(Br)cs3)cc21,,318.154,333.0186826,1,2,1,2,5.785,12.03,C1CCC2CC(C3CCCC3)CCC2C1,,,"antagonist,agonist",antagonist,36
714,1316,10743938,5d,P06401,PR,Homo sapiens,"5-Methyl-4-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(C#N)sc3C,CHEMBL132195,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 31nM,antagonist,78.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,109,nM,=,7.508638306,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(C#N)sc3C)cc21,78,276.279,294.1190696,1,3,1,2,5.2026,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
715,1316,16821785,35,P06401,PR,Homo sapiens,"5-methyl-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(C#N)sc3C,CHEMBL132195,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.51,,,,progesterone,,,,,,,,,,,,,,,=,7.51,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(C#N)sc3C)cc21,,276.279,294.1190696,1,3,1,2,5.2026,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
716,1317,9719599,11,P06401,PR,Homo sapiens,"3-Fluoro-5-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-benzonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(c3)C#N,CHEMBL117465,,cotransfection,-,Ki = 10nM,antagonist,82.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,30,nM,=,8,pKi,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,82,275.221,292.1375768,1,2,1,2,4.97178,35.82,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
717,1317,10743938,1,P06401,PR,Homo sapiens,"3-Fluoro-5-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-benzonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(c3)C#N,CHEMBL117465,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 10nM,antagonist,82.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,30,nM,=,8,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,82,275.221,292.1375768,1,2,1,2,4.97178,35.82,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
718,1317,16821785,30,P06401,PR,Homo sapiens,"3-fluoro-5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)benzonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(c3)C#N,CHEMBL117465,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8,,,,progesterone,,,,,,,,,,,,,,,=,8,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,,275.221,292.1375768,1,2,1,2,4.97178,35.82,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
719,1318,9719599,9,P06401,PR,Homo sapiens,"6-(3,5-Difluoro-phenyl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(F)c3,CHEMBL117586,,cotransfection,-,Ki = 10nM,antagonist,85.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,79,nM,=,8,pKi,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(F)c3)cc21,85,268.201,285.132906,1,1,1,2,5.2392,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
720,1318,16821785,28,P06401,PR,Homo sapiens,"6-(3,5-difluorophenyl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(F)c3,CHEMBL117586,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.1,,,,progesterone,,,,,,,,,,,,,,,=,8.1,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc(F)c3)cc21,,268.201,285.132906,1,1,1,2,5.2392,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
721,1319,9719599,13,P06401,PR,Homo sapiens,"6-(3-Fluoro-5-nitro-phenyl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(c3)[N+](=O)[O-],CHEMBL117308,,cotransfection,-,Ki = 5nM,antagonist,78.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,70,nM,=,8.301029996,pKi,B,other,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc([N+](=O)[O-])c3)cc21,78,295.208,312.127406,1,3,2,2,5.0083,55.17,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
722,1319,16821785,32,P06401,PR,Homo sapiens,"6-(3-fluoro-5-nitrophenyl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cc(F)cc(c3)[N+](=O)[O-],CHEMBL117308,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.3,,,,progesterone,,,,,,,,,,,,,,,=,8.3,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cc(F)cc([N+](=O)[O-])c3)cc21,,295.208,312.127406,1,3,2,2,5.0083,55.17,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
726,1320,10743938,6e,P06401,PR,Homo sapiens,"6-(5-Bromo-thiophen-2-yl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(Br)s3,CHEMBL339399,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 31nM,antagonist,78.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,65,nM,=,7.508638306,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3ccc(Br)s3)cc21,78,318.154,333.0186826,1,2,1,2,5.785,12.03,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
727,1320,16821785,41,P06401,PR,Homo sapiens,"6-(5-bromothiophen-2-yl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(Br)s3,CHEMBL339399,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.51,,,,progesterone,,,,,,,,,,,,,,,=,7.51,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccc(Br)s3)cc21,,318.154,333.0186826,1,2,1,2,5.785,12.03,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
728,1321,10743938,6h,P06401,PR,Homo sapiens,"5-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(C#N)s3,CHEMBL132193,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 55nM,antagonist,77.00%,antagonist,progesterone,,,,,,,EC50,=,35,nM,IC50,=,27,nM,=,7.259637311,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3ccc(C#N)s3)cc21,77,264.268,280.1034195,1,3,1,2,4.89418,35.82,C1CCC2CC(C3CCCC3)CCC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,36
729,1321,16821785,44,P06401,PR,Homo sapiens,"5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(C#N)s3,CHEMBL132193,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.26,,,,progesterone,,,,,,,,,,,,,,,=,7.26,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccc(C#N)s3)cc21,,264.268,280.1034195,1,3,1,2,4.89418,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,"antagonist,agonist",antagonist,36
730,1322,10743938,6f,P06401,PR,Homo sapiens,"5-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbaldehyde",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(C=O)s3,CHEMBL134786,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 80nM,partial antagonist,71.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,729,nM,=,7.096910013,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3ccc(C=O)s3)cc21,71,266.26,283.1030852,1,3,2,2,4.835,29.1,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,36
731,1322,16821785,42,P06401,PR,Homo sapiens,"5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbaldehyde",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(C=O)s3,CHEMBL134786,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.1,,,,progesterone,,,,,,,,,,,,,,,=,7.1,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccc(C=O)s3)cc21,,266.26,283.1030852,1,3,2,2,4.835,29.1,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,partial antagonist,36
732,1323,10743938,6d,P06401,PR,Homo sapiens,"6-(5-Chloro-thiophen-2-yl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(Cl)s3,CHEMBL133661,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 12nM,antagonist,75.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,43,nM,=,7.920818754,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3ccc(Cl)s3)cc21,75,273.703,289.0691982,1,2,1,2,5.6759,12.03,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
733,1323,16821785,40,P06401,PR,Homo sapiens,"6-(5-chlorothiophen-2-yl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(Cl)s3,CHEMBL133661,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.92,,,,progesterone,,,,,,,,,,,,,,,=,7.92,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccc(Cl)s3)cc21,,273.703,289.0691982,1,2,1,2,5.6759,12.03,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
734,1324,10743938,6g,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-(5-nitro-thiophen-2-yl)-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(s3)[N+](=O)[O-],CHEMBL133656,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 2.6nM,antagonist,77.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,31,nM,=,8.585026652,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3ccc([N+](=O)[O-])s3)cc21,77,284.255,300.0932488,1,4,2,2,4.9307,55.17,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
735,1324,16821785,43,P06401,PR,Homo sapiens,"2,2,4-trimethyl-6-(5-nitrothiophen-2-yl)-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccc(s3)[N+](=O)[O-],CHEMBL133656,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.59,,,,progesterone,,,,,,,,,,,,,,,=,8.59,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccc([N+](=O)[O-])s3)cc21,,284.255,300.0932488,1,4,2,2,4.9307,55.17,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
736,1325,9719599,10,P06401,PR,Homo sapiens,"3-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-benzonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(c3)C#N,CHEMBL115904,,cotransfection,-,Ki = 19nM,antagonist,81.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,38,nM,=,7.721246399,pKi,B,other,CC1=CC(C)(C)Nc2ccc(-c3cccc(C#N)c3)cc21,81,256.223,274.1469986,1,2,1,2,4.83268,35.82,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
737,1325,16821785,29,P06401,PR,Homo sapiens,"3-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)benzonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(c3)C#N,CHEMBL115904,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.72,,,,progesterone,,,,,,,,,,,,,,,=,7.72,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cccc(C#N)c3)cc21,,256.223,274.1469986,1,2,1,2,4.83268,35.82,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
738,1326,9719599,8,P06401,PR,Homo sapiens,"6-(3-Fluoro-phenyl)-2,2,4-trimethyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(F)c3,CHEMBL117585,,cotransfection,-,Ki = 182nM,antagonist,94.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,750,nM,=,6.739928612,pKi,,other,CC1=CC(C)(C)Nc2ccc(-c3cccc(F)c3)cc21,94,249.203,267.1423278,1,1,1,2,5.1001,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
739,1326,16821785,27,P06401,PR,Homo sapiens,"6-(3-fluorophenyl)-2,2,4-trimethyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(F)c3,CHEMBL117585,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.74,,,,progesterone,,,,,,,,,,,,,,,=,6.74,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cccc(F)c3)cc21,,249.203,267.1423278,1,1,1,2,5.1001,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
740,1327,9719599,12,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-(3-nitro-phenyl)-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(c3)[N+](=O)[O-],CHEMBL93027,,cotransfection,-,Ki = 20nM,antagonist,83.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,42,nM,=,7.698970004,pKi,B,other,CC1=CC(C)(C)Nc2ccc(-c3cccc([N+](=O)[O-])c3)cc21,83,276.21,294.1368278,1,3,2,2,4.8692,55.17,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,antagonist,antagonist,antagonist,119
741,1327,11591515,1,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-(3-nitro-phenyl)-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(c3)[N+](=O)[O-],CHEMBL93027,,PRE-luciferase,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 20nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,42,nM,=,7.698970004,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cccc([N+](=O)[O-])c3)cc21,,276.21,294.1368278,1,3,2,2,4.8692,55.17,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,,antagonist,antagonist,119
742,1327,16821785,31,P06401,PR,Homo sapiens,"2,2,4-trimethyl-6-(3-nitrophenyl)-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccc(c3)[N+](=O)[O-],CHEMBL93027,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.7,,,,progesterone,,,,,,,,,,,,,,,=,7.7,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cccc([N+](=O)[O-])c3)cc21,,276.21,294.1368278,1,3,2,2,4.8692,55.17,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,antagonist,119
743,1328,9719599,3,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccccc3,CHEMBL93463,,cotransfection,-,Ki = 133nM,partial antagonist,72.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,783,nM,=,6.876148359,pKi,,other,CC1=CC(C)(C)Nc2ccc(-c3ccccc3)cc21,72,230.205,249.1517496,1,1,1,2,4.961,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,119
744,1328,9873612,3,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccccc3,CHEMBL93463,,cotransfection,-,Ki = 133nM,partial antagonist,72.00%,antagonist,,,,,,,,,,,,IC50,=,783,nM,=,6.876148359,pKi,,other,CC1=CC(C)(C)Nc2ccc(-c3ccccc3)cc21,72,230.205,249.1517496,1,1,1,2,4.961,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,119
745,1328,16821785,26,P06401,PR,Homo sapiens,"2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3ccccc3,CHEMBL93463,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.88,,,,progesterone,,,,,,,,,,,,,,,=,6.88,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc(-c3ccccc3)cc21,,230.205,249.1517496,1,1,1,2,4.961,12.03,C1CCC(C2CCC3CCCCC3C2)CC1,,,antagonist,partial antagonist,119
746,1329,10743938,6a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-thiophen-2-yl-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccs3,CHEMBL337199,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 237nM,antagonist,85.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,416,nM,=,6.625251654,pIC50,,other,CC1=CC(C)(C)Nc2ccc(-c3cccs3)cc21,85,238.25,255.1081705,1,2,1,2,5.0225,12.03,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
747,1329,16821785,37,P06401,PR,Homo sapiens,"2,2,4-trimethyl-6-(thiophen-2-yl)-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3cccs3,CHEMBL337199,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.63,,,,progesterone,,,,,,,,,,,,,,,=,6.63,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc(-c3cccs3)cc21,,238.25,255.1081705,1,2,1,2,5.0225,12.03,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
751,1330,10743938,5a,P06401,PR,Homo sapiens,"3-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3ccsc3C#N,CHEMBL134258,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 > 100nM,antagonist,88.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,318,nM,>,7,pIC50,,other,CC1=CC(C)(C)Nc2ccc(-c3ccsc3C#N)cc21,88,264.268,280.1034195,1,3,1,2,4.89418,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
752,1331,10743938,5c,P06401,PR,Homo sapiens,"4-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3csc(c3)C#N,CHEMBL335992,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 3.5nM,antagonist,84.00%,antagonist,progesterone,,,,,,,EC50,=,34,nM,IC50,=,24,nM,=,8.455931956,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3csc(C#N)c3)cc21,84,264.268,280.1034195,1,3,1,2,4.89418,35.82,C1CCC2CC(C3CCCC3)CCC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,36
753,1331,16821785,34,P06401,PR,Homo sapiens,"4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3csc(c3)C#N,CHEMBL335992,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.46,,,,progesterone,,,,,,,,,,,,,,,=,8.46,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3csc(C#N)c3)cc21,,264.268,280.1034195,1,3,1,2,4.89418,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,"antagonist,agonist",antagonist,36
754,1332,10743938,5b,P06401,PR,Homo sapiens,"4-(2,2,4-Trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbaldehyde",CC1=CC(C)(C)Nc2ccc(cc12)c3csc(C=O)c3,CHEMBL337885,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 37nM,antagonist,83.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,245,nM,=,7.431798276,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3csc(C=O)c3)cc21,83,266.26,283.1030852,1,3,2,2,4.835,29.1,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
755,1332,16821785,33,P06401,PR,Homo sapiens,"4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbaldehyde",CC1=CC(C)(C)Nc2ccc(cc12)c3csc(C=O)c3,CHEMBL337885,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.43,,,,progesterone,,,,,,,,,,,,,,,=,7.43,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3csc(C=O)c3)cc21,,266.26,283.1030852,1,3,2,2,4.835,29.1,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
756,1333,10743938,6i,P06401,PR,Homo sapiens,"4-Bromo-5-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3sc(cc3Br)C#N,CHEMBL132192,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 433nM,antagonist,86.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,52,nM,=,6.363512104,pIC50,,other,CC1=CC(C)(C)Nc2ccc(-c3sc(C#N)cc3Br)cc21,86,344.172,358.0139316,1,3,1,2,5.65668,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
757,1333,16821785,45,P06401,PR,Homo sapiens,"4-bromo-5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3sc(cc3Br)C#N,CHEMBL132192,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.36,,,,progesterone,,,,,,,,,,,,,,,=,6.36,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc(-c3sc(C#N)cc3Br)cc21,,344.172,358.0139316,1,3,1,2,5.65668,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
758,1334,10743938,6k,P06401,PR,Homo sapiens,"4-Methyl-5-(2,2,4-trimethyl-1,2-dihydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3sc(cc3C)C#N,CHEMBL131855,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 26nM,antagonist,89.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,33,nM,=,7.585026652,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3sc(C#N)cc3C)cc21,89,276.279,294.1190696,1,3,1,2,5.2026,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
759,1334,16821785,47,P06401,PR,Homo sapiens,"4-methyl-5-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl)thiophene-2-carbonitrile",CC1=CC(C)(C)Nc2ccc(cc12)c3sc(cc3C)C#N,CHEMBL131855,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.59,,,,progesterone,,,,,,,,,,,,,,,=,7.59,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3sc(C#N)cc3C)cc21,,276.279,294.1190696,1,3,1,2,5.2026,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
760,1335,10743938,6b,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-6-(3-methyl-thiophen-2-yl)-1,2-dihydro-quinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3sccc3C,CHEMBL133794,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 25nM,antagonist,76.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,232,nM,=,7.602059991,pIC50,B,other,CC1=CC(C)(C)Nc2ccc(-c3sccc3C)cc21,76,250.261,269.1238206,1,2,1,2,5.33092,12.03,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
761,1335,16821785,38,P06401,PR,Homo sapiens,"2,2,4-trimethyl-6-(3-methylthiophen-2-yl)-1,2-dihydroquinoline",CC1=CC(C)(C)Nc2ccc(cc12)c3sccc3C,CHEMBL133794,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.6,,,,progesterone,,,,,,,,,,,,,,,=,7.6,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc(-c3sccc3C)cc21,,250.261,269.1238206,1,2,1,2,5.33092,12.03,C1CCC2CC(C3CCCC3)CCC2C1,,,antagonist,antagonist,36
762,1336,9873612,11a,P06401,PR,Homo sapiens,"1,3,3-Trimethyl-4,11-dihydro-3H-pyrido[3,2-a]carbazole",CC1=CC(C)(C)Nc2ccc3c4ccccc4[nH]c3c12,CHEMBL94183,,cotransfection,-,Ki > 1000nM,antagonist,87.00%,antagonist,,,,,,,,,,,,IC50,=,662,nM,>,6,pKi,,other,CC1=CC(C)(C)Nc2ccc3c([nH]c4ccccc43)c21,87,244.212,262.1469986,2,1,0,3,4.9285,27.82,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
763,1337,12781197,7,P06401,PR,Homo sapiens,"5-Bromomethylene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/Br)\c3c12,CHEMBL62700,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.1nM,agonist,135.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,2.2,nM,,,,,=,8.677780705,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/Br)Oc1ccc(F)cc1-3,135,369.128,385.0477545,1,2,0,2,6.1858,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
764,1337,16821785,68,P06401,PR,Homo sapiens,"(Z)-5-(bromomethylene)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/Br)\c3c12,CHEMBL62700,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.68,,,,progesterone,,,,,,,,,,,,,,,=,8.68,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/Br)Oc1ccc(F)cc1-3,,369.128,385.0477545,1,2,0,2,6.1858,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,agonist,agonist,515
765,1338,12781197,8,P06401,PR,Homo sapiens,"[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidene]-acetonitrile",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/C#N)\c3c12,CHEMBL62731,co-transaction assay,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 45nM,partial agonist,70.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,2700,nM,IC50,=,65,nM,=,7.346787486,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/C#N)Oc1ccc(F)cc1-3,70,315.242,332.1324914,1,3,0,2,5.35698,45.05,CC1CC2CCCCC2C2CCC3CCCCC3C12,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,515
766,1338,16821785,69,P06401,PR,Homo sapiens,"(Z)-2-(9-fluoro-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinolin-5-ylidene)acetonitrile",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/C#N)\c3c12,CHEMBL62731,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.35,,,,progesterone,,,,,,,,,,,,,,,=,7.35,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/C#N)Oc1ccc(F)cc1-3,,315.242,332.1324914,1,3,0,2,5.35698,45.05,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,"antagonist,agonist",partial agonist,515
767,1339,12781197,14,P06401,PR,Homo sapiens,"5-Cyclohexylmethylene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/C5CCCCC5)\c3c12,CHEMBL418670,co-transaction assay,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 100nM,partial antagonist,70.00%,antagonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,48,nM,IC50,=,800,nM,>,7,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/C1CCCCC1)Oc1ccc(F)cc1-3,70,361.29,389.2154927,1,2,1,2,7.4137,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,222
769,134,8627601,35,P06401,PR,Homo sapiens,"Acetic acid 5-bromo-2-((1S,6R)-4,6-dimethyl-2-methylene-cyclohex-3-enylmethyl)-4-methoxy-phenyl ester",COc1cc(C[C@H]2[C@H](C)CC(=CC2=C)C)c(OC(=O)C)cc1Br,CHEMBL51933,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 21nM,partial antagonist,52.00%,antagonist,,,,,,,,EC50,=,3005,nM,IC50,=,350,nM,=,7.677780705,pKi,B,radiometric,C=C1C=C(C)C[C@@H](C)[C@@H]1Cc1cc(OC)c(Br)cc1OC(C)=O,52,356.11,378.0830567,0,3,4,1,5.084,35.53,CC1CCCCC1CC1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,730
771,1340,12781197,9,P06401,PR,Homo sapiens,"[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidene]-acetaldehyde",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/C=O)\c3c12,CHEMBL65689,,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 100nM,antagonist,97.00%,antagonist,progesterone,,dexamethasone,2.5nM,,,,,,,,IC50,=,243,nM,>,7,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/C=O)Oc1ccc(F)cc1-3,97,317.234,335.132157,1,3,1,2,5.0323,38.33,CC1CC2CCCCC2C2CCC3CCCCC3C12,antagonist,antagonist,antagonist,antagonist,515
773,1342,9784110,25,P06401,PR,Homo sapiens,"5-[1-(3,5-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cc(F)cc(F)c5)\c3c12,CHEMBL342190,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12.6nM,agonist,90.00%,agonist,progesterone,,progesterone,,,,,EC50,=,47.7,nM,IC50,>,10000,nM,=,7.899629455,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)cc(F)c1)Oc1ccccc1-3,90,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
774,1343,9784110,22,P04150,GR,Homo sapiens,"5-[1-(2,5-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cc(F)ccc5F)\c3c12,CHEMBL137103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 173nM,partial antagonist,74.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,371,nM,=,6.761953897,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)ccc1F)Oc1ccccc1-3,74,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
775,1343,9784110,22,P06401,PR,Homo sapiens,"5-[1-(2,5-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cc(F)ccc5F)\c3c12,CHEMBL137103,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,137.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14.7,nM,IC50,>,10000,nM,=,8.823908741,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)ccc1F)Oc1ccccc1-3,137,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
776,1343,9784110,22,P10275,AR,Homo sapiens,"5-[1-(2,5-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cc(F)ccc5F)\c3c12,CHEMBL137103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 887nM,antagonist,81.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,1600,nM,=,6.05207638,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)ccc1F)Oc1ccccc1-3,81,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
777,1344,9784110,12,P06401,PR,Homo sapiens,"5-[1-(4-Bromo-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(Br)cc5)\c3c12,CHEMBL137902,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.7nM,agonist,114.00%,agonist,progesterone,,progesterone,,,,,EC50,=,31.5,nM,IC50,>,10000,nM,=,8.060480747,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(Br)cc1)Oc1ccccc1-3,114,422.196,443.0884764,1,2,1,3,7.614,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
778,1345,9784110,18,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-p-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(C)cc5)\c3c12,CHEMBL139468,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 70.0nM,partial antagonist,42.00%,antagonist,progesterone,,progesterone,,,,,EC50,>,10000,nM,IC50,=,590,nM,=,7.15490196,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(C)cc1)Oc1ccccc1-3,42,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
780,1347,9784110,24,P04150,GR,Homo sapiens,"5-[1-(3,4-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(F)c(F)c5)\c3c12,CHEMBL342426,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 237nM,antagonist,76.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,1650,nM,=,6.625251654,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)c(F)c1)Oc1ccccc1-3,76,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
781,1347,9784110,24,P06401,PR,Homo sapiens,"5-[1-(3,4-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(F)c(F)c5)\c3c12,CHEMBL342426,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.6nM,agonist,143.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14.7,nM,IC50,>,10000,nM,=,8.443697499,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)c(F)c1)Oc1ccccc1-3,143,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
782,1347,9784110,24,P10275,AR,Homo sapiens,"5-[1-(3,4-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(F)c(F)c5)\c3c12,CHEMBL342426,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,70.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,916,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)c(F)c1)Oc1ccccc1-3,70,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
783,1348,12954062,9c,P06401,PR,Homo sapiens,"7-Fluoro-5-[1-(4-fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccc(F)cc5)\c3c12,CHEMBL133117,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.5nM,agonist,175.00%,agonist,progesterone,,progesterone,,,,,EC50,=,4,nM,,,,,=,8.259637311,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)cc1)Oc1c(F)cccc1-3,175,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
784,1349,9784110,9,P06401,PR,Homo sapiens,"5-[1-(4-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(F)cc5)\c3c12,CHEMBL136464,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,150.00%,agonist,progesterone,,progesterone,,,,,EC50,=,59.5,nM,IC50,>,10000,nM,=,8.455931956,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)cc1)Oc1ccccc1-3,150,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
785,135,17890084,14,P03372,ERA,Homo sapiens,"(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-methylene-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=C)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL249700,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 640nM,partial agonist,29.00%,agonist,E2,,E2,,,,,EC50,>,1000,nM,,,,,=,6.193820026,pIC50,,radiometric,C=C1C=C2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,29,256.219,286.2296656,1,1,0,0,4.8663,20.23,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,partial agonist,,partial agonist,615
787,135,17890084,14,Q92731,ERB,Homo sapiens,"(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-methylene-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=C)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL249700,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 34nM,partial agonist,67.00%,agonist,E2,,E2,,,,,EC50,=,210,nM,,,,,=,7.468521083,pIC50,B,radiometric,C=C1C=C2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,67,256.219,286.2296656,1,1,0,0,4.8663,20.23,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,615
788,1350,9784110,21,P06401,PR,Homo sapiens,"5-[1-(2,4-Difluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccc(F)cc5F)\c3c12,CHEMBL428125,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,partial agonist,72.00%,agonist,progesterone,,progesterone,,,,,EC50,=,22,nM,IC50,=,550,nM,=,8.494850022,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)cc1F)Oc1ccccc1-3,72,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,222
789,1351,9784110,11,P06401,PR,Homo sapiens,"5-[1-(3-Bromo-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(Br)c5)\c3c12,CHEMBL137956,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 22.1nM,partial agonist,59.00%,agonist,progesterone,,progesterone,,,,,EC50,=,37,nM,IC50,>,10000,nM,=,7.655607726,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(Br)c1)Oc1ccccc1-3,59,422.196,443.0884764,1,2,1,3,7.614,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
790,1352,9784110,17,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-m-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(C)c5)\c3c12,CHEMBL344048,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 39.7nM,partial agonist,31.00%,agonist,progesterone,,progesterone,,,,,EC50,=,75,nM,IC50,>,10000,nM,=,7.401209493,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(C)c1)Oc1ccccc1-3,31,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
791,1353,9784110,14,P06401,PR,Homo sapiens,"5-[1-(3-Chloro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(Cl)c5)\c3c12,CHEMBL337262,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18.7nM,agonist,83.00%,agonist,progesterone,,progesterone,,,,,EC50,=,117,nM,IC50,>,10000,nM,=,7.728158393,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(Cl)c1)Oc1ccccc1-3,83,377.745,399.138992,1,2,1,3,7.5049,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
792,1354,12954062,9b,P06401,PR,Homo sapiens,"7-Fluoro-5-[1-(3-fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL130257,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.5nM,agonist,170.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.7,nM,,,,,=,8.259637311,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1c(F)cccc1-3,170,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
793,1355,9784110,8,P04150,GR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL32812,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 180nM,antagonist,98.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,458,nM,=,6.744727495,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,98,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
794,1355,9784110,8,P06401,PR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL32812,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.83nM,agonist,132.00%,agonist,progesterone,,progesterone,,,,,EC50,=,7.6,nM,IC50,>,10000,nM,=,9.080921908,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,132,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,"agonist,antagonist",agonist,222
795,1355,10212133,2,P06401,PR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL32812,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.83nM,agonist,132.00%,agonist,progesterone,,progesterone,,,,,EC50,=,7.6,nM,IC50,=,600,nM,=,9.080921908,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,132,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",agonist,"agonist,antagonist",agonist,222
796,1355,9784110,8,P10275,AR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL32812,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 798nM,antagonist,77.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,795,nM,=,6.097997109,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,77,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
798,1357,12954062,9a,P04150,GR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccccc5)\c3c12,CHEMBL413309,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 321nM,antagonist,82.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,250,nM,=,6.493494968,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1c(F)cccc1-3,82,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
799,1357,12954062,9a,P06401,PR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccccc5)\c3c12,CHEMBL413309,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.61nM,agonist,171.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.1,nM,,,,,=,9.214670165,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1c(F)cccc1-3,171,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
800,1357,12954062,9a,P10275,AR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccccc5)\c3c12,CHEMBL413309,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,60.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,900,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1c(F)cccc1-3,60,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
801,1358,12954062,7a,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134602,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 207nM,partial antagonist,73.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,2050,nM,=,6.684029655,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccc(F)cc1-3,73,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
802,1358,12954062,7a,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134602,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,176.00%,agonist,progesterone,,progesterone,,,,,EC50,=,5.3,nM,,,,,=,8.823908741,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccc(F)cc1-3,176,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
803,1358,12954062,7a,P10275,AR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134602,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,37.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,640,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccc(F)cc1-3,37,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
804,1359,9784110,6,P04150,GR,Homo sapiens,"2,2,4-Trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134421,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 299nM,antagonist,95.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,737,nM,=,6.524328812,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,95,342.292,365.1779644,1,2,1,3,6.8515,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
805,1359,9784110,6,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134421,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.9nM,agonist,126.00%,agonist,progesterone,,progesterone,,,,,EC50,=,24.4,nM,IC50,>,10000,nM,=,8.30980392,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,126,342.292,365.1779644,1,2,1,3,6.8515,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
806,1359,9784110,6,P10275,AR,Homo sapiens,"2,2,4-Trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL134421,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2660nM,antagonist,80.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,650,nM,=,5.575118363,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,80,342.292,365.1779644,1,2,1,3,6.8515,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
810,1360,12954062,7j,P06401,PR,Homo sapiens,"5-[1-(2-Bromo-phenyl)-meth-(Z)-ylidene]-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5Br)\c3c12,CHEMBL334586,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16.4nM,agonist,147.00%,agonist,progesterone,,progesterone,,,,,EC50,=,9,nM,,,,,=,7.785156152,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1Br)Oc1ccc(F)cc1-3,147,441.194,461.0790546,1,2,1,3,7.7531,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
811,1361,9784110,10,P06401,PR,Homo sapiens,"5-[1-(2-Bromo-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5Br)\c3c12,CHEMBL335591,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.5nM,agonist,127.00%,agonist,progesterone,,progesterone,,,,,EC50,=,57.8,nM,IC50,>,10000,nM,=,8.259637311,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1Br)Oc1ccccc1-3,127,422.196,443.0884764,1,2,1,3,7.614,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
812,1362,12954062,7k,P06401,PR,Homo sapiens,"2-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidenemethyl]-benzonitrile",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C#N)\c3c12,CHEMBL334747,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.4nM,agonist,78.00%,agonist,progesterone,,progesterone,,,,,EC50,=,11,nM,,,,,=,7.943095149,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C#N)Oc1ccc(F)cc1-3,78,387.308,408.1637915,1,3,1,3,6.86228,45.05,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
813,1363,12954062,7e,P06401,PR,Homo sapiens,"9-Fluoro-5-[1-(2-isopropyl-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC(C)c1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL132672,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,agonist,156.00%,agonist,progesterone,,progesterone,,,,,EC50,=,4,nM,,,,,=,8.721246399,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C(C)C)Oc1ccc(F)cc1-3,156,397.323,425.2154927,1,2,2,3,8.114,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
814,1364,12954062,18a,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(2-trifluoromethyl-phenyl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C(F)(F)F)\c3c12,CHEMBL133124,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 45.5nM,agonist,127.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14,nM,,,,,=,7.341988603,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C(F)(F)F)Oc1ccc(F)cc1-3,127,430.295,451.1559272,1,2,1,3,8.0094,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
815,1365,12954062,9d,P04150,GR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccccc5C)\c3c12,CHEMBL337856,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 232nM,antagonist,89.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,297,nM,=,6.634512015,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1c(F)cccc1-3,89,373.301,397.1841926,1,2,1,3,7.29902,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
816,1365,12954062,9d,P06401,PR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cccc(F)c4O\C(=C/c5ccccc5C)\c3c12,CHEMBL337856,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,163.00%,agonist,progesterone,,progesterone,,,,,EC50,=,1.4,nM,,,,,=,8.823908741,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1c(F)cccc1-3,163,373.301,397.1841926,1,2,1,3,7.29902,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
818,1366,12954062,7b,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL336736,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 236nM,antagonist,84.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,650,nM,=,6.627087997,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccc(F)cc1-3,84,373.301,397.1841926,1,2,1,3,7.29902,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
819,1366,12954062,7b,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL336736,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.55nM,agonist,178.00%,agonist,progesterone,,progesterone,,,,,EC50,=,3.6,nM,,,,,=,9.259637311,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccc(F)cc1-3,178,373.301,397.1841926,1,2,1,3,7.29902,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
820,1366,12954062,7b,P10275,AR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL336736,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,38.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,820,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccc(F)cc1-3,38,373.301,397.1841926,1,2,1,3,7.29902,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
821,1367,9784110,16,P04150,GR,Homo sapiens,"2,2,4-Trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL302362,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 564nM,antagonist,80.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,1050,nM,=,6.248720896,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,80,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
822,1367,9784110,16,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL302362,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.66nM,agonist,166.00%,agonist,progesterone,,progesterone,,,,,EC50,=,5.7,nM,IC50,>,10000,nM,=,9.180456064,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,166,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
823,1367,12781197,1 (LG120838),P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL302362,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.66nM,agonist,166.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,5.7,nM,,,,,=,9.180456064,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,166,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
824,1367,12954062,2,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL302362,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.66nM,agonist,166.00%,agonist,progesterone,,progesterone,,,,,EC50,=,5.7,nM,,,,,=,9.180456064,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,166,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
825,1367,9784110,16,P10275,AR,Homo sapiens,"2,2,4-Trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5C)\c3c12,CHEMBL302362,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 844nM,partial antagonist,70.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,1062,nM,=,6.073657553,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,70,354.303,379.1936144,1,2,1,3,7.15992,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
826,1368,12954062,7l,P06401,PR,Homo sapiens,"2-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidenemethyl]-benzaldehyde",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5C=O)\c3c12,CHEMBL422268,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.6nM,agonist,107.00%,agonist,progesterone,,progesterone,,,,,EC50,=,11,nM,,,,,=,8.585026652,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C=O)Oc1ccc(F)cc1-3,107,389.3,411.1634572,1,3,2,3,6.8031,38.33,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
827,1369,12954062,7i,P06401,PR,Homo sapiens,"5-[1-(2-Chloro-phenyl)-meth-(Z)-ylidene]-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5Cl)\c3c12,CHEMBL132256,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 22.4nM,agonist,146.00%,agonist,progesterone,,progesterone,,,,,EC50,=,12,nM,,,,,=,7.649751982,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1Cl)Oc1ccc(F)cc1-3,146,396.743,417.1295702,1,2,1,3,7.644,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
828,137,10212133,7,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2-dimethyl-4-methylene-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1(C)CC(=C)c2c(N1)ccc3c4ccccc4OC(c5ccc(Cl)cc5)c23,CHEMBL286130,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.6nM,antagonist,81.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,124,nM,IC50,=,1755,nM,=,7.935542011,pKi,B,radiometric,C=C1CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,81,365.734,387.138992,1,2,1,3,7.0962,21.26,CC1CCCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C12,"antagonist,agonist",antagonist,"antagonist,agonist","antagonist,partial agonist",693
829,137,10212133,7,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2-dimethyl-4-methylene-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1(C)CC(=C)c2c(N1)ccc3c4ccccc4OC(c5ccc(Cl)cc5)c23,CHEMBL286130,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.6nM,partial agonist,30.00%,agonist,progesterone,,progesterone,,,,,EC50,=,124,nM,IC50,=,1755,nM,=,7.935542011,pKi,B,radiometric,C=C1CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,30,365.734,387.138992,1,2,1,3,7.0962,21.26,CC1CCCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C12,"antagonist,agonist",partial agonist,"antagonist,agonist","antagonist,partial agonist",693
830,1370,9784110,13,P06401,PR,Homo sapiens,"5-[1-(2-Chloro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5Cl)\c3c12,CHEMBL344627,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.3nM,agonist,127.00%,agonist,progesterone,,progesterone,,,,,EC50,=,57.8,nM,IC50,>,10000,nM,=,8.886056648,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1Cl)Oc1ccccc1-3,127,377.745,399.138992,1,2,1,3,7.5049,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
831,1371,12954062,7h,P06401,PR,Homo sapiens,"9-Fluoro-5-[1-(2-fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5F)\c3c12,CHEMBL335249,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.62nM,agonist,190.00%,agonist,progesterone,,progesterone,,,,,EC50,=,7.3,nM,,,,,=,9.207608311,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1F)Oc1ccc(F)cc1-3,190,380.288,401.1591207,1,2,1,3,7.1297,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
832,1372,9784110,7,P06401,PR,Homo sapiens,"5-[1-(2-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5F)\c3c12,CHEMBL435822,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.6nM,agonist,98.00%,agonist,progesterone,,progesterone,,,,,EC50,=,29,nM,IC50,>,10000,nM,=,8.251811973,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1F)Oc1ccccc1-3,98,361.29,383.1685425,1,2,1,3,6.9906,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
833,1373,12954062,15,P04150,GR,Homo sapiens,"{2-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidenemethyl]-phenyl}-dimethyl-amine",CN(C)c1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL336353,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 493nM,antagonist,88.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,320,nM,=,6.307153081,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1N(C)C)Oc1ccc(F)cc1-3,88,399.319,426.2107417,1,3,2,3,7.0566,24.5,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
834,1373,12954062,15,P06401,PR,Homo sapiens,"{2-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidenemethyl]-phenyl}-dimethyl-amine",CN(C)c1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL336353,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.2nM,agonist,172.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.7,nM,,,,,=,8.920818754,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1N(C)C)Oc1ccc(F)cc1-3,172,399.319,426.2107417,1,3,2,3,7.0566,24.5,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
835,1373,12954062,15,P10275,AR,Homo sapiens,"{2-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidenemethyl]-phenyl}-dimethyl-amine",CN(C)c1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL336353,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 819nM,partial antagonist,60.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,1500,nM,=,6.086716098,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1N(C)C)Oc1ccc(F)cc1-3,60,399.319,426.2107417,1,3,2,3,7.0566,24.5,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
836,1374,12954062,7m,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(2-trifluoromethoxy-phenyl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccc5OC(F)(F)F)\c3c12,CHEMBL132578,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.4nM,agonist,136.00%,agonist,progesterone,,progesterone,,,,,EC50,=,11,nM,,,,,=,8.193820026,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1OC(F)(F)F)Oc1ccc(F)cc1-3,136,446.294,467.1508418,1,3,2,3,7.8892,30.49,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
837,1375,12954062,8c,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-pyridin-2-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccccn5)\c3c12,CHEMBL335879,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9.2nM,partial agonist,50.00%,agonist,progesterone,,progesterone,,,,,EC50,=,15,nM,,,,,=,8.036212173,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccn1)Oc1ccc(F)cc1-3,50,363.286,384.1637915,1,3,1,3,6.3856,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
838,1376,12954062,18c,P04150,GR,Homo sapiens,"9-Fluoro-5-[1-furan-2-yl-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5occc5)\c3c12,CHEMBL336169,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 140nM,partial antagonist,74.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,109,nM,=,6.853871964,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccco1)Oc1ccc(F)cc1-3,74,353.267,373.1478071,1,3,1,3,6.5836,34.4,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,221
839,1376,12954062,18c,P06401,PR,Homo sapiens,"9-Fluoro-5-[1-furan-2-yl-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5occc5)\c3c12,CHEMBL336169,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.7nM,agonist,138.00%,agonist,progesterone,,progesterone,,,,,EC50,=,1.7,nM,,,,,=,8.327902142,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccco1)Oc1ccc(F)cc1-3,138,353.267,373.1478071,1,3,1,3,6.5836,34.4,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,agonist,agonist,agonist,221
840,1376,12954062,18c,P10275,AR,Homo sapiens,"9-Fluoro-5-[1-furan-2-yl-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5occc5)\c3c12,CHEMBL336169,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki > 1000nM,antagonist,94.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,258,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccco1)Oc1ccc(F)cc1-3,94,353.267,373.1478071,1,3,1,3,6.5836,34.4,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,antagonist,antagonist,antagonist,antagonist,221
841,1377,12954062,8a,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-pyridin-4-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccncc5)\c3c12,CHEMBL336751,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,105.00%,agonist,progesterone,,progesterone,,,,,EC50,=,5.8,nM,,,,,=,8.823908741,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccncc1)Oc1ccc(F)cc1-3,105,363.286,384.1637915,1,3,1,3,6.3856,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
842,1378,12954062,8b,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(3-methyl-pyridin-4-yl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccncc5C)\c3c12,CHEMBL130141,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 232nM,antagonist,99.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,245,nM,=,6.634512015,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccncc1C)Oc1ccc(F)cc1-3,99,375.297,398.1794416,1,3,1,3,6.69402,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
843,1378,12954062,8b,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(3-methyl-pyridin-4-yl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccncc5C)\c3c12,CHEMBL130141,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.4nM,agonist,138.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2,nM,,,,,=,8.853871964,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccncc1C)Oc1ccc(F)cc1-3,138,375.297,398.1794416,1,3,1,3,6.69402,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
845,1379,12954062,18b,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-thiophen-3-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccsc5)\c3c12,CHEMBL134277,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 84nM,partial antagonist,45.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,100,nM,=,7.075720714,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccsc1)Oc1ccc(F)cc1-3,45,369.335,389.1249635,1,3,1,3,7.0521,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,221
846,1379,12954062,18b,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-thiophen-3-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccsc5)\c3c12,CHEMBL134277,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.3nM,agonist,174.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.71,nM,,,,,=,8.886056648,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccsc1)Oc1ccc(F)cc1-3,174,369.335,389.1249635,1,3,1,3,7.0521,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,agonist,agonist,agonist,221
847,1379,12954062,18b,P10275,AR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-thiophen-3-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ccsc5)\c3c12,CHEMBL134277,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 669nM,partial antagonist,52.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,215,nM,=,6.174573882,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccsc1)Oc1ccc(F)cc1-3,52,369.335,389.1249635,1,3,1,3,7.0521,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,221
851,1380,12954062,8d,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(3-methyl-pyridin-2-yl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ncccc5C)\c3c12,CHEMBL132363,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 874nM,antagonist,99.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,188,nM,=,6.058488567,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ncccc1C)Oc1ccc(F)cc1-3,99,375.297,398.1794416,1,3,1,3,6.69402,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
852,1380,12954062,8d,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(3-methyl-pyridin-2-yl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ncccc5C)\c3c12,CHEMBL132363,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.42nM,agonist,125.00%,agonist,progesterone,,progesterone,,,,,EC50,=,4.5,nM,,,,,=,9.37675071,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ncccc1C)Oc1ccc(F)cc1-3,125,375.297,398.1794416,1,3,1,3,6.69402,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
853,1380,12954062,8d,P10275,AR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(3-methyl-pyridin-2-yl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4O\C(=C/c5ncccc5C)\c3c12,CHEMBL132363,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki > 1000nM,antagonist,93.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,203,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ncccc1C)Oc1ccc(F)cc1-3,93,375.297,398.1794416,1,3,1,3,6.69402,34.15,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
854,1381,12781197,17,P06401,PR,Homo sapiens,"5-diphenylmethylene-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinolin-9-yl fluoride",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(=C(c5ccccc5)c6ccccc6)c3c12,CHEMBL303768,,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 100nM,antagonist,90.00%,antagonist,progesterone,,dexamethasone,2.5nM,,,,,,,,IC50,=,1930,nM,>,7,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(=C(c1ccccc1)c1ccccc1)Oc1ccc(F)cc1-3,90,433.356,459.1998427,1,2,2,4,8.4091,21.26,C1CCC(C(C2CCCCC2)C2CC3CCCCC3C3CCC4CCCCC4C32)CC1,antagonist,antagonist,antagonist,antagonist,262
855,1382,12781197,18,P06401,PR,Homo sapiens,"5-[1,3]Dithian-2-ylidene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(=C5SCCCS5)c3c12,CHEMBL65929,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.3nM,agonist,151.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,2.1,nM,,,,,=,8.200659451,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(=C1SCCCS1)Oc1ccc(F)cc1-3,151,389.391,411.1126845,1,4,0,2,6.9887,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
857,1383,9873735,17,P06401,PR,Homo sapiens,"9-Chloro-2,2,4,5-tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1Oc2ccc(Cl)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL286446,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.44nM,agonist,138.00%,agonist,progesterone,,progesterone,,,,,EC50,=,3.2,nM,,,,,=,9.356547324,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(C)Oc1ccc(Cl)cc1-3,138,305.679,325.1233419,1,2,0,2,6.0678,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
858,1383,10212133,3,P06401,PR,Homo sapiens,"9-Chloro-2,2,4,5-tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1Oc2ccc(Cl)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL286446,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.44nM,agonist,138.00%,agonist,progesterone,,progesterone,,,,,EC50,=,3.2,nM,,,,,=,9.356547324,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(C)Oc1ccc(Cl)cc1-3,138,305.679,325.1233419,1,2,0,2,6.0678,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
861,1384,9873735,14,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4,5-tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL116007,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.1nM,agonist,88.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14,nM,,,,,=,8.958607315,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(C)Oc1ccc(F)cc1-3,88,289.224,309.1528925,1,2,0,2,5.5535,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
863,1385,9873735,7,P06401,PR,Homo sapiens,"2,2,4,5-Tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL115174,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.3nM,agonist,114.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2066,nM,IC50,=,43,nM,=,8.48148606,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(C)Oc1ccccc1-3,114,270.226,291.1623143,1,2,0,2,5.4144,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",agonist,"antagonist,agonist",agonist,16
865,1386,9873735,10,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-(3-methyl-butyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC(C)CCC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL114607,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.7nM,partial agonist,64.00%,agonist,progesterone,,progesterone,,,,,EC50,=,13,nM,IC50,=,307,nM,=,8.769551079,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(CCC(C)C)Oc1ccccc1-3,64,318.27,347.2249145,1,2,3,2,6.8307,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,16
867,1387,9873735,11,P06401,PR,Homo sapiens,"5-(4-Chloro-butyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(CCCCCl)c3c12,CHEMBL332264,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,partial agonist,53.00%,agonist,progesterone,,progesterone,,,,,EC50,=,33,nM,IC50,=,6700,nM,=,8.494850022,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(CCCCCl)Oc1ccccc1-3,53,341.712,367.1702921,1,2,4,2,6.8036,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,16
868,1388,9784110,5,P06401,PR,Homo sapiens,"5-Benzyl-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(Cc5ccccc5)c3c12,CHEMBL138283,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.1nM,partial agonist,49.60%,agonist,progesterone,,progesterone,,,,,EC50,=,16.8,nM,IC50,=,270,nM,=,8.677780705,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(Cc1ccccc1)Oc1ccccc1-3,49.6,342.292,367.1936144,1,2,2,3,6.6372,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,222
873,139,8627601,8a,P06401,PR,Homo sapiens,"5-Bromo-2-(2,2-dimethyl-6-methylene-cyclohexylmethyl)-4-methoxy-phenol",COc1cc(CC2C(=C)CCCC2(C)C)c(O)cc1Br,CHEMBL48858,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 77nM,partial antagonist,55.00%,antagonist,,,,,,,,EC50,=,4020,nM,IC50,=,405,nM,=,7.113509275,pKi,B,radiometric,C=C1CCCC(C)(C)C1Cc1cc(OC)c(Br)cc1O,55,316.089,338.0881421,1,2,3,1,5.0883,29.46,CC1CCCCC1CC1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,730
891,1398,9464361,26,P06401,PR,Homo sapiens,"9-Chloro-5-(4-chloro-3-methyl-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(Cl)ccc4OC(c5ccc(Cl)c(C)c5)c3c12,CHEMBL94753,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.50nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,9.4,nM,,,,,=,9.301029996,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccc(Cl)cc1-3,,413.198,435.1156697,1,2,1,3,8.05802,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,agonist,partial agonist,61
892,1398,9667968,(+/-)-5,P06401,PR,Homo sapiens,"9-Chloro-5-(4-chloro-3-methyl-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(Cl)ccc4OC(c5ccc(Cl)c(C)c5)c3c12,CHEMBL94753,,,-,Ki = 0.50nM,partial agonist,73.00%,agonist,progesterone,,,,,,,EC50,=,9.4,nM,,,,,=,9.301029996,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccc(Cl)cc1-3,73,413.198,435.1156697,1,2,1,3,8.05802,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,61
894,1399,9464361,14,P06401,PR,Homo sapiens,"5-(4-Chloro-3-methyl-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(c5ccc(Cl)c(C)c5)c3c12,CHEMBL94749,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.49nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,2.7,nM,,,,,=,9.30980392,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccc(F)cc1-3,,396.743,419.1452203,1,2,1,3,7.54372,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,agonist,agonist,61
895,1399,9667968,(+/-)-3,P06401,PR,Homo sapiens,"5-(4-Chloro-3-methyl-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(c5ccc(Cl)c(C)c5)c3c12,CHEMBL94749,,,-,Ki = 0.48nM,agonist,95.00%,agonist,progesterone,,,,,,,EC50,=,3.6,nM,,,,,=,9.318758763,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccc(F)cc1-3,95,396.743,419.1452203,1,2,1,3,7.54372,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
905,140,8627601,27b,P06401,PR,Homo sapiens,"5-Bromo-2-((S)-2,2-dimethyl-6-methylene-cyclohexylmethyl)-4-methoxy-phenol",COc1cc(C[C@@H]2C(=C)CCCC2(C)C)c(O)cc1Br,CHEMBL51669,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 34nM,partial antagonist,45.00%,antagonist,,,,,,,,EC50,=,3264,nM,IC50,=,597,nM,=,7.468521083,pKi,B,radiometric,C=C1CCCC(C)(C)[C@@H]1Cc1cc(OC)c(Br)cc1O,45,316.089,338.0881421,1,2,3,1,5.0883,29.46,CC1CCCCC1CC1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,730
920,1406,9464360,15,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(c5ccc(Cl)cc5)c3c12,CHEMBL286595,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.7nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,14,nM,IC50,=,600,nM,=,9.15490196,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,,365.734,387.138992,1,2,1,3,7.0962,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",,"antagonist,agonist",agonist,61
921,1406,9464361,7,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(c5ccc(Cl)cc5)c3c12,CHEMBL286595,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.7nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,15,nM,,,,,=,9.15490196,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,,365.734,387.138992,1,2,1,3,7.0962,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,"antagonist,agonist",agonist,61
922,1406,10212133,1,P06401,PR,Homo sapiens,"5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(c5ccc(Cl)cc5)c3c12,CHEMBL286595,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.70nM,agonist,77.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14,nM,,,,,=,9.15490196,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,77,365.734,387.138992,1,2,1,3,7.0962,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,"antagonist,agonist",agonist,61
943,1418,9464361,22,P06401,PR,Homo sapiens,"9-Chloro-5-(3-chloro-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(Cl)ccc4OC(c5cccc(Cl)c5)c3c12,CHEMBL104183,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.48nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,3.6,nM,,,,,=,9.318758763,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccc(Cl)cc1-3,,401.187,421.1000197,1,2,1,3,7.7496,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,agonist,agonist,61
944,1418,9667968,(+/-)-4,P06401,PR,Homo sapiens,"5-(3-Chloro-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(Cl)ccc4OC(c5cccc(Cl)c5)c3c12,CHEMBL104183,,,-,Ki = 0.49nM,agonist,97.00%,agonist,progesterone,,,,,,,EC50,=,2.7,nM,,,,,=,9.30980392,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccc(Cl)cc1-3,97,401.187,421.1000197,1,2,1,3,7.7496,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
946,1419,9464361,13,P06401,PR,Homo sapiens,"5-(3-Chloro-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(c5cccc(Cl)c5)c3c12,CHEMBL416411,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.32nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,2.8,nM,,,,,=,9.494850022,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccc(F)cc1-3,,384.732,405.1295702,1,2,1,3,7.2353,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,agonist,agonist,61
947,1419,9667968,(+/-)-2,P06401,PR,Homo sapiens,"5-(3-Chloro-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(c5cccc(Cl)c5)c3c12,CHEMBL416411,,,-,Ki = 0.32nM,agonist,117.00%,agonist,progesterone,,,,,,,EC50,=,2.8,nM,,,,,=,9.494850022,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccc(F)cc1-3,117,384.732,405.1295702,1,2,1,3,7.2353,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
948,1419,10212133,4,P06401,PR,Homo sapiens,"5-(3-Chloro-phenyl)-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(c5cccc(Cl)c5)c3c12,CHEMBL416411,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.32nM,agonist,117.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.8,nM,,,,,=,9.494850022,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccc(F)cc1-3,117,384.732,405.1295702,1,2,1,3,7.2353,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
964,1425,9464360,13,P04150,PR,Homo sapiens,"2,2,4-Trimethyl-5-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(c5ccccc5)c3c12,CHEMBL101914,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.6nM,partial agonist,no detail about the percentage act,,,,,,,,,EC50,=,156,nM,IC50,=,290,nM,=,8.443697499,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccccc1)Oc1ccccc1-3,,330.281,353.1779644,1,2,1,3,6.4428,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",,"antagonist,agonist",partial agonist,61
965,1425,9784110,1,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(c5ccccc5)c3c12,CHEMBL101914,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.6nM,partial agonist,42.00%,agonist,progesterone,,progesterone,,,,,EC50,=,156,nM,IC50,=,290,nM,=,8.443697499,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccccc1)Oc1ccccc1-3,42,330.281,353.1779644,1,2,1,3,6.4428,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,61
967,1426,12781198,11n,P06401,PR,Homo sapiens,"7,9-Dibromo-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(Br)cc(Br)cc34)c12,CHEMBL66198,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,antagonist,86.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,1871,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(Br)cc(Br)cc1-3,86,418.023,432.9676884,1,2,0,2,6.3784,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
968,1427,12781198,11r,P06401,PR,Homo sapiens,"9-Chloro-2,2,4,7-tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(C)cc(Cl)cc34)c12,CHEMBL62798,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 205nM,antagonist,95.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,178,nM,=,6.688246139,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(C)cc(Cl)cc1-3,95,305.679,325.1233419,1,2,0,2,5.81522,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
969,1427,16821785,64,P06401,PR,Homo sapiens,"9-chloro-2,2,4,7-tetramethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(C)cc(Cl)cc34)c12,CHEMBL62798,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.69,,,,progesterone,,,,,,,,,,,,,,,=,6.69,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(C)cc(Cl)cc1-3,,305.679,325.1233419,1,2,0,2,5.81522,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
970,1428,12781198,11f,P06401,PR,Homo sapiens,"7-Chloro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(Cl)cccc34)c12,CHEMBL62714,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 273nM,antagonist,85.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,576,nM,=,6.563837353,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(Cl)cccc1-3,85,293.668,311.1076919,1,2,0,2,5.5068,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
971,1428,16821785,55,P06401,PR,Homo sapiens,"7-chloro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(Cl)cccc34)c12,CHEMBL62714,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.56,,,,progesterone,,,,,,,,,,,,,,,=,6.56,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(Cl)cccc1-3,,293.668,311.1076919,1,2,0,2,5.5068,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
972,1429,12781198,11p,P06401,PR,Homo sapiens,"9-Bromo-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(Br)cc34)c12,CHEMBL62761,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12.4nM,antagonist,76.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,57,nM,=,7.906578315,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Br)cc1-3,76,357.117,373.0477545,1,2,0,2,5.755,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
973,1429,16821785,62,P06401,PR,Homo sapiens,"9-bromo-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(Br)cc34)c12,CHEMBL62761,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.91,,,,progesterone,,,,,,,,,,,,,,,=,7.91,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Br)cc1-3,,357.117,373.0477545,1,2,0,2,5.755,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
975,143,8627601,34b,P06401,PR,Homo sapiens,"5-Bromo-4-methoxy-2-((1S,2R)-2-methyl-6-methylene-cyclohexylmethyl)-phenol",COc1cc(C[C@H]2[C@H](C)CCCC2=C)c(O)cc1Br,CHEMBL51788,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 69nM,partial antagonist,62.00%,antagonist,,,,,,,,EC50,=,3011,nM,IC50,=,320,nM,=,7.161150909,pKi,B,radiometric,C=C1CCC[C@@H](C)[C@@H]1Cc1cc(OC)c(Br)cc1O,62,304.078,324.072492,1,2,3,1,4.6982,29.46,CC1CCCCC1CC1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,730
977,1430,12781198,11q,P06401,PR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene-9-carbonitrile",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(cc34)C#N)c12,CHEMBL62227,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.5nM,partial antagonist,74.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,16.7,nM,=,8.346787486,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(C#N)cc1-3,74,303.231,320.1324914,1,3,0,2,4.86418,45.05,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
978,1430,16821785,63,P06401,PR,Homo sapiens,"7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline-9-carbonitrile",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(cc34)C#N)c12,CHEMBL62227,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.35,,,,progesterone,,,,,,,,,,,,,,,=,8.35,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(C#N)cc1-3,,303.231,320.1324914,1,3,0,2,4.86418,45.05,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
979,1431,12781198,11o,P06401,PR,Homo sapiens,"9-Chloro-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(Cl)cc34)c12,CHEMBL65743,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.6nM,partial antagonist,74.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,13.5,nM,=,8.251811973,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Cl)cc1-3,74,312.666,329.0982701,1,2,0,2,5.6459,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
980,1431,16821785,61,P06401,PR,Homo sapiens,"9-chloro-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(Cl)cc34)c12,CHEMBL65743,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.25,,,,progesterone,,,,,,,,,,,,,,,=,8.25,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Cl)cc1-3,,312.666,329.0982701,1,2,0,2,5.6459,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
981,1432,12781198,11m,P06401,PR,Homo sapiens,"7,9-Difluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(F)cc34)c12,CHEMBL418684,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.5nM,antagonist,83.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,25.4,nM,=,7.869666232,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,83,296.211,313.1278206,1,2,0,2,5.1316,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
982,1432,16821785,60,P06401,PR,Homo sapiens,"7,9-difluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cc(F)cc34)c12,CHEMBL418684,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.87,,,,progesterone,,,,,,,,,,,,,,,=,7.87,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,,296.211,313.1278206,1,2,0,2,5.1316,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
983,1433,12781198,11e,P06401,PR,Homo sapiens,"7-Fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cccc34)c12,CHEMBL63610,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 248nM,antagonist,90.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,118,nM,=,6.605548319,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cccc1-3,90,277.213,295.1372424,1,2,0,2,4.9925,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
984,1433,16821785,54,P06401,PR,Homo sapiens,"7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)cccc34)c12,CHEMBL63610,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.61,,,,progesterone,,,,,,,,,,,,,,,=,6.61,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cccc1-3,,277.213,295.1372424,1,2,0,2,4.9925,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
985,1434,12781198,11t,P06401,PR,Homo sapiens,"9-Bromo-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene-8-carbaldehyde",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)c(C=O)c(Br)cc34)c12,CHEMBL66650,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 290nM,partial antagonist,59.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,576,nM,=,6.537602002,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c-3cc(Br)c(C=O)c1F,59,385.127,401.0426691,1,3,1,2,5.5675,38.33,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
986,1434,16821785,66,P06401,PR,Homo sapiens,"9-bromo-7-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline-8-carbaldehyde",CC1=CC(C)(C)Nc2ccc3c(COc4c(F)c(C=O)c(Br)cc34)c12,CHEMBL66650,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.54,,,,progesterone,,,,,,,,,,,,,,,=,6.54,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c-3cc(Br)c(C=O)c1F,,385.127,401.0426691,1,3,1,2,5.5675,38.33,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
988,1436,12781198,11i,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-9-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(cc34)c5ccccc5)c12,CHEMBL65307,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,antagonist,92.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,2030,nM,>,6,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(-c2ccccc2)cc1-3,92,330.281,353.1779644,1,2,1,3,6.5204,21.26,C1CCC(C2CCC3CCC4C5CCCCC5CCC4C3C2)CC1,antagonist,antagonist,antagonist,antagonist,100
989,1437,12781198,11d,P06401,PR,Homo sapiens,"9-Bromo-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(Br)cc34)c12,CHEMBL63870,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15.0nM,partial antagonist,72.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,45,nM,=,7.823908741,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Br)cc1-3,72,338.119,355.0571763,1,2,0,2,5.6159,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
990,1437,16821785,53,P06401,PR,Homo sapiens,"9-bromo-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(Br)cc34)c12,CHEMBL63870,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.82,,,,progesterone,,,,,,,,,,,,,,,=,7.82,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Br)cc1-3,,338.119,355.0571763,1,2,0,2,5.6159,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
991,1438,9873735,19,P06401,PR,Homo sapiens,"2,2,4,9-Tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(C)cc34)c12,CHEMBL294116,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 50.2nM,partial antagonist,72.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,75,nM,=,7.299296283,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(C)cc1-3,72,270.226,291.1623143,1,2,0,2,5.16182,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
992,1438,12781198,11g,P06401,PR,Homo sapiens,"2,2,4,9-Tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(C)cc34)c12,CHEMBL294116,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 45nM,partial antagonist,72.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,76,nM,=,7.346787486,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(C)cc1-3,72,270.226,291.1623143,1,2,0,2,5.16182,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
993,1438,16821785,56,P06401,PR,Homo sapiens,"2,2,4,9-tetramethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(C)cc34)c12,CHEMBL294116,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.35,,,,progesterone,,,,,,,,,,,,,,,=,7.35,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(C)cc1-3,,270.226,291.1623143,1,2,0,2,5.16182,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
994,1439,9873735,16,P06401,PR,Homo sapiens,"9-Chloro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(Cl)cc34)c12,CHEMBL64123,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.6nM,agonist,105.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2194,nM,IC50,=,45,nM,=,8.443697499,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Cl)cc1-3,105,293.668,311.1076919,1,2,0,2,5.5068,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",agonist,"antagonist,agonist","agonist,partial antagonist",16
995,1439,12781198,11c,P06401,PR,Homo sapiens,"9-Chloro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(Cl)cc34)c12,CHEMBL64123,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12.9nM,partial antagonist,56.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,35.7,nM,=,7.88941029,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Cl)cc1-3,56,293.668,311.1076919,1,2,0,2,5.5068,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,"antagonist,agonist","agonist,partial antagonist",16
996,1439,16821785,52,P06401,PR,Homo sapiens,"9-chloro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(Cl)cc34)c12,CHEMBL64123,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.89,,,,progesterone,,,,,,,,,,,,,,,=,7.89,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Cl)cc1-3,,293.668,311.1076919,1,2,0,2,5.5068,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,"antagonist,agonist","agonist,partial antagonist",16
1000,1440,9873735,13,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(F)cc34)c12,CHEMBL65079,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.1nM,agonist,111.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2112,nM,IC50,=,26,nM,=,8.214670165,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(F)cc1-3,111,277.213,295.1372424,1,2,0,2,4.9925,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",agonist,"antagonist,agonist","agonist,partial antagonist",16
1001,1440,12781198,11b,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(F)cc34)c12,CHEMBL65079,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 19.3nM,partial antagonist,67.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,30.3,nM,=,7.714442691,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(F)cc1-3,67,277.213,295.1372424,1,2,0,2,4.9925,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,"antagonist,agonist","agonist,partial antagonist",16
1002,1440,16821785,51,P06401,PR,Homo sapiens,"9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(F)cc34)c12,CHEMBL65079,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.71,,,,progesterone,,,,,,,,,,,,,,,=,7.71,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(F)cc1-3,,277.213,295.1372424,1,2,0,2,4.9925,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,"antagonist,agonist","agonist,partial antagonist",16
1003,1441,12781198,11j,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-9-nitro-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(cc34)[N+](=O)[O-])c12,CHEMBL64294,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.8nM,partial antagonist,71.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,28.6,nM,=,8.167491087,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,71,304.22,322.1317424,1,4,1,2,4.7616,64.4,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
1004,1441,16821785,58,P06401,PR,Homo sapiens,"2,2,4-trimethyl-9-nitro-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccc(cc34)[N+](=O)[O-])c12,CHEMBL64294,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.17,,,,progesterone,,,,,,,,,,,,,,,=,8.17,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,,304.22,322.1317424,1,4,1,2,4.7616,64.4,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
1005,1442,9873735,6,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccccc34)c12,CHEMBL67362,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 84nM,antagonist,85.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,3081,nM,IC50,=,71,nM,=,7.075720714,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccccc1-3,85,258.215,277.1466642,1,2,0,2,4.8534,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,16
1006,1442,12781198,11a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c(COc4ccccc34)c12,CHEMBL67362,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 84nM,antagonist,85.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,111,nM,=,7.075720714,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccccc1-3,85,258.215,277.1466642,1,2,0,2,4.8534,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,"antagonist,agonist",antagonist,16
1007,1442,16821785,50,P06401,PR,Homo sapiens,"2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(COc4ccccc34)c12,CHEMBL67362,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.08,,,,progesterone,,,,,,,,,,,,,,,=,7.08,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccccc1-3,,258.215,277.1466642,1,2,0,2,4.8534,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,"antagonist,agonist",antagonist,16
1008,1443,9873612,9h,P06401,PR,Homo sapiens,"10-Fluoro-1,3,3-trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4c(F)cccc34)c12,CHEMBL91927,,cotransfection,-,Ki = 15.5nM,partial antagonist,71.00%,antagonist,,,,,,,,,,,,IC50,=,496,nM,=,7.809668302,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1c(F)cccc1-3,71,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,9
1009,1443,16821785,20,P06401,PR,Homo sapiens,"10-fluoro-1,3,3-trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4c(F)cccc34)c12,CHEMBL91927,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.81,,,,progesterone,,,,,,,,,,,,,,,=,7.81,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1c(F)cccc1-3,,261.214,279.1423278,1,1,0,2,5.0043,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,partial antagonist,9
1010,1444,9873612,9e,P06401,PR,Homo sapiens,"9-Bromo-1,3,3-trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(Br)ccc34)c12,CHEMBL446160,,cotransfection,-,Ki = 200nM,partial antagonist,43.00%,antagonist,,,,,,,,,,,,IC50,=,2330,nM,=,6.698970004,pKi,,other,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc(Br)ccc1-3,43,322.12,339.0622617,1,1,0,2,5.6277,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,9
1011,1444,16821785,19,P06401,PR,Homo sapiens,"9-bromo-1,3,3-trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(Br)ccc34)c12,CHEMBL446160,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.74,,,,progesterone,,,,,,,,,,,,,,,=,6.74,pKi,,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc(Br)ccc1-3,,322.12,339.0622617,1,1,0,2,5.6277,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,partial antagonist,9
1012,1445,9873612,9k,P06401,PR,Homo sapiens,"8-Fluoro-1,3,3-trimethyl-9-nitro-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(c(F)cc34)[N+](=O)[O-])c12,CHEMBL328804,,cotransfection,-,Ki = 97nM,partial antagonist,68.00%,antagonist,,,,,,,,,,,,IC50,=,3331,nM,=,7.013228266,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc([N+](=O)[O-])c(F)cc1-3,68,307.219,324.127406,1,3,1,2,4.9125,55.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,9
1013,1445,16821785,21,P06401,PR,Homo sapiens,"8-fluoro-1,3,3-trimethyl-9-nitro-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(c(F)cc34)[N+](=O)[O-])c12,CHEMBL328804,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.01,,,,progesterone,,,,,,,,,,,,,,,=,7.01,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc([N+](=O)[O-])c(F)cc1-3,,307.219,324.127406,1,3,1,2,4.9125,55.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,partial antagonist,9
1014,1446,9873612,9d,P06401,PR,Homo sapiens,"1,3,3-Trimethyl-9-nitro-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(ccc34)[N+](=O)[O-])c12,CHEMBL330235,,cotransfection,-,Ki = 57nM,antagonist,81.00%,antagonist,,,,,,,,,,,,IC50,=,1674,nM,=,7.244125144,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc([N+](=O)[O-])ccc1-3,81,288.221,306.1368278,1,3,1,2,4.7734,55.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
1015,1446,16821785,18,P06401,PR,Homo sapiens,"1,3,3-trimethyl-9-nitro-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4cc(ccc34)[N+](=O)[O-])c12,CHEMBL330235,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.24,,,,progesterone,,,,,,,,,,,,,,,=,7.24,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1cc([N+](=O)[O-])ccc1-3,,288.221,306.1368278,1,3,1,2,4.7734,55.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,antagonist,9
1016,1447,9873612,9a,P06401,PR,Homo sapiens,"1,3,3-Trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4ccccc34)c12,CHEMBL92730,,cotransfection,-,Ki = 13nM,antagonist,85.00%,antagonist,,,,,,,,,,,,IC50,=,549,nM,=,7.886056648,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1ccccc1-3,85,242.216,261.1517496,1,1,0,2,4.8652,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
1017,1447,16821785,17,P06401,PR,Homo sapiens,"1,3,3-trimethyl-4,11-dihydro-3H-indeno[2,1-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(Cc4ccccc34)c12,CHEMBL92730,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.89,,,,progesterone,,,,,,,,,,,,,,,=,7.89,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(c21)Cc1ccccc1-3,,242.216,261.1517496,1,1,0,2,4.8652,12.03,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,antagonist,9
1019,1449,18553958,"5a, rac, syn",P06401,PR,Homo sapiens,"rac, syn-5-(cyclohex-2-en-1-yl)-7,9-difluoro-2,2,4-trimethyl 2,5-dihydro-(1H)6-oxa-1-azachrysen",CC1=CC(C)(C)Nc2ccc3c4cc(F)cc(F)c4O[C@@H]([C@H]5CCCC=C5)c3c12,CHEMBL510305,-,,-,Ki = 4.8nM,agonist,171.00%,agonist,progesterone,,,,,,,EC50,=,3.4,nM,,,,,=,8.318758763,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)[C@H]([C@@H]1C=CCCC1)Oc1c(F)cc(F)cc1-3,171,368.277,393.1904209,1,2,1,2,7.029,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
1022,1450,18553958,(-)-6,P06401,PR,Homo sapiens,"(-)-7,9-difluoro-5-(6-methyl-7-oxa-bicyclo[4.1.0]hept-2-yl)-2,2,4-trimethyl 2,5-dihydro-(1H)-6-oxa-1-aza-chrysen",CC1=CC(C)(C)Nc2ccc3c4cc(F)cc(F)c4O[C@@H]([C@H]5CCC[C@@]6(C)O[C@@H]56)c3c12,CHEMBL507701,-,,-,Ki = 1.2nM,agonist,177.00%,agonist,progesterone,,,,,,,EC50,=,0.4,nM,,,,,=,8.920818754,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(c21)[C@H]([C@H]1CCC[C@@]2(C)O[C@@H]12)Oc1c(F)cc(F)cc1-3,177,396.287,423.2009855,1,3,1,2,6.6303,33.79,C1CCC2C(C1)CC(C1CCCC3CC31)C1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,19
1023,1451,9873612,10a,P06401,PR,Homo sapiens,"1,3,3-Trimethyl-3,4-dihydro-benzo[4,5]furo[2,3-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(oc4ccccc34)c12,CHEMBL327551,,cotransfection,-,Ki = 77nM,antagonist,88.00%,antagonist,,,,,,,,,,,,IC50,=,1144,nM,=,7.113509275,pKi,B,other,CC1=CC(C)(C)Nc2ccc3c(oc4ccccc43)c21,88,246.204,263.1310142,1,2,0,3,5.1934,25.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
1024,1451,16821785,23,P06401,PR,Homo sapiens,"1,3,3-trimethyl-3,4-dihydrobenzofuro[2,3-f]quinoline",CC1=CC(C)(C)Nc2ccc3c(oc4ccccc34)c12,CHEMBL327551,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.11,,,,progesterone,,,,,,,,,,,,,,,=,7.11,pKi,B,radiometric,CC1=CC(C)(C)Nc2ccc3c(oc4ccccc43)c21,,246.204,263.1310142,1,2,0,3,5.1934,25.17,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,antagonist,9
1025,1452,17890084,15,P03372,ERA,Homo sapiens,"(8R,9S,10R,13S,14S,17S)-3,10,13-trimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,CHEMBL250110,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 110nM,partial agonist,49.00%,agonist,E2,,E2,,,,,EC50,=,540,nM,,,,,=,6.958607315,pIC50,,radiometric,CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,49,256.219,286.2296656,1,1,0,0,4.8663,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
1027,1452,17890084,15,Q92731,ERB,Homo sapiens,"(8R,9S,10R,13S,14S,17S)-3,10,13-trimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,CHEMBL250110,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.4nM,partial agonist,59.00%,agonist,E2,,E2,,,,,EC50,=,220,nM,,,,,=,8.026872146,pIC50,B,radiometric,CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1,59,256.219,286.2296656,1,1,0,0,4.8663,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
1032,1456,18553958,(-)-5c,P06401,PR,Homo sapiens,"(-)-(S)-7,9-difluoro-2,2,4-trimethyl-5-((S)-3-methylcyclohex-2-enyl)-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=C[C@H](CCC1)[C@@H]2Oc3c(F)cc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL453579,-,,-,Ki = 4.4nM,agonist,145.00%,agonist,progesterone,,,,,,,EC50,=,0.5,nM,,,,,=,8.356547324,pKi,B,other,CC1=C[C@@H]([C@@H]2Oc3c(F)cc(F)cc3-c3ccc4c(c32)C(C)=CC(C)(C)N4)CCC1,145,380.288,407.2060709,1,2,1,2,7.4191,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
1033,1456,18553958,"5b, rac, syn",P06401,PR,Homo sapiens,"rac, syn-7,9-difluoro-5-(3-methylcyclohex-2-en-1-yl)-2,2,4-trimethyl 2,5-dihydro-(1H)6-oxa-1-aza-chrysen",CC1=C[C@H](CCC1)[C@@H]2Oc3c(F)cc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL453579,-,,-,Ki = 3.7nM,agonist,162.00%,agonist,progesterone,,,,,,,EC50,=,0.6,nM,,,,,=,8.431798276,pKi,B,other,CC1=C[C@@H]([C@@H]2Oc3c(F)cc(F)cc3-c3ccc4c(c32)C(C)=CC(C)(C)N4)CCC1,162,380.288,407.2060709,1,2,1,2,7.4191,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
1034,1456,18553958,(+)-5d,P06401,PR,Homo sapiens,"(+)-(S)-7,9-difluoro-2,2,4-trimethyl-5-((S)-3-methylcyclohex-2-enyl)-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=C[C@H](CCC1)[C@@H]2Oc3c(F)cc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL453579,-,,-,Ki > 1000nM,,11.00%,agonist,progesterone,,,,,,,EC50,=,50.8,nM,,,,,>,6,pKi,,other,CC1=C[C@@H]([C@@H]2Oc3c(F)cc(F)cc3-c3ccc4c(c32)C(C)=CC(C)(C)N4)CCC1,11,380.288,407.2060709,1,2,1,2,7.4191,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,,agonist,agonist,61
1036,1458,18553958,"4b, rac, anti",P06401,PR,Homo sapiens,"rac, anti-7,9-difluoro-5-(3-methylcyclohex-2-en-1-yl)-2,2,4-trimethyl 2,5-dihydro-(1H)6-oxa-1-aza-chrysen",CC1=C[C@@H](CCC1)[C@@H]2Oc3c(F)cc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL510373,-,,-,Ki = 14nM,agonist,100.00%,agonist,progesterone,,,,,,,EC50,=,5.4,nM,,,,,=,7.853871964,pKi,B,other,CC1=C[C@H]([C@@H]2Oc3c(F)cc(F)cc3-c3ccc4c(c32)C(C)=CC(C)(C)N4)CCC1,100,380.288,407.2060709,1,2,1,2,7.4191,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
1038,1459,10212133,28,P06401,PR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",CC1C(=O)C(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL34824,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,155.00%,agonist,progesterone,,progesterone,,,,,EC50,=,8.7,nM,,,,,=,8.455931956,pKi,B,radiometric,CC1C(=O)C(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,155,377.289,399.1634572,1,3,1,3,6.2599,38.33,CC1CCC2CCC3C4CCCCC4CC(CC4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,602
1043,1460,10212133,29,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-[1-phenyl-meth-(Z)-ylidene]-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",CC1C(=O)C(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5ccccc5)\c3c12,CHEMBL32603,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.9nM,agonist,133.00%,agonist,progesterone,,progesterone,,,,,EC50,=,17,nM,,,,,=,8.30980392,pKi,B,radiometric,CC1C(=O)C(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,133,358.291,381.172879,1,3,1,3,6.1208,38.33,CC1CCC2CCC3C4CCCCC4CC(CC4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,602
1057,1464,9873612,15a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-2,3,4,10-tetrahydro-1H-indeno[1,2-g]quinoline",CC1CC(C)(C)Nc2cc3Cc4ccccc4c3cc12,CHEMBL93894,,cotransfection,-,Ki = 87nM,partial antagonist,74.00%,antagonist,,,,,,,,,,,,IC50,=,424,nM,=,7.060480747,pKi,B,other,CC1CC(C)(C)Nc2cc3c(cc21)-c1ccccc1C3,74,242.216,263.1673997,1,1,0,2,4.9555,12.03,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,28
1060,1467,10212133,26,P06401,PR,Homo sapiens,"5-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1CC(C)(C)Nc2ccc3c4ccccc4O\C(=C/c5cccc(F)c5)\c3c12,CHEMBL34882,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.3nM,agonist,114.00%,agonist,progesterone,,progesterone,,,,,EC50,=,47,nM,,,,,=,8.200659451,pKi,B,radiometric,CC1CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,114,361.29,385.1841926,1,2,1,3,7.0809,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
1061,1468,12781198,12b,P06401,PR,Homo sapiens,"7,9-Difluoro-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1CC(C)(C)Nc2ccc3c(COc4c(F)cc(F)cc34)c12,CHEMBL63788,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 45nM,antagonist,89.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,40,nM,=,7.346787486,pKi,B,radiometric,CC1CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,89,296.211,315.1434707,1,2,0,2,5.2219,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
1062,1469,12781198,12c,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-7-nitro-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1CC(C)(C)Nc2ccc3c(COc4c3cc(F)cc4[N+](=O)[O-])c12,CHEMBL65380,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 370nM,antagonist,99.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,781,nM,=,6.431798276,pKi,,radiometric,CC1CC(C)(C)Nc2ccc3c(c21)COc1c-3cc(F)cc1[N+](=O)[O-],99,323.218,342.1379707,1,4,1,2,4.991,64.4,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
1063,147,21510635,4,P03372,ERA,Homo sapiens,"1-beta-Hydroxy-6,7R-dihydroxyeudesm-4(15)-ene",CC(C)[C@]1(O)CC[C@@]2(C)[C@H](O)CCC(=C)[C@@H]2[C@H]1O,CHEMBL1784261,,,Fluorescence polarization (FP) competition binding assay,IC50 = 2800000nM,partial agonist,67.30%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,=,2.552841969,pIC50,NB,FPA,C=C1CC[C@@H](O)[C@]2(C)CC[C@@](O)(C(C)C)[C@H](O)[C@@H]12,67.3,228.162,254.1881947,3,3,1,0,1.8616,60.69,CC1CCCC2CCCCC12,,partial agonist,,partial agonist,703
1064,1470,12781198,12a,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-9-nitro-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1CC(C)(C)Nc2ccc3c(COc4ccc(cc34)[N+](=O)[O-])c12,CHEMBL293409,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 144nM,antagonist,91.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,52,nM,=,6.841637508,pKi,,radiometric,CC1CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,91,304.22,324.1473925,1,4,1,2,4.8519,64.4,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
1065,1471,15925510,8,P06401,PR,Homo sapiens,"1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1H-pyrazole",CC1CC(=NN1S(=O)(=O)c2ccc(Cl)cc2)c3ccc(Cl)c(Cl)c3,CHEMBL190198,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 7.4 ,partial antagonist,72.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,6.7,,=,7.4,pKi,B,FPA,CC1CC(c2ccc(Cl)c(Cl)c2)=NN1S(=O)(=O)c1ccc(Cl)cc1,72,390.614,401.9763317,0,3,3,2,4.834,49.74,CC(C)(C1CCCCC1)C1CCC(C2CCCCC2)C1,antagonist,partial antagonist,antagonist,partial antagonist,1021
1069,1474,17887661,(+/-)4b,P10275,AR,Homo sapiens,rac-6-(2-methylpyrrolidin-1-yl)-4-trifluoromethyl-1H-quinolin-2-one,CC1CCCN1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL244895,Luciferase reporter gene assay,,,Ki = 72nM,partial agonist,39.00%,agonist,DHT,,,,,,,EC50,=,13,nM,,,,,=,7.142667504,pKi,B,other,CC1CCCN1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,39,281.172,296.1136478,1,2,1,2,3.5356,36.1,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,604
1074,1479,10340624,6b,P10275,AR,Homo sapiens,"6-Methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC1CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL283449,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9nM,partial agonist,48.00%,agonist,DHT,,DHT,,,,,EC50,=,15,nM,IC50,=,259,nM,=,8.045757491,pKi,B,radiometric,CC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,48,269.161,282.0979977,2,3,0,2,3.8783,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
1078,1480,10230628,18,P10275,AR,Homo sapiens,"5-Methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CC1CCNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL415289,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 1nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,2,nM,,,inactive,,=,9,pIC50,B,other,CC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,100,271.153,283.0820133,1,3,0,2,3.7309,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1080,1482,17439112,10g,P10275,AR,Homo sapiens,"(+/-)-1,2,3,6-tetrahydro-1,3-dimethyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1CN(C)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL268589,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 33nM,partial agonist,50.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,50,nM,IC50,=,21,nM,=,7.48148606,pKi,B,radiometric,CC1CN(C)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,50,285.16,298.0929123,1,3,0,2,2.764,45.33,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
1084,1483,17439112,(-)-10h,P10275,AR,Homo sapiens,"(-)-1,2,3,6-Tetrahydro-3-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1CN(CC(F)(F)F)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL227408,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 25nM,agonist,82.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,82,nM,IC50,>,10000,nM,=,7.602059991,pKi,B,radiometric,CC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,82,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,"agonist,antagonist","agonist,partial agonist",586
1085,1483,17439112,10h,P10275,AR,Homo sapiens,"(+/-)-1,2,3,6-Tetrahydro-3-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1CN(CC(F)(F)F)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL227408,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 15nM,agonist,104.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,104,nM,IC50,>,10000,nM,=,7.823908741,pKi,B,radiometric,CC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,104,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,"agonist,antagonist","agonist,partial agonist",586
1086,1483,17439112,(+)-10h,P10275,AR,Homo sapiens,"(+)-1,2,3,6-tetrahydro-3-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1CN(CC(F)(F)F)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL227408,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 75nM,partial agonist,35.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,35,nM,IC50,=,29,nM,=,7.124938737,pKi,B,radiometric,CC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,35,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"agonist,antagonist","agonist,partial agonist",586
1090,1486,17439112,15a,P10275,AR,Homo sapiens,"(+/-)-1,2,3,6-tetrahydro-2-methyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1COc2cc3NC(=O)C=C(c3cc2N1)C(F)(F)F,CHEMBL227033,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 113nM,agonist,80.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,80,nM,IC50,>,10000,nM,=,6.946921557,pKi,,radiometric,CC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1,80,273.149,284.0772623,2,3,0,2,2.7397,54.12,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1094,1487,17439112,16e,P10275,AR,Homo sapiens,"(+/-)-1,2,3,6-tetrahydro-2-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL227440,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.8nM,agonist,96.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,96,nM,IC50,>,10000,nM,=,8.107905397,pKi,B,radiometric,CC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,96,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1095,1488,17439112,16c,P10275,AR,Homo sapiens,"(+/-)-1-cyclopropylmethyl-1,2,3,6-tetrahydro-2-methyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC1COc2cc3NC(=O)C=C(c3cc2N1CC4CC4)C(F)(F)F,CHEMBL227394,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.0nM,partial agonist,65.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,65,nM,IC50,>,10000,nM,=,8.397940009,pKi,B,radiometric,CC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC1CC1,65,321.193,338.1242124,1,3,2,2,3.5442,45.33,CC1CCC2CC3C(CC4CC4)CCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,574
1119,150,12781197,6,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-methylene-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(=C)c3c12,CHEMBL64913,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.1nM,agonist,87.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,1000,nM,,,,,=,8.214670165,pKi,B,radiometric,C=C1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,87,289.224,307.1372424,1,2,0,2,5.4632,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
1120,150,16821785,67,P06401,PR,Homo sapiens,"9-fluoro-2,2,4-trimethyl-5-methylene-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CC1=CC(C)(C)Nc2ccc3c4cc(F)ccc4OC(=C)c3c12,CHEMBL64913,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.21,,,,progesterone,,,,,,,,,,,,,,,=,8.21,pKi,B,radiometric,C=C1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,,289.224,307.1372424,1,2,0,2,5.4632,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,agonist,agonist,515
1140,1509,10340624,6i,P10275,AR,Homo sapiens,"Trans-6,7-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@H]1CNc2cc3nc(O)cc(c3cc2C1C)C(F)(F)F,CHEMBL436344,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16nM,agonist,92.00%,agonist,DHT,,DHT,,,,,EC50,=,10,nM,,,,,=,7.795880017,pKi,B,radiometric,CC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,92,281.172,296.1136478,2,3,0,2,4.1243,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1144,1510,10340624,6j,P10275,AR,Homo sapiens,"Cis-6,7-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@@H]1CNc2cc3nc(O)cc(c3cc2C1C)C(F)(F)F,CHEMBL282204,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,partial agonist,62.00%,agonist,DHT,,DHT,,,,,EC50,=,22,nM,,,,,=,8.096910013,pKi,B,radiometric,CC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@H]1C,62,281.172,296.1136478,2,3,0,2,4.1243,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1155,1514,19464171,34,Q03181,PPARB,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((4-(trifluoromethyl)phenylamino)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(CNc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL503066,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 660nM,agonist,75.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,3100,nM,,,,,=,6.180456064,pKi,,radiometric,CCC#CCOc1cc(CNc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,75,539.405,569.1847641,2,5,10,3,7.6031,67.79,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1157,1515,19464171,36,P37231,PPARG,Homo sapiens,"2-(4-(4-(cyclopentyloxymethyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COC2CCCC2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL497204,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 76nM,agonist,92.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,500,nM,,,,,=,7.119186408,pKi,B,other,CCC#CCOc1cc(COC2CCCC2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,92,460.381,494.2126952,1,5,10,2,6.4314,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)C1,agonist,agonist,agonist,agonist,333
1158,1515,19464171,36,Q03181,PPARB,Homo sapiens,"2-(4-(4-(cyclopentyloxymethyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COC2CCCC2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL497204,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 150nM,agonist,95.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,900,nM,,,,,=,6.823908741,pKi,,radiometric,CCC#CCOc1cc(COC2CCCC2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,95,460.381,494.2126952,1,5,10,2,6.4314,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)C1,agonist,agonist,agonist,agonist,333
1160,1516,19464171,35,P37231,PPARG,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((tetrahydro-2H-pyran-4-yloxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COC2CCOCC2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL497203,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 200nM,agonist,96.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,1500,nM,,,,,=,6.698970004,pKi,,other,CCC#CCOc1cc(COC2CCOCC2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,96,476.38,510.2076098,1,6,10,2,5.6678,74.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1163,1517,19464171,37,P37231,PPARG,Homo sapiens,"2-(4-(4-((cyclopropylmethoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COCC2CC2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL496593,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 110nM,partial agonist,73.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,390,nM,,,,,=,6.958607315,pKi,,other,CCC#CCOc1cc(COCC2CC2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,73,448.37,480.1970451,1,5,11,2,5.8988,64.99,C(CC1CC1)CC1CCC(CC2CCCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,816
1164,1517,19464171,37,Q03181,PPARB,Homo sapiens,"2-(4-(4-((cyclopropylmethoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COCC2CC2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL496593,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 120nM,agonist,81.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1500,nM,,,,,=,6.920818754,pKi,,radiometric,CCC#CCOc1cc(COCC2CC2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,81,448.37,480.1970451,1,5,11,2,5.8988,64.99,C(CC1CC1)CC1CCC(CC2CCCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,816
1166,1518,19464171,21,P37231,PPARG,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL501440,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 33nM,partial agonist,34.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,160,nM,,,,,=,7.48148606,pKi,B,other,CCC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,34,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1167,1518,19464171,21,Q03181,PPARB,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL501440,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5nM,agonist,94.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,44,nM,,,,,=,8.301029996,pKi,B,radiometric,CCC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,94,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1169,1519,19464171,33,P37231,PPARG,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((5-(trifluoromethyl)pyridin-2-yloxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(cn2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL501982,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 84nM,partial agonist,65.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,490,nM,,,,,=,7.075720714,pKi,B,other,CCC#CCOc1cc(COc2ccc(C(F)(F)F)cn2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,65,543.393,571.1640287,1,6,10,3,6.965,77.88,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1170,1519,19464171,33,Q03181,PPARB,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((5-(trifluoromethyl)pyridin-2-yloxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(cn2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL501982,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 11nM,agonist,99.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1200,nM,,,,,=,7.958607315,pKi,B,radiometric,CCC#CCOc1cc(COc2ccc(C(F)(F)F)cn2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,99,543.393,571.1640287,1,6,10,3,6.965,77.88,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1175,1520,19464171,31,P37231,PPARG,Homo sapiens,"2-(4-(4-((4-chlorophenoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(Cl)cc2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL482857,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 39nM,partial agonist,37.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,560,nM,,,,,=,7.408935393,pKi,B,other,CCC#CCOc1cc(COc2ccc(Cl)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,37,507.845,536.1424227,1,5,10,3,7.2046,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1176,1520,19464171,31,Q03181,PPARB,Homo sapiens,"2-(4-(4-((4-chlorophenoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(Cl)cc2)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL482857,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 36nM,agonist,87.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,350,nM,,,,,=,7.443697499,pKi,B,radiometric,CCC#CCOc1cc(COc2ccc(Cl)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,87,507.845,536.1424227,1,5,10,3,7.2046,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1178,1521,19464171,32,P37231,PPARG,Homo sapiens,"2-(4-(4-((4-chloro-2-methylphenoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(Cl)cc2C)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL482659,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 150nM,partial agonist,38.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,610,nM,,,,,=,6.823908741,pKi,,other,CCC#CCOc1cc(COc2ccc(Cl)cc2C)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,38,519.856,550.1580728,1,5,10,3,7.51302,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1179,1521,19464171,32,Q03181,PPARB,Homo sapiens,"2-(4-(4-((4-chloro-2-methylphenoxy)methyl)-2-(pent-2-ynyloxy)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccc(Cl)cc2C)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL482659,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 28nM,partial agonist,70.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,370,nM,,,,,=,7.552841969,pKi,B,radiometric,CCC#CCOc1cc(COc2ccc(Cl)cc2C)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,70,519.856,550.1580728,1,5,10,3,7.51302,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1181,1522,19464171,29,P37231,PPARG,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((3-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2cccc(c2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL499038,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 30nM,partial agonist,26.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,300,nM,,,,,=,7.522878745,pKi,B,other,CCC#CCOc1cc(COc2cccc(C(F)(F)F)c2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,26,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1182,1522,19464171,29,Q03181,PPARB,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((3-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2cccc(c2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL499038,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 35nM,agonist,83.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,420,nM,,,,,=,7.455931956,pKi,B,radiometric,CCC#CCOc1cc(COc2cccc(C(F)(F)F)c2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,83,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1184,1523,19464171,30,P37231,PPARG,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((2-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccccc2C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL486892,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 170nM,partial agonist,64.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,4500,nM,,,,,=,6.769551079,pKi,,other,CCC#CCOc1cc(COc2ccccc2C(F)(F)F)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,64,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
1185,1523,19464171,30,Q03181,PPARB,Homo sapiens,"2-(4-(2-(pent-2-ynyloxy)-4-((2-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CCC#CCOc1cc(COc2ccccc2C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL486892,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 120nM,agonist,88.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1100,nM,,,,,=,6.920818754,pKi,,radiometric,CCC#CCOc1cc(COc2ccccc2C(F)(F)F)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,88,541.397,570.1687797,1,5,10,3,7.57,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
1189,1525,19926282,37,P06401,PR,Homo sapiens,"(S)-2-chloro-4-((2,5-dichlorobenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile",CCC(=O)N1CC[C@@H](C1)N(Cc2cc(Cl)ccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL589625,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,agonist,81.00%,agonist,progesterone,,,,,,,EC50,=,163,nM,,,,,=,7.602059991,pIC50,B,other,CCC(=O)N1CC[C@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)C1,81,416.61,435.0671953,0,3,5,2,5.53598,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
1190,1526,19926282,36,P06401,PR,Homo sapiens,(S)-2-chloro-4-((5-fluoro-2-methylbenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile,CCC(=O)N1CC[C@@H](C1)N(Cc2cc(F)ccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL590100,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,69.00%,agonist,progesterone,,,,,,,EC50,=,75,nM,,,,,=,7.602059991,pIC50,B,other,CCC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,69,376.713,399.1513683,0,3,5,2,4.6767,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
1191,1527,19926282,34,P06401,PR,Homo sapiens,(S)-4-((2-bromobenzyl)(1-propionylpyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CCC(=O)N1CC[C@@H](C1)N(Cc2ccccc2Br)c3ccc(C#N)c(Cl)c3,CHEMBL607030,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 8nM,agonist,95.00%,agonist,progesterone,,,,,,,EC50,=,0.4,nM,,,,,=,8.096910013,pIC50,B,other,CCC(=O)N1CC[C@H](N(Cc2ccccc2Br)c2ccc(C#N)c(Cl)c2)C1,95,425.608,445.0556521,0,3,5,2,4.99168,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
1192,1528,19926282,31,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-propionylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CCC(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL600465,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,69.00%,agonist,progesterone,,,,,,,EC50,=,24,nM,,,,,=,7.602059991,pIC50,B,other,CCC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,69,414.709,435.1325246,0,3,5,2,5.24798,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
1193,1529,19926282,35,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-methylbenzyl)(1-propionylpyrrolidin-3-yl)amino)benzonitrile,CCC(=O)N1CC[C@@H](C1)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL592532,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 16nM,partial agonist,66.00%,agonist,progesterone,,,,,,,EC50,=,2.1,nM,,,,,=,7.795880017,pIC50,B,other,CCC(=O)N1CC[C@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)C1,66,357.715,381.1607901,0,3,5,2,4.5376,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
1195,1530,20584610,19,P10275,AR,Homo sapiens,"4-[(1R,2R,6S,7S)-3,5-dioxo-9-propionyl-11-oxa-4,9-diazatricyclo[5.3.1.02,6]undec-4-yl]-2-(trifluoromethyl)benzonitrile",CCC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1209904,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 84nM,antagonist,95.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,129,nM,=,7.075720714,pKi,B,radiometric,CCC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,95,415.242,435.1405908,0,5,2,1,2.48248,90.71,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
1214,1540,20079636,10,P37231,PPARG,Homo sapiens,"4'-((2,3-dimethyl-5-(2-phenylbutanamido)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid",CCC(C(=O)Nc1ccc2c(c1)c(C)c(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c5ccccc5,CHEMBL601861,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 574nM,partial agonist,37.00%,agonist,rosiglitazone,,,,,,,EC50,=,338,nM,,,,,=,6.241088108,pIC50,,radiometric,CCC(C(=O)Nc1ccc2c(c1)c(C)c(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,37,484.385,516.2412929,2,3,8,5,7.80394,71.33,CC(CC1CCCCC1)CC1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1041
1216,1540,20079636,10,Q07869,PPARA,Homo sapiens,"4'-((2,3-dimethyl-5-(2-phenylbutanamido)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid",CCC(C(=O)Nc1ccc2c(c1)c(C)c(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c5ccccc5,CHEMBL601861,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial agonist,45.00%,agonist,GW735,,,,,,,EC50,=,6140,nM,,,,,>,5,pIC50,NB,radiometric,CCC(C(=O)Nc1ccc2c(c1)c(C)c(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,45,484.385,516.2412929,2,3,8,5,7.80394,71.33,CC(CC1CCCCC1)CC1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1041
1221,1543,17257838,9g,P10275,AR,Homo sapiens,"7-(tert-pentylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCC(C)(C)Nc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706883,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 110nM,antagonist,93.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,209,nM,=,6.958607315,pIC50,,radiometric,CCC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,93,281.172,298.1292978,2,2,3,2,4.1474,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
1225,1544,14592510,24,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-[2-(2,2-Difluoro-ethoxy)-3,5-bis-(1,1-dimethyl-propyl)-phenyl]-6-fluoro-3-methyl-octa-2,4,6-trienoic acid",CCC(C)(C)c1cc(\C(=C(\F)/C=C/C(=C/C(=O)O)/C)\C)c(OCC(F)F)c(c1)C(C)(C)CC,CHEMBL130231,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 28.7nM,antagonist,90.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,13.7,nM,=,7.542118103,pKi,B,radiometric,CCC(C)(C)c1cc(/C(C)=C(F)\C=C\C(C)=C\C(=O)O)c(OCC(F)F)c(C(C)(C)CC)c1,90,429.288,466.2694797,1,2,11,1,7.9933,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
1229,1545,12801232,13a,P19793,RXRA,Homo sapiens,"7-[3,5-Bis-(1,1-dimethyl-propyl)-2-methoxy-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CCC(C)(C)c1cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c(OC)c(c1)C(C)(C)CC,CHEMBL91185,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 2nM,partial agonist,35.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,506,nM,,,,,=,8.698970004,pKi,B,radiometric,CCC(C)(C)c1cc(/C(C)=C\C=C\C(C)=C\C(=O)O)c(OC)c(C(C)(C)CC)c1,35,360.283,398.2820951,1,2,9,1,7.0608,46.53,C1CCCCC1,agonist,partial agonist,agonist,partial agonist,205
1231,1546,12801232,13c,P19793,RXRA,Homo sapiens,"7-[2-(2,2-Difluoro-ethoxy)-3,5-bis-(1,1-dimethyl-propyl)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CCC(C)(C)c1cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c(OCC(F)F)c(c1)C(C)(C)CC,CHEMBL313647,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 29nM,antagonist,90.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,16,nM,=,7.537602002,pKi,B,radiometric,CCC(C)(C)c1cc(/C(C)=C\C=C\C(C)=C\C(=O)O)c(OCC(F)F)c(C(C)(C)CC)c1,90,410.29,448.2789015,1,2,11,1,7.6961,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
1244,1553,17267219,(+/-)-6l,P10275,AR,Homo sapiens,"(+/-)-6-(sec-butyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CCC(C)N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL393865,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 29nM,agonist,86.00%,agonist,DHT,,,,,,,EC50,=,5.9,nM,IC50,>,10000,nM,=,7.537602002,pIC50,B,radiometric,CCC(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,86,350.177,366.1166825,1,2,4,2,4.7141,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
1273,1571,16821781,52,P04150,GR,Homo sapiens,"2-{[1-(1-ethylpropyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-methyl}-3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)propanamide",CCC(CC)C1(CC(O)(C(=O)Nc2ccc3C(=O)ON=C(C)c3c2)C(F)(F)F)CCCc4ccccc14,CHEMBL211441,,,,PIC50 = 8.28,partial agonist,no detail about the percentage act,,,,,,,,,PEC50,=,8.2,,PIC50,=,7.18,,=,8.28,pIC50,B,other,CCC(CC)C1(CC(O)(C(=O)Nc2ccc3c(=O)onc(C)c3c2)C(F)(F)F)CCCc2ccccc21,,485.312,516.2235921,2,5,7,3,5.82892,92.43,CC(CCC1CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",,"antagonist,agonist",partial agonist,1123
1274,1571,18038970,8,P04150,GR,Homo sapiens,"3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-2-((1-(pentan-3-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propanamide",CCC(CC)C1(CC(O)(C(=O)Nc2ccc3C(=O)ON=C(C)c3c2)C(F)(F)F)CCCc4ccccc14,CHEMBL211441,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.28,partial agonist,47.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.2,,PIC50,=,7.18,,=,8.28,pIC50,B,FPA,CCC(CC)C1(CC(O)(C(=O)Nc2ccc3c(=O)onc(C)c3c2)C(F)(F)F)CCCc2ccccc21,47,485.312,516.2235921,2,5,7,3,5.82892,92.43,CC(CCC1CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1123
1288,1577,24239189,18,P04150,GR,Homo sapiens,"N-(1-(4-hydroxy-3,5-dimethylphenyl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CCC(Cc1cc(C)c(O)c(C)c1)NS(=O)(=O)c2c(C)cc(C)cc2C,CHEMBL3094484,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 12nM,partial agonist,58.00%,agonist,dexamethasone,,,,,,,IC50,=,89,nM,,,,,=,7.920818754,pIC50,B,FPA,CCC(Cc1cc(C)c(O)c(C)c1)NS(=O)(=O)c1c(C)cc(C)cc1C,58,346.302,375.1868148,2,3,6,2,4.2339,66.4,CC(C)(CCCC1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1256
1294,1579,24239189,10,P04150,GR,Homo sapiens,"N-(1-(3,5-dimethylphenyl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CCC(Cc1cc(C)cc(C)c1)NS(=O)(=O)c2c(C)cc(C)cc2C,CHEMBL3094476,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,partial agonist,36.00%,agonist,dexamethasone,,,,,,,IC50,>,10000,nM,,,,,=,7.958607315,pIC50,B,FPA,CCC(Cc1cc(C)cc(C)c1)NS(=O)(=O)c1c(C)cc(C)cc1C,36,330.303,359.1919002,1,2,6,2,4.5283,46.17,CC(C)(CCCC1CCCCC1)C1CCCCC1,,partial agonist,,partial agonist,1256
1313,1585,24239189,16,P04150,GR,Homo sapiens,"rac-N-(1-(4-hydroxy-2,3-dimethylphenyl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CCC(Cc1ccc(O)c(C)c1C)NS(=O)(=O)c2c(C)cc(C)cc2C,CHEMBL3094482,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,81.00%,agonist,dexamethasone,,,,,,,IC50,=,15,nM,,,,,=,8.301029996,pIC50,B,FPA,CCC(Cc1ccc(O)c(C)c1C)NS(=O)(=O)c1c(C)cc(C)cc1C,81,346.302,375.1868148,2,3,6,2,4.2339,66.4,CC(C)(CCCC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1256
1316,1586,24239189,19,P04150,GR,Homo sapiens,"N-(1-(4-hydroxynaphthalen-1-yl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CCC(Cc1ccc(O)c2ccccc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3094485,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,80.00%,agonist,dexamethasone,,,,,,,IC50,=,23,nM,,,,,=,8.522878745,pIC50,B,FPA,CCC(Cc1ccc(O)c2ccccc12)NS(=O)(=O)c1c(C)cc(C)cc1C,80,370.324,397.1711647,2,3,6,3,4.77026,66.4,CC(C)(CCCC1CCCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1248
1328,1590,16973358,6,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CCC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL376325,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 1100nM,agonist,99.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,65,nM,,,,,=,5.958607315,pKi,,radiometric,CCC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,99,356.252,380.1736072,1,5,9,3,4.31982,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
1329,1590,16973358,6,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CCC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL376325,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1300nM,agonist,106.00%,agonist,GW2331,,GW2331,,,,,EC50,=,150,nM,,,,,=,5.886056648,pKi,,radiometric,CCC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,106,356.252,380.1736072,1,5,9,3,4.31982,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
1345,1596,20079636,7b,P37231,PPARG,Homo sapiens,"4'-((2,3-dimethyl-5-(1-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid",CCC(NC(=O)c1ccc2c(c1)c(C)c(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c5ccccc5,CHEMBL602468,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8nM,partial agonist,31.00%,agonist,rosiglitazone,,,,,,,EC50,=,0.8,nM,,,,,=,8.096910013,pIC50,B,radiometric,CCC(NC(=O)c1ccc2c(c1)c(C)c(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,31,484.385,516.2412929,2,3,8,5,7.55274,71.33,CC(CCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1129
1348,1597,20079636,7e,P37231,PPARG,Homo sapiens,4'-((2-methyl-3-(methylthio)-5-(1-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCC(NC(=O)c1ccc2c(c1)c(SC)c(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c5ccccc5,CHEMBL606422,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,partial agonist,36.00%,agonist,rosiglitazone,,,,,,,EC50,=,1,nM,,,,,=,7.920818754,pIC50,B,radiometric,CCC(NC(=O)c1ccc2c(c1)c(SC)c(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,36,516.452,548.2133639,2,4,9,5,7.96622,71.33,CC(CCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1129
1351,1598,20079636,7a,P37231,PPARG,Homo sapiens,4'-((2-methyl-5-(1-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCC(NC(=O)c1ccc2c(cc(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c1)c5ccccc5,CHEMBL602263,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 18nM,partial agonist,43.00%,agonist,rosiglitazone,,,,,,,EC50,=,17,nM,,,,,=,7.744727495,pIC50,B,radiometric,CCC(NC(=O)c1ccc2c(c1)cc(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,43,472.374,502.2256428,2,3,8,5,7.24432,71.33,CC(CCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1129
1353,1598,20079636,7a,Q07869,PPARA,Homo sapiens,4'-((2-methyl-5-(1-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCC(NC(=O)c1ccc2c(cc(C)n2Cc3ccc(cc3)c4ccccc4C(=O)O)c1)c5ccccc5,CHEMBL602263,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7040nM,agonist,114.00%,agonist,GW735,,,,,,,EC50,=,4960,nM,,,,,=,5.152427341,pIC50,,radiometric,CCC(NC(=O)c1ccc2c(c1)cc(C)n2Cc1ccc(-c2ccccc2C(=O)O)cc1)c1ccccc1,114,472.374,502.2256428,2,3,8,5,7.24432,71.33,CC(CCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,agonist,agonist,agonist,1129
1354,1599,20079636,6a,P37231,PPARG,Homo sapiens,4'-((2-methyl-6-(1-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCC(NC(=O)c1ccc2cc(C)n(Cc3ccc(cc3)c4ccccc4C(=O)O)c2c1)c5ccccc5,CHEMBL606425,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 321nM,partial agonist,26.00%,agonist,rosiglitazone,,,,,,,EC50,=,163,nM,,,,,=,6.493494968,pIC50,,radiometric,CCC(NC(=O)c1ccc2cc(C)n(Cc3ccc(-c4ccccc4C(=O)O)cc3)c2c1)c1ccccc1,26,472.374,502.2256428,2,3,8,5,7.24432,71.33,CC(CCC1CCCCC1)C1CCC2CCC(CC3CCC(C4CCCCC4)CC3)C2C1,agonist,partial agonist,agonist,partial agonist,1131
1366,1600,24656565,3,P04150,GR,Homo sapiens,"3-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5-(5-fluoro-2-methoxyphenyl)-5-methylhexan-3-ol",CCC(O)(Cc1cc2ccncc2[nH]1)CC(C)(C)c3cc(F)ccc3OC,CHEMBL3233270,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 51nM,partial agonist,50.00%,agonist,,,,,,,,IC50,=,220,nM,,,,,=,7.292429824,pIC50,B,FPA,CCC(O)(Cc1cc2ccncc2[nH]1)CC(C)(C)c1cc(F)ccc1OC,50,343.252,370.2056563,2,3,7,3,4.7621,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
1369,1601,15603954,26,P37231,PPARG,Homo sapiens,2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-butyric acid,CCC(Oc1cccc(Cc2c(C)n(C(=O)c3ccc(OC)cc3)c4ccc(OC(F)(F)F)cc24)c1)C(=O)O,CHEMBL178236,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3nM,partial agonist,36.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCC(Oc1cccc(Cc2c(C)n(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc23)c1)C(=O)O,36,515.314,541.1712222,1,6,9,4,6.37822,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
1372,1602,15603954,21,P37231,PPARG,Homo sapiens,2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-butyric acid,CCC(Oc1ccccc1Cc2c(C)n(C(=O)c3ccc(OC)cc3)c4ccc(OC(F)(F)F)cc24)C(=O)O,CHEMBL179542,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3nM,partial agonist,67.00%,agonist,Rosiglitazone,,,,,,,EC50,=,6,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCC(Oc1ccccc1Cc1c(C)n(C(=O)c2ccc(OC)cc2)c2ccc(OC(F)(F)F)cc12)C(=O)O,67,515.314,541.1712222,1,6,9,4,6.37822,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
1374,1604,23953070,6b,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(thiazol-2-yl)pentanamide",CCC(c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)C(=O)Nc4nccs4,CHEMBL2426635,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 9.8nM,partial agonist,62.00%,agonist,,,,,,,,EC50,=,87,nM,,,,,=,8.008773924,pKi,B,FPA,CCC(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)C(=O)Nc1nccs1,62,399.345,422.1576606,1,5,6,4,5.7796,59.81,CC(CCC1CCC2C(CCC2C2CCCCC2)C1)CC1CCCC1,agonist,partial agonist,agonist,partial agonist,1108
1375,1605,19376703,25,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)amino)-2-chlorobenzonitrile",CCC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL557293,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 16nM,agonist,97.00%,agonist,progesterone,,,,,,,EC50,=,0.02,nM,,,,,=,7.795880017,pIC50,B,FPA,CCC(c1nncn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,97,381.161,399.101751,0,5,6,3,5.15148,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
1376,1606,19376703,14,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-methyl-1H-tetrazol-5-yl)propyl)amino)-2-chlorobenzonitrile,CCC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL556892,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,partial agonist,73.00%,agonist,progesterone,,,,,,,EC50,=,0.04,nM,,,,,=,7.886056648,pIC50,B,FPA,CCC(c1nnnn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,73,383.157,400.0969999,0,6,6,3,4.54648,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
1377,1607,12781197,13,P06401,PR,Homo sapiens,"5-Butylidene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCC\C=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL65014,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.1nM,agonist,90.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,28,nM,,,,,=,8.508638306,pKi,B,radiometric,CCC/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,90,325.257,349.1841926,1,2,2,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
1378,1607,16821785,70,P06401,PR,Homo sapiens,"(Z)-5-butylidene-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",CCC\C=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL65014,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.51,,,,progesterone,,,,,,,,,,,,,,,=,8.51,pKi,B,radiometric,CCC/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,,325.257,349.1841926,1,2,2,2,6.6335,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,,,agonist,agonist,515
1390,1612,16107159,34 (racemic),P37231,PPARG,Homo sapiens,"5-[3-(4-tert-Butyl-2-chloro-phenoxy)-propoxy]-2-ethyl-2,3-dihydro-benzofuran-2-carboxylic acid",CCC1(Cc2cc(OCCCOc3ccc(cc3Cl)C(C)(C)C)ccc2O1)C(=O)O,CHEMBL190968,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4330nM,partial agonist,56.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,=,5.363512104,pIC50,,radiometric,CCC1(C(=O)O)Cc2cc(OCCCOc3ccc(C(C)(C)C)cc3Cl)ccc2O1,56,403.712,432.1703517,1,4,8,2,5.6537,64.99,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,455
1402,1616,16107159,35 (racemic),P37231,PPARG,Homo sapiens,"5-[3-(2-Chloro-4-trifluoromethylsulfanyl-phenoxy)-propoxy]-2-ethyl-2,3-dihydro-benzofuran-2-carboxylic acid",CCC1(Cc2cc(OCCCOc3ccc(SC(F)(F)F)cc3Cl)ccc2O1)C(=O)O,CHEMBL425725,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6770nM,partial agonist,30.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,=,5.169411331,pIC50,,radiometric,CCC1(C(=O)O)Cc2cc(OCCCOc3ccc(SC(F)(F)F)cc3Cl)ccc2O1,30,456.74,476.0672071,1,5,9,2,5.9681,64.99,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,455
1416,1625,16821781,36,P04150,GR,Homo sapiens,"3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)-2-[(1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]-propanamide",CCC1(CC(O)(C(=O)Nc2ccc3C(=O)ON=C(C)c3c2)C(F)(F)F)CCCc4ccccc14,CHEMBL210077,MMTV agonim,MMTV antagonim,,PIC50 = 8.21,partial agonist,31.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.04,,PIC50,=,6.7,,=,8.21,pIC50,B,other,CCC1(CC(O)(C(=O)Nc2ccc3c(=O)onc(C)c3c2)C(F)(F)F)CCCc2ccccc21,31,449.279,474.1766419,2,5,5,3,4.80272,92.43,CC(CCC1CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1123
1419,1627,17616395,21D1E1,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3)C(F)(F)F)CCCc4ccccc14,CHEMBL237973,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.7,agonist,98.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.11,,,,,,=,7.7,pIC50,B,FPA,CCC1(CC(O)(CNC(=O)c2cnn(-c3ccc(F)cc3)c2N)C(F)(F)F)CCCc2ccccc21,98,476.304,504.214839,3,5,7,3,4.6912,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
1420,1627,17616395,21D1E2,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3)C(F)(F)F)CCCc4ccccc14,CHEMBL237973,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.01,agonist,93.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.97,,,,,,=,8.01,pIC50,B,FPA,CCC1(CC(O)(CNC(=O)c2cnn(-c3ccc(F)cc3)c2N)C(F)(F)F)CCCc2ccccc21,93,476.304,504.214839,3,5,7,3,4.6912,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
1421,1628,17616395,22D1E1,P04150,GR,Homo sapiens,"5-amino-1-(2,4-difluorophenyl)-N-(2-((1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-4-carboxamide",CCC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3F)C(F)(F)F)CCCc4ccccc14,CHEMBL393011,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.33,agonist,98.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.84,,,,,,=,8.33,pIC50,B,FPA,CCC1(CC(O)(CNC(=O)c2cnn(-c3ccc(F)cc3F)c2N)C(F)(F)F)CCCc2ccccc21,98,495.302,522.2054172,3,5,7,3,4.8303,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
1422,1628,17616395,22D1E2,P04150,GR,Homo sapiens,"5-amino-1-(2,4-difluorophenyl)-N-(2-((1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-4-carboxamide",CCC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3F)C(F)(F)F)CCCc4ccccc14,CHEMBL393011,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.33,agonist,99.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.91,,,,,,=,8.33,pIC50,B,FPA,CCC1(CC(O)(CNC(=O)c2cnn(-c3ccc(F)cc3F)c2N)C(F)(F)F)CCCc2ccccc21,99,495.302,522.2054172,3,5,7,3,4.8303,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
1423,1629,17616395,20D1E1,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-phenyl-1H-pyrazole-4-carboxamide",CCC1(CC(O)(CNC(=O)c2cnn(c2N)c3ccccc3)C(F)(F)F)CCCc4ccccc14,CHEMBL394168,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.13,agonist,106.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.25,,,,,,=,8.13,pIC50,B,FPA,CCC1(CC(O)(CNC(=O)c2cnn(-c3ccccc3)c2N)C(F)(F)F)CCCc2ccccc21,106,457.306,486.2242608,3,5,7,3,4.5521,93.17,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1247
1428,1631,18038970,45D1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl) amino]methyl}-2-propanol",CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL238147,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.83,partial agonist,73.20%,agonist,dexamethasone,,,,,,,PEC50,=,7.88,,,,,,=,7.83,pIC50,B,FPA,CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc2ccccc21,73.2,413.293,442.2231982,2,3,6,3,6.32292,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,partial agonist,agonist,partial agonist,989
1429,1631,18038970,45D1E1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl) amino]methyl}-2-propanol",CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL238147,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.83,partial agonist,62.10%,agonist,dexamethasone,,,,,,,PEC50,=,7.96,,,,,,=,7.83,pIC50,B,FPA,CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc2ccccc21,62.1,413.293,442.2231982,2,3,6,3,6.32292,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,partial agonist,agonist,partial agonist,989
1430,1631,18038970,45D2,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl) amino]methyl}-2-propanol",CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL238147,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.73,partial agonist,42.50%,agonist,dexamethasone,,,,,,,PEC50,=,6.79,,,,,,=,7.73,pIC50,B,FPA,CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc2ccccc21,42.5,413.293,442.2231982,2,3,6,3,6.32292,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,partial agonist,agonist,partial agonist,989
1431,1631,18038970,45D2E1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-{[(2-methyl-5-quinolinyl) amino]methyl}-2-propanol",CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL238147,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.76,,19.50%,agonist,dexamethasone,,,,,,,PEC50,=,6.54,,,,,,=,7.76,pIC50,B,FPA,CCC1(CC(O)(CNc2cccc3nc(C)ccc23)C(F)(F)F)CCCc2ccccc21,19.5,413.293,442.2231982,2,3,6,3,6.32292,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,,agonist,partial agonist,989
1433,1633,18038970,22D1E1,P04150,GR,Homo sapiens,"2-{2-[(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxypropyl}-1H-indole-3-carbonitrile",CCC1(CC(O)(Cc2[nH]c3ccccc3c2C#N)C(F)(F)F)CCCc4ccccc14,CHEMBL391942,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.12,antagonist,97.80%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,7.24,,=,8.12,pIC50,B,FPA,CCC1(CC(O)(Cc2[nH]c3ccccc3c2C#N)C(F)(F)F)CCCc2ccccc21,97.8,401.282,426.1918981,2,2,5,3,5.94988,59.81,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,antagonist,antagonist,antagonist,antagonist,43
1435,1635,18038970,21D1,P04150,GR,Homo sapiens,"2-{2-[(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxypropyl}-4-methyl-1H-indole-6-carbonitrile",CCC1(CC(O)(Cc2cc3c(C)cc(cc3[nH]2)C#N)C(F)(F)F)CCCc4ccccc14,CHEMBL236018,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.05,partial agonist,38.40%,agonist,dexamethasone,,,,,,,PEC50,=,7.23,,,,,,=,7.05,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3c(C)cc(C#N)cc3[nH]2)C(F)(F)F)CCCc2ccccc21,38.4,413.293,440.2075481,2,2,5,3,6.2583,59.81,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,agonist,partial agonist,agonist,partial agonist,43
1436,1635,18038970,21D1E2,P04150,GR,Homo sapiens,"2-{2-[(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxypropyl}-4-methyl-1H-indole-6-carbonitrile",CCC1(CC(O)(Cc2cc3c(C)cc(cc3[nH]2)C#N)C(F)(F)F)CCCc4ccccc14,CHEMBL236018,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.41,partial agonist,36.40%,agonist,dexamethasone,,,,,,,PEC50,=,7.29,,,,,,=,7.41,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3c(C)cc(C#N)cc3[nH]2)C(F)(F)F)CCCc2ccccc21,36.4,413.293,440.2075481,2,2,5,3,6.2583,59.81,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,agonist,partial agonist,agonist,partial agonist,43
1437,1636,18038970,20D1E1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-indol-2-ylmethyl)-2-propanol",CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL235800,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.85,antagonist,77.30%,antagonist,dexamethasone,,,,,,,PEC50,=,7.21,,PIC50,=,6.61,,=,7.85,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc2ccccc21,77.3,375.264,401.1966491,2,1,5,3,6.0782,36.02,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,43
1438,1636,18038970,20D1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-indol-2-ylmethyl)-2-propanol",CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL235800,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,,20.30%,agonist,dexamethasone,,,,,,,PEC50,=,7.19,,,,,,=,7.5,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc2ccccc21,20.3,375.264,401.1966491,2,1,5,3,6.0782,36.02,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,agonist,,"antagonist,agonist",antagonist,43
1439,1636,18038970,20D1E2,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-indol-2-ylmethyl)-2-propanol",CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL235800,,,Fluorescence polarization (FP) competition binding assay,PIC50 = 5.9,,,,dexamethasone,,,,,,,,,,,,,,,=,5.9,pIC50,,FPA,CCC1(CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F)CCCc2ccccc21,,375.264,401.1966491,2,1,5,3,6.0782,36.02,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,,,"antagonist,agonist",antagonist,43
1440,1637,18038970,23D1E1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-2-propanol",CCC1(CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL391943,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.05,antagonist,87.00%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,6.13,,=,8.05,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)CCCc2ccccc21,87,377.26,402.1918981,2,2,5,3,5.4732,48.91,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,antagonist,antagonist,antagonist,antagonist,43
1441,1637,18038970,23D1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-2-propanol",CCC1(CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)CCCc4ccccc14,CHEMBL391943,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.55,,9.10%,agonist,dexamethasone,,,,,,,PEC50,<,6,,,,,,=,7.55,pIC50,B,FPA,CCC1(CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)CCCc2ccccc21,9.1,377.26,402.1918981,2,2,5,3,5.4732,48.91,C1CCC2CC(CCCC3CCCC4CCCCC43)CC2C1,,,antagonist,antagonist,43
1442,1638,18038970,33D1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(4-quinolinylmethyl)-2-propanol",CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL398572,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.82,partial agonist,63.50%,agonist,dexamethasone,,,,,,,PEC50,=,7.42,,PIC50,=,5.3,,=,7.82,pIC50,B,FPA,CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc2ccccc21,63.5,387.275,413.1966491,1,2,5,3,6.1451,33.12,C1CCC2C(C1)CCCC2CCCC1CCCC2CCCCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,27
1443,1638,18038970,33D1E1,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(4-quinolinylmethyl)-2-propanol",CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL398572,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.0,,21.50%,agonist,dexamethasone,,,,,,,PEC50,<,6,,,,,,=,8,pIC50,B,FPA,CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc2ccccc21,21.5,387.275,413.1966491,1,2,5,3,6.1451,33.12,C1CCC2C(C1)CCCC2CCCC1CCCC2CCCCC21,,,"antagonist,agonist",partial agonist,27
1444,1638,18038970,33D2,P04150,GR,Homo sapiens,"3-(1-ethyl-1,2,3,4-tetrahydro-1-naphthalenyl)-1,1,1-trifluoro-2-(4-quinolinylmethyl)-2-propanol",CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc4ccccc14,CHEMBL398572,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.48,,7.80%,agonist,dexamethasone,,,,,,,PEC50,<,5,,,,,,=,7.48,pIC50,B,FPA,CCC1(CC(O)(Cc2ccnc3ccccc23)C(F)(F)F)CCCc2ccccc21,7.8,387.275,413.1966491,1,2,5,3,6.1451,33.12,C1CCC2C(C1)CCCC2CCCC1CCCC2CCCCC21,,,"antagonist,agonist",partial agonist,27
1446,164,17257838,9h,P10275,AR,Homo sapiens,"7-(2-methylbut-3-en-2-ylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)(Nc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F)C=C,CHEMBL3706884,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 118nM,antagonist,92.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,122,nM,=,6.928117993,pIC50,,radiometric,C=CC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,92,281.172,296.1136478,2,2,3,2,3.9234,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
1448,1641,10340624,6h,P10275,AR,Homo sapiens,"6,6-Diethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1(CC)CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL282866,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 58nM,partial antagonist,73.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,73,nM,=,7.236572006,pKi,B,radiometric,CCC1(CC)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,73,305.194,324.1449479,2,3,2,2,4.8326,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
1453,1645,16730987,34,P03372,ERA,Homo sapiens,"rac-6-bromo-9a-ethyl-1-fluoro-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nc(F)c4c3C2)Br,CHEMBL211870,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 197nM,partial agonist,71.00%,agonist,E2,,E2,,,,,EC50,=,33.1,nM,,,,,=,6.705533774,pIC50,,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]nc(F)c3c1C2,71,335.091,348.0273534,1,2,1,2,4.1234,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1454,1645,16730987,34,Q92731,ERB,Homo sapiens,"rac-6-bromo-9a-ethyl-1-fluoro-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nc(F)c4c3C2)Br,CHEMBL211870,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.6nM,agonist,81.00%,agonist,E2,,E2,,,,,EC50,=,0.8,nM,,,,,=,8.795880017,pIC50,B,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]nc(F)c3c1C2,81,335.091,348.0273534,1,2,1,2,4.1234,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1455,1646,16730987,28,P03372,ERA,Homo sapiens,"rac-6-bromo-9a-ethyl-9,9a-dihydroindeno[2,1-e]indazole-7,10(3H,8H)-dione",CCC12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2=O)Br,CHEMBL379595,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 352nM,partial agonist,65.00%,agonist,E2,,E2,,,,,EC50,=,49,nM,,,,,=,6.453457337,pIC50,,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]ncc3c1C2=O,65,332.092,344.0160398,1,3,1,2,3.6245,62.82,CC1CCC2C(C)C3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,600
1456,1646,16730987,28,Q92731,ERB,Homo sapiens,"rac-6-bromo-9a-ethyl-9,9a-dihydroindeno[2,1-e]indazole-7,10(3H,8H)-dione",CCC12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2=O)Br,CHEMBL379595,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8.0nM,agonist,85.00%,agonist,E2,,E2,,,,,EC50,=,1.5,nM,,,,,=,8.096910013,pIC50,B,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]ncc3c1C2=O,85,332.092,344.0160398,1,3,1,2,3.6245,62.82,CC1CCC2C(C)C3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,600
1457,1647,16777408,36,P03372,ERA,Homo sapiens,"6-bromo-9a-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL385028,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 5170nM,partial agonist,61.00%,agonist,ref agonist,,E2,,,,,EC50,=,1267,nM,,,,,=,5.286509457,pIC50,,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,61,318.089,331.0320242,1,3,1,2,3.3793,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1458,1647,16777408,36,Q92731,ERB,Homo sapiens,"6-bromo-9a-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL385028,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 60nM,agonist,90.00%,agonist,ref agonist,,E2,,,,,EC50,=,46,nM,,,,,=,7.22184875,pIC50,B,radiometric,CCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,90,318.089,331.0320242,1,3,1,2,3.3793,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1459,1648,16730987,24,P03372,ERA,Homo sapiens,"rac-methyl 9a-ethyl-7-oxo-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole-6-carboxylate",CCC12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C(=O)OC,CHEMBL209650,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial agonist,33.00%,agonist,E2,,E2,,,,,EC50,=,1170,nM,,,,,>,5,pIC50,NB,radiometric,CCC12CCC(=O)C(C(=O)OC)=C1c1ccc3[nH]ncc3c1C2,33,292.209,310.1317424,1,4,2,2,2.8049,72.05,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1460,1648,16730987,24,Q92731,ERB,Homo sapiens,"rac-methyl 9a-ethyl-7-oxo-3,7,8,9,9a,10-hexahydroindeno[2,1-e]indazole-6-carboxylate",CCC12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C(=O)OC,CHEMBL209650,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 207nM,partial agonist,61.00%,agonist,E2,,E2,,,,,EC50,=,210,nM,,,,,=,6.684029655,pIC50,,radiometric,CCC12CCC(=O)C(C(=O)OC)=C1c1ccc3[nH]ncc3c1C2,61,292.209,310.1317424,1,4,2,2,2.8049,72.05,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1463,165,15026058,13,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-(1-methyl-allyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(C(C)C=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL46029,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.2nM,partial agonist,73.00%,agonist,dexamethasone,,,,,,,IC50,=,110,nM,,,,,=,8.657577319,pIC50,B,radiometric,C=CC(C)C1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,73,334.269,361.2041791,1,3,3,2,6.2252,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1471,1653,16777408,24,P03372,ERA,Homo sapiens,"9a-ethyl-6-methyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C,CHEMBL379314,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1900nM,partial agonist,62.00%,agonist,ref agonist,,E2,,,,,EC50,=,671,nM,,,,,=,5.721246399,pIC50,,radiometric,CCC12CCC(=O)C(C)=C1c1ccc3[nH]nnc3c1C2,62,250.196,267.1371622,1,3,1,2,3.0468,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1472,1653,16777408,24,Q92731,ERB,Homo sapiens,"9a-ethyl-6-methyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C,CHEMBL379314,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 24nM,agonist,86.00%,agonist,ref agonist,,E2,,,,,EC50,=,20,nM,,,,,=,7.619788758,pIC50,B,radiometric,CCC12CCC(=O)C(C)=C1c1ccc3[nH]nnc3c1C2,86,250.196,267.1371622,1,3,1,2,3.0468,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1473,1654,16777408,44,P03372,ERA,Homo sapiens,"9a-ethyl-6-(4-hydroxy-phenyl)-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)c5ccc(O)cc5,CHEMBL215428,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 81nM,partial agonist,37.00%,agonist,ref agonist,,E2,,,,,EC50,=,901,nM,,,,,=,7.091514981,pIC50,B,radiometric,CCC12CCC(=O)C(c3ccc(O)cc3)=C1c1ccc3[nH]nnc3c1C2,37,326.25,345.1477268,2,4,2,3,3.8897,78.87,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,571
1477,1656,16730987,2,P03372,ERA,Homo sapiens,"rac-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC12CCC(=O)C=C1c3ccc4[nH]ncc4c3C2,CHEMBL377616,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial agonist,37.00%,agonist,E2,,E2,,,,,EC50,>,1000,nM,,,,,>,5,pIC50,NB,radiometric,CCC12CCC(=O)C=C1c1ccc3[nH]ncc3c1C2,37,236.189,252.1262631,1,2,1,2,3.2617,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,,partial agonist,,partial agonist,568
1478,1656,16730987,2,Q92731,ERB,Homo sapiens,"rac-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC12CCC(=O)C=C1c3ccc4[nH]ncc4c3C2,CHEMBL377616,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 618nM,agonist,84.00%,agonist,E2,,E2,,,,,EC50,=,76,nM,,,,,=,6.209011525,pIC50,,radiometric,CCC12CCC(=O)C=C1c1ccc3[nH]ncc3c1C2,84,236.189,252.1262631,1,2,1,2,3.2617,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1480,1657,16777408,23,Q92731,ERB,Homo sapiens,"9a-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC12CCC(=O)C=C1c3ccc4[nH]nnc4c3C2,CHEMBL438616,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 3041nM,partial agonist,71.00%,agonist,ref agonist,,E2,,,,,EC50,=,475,nM,,,,,=,5.51698358,pIC50,,radiometric,CCC12CCC(=O)C=C1c1ccc3[nH]nnc3c1C2,71,238.185,253.1215121,1,3,1,2,2.6567,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1482,1659,16730987,9,P03372,ERA,Homo sapiens,"rac-6,9a-diethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC1=C2c3ccc4[nH]ncc4c3CC2(CC)CCC1=O,CHEMBL211953,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 223nM,partial agonist,67.00%,agonist,E2,,E2,,,,,EC50,=,59,nM,,,,,=,6.651695137,pIC50,,radiometric,CCC1=C2c3ccc4[nH]ncc4c3CC2(CC)CCC1=O,67,260.211,280.1575633,1,2,2,2,4.0419,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1483,1659,16730987,9,Q92731,ERB,Homo sapiens,"rac-6,9a-diethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CCC1=C2c3ccc4[nH]ncc4c3CC2(CC)CCC1=O,CHEMBL211953,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4.0nM,agonist,77.00%,agonist,E2,,E2,,,,,EC50,=,1.7,nM,,,,,=,8.397940009,pIC50,B,radiometric,CCC1=C2c3ccc4[nH]ncc4c3CC2(CC)CCC1=O,77,260.211,280.1575633,1,2,2,2,4.0419,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1485,1660,16777408,25,P03372,ERA,Homo sapiens,"6,9a-diethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL213481,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1322nM,agonist,88.00%,agonist,ref agonist,,E2,,,,,EC50,=,460,nM,,,,,=,5.878768545,pIC50,,radiometric,CCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,88,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1486,1660,16777408,25,Q92731,ERB,Homo sapiens,"6,9a-diethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL213481,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 18nM,agonist,90.00%,agonist,ref agonist,,E2,,,,,EC50,=,7.3,nM,,,,,=,7.744727495,pIC50,B,radiometric,CCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,90,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1489,1662,16777408,(S)-25,P03372,ERA,Homo sapiens,"(S)(-)-6,9a-diethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC1=C2c3ccc4[nH]nnc4c3C[C@]2(CC)CCC1=O,CHEMBL385949,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 647nM,agonist,85.00%,agonist,ref agonist,,E2,,,,,EC50,=,140,nM,,,,,=,6.189095719,pIC50,,radiometric,CCC1=C2c3ccc4[nH]nnc4c3C[C@]2(CC)CCC1=O,85,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1490,1662,16777408,(S)-25,Q92731,ERB,Homo sapiens,"(S)(-)-6,9a-diethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCC1=C2c3ccc4[nH]nnc4c3C[C@]2(CC)CCC1=O,CHEMBL385949,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 5.7nM,agonist,99.00%,agonist,ref agonist,,E2,,,,,EC50,=,5.8,nM,,,,,=,8.244125144,pIC50,B,radiometric,CCC1=C2c3ccc4[nH]nnc4c3C[C@]2(CC)CCC1=O,99,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1492,1664,10230628,29,P10275,AR,Homo sapiens,"cis-7-Ethyl-5-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1CC(C)c2cc3C(=CC(=O)Oc3cc2N1)C(F)(F)F,CHEMBL269305,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 11nM,agonist,86.00%,agonist,DHT,,,,,,,EC50,=,8,nM,,,inactive,,=,7.958607315,pIC50,B,other,CCC1CC(C)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,86,295.175,311.1133134,1,3,1,2,4.5095,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1493,1665,10230628,28,P10275,AR,Homo sapiens,"trans-5,7-Diethyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1CC(CC)c2cc3C(=CC(=O)Oc3cc2N1)C(F)(F)F,CHEMBL6721,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 7nM,agonist,86.00%,agonist,DHT,,,,,,,EC50,=,26,nM,,,inactive,,=,8.15490196,pIC50,B,other,CCC1CC(CC)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,86,307.186,325.1289635,1,3,2,2,4.8996,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1494,1666,10340624,4c,P10275,AR,Homo sapiens,"6-Ethyl-1,9-dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCN(C)c2cc3N(C)C(=O)C=C(c3cc12)C(F)(F)F,CHEMBL27413,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 263nM,antagonist,83.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,216,nM,=,6.580044252,pKi,,radiometric,CCC1CCN(C)c2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,83,305.194,324.1449479,0,3,1,2,3.8908,25.24,CC1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,586
1495,1667,10340624,4a,P10275,AR,Homo sapiens,"6-Ethyl-9-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCN(C)c2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL27945,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 630nM,partial agonist,74.00%,agonist,DHT,,DHT,,,,,EC50,=,158,nM,,,,,=,6.200659451,pKi,,radiometric,CCC1CCN(C)c2cc3nc(O)cc(C(F)(F)F)c3cc21,74,293.183,310.1292978,1,3,1,2,4.2927,36.36,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1496,1668,10230628,32,P10275,AR,Homo sapiens,"5-Ethyl-8-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1CCN(C)c2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL6530,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 276nM,partial agonist,70.00%,agonist,DHT,,,,,,,EC50,=,209,nM,,,inactive,,=,6.559090918,pIC50,,other,CCC1CCN(C)c2cc3oc(=O)cc(C(F)(F)F)c3cc21,70,295.175,311.1133134,0,3,1,2,4.1453,33.45,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1497,1669,10340624,4d,P10275,AR,Homo sapiens,"4-Ethyl-8-oxo-6-trifluoromethyl-3,4,8,9-tetrahydro-2H-pyrido[3,2-g]quinoline-1-carbaldehyde",CCC1CCN(C=O)c2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL27372,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,partial agonist,72.00%,agonist,DHT,,DHT,,,,,EC50,=,137,nM,,,,,>,6,pKi,,radiometric,CCC1CCN(C=O)c2cc3nc(O)cc(C(F)(F)F)c3cc21,72,309.182,324.1085624,1,3,2,2,3.8193,53.43,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1500,1670,9925725,8,P10275,AR,Homo sapiens,"6-Ethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCNc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL390728,luciferase reporter gene assay,luciferase reporter gene assay,-,Ki = 17nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,100,nM,IC50,=,7481,nM,=,7.769551079,pKi,B,other,CCC1CCNc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,100,281.172,296.1136478,2,2,1,2,3.8561,44.89,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,586
1501,1670,10340624,4,P10275,AR,Homo sapiens,"6-Ethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCNc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL390728,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7nM,agonist,100.00%,agonist,DHT,,DHT,,,,,EC50,=,4,nM,IC50,=,4580,nM,=,8.15490196,pKi,B,radiometric,CCC1CCNc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,100,281.172,296.1136478,2,2,1,2,3.8561,44.89,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,586
1502,1670,17439112,"3c, LG121071",P10275,AR,Homo sapiens,"6-ethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCNc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL390728,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 11nM,agonist,100.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,100,nM,IC50,>,10000,nM,=,7.958607315,pKi,B,radiometric,CCC1CCNc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,100,281.172,296.1136478,2,2,1,2,3.8561,44.89,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,"antagonist,agonist",agonist,586
1503,1671,10340624,4b,P10275,AR,Homo sapiens,"6-Ethyl-1-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCNc2cc3N(C)C(=O)C=C(c3cc12)C(F)(F)F,CHEMBL27297,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9nM,partial antagonist,45.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,20,nM,=,8.045757491,pKi,B,radiometric,CCC1CCNc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,45,293.183,310.1292978,1,3,1,2,3.8665,34.03,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
1504,1672,10230628,19,P10275,AR,Homo sapiens,"5-Ethyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1CCNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL6843,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 5nM,agonist,119.00%,agonist,DHT,,,,,,,EC50,=,2,nM,,,inactive,,=,8.301029996,pIC50,B,other,CCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,119,283.164,297.0976633,1,3,1,2,4.121,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1505,1673,17257838,6,P10275,AR,Homo sapiens,"8-ethyl-4-trifluoromethyl-4a,6,7,8,9,10a-hexahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1CCc2cc3C(=CC(=O)Nc3cc2N1)C(F)(F)F,CHEMBL3706874,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,partial antagonist,55.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,27,nM,=,7.958607315,pIC50,B,radiometric,CCC1CCc2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2N1,55,281.172,296.1136478,2,2,1,2,3.6836,44.89,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
1506,1674,10230628,30,P10275,AR,Homo sapiens,"trans-7-Ethyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1CCc2cc3C(=CC(=O)Oc3cc2N1)C(F)(F)F,CHEMBL266473,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 1nM,agonist,79.00%,agonist,DHT,,,,,,,EC50,=,7,nM,,,inactive,,=,9,pIC50,B,other,CCC1CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,79,283.164,297.0976633,1,3,1,2,3.9485,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1507,1675,17439112,10i,P10275,AR,Homo sapiens,"(+/-)-3-ethyl-1,2,3,6-tetrahydro-1-methyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1CN(C)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL227463,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 58nM,partial agonist,28.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,28,nM,IC50,=,32,nM,=,7.236572006,pKi,B,radiometric,CCC1CN(C)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,28,297.171,312.1085624,1,3,1,2,3.1541,45.33,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
1508,1676,17439112,10k,P10275,AR,Homo sapiens,"(+/-)-3-ethyl-1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1CN(CC(F)(F)F)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL376360,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 30nM,partial agonist,72.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,72,nM,IC50,>,10000,nM,=,7.522878745,pKi,B,radiometric,CCC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,72,366.176,380.095947,1,3,2,2,4.0866,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1509,1677,17439112,10j,P10275,AR,Homo sapiens,"(+/-)-1,3-diethyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1CN(CC)c2cc3C(=CC(=O)Nc3cc2O1)C(F)(F)F,CHEMBL388831,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 34nM,partial agonist,53.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,53,nM,IC50,>,10000,nM,=,7.468521083,pKi,B,radiometric,CCC1CN(CC)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,53,309.182,326.1242124,1,3,2,2,3.5442,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1512,1679,17439112,16b,P10275,AR,Homo sapiens,"(+/-)-1,2-diethyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1COc2cc3NC(=O)C=C(c3cc2N1CC)C(F)(F)F,CHEMBL224207,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5.6nM,agonist,80.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,80,nM,IC50,>,10000,nM,=,8.251811973,pKi,B,radiometric,CCC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC,80,309.182,326.1242124,1,3,2,2,3.5442,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1518,1680,17439112,16f,P10275,AR,Homo sapiens,"(+/-)-2-ethyl-1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL388997,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 9.4nM,partial agonist,69.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,69,nM,IC50,>,10000,nM,=,8.026872146,pKi,B,radiometric,CCC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,69,366.176,380.095947,1,3,2,2,4.0866,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1522,1681,17439112,16d,P10275,AR,Homo sapiens,"(+/-)-1-(cyclopropylmethyl)-2-ethyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCC1COc2cc3NC(=O)C=C(c3cc2N1CC4CC4)C(F)(F)F,CHEMBL389481,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 23nM,partial agonist,71.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,71,nM,IC50,>,10000,nM,=,7.638272164,pKi,B,radiometric,CCC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC1CC1,71,333.204,352.1398625,1,3,3,2,3.9343,45.33,CC1CCC2CC3C(CC4CC4)CCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,574
1524,1683,10230628,31,P10275,AR,Homo sapiens,"7-Ethyl-6-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCC1Nc2cc3OC(=O)C=C(c3cc2CC1C)C(F)(F)F,CHEMBL6654,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 7nM,agonist,138.00%,agonist,DHT,,,,,,,EC50,=,1,nM,,,inactive,,=,8.15490196,pIC50,B,other,CCC1Nc2cc3oc(=O)cc(C(F)(F)F)c3cc2CC1C,138,295.175,311.1133134,1,3,1,2,4.1945,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
1539,169,21115247,9,P04150,GR,Homo sapiens,"4-allyl-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2-dihydroquinolin-3(4H)-one",Cc1cc(c(Cl)c2c1NC(C)(C)C(=O)C2(C)CC=C)c3cccc4cc[nH]c34,CHEMBL1644756,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.5nM,agonist,223.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.4,nM,,,,,=,8.455931956,pIC50,B,radiometric,C=CCC1(C)C(=O)C(C)(C)Nc2c(C)cc(-c3cccc4cc[nH]c34)c(Cl)c21,223,367.73,392.1655411,2,2,3,3,6.40372,44.89,CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,646
1545,1692,11728194,26,P04150,GR,Homo sapiens,"5-Ethyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCC1Oc2cccc(OC)c2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL141344,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 14nM,partial agonist,62.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,264,nM,,,,,=,7.853871964,pKi,B,radiometric,CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,62,310.247,335.188529,1,3,2,2,5.8131,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1547,1693,10340624,6k,P10275,AR,Homo sapiens,"Trans-6-Ethyl-7-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC1[C@@H](C)CNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL418198,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,agonist,106.00%,agonist,DHT,,DHT,,,,,EC50,=,7,nM,IC50,=,2710,nM,=,8.096910013,pKi,B,radiometric,CCC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,106,293.183,310.1292978,2,3,1,2,4.5144,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,586
1548,1694,17533125,2s,P37231,PPARG,Homo sapiens,N-((S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propyl)-butyramide,CCCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1)Nc4ccccc4C(=O)c5ccccc5,CHEMBL395527,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 7.06,partial agonist,57.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,7.06,pKi,B,radiometric,CCCC(=O)NC[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)Nc1ccccc1C(=O)c1ccccc1,57,562.435,601.2940567,2,6,15,5,7.44202,93.46,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,,partial agonist,,partial agonist,881
1577,1701,16973358,7,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)pentanoic acid,CCCC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL374296,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 240nM,partial agonist,69.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,454,nM,,,,,=,6.619788758,pKi,,radiometric,CCCC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,69,368.263,394.1892573,1,5,10,3,4.70992,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
1578,1701,16973358,7,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)pentanoic acid,CCCC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL374296,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 880nM,agonist,92.00%,agonist,GW2331,,GW2331,,,,,EC50,=,770,nM,,,,,=,6.055517328,pKi,,radiometric,CCCC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,92,368.263,394.1892573,1,5,10,3,4.70992,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
1579,1702,15603954,27,P37231,PPARG,Homo sapiens,2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-pentanoic acid,CCCC(Oc1cccc(Cc2c(C)n(C(=O)c3ccc(OC)cc3)c4ccc(OC(F)(F)F)cc24)c1)C(=O)O,CHEMBL445921,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4nM,partial agonist,42.00%,agonist,Rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,8.397940009,pIC50,B,radiometric,CCCC(Oc1cccc(Cc2c(C)n(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc23)c1)C(=O)O,42,527.325,555.1868723,1,6,10,4,6.76832,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
1582,1703,23953070,6c,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(1,3,4-thiadiazol-2-yl)hexanamide",CCCC(c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)C(=O)Nc4nncs4,CHEMBL2426636,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 1.7nM,partial agonist,60.00%,agonist,,,,,,,,EC50,=,18,nM,,,,,=,8.769551079,pKi,B,FPA,CCCC(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)C(=O)Nc1nncs1,60,413.352,437.1685596,1,6,7,4,5.5647,72.7,CC(CCC1CCC2C(CCC2C2CCCCC2)C1)CC1CCCC1,agonist,partial agonist,agonist,partial agonist,1108
1585,1704,19376703,33,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4,5-dimethyl-4H-1,2,4-triazol-3-yl)butyl)amino)-2-chlorobenzonitrile",CCCC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnc(C)n3C,CHEMBL555562,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 50nM,agonist,87.00%,agonist,progesterone,,,,,,,EC50,=,4,nM,,,,,=,7.301029996,pIC50,B,FPA,CCCC(c1nnc(C)n1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,87,405.183,427.1330511,0,5,7,3,5.85,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
1586,1705,19376703,26,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4-methyl-4H-1,2,4-triazol-3-yl)butyl)amino)-2-chlorobenzonitrile",CCCC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL562509,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,agonist,84.00%,agonist,progesterone,,,,,,,EC50,=,0.05,nM,,,,,=,7.886056648,pIC50,B,FPA,CCCC(c1nncn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,84,393.172,413.117401,0,5,7,3,5.54158,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
1594,1710,16777408,37,P03372,ERA,Homo sapiens,"6-bromo-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL213070,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 3301nM,agonist,93.00%,agonist,ref agonist,,E2,,,,,EC50,=,561,nM,,,,,=,5.481354476,pIC50,,radiometric,CCCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,93,330.1,345.0476742,1,3,2,2,3.7694,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1595,1710,16777408,37,Q92731,ERB,Homo sapiens,"6-bromo-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL213070,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 43nM,agonist,82.00%,agonist,ref agonist,,E2,,,,,EC50,=,18,nM,,,,,=,7.366531544,pIC50,B,radiometric,CCCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,82,330.1,345.0476742,1,3,2,2,3.7694,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1600,1713,16777408,26,P03372,ERA,Homo sapiens,"6-methyl-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C,CHEMBL212392,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 6173nM,agonist,84.00%,agonist,ref agonist,,E2,,,,,EC50,=,449,nM,,,,,=,5.209503723,pIC50,,radiometric,CCCC12CCC(=O)C(C)=C1c1ccc3[nH]nnc3c1C2,84,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1601,1713,16777408,26,Q92731,ERB,Homo sapiens,"6-methyl-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C,CHEMBL212392,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 81nM,agonist,89.00%,agonist,ref agonist,,E2,,,,,EC50,=,17,nM,,,,,=,7.091514981,pIC50,B,radiometric,CCCC12CCC(=O)C(C)=C1c1ccc3[nH]nnc3c1C2,89,262.207,281.1528122,1,3,2,2,3.4369,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1602,1714,16777408,27,P03372,ERA,Homo sapiens,"6-ethyl-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL213529,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 612nM,partial agonist,74.00%,agonist,ref agonist,,E2,,,,,EC50,=,120,nM,,,,,=,6.213248578,pIC50,,radiometric,CCCC12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,74,274.218,295.1684623,1,3,3,2,3.827,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1603,1714,16777408,27,Q92731,ERB,Homo sapiens,"6-ethyl-9a-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL213529,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 18nM,agonist,90.00%,agonist,ref agonist,,E2,,,,,EC50,=,7.7,nM,,,,,=,7.744727495,pIC50,B,radiometric,CCCC12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,90,274.218,295.1684623,1,3,3,2,3.827,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1606,1716,16777408,41,P03372,ERA,Homo sapiens,"9a-ethyl-6-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL378883,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 352nM,agonist,76.00%,agonist,ref agonist,,E2,,,,,EC50,=,794,nM,,,,,=,6.453457337,pIC50,,radiometric,CCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,76,274.218,295.1684623,1,3,3,2,3.827,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1607,1716,16777408,41,Q92731,ERB,Homo sapiens,"9a-ethyl-6-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL378883,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 11nM,agonist,78.00%,agonist,ref agonist,,E2,,,,,EC50,=,14,nM,,,,,=,7.958607315,pIC50,B,radiometric,CCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,78,274.218,295.1684623,1,3,3,2,3.827,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1610,1718,10340624,6c,P10275,AR,Homo sapiens,"6-Propyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCCC1CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL280865,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 29nM,partial agonist,63.00%,agonist,DHT,,DHT,,,,,EC50,=,19,nM,,,,,=,7.537602002,pKi,B,radiometric,CCCC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,63,293.183,310.1292978,2,3,2,2,4.6585,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1611,1719,10230628,20,P10275,AR,Homo sapiens,"5-Propyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CCCC1CCNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL6855,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 2nM,partial agonist,65.00%,agonist,DHT,,,,,,,EC50,=,5,nM,,,inactive,,=,8.698970004,pIC50,B,other,CCCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,65,295.175,311.1133134,1,3,2,2,4.5111,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
1617,1722,11728194,28,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-propyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCC1Oc2cccc(OC)c2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL336041,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5.0nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,75,nM,,,,,=,8.301029996,pKi,B,radiometric,CCCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,92,322.258,349.2041791,1,3,3,2,6.2032,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
1637,1732,16632357,19,Q92731,ERB,Homo sapiens,"(R,S)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)Br,CHEMBL209851,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,agonist,81.00%,agonist,,,E2,,,,,EC50,=,4,nM,,,,,=,8.744727495,pIC50,B,radiometric,CCCCC12CCC(=O)C(Br)=C1c1ccc(O)cc1C2,81,316.089,334.0568419,1,2,3,1,4.5938,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,agonist,agonist,agonist,582
1638,1732,16730987,1,Q92731,ERB,Homo sapiens,"rac-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)Br,CHEMBL209851,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,,,,,,E2,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,CCCCC12CCC(=O)C(Br)=C1c1ccc(O)cc1C2,,316.089,334.0568419,1,2,3,1,4.5938,37.3,CC1CCC2CC3CCCCC3C2C1,,,agonist,agonist,582
1641,1734,16777408,1,P03372,ERA,Homo sapiens,"(+/-)-6-bromo-9a-butyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL214693,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 141nM,partial agonist,68.00%,agonist,ref agonist,,E2,,,,,EC50,=,94,nM,,,,,=,6.850780887,pIC50,,radiometric,CCCCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,68,342.111,359.0633243,1,3,3,2,4.1595,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1642,1734,16777408,1,Q92731,ERB,Homo sapiens,"(+/-)-6-bromo-9a-butyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL214693,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.8nM,agonist,81.00%,agonist,ref agonist,,E2,,,,,EC50,=,4,nM,,,,,=,8.744727495,pIC50,B,radiometric,CCCCC12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,81,342.111,359.0633243,1,3,3,2,4.1595,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1644,1735,16632357,26,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-3-oxo-2,3,9,9a-tetrahydro-1H-fluorene-4-carbonitrile",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)C#N,CHEMBL376986,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 38nM,agonist,93.00%,agonist,,,E2,,,,,EC50,=,5,nM,,,,,=,7.420216403,pIC50,B,radiometric,CCCCC12CCC(=O)C(C#N)=C1c1ccc(O)cc1C2,93,262.203,281.1415788,1,3,3,1,3.76498,61.09,CC1CCC2CC3CCCCC3C2C1,agonist,agonist,agonist,agonist,582
1646,1736,16632357,27,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-4-(trifluoromethyl)-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)C(F)(F)F,CHEMBL208978,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.5nM,agonist,81.00%,agonist,,,E2,,,,,EC50,=,40,nM,,,,,=,8.823908741,pIC50,B,radiometric,CCCCC12CCC(=O)C(C(F)(F)F)=C1c1ccc(O)cc1C2,81,305.19,324.1337145,1,2,3,1,4.8037,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,agonist,agonist,agonist,582
1648,1737,16632357,12,Q92731,ERB,Homo sapiens,"(R,S)-9a-butyl-7-hydroxy-4-methyl-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)C,CHEMBL381495,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 16nM,agonist,112.00%,agonist,,,E2,,,,,EC50,=,20,nM,,,,,=,7.795880017,pIC50,B,radiometric,CCCCC12CCC(=O)C(C)=C1c1ccc(O)cc1C2,112,248.196,270.1619799,1,2,3,1,4.2613,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,agonist,agonist,agonist,582
1652,1739,16777408,28,Q92731,ERB,Homo sapiens,"9a-butyl-6-methyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C,CHEMBL377457,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 27nM,agonist,96.00%,agonist,ref agonist,,E2,,,,,EC50,=,20,nM,,,,,=,7.568636236,pIC50,B,radiometric,CCCCC12CCC(=O)C(C)=C1c1ccc3[nH]nnc3c1C2,96,274.218,295.1684623,1,3,3,2,3.827,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1657,1741,16632357,20,Q92731,ERB,Homo sapiens,"9a-butyl-4-ethyl-7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)CC,CHEMBL209803,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,partial agonist,66.00%,agonist,,,E2,,,,,EC50,=,2,nM,,,,,=,7.886056648,pIC50,B,radiometric,CCCCC12CCC(=O)C(CC)=C1c1ccc(O)cc1C2,66,260.207,284.17763,1,2,4,1,4.6514,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,partial agonist,agonist,partial agonist,582
1659,1742,16632357,21,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-4-propyl-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)CCC,CHEMBL209402,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.5nM,partial agonist,64.00%,agonist,,,E2,,,,,EC50,=,4,nM,,,,,=,8.823908741,pIC50,B,radiometric,CCCCC12CCC(=O)C(CCC)=C1c1ccc(O)cc1C2,64,272.218,298.1932801,1,2,5,1,5.0415,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,partial agonist,agonist,partial agonist,582
1660,1743,16777408,43,P03372,ERA,Homo sapiens,"9a-butyl-6-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CCC,CHEMBL380188,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1249nM,partial agonist,52.00%,agonist,ref agonist,,E2,,,,,EC50,=,1178,nM,,,,,=,5.903437562,pIC50,,radiometric,CCCCC12CCC(=O)C(CCC)=C1c1ccc3[nH]nnc3c1C2,52,298.24,323.1997624,1,3,5,2,4.6072,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1661,1743,16777408,43,Q92731,ERB,Homo sapiens,"9a-butyl-6-propyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CCC,CHEMBL380188,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 58nM,agonist,77.00%,agonist,ref agonist,,E2,,,,,EC50,=,96,nM,,,,,=,7.236572006,pIC50,B,radiometric,CCCCC12CCC(=O)C(CCC)=C1c1ccc3[nH]nnc3c1C2,77,298.24,323.1997624,1,3,5,2,4.6072,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
1663,1744,16632357,28,Q92731,ERB,Homo sapiens,"9a-butyl-4-chloro-7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)Cl,CHEMBL379109,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5.3nM,agonist,78.00%,agonist,,,E2,,,,,EC50,=,11,nM,,,,,=,8.27572413,pIC50,B,radiometric,CCCCC12CCC(=O)C(Cl)=C1c1ccc(O)cc1C2,78,271.638,290.1073575,1,2,3,1,4.4377,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,agonist,agonist,agonist,582
1665,1745,16632357,29,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-4-iodo-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)I,CHEMBL379821,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,partial agonist,70.00%,agonist,,,E2,,,,,EC50,=,4,nM,,,,,=,8.886056648,pIC50,B,radiometric,CCCCC12CCC(=O)C(I)=C1c1ccc(O)cc1C2,70,363.089,382.0429778,1,2,3,1,4.6339,37.3,CC1CCC2CC3CCCCC3C2C1,agonist,partial agonist,agonist,partial agonist,582
1667,1746,16632357,25,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-4-phenyl-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)c4ccccc4,CHEMBL380469,Transactivation,Transactivation,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.2nM,partial agonist,41.00%,agonist,,,E2,,,,,EC50,=,5,nM,IC50,=,2,nM,=,8.920818754,pIC50,B,radiometric,CCCCC12CCC(=O)C(c3ccccc3)=C1c1ccc(O)cc1C2,41,308.251,332.17763,1,2,4,2,5.3986,37.3,CC1CCC2CC3CCCCC3C2C1C1CCCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,584
1669,1747,16632357,23,Q92731,ERB,Homo sapiens,"9a-butyl-4-(furan-2-yl)-7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)c4occc4,CHEMBL378675,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.1nM,agonist,80.00%,agonist,,,E2,,,,,EC50,=,5,nM,,,,,=,8.508638306,pIC50,B,radiometric,CCCCC12CCC(=O)C(c3ccco3)=C1c1ccc(O)cc1C2,80,300.228,322.1568946,1,3,4,2,4.9916,50.44,CC1CCC2CC3CCCCC3C2C1C1CCCC1,agonist,agonist,agonist,agonist,583
1670,1748,16777408,46,P03372,ERA,Homo sapiens,"9a-butyl-6-furan-2-yl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)c5occc5,CHEMBL214200,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1119nM,partial agonist,44.00%,agonist,ref agonist,,E2,,,,,EC50,=,870,nM,,,,,=,5.951169913,pIC50,,radiometric,CCCCC12CCC(=O)C(c3ccco3)=C1c1ccc3[nH]nnc3c1C2,44,326.25,347.1633769,1,4,4,3,4.5573,71.78,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCC1,agonist,partial agonist,agonist,partial agonist,570
1671,1748,16777408,46,Q92731,ERB,Homo sapiens,"9a-butyl-6-furan-2-yl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)c5occc5,CHEMBL214200,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 7.4nM,agonist,82.00%,agonist,ref agonist,,E2,,,,,EC50,=,6.5,nM,,,,,=,8.13076828,pIC50,B,radiometric,CCCCC12CCC(=O)C(c3ccco3)=C1c1ccc3[nH]nnc3c1C2,82,326.25,347.1633769,1,4,4,3,4.5573,71.78,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCC1,agonist,agonist,agonist,agonist,570
1673,1749,16632357,24,Q92731,ERB,Homo sapiens,"9a-butyl-7-hydroxy-4-(thiophen-2-yl)-1,2,9,9a-tetrahydrofluoren-3-one",CCCCC12CCC(=O)C(=C1c3ccc(O)cc3C2)c4cccs4,CHEMBL209429,Transactivation,Transactivation,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.6nM,partial agonist,52.00%,agonist,,,E2,,,,,EC50,=,4,nM,IC50,=,9,nM,=,8.795880017,pIC50,B,radiometric,CCCCC12CCC(=O)C(c3cccs3)=C1c1ccc(O)cc1C2,52,316.296,338.1340509,1,3,4,2,5.4601,37.3,CC1CCC2CC3CCCCC3C2C1C1CCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,583
1681,1753,16777408,45,P03372,ERA,Homo sapiens,"6-butyl-9a-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL213051,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1127nM,partial agonist,45.00%,agonist,ref agonist,,E2,,,,,EC50,=,681,nM,,,,,=,5.948076084,pIC50,,radiometric,CCCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,45,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1682,1753,16777408,45,Q92731,ERB,Homo sapiens,"6-butyl-9a-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,CHEMBL213051,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 43nM,partial agonist,39.00%,agonist,ref agonist,,E2,,,,,EC50,=,60,nM,,,,,=,7.366531544,pIC50,B,radiometric,CCCCC1=C2c3ccc4[nH]nnc4c3CC2(CC)CCC1=O,39,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
1683,1754,9873735,22,P06401,PR,Homo sapiens,"5-Butyl-8-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2cc(F)ccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL321243,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 26.5nM,antagonist,83.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,5285,nM,IC50,=,538,nM,=,7.576754126,pKi,B,radiometric,CCCCC1Oc2cc(F)ccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,83,325.257,351.1998427,1,2,3,2,6.7238,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,16
1685,1755,9873735,20,P06401,PR,Homo sapiens,"5-Butyl-2,2,4,9-tetramethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2ccc(C)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL114941,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.2nM,partial agonist,58.00%,agonist,progesterone,,progesterone,,,,,EC50,=,16,nM,,,,,=,8.920818754,pKi,B,radiometric,CCCCC1Oc2ccc(C)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,58,318.27,347.2249145,1,2,3,2,6.89312,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1688,1756,9873735,18,P06401,PR,Homo sapiens,"5-Butyl-9-chloro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2ccc(Cl)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL112987,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.87nM,partial agonist,70.00%,agonist,progesterone,,progesterone,,,,,EC50,=,6.8,nM,,,,,=,9.060480747,pKi,B,radiometric,CCCCC1Oc2ccc(Cl)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,70,341.712,367.1702921,1,2,3,2,7.2381,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1691,1757,9873735,15,P06401,PR,Homo sapiens,"5-Butyl-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL326092,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.9nM,agonist,77.00%,agonist,progesterone,,progesterone,,,,,EC50,=,15,nM,,,,,=,8.537602002,pKi,B,radiometric,CCCCC1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,77,325.257,351.1998427,1,2,3,2,6.7238,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
1694,1758,9873735,21,P06401,PR,Homo sapiens,"5-Butyl-9-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2ccc(OC)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL322108,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,partial agonist,66.00%,agonist,progesterone,,progesterone,,,,,EC50,=,9.3,nM,,,,,=,8.455931956,pKi,B,radiometric,CCCCC1Oc2ccc(OC)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,66,334.269,363.2198292,1,3,4,2,6.5933,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1696,1759,11728194,30,P04150,GR,Homo sapiens,"5-Butyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2cccc(OC)c2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL140336,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 3.7nM,partial agonist,35.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,405,nM,,,,,=,8.431798276,pKi,B,radiometric,CCCCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,35,334.269,363.2198292,1,3,4,2,6.5933,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1700,1760,9873735,8,P06401,PR,Homo sapiens,"5-Butyl-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL325221,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.95nM,partial agonist,38.00%,agonist,progesterone,,progesterone,,,,,EC50,=,11,nM,IC50,=,997,nM,=,9.022276395,pKi,B,radiometric,CCCCC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,38,306.259,333.2092645,1,2,3,2,6.5847,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,16
1710,1766,9873735,9,P06401,PR,Homo sapiens,"5-Hexyl-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCCCCC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL115173,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 23nM,antagonist,77.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,375,nM,=,7.638272164,pKi,B,radiometric,CCCCCCC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,77,330.281,361.2405646,1,2,5,2,7.3649,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
1715,177,18442912,9g,P10275,AR,Homo sapiens,"5-allyl-10-methoxy-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1cccc2OC(CC=C)c3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL258384,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1593nM,partial antagonist,63.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,144,nM,=,5.797784224,pKi,,radiometric,C=CCC1Oc2cccc(OC)c2-c2ccc3[nH]c(=O)cc(C)c3c21,63,314.235,333.1364935,1,3,3,3,4.52172,51.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,antagonist,partial antagonist,antagonist,partial antagonist,634
1729,1778,17292606,2b,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(heptyl)amino)acetic acid,CCCCCCCN(CC(=O)O)Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1,CHEMBL248530,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2300nM,partial agonist,66.00%,agonist,Rosiglitazone,,,,,,,EC50,=,136,nM,,,,,=,5.638272164,pIC50,,FPA,CCCCCCCN(CC(=O)O)Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1,66,428.318,464.2675076,1,5,15,3,6.12852,75.8,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
1730,1778,17292606,2b,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(heptyl)amino)acetic acid,CCCCCCCN(CC(=O)O)Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1,CHEMBL248530,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1050nM,partial agonist,63.00%,agonist,GW2331,,,,,,,EC50,=,180,nM,,,,,=,5.978810701,pIC50,,FPA,CCCCCCCN(CC(=O)O)Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1,63,428.318,464.2675076,1,5,15,3,6.12852,75.8,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
1731,1779,15771468,GW-2331,P37231,PPARG,Homo sapiens,"2-(4-{2-[3-(2,4-Difluoro-phenyl)-1-heptyl-ureido]-ethyl}-phenoxy)-2-methyl-butyric acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 316nM,partial agonist,64.00%,agonist,rosiglitazone,,,,,,,EC50,=,425,nM,,,,,=,6.500312917,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,64,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,agonist,partial agonist,agonist,"partial agonist,agonist",1221
1732,1779,17292606,GW-2331,P37231,PPARG,Homo sapiens,"(S)-2-(4-(2-(3-(2,4-difluorophenyl)-1-heptylureido)ethyl)phenoxy)-2-methylbutanoic acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 670nM,agonist,90.00%,agonist,Rosiglitazone,,,,,,,EC50,=,249,nM,,,,,=,6.173925197,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,90,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,agonist,agonist,agonist,"partial agonist,agonist",1221
1733,1779,18291645,GW-2331,P37231,PPARG,Homo sapiens,"(S)-2-(4-(2-(3-(2,4-difluorophenyl)-1-heptylureido)ethyl)phenoxy)-2-methylbutanoic acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 600nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,243,nM,,,,,=,6.22184875,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,agonist,,agonist,"partial agonist,agonist",1221
1734,1779,15771468,GW-2331,Q07869,PPARA,Homo sapiens,"2-(4-{2-[3-(2,4-Difluoro-phenyl)-1-heptyl-ureido]-ethyl}-phenoxy)-2-methyl-butyric acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 538nM,agonist,102.00%,agonist,GW2331,,,,,,,EC50,<,20,nM,,,,,=,6.269217724,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,102,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,,agonist,agonist,agonist,1221
1735,1779,17292606,GW-2331,Q07869,PPARA,Homo sapiens,"(S)-2-(4-(2-(3-(2,4-difluorophenyl)-1-heptylureido)ethyl)phenoxy)-2-methylbutanoic acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 348nM,agonist,79.00%,agonist,GW2331,,,,,,,EC50,=,71,nM,,,,,=,6.458420756,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,79,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,agonist,agonist,agonist,agonist,1221
1736,1779,18291645,GW-2331,Q07869,PPARA,Homo sapiens,"(S)-2-(4-(2-(3-(2,4-difluorophenyl)-1-heptylureido)ethyl)phenoxy)-2-methylbutanoic acid",CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,CHEMBL248906,reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 740nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,45,nM,,,,,=,6.13076828,pIC50,,FPA,CCCCCCCN(CCc1ccc(O[C@@](C)(CC)C(=O)O)cc1)C(=O)Nc1ccc(F)cc1F,,454.303,490.2643141,2,3,14,2,6.6439,78.87,CC(CCCC1CCCCC1)CC1CCCCC1,agonist,,agonist,agonist,1221
1737,178,11728194,36,P04150,GR,Homo sapiens,"(-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL266282,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.4nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,14,nM,,,,,=,8.853871964,pKi,B,radiometric,C=CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,87,322.258,347.188529,1,3,3,2,5.9792,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,"agonist,partial agonist",16
1738,178,11728194,18,P04150,GR,Homo sapiens,"(+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL266282,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.5nM,partial agonist,68.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,33,nM,,,,,=,8.602059991,pKi,B,radiometric,C=CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,68,322.258,347.188529,1,3,3,2,5.9792,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,"agonist,partial agonist",16
1739,178,11728194,37,P04150,GR,Homo sapiens,"(+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL266282,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 150nM,partial agonist,55.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,520,nM,,,,,=,6.823908741,pKi,,radiometric,C=CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,55,322.258,347.188529,1,3,3,2,5.9792,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,"agonist,partial agonist",16
1740,178,15026058,(-)4a,P04150,GR,Homo sapiens,"5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL266282,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.5nM,partial agonist,68.00%,agonist,dexamethasone,,,,,,,IC50,=,33,nM,,,,,=,8.602059991,pIC50,B,radiometric,C=CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,68,322.258,347.188529,1,3,3,2,5.9792,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,"agonist,partial agonist",16
1752,1782,15006411,39,P19793,RXRA,Homo sapiens,"(E)-3-[4-(3,5-Di-tert-butyl-2-heptyloxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid",CCCCCCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)c2cccc3sc(cc23)\C(=C\C(=O)O)\C,CHEMBL291034,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5nM,antagonist,96.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,83,nM,=,8.301029996,pKi,B,radiometric,CCCCCCCOc1c(-c2cccc3sc(/C(C)=C/C(=O)O)cc23)cc(C(C)(C)C)cc1C(C)(C)C,96,476.427,520.3011163,1,3,10,3,10.0004,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
1762,1789,19349176,rac-2Ea,P37231,PPARG,Homo sapiens,2-(hexyloxy)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCCCCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL482740,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,agonist,85.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,4,nM,,,,,=,8.698970004,pIC50,B,radiometric,CCCCCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,85,474.388,507.2079442,1,6,14,4,7.07882,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
1763,1789,19349176,rac-2Ea,Q07869,PPARA,Homo sapiens,2-(hexyloxy)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCCCCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL482740,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 120nM,agonist,115.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,249,nM,,,,,=,6.920818754,pIC50,,radiometric,CCCCCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,115,474.388,507.2079442,1,6,14,4,7.07882,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
1777,1793,21414782,24,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-pentylsulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760406,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.1,partial agonist,50.00%,agonist,,,,,,,,PEC50,=,6.4,,,,,,=,6.1,pIC50,,radiometric,CCCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,50,509.841,543.1846219,1,4,11,3,7.16966,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1785,1797,16137885,24a,P37231,PPARG,Homo sapiens,(E)-8-Hydroxy-8-(3-pentyloxy-naphthalen-2-yl)-oct-5-enoic acid methyl ester,CCCCCOc1cc2ccccc2cc1C(O)C\C=C\CCCC(=O)OC,CHEMBL198708,,,,Ki = 718nM,partial agonist,26.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,=,6.143875556,pKi,,other,CCCCCOc1cc2ccccc2cc1C(O)C/C=C/CCCC(=O)OC,26,352.26,384.2300595,1,4,12,2,5.7318,55.76,C1CCC2CCCCC2C1,,partial agonist,,partial agonist,41
1786,1798,16137885,26a,P37231,PPARG,Homo sapiens,Sodium salt (E)-8-hydroxy-8-(3-pentyloxy-naphthalen-2-yl)-oct-5-enoate,[Na+].CCCCCOc1cc2ccccc2cc1C(O)C\C=C/CCCC(=O)[O-],CHEMBL2113107,,,,Ki = 1030nM,agonist,85.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1503,nM,,,,,=,5.987162775,pKi,,other,CCCCCOc1cc2ccccc2cc1C(O)C/C=C\CCCC(=O)[O-].[Na+],85,363.239,392.1963537,1,4,12,2,1.3127,69.59,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
1787,1799,16137885,22a,P37231,PPARG,Homo sapiens,8-Hydroxy-8-(3-pentyloxy-naphthalen-2-yl)-oct-5-ynoic acid methyl ester,CCCCCOc1cc2ccccc2cc1C(O)CC#CCCCC(=O)OC,CHEMBL198166,,,,Ki = 695nM,partial agonist,58.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,=,6.158015195,pKi,,other,CCCCCOc1cc2ccccc2cc1C(O)CC#CCCCC(=O)OC,58,352.26,382.2144094,1,4,10,2,5.179,55.76,C1CCC2CCCCC2C1,,partial agonist,,partial agonist,41
1797,180,9873735,12,P06401,PR,Homo sapiens,"5-Allyl-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC1=CC(C)(C)Nc2ccc3c4ccccc4OC(CC=C)c3c12,CHEMBL8639,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.8nM,partial agonist,62.00%,agonist,progesterone,,progesterone,,,,,EC50,=,9,nM,IC50,=,561,nM,=,8.318758763,pKi,B,radiometric,C=CCC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,62,294.248,317.1779644,1,2,2,2,5.9706,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,16
1801,1801,16137885,27a,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(3-pentyloxy-naphthalen-2-yl)-octanoate,[Na+].CCCCCOc1cc2ccccc2cc1C(O)CCCCCCC(=O)[O-],CHEMBL199121,,,,Ki = 969nM,partial agonist,51.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,=,6.013676223,pKi,,other,CCCCCOc1cc2ccccc2cc1C(O)CCCCCCC(=O)[O-].[Na+],51,363.239,394.2120038,1,4,13,2,1.5367,69.59,C1CCC2CCCCC2C1,,partial agonist,,partial agonist,41
1802,1802,16137885,25a,P37231,PPARG,Homo sapiens,9-Hydroxy-9-(3-pentyloxy-naphthalen-2-yl)-nonanoic acid methyl ester,CCCCCOc1cc2ccccc2cc1C(O)CCCCCCCC(=O)OC,CHEMBL198170,,,,Ki = 579nM,partial agonist,34.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1356,nM,,,,,=,6.237321436,pKi,,other,CCCCCOc1cc2ccccc2cc1C(O)CCCCCCCC(=O)OC,34,364.271,400.2613596,1,4,14,2,6.3459,55.76,C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,41
1806,1806,16137885,15a,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(2-pentyloxy-phenyl)-oct-5-ynoate,[Na+].CCCCCOc1ccccc1C(O)CC#CCCCC(=O)[O-],CHEMBL370374,,,,Ki > 10000nM,partial agonist,32.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,>,5,pKi,NB,other,CCCCCOc1ccccc1C(O)CC#CCCCC(=O)[O-].[Na+],32,315.195,340.1650536,1,4,10,1,-0.3933,69.59,C1CCCCC1,,partial agonist,,partial agonist,205
1807,1807,16137885,17a,P37231,PPARG,Homo sapiens,8-Hydroxy-8-(2-pentyloxy-phenyl)-octanoic acid methyl ester,CCCCCOc1ccccc1C(O)CCCCCCC(=O)OC,CHEMBL197268,,,,Ki = 515nM,partial agonist,42.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,=,6.288192771,pKi,,other,CCCCCOc1ccccc1C(O)CCCCCCC(=O)OC,42,304.216,336.2300595,1,4,13,1,4.8026,55.76,C1CCCCC1,,partial agonist,,partial agonist,205
1808,1808,16137885,19a,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(2-pentyloxy-phenyl)-octanoate,[Na+].CCCCCOc1ccccc1C(O)CCCCCCC(=O)[O-],CHEMBL196261,,,,Ki = 6690nM,partial agonist,29.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,=,5.174573882,pKi,,other,CCCCCOc1ccccc1C(O)CCCCCCC(=O)[O-].[Na+],29,315.195,344.1963537,1,4,13,1,0.3835,69.59,C1CCCCC1,,partial agonist,,partial agonist,205
1809,1809,16137885,24b,P37231,PPARG,Homo sapiens,(E)-8-Hydroxy-8-(2-pentyloxy-quinolin-3-yl)-oct-5-enoic acid methyl ester,CCCCCOc1nc2ccccc2cc1C(O)C\C=C/CCCC(=O)OC,CHEMBL2113106,,,,Ki = 1330nM,agonist,141.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1546,nM,,,,,=,5.876148359,pKi,,other,CCCCCOc1nc2ccccc2cc1C(O)C/C=C\CCCC(=O)OC,141,354.256,385.2253085,1,5,12,2,5.1268,68.65,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
1810,181,11728194,34,P04150,GR,Homo sapiens,"5-But-3-enyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CCC=C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL141915,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 8.1nM,partial agonist,57.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,78,nM,,,,,=,8.091514981,pKi,B,radiometric,C=CCCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,57,334.269,361.2041791,1,3,4,2,6.3693,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
1812,1810,16137885,26b,P37231,PPARG,Homo sapiens,Sodium salt (E)-8-hydroxy-8-(2-pentyloxy-quinolin-3-yl)-oct-5-enoate,[Na+].CCCCCOc1nc2ccccc2cc1C(O)C\C=C/CCCC(=O)[O-],CHEMBL2113108,,,,Ki > 10000nM,partial agonist,62.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1195,nM,,,,,>,5,pKi,NB,other,CCCCCOc1nc2ccccc2cc1C(O)C/C=C\CCCC(=O)[O-].[Na+],62,365.235,393.1916027,1,5,12,2,0.7077,82.48,C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,41
1813,1811,16137885,22b,P37231,PPARG,Homo sapiens,8-Hydroxy-8-(2-pentyloxy-quinolin-3-yl)-oct-5-ynoic acid methyl ester,CCCCCOc1nc2ccccc2cc1C(O)CC#CCCCC(=O)OC,CHEMBL197684,,,,Ki > 10000nM,partial agonist,42.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1413,nM,,,,,>,5,pKi,NB,other,CCCCCOc1nc2ccccc2cc1C(O)CC#CCCCC(=O)OC,42,354.256,383.2096584,1,5,10,2,4.574,68.65,C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,41
1814,1812,16137885,23b,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(2-pentyloxy-quinolin-3-yl)-oct-5-ynoate,[Na+].CCCCCOc1nc2ccccc2cc1C(O)CC#CCCCC(=O)[O-],CHEMBL383607,,,,Ki = 947nM,partial agonist,72.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,617,nM,,,,,=,6.023650021,pKi,,other,CCCCCOc1nc2ccccc2cc1C(O)CC#CCCCC(=O)[O-].[Na+],72,365.235,391.1759526,1,5,10,2,0.1549,82.48,C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,41
1815,1813,16137885,27b,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(2-pentyloxy-quinolin-3-yl)-octanoate,[Na+].CCCCCOc1nc2ccccc2cc1C(O)CCCCCC(=O)[O-],CHEMBL2113109,,,,Ki = 2860nM,agonist,85.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,1566,nM,,,,,=,5.543633967,pKi,,other,CCCCCOc1nc2ccccc2cc1C(O)CCCCCC(=O)[O-].[Na+],85,353.224,381.1916027,1,5,12,2,0.5416,82.48,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
1816,1814,16137885,25b,P37231,PPARG,Homo sapiens,9-Hydroxy-9-(2-pentyloxy-quinolin-3-yl)-nonanoic acid methyl ester,CCCCCOc1nc2ccccc2cc1C(O)CCCCCCCC(=O)OC,CHEMBL199125,,,,Ki > 10000nM,partial agonist,41.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,>,5,pKi,NB,other,CCCCCOc1nc2ccccc2cc1C(O)CCCCCCCC(=O)OC,41,366.267,401.2566086,1,5,14,2,5.7409,68.65,C1CCC2CCCCC2C1,,partial agonist,,partial agonist,41
1818,1816,16137885,18b,P37231,PPARG,Homo sapiens,Sodium salt (E)-8-hydroxy-8-(2-pentyloxy-pyridin-3-yl)-oct-5-enoate,[Na+].CCCCCOc1ncccc1C(O)C\C=C\CCCC(=O)[O-],CHEMBL196260,,,,Ki > 10000nM,partial agonist,31.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,>,5,pKi,NB,other,CCCCCOc1ncccc1C(O)C/C=C/CCCC(=O)[O-].[Na+],31,317.191,343.1759526,1,5,12,1,-0.4455,82.48,C1CCCCC1,,partial agonist,,partial agonist,205
1819,1817,16137885,14b,P37231,PPARG,Homo sapiens,8-Hydroxy-8-(2-pentyloxy-pyridin-3-yl)-oct-5-ynoic acid methyl ester,CCCCCOc1ncccc1C(O)CC#CCCCC(=O)OC,CHEMBL373318,,,,Ki > 10000nM,partial agonist,45.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,549,nM,,,,,>,5,pKi,NB,other,CCCCCOc1ncccc1C(O)CC#CCCCC(=O)OC,45,306.212,333.1940083,1,5,10,1,3.4208,68.65,C1CCCCC1,agonist,partial agonist,agonist,partial agonist,205
1824,1820,16137885,19b,P37231,PPARG,Homo sapiens,Sodium salt 8-hydroxy-8-(2-pentyloxy-pyridin-3-yl)-octanoate,[Na+].CCCCCOc1ncccc1C(O)CCCCCCC(=O)[O-],CHEMBL198034,,,,Ki > 10000nM,partial agonist,27.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,>,10000,nM,,,,,>,5,pKi,NB,other,CCCCCOc1ncccc1C(O)CCCCCCC(=O)[O-].[Na+],27,317.191,345.1916027,1,5,13,1,-0.2215,82.48,C1CCCCC1,,partial agonist,,partial agonist,205
1833,1826,10673099,17,P03372,ERA,Homo sapiens,"11-((7S,13S,17S)-3,17-Dihydroxy-13-methyl-6-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-ylsulfanyl)-undecanoic acid butyl-methyl-amide",CCCCN(C)C(=O)CCCCCCCCCCS[C@H]1[C@@H]2[C@H](CC[C@]3(C)[C@@H](O)CC[C@@H]23)c4ccc(O)cc4C1=O,CHEMBL1628199,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 33nM,antagonist,97.00%,antagonist,E2,,E2,2nM,,,,EC50,=,28,nM,IC50,=,519,nM,=,7.48148606,pIC50,B,radiometric,CCCCN(C)C(=O)CCCCCCCCCCS[C@@H]1C(=O)c2cc(O)ccc2[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,97,518.444,571.3695302,2,5,15,1,7.7305,77.84,CC1CC2C3CCCC3CCC2C2CCCCC12,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,497
1835,1827,10673099,12,P03372,ERA,Homo sapiens,"11-((7R,13S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-ylsulfanyl)-undecanoic acid butyl-methyl-amide",CCCCN(C)C(=O)CCCCCCCCCCS[C@@H]1Cc2cc(O)ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]13,CHEMBL1627354,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,antagonist,99.00%,antagonist,E2,,E2,2nM,,,,,,inactive,,IC50,=,3.5,nM,=,8.045757491,pIC50,B,radiometric,CCCCN(C)C(=O)CCCCCCCCCCS[C@@H]1Cc2cc(O)ccc2[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,99,502.445,557.3902656,2,4,15,1,8.0903,60.77,C1CCC2C(C1)CCC1C3CCCC3CCC21,antagonist,antagonist,antagonist,antagonist,15
1837,1828,10673099,18,P03372,ERA,Homo sapiens,"11-((6R,7S,13S,17S)-3,6,17-Trihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-ylsulfanyl)-undecanoic acid butyl-methyl-amide",CCCCN(C)C(=O)CCCCCCCCCCS[C@@H]1[C@H](O)c2cc(O)ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]13,CHEMBL1627351,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 32nM,antagonist,98.00%,antagonist,E2,,E2,2nM,,,,EC50,=,40,nM,IC50,=,316,nM,=,7.494850022,pIC50,B,radiometric,CCCCN(C)C(=O)CCCCCCCCCCS[C@@H]1[C@H](O)c2cc(O)ccc2[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]21,98,518.444,573.3851802,3,5,15,1,7.5812,81,C1CCC2C(C1)CCC1C3CCCC3CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,15
1848,1835,17267219,6h,P10275,AR,Homo sapiens,"6-(butyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CCCCN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL393864,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 33nM,partial agonist,69.00%,agonist,DHT,,,,,,,EC50,=,6.8,nM,IC50,>,10000,nM,=,7.48148606,pIC50,B,radiometric,CCCCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,69,350.177,366.1166825,1,2,5,2,4.7157,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
1849,1836,17034117,4f,P10275,AR,Homo sapiens,"6-N,N-dibutylamino-4-trifluoromethylquinolin-2(1H)-one",CCCCN(CCCC)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL216949,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 222nM,partial agonist,68.00%,agonist,DHT,,,,,,,EC50,=,1283,nM,IC50,=,29.5,nM,=,6.653647026,pKi,,radiometric,CCCCN(CCCC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,68,317.205,340.176248,1,3,7,2,5.3658,36.36,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
1857,184,15115388,31,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-pent-4-en-1-ol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)CCC=C)c4ccc(F)cc4,CHEMBL79335,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,agonist,91.70%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,4.4,nM,,,,,=,8.958607315,pIC50,B,radiometric,C=CCC[C@H](O)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,91.7,339.264,366.2107417,1,3,5,2,5.0844,38.05,C1CCC(C2CCC3CC4CCCCC4CC32)CC1,agonist,agonist,agonist,agonist,97
1898,1856,21414782,36,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-4,6-difluorobiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cc(c(F)cc1F)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760418,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,pIC50 = 5.5,partial agonist,27.00%,agonist,,,,,,,,PEC50,=,5.9,,,,,,=,5.5,pIC50,,radiometric,CCCCN(c1cc(-c2ccc(Cl)cc2)c(F)cc1F)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,27,523.815,551.1344781,1,4,10,3,6.74934,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1901,1857,21414782,31,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-5-(trifluoromethyl)biphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cc(cc(c1)C(F)(F)F)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760413,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.2,partial agonist,69.00%,agonist,,,,,,,,PEC50,=,7,,,,,,=,7.2,pIC50,B,radiometric,CCCCN(c1cc(-c2ccc(Cl)cc2)cc(C(F)(F)F)c1)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,69,554.824,583.1407064,1,4,10,3,7.48994,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1904,1858,21414782,35,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-4-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cc(ccc1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760417,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,pIC50 = 5.8,partial agonist,36.00%,agonist,,,,,,,,PEC50,=,6.1,,,,,,=,5.8,pIC50,,radiometric,CCCCN(c1cc(-c2ccc(Cl)cc2)ccc1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,36,497.83,529.1689718,1,4,10,3,6.77956,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1907,1859,21414782,34,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-4-(trifluoromethoxy)biphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cc(ccc1OC(F)(F)F)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760416,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,pIC50 = 5.5,partial agonist,30.00%,agonist,,,,,,,,PEC50,=,6,,,,,,=,5.5,pIC50,,radiometric,CCCCN(c1cc(-c2ccc(Cl)cc2)ccc1OC(F)(F)F)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,30,570.823,599.135621,1,5,11,3,7.36974,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1913,1861,21414782,33,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-6-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1ccc(C)c(c1)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760415,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.4,partial agonist,41.00%,agonist,,,,,,,,PEC50,=,6.9,,,,,,=,6.4,pIC50,,radiometric,CCCCN(c1ccc(C)c(-c2ccc(Cl)cc2)c1)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,41,497.83,529.1689718,1,4,10,3,6.77956,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1916,1862,21414782,32,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-6-fluorobiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1ccc(F)c(c1)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760414,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.7,partial agonist,48.00%,agonist,,,,,,,,PEC50,=,7.4,,,,,,=,6.7,pIC50,,radiometric,CCCCN(c1ccc(F)c(-c2ccc(Cl)cc2)c1)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,48,504.817,533.1438999,1,4,10,3,6.61024,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1919,1863,21414782,42,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(2-methyl-4'-(trifluoromethyl)biphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(cc2)C(F)(F)F)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760424,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,64.00%,agonist,,,,,,,,PEC50,=,8.2,,,,,,=,7.8,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,64,531.382,563.1953288,1,4,10,3,7.14496,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1922,1864,21414782,47,Q03181,PPARB,Homo sapiens,"2-{[4-({butyl[2-chloro-4'-(trifluoromethyl)-3-biphenylyl]amino}sulfonyl)-2,3-dimethylphenyl]oxy}propanoic acid",CCCCN(c1cccc(c1Cl)c2ccc(cc2)C(F)(F)F)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760428,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.2,partial agonist,59.00%,agonist,,,,,,,,PEC50,=,8.6,,,,,,=,8.2,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,59,554.824,583.1407064,1,4,10,3,7.48994,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1925,1865,21414782,44,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(2,4'-dimethylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(C)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760426,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.1,partial agonist,59.00%,agonist,,,,,,,,PEC50,=,7.5,,,,,,=,7.1,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(C)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,59,474.388,509.2235942,1,4,10,3,6.43458,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1928,1866,21414782,40,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(3',4'-dichloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)c(Cl)c2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760422,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.9,partial agonist,47.00%,agonist,,,,,,,,PEC50,=,6.9,,,,,,=,6.9,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(Cl)c(Cl)c2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,47,533.283,563.1299995,1,4,10,3,7.43296,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1931,1867,21414782,3,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760267,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.3,partial agonist,56.00%,agonist,,,,,,,,PEC50,=,7.6,,,,,,=,7.3,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,56,497.83,529.1689718,1,4,10,3,6.77956,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1934,1868,21414782,16,Q03181,PPARB,Homo sapiens,2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2-cyclohexylphenoxy)propanoic acid,CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(c3)C4CCCCC4,CHEMBL1760274,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,62.00%,agonist,,,,,,,,PEC50,=,7.8,,,,,,=,7.8,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C2CCCCC2)c1,62,545.874,583.215922,1,4,11,3,8.21042,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCC(C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,1165
1937,1869,21414782,17,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dichlorophenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(Cl)c3Cl,CHEMBL1760399,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.1,partial agonist,70.00%,agonist,,,,,,,,PEC50,=,7.2,,,,,,=,7.1,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(Cl)c1Cl,70,544.714,569.059727,1,4,10,3,7.46952,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1942,1870,21414782,19,Q03181,PPARB,Homo sapiens,2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-3-chloro-2-fluorophenoxy)propanoic acid,CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(F)c3Cl,CHEMBL1760401,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.6,agonist,81.00%,agonist,,,,,,,,PEC50,=,6.4,,,,,,=,6.6,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(F)c1Cl,81,528.259,553.0892775,1,4,10,3,6.95522,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1164
1945,1871,21414782,21,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-difluorophenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(F)c3F,CHEMBL1760403,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.2,partial agonist,73.00%,agonist,,,,,,,,PEC50,=,6.5,,,,,,=,6.2,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(F)c1F,73,511.804,537.1188281,1,4,10,3,6.44092,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1948,1872,21414782,20,Q03181,PPARB,Homo sapiens,2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2-fluoro-3-methoxyphenoxy)propanoic acid,CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(F)c3OC,CHEMBL1760402,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.3,partial agonist,53.00%,agonist,,,,,,,,PEC50,=,6.3,,,,,,=,6.3,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(F)c1OC,53,520.816,549.1388145,1,5,11,3,6.31042,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1951,1873,21414782,18,Q03181,PPARB,Homo sapiens,2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-3-chloro-2-methoxyphenoxy)propanoic acid,CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(OC)c3Cl,CHEMBL1760400,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.8,partial agonist,70.00%,agonist,,,,,,,,PEC50,=,6.5,,,,,,=,6.8,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(OC)c1Cl,70,537.271,565.109264,1,5,11,3,6.82472,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1957,1875,21414782,13,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)butanoic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(CC)C(=O)O)c(C)c3C,CHEMBL1760269,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.2,partial agonist,51.00%,agonist,,,,,,,,PEC50,=,6.9,,,,,,=,7.2,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(CC)C(=O)O)c(C)c1C,51,509.841,543.1846219,1,4,11,3,7.16966,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1963,1877,21414782,12,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)acetic acid",CCCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OCC(=O)O)c(C)c3C,CHEMBL1760268,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,agonist,85.00%,agonist,,,,,,,,PEC50,=,8.7,,,,,,=,7.9,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OCC(=O)O)c(C)c1C,85,485.819,515.1533217,1,4,10,3,6.39106,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1164
1969,1880,21414782,29,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(2,4'-dichlorobiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1Cl)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760411,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.1,partial agonist,53.00%,agonist,,,,,,,,PEC50,=,8,,,,,,=,8.1,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,53,521.272,549.1143494,1,4,10,3,7.12454,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1972,1881,21414782,30,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-chloro-2-methoxybiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1OC)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760412,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.6,partial agonist,66.00%,agonist,,,,,,,,PEC50,=,7.7,,,,,,=,7.6,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(Cl)cc2)c1OC)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,66,513.829,545.1638864,1,5,11,3,6.47974,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1975,1882,21414782,43,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(2-methyl-4'-(trifluoromethoxy)biphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(OC(F)(F)F)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760425,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.1,partial agonist,49.00%,agonist,,,,,,,,PEC50,=,7.4,,,,,,=,7.1,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,49,547.381,579.1902434,1,5,11,3,7.02476,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1978,1883,21414782,46,Q03181,PPARB,Homo sapiens,"2-({4-[(butyl{2-chloro-4'-[(trifluoromethyl)oxy]-3-biphenylyl}amino)sulfonyl]-2,3-dimethylphenyl}oxy)propanoic acid",CCCCN(c1cccc(c1Cl)c2ccc(OC(F)(F)F)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760005,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,51.00%,agonist,,,,,,,,PEC50,=,8.6,,,,,,=,7.8,pIC50,B,radiometric,CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,51,570.823,599.135621,1,5,11,3,7.36974,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1981,1884,21414782,45,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(4'-methoxy-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccc(OC)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760427,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.0,partial agonist,56.00%,agonist,,,,,,,,PEC50,=,7.4,,,,,,=,7,pIC50,,radiometric,CCCCN(c1cccc(-c2ccc(OC)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,56,490.387,525.2185088,1,5,11,3,6.13476,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1984,1885,21414782,39,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(3'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2cccc(Cl)c2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760421,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.2,partial agonist,42.00%,agonist,,,,,,,,PEC50,=,6.3,,,,,,=,6.2,pIC50,,radiometric,CCCCN(c1cccc(-c2cccc(Cl)c2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,42,497.83,529.1689718,1,4,10,3,6.77956,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1987,1886,21414782,41,Q03181,PPARB,Homo sapiens,"2-(4-(N-butyl-N-(2'-chloro-2-methylbiphenyl-3-yl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCCN(c1cccc(c1C)c2ccccc2Cl)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760423,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.8,partial agonist,34.00%,agonist,,,,,,,,PEC50,=,5.7,,,,,,=,5.8,pIC50,,radiometric,CCCCN(c1cccc(-c2ccccc2Cl)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,34,497.83,529.1689718,1,4,10,3,6.77956,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
1997,1890,17257838,9c,P10275,AR,Homo sapiens,"7-(butylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCCCNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706879,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 50nM,antagonist,86.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,67,nM,=,7.301029996,pIC50,B,radiometric,CCCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,86,269.161,284.1136478,2,2,4,2,3.7589,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
2002,1892,15125928,13,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Butoxy-3,5-di-tert-butyl-phenyl)-1H-indol-5-yl]-but-2-enoic acid",CCCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)c2c[nH]c3ccc(cc23)\C(=C\C(=O)O)\C,CHEMBL93246,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,antagonist,93.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,26.4,nM,=,8.494850022,pKi,B,radiometric,CCCCOc1c(-c2c[nH]c3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)(C)C)cc1C(C)(C)C,93,422.334,461.2929941,2,2,7,3,8.0967,62.32,C1CCC(C2CCC3CCCCC32)CC1,antagonist,antagonist,antagonist,antagonist,111
2004,1893,15125928,11,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Butoxy-3,5-diisopropyl-phenyl)-1H-indol-5-yl]-but-2-enoic acid",CCCCOc1c(cc(cc1c2c[nH]c3ccc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL92798,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7.4nM,antagonist,87.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,21.1,nM,=,8.13076828,pKi,B,radiometric,CCCCOc1c(-c2c[nH]c3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,87,398.312,433.261694,2,2,9,3,7.7485,62.32,C1CCC(C2CCC3CCCCC32)CC1,antagonist,antagonist,antagonist,antagonist,111
2008,1894,15006411,66,P19793,RXRA,Homo sapiens,"(Z)-3-[7-(2-Butoxy-3,5-diisopropyl-phenyl)-benzofuran-2-yl]-2-fluoro-but-2-enoic acid",CCCCOc1c(cc(cc1c2cccc3cc(oc23)\C(=C(/F)\C(=O)O)\C)C(C)C)C(C)C,CHEMBL290246,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16nM,antagonist,93.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,11,nM,=,7.795880017,pKi,B,radiometric,CCCCOc1c(-c2cccc3cc(/C(C)=C(\F)C(=O)O)oc23)cc(C(C)C)cc1C(C)C,93,419.302,452.2362878,1,3,9,3,8.3106,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
2012,1895,15125928,12,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Butoxy-3,5-diisopropyl-phenyl)-1-methyl-1H-indol-5-yl]-but-2-enoic acid",CCCCOc1c(cc(cc1c2cn(C)c3ccc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL421748,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 740nM,antagonist,86.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,1533,nM,=,6.13076828,pKi,,radiometric,CCCCOc1c(-c2cn(C)c3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,86,410.323,447.277344,1,3,9,3,7.7589,51.46,C1CCC(C2CCC3CCCCC32)CC1,antagonist,antagonist,antagonist,antagonist,111
2016,1896,14592510,22,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-(2-Butoxy-3,5-diisopropyl-phenyl)-6-fluoro-3-methyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1\C(=C(\F)/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL131826,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 4.4nM,antagonist,92.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,4.7,nM,=,8.356547324,pKi,B,radiometric,CCCCOc1c(/C(C)=C(F)\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,92,367.27,402.2570232,1,2,10,1,7.3999,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2020,1897,12951091,7,P19793,RXRA,Homo sapiens,"(2Z,4E,6Z)-7-(2-Butoxy-3,5-di-tert-butyl-phenyl)-3-trifluoromethyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C(F)(F)F)\C,CHEMBL107554,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 5208nM,partial antagonist,65.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,805.8,nM,=,5.283329024,pKi,,radiometric,CCCCOc1c(/C(C)=C\C=C\C(=C\C(=O)O)C(F)(F)F)cc(C(C)(C)C)cc1C(C)(C)C,65,429.288,466.2694797,1,2,8,1,7.9933,46.53,C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,205
2022,1898,12951091,6,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(2-Butoxy-3,5-di-tert-butyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL110195,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 3.8nM,antagonist,91.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,3.3,nM,=,8.420216403,pKi,B,radiometric,CCCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)C)cc1C(C)(C)C,91,372.294,412.2977451,1,2,8,1,7.4509,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2025,1899,12801232,11g,P19793,RXRA,Homo sapiens,"7-(2-Butoxy-3,5-diisopropyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL414218,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 4nM,antagonist,91.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,4,nM,=,8.397940009,pKi,B,radiometric,CCCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,91,348.272,384.266445,1,2,10,1,7.1027,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2026,1899,15125928,3,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(2-Butoxy-3,5-diisopropyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL414218,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4nM,antagonist,91.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,4,nM,=,8.397940009,pKi,B,radiometric,CCCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,91,348.272,384.266445,1,2,10,1,7.1027,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2037,1900,14592510,42c,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(2-Butoxy-3-isopropyl-5-pentafluoroethyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(F)(F)C(F)(F)F)C(C)C,CHEMBL424269,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 21.4nM,antagonist,93.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,4,nM,=,7.669586227,pKi,B,radiometric,CCCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(F)(F)C(F)(F)F)cc1C(C)C,93,431.251,460.2036859,1,2,10,1,7.6334,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2052,1909,10743937,11b,P10275,AR,Homo sapiens,"8-Butylsulfanyl-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CCCCSc1cc(c2cc3CCC(C)(C)Nc3cc2n1)C(F)(F)F,CHEMBL133715,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,75.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,1866,nM,>,6,pKi,,other,CCCCSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,75,345.284,368.1534044,1,3,4,2,6.2825,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
2064,1916,16777408,38,P03372,ERA,Homo sapiens,"(S)(-)-6-bromo-9a-butyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL215802,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1906nM,agonist,80.00%,agonist,ref agonist,,E2,,,,,EC50,=,519,nM,,,,,=,5.719877104,pIC50,,radiometric,CCCC[C@@]12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,80,342.111,359.0633243,1,3,3,2,4.1595,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2065,1916,16777408,38,Q92731,ERB,Homo sapiens,"(S)(-)-6-bromo-9a-butyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)Br,CHEMBL215802,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 5.7nM,agonist,85.00%,agonist,ref agonist,,E2,,,,,EC50,=,5.5,nM,,,,,=,8.244125144,pIC50,B,radiometric,CCCC[C@@]12CCC(=O)C(Br)=C1c1ccc3[nH]nnc3c1C2,85,342.111,359.0633243,1,3,3,2,4.1595,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2072,192,19376700,3a,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(6-((allyloxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)-2-ethoxypropanoic acid",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N\OCC=C)\c4ccccc4)cc1)C(=O)O,CHEMBL562659,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 54.2nM,agonist,150.00%,agonist,Rosiglitazone,1000nM,rosiglitazone,,,,,EC50,=,13,nM,,,,,=,7.266000713,pIC50,B,radiometric,C=CCO/N=C(\c1ccccc1)c1ccc2c(c1)C(C)(C)CCN2CCOc1ccc(C[C@H](OCC)C(=O)O)cc1,150,516.383,556.2937224,1,6,14,3,6.2405,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
2075,1921,16777408,40,P03372,ERA,Homo sapiens,"(S)-9a-butyl-6-trifluoromethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C(F)(F)F,CHEMBL384709,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 896nM,agonist,81.00%,agonist,ref agonist,,E2,,,,,EC50,=,169,nM,,,,,=,6.04769199,pIC50,,radiometric,CCCC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nnc3c1C2,81,331.212,349.1401969,1,3,3,2,4.3694,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2076,1921,16777408,40,Q92731,ERB,Homo sapiens,"(S)-9a-butyl-6-trifluoromethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C(F)(F)F,CHEMBL384709,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 3.2nM,agonist,83.00%,agonist,ref agonist,,E2,,,,,EC50,=,2.3,nM,,,,,=,8.494850022,pIC50,B,radiometric,CCCC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nnc3c1C2,83,331.212,349.1401969,1,3,3,2,4.3694,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2085,1925,16777408,(S)-29,P03372,ERA,Homo sapiens,"(S)(-)-9a-Butyl-6-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL441366,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 220nM,agonist,78.00%,agonist,ref agonist,,E2,,,,,EC50,=,30,nM,,,,,=,6.657577319,pIC50,,radiometric,CCCC[C@@]12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,78,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2086,1925,16777408,(S)-29,Q92731,ERB,Homo sapiens,"(S)(-)-9a-Butyl-6-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL441366,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 5.1nM,agonist,91.00%,agonist,ref agonist,,E2,,,,,EC50,=,0.4,nM,,,,,=,8.292429824,pIC50,B,radiometric,CCCC[C@@]12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,91,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2088,1926,16777408,47,Q92731,ERB,Homo sapiens,"(S)(-)-9a-butyl-6-thiophen-2-yl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)c5cccs5,CHEMBL214692,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 2.3nM,partial agonist,55.00%,agonist,ref agonist,,E2,,,,,EC50,=,0.96,nM,,,,,=,8.638272164,pIC50,B,radiometric,CCCC[C@@]12CCC(=O)C(c3cccs3)=C1c1ccc3[nH]nnc3c1C2,55,342.318,363.1405333,1,4,4,3,5.0258,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCC1,agonist,partial agonist,agonist,partial agonist,570
2096,1930,16777408,(R)-29,P03372,ERA,Homo sapiens,"(R)(+)-9a-butyl-6-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL377046,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 4753nM,partial agonist,29.00%,agonist,ref agonist,,E2,,,,,EC50,=,391,nM,,,,,=,5.323032186,pIC50,,radiometric,CCCC[C@]12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,29,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
2097,1930,16777408,(R)-29,Q92731,ERB,Homo sapiens,"(R)(+)-9a-butyl-6-ethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CCCC[C@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)CC,CHEMBL377046,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 242nM,agonist,88.00%,agonist,ref agonist,,E2,,,,,EC50,=,28,nM,,,,,=,6.616184634,pIC50,,radiometric,CCCC[C@]12CCC(=O)C(CC)=C1c1ccc3[nH]nnc3c1C2,88,286.229,309.1841124,1,3,4,2,4.2171,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
2098,1931,10743937,12b,P10275,AR,Homo sapiens,"8-(Butane-1-sulfinyl)-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CCCC[S+]([O-])c1cc(c2cc3CCC(C)(C)Nc3cc2n1)C(F)(F)F,CHEMBL132295,,cotransfection,hAR transfected into COS-1 cells,Ki = 96nM,antagonist,96.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,335,nM,=,7.017728767,pKi,B,other,CCCC[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,96,361.283,384.148319,1,3,4,2,5.298,47.98,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
2102,1934,19757405,9cRA,P19793,RXRA,Homo sapiens,,CCCCc1cc2c(cc1C(=C3CC3)c4ccc(cc4)C(=O)[O-])C(CCC2(C)C)(C)C, ZINC28459938,,transcriptional activity assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 67 nM,agonist,100.00%,agonist,9cRA,100nM,9cRA,7.5nM,,,,,,,,,,,,=,7.173925197,pIC50,B,radiometric,CCCCc1cc2c(cc1C(=C1CC1)c1ccc(C(=O)[O-])cc1)C(C)(C)CCC2(C)C,100,380.317,415.2642539,0,2,6,2,6.3374,40.13,C1CCC(C(C2CC2)C2CCC3CCCCC3C2)CC1,,agonist,,agonist,217
2103,1934,19757405,SR11179,P19793,RXRA,Homo sapiens,,CCCCc1cc2c(cc1C(=C3CC3)c4ccc(cc4)C(=O)[O-])C(CCC2(C)C)(C)C, ZINC28459938,,transcriptional activity assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 450nM,,,,9cRA,100nM,9cRA,7.5nM,,,,,,,,IC50,>,10000,nM,=,6.346787486,pIC50,,radiometric,CCCCc1cc2c(cc1C(=C1CC1)c1ccc(C(=O)[O-])cc1)C(C)(C)CCC2(C)C,,380.317,415.2642539,0,2,6,2,6.3374,40.13,C1CCC(C(C2CC2)C2CCC3CCCCC3C2)CC1,,,,agonist,217
2129,1949,9873612,13a,P06401,PR,Homo sapiens,"11-Butyl-1,3,3-trimethyl-4,11-dihydro-3H-pyrido[3,2-a]carbazole",CCCCn1c2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL330726,,cotransfection,-,Ki = 77nM,antagonist,90.00%,antagonist,,,,,,,,,,,,IC50,=,416,nM,=,7.113509275,pKi,B,other,CCCCn1c2ccccc2c2ccc3c(c21)C(C)=CC(C)(C)N3,90,292.256,318.2095988,1,2,3,3,6.202,16.96,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
2130,1949,16821785,25,P06401,PR,Homo sapiens,"11-butyl-1,3,3-trimethyl-4,11-dihydro-3H-pyrido[3,2-a]carbazole",CCCCn1c2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL330726,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.11,,,,progesterone,,,,,,,,,,,,,,,=,7.11,pKi,B,radiometric,CCCCn1c2ccccc2c2ccc3c(c21)C(C)=CC(C)(C)N3,,292.256,318.2095988,1,2,3,3,6.202,16.96,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,antagonist,9
2132,195,17681466,41,P04150,GR,Homo sapiens,"(-)-4-(1-(allyloxy)ethyl)-6-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-1,2-dihydroquinoline",Cl.COc1ccc(F)cc1c2ccc3NC(C)(C)C=C(C(C)OCC=C)c3c2,CHEMBL537887,IL-6 inhibition ,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,partial agonist,46.00%,agonist,,,,,,,,IC50,=,260,nM,,,,,=,6.958607315,pIC50,,FPA,C=CCOC(C)C1=CC(C)(C)Nc2ccc(-c3cc(F)ccc3OC)cc21.Cl,46,376.709,403.171435,1,3,6,2,6.1017,30.49,C1CCC(C2CCC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,119
2140,1954,17267219,6g,P10275,AR,Homo sapiens,"6-(propyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CCCN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237261,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,agonist,88.00%,agonist,DHT,,,,,,,EC50,=,1.3,nM,IC50,>,10000,nM,=,7.920818754,pIC50,B,radiometric,CCCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,88,338.166,352.1010324,1,2,4,2,4.3256,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
2141,1955,17257838,10d,P10275,AR,Homo sapiens,"7-(propyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCCN(CC(F)(F)F)c1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706895,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 241nM,antagonist,89.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,549,nM,=,6.617982957,pIC50,,radiometric,CCCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,89,338.166,352.1010324,1,2,4,2,4.3256,36.1,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
2143,1956,19019676,16c,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-propylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(F)cccc3F,CHEMBL465927,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,128.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.6,,,,,,=,7.8,pIC50,B,FPA,CCCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,128,520.284,543.1705089,3,6,9,3,3.4474,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
2147,1959,17034117,4e,P10275,AR,Homo sapiens,"6-N,N-dipropylamino-4-trifluoromethylquinolin-2(1H)-one",CCCN(CCC)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL442240,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 64nM,partial agonist,72.00%,agonist,DHT,,,,,,,EC50,=,1.5,nM,IC50,>,10000,nM,=,7.193820026,pKi,B,radiometric,CCCN(CCC)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,72,293.183,312.1449479,1,2,5,2,4.1733,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
2148,1959,17267219,6b,P10275,AR,Homo sapiens,6-(dipropylamino)-4-(trifluoromethyl)quinolin-2(1H)-one,CCCN(CCC)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL442240,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 64nM,partial agonist,72.00%,agonist,DHT,,,,,,,EC50,=,1.5,nM,IC50,>,10000,nM,=,7.193820026,pIC50,B,radiometric,CCCN(CCC)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,72,293.183,312.1449479,1,2,5,2,4.1733,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
2161,1964,21414782,23,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-propylsulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760405,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.9,partial agonist,55.00%,agonist,,,,,,,,PEC50,=,7.1,,,,,,=,6.9,pIC50,,radiometric,CCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,55,485.819,515.1533217,1,4,9,3,6.38946,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
2172,1969,17439112,10c,P10275,AR,Homo sapiens,"1,2,3,6-tetrahydro-1-propyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCCN1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL227590,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 9.6nM,agonist,83.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,83,nM,IC50,>,10000,nM,=,8.017728767,pKi,B,radiometric,CCCN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,83,297.171,312.1085624,1,3,2,2,3.1557,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
2175,1970,19616429,18,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-methylbenzyl)(5-oxo-1-propylpyrrolidin-3-yl)amino)benzonitrile,CCCN1C[C@H](CC1=O)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL552285,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 80nM,partial agonist,49.00%,agonist,progesterone,,,,,,,EC50,=,1415,nM,,,,,=,7.096910013,pIC50,B,other,CCCN1C[C@@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)CC1=O,49,357.715,381.1607901,0,3,6,2,4.5376,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
2176,1971,20584610,18,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-1,7-Dimethyl-3,5-dioxo-9-propyl-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CCCN1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1209903,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 14nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,14,nM,=,7.853871964,pKi,B,radiometric,CCCN1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,399.243,421.1613262,0,5,3,1,2.95588,73.64,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
2177,1972,9871534,20,P10275,AR,Homo sapiens,"(5bR,9aR)-1-Methyl-10-propyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CCCN1[C@@H]2CCCC[C@@H]2c3cc4C(=CC(=O)N(C)c4cc13)C(F)(F)F,CHEMBL165912,,,,Ki = 63nM,partial antagonist,48.00%,antagonist,DHT,,,,,,,EC50,=,324,nM,IC50,=,27,nM,=,7.200659451,pKi,B,other,CCCN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,48,341.227,364.176248,0,3,2,2,4.8135,25.24,CC1CCC2CC3C(CC2C1)CC1CCCCC13,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,573
2182,1976,19162487,4k,P55055,LXRB,Homo sapiens,3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]-N-propylbenzamide,CCCNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL518033,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 25nM,partial agonist,45.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,1180,nM,,,,,=,7.602059991,pIC50,B,radiometric,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,45,407.751,430.1448057,1,3,6,4,6.79572,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
2184,1977,19162487,4b,P55055,LXRB,Homo sapiens,3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-N-propylbenzamide,CCCNC(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL480298,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.5nM,agonist,107.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,1525,nM,,,,,=,8.070581074,pIC50,B,radiometric,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,107,513.369,540.2024628,1,3,8,5,8.4435,51.22,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
2185,1977,19162487,4b,Q13133,LXRA,Homo sapiens,3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-N-propylbenzamide,CCCNC(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL480298,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 91nM,partial agonist,43.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,2709,nM,,,,,=,7.040958608,pIC50,B,radiometric,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,43,513.369,540.2024628,1,3,8,5,8.4435,51.22,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,278
2187,1979,20469868,19e,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-propyl-3-(trifluoromethyl)benzenesulfonamide,CCCNS(=O)(=O)c1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1085380,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,partial antagonist,63.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.5,,=,7.5,pIC50,B,FPA,CCCNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,63,458.331,477.1134107,1,4,6,4,5.5387,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,107
2195,1981,17257838,11e,P10275,AR,Homo sapiens,"6-methyl-7-(propylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCCNc1cc2NC(=O)C=C(c2cc1C)C(F)(F)F,CHEMBL3706900,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 641nM,antagonist,93.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,674,nM,=,6.19314197,pIC50,,radiometric,CCCNc1cc2[nH]c(=O)cc(C(F)(F)F)c2cc1C,93,269.161,284.1136478,2,2,3,2,3.67722,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
2196,1982,17257838,7,P10275,AR,Homo sapiens,"7-(propylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCCNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706875,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 37nM,antagonist,86.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,32,nM,=,7.431798276,pIC50,B,radiometric,CCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,86,257.15,270.0979977,2,2,3,2,3.3688,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
2197,1983,17034117,4a,P10275,AR,Homo sapiens,6-N-propyl-4-trifluoromethylquinolin-2(1H)-one,CCCNc1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL405835,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 54nM,partial antagonist,72.00%,antagonist,DHT,,,,,,,EC50,=,2022,nM,IC50,=,27.5,nM,=,7.26760624,pKi,B,radiometric,CCCNc1ccc2nc(O)cc(C(F)(F)F)c2c1,72,257.15,270.0979977,2,3,3,2,3.7811,45.15,CC1CCC2CCCCC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,651
2204,1987,18511276,33d,P37231,PPARG,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(propoxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",CCCOC(=O)N1CCC(C(=O)O)C(=C1)Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL256142,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 88nM,agonist,150.00%,agonist,ref agonist,,,,,,,EC50,=,8,nM,,,,,=,7.055517328,pIC50,B,FPA,CCCOC(=O)N1C=C(Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C(C(=O)O)CC1,150,472.327,504.2260367,1,6,10,3,5.65102,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
2205,1987,18511276,33d,Q07869,PPARA,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(propoxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",CCCOC(=O)N1CCC(C(=O)O)C(=C1)Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL256142,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 499nM,agonist,109.00%,agonist,ref agonist,,,,,,,EC50,=,8,nM,,,,,=,6.301899454,pIC50,,FPA,CCCOC(=O)N1C=C(Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C(C(=O)O)CC1,109,472.327,504.2260367,1,6,10,3,5.65102,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
2206,1988,18511276,13d,P37231,PPARG,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(propoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CCCOC(=O)N1CCC(=C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL256569,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1320nM,agonist,87.00%,agonist,ref agonist,,,,,,,EC50,=,180,nM,,,,,=,5.879426069,pIC50,,FPA,CCCOC(=O)N1CCC(C(=O)O)=C(Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,87,472.327,504.2260367,1,6,10,3,5.44752,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
2207,1988,18511276,13d,Q07869,PPARA,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(propoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CCCOC(=O)N1CCC(=C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL256569,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 970nM,agonist,85.00%,agonist,ref agonist,,,,,,,EC50,=,40,nM,,,,,=,6.013228266,pIC50,,FPA,CCCOC(=O)N1CCC(C(=O)O)=C(Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,85,472.327,504.2260367,1,6,10,3,5.44752,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
2208,1989,17005393,14,P37231,PPARG,Homo sapiens,"5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-8-(2-carboxy-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid propyl ester",CCCOC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccc(cc4)c5ccccc5)ccc(CCC(=O)O)c2C1,CHEMBL219836,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 21nM,partial agonist,55.00%,agonist,ref agonist,,,,,,,EC50,=,3,nM,,,,,=,7.677780705,pIC50,B,radiometric,CCCOC(=O)N1CCc2c(OCCc3nc(-c4ccc(-c5ccccc5)cc4)oc3C)ccc(CCC(=O)O)c2C1,55,532.382,568.2573369,1,6,11,4,6.86042,102.1,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCCC54)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,149
2209,1989,17005393,14,Q07869,PPARA,Homo sapiens,"5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-8-(2-carboxy-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid propyl ester",CCCOC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccc(cc4)c5ccccc5)ccc(CCC(=O)O)c2C1,CHEMBL219836,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",no binding,partial agonist,27.00%,agonist,ref agonist,,,,,,,EC50,=,2393,nM,,,,,,,NEG,NB,radiometric,CCCOC(=O)N1CCc2c(OCCc3nc(-c4ccc(-c5ccccc5)cc4)oc3C)ccc(CCC(=O)O)c2C1,27,532.382,568.2573369,1,6,11,4,6.86042,102.1,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCCC54)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,149
2212,1990,17005393,13,P37231,PPARG,Homo sapiens,"3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-(propoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",CCCOC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccccc4)ccc(CCC(=O)O)c2C1,CHEMBL376460,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,partial agonist,61.00%,agonist,ref agonist,,,,,,,EC50,=,12,nM,,,,,=,7.958607315,pIC50,B,radiometric,CCCOC(=O)N1CCc2c(OCCc3nc(-c4ccccc4)oc3C)ccc(CCC(=O)O)c2C1,61,460.316,492.2260367,1,6,10,3,5.19342,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
2213,1990,17005393,13,Q07869,PPARA,Homo sapiens,"3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-(propoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",CCCOC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccccc4)ccc(CCC(=O)O)c2C1,CHEMBL376460,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4684nM,partial agonist,47.00%,agonist,ref agonist,,,,,,,EC50,=,561,nM,,,,,=,5.329383114,pIC50,,radiometric,CCCOC(=O)N1CCc2c(OCCc3nc(-c4ccccc4)oc3C)ccc(CCC(=O)O)c2C1,47,460.316,492.2260367,1,6,10,3,5.19342,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
2214,1991,20584610,24,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid propyl ester",CCCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210033,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 6.6nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,9.3,nM,=,8.180456064,pKi,B,radiometric,CCCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,443.252,465.1511555,0,6,3,1,3.09248,99.94,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
2217,1993,19349176,rac-3Ca,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL519974,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,agonist,81.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,16,nM,,,,,=,8.15490196,pIC50,B,radiometric,CCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,81,430.31,459.204573,1,5,11,4,5.84702,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
2218,1993,19349176,rac-3Ca,Q07869,PPARA,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL519974,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 69nM,partial agonist,56.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,87,nM,,,,,=,7.161150909,pIC50,B,radiometric,CCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,56,430.31,459.204573,1,5,11,4,5.84702,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
2219,1994,19349176,rac-2Ca,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL521462,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,partial agonist,64.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,12,nM,,,,,=,8.397940009,pIC50,B,radiometric,CCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,64,438.355,465.160994,1,6,11,4,5.90852,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
2220,1994,19349176,rac-2Ca,Q07869,PPARA,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL521462,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 175nM,agonist,123.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,75,nM,,,,,=,6.756961951,pIC50,,radiometric,CCCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,123,438.355,465.160994,1,6,11,4,5.90852,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
2221,1995,16737814,27,P37231,PPARG,Homo sapiens,3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL377898,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 399nM,partial agonist,42.00%,agonist,Edaglitazone,,,,,,,EC50,=,2000,nM,,,,,=,6.399027104,pIC50,,radiometric,CCCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c1)C(=O)O,42,461.29,486.1766419,1,5,9,4,6.09412,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
2223,1995,16737814,27,Q07869,PPARA,Homo sapiens,3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)-2-propoxypropanoic acid,CCCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL377898,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 40nM,agonist,118.00%,agonist,Farglitazar,,,,,,,EC50,=,510,nM,,,,,=,7.397940009,pIC50,B,radiometric,CCCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c1)C(=O)O,118,461.29,486.1766419,1,5,9,4,6.09412,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
2225,1996,9873735,28,P06401,PR,Homo sapiens,"9-Chloro-2,2,4-trimethyl-5-propoxy-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCOC1Oc2ccc(Cl)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL116221,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,104.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14,nM,,,,,=,8.823908741,pKi,B,radiometric,CCCOC1Oc2ccc(Cl)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,104,345.7,369.1495567,1,3,3,2,6.432,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
2227,1997,9873735,26,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-propoxy-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCOC1Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL113098,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.0nM,partial agonist,46.00%,agonist,progesterone,,progesterone,,,,,EC50,=,26,nM,,,,,=,8.22184875,pKi,B,radiometric,CCCOC1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,46,329.245,353.1791072,1,3,3,2,5.9177,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
2228,1998,9873735,24,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-propoxy-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCOC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL113099,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 64nM,antagonist,88.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,890,nM,IC50,=,69,nM,=,7.193820026,pKi,B,radiometric,CCCOC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,88,310.247,335.188529,1,3,3,2,5.7786,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,16
2230,2,11728194,35,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-prop-2-ynyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC#C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL138098,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.7nM,agonist,88.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,34,nM,,,,,=,8.568636236,pKi,B,radiometric,C#CCC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,88,322.258,345.172879,1,3,2,2,5.4264,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
2236,2000,19349176,(S)-2Ca,Q07869,PPARA,Homo sapiens,(S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-propoxypropanoic acid,CCCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL484606,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 393nM,agonist,204.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,13,nM,,,,,=,6.40560745,pIC50,,radiometric,CCCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,204,438.355,465.160994,1,6,11,4,5.90852,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
2238,2001,15125928,14,P19793,RXRA,Homo sapiens,"(E)-3-[3-(3,5-Di-tert-butyl-2-propoxy-phenyl)-1H-indol-5-yl]-but-2-enoic acid",CCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)c2c[nH]c3ccc(cc23)\C(=C\C(=O)O)\C,CHEMBL92447,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.6nM,antagonist,81.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,30.1,nM,=,8.795880017,pKi,B,radiometric,CCCOc1c(-c2c[nH]c3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)(C)C)cc1C(C)(C)C,81,410.323,447.277344,2,2,6,3,7.7066,62.32,C1CCC(C2CCC3CCCCC32)CC1,antagonist,antagonist,antagonist,antagonist,111
2242,2002,15006411,58,P19793,RXRA,Homo sapiens,"(E)-3-[7-(3,5-Diisopropyl-2-propoxy-phenyl)-benzofuran-2-yl]-but-2-enoic acid",CCCOc1c(cc(cc1c2cccc3cc(oc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL41675,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 44nM,partial antagonist,74.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,129,nM,=,7.356547324,pKi,B,radiometric,CCCOc1c(-c2cccc3cc(/C(C)=C/C(=O)O)oc23)cc(C(C)C)cc1C(C)C,74,388.293,420.2300595,1,3,8,3,7.6233,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,partial antagonist,antagonist,partial antagonist,138
2246,2003,15006411,34,P19793,RXRA,Homo sapiens,"(E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid",CCCOc1c(cc(cc1c2cccc3sc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL41742,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 14nM,antagonist,81.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,16,nM,=,7.853871964,pKi,B,radiometric,CCCOc1c(-c2cccc3sc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,81,404.361,436.2072159,1,3,8,3,8.0918,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
2250,2004,12801232,12e,P19793,RXRA,Homo sapiens,"7-(3,5-Di-tert-butyl-2-propoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL420249,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 14nM,partial antagonist,74.00%,antagonist,?,,9-Cis-RA,,,,,,,,,IC50,=,43,nM,=,7.853871964,pKi,B,radiometric,CCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)C)cc1C(C)(C)C,74,360.283,398.2820951,1,2,7,1,7.0608,46.53,C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,205
2252,2005,12801232,13d,P19793,RXRA,Homo sapiens,"7-[3,5-Bis-(1,1-dimethyl-propyl)-2-propoxy-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CCCOc1c(cc(cc1C(C)(C)CC)C(C)(C)CC)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL90254,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 23nM,antagonist,88.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,13,nM,=,7.638272164,pKi,B,radiometric,CCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)CC)cc1C(C)(C)CC,88,384.305,426.3133952,1,2,11,1,7.841,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2254,2006,12801232,11f,P19793,RXRA,Homo sapiens,"7-(3,5-Diisopropyl-2-propoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL91779,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,85.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,4,nM,=,8.522878745,pKi,B,radiometric,CCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,85,336.261,370.2507949,1,2,9,1,6.7126,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2258,2007,14592510,57,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(5-Isopropyl-3-pentafluoroethyl-2-propoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCOc1c(cc(cc1C(F)(F)C(F)(F)F)C(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL131122,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 85.8nM,antagonist,80.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,10.7,nM,=,7.066512712,pKi,B,radiometric,CCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(F)(F)C(F)(F)F,80,419.24,446.1880358,1,2,9,1,7.2433,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2264,2008,14592510,42b,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(3-Isopropyl-5-pentafluoroethyl-2-propoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(F)(F)C(F)(F)F)C(C)C,CHEMBL132568,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 25.6nM,antagonist,91.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,5.1,nM,=,7.591760035,pKi,B,radiometric,CCCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(F)(F)C(F)(F)F)cc1C(C)C,91,419.24,446.1880358,1,2,9,1,7.2433,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
2272,2009,12954061,25c,P19793,RXRA,Homo sapiens,"5-[2-(3,5-Diisopropyl-2-propoxy-phenyl)-cyclopent-1-enyl]-3-methyl-penta-2,4-dienoic acid",CCCOc1c(cc(cc1C2=C(CCC2)\C=C\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL133176,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,antagonist,80.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,3.3,nM,=,8.721246399,pKi,B,radiometric,CCCOc1c(C2=C(/C=C/C(C)=C/C(=O)O)CCC2)cc(C(C)C)cc1C(C)C,80,360.283,396.266445,1,2,9,1,7.2468,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,"antagonist,partial antagonist",129
2273,2009,12954061,25a,P19793,RXRA,Homo sapiens,"5-[2-(3,5-Diisopropyl-2-propoxy-phenyl)-cyclopent-1-enyl]-3-methyl-penta-2,4-dienoic acid",CCCOc1c(cc(cc1C2=C(CCC2)\C=C\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL133176,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,partial antagonist,72.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,4.5,nM,=,8.721246399,pKi,B,radiometric,CCCOc1c(C2=C(/C=C/C(C)=C/C(=O)O)CCC2)cc(C(C)C)cc1C(C)C,72,360.283,396.266445,1,2,9,1,7.2468,46.53,C1CCC(C2CCCC2)CC1,antagonist,partial antagonist,antagonist,"antagonist,partial antagonist",129
2291,2014,19926282,11,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-(propylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CCCS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL592755,,,,IC50 = 80nM,partial agonist,41.00%,agonist,,,,,,,,EC50,=,2630,nM,,,,,=,7.096910013,pIC50,B,other,CCCS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,41,462.775,485.1151603,0,4,7,2,5.05118,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
2293,2016,21257309,19b,P04150,GR,Homo sapiens,(S)-N-isopropyl-3-(6-methyl-4-(2-(propylsulfonamido)propylamino)-1H-indazol-1-yl)benzamide,CCCS(=O)(=O)N[C@@H](C)CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)NC(C)C,CHEMBL1668084,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,85.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.1,,,,,,=,7.9,pIC50,B,FPA,CCCS(=O)(=O)N[C@@H](C)CNc1cc(C)cc2c1cnn2-c1cccc(C(=O)NC(C)C)c1,85,438.363,471.2304109,3,6,10,3,3.60192,105.12,C1CCC(C2CCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,111
2294,2017,20469868,20c,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-1-propanesulfonamide,CCCS(=O)(=O)Nc1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1084632,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,antagonist,89.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.7,,=,7.8,pIC50,B,FPA,CCCS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,89,458.331,477.1134107,1,4,6,4,6.0021,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,107
2299,2019,19932617,7j,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(3-(propylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,CCCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL595580,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.6nM,partial agonist,50.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,251,nM,,,,,=,8.585026652,pIC50,B,radiometric,CCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,50,463.351,485.1272492,0,4,6,4,7.20502,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
2305,2021,9873735,31,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-propylsulfanyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCSC1Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL325213,cotransfection,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.6nM,partial antagonist,63.00%,antagonist,progesterone,,progesterone,,,,,EC50,=,12,nM,IC50,=,345,nM,=,8.180456064,pKi,B,radiometric,CCCSC1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,63,345.313,369.1562636,1,3,3,2,6.6343,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,16
2306,2022,9873735,30,P06401,PR,Homo sapiens,"2,2,4-Trimethyl-5-propylsulfanyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCSC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL114611,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 24.3nM,antagonist,86.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,187,nM,=,7.614393726,pKi,B,radiometric,CCCSC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,86,326.315,351.1656854,1,3,3,2,6.4952,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
2313,2027,10230629,10,P10275,AR,Homo sapiens,"(R)-8-Propyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CCC[C@@H]1CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL268569,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 24nM,antagonist,84.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,32,nM,=,7.619788758,pKi,B,radiometric,CCC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,84,293.183,310.1292978,2,3,2,2,4.486,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,586
2322,2031,10230629,27,P10275,AR,Homo sapiens,2-Hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide,CCC[C@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1CC)C(F)(F)F,CHEMBL7231,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 32nM,partial agonist,69.00%,agonist,DHT,,DHT,,,,,EC50,=,16,nM,,,inactive,,=,7.494850022,pKi,B,radiometric,CCC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,69,317.205,338.160598,2,3,3,2,5.1221,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
2369,2053,12617924,15,Q03181,PPARB,Homo sapiens,3-{4-[4-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-butoxy]-phenyl}-propionic acid,CCCc1c(OCCCCOc2ccc(CCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL172931,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 37.5nM,partial agonist,74.00%,agonist,,,L-783483,2.5nM,,,,EC50,=,74% at 3uM,,,,,,=,7.425968732,pKi,B,radiometric,CCCc1c(OCCCCOc2ccc(CCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,74,442.321,473.2202231,1,5,13,4,6.7025,81.79,C(CCCC1CCC2C(CCC2C2CCCCC2)C1)CCC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1109
2375,2055,12617924,20,Q03181,PPARB,Homo sapiens,2-{4-[4-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-butoxy]-phenoxy}-propionic acid,CCCc1c(OCCCCOc2ccc(OC(C)C(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL369607,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 136nM,agonist,117.00%,agonist,,,L-783483,2.5nM,,,,EC50,=,117% at 3uM,,,,,,=,6.866461092,pKi,,radiometric,CCCc1c(OCCCCOc2ccc(OC(C)C(=O)O)cc2)ccc2c(-c3ccccc3)noc12,117,458.32,489.2151377,1,6,13,4,6.5372,91.02,C(CCCC1CCC2C(CCC2C2CCCCC2)C1)CCC1CCCCC1,agonist,agonist,agonist,agonist,1109
2392,2061,12617924,24,Q03181,PPARB,Homo sapiens,{3-[4-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-butoxy]-phenoxy}-acetic acid,CCCc1c(OCCCCOc2cccc(OCC(=O)O)c2)ccc3c(noc13)c4ccccc4,CHEMBL173409,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 47nM,agonist,127.00%,agonist,,,L-783483,2.5nM,,,,EC50,=,127% at 3uM,,,,,,=,7.327902142,pKi,B,radiometric,CCCc1c(OCCCCOc2cccc(OCC(=O)O)c2)ccc2c(-c3ccccc3)noc12,127,446.309,475.1994876,1,6,13,4,6.1487,91.02,C(CCCC1CCC2C(CCC2C2CCCCC2)C1)CCC1CCCCC1,agonist,agonist,agonist,agonist,1109
2478,2085,12617924,27,Q07869,PPARA,Homo sapiens,(E)-3-{4-[3-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propoxy]-phenyl}-acrylic acid,CCCc1c(OCCCOc2ccc(\C=C\C(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL172959,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 50nM,partial agonist,56.00%,agonist,,,L-797773,5nM,,,,EC50,=,56% at 3uM,,,,,,=,7.301029996,pKi,B,radiometric,CCCc1c(OCCCOc2ccc(/C=C/C(=O)O)cc2)ccc2c(-c3ccccc3)noc12,56,430.31,457.188923,1,5,11,4,6.393,81.79,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,456
2492,2089,12617924,14,P37231,PPARG,Homo sapiens,3-{4-[3-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propoxy]-phenyl}-propionic acid,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL435704,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 32nM,agonist,99.00%,agonist,,,L-797773,5nM,,,,EC50,=,99% at 3uM,,,,,,=,7.494850022,pKi,B,radiometric,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,99,430.31,459.204573,1,5,12,4,6.3124,81.79,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,456
2493,2089,12617924,14,Q03181,PPARB,Homo sapiens,3-{4-[3-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propoxy]-phenyl}-propionic acid,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL435704,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2nM,partial agonist,74.00%,agonist,,,L-783483,2.5nM,,,,EC50,=,74% at 3uM,,,,,,=,8.698970004,pKi,B,radiometric,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,74,430.31,459.204573,1,5,12,4,6.3124,81.79,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,456
2494,2089,12617924,14,Q07869,PPARA,Homo sapiens,3-{4-[3-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propoxy]-phenyl}-propionic acid,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL435704,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.3nM,partial agonist,42.00%,agonist,,,L-797773,5nM,,,,EC50,=,42% at 3uM,,,,,,=,8.13667714,pKi,B,radiometric,CCCc1c(OCCCOc2ccc(CCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,42,430.31,459.204573,1,5,12,4,6.3124,81.79,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,456
2560,2116,12657263,3,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)\C(=N\O)\CC,CHEMBL23874,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 48nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,15,nM,,,,,=,7.318758763,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(/C(CC)=N/O)c1O,,437.775,465.1376717,3,6,12,2,5.7747,99.35,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2561,2116,12657263,3,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)\C(=N\O)\CC,CHEMBL23874,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,9,nM,,,,,=,8,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(/C(CC)=N/O)c1O,,437.775,465.1376717,3,6,12,2,5.7747,99.35,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2562,2116,12657263,3,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)\C(=N\O)\CC,CHEMBL23874,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 100nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,74,nM,,,,,=,7,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(/C(CC)=N/O)c1O,,437.775,465.1376717,3,6,12,2,5.7747,99.35,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2563,2117,12657263,2,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-propionyl-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)CC,CHEMBL25710,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 300nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,70,nM,,,,,=,6.522878745,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(=O)CC)c1O,,423.768,450.1267726,2,5,12,2,5.7791,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2564,2117,12657263,2,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-propionyl-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)CC,CHEMBL25710,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,10,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(=O)CC)c1O,,423.768,450.1267726,2,5,12,2,5.7791,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2565,2117,12657263,2,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(3-hydroxy-4-propionyl-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)CC,CHEMBL25710,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 600nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,260,nM,,,,,=,6.22184875,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(=O)CC)c1O,,423.768,450.1267726,2,5,12,2,5.7791,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2566,2118,12657263,1,P37231,PPARG,Homo sapiens,{4-[3-(4-Acetyl-3-hydroxy-2-propyl-phenoxy)-propylsulfanyl]-3-chloro-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)C,CHEMBL23881,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 580nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,230,nM,,,,,=,6.236572006,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(C)=O)c1O,,411.757,436.1111226,2,5,11,2,5.389,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2567,2118,12657263,1,Q03181,PPARB,Homo sapiens,{4-[3-(4-Acetyl-3-hydroxy-2-propyl-phenoxy)-propylsulfanyl]-3-chloro-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)C,CHEMBL23881,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,80,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(C)=O)c1O,,411.757,436.1111226,2,5,11,2,5.389,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2568,2118,12657263,1,Q07869,PPARA,Homo sapiens,{4-[3-(4-Acetyl-3-hydroxy-2-propyl-phenoxy)-propylsulfanyl]-3-chloro-phenyl}-acetic acid,CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)C,CHEMBL23881,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7400nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,1600,nM,,,,,=,5.13076828,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc(C(C)=O)c1O,,411.757,436.1111226,2,5,11,2,5.389,83.83,C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,466
2569,2119,12657263,7,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(coc13)c4ccccc4,CHEMBL278994,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 94nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,9,nM,,,,,=,7.026872146,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(-c3ccccc3)coc12,,467.824,494.131858,1,4,11,4,7.894,59.67,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,456
2570,2119,12657263,7,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(coc13)c4ccccc4,CHEMBL278994,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,6,nM,,,,,=,8.22184875,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(-c3ccccc3)coc12,,467.824,494.131858,1,4,11,4,7.894,59.67,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,456
2571,2119,12657263,7,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(coc13)c4ccccc4,CHEMBL278994,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 54nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,18,nM,,,,,=,7.26760624,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(-c3ccccc3)coc12,,467.824,494.131858,1,4,11,4,7.894,59.67,C1CCC(CCCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,456
2577,2121,12657263,5,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 140nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,23,nM,,,,,=,6.853871964,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2578,2121,16529931,1,P37231,PPARG,Homo sapiens,2-(3-chloro-4-(3-(7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 195nM,,,,,,,,,,,,,,,,,,,=,6.709965389,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,,agonist,agonist,455
2579,2121,15911262,1,P55055,LXRB,Homo sapiens,{3-Chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24.9nM,partial agonist,35.00%,agonist,,,Methyl-AA,,,,,EC50,=,1080,nM,,,,,=,7.603800653,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,35,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,455
2580,2121,16124770,12,P55055,LXRB,Homo sapiens,2-(3-chloro-4-(3-(7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,HTFR assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 25nM,partial agonist,35.00%,agonist,maximal inhibition (no details),,Methyl-AA,,,,,EC50,=,16,nM,,,,,=,7.602059991,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,35,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,455
2581,2121,16529931,1,P55055,LXRB,Homo sapiens,2-(3-chloro-4-(3-(7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,7300,nM,,,,,=,7.552841969,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,,agonist,partial agonist,455
2582,2121,12657263,5,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,5,nM,,,,,=,8,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2583,2121,16529931,1,Q03181,PPARB,Homo sapiens,2-(3-chloro-4-(3-(7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,,,,,,,,,,,,,,,,,,,=,8.397940009,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,,agonist,agonist,455
2584,2121,12657263,5,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 310nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,125,nM,,,,,=,6.508638306,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2585,2121,16529931,1,Q07869,PPARA,Homo sapiens,2-(3-chloro-4-(3-(7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(noc13)C(F)(F)F,CHEMBL23296,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 280nM,,,,,,,,,,,,,,,,,,,=,6.552841969,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,,466.759,487.0831915,1,5,10,3,6.6408,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,,agonist,agonist,455
2589,2122,12657263,6,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)coc13,CHEMBL23670,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 560nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,102,nM,,,,,=,6.251811973,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)coc12,,419.78,446.131858,1,4,11,3,6.7894,59.67,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2590,2122,12657263,6,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)coc13,CHEMBL23670,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 40nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,12,nM,,,,,=,7.397940009,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)coc12,,419.78,446.131858,1,4,11,3,6.7894,59.67,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2591,2122,12657263,6,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)coc13,CHEMBL23670,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1730nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,1300,nM,,,,,=,5.761953897,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)coc12,,419.78,446.131858,1,4,11,3,6.7894,59.67,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2592,2123,12657263,4,P37231,PPARG,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)noc13,CHEMBL279053,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 110nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,19,nM,,,,,=,6.958607315,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)noc12,,421.776,447.127107,1,5,11,3,6.1844,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2593,2123,12657263,4,Q03181,PPARB,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)noc13,CHEMBL279053,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4nM,agonist,> 80%,agonist,,,L-783483,2.5nM,,,,EC50,=,11,nM,,,,,=,8.397940009,pIC50,B,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)noc12,,421.776,447.127107,1,5,11,3,6.1844,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2594,2123,12657263,4,Q07869,PPARA,Homo sapiens,{3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)noc13,CHEMBL279053,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 570nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,247,nM,,,,,=,6.244125144,pIC50,,radiometric,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(CC)noc12,,421.776,447.127107,1,5,11,3,6.1844,72.56,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,455
2630,2132,12617924,29,P37231,PPARG,Homo sapiens,4-{4-[2-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-ethoxy]-phenyl}-butyric acid,CCCc1c(OCCOc2ccc(CCCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL173236,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 616nM,partial agonist,72.00%,agonist,,,L-797773,5nM,,,,EC50,=,72% at 3uM,,,,,,=,6.210419288,pKi,,radiometric,CCCc1c(OCCOc2ccc(CCCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,72,430.31,459.204573,1,5,12,4,6.3124,81.79,C1CCC(CCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,422
2631,2132,12617924,29,Q03181,PPARB,Homo sapiens,4-{4-[2-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-ethoxy]-phenyl}-butyric acid,CCCc1c(OCCOc2ccc(CCCC(=O)O)cc2)ccc3c(noc13)c4ccccc4,CHEMBL173236,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 156nM,partial agonist,69.00%,agonist,,,L-783483,2.5nM,,,,EC50,=,69% at 3uM,,,,,,=,6.806875402,pKi,,radiometric,CCCc1c(OCCOc2ccc(CCCC(=O)O)cc2)ccc2c(-c3ccccc3)noc12,69,430.31,459.204573,1,5,12,4,6.3124,81.79,C1CCC(CCCCC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,422
2635,2135,15974597,54,P10826,PPARA,Homo sapiens,"(S)-(5-Chloro-3-ethyl-2-oxo-7-propyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1c(O[C@H](C(=O)O)c2ccc(cc2)C(C)C)c(Cl)cc3N(CC)C(=O)Oc13,CHEMBL371778,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1410nM,agonist,571.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,670,nM,,,,,=,5.850780887,pIC50,,radiometric,CCCc1c(O[C@H](C(=O)O)c2ccc(C(C)C)cc2)c(Cl)cc2c1oc(=O)n2CC,571,405.708,431.1499506,1,5,8,3,5.5484,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,agonist,agonist,agonist,550
2636,2135,15974597,54,P37231,PPARG,Homo sapiens,"(S)-(5-Chloro-3-ethyl-2-oxo-7-propyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1c(O[C@H](C(=O)O)c2ccc(cc2)C(C)C)c(Cl)cc3N(CC)C(=O)Oc13,CHEMBL371778,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 520nM,partial agonist,48.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,360,nM,,,,,=,6.283996656,pIC50,,radiometric,CCCc1c(O[C@H](C(=O)O)c2ccc(C(C)C)cc2)c(Cl)cc2c1oc(=O)n2CC,48,405.708,431.1499506,1,5,8,3,5.5484,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2638,2137,20079636,17a,P37231,PPARG,Homo sapiens,4'-((3-(methylthio)-5-(2-phenylbutanamido)-2-propyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCCc1c(SC)c2cc(NC(=O)C(CC)c3ccccc3)ccc2n1Cc4ccc(cc4)c5ccccc5C(=O)O,CHEMBL590983,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 36nM,partial agonist,32.00%,agonist,rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,7.443697499,pIC50,B,radiometric,CCCc1c(SC)c2cc(NC(=O)C(CC)c3ccccc3)ccc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,32,540.474,576.244664,2,4,11,5,8.8615,71.33,CC(CC1CCCCC1)CC1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1041
2641,2138,20079636,17b,P37231,PPARG,Homo sapiens,4'-((3-(methylthio)-6-(2-phenylbutanamido)-2-propyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCCc1c(SC)c2ccc(NC(=O)C(CC)c3ccccc3)cc2n1Cc4ccc(cc4)c5ccccc5C(=O)O,CHEMBL590984,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 490nM,partial agonist,48.00%,agonist,rosiglitazone,,,,,,,EC50,=,201,nM,,,,,=,6.30980392,pIC50,,radiometric,CCCc1c(SC)c2ccc(NC(=O)C(CC)c3ccccc3)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,48,540.474,576.244664,2,4,11,5,8.8615,71.33,CC(CC1CCCCC1)CC1CCC2CCC(CC3CCC(C4CCCCC4)CC3)C2C1,agonist,partial agonist,agonist,partial agonist,1045
2660,2145,17267219,7d,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-propylquinolin-2(1H)-one",CCCC1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL392004,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 42nM,antagonist,83.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,36,nM,=,7.37675071,pIC50,B,radiometric,CCCc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,83,350.177,366.1166825,1,2,5,2,4.4116,36.1,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
2661,2146,15974597,30,P10826,PPARA,Homo sapiens,"[4-(2,2-Dimethyl-propionyl)-2,6-dipropyl-phenoxy]-phenyl-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)C(C)(C)C,CHEMBL191235,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 130nM,agonist,1455.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,160,nM,,,,,=,6.886056648,pIC50,,radiometric,CCCc1cc(C(=O)C(C)(C)C)cc(CCC)c1OC(C(=O)O)c1ccccc1,1455,364.271,396.2300595,1,3,9,2,6.0251,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2662,2146,15974597,30,P37231,PPARG,Homo sapiens,"[4-(2,2-Dimethyl-propionyl)-2,6-dipropyl-phenoxy]-phenyl-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)C(C)(C)C,CHEMBL191235,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2700nM,partial agonist,53.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,5.568636236,pIC50,,radiometric,CCCc1cc(C(=O)C(C)(C)C)cc(CCC)c1OC(C(=O)O)c1ccccc1,53,364.271,396.2300595,1,3,9,2,6.0251,63.6,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
2663,2147,15974597,29,P10826,PPARA,Homo sapiens,"(4-Isobutyryl-2,6-dipropyl-phenoxy)-phenyl-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)C(C)C,CHEMBL371195,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 160nM,agonist,1650.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,250,nM,,,,,=,6.795880017,pIC50,,radiometric,CCCc1cc(C(=O)C(C)C)cc(CCC)c1OC(C(=O)O)c1ccccc1,1650,352.26,382.2144094,1,3,10,2,5.635,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2664,2147,15974597,29,P37231,PPARG,Homo sapiens,"(4-Isobutyryl-2,6-dipropyl-phenoxy)-phenyl-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)C(C)C,CHEMBL371195,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3160nM,partial agonist,32.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,5.500312917,pIC50,,radiometric,CCCc1cc(C(=O)C(C)C)cc(CCC)c1OC(C(=O)O)c1ccccc1,32,352.26,382.2144094,1,3,10,2,5.635,63.6,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
2671,2150,15974597,36,P10826,PPARA,Homo sapiens,(4-Isopropyl-phenyl)-(2-methyl-4-propionyl-6-propyl-phenoxy)-acetic acid,CCCc1cc(cc(C)c1OC(C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL189066,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 160nM,agonist,810.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,160,nM,,,,,=,6.795880017,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(C)c1OC(C(=O)O)c1ccc(C(C)C)cc1,810,352.26,382.2144094,1,3,9,2,5.86832,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2672,2150,15974597,36,P37231,PPARG,Homo sapiens,(4-Isopropyl-phenyl)-(2-methyl-4-propionyl-6-propyl-phenoxy)-acetic acid,CCCc1cc(cc(C)c1OC(C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL189066,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 260nM,partial agonist,70.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,197,nM,,,,,=,6.585026652,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(C)c1OC(C(=O)O)c1ccc(C(C)C)cc1,70,352.26,382.2144094,1,3,9,2,5.86832,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
2677,2153,15974597,28,P10826,PPARA,Homo sapiens,"Phenyl-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)CC,CHEMBL364467,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 51nM,agonist,1233.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,100,nM,,,,,=,7.292429824,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1OC(C(=O)O)c1ccccc1,1233,340.249,368.1987594,1,3,10,2,5.389,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2678,2153,15974597,28,P37231,PPARG,Homo sapiens,"Phenyl-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1OC(C(=O)O)c2ccccc2)C(=O)CC,CHEMBL364467,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2760nM,partial agonist,28.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,5.559090918,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1OC(C(=O)O)c1ccccc1,28,340.249,368.1987594,1,3,10,2,5.389,63.6,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
2681,2155,15974597,40,P10826,PPARA,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL187557,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 23nM,agonist,1067.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,56,nM,,,,,=,7.638272164,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,1067,376.282,410.2457096,1,3,11,2,6.5124,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2682,2155,15974597,40,P37231,PPARG,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL187557,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 75nM,partial agonist,50.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,150,nM,,,,,=,7.124938737,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,50,376.282,410.2457096,1,3,11,2,6.5124,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
2683,2156,15974597,43,P10826,PPARA,Homo sapiens,"(S)-(4-Propionyl-2,6-dipropyl-phenoxy)-(4-trifluoromethyl-phenyl)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(cc2)C(F)(F)F)C(=O)CC,CHEMBL190938,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 89nM,agonist,1448.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,250,nM,,,,,=,7.050609993,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(C(F)(F)F)cc1,1448,409.254,436.186144,1,3,10,2,6.4078,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2684,2156,15974597,43,P37231,PPARG,Homo sapiens,"(S)-(4-Propionyl-2,6-dipropyl-phenoxy)-(4-trifluoromethyl-phenyl)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(cc2)C(F)(F)F)C(=O)CC,CHEMBL190938,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 210nM,partial agonist,56.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.677780705,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(C(F)(F)F)cc1,56,409.254,436.186144,1,3,10,2,6.4078,63.6,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
2685,2157,15974597,39,P10826,PPARA,Homo sapiens,"(S)-(4-Isobutyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(CC(C)C)cc2)C(=O)CC,CHEMBL188751,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 58nM,agonist,807.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,39,nM,,,,,=,7.236572006,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(CC(C)C)cc1,807,388.293,424.2613596,1,3,12,2,6.5875,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2686,2157,15974597,39,P37231,PPARG,Homo sapiens,"(S)-(4-Isobutyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(CC(C)C)cc2)C(=O)CC,CHEMBL188751,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 220nM,partial agonist,66.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,180,nM,,,,,=,6.657577319,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(CC(C)C)cc1,66,388.293,424.2613596,1,3,12,2,6.5875,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
2687,2158,15974597,38,P10826,PPARA,Homo sapiens,"(S)-(4-Ethyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(CC)cc2)C(=O)CC,CHEMBL370021,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 64nM,agonist,675.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,76,nM,,,,,=,7.193820026,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(CC)cc1,675,364.271,396.2300595,1,3,11,2,5.9514,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2688,2158,15974597,38,P37231,PPARG,Homo sapiens,"(S)-(4-Ethyl-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(CC)cc2)C(=O)CC,CHEMBL370021,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 210nM,partial agonist,40.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,480,nM,,,,,=,6.677780705,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(CC)cc1,40,364.271,396.2300595,1,3,11,2,5.9514,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
2689,2159,15974597,42,P10826,PPARA,Homo sapiens,"(S)-(4-Isopropoxy-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(OC(C)C)cc2)C(=O)CC,CHEMBL191276,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 43nM,agonist,479.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,110,nM,,,,,=,7.366531544,pIC50,B,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(OC(C)C)cc1,479,392.281,426.2406242,1,4,12,2,6.1762,72.83,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2690,2159,15974597,42,P37231,PPARG,Homo sapiens,"(S)-(4-Isopropoxy-phenyl)-(4-propionyl-2,6-dipropyl-phenoxy)-acetic acid",CCCc1cc(cc(CCC)c1O[C@H](C(=O)O)c2ccc(OC(C)C)cc2)C(=O)CC,CHEMBL191276,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,partial agonist,59.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.698970004,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(CCC)c1O[C@H](C(=O)O)c1ccc(OC(C)C)cc1,59,392.281,426.2406242,1,4,12,2,6.1762,72.83,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
2693,2160,15974597,37,P10826,PPARA,Homo sapiens,(S)-(2-Chloro-4-propionyl-6-propyl-phenoxy)-(4-isopropyl-phenyl)-acetic acid,CCCc1cc(cc(Cl)c1O[C@H](C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL426451,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 260nM,agonist,1138.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,260,nM,,,,,=,6.585026652,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(Cl)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,1138,375.702,402.159787,1,3,9,2,6.2133,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2694,2160,15974597,37,P37231,PPARG,Homo sapiens,(S)-(2-Chloro-4-propionyl-6-propyl-phenoxy)-(4-isopropyl-phenyl)-acetic acid,CCCc1cc(cc(Cl)c1O[C@H](C(=O)O)c2ccc(cc2)C(C)C)C(=O)CC,CHEMBL426451,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 220nM,agonist,77.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,360,nM,,,,,=,6.657577319,pIC50,,radiometric,CCCc1cc(C(=O)CC)cc(Cl)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,77,375.702,402.159787,1,3,9,2,6.2133,63.6,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
2933,2233,16107159,32 (racemic),P37231,PPARG,Homo sapiens,"2-Ethyl-5-[3-(2-propyl-4-trifluoromethylsulfanyl-phenoxy)-propoxy]-2,3-dihydro-benzofuran-2-carboxylic acid",CCCc1cc(SC(F)(F)F)ccc1OCCCOc2ccc3OC(CC)(Cc3c2)C(=O)O,CHEMBL192500,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3110nM,partial agonist,59.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,=,5.507239611,pIC50,,radiometric,CCCc1cc(SC(F)(F)F)ccc1OCCCOc1ccc2c(c1)CC(CC)(C(=O)O)O2,59,457.32,484.1531296,1,5,11,2,6.2672,64.99,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,455
2936,2234,15974597,56,P10826,PPARA,Homo sapiens,"(S)-(2-Isopropyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2C(=O)N(Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C)C(C)C,CHEMBL191556,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 230nM,agonist,889.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.638272164,pIC50,,radiometric,CCCc1cc2c(=O)n(C(C)C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,889,418.299,453.2515232,1,5,10,3,6.4085,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,,agonist,,agonist,680
2937,2234,15974597,56,P37231,PPARG,Homo sapiens,"(S)-(2-Isopropyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2C(=O)N(Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C)C(C)C,CHEMBL191556,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 160nM,partial agonist,38.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,430,nM,,,,,=,6.795880017,pIC50,,radiometric,CCCc1cc2c(=O)n(C(C)C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,38,418.299,453.2515232,1,5,10,3,6.4085,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,partial agonist,agonist,partial agonist,680
2938,2235,15974597,58,P10826,PPARA,Homo sapiens,"(S)-(4-Isobutyl-phenyl)-(2-isopropyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-acetic acid",CCCc1cc2C(=O)N(Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(CC(C)C)cc3)C(C)C,CHEMBL365097,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 790nM,agonist,382.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,,nM,,,,,=,6.102372909,pIC50,,radiometric,CCCc1cc2c(=O)n(C(C)C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(CC(C)C)cc1,382,430.31,467.2671733,1,5,11,3,6.4836,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,agonist,agonist,agonist,680
2939,2235,15974597,58,P37231,PPARG,Homo sapiens,"(S)-(4-Isobutyl-phenyl)-(2-isopropyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-acetic acid",CCCc1cc2C(=O)N(Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(CC(C)C)cc3)C(C)C,CHEMBL365097,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 260nM,partial agonist,35.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,370,nM,,,,,=,6.585026652,pIC50,,radiometric,CCCc1cc2c(=O)n(C(C)C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(CC(C)C)cc1,35,430.31,467.2671733,1,5,11,3,6.4836,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,partial agonist,agonist,partial agonist,680
2940,2236,15974597,7,P10826,PPARA,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(2-methyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-acetic acid",CCCc1cc2C(=O)N(C)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL191149,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 74nM,agonist,1005.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,7.13076828,pIC50,B,radiometric,CCCc1cc2c(=O)n(C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,1005,394.277,425.2202231,1,5,9,3,5.3646,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,,agonist,,agonist,680
2941,2236,15974597,7,P37231,PPARG,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(2-methyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-acetic acid",CCCc1cc2C(=O)N(C)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL191149,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 210nM,partial agonist,41.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,390,nM,,,,,=,6.677780705,pIC50,,radiometric,CCCc1cc2c(=O)n(C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,41,394.277,425.2202231,1,5,9,3,5.3646,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,partial agonist,agonist,partial agonist,680
2942,2237,15974597,55,P10826,PPARA,Homo sapiens,"(S)-(2-Methyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-phenyl-acetic acid",CCCc1cc2C(=O)N(C)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccccc3,CHEMBL427530,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 850nM,agonist,1005.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,270,nM,,,,,=,6.070581074,pIC50,,radiometric,CCCc1cc2c(=O)n(C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccccc1,1005,358.244,383.1732729,1,5,8,3,4.2412,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,agonist,agonist,agonist,680
2943,2237,15974597,55,P37231,PPARG,Homo sapiens,"(S)-(2-Methyl-3-oxo-5,7-dipropyl-2,3-dihydro-benzo[d]isoxazol-6-yloxy)-phenyl-acetic acid",CCCc1cc2C(=O)N(C)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccccc3,CHEMBL427530,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3800nM,partial agonist,41.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,390,nM,,,,,=,5.420216403,pIC50,,radiometric,CCCc1cc2c(=O)n(C)oc2c(CCC)c1O[C@H](C(=O)O)c1ccccc1,41,358.244,383.1732729,1,5,8,3,4.2412,81.67,CC1CCC2CC(CCC3CCCCC3)CCC12,agonist,partial agonist,agonist,partial agonist,680
2946,2239,17257838,11c,P10275,AR,Homo sapiens,"7-amino-6-propyl-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCCc1cc2C(=CC(=O)Nc2cc1N)C(F)(F)F,CHEMBL3706898,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,partial agonist,34.00%,agonist,DHT,,,,,,,EC50,=,83,nM,IC50,=,19,nM,=,8.045757491,pIC50,B,radiometric,CCCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,34,257.15,270.0979977,2,2,2,2,3.0816,58.88,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
2965,2248,15974597,49,P10826,PPARA,Homo sapiens,"(S)-(3-Isopropyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(C(C)C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL193082,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 72nM,agonist,508.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,140,nM,,,,,=,7.142667504,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2C(C)C)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,508,418.299,453.2515232,1,5,10,3,6.4085,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,agonist,agonist,agonist,550
2966,2248,15974597,49,P37231,PPARG,Homo sapiens,"(S)-(3-Isopropyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(C(C)C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL193082,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 51nM,partial agonist,38.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,140,nM,,,,,=,7.292429824,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2C(C)C)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,38,418.299,453.2515232,1,5,10,3,6.4085,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2967,2249,15974597,52,P10826,PPARA,Homo sapiens,"(S)-(3-Isopropyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-phenyl-acetic acid",CCCc1cc2N(C(C)C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccccc3,CHEMBL372220,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 550nM,agonist,1221.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.259637311,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2C(C)C)c(CCC)c1O[C@H](C(=O)O)c1ccccc1,1221,382.266,411.204573,1,5,9,3,5.2851,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,,agonist,,agonist,550
2968,2249,15974597,52,P37231,PPARG,Homo sapiens,"(S)-(3-Isopropyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-phenyl-acetic acid",CCCc1cc2N(C(C)C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccccc3,CHEMBL372220,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1790nM,partial agonist,27.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,5.747146969,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2C(C)C)c(CCC)c1O[C@H](C(=O)O)c1ccccc1,27,382.266,411.204573,1,5,9,3,5.2851,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,,partial agonist,,partial agonist,550
2972,2250,15974597,47,P10826,PPARA,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(3-methyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCc1cc2N(C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL190517,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 393nM,agonist,680.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.40560745,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2C)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,680,394.277,425.2202231,1,5,9,3,5.3646,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,,agonist,,agonist,550
2973,2250,15974597,47,P37231,PPARG,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-(3-methyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCc1cc2N(C)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL190517,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 85nM,partial agonist,42.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,640,nM,,,,,=,7.070581074,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2C)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,42,394.277,425.2202231,1,5,9,3,5.3646,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2974,2251,15974597,51,P10826,PPARA,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-[2-oxo-5,7-dipropyl-3-(2,2,2-trifluoro-ethyl)-2,3-dihydro-benzooxazol-6-yloxy]-acetic acid",CCCc1cc2N(CC(F)(F)F)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL192521,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 100nM,agonist,123.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,310,nM,,,,,=,7,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC(F)(F)F)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,123,463.282,493.2076077,1,5,10,3,6.3899,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,agonist,agonist,agonist,550
2975,2251,15974597,51,P37231,PPARG,Homo sapiens,"(S)-(4-Isopropyl-phenyl)-[2-oxo-5,7-dipropyl-3-(2,2,2-trifluoro-ethyl)-2,3-dihydro-benzooxazol-6-yloxy]-acetic acid",CCCc1cc2N(CC(F)(F)F)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL192521,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 110nM,partial agonist,38.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,140,nM,,,,,=,6.958607315,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC(F)(F)F)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,38,463.282,493.2076077,1,5,10,3,6.3899,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2976,2252,15974597,6,P10826,PPARA,Homo sapiens,"(S)-(3-Ethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(CC)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL364378,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 74nM,agonist,440.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,290,nM,,,,,=,7.13076828,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2CC)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,440,406.288,439.2358732,1,5,10,3,5.8475,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,agonist,agonist,agonist,550
2977,2252,15974597,6,P37231,PPARG,Homo sapiens,"(S)-(3-Ethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(CC)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(cc3)C(C)C,CHEMBL364378,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 99nM,partial agonist,36.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,120,nM,,,,,=,7.004364805,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2CC)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,36,406.288,439.2358732,1,5,10,3,5.8475,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2978,2253,15974597,53,P10826,PPARA,Homo sapiens,"(S)-(4-Chloro-phenyl)-(3-ethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCc1cc2N(CC)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(Cl)cc3,CHEMBL188095,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 260nM,agonist,861.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,670,nM,,,,,=,6.585026652,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC)c(CCC)c1O[C@H](C(=O)O)c1ccc(Cl)cc1,861,405.708,431.1499506,1,5,9,3,5.3775,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,agonist,agonist,agonist,550
2979,2253,15974597,53,P37231,PPARG,Homo sapiens,"(S)-(4-Chloro-phenyl)-(3-ethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCc1cc2N(CC)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c3ccc(Cl)cc3,CHEMBL188095,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 220nM,partial agonist,57.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.657577319,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC)c(CCC)c1O[C@H](C(=O)O)c1ccc(Cl)cc1,57,405.708,431.1499506,1,5,9,3,5.3775,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,,partial agonist,,partial agonist,550
2980,2254,15974597,50,P10826,PPARA,Homo sapiens,"(S)-(3-Cyclopropylmethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(CC3CC3)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c4ccc(cc4)C(C)C,CHEMBL364274,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 130nM,partial agonist,63.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.886056648,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC2CC2)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,63,430.31,465.2515232,1,5,11,3,6.2376,81.67,CC1CC2CC(CCC3CCCCC3)CCC2C1CC1CC1,,partial agonist,,partial agonist,548
2981,2254,15974597,50,P37231,PPARG,Homo sapiens,"(S)-(3-Cyclopropylmethyl-2-oxo-5,7-dipropyl-2,3-dihydro-benzooxazol-6-yloxy)-(4-isopropyl-phenyl)-acetic acid",CCCc1cc2N(CC3CC3)C(=O)Oc2c(CCC)c1O[C@H](C(=O)O)c4ccc(cc4)C(C)C,CHEMBL364274,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 120nM,partial agonist,36.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,330,nM,,,,,=,6.920818754,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CC2CC2)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,36,430.31,465.2515232,1,5,11,3,6.2376,81.67,CC1CC2CC(CCC3CCCCC3)CCC2C1CC1CC1,agonist,partial agonist,agonist,partial agonist,548
2982,2255,15974597,48,P10826,PPARA,Homo sapiens,"i(S)-(4-Isopropyl-phenyl)-(2-oxo-3,5,7-tripropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCN1C(=O)Oc2c(CCC)c(O[C@H](C(=O)O)c3ccc(cc3)C(C)C)c(CCC)cc12,CHEMBL192636,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 150nM,agonist,218.00%,agonist,ref full agonist (no details),,,,,,,,,,,,,,,=,6.823908741,pIC50,,radiometric,CCCc1cc2c(oc(=O)n2CCC)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,218,418.299,453.2515232,1,5,11,3,6.2376,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,,agonist,,agonist,550
2983,2255,15974597,48,P37231,PPARG,Homo sapiens,"i(S)-(4-Isopropyl-phenyl)-(2-oxo-3,5,7-tripropyl-2,3-dihydro-benzooxazol-6-yloxy)-acetic acid",CCCN1C(=O)Oc2c(CCC)c(O[C@H](C(=O)O)c3ccc(cc3)C(C)C)c(CCC)cc12,CHEMBL192636,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 87nM,partial agonist,54.00%,agonist,ref full agonist (no details),,,,,,,EC50,=,120,nM,,,,,=,7.060480747,pIC50,B,radiometric,CCCc1cc2c(oc(=O)n2CCC)c(CCC)c1O[C@H](C(=O)O)c1ccc(C(C)C)cc1,54,418.299,453.2515232,1,5,11,3,6.2376,81.67,CC1CC2CCC(CCC3CCCCC3)CC2C1,agonist,partial agonist,agonist,partial agonist,550
2984,2256,20079636,16a,P37231,PPARG,Homo sapiens,4'-((5-(2-phenylbutanamido)-2-propyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid,CCCc1cc2cc(NC(=O)C(CC)c3ccccc3)ccc2n1Cc4ccc(cc4)c5ccccc5C(=O)O,CHEMBL601222,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 26nM,partial agonist,65.00%,agonist,rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,7.585026652,pIC50,B,radiometric,CCCc1cc2cc(NC(=O)C(CC)c3ccccc3)ccc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,65,496.396,530.2569429,2,3,10,5,8.1396,71.33,CC(CC1CCCCC1)CC1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1041
2987,2257,21899328,21,P04150,GR,Homo sapiens,"[(5S)-2-[(4-Propyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CCCc1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911151,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.4nM,partial agonist,44.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,126,nM,IC50,=,36,nM,=,8.619788758,pKi,B,FPA,CCCc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,44,444.39,470.1776471,1,6,6,4,6.4551,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
2988,2258,15863293,9,P37231,PPARG,Homo sapiens,(S)-2-{5-[1-(6-Chloro-benzo[d]isoxazol-3-yl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-2-propyl-phenoxy}-propionic acid,CCCc1ccc(Oc2c(C)n(c3noc4cc(Cl)ccc34)c5ccc(OC(F)(F)F)cc25)cc1O[C@@H](C)C(=O)O,CHEMBL365315,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,partial agonist,33.00%,agonist,Rosiglitazone,,,,,,,EC50,=,39,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCCc1ccc(Oc2c(C)n(-c3noc4cc(Cl)ccc34)c3ccc(OC(F)(F)F)cc23)cc1O[C@@H](C)C(=O)O,33,564.774,588.1274988,1,7,9,5,8.22882,95.95,C1CCC(CC2CC(C3CCC4CCCCC43)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,231
2993,2261,12954062,7d,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(2-propyl-phenyl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCCc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL133483,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.6nM,agonist,123.00%,agonist,progesterone,,progesterone,,,,,EC50,=,4.5,nM,,,,,=,8.795880017,pKi,B,radiometric,CCCc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,123,397.323,425.2154927,1,2,3,3,7.9431,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
2998,2264,20382019,8h,P55055,LXRB,Homo sapiens,4-(3'-(methylsulfonyl)biphenyl-3-yl)-3-propyl-8-(trifluoromethyl)quinoline,CCCc1cnc2c(cccc2c1c3cccc(c3)c4cccc(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1096719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.8nM,agonist,98.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,106,nM,,,,,=,8.420216403,pIC50,B,radiometric,CCCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,98,447.352,469.1323346,0,3,5,4,6.9436,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
3001,2265,20079636,1,P37231,PPARG,Homo sapiens,Telmisartan,CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,CHEMBL1017,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12200nM,partial agonist,49.00%,agonist,rosiglitazone,,,,,,,EC50,=,2020,nM,,,,,=,4.913640169,pIC50,NB,radiometric,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,49,484.389,514.2368762,1,5,7,6,7.26442,72.94,C1CCC(C2CCC(CC3CCC4CCC(C5CC6CCCCC6C5)CC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,156
3004,2266,16610787,1ax,P03372,ERA,Homo sapiens,"5,7-dihydroxy-3-(4-hydroxyphenyl)-2-propyl-3H-quinazolin-4-one",CCCC1=Nc2cc(O)cc(O)c2C(=O)N1c3ccc(O)cc3,CHEMBL206499,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5365nM,partial agonist,43.00%,agonist,,,E1,11nM,,,,,,,,,,,,=,5.270430274,pIC50,,radiometric,CCCc1nc2cc(O)cc(O)c2c(=O)n1-c1ccc(O)cc1,43,296.197,312.111007,3,6,3,3,2.455,95.58,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
3027,2276,24980053,"7, BMS-791826",P04150,GR,Homo sapiens,"(S)-4-(5-(1-(1,3,4-thiadiazol-2-ylamino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-N-ethyl-N-methylbenzamide",CCN(C)C(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL3315049,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.6nM,partial agonist,57.00%,agonist,dexamethasone,,,,,,,EC50,=,98.5,nM,,,,,=,8.795880017,pKi,B,FPA,CCN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,57,486.407,513.1834607,1,7,6,4,5.5945,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,agonist,partial agonist,agonist,partial agonist,956
3029,2277,21899328,36,P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Ethylmethylamino)carbonyl]-3-phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CCN(C)C(=O)c1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911273,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 0.67nM,agonist,76.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,32.4,nM,IC50,=,36.7,nM,=,9.173925197,pKi,B,FPA,CCN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,76,486.407,513.1834607,1,7,6,4,5.5945,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",agonist,"antagonist,agonist",agonist,956
3030,2278,21899328,38,P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Ethylmethylamino)carbonyl]-3-chlorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano-[2,3-b]pyridin-5-acetamide",CCN(C)C(=O)c1ccc(cc1Cl)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911275,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 15.7nM,partial agonist,46.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,702,nM,IC50,=,721.1,nM,=,7.804100348,pKi,B,FPA,CCN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1Cl,46,521.86,547.1444884,1,7,6,4,6.2479,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
3031,2279,21899328,"37, BMS-791826",P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Ethylmethylamino)carbonyl]-3-fluorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano-[2,3-b]pyridin-5-acetamide",CCN(C)C(=O)c1ccc(cc1F)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911274,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.64nM,partial agonist,57.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,98.5,nM,IC50,=,113.4,nM,=,8.785156152,pKi,B,FPA,CCN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1F,57,505.405,531.1740389,1,7,6,4,5.7336,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
3032,228,15115388,30,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-but-3-en-1-ol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)CC=C)c4ccc(F)cc4,CHEMBL309243,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.9nM,agonist,82.90%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,9.3,nM,,,,,=,8.408935393,pIC50,B,radiometric,C=CC[C@H](O)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,82.9,327.253,352.1950916,1,3,4,2,4.6943,38.05,C1CCC(C2CCC3CC4CCCCC4CC32)CC1,agonist,agonist,agonist,agonist,97
3033,2280,17257838,10c,P10275,AR,Homo sapiens,"7-(ethyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCN(CC(F)(F)F)c1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706894,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 30nM,antagonist,79.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,42,nM,=,7.522878745,pIC50,B,radiometric,CCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,79,326.155,338.0853823,1,2,3,2,3.9355,36.1,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
3034,2281,17034117,4k,P10275,AR,Homo sapiens,"6-N-ethyl-N-(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one",CCN(CC(F)(F)F)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL217769,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.1nM,agonist,107.00%,agonist,DHT,,,,,,,EC50,=,0.4,nM,IC50,>,10000,nM,=,8.148741651,pKi,B,radiometric,CCN(CC(F)(F)F)c1ccc2nc(O)cc(C(F)(F)F)c2c1,107,326.155,338.0853823,1,3,3,2,4.3478,36.36,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
3035,2281,17267219,6f,P10275,AR,Homo sapiens,"6-(ethyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CCN(CC(F)(F)F)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL217769,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.1nM,agonist,107.00%,agonist,DHT,,,,,,,EC50,=,0.4,nM,IC50,>,10000,nM,=,8.148741651,pIC50,B,radiometric,CCN(CC(F)(F)F)c1ccc2nc(O)cc(C(F)(F)F)c2c1,107,326.155,338.0853823,1,3,3,2,4.3478,36.36,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
3037,2282,19019676,13o,P04150,GR,Homo sapiens,"(+/-)-5-amino-1-(4-fluorophenyl)-N-(3,3,3-trifluoro-2-hydroxy-2-((2,4,6-trichloro-N-ethylbenzamido)methyl)propyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(Cl)cc(Cl)cc3Cl,CHEMBL518451,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.2,agonist,86.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,8.2,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cc(Cl)cc1Cl,86,576.636,595.0567854,3,6,8,3,4.7393,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3040,2283,19019676,13h,P04150,GR,Homo sapiens,"5-amino-N-(2-((2,6-dichloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(Cl)cccc3Cl,CHEMBL461012,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.5,agonist,120.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,8.7,,,,,,=,8.5,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl,120,541.183,561.0957578,3,6,8,3,4.0859,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3043,2284,19019676,13i,P04150,GR,Homo sapiens,"5-amino-N-(2-((N-ethyl-2,6-difluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(F)cccc3F,CHEMBL467633,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,122.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,8.1,,,,,,=,8.1,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,122,508.273,529.1548589,3,6,8,3,3.0573,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3046,2285,19019676,13j,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((N-ethyl-2-fluoro-6-(methylsulfonyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(F)cccc3S(=O)(=O)C,CHEMBL516033,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.3,agonist,128.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.6,,,,,,=,7.3,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1S(C)(=O)=O,128,565.351,589.141831,3,8,9,3,2.3217,147.62,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3052,2287,19019676,13n,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((2-chloro-N-ethyl-4-fluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccc(F)cc3Cl,CHEMBL479431,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.7,partial agonist,56.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.5,,,,,,=,7.7,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccc(F)cc1Cl,56,524.728,545.1253083,3,6,8,3,3.5716,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1316
3055,2288,19019676,14c,P04150,GR,Homo sapiens,"N-(2-((5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-N-ethyl-1H-indole-5-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccc4[nH]ccc4c3,CHEMBL465919,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.2,agonist,112.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,8.5,,,,,,=,8.2,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccc2[nH]ccc2c1,112,508.306,532.1846015,4,6,8,4,3.2604,129.27,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCC2CCCC2C1,agonist,agonist,agonist,agonist,1315
3058,2289,19019676,13k,P04150,GR,Homo sapiens,"rac-5-amino-N-(2-((3-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3cccc(Cl)c3,CHEMBL519947,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,125.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.6,,,,,,=,7.8,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1cccc(Cl)c1,125,505.73,527.1347301,3,6,8,3,3.4325,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3062,2290,19019676,13l,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((2-chloro-N-ethyl-3-fluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3cccc(F)c3Cl,CHEMBL520750,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,106.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,8.1,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1cccc(F)c1Cl,106,524.728,545.1253083,3,6,8,3,3.5716,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3067,2291,19019676,13a,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3,CHEMBL481185,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.3,agonist,104.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.3,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1,104,470.277,493.1737025,3,6,8,3,2.7791,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3068,2291,19019676,13c,P04150,GR,Homo sapiens,"5-amino-N-(2-((N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3,CHEMBL481185,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,108.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.6,,,,,,=,7.9,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1,108,470.277,493.1737025,3,6,8,3,2.7791,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3069,2291,19019676,13b,P04150,GR,Homo sapiens,"5-amino-N-(2-((N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3,CHEMBL481185,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.9,,,,dexamethasone,,dexamethasone,,,,,PEC50,<,5.2,,,,,,=,6.9,pIC50,,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1,,470.277,493.1737025,3,6,8,3,2.7791,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,,,agonist,agonist,1316
3074,2292,19019676,13f,P04150,GR,Homo sapiens,"5-amino-N-(2-((N-ethyl-2-fluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3F,CHEMBL462282,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.7,,,,,,=,7.9,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1F,130,489.275,511.1642807,3,6,8,3,2.9182,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3077,2293,19019676,13g,P04150,GR,Homo sapiens,"5-amino-N-(2-((N-ethyl-2-(methylsulfonyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3S(=O)(=O)C,CHEMBL512127,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.2,agonist,120.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.8,,,,,,=,7.2,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O,120,546.353,571.1512528,3,8,9,3,2.1826,147.62,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
3080,2294,19019676,14a,P04150,GR,Homo sapiens,"(+/-)-N-(2-((5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-2-chloro-N-ethylnicotinamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3cccnc3Cl,CHEMBL481784,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.4,partial agonist,74.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.1,,,,,,=,7.4,pIC50,B,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1cccnc1Cl,74,507.726,528.1299791,3,7,8,3,2.8275,126.37,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1316
3082,2295,16876993,rac-42,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(2-hydroxy-2-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CC(O)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL448111,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 500nM,agonist,97.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,6.301029996,pIC50,,radiometric,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,97,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,396
3083,2295,16876993,rac-42,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(2-hydroxy-2-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CC(O)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL448111,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 500nM,partial agonist,63.00%,agonist,T0901317,,,,,,,EC50,=,1000,nM,,,,,=,6.301029996,pIC50,,radiometric,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,63,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,396
3102,2301,19162487,4d,P55055,LXRB,Homo sapiens,"3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-N,N-diethylbenzamide",CCN(CC)C(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL505445,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.8nM,agonist,83.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,144,nM,,,,,=,8.552841969,pIC50,B,radiometric,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,83,525.38,554.2181128,0,3,8,5,8.7857,42.43,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
3103,2301,19162487,4d,Q13133,LXRA,Homo sapiens,"3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-N,N-diethylbenzamide",CCN(CC)C(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL505445,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,partial agonist,73.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,675,nM,,,,,=,7.920818754,pIC50,B,radiometric,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,73,525.38,554.2181128,0,3,8,5,8.7857,42.43,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,278
3121,2311,17553679,10,P04150,GR,Homo sapiens,"(Z)-5-(2-((diethylamino)methyl)-4-fluorobenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",CCN(CC)Cc1cc(F)ccc1\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL3706937,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.1nM,antagonist,167.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,79,nM,IC50,=,85,nM,=,8.508638306,pKi,B,radiometric,CCN(CC)Cc1cc(F)ccc1/C=C1\Oc2ccc(O)c(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,167,479.361,514.2631712,2,5,6,3,7.5466,53.96,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
3133,2315,17257838,10b,P10275,AR,Homo sapiens,"7-(diethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCN(CC)c1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706893,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 463nM,antagonist,90.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,591,nM,=,6.334419009,pIC50,,radiometric,CCN(CC)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,90,269.161,284.1136478,1,2,3,2,3.3931,36.1,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
3134,2316,17034117,4d,P10275,AR,Homo sapiens,"6-N,N-diethylamino-4-trifluoromethylquinolin-2(1H)-one",CCN(CC)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL277378,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.4nM,agonist,94.00%,agonist,DHT,,,,,,,EC50,=,2.1,nM,IC50,>,10000,nM,=,8.356547324,pKi,B,radiometric,CCN(CC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,94,269.161,284.1136478,1,3,3,2,3.8054,36.36,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
3135,2316,17267219,6a,P10275,AR,Homo sapiens,6-(diethylamino)-4-(trifluoromethyl)quinolin-2(1H)-one,CCN(CC)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL277378,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4.4nM,agonist,94.00%,agonist,DHT,,,,,,,EC50,=,2.1,nM,IC50,>,10000,nM,=,8.356547324,pIC50,B,radiometric,CCN(CC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,94,269.161,284.1136478,1,3,3,2,3.8054,36.36,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
3143,2320,16876993,15,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(phenethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CCc1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215585,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 610nM,agonist,76.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,6.214670165,pIC50,,radiometric,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,76,372.203,391.1370835,1,2,6,2,5.0678,23.47,C1CCC(CCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,396
3144,2320,16876993,15,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(phenethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CCc1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215585,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 120nM,agonist,80.00%,agonist,T0901317,,,,,,,EC50,=,1000,nM,,,,,=,6.920818754,pIC50,,radiometric,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,80,372.203,391.1370835,1,2,6,2,5.0678,23.47,C1CCC(CCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,396
3145,2321,16876993,16,P55055,LXRB,Homo sapiens,"2-(3-chloro-4-(ethyl(phenethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CCc1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386530,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,72.00%,agonist,T0901317,,,,,,,EC50,=,90,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,72,407.656,425.0981112,1,2,6,2,5.7212,23.47,C1CCC(CCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,396
3146,2321,16876993,16,Q13133,LXRA,Homo sapiens,"2-(3-chloro-4-(ethyl(phenethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(CCc1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386530,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6nM,agonist,78.00%,agonist,T0901317,,,,,,,EC50,=,800,nM,,,,,=,8.22184875,pIC50,B,radiometric,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,78,407.656,425.0981112,1,2,6,2,5.7212,23.47,C1CCC(CCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,396
3147,2322,21257309,7,P04150,GR,Homo sapiens,"(R)-2,6-dichloro-N-ethyl-N-(3,3,3-trifluoro-2-((1-(4-fluorophenyl)-1H-indazol-4-ylamino)methyl)-2-hydroxypropyl)benzamide",CCN(C[C@](O)(CNc1cccc2c1cnn2c3ccc(F)cc3)C(F)(F)F)C(=O)c4c(Cl)cccc4Cl,CHEMBL1668063,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,122.00%,agonist,,,dexamethasone,,,,,PEC50,=,9.5,,,,,,=,7.8,pIC50,B,FPA,CCN(C[C@](O)(CNc1cccc2c1cnn2-c1ccc(F)cc1)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl,122,547.21,568.1055942,2,5,8,4,6.339,70.39,CC(CCCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1295
3149,2324,16876993,8,P55055,LXRB,Homo sapiens,"2-(4-(benzyl(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL383959,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,partial agonist,71.00%,agonist,T0901317,,,,,,,EC50,=,400,nM,,,,,=,7.522878745,pIC50,B,radiometric,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,71,360.192,377.1214335,1,2,5,2,5.0253,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3150,2324,16876993,8,Q13133,LXRA,Homo sapiens,"2-(4-(benzyl(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL383959,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,1100,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,360.192,377.1214335,1,2,5,2,5.0253,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3151,2325,16876993,9,P55055,LXRB,Homo sapiens,"2-(4-(benzyl(ethyl)amino)-3-chlorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215663,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,agonist,91.00%,agonist,T0901317,,,,,,,EC50,=,80,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,91,395.645,411.0824611,1,2,5,2,5.6787,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3152,2325,16876993,9,Q13133,LXRA,Homo sapiens,"2-(4-(benzyl(ethyl)amino)-3-chlorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215663,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,agonist,88.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,88,395.645,411.0824611,1,2,5,2,5.6787,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3153,2326,16876993,12,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(pyridin-2-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccn1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214727,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 460nM,partial agonist,74.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,6.337242168,pIC50,,radiometric,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,74,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3154,2326,16876993,12,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(pyridin-2-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccccn1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214727,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1500nM,partial agonist,70.00%,agonist,T0901317,,,,,,,EC50,=,700,nM,,,,,=,5.823908741,pIC50,,radiometric,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,70,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3155,2327,16876993,13,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(pyridin-3-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1cccnc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL216055,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2320nM,agonist,106.00%,agonist,T0901317,,,,,,,EC50,=,2300,nM,,,,,=,5.634512015,pIC50,,radiometric,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,106,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3156,2327,16876993,13,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(pyridin-3-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1cccnc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL216055,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2700nM,agonist,88.00%,agonist,T0901317,,,,,,,EC50,=,4300,nM,,,,,=,5.568636236,pIC50,,radiometric,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,88,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3159,2329,16876993,14,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(pyridin-4-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccncc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214275,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1680nM,agonist,93.00%,agonist,T0901317,,,,,,,EC50,=,500,nM,,,,,=,5.774690718,pIC50,,radiometric,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,93,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3160,2329,16876993,14,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(pyridin-4-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1ccncc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214275,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1700nM,agonist,108.00%,agonist,T0901317,,,,,,,EC50,=,2100,nM,,,,,=,5.769551079,pIC50,,radiometric,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,108,362.188,378.1166825,1,3,5,2,4.4203,36.36,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3163,2330,16876993,10,P55055,LXRB,Homo sapiens,"1,1,1,3,3,3-hexafluoro-2-(4-(methyl(thiazol-4-ylmethyl)amino)phenyl)propan-2-ol",CCN(Cc1cscn1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386174,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,84.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,84,370.233,384.0731034,1,4,5,2,4.4818,36.36,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
3164,2330,16876993,10,Q13133,LXRA,Homo sapiens,"1,1,1,3,3,3-hexafluoro-2-(4-(methyl(thiazol-4-ylmethyl)amino)phenyl)propan-2-ol",CCN(Cc1cscn1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386174,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 600nM,agonist,132.00%,agonist,T0901317,,,,,,,EC50,=,3300,nM,,,,,=,6.22184875,pIC50,,radiometric,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,132,370.233,384.0731034,1,4,5,2,4.4818,36.36,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
3165,2331,16876993,11,P55055,LXRB,Homo sapiens,"2-(3-chloro-4-(ethyl(thiazol-4-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1cscn1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215036,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,agonist,112.00%,agonist,T0901317,,,,,,,EC50,=,160,nM,,,,,=,8.698970004,pIC50,B,radiometric,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,112,405.686,418.034131,1,4,5,2,5.1352,36.36,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
3166,2331,16876993,11,Q13133,LXRA,Homo sapiens,"2-(3-chloro-4-(ethyl(thiazol-4-ylmethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1cscn1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215036,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,agonist,122.00%,agonist,T0901317,,,,,,,EC50,=,500,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,122,405.686,418.034131,1,4,5,2,5.1352,36.36,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
3167,2332,16876993,20,P55055,LXRB,Homo sapiens,"2-(4-(ethyl((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(c2)C(F)(F)F)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214867,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,72.00%,agonist,T0901317,,,,,,,EC50,=,60,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,72,507.247,526.1302818,1,4,6,3,7.00752,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,321
3168,2332,16876993,20,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(c2)C(F)(F)F)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214867,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6nM,agonist,96.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,8.22184875,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,96,507.247,526.1302818,1,4,6,3,7.00752,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3169,2333,16876993,21,P55055,LXRB,Homo sapiens,"2-(3-chloro-4-(ethyl((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(c2)C(F)(F)F)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL383944,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,30,nM,,,,,=,8.15490196,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,100,542.7,560.0913095,1,4,6,3,7.66092,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3170,2333,16876993,21,Q13133,LXRA,Homo sapiens,"2-(3-chloro-4-(ethyl((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(c2)C(F)(F)F)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL383944,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6nM,agonist,130.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,8.22184875,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,130,542.7,560.0913095,1,4,6,3,7.66092,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3171,2334,16876993,17,P55055,LXRB,Homo sapiens,"2-(4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(Cl)c2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215789,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,agonist,86.00%,agonist,T0901317,,,,,,,EC50,=,60,nM,,,,,=,8.301029996,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,86,473.695,492.1039248,1,4,6,3,6.64212,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3172,2334,16876993,17,Q13133,LXRA,Homo sapiens,"2-(4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(methyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(Cl)c2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215789,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,agonist,90.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,8.301029996,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,90,473.695,492.1039248,1,4,6,3,6.64212,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3173,2335,16876993,18,P55055,LXRB,Homo sapiens,"2-(3-chloro-4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(Cl)c2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215108,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,agonist,94.00%,agonist,T0901317,,,,,,,EC50,=,40,nM,,,,,=,8.397940009,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,94,509.148,526.0649525,1,4,6,3,7.29552,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3174,2335,16876993,18,Q13133,LXRA,Homo sapiens,"2-(3-chloro-4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(Cc1nc(oc1C)c2cccc(Cl)c2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215108,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,agonist,78.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,8.698970004,pIC50,B,radiometric,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,78,509.148,526.0649525,1,4,6,3,7.29552,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
3179,2339,16876993,rac-31,P55055,LXRB,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenyl-1-(piperidin-1-yl)ethanone",CCN(C(C(=O)N1CCCCC1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL409212,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1200nM,partial agonist,26.00%,agonist,T0901317,,,,,,,EC50,=,2200,nM,,,,,=,5.920818754,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,26,462.264,488.1898474,1,3,6,2,5.5789,43.78,CC(C1CCCCC1)C(CC1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,906
3180,2339,16876993,rac-31,Q13133,LXRA,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenyl-1-(piperidin-1-yl)ethanone",CCN(C(C(=O)N1CCCCC1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL409212,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2200nM,partial agonist,49.00%,agonist,T0901317,,,,,,,EC50,=,2200,nM,,,,,=,5.657577319,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,49,462.264,488.1898474,1,3,6,2,5.5789,43.78,CC(C1CCCCC1)C(CC1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,906
3183,2340,16876993,rac-32,P55055,LXRB,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-1-morpholino-2-phenylethanone",CCN(C(C(=O)N1CCOCC1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385544,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1400nM,agonist,88.00%,agonist,T0901317,,,,,,,EC50,=,2300,nM,,,,,=,5.853871964,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,88,466.252,490.1691119,1,4,6,2,4.4252,53.01,CC(C1CCCCC1)C(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,906
3184,2340,16876993,rac-32,Q13133,LXRA,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-1-morpholino-2-phenylethanone",CCN(C(C(=O)N1CCOCC1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385544,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5400nM,partial agonist,47.00%,agonist,T0901317,,,,,,,EC50,=,8500,nM,,,,,=,5.26760624,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,47,466.252,490.1691119,1,4,6,2,4.4252,53.01,CC(C1CCCCC1)C(CC1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,906
3185,2341,16876993,rac-29,P55055,LXRB,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-N-methyl-2-phenylacetamide",CCN(C(C(=O)NC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215154,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 22000nM,partial agonist,32.00%,agonist,T0901317,,,,,,,EC50,=,11000,nM,,,,,=,4.657577319,pIC50,NB,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,32,414.22,434.1428972,2,3,6,2,4.3124,52.57,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3187,2342,16876993,rac-28,P55055,LXRB,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylacetic acid",CCN(C(C(=O)O)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215327,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13800nM,agonist,95.00%,agonist,T0901317,,,,,,,EC50,=,5400,nM,,,,,=,4.860120914,pIC50,NB,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,95,404.201,421.1112627,2,3,6,2,4.651,60.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3188,2342,16876993,rac-28,Q13133,LXRA,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylacetic acid",CCN(C(C(=O)O)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215327,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5200nM,agonist,77.00%,agonist,T0901317,,,,,,,EC50,=,9400,nM,,,,,=,5.283996656,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,77,404.201,421.1112627,2,3,6,2,4.651,60.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3189,2343,16876993,rac-27,P55055,LXRB,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylacetate",CCN(C(C(=O)OC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214942,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 900nM,partial agonist,50.00%,agonist,T0901317,,,,,,,EC50,=,2200,nM,,,,,=,6.045757491,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,50,416.212,435.1269128,1,4,6,2,4.7394,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3190,2343,16876993,rac-27,Q13133,LXRA,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylacetate",CCN(C(C(=O)OC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214942,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 700nM,partial agonist,33.00%,agonist,T0901317,,,,,,,EC50,=,2300,nM,,,,,=,6.15490196,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,33,416.212,435.1269128,1,4,6,2,4.7394,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3191,2344,16876993,rac-36,P55055,LXRB,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-N,N-dimethyl-2-phenylpropanamide",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(C)(C(=O)N(C)C)c2ccccc2,CHEMBL214948,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,partial agonist,63.00%,agonist,T0901317,,,,,,,EC50,=,70,nM,,,,,=,7.22184875,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,63,438.242,462.1741973,1,3,6,2,4.8287,43.78,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3192,2344,16876993,rac-36,Q13133,LXRA,Homo sapiens,"2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-N,N-dimethyl-2-phenylpropanamide",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(C)(C(=O)N(C)C)c2ccccc2,CHEMBL214948,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,partial agonist,67.00%,agonist,T0901317,,,,,,,EC50,=,400,nM,,,,,=,6.698970004,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,67,438.242,462.1741973,1,3,6,2,4.8287,43.78,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3193,2345,16876993,rac-33,P55055,LXRB,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylpropanoate",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(C)(C(=O)OC)c2ccccc2,CHEMBL215904,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8nM,agonist,105.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,8.096910013,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,105,428.223,449.1425629,1,4,6,2,4.9135,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3194,2345,16876993,rac-33,Q13133,LXRA,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylpropanoate",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(C)(C(=O)OC)c2ccccc2,CHEMBL215904,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,81.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,81,428.223,449.1425629,1,4,6,2,4.9135,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3195,2346,16876993,rac-34,P55055,LXRB,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylbutanoate",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(CC)(C(=O)OC)c2ccccc2,CHEMBL263089,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 40nM,agonist,89.00%,agonist,T0901317,,,,,,,EC50,=,70,nM,,,,,=,7.397940009,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,89,440.234,463.1582129,1,4,7,2,5.3036,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3196,2346,16876993,rac-34,Q13133,LXRA,Homo sapiens,"methyl 2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylbutanoate",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)C(CC)(C(=O)OC)c2ccccc2,CHEMBL263089,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,94.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,94,440.234,463.1582129,1,4,7,2,5.3036,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3197,2347,16876993,rac-43,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385411,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 900nM,partial agonist,53.00%,agonist,T0901317,,,,,,,EC50,=,700,nM,,,,,=,6.045757491,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,53,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3198,2347,16876993,rac-43,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385411,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1100nM,agonist,87.00%,agonist,T0901317,,,,,,,EC50,=,1900,nM,,,,,=,5.958607315,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,87,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3199,2348,16876993,rac-45,P55055,LXRB,Homo sapiens,"2-(4-(ethyl(2-methoxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(COC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215598,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 300nM,partial agonist,73.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,6.522878745,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,73,400.213,421.1476482,1,3,7,2,5.2128,32.7,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3200,2348,16876993,rac-45,Q13133,LXRA,Homo sapiens,"2-(4-(ethyl(2-methoxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(COC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215598,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 400nM,agonist,111.00%,agonist,T0901317,,,,,,,EC50,=,900,nM,,,,,=,6.397940009,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,111,400.213,421.1476482,1,3,7,2,5.2128,32.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3201,2349,16876993,rac-51,P55055,LXRB,Homo sapiens,"2-(2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylethoxy)-N,N-dimethylacetamide",CCN(C(COCC(=O)N(C)C)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215129,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,partial agonist,67.00%,agonist,T0901317,,,,,,,EC50,=,260,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,67,466.252,492.184762,1,4,9,2,4.6712,53.01,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3202,2349,16876993,rac-51,Q13133,LXRA,Homo sapiens,"2-(2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylethoxy)-N,N-dimethylacetamide",CCN(C(COCC(=O)N(C)C)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215129,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 900nM,agonist,87.00%,agonist,T0901317,,,,,,,EC50,=,800,nM,,,,,=,6.045757491,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,87,466.252,492.184762,1,4,9,2,4.6712,53.01,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3209,2352,16876993,rac-47,P55055,LXRB,Homo sapiens,"methyl 2-(2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylethoxy)acetate",CCN(C(COCC(=O)OC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385052,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 500nM,partial agonist,65.00%,agonist,T0901317,,,,,,,EC50,=,900,nM,,,,,=,6.301029996,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,65,456.233,479.1531275,1,5,9,2,4.756,59,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3210,2352,16876993,rac-47,Q13133,LXRA,Homo sapiens,"methyl 2-(2-(ethyl(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)amino)-2-phenylethoxy)acetate",CCN(C(COCC(=O)OC)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385052,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 600nM,partial agonist,54.00%,agonist,T0901317,,,,,,,EC50,=,2200,nM,,,,,=,6.22184875,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,54,456.233,479.1531275,1,5,9,2,4.756,59,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3213,2354,16876993,rac-46,P55055,LXRB,Homo sapiens,"2-(4-((2-(benzyloxy)-1-phenylethyl)(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(COCc1ccccc1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215647,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 300nM,agonist,85.00%,agonist,T0901317,,,,,,,EC50,=,600,nM,,,,,=,6.522878745,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,85,472.279,497.1789484,1,3,9,3,6.7832,32.7,C1CCC(CCCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,464
3214,2354,16876993,rac-46,Q13133,LXRA,Homo sapiens,"2-(4-((2-(benzyloxy)-1-phenylethyl)(ethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(COCc1ccccc1)c2ccccc2)c3ccc(cc3)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215647,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,partial agonist,55.00%,agonist,T0901317,,,,,,,EC50,=,1900,nM,,,,,=,6.698970004,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,55,472.279,497.1789484,1,3,9,3,6.7832,32.7,C1CCC(CCCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,464
3215,2355,24239186,17,P51449,RORG,Homo sapiens,"N-ethyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)benzenesulfonamide",CCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c2ccccc2,CHEMBL2326845,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 245nM,inverse agonist,-97.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,190,nM,,,,,=,6.610833916,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,-97,412.246,427.0676837,1,3,5,2,4.214,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
3216,2356,16876993,R-43,P55055,LXRB,Homo sapiens,"(R)-2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN([C@@H](CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385489,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 500nM,agonist,91.00%,agonist,T0901317,,,,,,,EC50,=,400,nM,,,,,=,6.301029996,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,91,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3217,2356,16876993,R-43,Q13133,LXRA,Homo sapiens,"(R)-2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN([C@@H](CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL385489,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1300nM,partial agonist,65.00%,agonist,T0901317,,,,,,,EC50,=,1500,nM,,,,,=,5.886056648,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,65,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3218,2357,16876993,S-43,P55055,LXRB,Homo sapiens,"(S)-2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN([C@H](CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214832,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 400nM,agonist,92.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,6.397940009,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,92,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3219,2357,16876993,S-43,Q13133,LXRA,Homo sapiens,"(S)-2-(4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN([C@H](CO)c1ccccc1)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214832,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 500nM,partial agonist,73.00%,agonist,T0901317,,,,,,,EC50,=,500,nM,,,,,=,6.301029996,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,73,388.202,407.1319982,2,3,6,2,4.5587,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3220,2358,16876993,rac-35,P55055,LXRB,Homo sapiens,"methyl 2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylbutanoate",CCN(c1ccc(cc1Cl)C(O)(C(F)(F)F)C(F)(F)F)C(CC)(C(=O)OC)c2ccccc2,CHEMBL215167,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,partial agonist,64.00%,agonist,T0901317,,,,,,,EC50,=,70,nM,,,,,=,7.522878745,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,64,475.687,497.1192406,1,4,7,2,5.957,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
3221,2358,16876993,rac-35,Q13133,LXRA,Homo sapiens,"methyl 2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylbutanoate",CCN(c1ccc(cc1Cl)C(O)(C(F)(F)F)C(F)(F)F)C(CC)(C(=O)OC)c2ccccc2,CHEMBL215167,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,99.00%,agonist,T0901317,,,,,,,EC50,=,500,nM,,,,,=,7.22184875,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,99,475.687,497.1192406,1,4,7,2,5.957,49.77,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3222,2359,16876993,rac-44,P55055,LXRB,Homo sapiens,"2-(3-chloro-4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(CO)c1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214741,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 90nM,agonist,98.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,7.045757491,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,98,423.655,441.0930258,2,3,6,2,5.2121,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3223,2359,16876993,rac-44,Q13133,LXRA,Homo sapiens,"2-(3-chloro-4-(ethyl(2-hydroxy-1-phenylethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",CCN(C(CO)c1ccccc1)c2ccc(cc2Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214741,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,agonist,75.00%,agonist,T0901317,,,,,,,EC50,=,400,nM,,,,,=,6.698970004,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,75,423.655,441.0930258,2,3,6,2,5.2121,43.7,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
3224,236,15911283,44,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4'-vinyl-(4'R,4aS,5'S)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CC[C@@]24OC[C@H](O4)C=C)c5ccc(F)cc5,CHEMBL193704,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,partial agonist,32.00%,agonist,dexamethasone,,dexamethasone,,,,,,,,,,,,,=,7.420216403,pIC50,B,radiometric,C=C[C@@H]1CO[C@@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,32,331.241,352.1587061,0,4,2,2,4.0487,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,,partial agonist,,partial agonist,91
3225,2360,16876993,rac-55,P55055,LXRB,Homo sapiens,"4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)benzoic acid",CCN(C(COc1ccc(cc1)C(=O)O)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386260,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,agonist,89.00%,agonist,T0901317,,,,,,,EC50,=,1100,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,89,539.73,561.1141552,2,4,9,3,6.997,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,438
3226,2360,16876993,rac-55,Q13133,LXRA,Homo sapiens,"4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)benzoic acid",CCN(C(COc1ccc(cc1)C(=O)O)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL386260,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,partial agonist,61.00%,agonist,T0901317,,,,,,,EC50,=,3700,nM,,,,,=,7,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,61,539.73,561.1141552,2,4,9,3,6.997,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3227,2361,16876993,rac-52,P55055,LXRB,Homo sapiens,"methyl 4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)benzoate",CCN(C(COc1ccc(cc1)C(=O)OC)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215130,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,agonist,79.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,79,551.741,575.1298052,1,5,9,3,7.0854,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,438
3228,2361,16876993,rac-52,Q13133,LXRA,Homo sapiens,"methyl 4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)benzoate",CCN(C(COc1ccc(cc1)C(=O)OC)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215130,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,94.00%,agonist,T0901317,,,,,,,EC50,=,700,nM,,,,,=,7.22184875,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,94,551.741,575.1298052,1,5,9,3,7.0854,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,438
3229,2362,16876993,rac-56,P55055,LXRB,Homo sapiens,"2-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)acetic acid",CCN(C(COc1ccc(CC(=O)O)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214546,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,partial agonist,54.00%,agonist,T0901317,,,,,,,EC50,=,2400,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,54,551.741,575.1298052,2,4,10,3,6.9259,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3230,2362,16876993,rac-56,Q13133,LXRA,Homo sapiens,"2-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)acetic acid",CCN(C(COc1ccc(CC(=O)O)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214546,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,partial agonist,65.00%,agonist,T0901317,,,,,,,EC50,=,5500,nM,,,,,=,7,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,65,551.741,575.1298052,2,4,10,3,6.9259,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3231,2363,16876993,rac-53,P55055,LXRB,Homo sapiens,"methyl 2-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)acetate",CCN(C(COc1ccc(CC(=O)OC)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215959,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,98.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,7.522878745,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,98,563.752,589.1454553,1,5,10,3,7.0143,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,438
3232,2363,16876993,rac-53,Q13133,LXRA,Homo sapiens,"methyl 2-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)acetate",CCN(C(COc1ccc(CC(=O)OC)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL215959,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,partial agonist,65.00%,agonist,T0901317,,,,,,,EC50,=,1100,nM,,,,,=,6.698970004,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,65,563.752,589.1454553,1,5,10,3,7.0143,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3233,2364,16876993,rac-57,P55055,LXRB,Homo sapiens,"3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoic acid",CCN(C(COc1ccc(CCC(=O)O)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL269442,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,partial agonist,55.00%,agonist,T0901317,,,,,,,EC50,=,1200,nM,,,,,=,8.15490196,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,55,563.752,589.1454553,2,4,11,3,7.316,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3234,2364,16876993,rac-57,Q13133,LXRA,Homo sapiens,"3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoic acid",CCN(C(COc1ccc(CCC(=O)O)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL269442,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,partial agonist,72.00%,agonist,T0901317,,,,,,,EC50,=,4500,nM,,,,,=,7.22184875,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,72,563.752,589.1454553,2,4,11,3,7.316,70,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3235,2365,16876993,rac-54,P55055,LXRB,Homo sapiens,"methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate",CCN(C(COc1ccc(CCC(=O)OC)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214687,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,98.00%,agonist,T0901317,,,,,,,EC50,=,600,nM,,,,,=,7.301029996,pIC50,B,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,98,575.763,603.1611054,1,5,11,3,7.4044,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,438
3236,2365,16876993,rac-54,Q13133,LXRA,Homo sapiens,"methyl 3-(4-(2-((2-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)(ethyl)amino)-2-phenylethoxy)phenyl)propanoate",CCN(C(COc1ccc(CCC(=O)OC)cc1)c2ccccc2)c3ccc(cc3Cl)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL214687,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,partial agonist,43.00%,agonist,T0901317,,,,,,,EC50,=,1400,nM,,,,,=,7,pIC50,,radiometric,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,43,575.763,603.1611054,1,5,11,3,7.4044,59,C1CCC(CCC(CC2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,438
3240,2368,17034117,4g,P10275,AR,Homo sapiens,6-(N-ethyl-N-isopropylamino)-4-trifluoromethylquinolin-2(1H)-one,CCN(C(C)C)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL217402,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.4nM,agonist,77.00%,agonist,DHT,,,,,,,EC50,=,2.2,nM,IC50,>,10000,nM,=,8.13076828,pKi,B,radiometric,CCN(c1ccc2nc(O)cc(C(F)(F)F)c2c1)C(C)C,77,281.172,298.1292978,1,3,3,2,4.1939,36.36,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
3241,2369,24239186,27,P51449,RORG,Homo sapiens,"N-ethyl-N-(3-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)benzenesulfonamide",CCN(c1cccc(c1)C(O)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c2ccccc2,CHEMBL3094384,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 329nM,inverse agonist,-94.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,900,nM,,,,,=,6.482804102,pIC50,,radiometric,CCN(c1cccc(C(O)(C(F)(F)F)C(F)(F)F)c1)S(=O)(=O)c1ccccc1,-94,412.246,427.0676837,1,3,5,2,4.214,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
3242,237,15911283,40,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4'-vinyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CC[C@]24OC[C@H](O4)C=C)c5ccc(F)cc5,CHEMBL194013,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.8nM,partial agonist,36.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,9,nM,,,,,=,8.236572006,pIC50,B,radiometric,C=C[C@@H]1CO[C@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,36,331.241,352.1587061,0,4,2,2,4.0487,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,91
3243,2370,20469868,21b,P04150,GR,Homo sapiens,N-Ethyl-4-[1-(4-fluorophenyl)-1H-indazol-5-yl]-N-phenyl-3-(trifluoromethyl)benzenesulfonamide,CCN(c1ccccc1)S(=O)(=O)c2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1086115,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,partial agonist,40.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.7,,,,,,=,7.8,pIC50,B,FPA,CCN(c1ccccc1)S(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,40,518.386,539.1290608,0,4,6,5,7.0656,55.2,CC(C)(CC1CCCCC1)C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,1134
3260,2376,17439112,10b,P10275,AR,Homo sapiens,"1-ethyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino-[3,2-g]quinolin-7-one",CCN1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL224204,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.2nM,agonist,92.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,92,nM,IC50,>,10000,nM,=,8.920818754,pKi,B,radiometric,CCN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,92,285.16,298.0929123,1,3,1,2,2.7656,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3261,2377,19616429,21,P06401,PR,Homo sapiens,"(S)-2-chloro-4-((2,5-dichlorobenzyl)(1-ethyl-5-oxopyrrolidin-3-yl)amino)benzonitrile",CCN1C[C@H](CC1=O)N(Cc2cc(Cl)ccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL565022,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 10nM,partial agonist,52.00%,agonist,progesterone,,,,,,,EC50,=,0.8,nM,,,,,=,8,pIC50,B,other,CCN1C[C@@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)CC1=O,52,404.599,421.0515452,0,3,5,2,5.14588,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
3262,2378,19616429,22,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chloro-5-fluorobenzyl)(1-ethyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,CCN1C[C@H](CC1=O)N(Cc2cc(F)ccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL552023,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 10nM,partial agonist,53.00%,agonist,progesterone,,,,,,,EC50,=,0.3,nM,,,,,=,8,pIC50,B,other,CCN1C[C@@H](N(Cc2cc(F)ccc2Cl)c2ccc(C#N)c(Cl)c2)CC1=O,53,388.144,405.0810958,0,3,5,2,4.63158,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
3263,2379,19616429,16,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-ethyl-5-oxopyrrolidin-3-yl)(2-methylbenzyl)amino)benzonitrile,CCN1C[C@H](CC1=O)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL540476,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 15nM,partial agonist,57.00%,agonist,progesterone,,,,,,,EC50,=,0.8,nM,,,,,=,7.823908741,pIC50,B,other,CCN1C[C@@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)CC1=O,57,345.704,367.14514,0,3,5,2,4.1475,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
3266,2380,17439112,16a,P10275,AR,Homo sapiens,"(+/-)-1-ethyl-1,2,3,6-tetrahydro-2-methyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CCN1C(C)COc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL227305,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.2nM,partial agonist,61.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,61,nM,IC50,>,10000,nM,=,8.37675071,pKi,B,radiometric,CCN1c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2OCC1C,61,297.171,312.1085624,1,3,1,2,3.1541,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3269,2383,20584610,26,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid ethylamide",CCNC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210907,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 176nM,antagonist,97.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,313,nM,=,6.754487332,pKi,,radiometric,CCNC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,97,429.249,450.1514898,1,5,2,1,2.27538,102.74,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
3270,2384,24980053,23,P04150,GR,Homo sapiens,"(S)-N-(ethylcarbamoyl)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CCNC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5,CHEMBL3315058,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 5.7nM,agonist,86.00%,agonist,dexamethasone,,,,,,,EC50,=,241,nM,,,,,=,8.244125144,pKi,B,FPA,CCNC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,86,515.351,546.2278483,2,6,5,3,4.4696,109.86,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,863
3280,2390,23294830,9,P37231,PPARG,Homo sapiens,"2-(5-Chloropyridin-3-yloxy)-5-(3,4-dichlorophenylsulfonamido)-N-ethylbenzamide",CCNC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)c(Cl)c2)ccc1Oc3cncc(Cl)c3,CHEMBL2331775,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 35nM,partial agonist,30.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,20,nM,,,,,=,7.455931956,pIC50,B,radiometric,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)c(Cl)c2)ccc1Oc1cncc(Cl)c1,30,484.663,498.99271,2,5,7,3,5.3846,97.39,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
3283,2393,23294830,11,P37231,PPARG,Homo sapiens,2-(5-Chloropyridin-3-yloxy)-N-ethyl-5-(4-iodophenylsulfonamido)benzamide,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(I)cc2)ccc1Oc3cncc(Cl)c3,CHEMBL2331777,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 25nM,partial agonist,40.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,20,nM,,,,,=,7.602059991,pIC50,B,radiometric,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(I)cc2)ccc1Oc1cncc(Cl)c1,40,540.661,556.9673027,2,5,7,3,4.6824,97.39,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
3284,2394,23294830,12,P37231,PPARG,Homo sapiens,2-(5-Chloropyridin-3-yloxy)-N-ethyl-5-(4-methoxyphenylsulfonamido)benzamide,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(OC)cc2)ccc1Oc3cncc(Cl)c3,CHEMBL2331559,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 400nM,partial agonist,33.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,2000,nM,,,,,=,6.397940009,pIC50,,radiometric,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(OC)cc2)ccc1Oc1cncc(Cl)c1,33,441.767,461.0812194,2,6,8,3,4.0864,106.62,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
3286,2396,23294830,13,P37231,PPARG,Homo sapiens,2-(5-Chloropyridin-3-yloxy)-N-ethyl-5-(4-nitrophenylsulfonamido)benzamide,CCNC(=O)c1cc(NS(=O)(=O)c2ccc(cc2)[N+](=O)[O-])ccc1Oc3cncc(Cl)c3,CHEMBL2331778,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 49nM,partial agonist,40.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,400,nM,,,,,=,7.30980392,pIC50,B,radiometric,CCNC(=O)c1cc(NS(=O)(=O)c2ccc([N+](=O)[O-])cc2)ccc1Oc1cncc(Cl)c1,40,459.762,476.0557329,2,7,8,3,3.986,140.53,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
3288,2398,19162487,4j,P55055,LXRB,Homo sapiens,3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]-N-ethylbenzamide,CCNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461891,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,partial agonist,55.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,1272,nM,,,,,=,7.698970004,pIC50,B,radiometric,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,55,395.74,416.1291556,1,3,5,4,6.40562,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
3289,2398,19162487,4j,Q13133,LXRA,Homo sapiens,3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]-N-ethylbenzamide,CCNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461891,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 272nM,partial agonist,28.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,2102,nM,,,,,=,6.565431096,pIC50,,radiometric,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,28,395.74,416.1291556,1,3,5,4,6.40562,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
3300,2402,20469868,19c,P04150,GR,Homo sapiens,N-Ethyl-4-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)benzenesulfonamide,CCNS(=O)(=O)c1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1085853,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.7,antagonist,76.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.7,,=,7.7,pIC50,B,FPA,CCNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,76,446.32,463.0977607,1,4,5,4,5.1486,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,107
3304,2404,17257838,9b,P10275,AR,Homo sapiens,"7-(ethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706878,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 29nM,antagonist,77.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,35,nM,=,7.537602002,pIC50,B,radiometric,CCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,77,245.139,256.0823476,2,2,2,2,2.9787,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
3314,2409,21316964,(+/-)-14,P04150,GR,Homo sapiens,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-ethyl oxime",CCO\N=C\c1c(cc(C)c2NC(C)(C)[C@H](O)[C@@H](C)c12)c3cccc4cc[nH]c34,CHEMBL1682424,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.2,nM,,,,,=,8.823908741,pKi,B,radiometric,CCO/N=C/c1c(-c2cccc3cc[nH]c23)cc(C)c2c1[C@H](C)[C@@H](O)C(C)(C)N2,130,362.283,391.2259772,3,4,4,3,5.18222,69.64,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
3316,2410,21324689,27,P04150,GR,Homo sapiens,"rac-5,7-difluoro-3-hydroxy-2,2-dimethyl-6-(3-methyl-1H-indol-7-yl)-2,3-dihydroquinolin-4(1H)-one O-ethyl oxime",CCO\N=C\1/C(O)C(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4c(C)c[nH]c34,CHEMBL1762210,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.6nM,partial agonist,73.00%,agonist,dexamethasone,,,,,,,EC50,=,1.5,nM,,,,,=,9.22184875,pKi,B,radiometric,CCO/N=C1/c2c(cc(F)c(-c3cccc4c(C)c[nH]c34)c2F)NC(C)(C)C1O,73,376.257,399.1758334,3,4,3,3,4.72712,69.64,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,partial agonist,agonist,partial agonist,700
3321,2412,23276448,5,P10827,TRA,Homo sapiens,Axitirome,CCOC(=O)C(=O)Nc1cc(C)c(Oc2ccc(O)c(c2)C(O)c3ccc(F)cc3)c(C)c1,CHEMBL159682,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 40nM,agonist,104.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.397940009,pKi,B,radiometric,CCOC(=O)C(=O)Nc1cc(C)c(Oc2ccc(O)c(C(O)c3ccc(F)cc3)c2)c(C)c1,104,429.274,453.1587657,3,6,6,3,4.52374,105.09,C1CCC(CC2CCCC(CC3CCCCC3)C2)CC1,,agonist,,agonist,288
3322,2412,23276448,5,P10828,TRB,Homo sapiens,Axitirome,CCOC(=O)C(=O)Nc1cc(C)c(Oc2ccc(O)c(c2)C(O)c3ccc(F)cc3)c(C)c1,CHEMBL159682,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.17nM,agonist,94.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.663540266,pKi,B,radiometric,CCOC(=O)C(=O)Nc1cc(C)c(Oc2ccc(O)c(C(O)c3ccc(F)cc3)c2)c(C)c1,94,429.274,453.1587657,3,6,6,3,4.52374,105.09,C1CCC(CC2CCCC(CC3CCCCC3)C2)CC1,,agonist,,agonist,288
3325,2414,18255290,29,P37231,PPARG,Homo sapiens,"ethyl 2-ethoxy-3-(4-(2-(6-((hydroxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoate",CCOC(Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/O)\c4ccccc4)cc1)C(=O)OCC,CHEMBL253851,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 618nM,agonist,100.00%,agonist,,,,,,,,EC50,=,48,nM,,,,,=,6.209011525,pKi,,radiometric,CCOC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\O)c4ccccc4)ccc32)cc1)OCC,100,504.372,544.2937224,1,7,12,3,5.9906,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3326,2415,18255290,30,P37231,PPARG,Homo sapiens,"ethyl 2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoate",CCOC(Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)OCC,CHEMBL399629,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10000nM,agonist,113.00%,agonist,,,,,,,,EC50,=,19,nM,,,,,=,5,pKi,NB,radiometric,CCOC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)OCC,113,516.383,558.3093724,0,7,13,3,6.1628,69.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3327,2416,16125384,16,P55055,LXRB,Homo sapiens,"3-[((4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carbonyl)-amino]-adamantane-1-carboxylic acid ethyl ester",CCOC(=O)C12CC3CC(CC(C3)(C1)NC(=O)[C@@]4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(O)cc56)C2,CHEMBL196335,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 530nM,partial agonist,51.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.27572413,pIC50,,radiometric,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,51,438.333,479.3035588,2,4,4,1,5.4208,75.63,CC(CC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,916
3329,2417,21269824,Reference,Q96RI1,FXR,Homo sapiens,"ethyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate",CCOC(=O)C1=CN(CC(C)(C)c2c1[nH]c3ccccc23)C(=O)c4ccc(F)c(F)c4,CHEMBL510862,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 21nM,partial agonist,39.00%,agonist,GW4064,,,,,,,EC50,=,85,nM,,,,,=,7.677780705,pIC50,B,radiometric,CCOC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,39,402.271,424.159849,1,3,3,3,4.7837,62.4,CC(C1CCCCC1)C1CCC2CC3CCCCC3C2CC1,agonist,partial agonist,agonist,partial agonist,844
3330,2417,D3R,FXR_5,Q96RI1,FXR,Homo sapiens,,CCOC(=O)C1=CN(CC(C)(C)c2c1[nH]c3ccccc23)C(=O)c4ccc(F)c(F)c4,,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1420nM,,,,,,"2,N-dicyclohexyl-2-[2-(2,4-dimethoxy-phenyl)-benzoimidazol-1-yl]acetamide",,,,,,,,,,,,,=,5.847711656,pIC50,,radiometric,CCOC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,,402.271,424.159849,1,3,3,3,4.7837,62.4,CC(C1CCCCC1)C1CCC2CC3CCCCC3C2CC1,,,agonist,partial agonist,844
3332,2419,11728194,16,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene-5-carboxylic acid ethyl ester",CCOC(=O)C1Oc2cccc(OC)c2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL138003,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 25nM,partial agonist,33.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,320,nM,,,,,=,7.602059991,pKi,B,radiometric,CCOC(=O)C1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,33,354.256,379.1783583,1,5,3,2,4.9662,56.79,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
3338,2422,17267219,6u,P10275,AR,Homo sapiens,"ethyl 2-((2-oxo-4-(trifluoromethyl)-1,2,4a,8a-tetrahydroquinolin-6-yl)(2,2,2-trifluoroethyl)amino)acetate",CCOC(=O)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL3706928,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 19nM,partial agonist,59.00%,agonist,DHT,,,,,,,EC50,=,20,nM,IC50,>,10000,nM,=,7.721246399,pIC50,B,radiometric,CCOC(=O)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,59,382.175,396.0908616,1,4,5,2,3.4787,62.4,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
3341,2425,19595590,17,P06401,PR,Homo sapiens,(S)-ethyl 2-(3-((3-chloro-4-cyanophenyl)(2-chlorobenzyl)amino)pyrrolidin-1-yl)acetate,CCOC(=O)CN1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL559261,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,partial agonist,45.00%,agonist,progesterone,,,,,,,EC50,=,10,nM,,,,,=,8.096910013,pIC50,B,FPA,CCOC(=O)CN1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,45,409.167,431.1167323,0,5,7,2,4.50908,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
3343,2427,19926282,28,P06401,PR,Homo sapiens,(S)-ethyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CCOC(=O)N1CC[C@@H](C1)N(Cc2cc(F)ccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL601472,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 30nM,partial agonist,43.00%,agonist,progesterone,,,,,,,EC50,=,364,nM,,,,,=,7.522878745,pIC50,B,other,CCOC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,43,392.712,415.1462829,0,4,5,2,4.8966,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
3347,2429,25686852,3c,Q07869,PPARA,Homo sapiens,"(3S,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@@H](C1)C(=O)O,CHEMBL3398437,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,partial agonist,27.00%,agonist,GW2331,1000nM,,,,,,EC50,=,10900,nM,,,,,>,5,pIC50,NB,FPA,CCOC(=O)N1C[C@@H](C(=O)O)[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,27,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,187
3348,243,15911283,42,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4'-vinyl-(4'S,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CC[C@]24OC[C@@H](O4)C=C)c5ccc(F)cc5,CHEMBL194059,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.6nM,partial agonist,47.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,25,nM,,,,,=,8.251811973,pIC50,B,radiometric,C=C[C@H]1CO[C@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,47,331.241,352.1587061,0,4,2,2,4.0487,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,91
3349,2430,25686852,5d,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)[C@H](C1)C(=O)O,CHEMBL3398458,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 690nM,partial agonist,64.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,540,nM,,,,,=,6.161150909,pIC50,,FPA,CCOC(=O)N1C[C@@H](CCc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)[C@@H](C(=O)O)C1,64,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
3350,2430,25686852,5d,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)[C@H](C1)C(=O)O,CHEMBL3398458,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3270nM,agonist,133.00%,agonist,GW2331,1000nM,,,,,,EC50,=,20,nM,,,,,=,5.485452247,pIC50,,FPA,CCOC(=O)N1C[C@@H](CCc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)[C@@H](C(=O)O)C1,133,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
3351,2431,25686852,5a,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](CCc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398455,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 490nM,partial agonist,26.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,710,nM,,,,,=,6.30980392,pIC50,,FPA,CCOC(=O)N1C[C@@H](CCc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,26,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCCC(CCC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,194
3352,2431,25686852,5a,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](CCc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398455,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2690nM,agonist,117.00%,agonist,GW2331,1000nM,,,,,,EC50,=,200,nM,,,,,=,5.57024772,pIC50,,FPA,CCOC(=O)N1C[C@@H](CCc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,117,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCCC(CCC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,194
3353,2432,25686852,3i,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)[C@H](C1)C(=O)O,CHEMBL3398442,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 2680nM,agonist,76.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,300,nM,,,,,=,5.571865206,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)[C@@H](C(=O)O)C1,76,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
3354,2432,25686852,3i,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)[C@H](C1)C(=O)O,CHEMBL3398442,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2020nM,agonist,96.00%,agonist,GW2331,1000nM,,,,,,EC50,=,6,nM,,,,,=,5.694648631,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)[C@@H](C(=O)O)C1,96,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
3355,2433,25686852,3b,P37231,PPARG,Homo sapiens,"cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398436,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 1510nM,agonist,75.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,9,nM,,,,,=,5.821023053,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,75,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",187
3356,2433,25686852,3a,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398436,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 1900nM,partial agonist,58.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,750,nM,,,,,=,5.721246399,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,58,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",187
3357,2433,25686852,3a,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398436,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 170nM,agonist,170.00%,agonist,GW2331,1000nM,,,,,,EC50,=,10,nM,,,,,=,6.769551079,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,170,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,187
3358,2433,25686852,3b,Q07869,PPARA,Homo sapiens,"cis-(3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398436,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 260nM,agonist,127.00%,agonist,GW2331,1000nM,,,,,,EC50,=,3,nM,,,,,=,6.585026652,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,127,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,187
3360,2434,25686852,6c,Q07869,PPARA,Homo sapiens,"cis-2-((3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@@H](CC(=O)O)C1,CHEMBL3398464,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 5550nM,partial agonist,32.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2870,nM,,,,,=,5.255707017,pIC50,,FPA,CCOC(=O)N1C[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](CC(=O)O)C1,32,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,187
3361,2435,20584610,23,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid ethyl ester",CCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1209973,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 5.7nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,65,nM,=,8.244125144,pKi,B,radiometric,CCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,431.241,451.1355054,0,6,2,1,2.70238,99.94,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
3364,2437,25686852,1a,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@@H]([C@@H](C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C(=O)O,CHEMBL3398424,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 > 10000nM,partial agonist,58.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,2400,nM,,,,,>,5,pIC50,NB,FPA,CCOC(=O)N1C[C@H](C(=O)O)[C@H](c2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,58,436.294,464.1947366,1,6,8,3,4.52802,102.1,C1CCC(C2CCC(CCCC3CCCC(C4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,180
3367,2438,25686852,6a,Q07869,PPARA,Homo sapiens,"(+/-)-trans-2-((3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@H](CC(=O)O)[C@@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1,CHEMBL3398462,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2120nM,agonist,143.00%,agonist,GW2331,1000nM,,,,,,EC50,=,6,nM,,,,,=,5.673664139,pIC50,,FPA,CCOC(=O)N1C[C@H](CC(=O)O)[C@@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,143,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,187
3370,244,15911283,28,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4',5'-divinyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CCC24O[C@H](C=C)[C@H](O4)C=C)c5ccc(F)cc5,CHEMBL195723,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.0nM,partial agonist,58.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,2.6,nM,,,,,=,8.096910013,pIC50,B,radiometric,C=C[C@H]1OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1C=C,58,355.263,378.1743562,0,4,3,2,4.6033,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,91
3373,2440,25686852,2a,P37231,PPARG,Homo sapiens,"(+/-)-cis-2-((3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@H](CC(=O)O)[C@@H](C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL3398430,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 910nM,agonist,85.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,20,nM,,,,,=,6.040958608,pIC50,,FPA,CCOC(=O)N1C[C@H](CC(=O)O)[C@H](c2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,85,448.305,478.2103867,1,6,9,3,4.91812,102.1,C1CCC(C2CCC(CCCC3CCCC(C4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,180
3374,2440,25686852,2a,Q07869,PPARA,Homo sapiens,"(+/-)-cis-2-((3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@H](CC(=O)O)[C@@H](C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL3398430,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 990nM,partial agonist,70.00%,agonist,GW2331,1000nM,,,,,,EC50,=,1130,nM,,,,,=,6.004364805,pIC50,,FPA,CCOC(=O)N1C[C@H](CC(=O)O)[C@H](c2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)C1,70,448.305,478.2103867,1,6,9,3,4.91812,102.1,C1CCC(C2CCC(CCCC3CCCC(C4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,180
3376,2441,25686852,5f,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4R)-1-(ethoxycarbonyl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@H](CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)[C@H](C1)C(=O)O,CHEMBL3398460,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1810nM,agonist,81.00%,agonist,GW2331,1000nM,,,,,,EC50,=,10,nM,,,,,=,5.742321425,pIC50,,FPA,CCOC(=O)N1C[C@H](CCc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)[C@@H](C(=O)O)C1,81,460.316,492.2260367,1,6,10,3,4.99322,102.1,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
3377,2442,25686852,3g,P37231,PPARG,Homo sapiens,"(+/-)-trans-(3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398440,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 8110nM,agonist,105.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,2850,nM,,,,,=,5.090979146,pIC50,,FPA,CCOC(=O)N1C[C@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,105,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,187
3378,2442,25686852,3g,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4R)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",CCOC(=O)N1C[C@H](Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)[C@H](C1)C(=O)O,CHEMBL3398440,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2120nM,agonist,96.00%,agonist,GW2331,1000nM,,,,,,EC50,=,150,nM,,,,,=,5.673664139,pIC50,,FPA,CCOC(=O)N1C[C@H](Cc2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](C(=O)O)C1,96,448.305,478.2103867,1,6,9,3,4.60312,102.1,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,187
3381,2444,25686852,2c,P37231,PPARG,Homo sapiens,"(+/-)-trans-2-((3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@H](CC(=O)O)[C@H](C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL3398432,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 5460nM,agonist,104.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,9680,nM,,,,,=,5.262807357,pIC50,,FPA,CCOC(=O)N1C[C@H](c2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](CC(=O)O)C1,104,448.305,478.2103867,1,6,9,3,4.91812,102.1,C1CCC(C2CCC(CCCC3CCCC(C4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,180
3382,2444,25686852,2c,Q07869,PPARA,Homo sapiens,"(+/-)-trans-2-((3R,4S)-1-(ethoxycarbonyl)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pyrrolidin-3-yl)acetic acid",CCOC(=O)N1C[C@H](CC(=O)O)[C@H](C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL3398432,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,agonist,88.00%,agonist,GW2331,1000nM,,,,,,EC50,=,8100,nM,,,,,>,5,pIC50,NB,FPA,CCOC(=O)N1C[C@H](c2cccc(OCCc3nc(-c4ccccc4)oc3C)c2)[C@@H](CC(=O)O)C1,88,448.305,478.2103867,1,6,9,3,4.91812,102.1,C1CCC(C2CCC(CCCC3CCCC(C4CCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,180
3383,2445,18255290,31,P37231,PPARG,Homo sapiens,"(S)-ethyl 2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoate",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)OCC,CHEMBL254054,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10000nM,agonist,185.00%,agonist,,,,,,,,EC50,=,14,nM,,,,,=,5,pKi,NB,radiometric,CCOC(=O)[C@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)OCC,185,516.383,558.3093724,0,7,13,3,6.1628,69.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3389,245,15911283,22,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4',5'-divinyl-(4'R,4aS,5'R)-spiro[4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CCCC24O[C@H](C=C)[C@H](O4)C=C)c5ccc(F)cc5,CHEMBL382102,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.2nM,partial agonist,65.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.3,nM,,,,,=,8.920818754,pIC50,B,radiometric,C=C[C@H]1OC2(CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1C=C,65,367.274,392.1900063,0,4,3,2,4.9934,36.28,C1CCC(C2CCC3CC4C(CCCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,95
3412,2466,16973358,15,P37231,PPARG,Homo sapiens,2-ethoxy-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CCOC(CC)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL218950,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 14400nM,partial agonist,64.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,2810,nM,,,,,=,4.841637508,pKi,NB,radiometric,CCOC(CC)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,64,396.273,424.199822,1,6,11,3,4.47892,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
3413,2466,16973358,15,Q07869,PPARA,Homo sapiens,2-ethoxy-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CCOC(CC)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL218950,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15100nM,partial agonist,64.00%,agonist,GW2331,,GW2331,,,,,EC50,=,4670,nM,,,,,=,4.821023053,pKi,NB,radiometric,CCOC(CC)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,64,396.273,424.199822,1,6,11,3,4.47892,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
3414,2467,16979341,15,P37231,PPARG,Homo sapiens,2-ethoxy-3-(5-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)pyridin-2-yl)propanoic acid,CCOC(Cc1ccc(OCCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL221529,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 1100nM,agonist,87.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,887,nM,,,,,=,5.958607315,pKi,,radiometric,CCOC(Cc1ccc(OCCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,87,384.262,410.1841719,1,6,11,3,4.08882,94.68,C1CCC(CCCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,436
3415,2467,16979341,15,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(5-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)pyridin-2-yl)propanoic acid,CCOC(Cc1ccc(OCCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL221529,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 840nM,agonist,76.00%,agonist,GW2331,,GW2331,,,,,EC50,=,886,nM,,,,,=,6.075720714,pIC50,,radiometric,CCOC(Cc1ccc(OCCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,76,384.262,410.1841719,1,6,11,3,4.08882,94.68,C1CCC(CCCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,436
3416,2468,18255290,34,P37231,PPARG,Homo sapiens,"2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoic acid",CCOC(Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)O,CHEMBL398677,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 48nM,agonist,167.00%,agonist,,,,,,,,EC50,=,11,nM,,,,,=,7.318758763,pKi,B,radiometric,CCOC(Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)C(=O)O,167,492.361,530.2780723,1,6,12,3,5.6843,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3418,247,17890084,13,P03372,ERA,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-13-methyl-3-methylene-10-vinyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=C)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL400480,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial agonist,49.00%,agonist,E2,,E2,,,,,EC50,=,430,nM,,,,,>,5,pIC50,NB,radiometric,C=C[C@]12CCC(=C)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,49,268.23,298.2296656,1,1,1,0,5.0324,20.23,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,615
3420,247,17890084,13,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-13-methyl-3-methylene-10-vinyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=C)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL400480,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 120nM,partial agonist,59.00%,agonist,E2,,E2,,,,,EC50,=,230,nM,,,,,=,6.920818754,pIC50,,radiometric,C=C[C@]12CCC(=C)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,59,268.23,298.2296656,1,1,1,0,5.0324,20.23,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,615
3421,2470,19349176,rac-2Ba,P37231,PPARG,Homo sapiens,2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL485537,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,agonist,100.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,18,nM,,,,,=,8.15490196,pIC50,B,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,100,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3422,2470,19349176,rac-2Ba,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL485537,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 22nM,agonist,164.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,27,nM,,,,,=,7.657577319,pIC50,B,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,164,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3423,2471,16979341,9,P37231,PPARG,Homo sapiens,2-ethoxy-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL373430,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 73nM,agonist,96.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,129,nM,,,,,=,7.13667714,pKi,B,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,96,372.251,396.1685219,1,6,10,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
3424,2471,16979341,9,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL373430,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2000nM,agonist,100.00%,agonist,GW2331,,GW2331,,,,,EC50,=,1230,nM,,,,,=,5.698970004,pIC50,,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,100,372.251,396.1685219,1,6,10,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
3425,2472,16973358,13,P37231,PPARG,Homo sapiens,2-ethoxy-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL220597,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 150nM,agonist,105.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,6,nM,,,,,=,6.823908741,pKi,,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,105,372.251,396.1685219,1,6,10,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
3426,2472,16973358,13,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CCOC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL220597,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 43nM,agonist,96.00%,agonist,GW2331,,GW2331,,,,,EC50,=,33,nM,,,,,=,7.366531544,pKi,B,radiometric,CCOC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,96,372.251,396.1685219,1,6,10,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
3427,2473,16737814,29,P37231,PPARG,Homo sapiens,2-ethoxy-3-(3-methyl-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(c1)c(C)cn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)C(=O)O,CHEMBL384203,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 223nM,agonist,113.00%,agonist,Edaglitazone,,,,,,,EC50,=,60,nM,,,,,=,6.651695137,pIC50,,radiometric,CCOC(Cc1ccc2c(c1)c(C)cn2Cc1nc(-c2ccc(C(F)(F)F)cc2)oc1C)C(=O)O,113,461.29,486.1766419,1,5,8,4,6.01244,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3428,2473,16737814,29,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(3-methyl-1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(c1)c(C)cn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)C(=O)O,CHEMBL384203,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 218nM,agonist,295.00%,agonist,Farglitazar,,,,,,,EC50,=,170,nM,,,,,=,6.661543506,pIC50,,radiometric,CCOC(Cc1ccc2c(c1)c(C)cn2Cc1nc(-c2ccc(C(F)(F)F)cc2)oc1C)C(=O)O,295,461.29,486.1766419,1,5,8,4,6.01244,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3432,2475,16737814,22,P37231,PPARG,Homo sapiens,"3-(1-((2-(3,5-dimethylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(C)cc(C)c4)c1)C(=O)O,CHEMBL380070,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,agonist,126.00%,agonist,Edaglitazone,,,,,,,EC50,=,40,nM,,,,,=,7.420216403,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(C)cc(C)c3)oc2C)c1)C(=O)O,126,404.296,432.2049074,1,5,8,4,5.30206,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3433,2475,16737814,22,Q07869,PPARA,Homo sapiens,"3-(1-((2-(3,5-dimethylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(C)cc(C)c4)c1)C(=O)O,CHEMBL380070,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 181nM,agonist,87.00%,agonist,Farglitazar,,,,,,,EC50,=,20,nM,,,,,=,6.742321425,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(C)cc(C)c3)oc2C)c1)C(=O)O,87,404.296,432.2049074,1,5,8,4,5.30206,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3434,2476,16737814,23,P37231,PPARG,Homo sapiens,"3-(1-((2-(3,5-dichlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(Cl)cc(Cl)c4)c1)C(=O)O,CHEMBL210163,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 71nM,agonist,104.00%,agonist,Edaglitazone,,,,,,,EC50,=,70,nM,,,,,=,7.148741651,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(Cl)cc(Cl)c3)oc2C)c1)C(=O)O,104,451.18,472.0956625,1,5,8,4,5.99202,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3435,2476,16737814,23,Q07869,PPARA,Homo sapiens,"3-(1-((2-(3,5-dichlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(Cl)cc(Cl)c4)c1)C(=O)O,CHEMBL210163,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 419nM,agonist,96.00%,agonist,Farglitazar,,,,,,,EC50,=,30,nM,,,,,=,6.377785977,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(Cl)cc(Cl)c3)oc2C)c1)C(=O)O,96,451.18,472.0956625,1,5,8,4,5.99202,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3436,2477,16737814,24,P37231,PPARG,Homo sapiens,"3-(1-((2-(3,5-dimethoxyphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(OC)cc(OC)c4)c1)C(=O)O,CHEMBL211839,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 25nM,agonist,139.00%,agonist,Edaglitazone,,,,,,,EC50,=,10,nM,,,,,=,7.602059991,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(OC)cc(OC)c3)oc2C)c1)C(=O)O,139,436.294,464.1947366,1,7,10,4,4.70242,95.95,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3437,2477,16737814,24,Q07869,PPARA,Homo sapiens,"3-(1-((2-(3,5-dimethoxyphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid",CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cc(OC)cc(OC)c4)c1)C(=O)O,CHEMBL211839,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 253nM,agonist,133.00%,agonist,Farglitazar,,,,,,,EC50,=,90,nM,,,,,=,6.596879479,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cc(OC)cc(OC)c3)oc2C)c1)C(=O)O,133,436.294,464.1947366,1,7,10,4,4.70242,95.95,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3438,2478,16737814,21,P37231,PPARG,Homo sapiens,3-(1-((2-(4-tert-butylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(C)(C)C)c1)C(=O)O,CHEMBL213602,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 15nM,agonist,131.00%,agonist,Edaglitazone,,,,,,,EC50,=,180,nM,,,,,=,7.823908741,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(C)(C)C)cc3)oc2C)c1)C(=O)O,131,428.318,460.2362075,1,5,8,4,5.98272,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3439,2478,16737814,21,Q07869,PPARA,Homo sapiens,3-(1-((2-(4-tert-butylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(C)(C)C)c1)C(=O)O,CHEMBL213602,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 173nM,partial agonist,63.00%,agonist,Farglitazar,,,,,,,EC50,=,730,nM,,,,,=,6.761953897,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(C)(C)C)cc3)oc2C)c1)C(=O)O,63,428.318,460.2362075,1,5,8,4,5.98272,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3440,2479,16737814,20,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(4-isopropylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(C)C)c1)C(=O)O,CHEMBL387023,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,123.00%,agonist,Edaglitazone,,,,,,,EC50,=,120,nM,,,,,=,7.886056648,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(C)C)cc3)oc2C)c1)C(=O)O,123,416.307,446.2205574,1,5,9,4,5.80862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3441,2479,16737814,20,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(4-isopropylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(C)C)c1)C(=O)O,CHEMBL387023,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 117nM,partial agonist,68.00%,agonist,Farglitazar,,,,,,,EC50,=,410,nM,,,,,=,6.931814138,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(C)C)cc3)oc2C)c1)C(=O)O,68,416.307,446.2205574,1,5,9,4,5.80862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3444,2480,16737814,18,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL213675,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 321nM,agonist,92.00%,agonist,Edaglitazone,,,,,,,EC50,=,470,nM,,,,,=,6.493494968,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c1)C(=O)O,92,449.279,472.1609919,1,5,8,4,5.70402,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3445,2480,16737814,18,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL213675,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 70nM,agonist,132.00%,agonist,Farglitazar,,,,,,,EC50,=,170,nM,,,,,=,7.15490196,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c1)C(=O)O,132,449.279,472.1609919,1,5,8,4,5.70402,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3446,2481,16737814,19,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(4-ethylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(CC)cc4)c1)C(=O)O,CHEMBL213678,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 27nM,agonist,113.00%,agonist,Edaglitazone,,,,,,,EC50,=,190,nM,,,,,=,7.568636236,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(CC)cc3)oc2C)c1)C(=O)O,113,404.296,432.2049074,1,5,9,4,5.24762,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3447,2481,16737814,19,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(4-ethylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(CC)cc4)c1)C(=O)O,CHEMBL213678,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 166nM,partial agonist,56.00%,agonist,Farglitazar,,,,,,,EC50,=,70,nM,,,,,=,6.779891912,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(CC)cc3)oc2C)c1)C(=O)O,56,404.296,432.2049074,1,5,9,4,5.24762,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3448,2482,16737814,25,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(F)c(C)c4)c1)C(=O)O,CHEMBL265364,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 135nM,agonist,121.00%,agonist,Edaglitazone,,,,,,,EC50,=,140,nM,,,,,=,6.869666232,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(F)c(C)c3)oc2C)c1)C(=O)O,121,411.283,436.1798355,1,5,8,4,5.13274,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3449,2482,16737814,25,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(F)c(C)c4)c1)C(=O)O,CHEMBL265364,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 149nM,agonist,87.00%,agonist,Farglitazar,,,,,,,EC50,=,50,nM,,,,,=,6.826813732,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(F)c(C)c3)oc2C)c1)C(=O)O,87,411.283,436.1798355,1,5,8,4,5.13274,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3450,2483,16737814,17,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(4-fluorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(F)cc4)c1)C(=O)O,CHEMBL214272,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 377nM,agonist,83.00%,agonist,Edaglitazone,,,,,,,EC50,=,770,nM,,,,,=,6.42365865,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(F)cc3)oc2C)c1)C(=O)O,83,399.272,422.1641854,1,5,8,4,4.82432,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3451,2483,16737814,17,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(4-fluorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(F)cc4)c1)C(=O)O,CHEMBL214272,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 121nM,agonist,105.00%,agonist,Farglitazar,,,,,,,EC50,=,630,nM,,,,,=,6.91721463,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccc(F)cc3)oc2C)c1)C(=O)O,105,399.272,422.1641854,1,5,8,4,4.82432,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3452,2484,16737814,16,P37231,PPARG,Homo sapiens,3-(1-((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cccc(Cl)c4)c1)C(=O)O,CHEMBL211513,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,agonist,125.00%,agonist,Edaglitazone,,,,,,,EC50,=,60,nM,,,,,=,7.619788758,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cccc(Cl)c3)oc2C)c1)C(=O)O,125,415.727,438.1346349,1,5,8,4,5.33862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3453,2484,16737814,16,Q07869,PPARA,Homo sapiens,3-(1-((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4cccc(Cl)c4)c1)C(=O)O,CHEMBL211513,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 396nM,agonist,75.00%,agonist,Farglitazar,,,,,,,EC50,=,130,nM,,,,,=,6.402304814,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3cccc(Cl)c3)oc2C)c1)C(=O)O,75,415.727,438.1346349,1,5,8,4,5.33862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3454,2485,16737814,7,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-phenyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4)c1)C(=O)O,CHEMBL209546,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 178nM,agonist,93.00%,agonist,Edaglitazone,,,,,,,EC50,=,23,nM,,,,,=,6.749579998,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3)oc2C)c1)C(=O)O,93,380.274,404.1736072,1,5,8,4,4.68522,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3455,2485,16737814,7,Q03181,PPARB,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-phenyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4)c1)C(=O)O,CHEMBL209546,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 > 10000nM,agonist,93.00%,agonist,GW501516,,,,,,,EC50,=,8400,nM,,,,,>,5,pIC50,NB,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3)oc2C)c1)C(=O)O,93,380.274,404.1736072,1,5,8,4,4.68522,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3456,2485,16737814,7,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-phenyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4)c1)C(=O)O,CHEMBL209546,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 368nM,partial agonist,50.00%,agonist,,,,,,,,EC50,=,840,nM,,,,,=,6.434152181,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3)oc2C)c1)C(=O)O,50,380.274,404.1736072,1,5,8,4,4.68522,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3457,2486,16737814,12,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-o-tolyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4C)c1)C(=O)O,CHEMBL211371,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 316nM,agonist,92.00%,agonist,Edaglitazone,,,,,,,EC50,=,990,nM,,,,,=,6.500312917,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3C)oc2C)c1)C(=O)O,92,392.285,418.1892573,1,5,8,4,4.99364,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3458,2486,16737814,12,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((5-methyl-2-o-tolyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4C)c1)C(=O)O,CHEMBL211371,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 125nM,agonist,77.00%,agonist,Farglitazar,,,,,,,EC50,=,830,nM,,,,,=,6.903089987,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3C)oc2C)c1)C(=O)O,77,392.285,418.1892573,1,5,8,4,4.99364,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3459,2487,16737814,13,P37231,PPARG,Homo sapiens,3-(1-((2-(2-chlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4Cl)c1)C(=O)O,CHEMBL209749,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 251nM,agonist,82.00%,agonist,Edaglitazone,,,,,,,EC50,=,760,nM,,,,,=,6.600326279,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3Cl)oc2C)c1)C(=O)O,82,415.727,438.1346349,1,5,8,4,5.33862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3460,2487,16737814,13,Q07869,PPARA,Homo sapiens,3-(1-((2-(2-chlorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)-2-ethoxypropanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4Cl)c1)C(=O)O,CHEMBL209749,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 73nM,agonist,80.00%,agonist,Farglitazar,,,,,,,EC50,=,810,nM,,,,,=,7.13667714,pIC50,B,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3Cl)oc2C)c1)C(=O)O,80,415.727,438.1346349,1,5,8,4,5.33862,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3461,2488,16737814,11,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(2-fluorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4F)c1)C(=O)O,CHEMBL380404,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 196nM,agonist,94.00%,agonist,Edaglitazone,,,,,,,EC50,=,800,nM,,,,,=,6.707743929,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3F)oc2C)c1)C(=O)O,94,399.272,422.1641854,1,5,8,4,4.82432,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3462,2488,16737814,11,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(2-fluorophenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4F)c1)C(=O)O,CHEMBL380404,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 735nM,partial agonist,52.00%,agonist,Farglitazar,,,,,,,EC50,=,1000,nM,,,,,=,6.133712661,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3F)oc2C)c1)C(=O)O,52,399.272,422.1641854,1,5,8,4,4.82432,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3469,249,17448656,4,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-17-hydroxy-13-methyl-10-vinyl-1,7,8,10,11,12,13,15,16,17-decahydro-2H-cyclopenta[a]phenanthren-3(6H,9H,14H)-one",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246140,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 482nM,partial agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,379,nM,,,,,=,6.316952962,pIC50,,radiometric,C=C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,,272.218,300.2089301,1,2,1,0,4.0453,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,agonist,agonist,615
3470,249,17890084,16,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-17-hydroxy-13-methyl-10-vinyl-1,7,8,10,11,12,13,15,16,17-decahydro-2H-cyclopenta[a]phenanthren-3(6H,9H,14H)-one",C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246140,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 780nM,agonist,78.00%,agonist,E2,,E2,,,,,EC50,=,380,nM,,,,,=,6.107905397,pIC50,,radiometric,C=C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,78,272.218,300.2089301,1,2,1,0,4.0453,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
3471,2490,16737814,14,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-((2-(2-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4OC)c1)C(=O)O,CHEMBL378705,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 742nM,partial agonist,69.00%,agonist,Edaglitazone,,,,,,,EC50,=,1100,nM,,,,,=,6.129596095,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3OC)oc2C)c1)C(=O)O,69,408.284,434.1841719,1,6,9,4,4.69382,86.72,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
3472,2490,16737814,14,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-((2-(2-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CCOC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4OC)c1)C(=O)O,CHEMBL378705,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 181nM,agonist,107.00%,agonist,Farglitazar,,,,,,,EC50,=,1000,nM,,,,,=,6.742321425,pIC50,,radiometric,CCOC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3OC)oc2C)c1)C(=O)O,107,408.284,434.1841719,1,6,9,4,4.69382,86.72,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
3473,2491,16737814,10,P37231,PPARG,Homo sapiens,2-ethoxy-3-(1-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)-1H-indol-4-yl)propanoic acid,CCOC(Cc1cccc2c1ccn2CCCc3nc(oc3C)c4ccccc4)C(=O)O,CHEMBL213487,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 274nM,agonist,76.00%,agonist,Edaglitazone,,,,,,,EC50,=,90,nM,,,,,=,6.562249437,pIC50,,radiometric,CCOC(Cc1cccc2c1ccn2CCCc1nc(-c2ccccc2)oc1C)C(=O)O,76,404.296,432.2049074,1,5,10,4,5.26972,77.49,C1CCC(C2CCC(CCCC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,172
3474,2491,16737814,10,Q07869,PPARA,Homo sapiens,2-ethoxy-3-(1-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)-1H-indol-4-yl)propanoic acid,CCOC(Cc1cccc2c1ccn2CCCc3nc(oc3C)c4ccccc4)C(=O)O,CHEMBL213487,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 756nM,partial agonist,71.00%,agonist,Farglitazar,,,,,,,EC50,=,190,nM,,,,,=,6.121478205,pIC50,,radiometric,CCOC(Cc1cccc2c1ccn2CCCc1nc(-c2ccccc2)oc1C)C(=O)O,71,404.296,432.2049074,1,5,10,4,5.26972,77.49,C1CCC(C2CCC(CCCC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,172
3493,250,17890084,8,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-3,13,17-trimethyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC1=CC2=CC[C@H]3[C@@H]4CC[C@](C)(O)[C@@]4(C)CC[C@@H]3[C@]2(CC1)C=C,CHEMBL398634,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 53nM,partial agonist,52.00%,agonist,E2,,E2,,,,,EC50,=,480,nM,,,,,=,7.27572413,pIC50,B,radiometric,C=C[C@]12CCC(C)=CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,52,280.241,312.2453156,1,1,1,0,5.4225,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3497,2502,15582409,1d,P37231,PPARG,Homo sapiens,(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenoxy)-propoxy]-phenyl}-propionic acid,CCO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,CHEMBL360368,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 44nM,agonist,85.00%,agonist,standard,,,,,,,EC50,=,282,nM,,,,,=,7.356547324,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,85,408.28,436.1885886,1,5,13,3,5.359,74.22,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,468
3499,2502,15582409,1d,Q07869,PPARA,Homo sapiens,(S)-2-Ethoxy-3-{4-[3-(4-phenoxy-phenoxy)-propoxy]-phenyl}-propionic acid,CCO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,CHEMBL360368,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1686nM,partial agonist,30.00%,agonist,standard,,,,,,,EC50,=,2754,nM,,,,,=,5.77314243,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,30,408.28,436.1885886,1,5,13,3,5.359,74.22,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,468
3500,2503,19376700,3c,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(6-((cyclopropylmethoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)-2-ethoxypropanoic acid",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N\OCC4CC4)\c5ccccc5)cc1)C(=O)O,CHEMBL537921,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 254nM,agonist,165.00%,agonist,Rosiglitazone,1000nM,rosiglitazone,,,,,EC50,=,7.52,nM,,,,,=,6.595166283,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N/OCC4CC4)c4ccccc4)ccc32)cc1)C(=O)O,165,528.394,570.3093724,1,6,14,3,6.4645,80.59,C1CCC(CCCC2CCCC3CC(C(CCCC4CC4)C4CCCCC4)CCC23)CC1,agonist,agonist,agonist,agonist,390
3501,2504,19376700,3b,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(6-((benzyloxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)-2-ethoxypropanoic acid",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N\OCc4ccccc4)\c5ccccc5)cc1)C(=O)O,CHEMBL556643,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 18.4nM,agonist,124.00%,agonist,Rosiglitazone,1000nM,rosiglitazone,,,,,EC50,=,7,nM,,,,,=,7.735182177,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N/OCc4ccccc4)c4ccccc4)ccc32)cc1)C(=O)O,124,564.427,606.3093724,1,6,14,4,7.2547,80.59,C1CCC(CCCC2CCCC3CC(C(CCCC4CCCCC4)C4CCCCC4)CCC23)CC1,agonist,agonist,agonist,agonist,391
3502,2505,18255290,35,P37231,PPARG,Homo sapiens,"(S)-2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoic acid",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)O,CHEMBL253416,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 10000nM,agonist,185.00%,agonist,,,,,,,,EC50,=,14,nM,,,,,>,5,pKi,NB,radiometric,CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)C(=O)O,185,492.361,530.2780723,1,6,12,3,5.6843,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3503,2505,18255290,(S)-37,P37231,PPARG,Homo sapiens,"(S)-2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoic acid",CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)O,CHEMBL253416,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,agonist,95.00%,agonist,,,,,,,,EC50,=,7.85,nM,,,,,=,7.744727495,pKi,B,radiometric,CCO[C@@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)C(=O)O,95,492.361,530.2780723,1,6,12,3,5.6843,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3508,2507,12672231,4,P37231,PPARG,Homo sapiens,2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O,CHEMBL282686,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 350nM,agonist,no detail about the percentage act,,,,ragaglitazar,,,,,,,,,,,,,=,6.455931956,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,,384.28,408.1242741,1,6,11,2,2.6787,99.13,C1CCC(CCCC2CCCCC2)CC1,,,agonist,agonist,396
3509,2507,15293980,7,P37231,PPARG,Homo sapiens,(S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O,CHEMBL282686,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,250,nM,,,,,=,6.698970004,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,,384.28,408.1242741,1,6,11,2,2.6787,99.13,C1CCC(CCCC2CCCCC2)CC1,agonist,,agonist,agonist,396
3510,2507,18255290,tesagllitazar,P37231,PPARG,Homo sapiens,(S)-3-(4-(4-(methylsulfonyloxy)phenethoxy)phenyl)-2-ethoxypropanoic acid,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O,CHEMBL282686,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,agonist,76.00%,agonist,,,,,,,,EC50,=,37,nM,,,,,=,7.744727495,pKi,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,76,384.28,408.1242741,1,6,11,2,2.6787,99.13,C1CCC(CCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,396
3513,2508,19349176,(S)-2Bf,P37231,PPARG,Homo sapiens,(S)-3-(4-(2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-ethoxypropanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)c5ccsc15)C(=O)O,CHEMBL485187,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,61.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,431,nM,,,,,=,8.522878745,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(-c4ccccc4)cc3)oc2C)c2ccsc12)C(=O)O,61,498.41,527.176644,1,6,11,5,7.18542,81.79,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCC45)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,148
3514,2508,19349176,(S)-2Bf,Q07869,PPARA,Homo sapiens,(S)-3-(4-(2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-ethoxypropanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)c5ccsc15)C(=O)O,CHEMBL485187,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 194nM,agonist,92.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,167,nM,,,,,=,6.71219827,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(-c4ccccc4)cc3)oc2C)c2ccsc12)C(=O)O,92,498.41,527.176644,1,6,11,5,7.18542,81.79,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCC45)C3)CC2)CC1,agonist,agonist,agonist,agonist,148
3515,2509,19349176,(S)-3Bb,P37231,PPARG,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccccc14)C(=O)O,CHEMBL521170,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 27nM,agonist,156.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,21,nM,,,,,=,7.568636236,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccccc12)C(=O)O,156,487.304,513.1763076,1,5,10,4,6.47572,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
3516,2509,19349176,(S)-3Bb,Q07869,PPARA,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccccc14)C(=O)O,CHEMBL521170,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 905nM,agonist,135.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,11,nM,,,,,=,6.043351421,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccccc12)C(=O)O,135,487.304,513.1763076,1,5,10,4,6.47572,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
3519,251,17890084,4,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-3,13-dimethyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@]2(CC1)C=C,CHEMBL398456,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,92.00%,agonist,E2,,E2,,,,,EC50,=,69,nM,,,,,=,8.045757491,pIC50,B,radiometric,C=C[C@]12CCC(C)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,92,268.23,298.2296656,1,1,1,0,5.0324,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
3520,2510,19349176,(S)-2Bb,P37231,PPARG,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccsc14)C(=O)O,CHEMBL484000,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 17nM,agonist,89.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,9,nM,,,,,=,7.769551079,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccsc12)C(=O)O,89,495.349,519.1327285,1,6,10,4,6.53722,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3521,2510,19349176,(S)-2Bb,Q07869,PPARA,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccsc14)C(=O)O,CHEMBL484000,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 63nM,partial agonist,43.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,89,nM,,,,,=,7.200659451,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccsc12)C(=O)O,43,495.349,519.1327285,1,6,10,4,6.53722,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
3522,2511,19349176,(S)-3Ba,P37231,PPARG,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL484725,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 36nM,partial agonist,72.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,37,nM,,,,,=,7.443697499,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,72,418.299,445.188923,1,5,10,4,5.45692,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
3523,2511,19349176,(S)-3Ba,Q07869,PPARA,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL484725,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 198nM,agonist,78.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,11,nM,,,,,=,6.70333481,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,78,418.299,445.188923,1,5,10,4,5.45692,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
3524,2512,19349176,(S)-2Ba,P37231,PPARG,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL484962,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 21nM,partial agonist,63.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,21,nM,,,,,=,7.677780705,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,63,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
3525,2512,19349176,(S)-2Ba,Q07869,PPARA,Homo sapiens,(S)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL484962,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,agonist,109.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,27,nM,,,,,=,7.27572413,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,109,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3526,2513,19349176,(S)-4Ba,P37231,PPARG,Homo sapiens,(S)-2-ethoxy-3-(7-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-4-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4sccc14)C(=O)O,CHEMBL519351,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,partial agonist,40.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,7,nM,,,,,=,7.886056648,pIC50,B,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2sccc12)C(=O)O,40,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
3527,2513,19349176,(S)-4Ba,Q07869,PPARA,Homo sapiens,(S)-2-ethoxy-3-(7-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-4-yl)propanoic acid,CCO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4sccc14)C(=O)O,CHEMBL519351,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 333nM,agonist,89.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,58,nM,,,,,=,6.477555766,pIC50,,radiometric,CCO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2sccc12)C(=O)O,89,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3528,2514,18255290,36,P37231,PPARG,Homo sapiens,"(R)-2-ethoxy-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoic acid",CCO[C@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/OC)\c4ccccc4)cc1)C(=O)O,CHEMBL253417,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 89nM,agonist,107.00%,agonist,,,,,,,,EC50,=,65,nM,,,,,=,7.050609993,pKi,B,radiometric,CCO[C@H](Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\OC)c4ccccc4)ccc32)cc1)C(=O)O,107,492.361,530.2780723,1,6,12,3,5.6843,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
3531,2516,19349176,(R)-2Ba,P37231,PPARG,Homo sapiens,(R)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519153,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2680nM,agonist,81.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,787,nM,,,,,=,5.571865206,pIC50,,radiometric,CCO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,81,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
3532,2516,19349176,(R)-2Ba,Q07869,PPARA,Homo sapiens,(R)-2-ethoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CCO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519153,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2370nM,partial agonist,73.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,1910,nM,,,,,=,5.625251654,pIC50,,radiometric,CCO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,73,426.344,451.1453439,1,6,10,4,5.51842,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
3534,2517,15125928,5,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Ethoxy-3,5-diisopropyl-phenyl)-1H-indazol-5-yl]-but-2-enoic acid",CCOc1c(cc(cc1c2[nH]nc3ccc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL91979,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 69.2nM,partial agonist,43.00%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,235,nM,,,,,=,7.159893906,pKi,B,radiometric,CCOc1c(-c2[nH]nc3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,43,376.286,406.2256428,2,3,7,3,6.3633,75.21,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
3537,2518,15006411,57,P19793,RXRA,Homo sapiens,"(E)-3-[7-(2-Ethoxy-3,5-diisopropyl-phenyl)-benzofuran-2-yl]-but-2-enoic acid",CCOc1c(cc(cc1c2cccc3cc(oc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL289057,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 22nM,partial agonist,31.00%,agonist,,,ATRA,,,,,EC50,=,74,nM,,,,,=,7.657577319,pKi,B,radiometric,CCOc1c(-c2cccc3cc(/C(C)=C/C(=O)O)oc23)cc(C(C)C)cc1C(C)C,31,376.282,406.2144094,1,3,7,3,7.2332,59.67,C1CCC(C2CCCC3CCCC32)CC1,agonist,partial agonist,agonist,partial agonist,138
3541,2519,15006411,63,P19793,RXRA,Homo sapiens,"(E)-3-[7-(2-Ethoxy-3,5-diisopropyl-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid",CCOc1c(cc(cc1c2cccc3cc(sc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL417520,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 271nM,partial agonist,35.00%,agonist,,,ATRA,,,,,EC50,=,390,nM,,,,,=,6.567030709,pKi,,radiometric,CCOc1c(-c2cccc3cc(/C(C)=C/C(=O)O)sc23)cc(C(C)C)cc1C(C)C,35,392.35,422.1915658,1,3,7,3,7.7017,46.53,C1CCC(C2CCCC3CCCC32)CC1,agonist,partial agonist,agonist,partial agonist,138
3544,252,17890084,5,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-3-ethyl-13-methyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CCC1=CC2=CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@]2(CC1)C=C,CHEMBL249903,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 115nM,partial agonist,54.00%,agonist,E2,,E2,,,,,EC50,=,565,nM,,,,,=,6.93930216,pIC50,,radiometric,C=C[C@]12CCC(CC)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,54,280.241,312.2453156,1,1,2,0,5.4225,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3554,2522,15125928,4,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Ethoxy-3,5-diisopropyl-phenyl)-benzo[d]isoxazol-5-yl]-but-2-enoic acid",CCOc1c(cc(cc1c2noc3ccc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL328507,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 648nM,partial agonist,36.00%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,1024,nM,,,,,=,6.188424994,pKi,,radiometric,CCOc1c(-c2noc3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,36,378.278,407.2096584,1,4,7,3,6.6282,72.56,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
3556,2523,12951091,9,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-(3,5-Di-tert-butyl-2-ethoxy-phenyl)-8,8,8-trifluoro-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C(F)(F)F,CHEMBL107555,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 50.3nM,partial antagonist,30.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,38,nM,=,7.298432015,pKi,B,radiometric,CCOc1c(/C(=C\C=C\C(C)=C\C(=O)O)C(F)(F)F)cc(C(C)(C)C)cc1C(C)(C)C,30,405.266,438.2381796,1,2,6,1,7.2131,46.53,C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,205
3559,2524,12801232,12b,P19793,RXRA,Homo sapiens,"7-(3,5-Di-tert-butyl-2-ethoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL92050,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 11nM,partial antagonist,61.00%,antagonist,?,,9-Cis-RA,,,,,EC50,=,18,nM,IC50,=,8,nM,=,7.958607315,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)C)cc1C(C)(C)C,61,348.272,384.266445,1,2,6,1,6.6707,46.53,C1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,205
3560,2524,12951091,8,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(3,5-Di-tert-butyl-2-ethoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL92050,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 11.4nM,partial antagonist,61.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,6.4,nM,=,7.943095149,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)C)cc1C(C)(C)C,61,348.272,384.266445,1,2,6,1,6.6707,46.53,C1CCCCC1,antagonist,partial antagonist,"antagonist,agonist",partial antagonist,205
3562,2525,12801232,13b,P19793,RXRA,Homo sapiens,"7-[3,5-Bis-(1,1-dimethyl-propyl)-2-ethoxy-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1C(C)(C)CC)C(C)(C)CC)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL315986,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 2nM,partial antagonist,72.00%,antagonist,?,,9-Cis-RA,,,,,,,,,IC50,=,17,nM,=,8.698970004,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)CC)cc1C(C)(C)CC,72,372.294,412.2977451,1,2,10,1,7.4509,46.53,C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,205
3565,2526,12801232,11b,P19793,RXRA,Homo sapiens,"7-(2-Ethoxy-3,5-diisopropyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL88740,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 2nM,partial agonist,58.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,2,nM,,,,,=,8.698970004,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,58,324.25,356.2351449,1,2,8,1,6.3225,46.53,C1CCCCC1,agonist,partial agonist,agonist,partial agonist,205
3566,2526,15125928,2,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(2-Ethoxy-3,5-diisopropyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL88740,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,partial agonist,58.00%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,2,nM,,,,,=,8.698970004,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,58,324.25,356.2351449,1,2,8,1,6.3225,46.53,C1CCCCC1,agonist,partial agonist,agonist,partial agonist,205
3570,2527,14592510,42a,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-(2-Ethoxy-3-isopropyl-5-pentafluoroethyl-phenyl)-3-methyl-octa-2,4,6-trienoic acid",CCOc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(F)(F)C(F)(F)F)C(C)C,CHEMBL133896,CV-1 cellscotransfected with the luciferase reporter plasmid ,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 6.3nM,partial agonist,39.00%,agonist,,,9-Cis-RA,,,,,EC50,=,92,nM,IC50,=,5.3,nM,=,8.200659451,pKi,B,radiometric,CCOc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(F)(F)C(F)(F)F)cc1C(C)C,39,407.229,432.1723858,1,2,8,1,6.8532,46.53,C1CCCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,205
3576,253,17890084,7,P03372,ERA,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-3-chloro-13-methyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CC=C4C=C(Cl)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL430395,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 57400nM,partial agonist,38.00%,agonist,E2,,E2,,,,,EC50,=,820,nM,,,,,=,4.241088108,pIC50,NB,radiometric,C=C[C@]12CCC(Cl)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,38,291.672,318.1750432,1,1,1,0,5.2088,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3577,253,17890084,7,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-3-chloro-13-methyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",C[C@]12CC[C@H]3[C@@H](CC=C4C=C(Cl)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL430395,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 64nM,agonist,84.00%,agonist,E2,,E2,,,,,EC50,=,170,nM,,,,,=,7.193820026,pIC50,B,radiometric,C=C[C@]12CCC(Cl)=CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,84,291.672,318.1750432,1,1,1,0,5.2088,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
3605,2545,18442912,5g,P10275,AR,Homo sapiens,"9-ethoxy-10-methoxy-4-methyl-1H-chromeno[3,4-f]quinoline-2,5-dione",CCOc1ccc2OC(=O)c3c(ccc4NC(=O)C=C(C)c34)c2c1OC,CHEMBL256977,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 62nM,partial agonist,33.00%,agonist,DHT,,,,,,,EC50,=,18,nM,IC50,>,10000,nM,=,7.20760831,pKi,B,radiometric,CCOc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1OC,33,334.222,351.1106726,1,5,3,4,3.50342,81.53,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,agonist,partial agonist,agonist,partial agonist,636
3611,2548,16153845,7,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-3-(3-ethoxy-phenoxy)-1H-indole-2-carboxylic acid,CCOc1cccc(Oc2c(C(=O)O)n(c3ccc(cc3)C(C)(C)C)c4ccccc24)c1,CHEMBL372107,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 49nM,partial agonist,30.00%,agonist,maximal activation (no details),,,,,,,EC50,=,233,nM,,,,,=,7.30980392,pIC50,B,radiometric,CCOc1cccc(Oc2c(C(=O)O)n(-c3ccc(C(C)(C)C)cc3)c3ccccc23)c1,30,402.3,429.1940083,1,4,6,4,6.8172,60.69,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
3618,255,17890084,3,P03372,ERA,Homo sapiens,"(3R,8R,9S,10S,13S,14S,17S)-3,13-dimethyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@@]1(O)CC[C@]2(C=C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC=C2C1,CHEMBL251515,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial agonist,27.00%,agonist,E2,,E2,,,,,EC50,>,1000,nM,,,,,>,5,pIC50,NB,radiometric,C=C[C@]12CC[C@@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,27,284.229,316.2402303,2,2,1,0,4.2272,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,partial agonist,,partial agonist,15
3620,255,17890084,3,Q92731,ERB,Homo sapiens,"(3R,8R,9S,10S,13S,14S,17S)-3,13-dimethyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@@]1(O)CC[C@]2(C=C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC=C2C1,CHEMBL251515,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2490nM,partial agonist,31.00%,agonist,E2,,E2,,,,,EC50,>,1000,nM,,,,,=,5.603800653,pIC50,,radiometric,C=C[C@]12CC[C@@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,31,284.229,316.2402303,2,2,1,0,4.2272,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,partial agonist,,partial agonist,15
3626,2553,19926282,9,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-(ethylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CCS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL590863,,,,IC50 = 40nM,partial agonist,26.00%,agonist,,,,,,,,EC50,=,3160,nM,,,,,=,7.397940009,pIC50,B,other,CCS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,26,450.764,471.0995103,0,4,6,2,4.66108,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
3627,2554,20584610,31,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Ethanesulfonyl-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CCS(=O)(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210036,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 16nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,85,nM,=,7.795880017,pKi,B,radiometric,CCS(=O)(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,451.297,471.1075764,0,6,3,1,1.89558,107.78,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
3629,2556,23916594,4h,P04150,GR,Homo sapiens,N-((3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenylpropyl)ethanesulfonamide,CCS(=O)(=O)NCC(C)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426121,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.87nM,agonist,111.00%,agonist,dexamethasone,,,,,,,EC50,=,12.8,nM,,,,,=,9.060480747,pIC50,B,FPA,CCS(=O)(=O)NCC(C)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,111,425.359,451.1729763,1,4,8,4,4.8719,63.99,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
3630,2557,20469868,20a,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]ethanesulfonamide,CCS(=O)(=O)Nc1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1085625,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 8.0,partial antagonist,72.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.7,,=,8,pIC50,B,FPA,CCS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,72,446.32,463.0977607,1,4,5,4,5.612,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,107
3640,2561,25516791,39,P04150,GR,Homo sapiens,"2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide",CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(=O)N)C(F)(F)F)[nH]c2cn1,CHEMBL3358950,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 70nM,agonist,88.00%,agonist,dexamethasone,,,,,,,IC50,=,46,nM,,,,,=,7.15490196,pIC50,B,FPA,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,88,490.329,515.1501902,3,5,8,3,3.7983,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
3641,2562,25516791,38,P04150,GR,Homo sapiens,"2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)benzamide",CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(=O)N)C(F)(F)F)[nH]c2cn1,CHEMBL3358949,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 370nM,agonist,86.00%,agonist,dexamethasone,,,,,,,IC50,=,100,nM,,,,,=,6.431798276,pIC50,,FPA,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1,86,471.331,497.159612,3,5,8,3,3.6592,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
3642,2563,25516791,(R)-39,P04150,GR,Homo sapiens,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide",CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(=O)N)C(F)(F)F)[nH]c2cn1,CHEMBL3358954,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 55nM,agonist,88.00%,agonist,dexamethasone,,,,,,,IC50,=,23,nM,,,,,=,7.259637311,pIC50,B,FPA,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,88,490.329,515.1501902,3,5,8,3,3.7983,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
3643,2564,25516791,(R)-38,P04150,GR,Homo sapiens,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)benzamide",CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(=O)N)C(F)(F)F)[nH]c2cn1,CHEMBL3358953,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 95nM,agonist,87.00%,agonist,dexamethasone,,,,,,,IC50,=,43,nM,,,,,=,7.022276395,pIC50,B,FPA,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1,87,471.331,497.159612,3,5,8,3,3.6592,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
3644,2565,21899328,25,P04150,GR,Homo sapiens,"[(5S)-2-[4-(Ethylsulfonyl))phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CCS(=O)(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911155,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 4.0nM,antagonist,85.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,206,nM,IC50,=,196,nM,=,8.397940009,pKi,B,FPA,CCS(=O)(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,85,496.444,520.1238972,1,8,6,4,5.2962,111.14,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
3666,258,17890084,10,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-13,17-dimethyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C=C)[C@H]3CC[C@]12C,CHEMBL250109,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 25nM,partial agonist,65.00%,agonist,E2,,E2,,,,,EC50,=,190,nM,,,,,=,7.602059991,pIC50,B,radiometric,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,65,284.229,316.2402303,2,2,1,0,4.2272,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3676,2588,20382019,8k,P55055,LXRB,Homo sapiens,4-(3'-(ethylsulfonyl)biphenyl-3-yl)-3-methyl-8-(trifluoromethyl)quinoline,CCS(=O)(=O)c1cccc(c1)c2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F,CHEMBL1098832,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.2nM,partial agonist,67.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,580,nM,,,,,=,8.283996656,pIC50,B,radiometric,CCS(=O)(=O)c1cccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,67,435.341,455.1166845,0,3,4,4,6.68962,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,162
3678,2589,20382019,8j,P55055,LXRB,Homo sapiens,4-(3'-(ethylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CCS(=O)(=O)c1cccc(c1)c2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F,CHEMBL1098831,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 33nM,partial agonist,30.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,1080,nM,,,,,=,7.48148606,pIC50,B,radiometric,CCS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,30,423.33,441.1010345,0,3,4,4,6.3812,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,162
3680,259,17448656,1,P03372,ERA,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246138,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2240nM,partial agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,980,nM,,,,,=,5.649751982,pIC50,,radiometric,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,,272.218,302.2245802,2,2,1,0,3.8371,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,partial agonist,15
3681,259,17890084,1,P03372,ERA,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246138,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2240nM,partial agonist,35.00%,agonist,E2,,E2,,,,,EC50,=,980,nM,,,,,=,5.649751982,pIC50,,radiometric,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,35,272.218,302.2245802,2,2,1,0,3.8371,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3683,259,17448656,1,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246138,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,partial agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,4,nM,,,,,=,7.958607315,pIC50,B,radiometric,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,,272.218,302.2245802,2,2,1,0,3.8371,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
3684,259,17890084,1,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-13-methyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C=C)[C@@H]1CC[C@@H]2O,CHEMBL246138,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,agonist,90.00%,agonist,E2,,E2,,,,,EC50,=,4.1,nM,,,,,=,7.958607315,pIC50,B,radiometric,C=C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,90,272.218,302.2245802,2,2,1,0,3.8371,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
3691,2593,19932617,7i,P55055,LXRB,Homo sapiens,4-(3-(3-(ethylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,CCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL593473,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.6nM,partial agonist,73.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,55,nM,,,,,=,8.795880017,pIC50,B,radiometric,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,73,451.34,471.1115992,0,4,5,4,6.81492,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
3693,2594,20005711,7b,P55055,LXRB,Homo sapiens,"3-(3-(3-(ethylsulfonyl)phenoxy)phenyl)-2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)nc4c(cccn34)C(F)(F)F)c1,CHEMBL595937,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,partial agonist,39.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,680,nM,,,,,=,7.522878745,pIC50,B,radiometric,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,39,441.325,460.1068481,0,5,5,4,5.91442,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
3694,2594,20005711,7b,Q13133,LXRA,Homo sapiens,"3-(3-(3-(ethylsulfonyl)phenoxy)phenyl)-2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)nc4c(cccn34)C(F)(F)F)c1,CHEMBL595937,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 561nM,partial agonist,26.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,2280,nM,,,,,=,6.251037139,pIC50,,radiometric,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,26,441.325,460.1068481,0,5,5,4,5.91442,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
3706,260,17890084,2,P03372,ERA,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-3,13-dimethyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]1(O)CC[C@]2(C=C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC=C2C1,CHEMBL398455,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5300nM,partial agonist,28.00%,agonist,E2,,E2,,,,,EC50,>,1000,nM,,,,,=,5.27572413,pIC50,,radiometric,C=C[C@]12CC[C@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,28,284.229,316.2402303,2,2,1,0,4.2272,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,partial agonist,,partial agonist,15
3708,260,17890084,2,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10S,13S,14S,17S)-3,13-dimethyl-10-vinyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]1(O)CC[C@]2(C=C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC=C2C1,CHEMBL398455,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 255nM,partial agonist,57.00%,agonist,E2,,E2,,,,,EC50,=,240,nM,,,,,=,6.59345982,pIC50,,radiometric,C=C[C@]12CC[C@](C)(O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,57,284.229,316.2402303,2,2,1,0,4.2272,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,partial agonist,agonist,partial agonist,15
3718,2605,24239189,23,P04150,GR,Homo sapiens,"(S)-N-(1-(4-hydroxy-2,3-dimethylphenyl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CC[C@@H](Cc1ccc(O)c(C)c1C)NS(=O)(=O)c2c(C)cc(C)cc2C,CHEMBL3094468,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,agonist,77.00%,agonist,dexamethasone,,,,,,,IC50,=,22,nM,,,,,=,8.698970004,pIC50,B,FPA,CC[C@@H](Cc1ccc(O)c(C)c1C)NS(=O)(=O)c1c(C)cc(C)cc1C,77,346.302,375.1868148,2,3,6,2,4.2339,66.4,CC(C)(CCCC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1256
3729,2609,24215891,27,P04150,GR,Homo sapiens,"(S)-2-amino-4,6-dichloro-N-(1-(3-cyano-1H-indol-1-yl)butan-2-yl)benzenesulfonamide",CC[C@@H](Cn1cc(C#N)c2ccccc12)NS(=O)(=O)c3c(N)cc(Cl)cc3Cl,CHEMBL3093463,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1nM,agonist,87.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,7,nM,,,,,=,9,pIC50,B,FPA,CC[C@@H](Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,87,419.208,436.0527522,2,5,6,3,4.15908,100.91,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1240
3732,261,21316964,(+/-)-17,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-5-vinyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(C=C)c12)c3cccc4cc[nH]c34,CHEMBL1682427,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 19.6nM,agonist,152.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,40,nM,,,,,=,7.707743929,pKi,B,radiometric,C=Cc1c(-c2cccc3cc[nH]c23)cc(C)c2c1[C@H](C)[C@@H](O)C(C)(C)N2,152,320.266,346.2045135,3,2,2,3,5.45482,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
3733,2610,24215891,26,P04150,GR,Homo sapiens,"(S)-2-amino-4,6-dichloro-N-(1-(3-methyl-1H-indol-1-yl)butan-2-yl)benzenesulfonamide",CC[C@@H](Cn1cc(C)c2ccccc12)NS(=O)(=O)c3c(N)cc(Cl)cc3Cl,CHEMBL3093462,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,agonist,87.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,FPA,CC[C@@H](Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,87,405.201,425.0731533,2,4,6,3,4.59582,77.12,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1240
3736,2611,24215891,25,P04150,GR,Homo sapiens,"(S)-N-(1-(1H-indol-1-yl)butan-2-yl)-2-amino-4,6-dichlorobenzenesulfonamide",CC[C@@H](Cn1ccc2ccccc12)NS(=O)(=O)c3c(N)cc(Cl)cc3Cl,CHEMBL3093461,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,partial agonist,46.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,>,2000,nM,,,,,=,8.698970004,pIC50,B,FPA,CC[C@@H](Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,46,393.19,411.0575032,2,4,6,3,4.2874,77.12,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,,partial agonist,,partial agonist,1240
3740,2612,19507861,"6-(R), JNJ-26529152",Q07869,PPARA,Homo sapiens,(R)-2-(3-(3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl)phenoxy)butanoic acid,CC[C@@H](Oc1cccc(c1)n2c(C)c(C(=O)c3ccc(OC)cc3)c4ccc(OC(F)(F)F)cc24)C(=O)O,CHEMBL490029,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 50000nM,partial agonist,33.00%,agonist,rosiglitazone,,TZD4,,,,,,,,,,,,,>,4.301029996,pIC50,NB,radiometric,CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,33,503.303,527.1555721,1,6,9,4,6.31912,86.99,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,,partial agonist,,partial agonist,852
3746,2616,10230629,9,P10275,AR,Homo sapiens,"(R)-8-Ethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL7177,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,partial antagonist,55.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,11,nM,=,8.096910013,pKi,B,radiometric,CC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,55,281.172,296.1136478,2,3,1,2,4.0959,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
3747,2617,17439112,(R)-16f,P10275,AR,Homo sapiens,"(2R)-2-ethyl-1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC[C@@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL226558,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.8nM,agonist,85.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,85,nM,IC50,>,10000,nM,=,8.552841969,pKi,B,radiometric,CC[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,85,366.176,380.095947,1,3,2,2,4.0866,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3748,2618,10230629,15,P10275,AR,Homo sapiens,"(6S,8R)-8-Ethyl-6-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1C[C@H](C)c2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL7373,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 21nM,partial antagonist,40.00%,antagonist,DHT,,DHT,,,,,EC50,=,119,nM,IC50,=,137,nM,=,7.677780705,pKi,B,radiometric,CC[C@@H]1C[C@H](C)c2cc3c(C(F)(F)F)cc(O)nc3cc2N1,40,293.183,310.1292978,2,3,1,2,4.6569,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
3752,262,21316964,(+/-)-25,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-7-vinyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)c(C=C)c(cc12)c3cccc4cc[nH]c34,CHEMBL1682435,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.1nM,agonist,110.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,18,nM,,,,,=,8.508638306,pKi,B,radiometric,C=Cc1c(-c2cccc3cc[nH]c23)cc2c(c1C)NC(C)(C)[C@H](O)[C@H]2C,110,320.266,346.2045135,3,2,2,3,5.45482,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
3753,2620,10230629,23,P10275,AR,Homo sapiens,"(7R,8R)-7-Ethyl-8-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1C)C(F)(F)F,CHEMBL266269,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,partial agonist,39.00%,agonist,DHT,,DHT,,,,,EC50,=,10,nM,,,inactive,,=,7.823908741,pKi,B,radiometric,CC[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,39,293.183,310.1292978,2,3,1,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3754,2621,10230629,25,P10275,AR,Homo sapiens,"(7R,8R)-7,8-Diethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1CC)C(F)(F)F,CHEMBL7421,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 29nM,partial agonist,64.00%,agonist,DHT,,DHT,,,,,EC50,=,20,nM,,,inactive,,=,7.537602002,pKi,B,radiometric,CC[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,64,305.194,324.1449479,2,3,2,2,4.732,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3759,2625,10230628,24,P10275,AR,Homo sapiens,"trans-5-Ethyl-6-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CC[C@H]1[C@H](C)CNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL2112312,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 0.3nM,agonist,113.00%,agonist,DHT,,,,,,,EC50,=,1,nM,,,inactive,,=,9.522878745,pIC50,B,other,CC[C@@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,113,295.175,311.1133134,1,3,1,2,4.367,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3792,2641,16107159,37,P37231,PPARG,Homo sapiens,"(S)-5-{3-[2-Chloro-4-(2,2,2-trifluoro-ethyl)-phenoxy]-propoxy}-2-ethyl-2,3-dihydro-benzofuran-2-carboxylic acid",CC[C@]1(Cc2cc(OCCCOc3ccc(CC(F)(F)F)cc3Cl)ccc2O1)C(=O)O,CHEMBL189110,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 15000nM,partial agonist,28.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,>,4.823908741,pIC50,NB,radiometric,CC[C@@]1(C(=O)O)Cc2cc(OCCCOc3ccc(CC(F)(F)F)cc3Cl)ccc2O1,28,436.684,458.1107861,1,4,9,2,5.461,64.99,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,455
3798,2643,16107159,27,P37231,PPARG,Homo sapiens,"(S)-5-[3-(2-Chloro-4-trifluoromethoxy-phenoxy)-propoxy]-2-ethyl-2,3-dihydro-benzofuran-2-carboxylic acid",CC[C@]1(Cc2cc(OCCCOc3ccc(OC(F)(F)F)cc3Cl)ccc2O1)C(=O)O,CHEMBL190603,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 15000nM,partial agonist,30.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,>,4.823908741,pIC50,NB,radiometric,CC[C@@]1(C(=O)O)Cc2cc(OCCCOc3ccc(OC(F)(F)F)cc3Cl)ccc2O1,30,440.672,460.0900507,1,5,9,2,5.2548,74.22,C1CCC(CCCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,455
3804,2645,16730987,13,P03372,ERA,Homo sapiens,"(S)-6-bromo-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)Br,CHEMBL214034,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 249nM,partial agonist,50.00%,agonist,E2,,E2,,,,,EC50,=,65,nM,,,,,=,6.603800653,pIC50,,radiometric,CC[C@@]12CCC(=O)C(Br)=C1c1ccc3[nH]ncc3c1C2,50,316.093,330.0367752,1,2,1,2,3.9843,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3805,2645,16730987,13,Q92731,ERB,Homo sapiens,"(S)-6-bromo-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)Br,CHEMBL214034,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.2nM,partial agonist,74.00%,agonist,E2,,E2,,,,,EC50,=,0.7,nM,,,,,=,8.657577319,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(Br)=C1c1ccc3[nH]ncc3c1C2,74,316.093,330.0367752,1,2,1,2,3.9843,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3806,2646,16730987,35,P03372,ERA,Homo sapiens,"(S)-9a-ethyl-1-fluoro-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nc(F)c4c3C2)C(F)(F)F,CHEMBL385680,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 50.9nM,agonist,75.00%,agonist,E2,,E2,,,,,EC50,=,8.3,nM,,,,,=,7.293282218,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nc(F)c3c1C2,75,324.192,338.1042259,1,2,1,2,4.3333,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3807,2646,16730987,35,Q92731,ERB,Homo sapiens,"(S)-9a-ethyl-1-fluoro-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nc(F)c4c3C2)C(F)(F)F,CHEMBL385680,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.3nM,partial agonist,67.00%,agonist,E2,,E2,,,,,EC50,=,0.2,nM,,,,,=,9.522878745,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nc(F)c3c1C2,67,324.192,338.1042259,1,2,1,2,4.3333,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3808,2647,16730987,19,P03372,ERA,Homo sapiens,"(S)-9a-ethyl-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C(F)(F)F,CHEMBL208929,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 360nM,partial agonist,66.00%,agonist,E2,,E2,,,,,EC50,=,50,nM,,,,,=,6.443697499,pIC50,,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]ncc3c1C2,66,305.194,320.1136478,1,2,1,2,4.1942,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3809,2647,16730987,19,Q92731,ERB,Homo sapiens,"(S)-9a-ethyl-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C(F)(F)F,CHEMBL208929,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.8nM,agonist,79.00%,agonist,E2,,E2,,,,,EC50,=,0.6,nM,,,,,=,8.552841969,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]ncc3c1C2,79,305.194,320.1136478,1,2,1,2,4.1942,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3810,2648,16730987,29,P03372,ERA,Homo sapiens,"(R)-9a-ethyl-6-(trifluoromethyl)-9,9a-dihydroindeno[2,1-e]indazole-7,10(3H,8H)-dione",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2=O)C(F)(F)F,CHEMBL215409,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 58nM,agonist,90.00%,agonist,E2,,E2,,,,,EC50,=,10.4,nM,,,,,=,7.236572006,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]ncc3c1C2=O,90,321.193,334.0929123,1,3,1,2,3.8344,62.82,CC1CCC2C(C)C3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,600
3811,2648,16730987,29,Q92731,ERB,Homo sapiens,"(R)-9a-ethyl-6-(trifluoromethyl)-9,9a-dihydroindeno[2,1-e]indazole-7,10(3H,8H)-dione",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2=O)C(F)(F)F,CHEMBL215409,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.5nM,agonist,86.00%,agonist,E2,,E2,,,,,EC50,=,0.4,nM,,,,,=,8.823908741,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]ncc3c1C2=O,86,321.193,334.0929123,1,3,1,2,3.8344,62.82,CC1CCC2C(C)C3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,600
3812,2649,16777408,(S)-39,P03372,ERA,Homo sapiens,"(S)(-)-9a-Ethyl-6-trifluoromethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C(F)(F)F,CHEMBL212391,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1678nM,agonist,78.00%,agonist,ref agonist,,E2,,,,,EC50,=,241,nM,,,,,=,5.775208044,pIC50,,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nnc3c1C2,78,307.19,321.1088967,1,3,1,2,3.5892,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3813,2649,16777408,(S)-39,Q92731,ERB,Homo sapiens,"(S)(-)-9a-Ethyl-6-trifluoromethyl-8,9,9a,10-tetrahydro-3H-1,2,3-triaza-cyclopenta[a]fluoren-7-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]nnc4c3C2)C(F)(F)F,CHEMBL212391,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 11nM,agonist,76.00%,agonist,ref agonist,,E2,,,,,EC50,=,4.9,nM,,,,,=,7.958607315,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C(F)(F)F)=C1c1ccc3[nH]nnc3c1C2,76,307.19,321.1088967,1,3,1,2,3.5892,58.64,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3818,2651,16730987,5,P03372,ERA,Homo sapiens,"(S)-9a-ethyl-6-methyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C,CHEMBL210074,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1360nM,agonist,78.00%,agonist,E2,,E2,,,,,EC50,=,104,nM,,,,,=,5.866461092,pIC50,,radiometric,CC[C@@]12CCC(=O)C(C)=C1c1ccc3[nH]ncc3c1C2,78,248.2,266.1419132,1,2,1,2,3.6518,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3819,2651,16730987,5,Q92731,ERB,Homo sapiens,"(S)-9a-ethyl-6-methyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C,CHEMBL210074,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.2nM,agonist,91.00%,agonist,E2,,E2,,,,,EC50,=,2.1,nM,,,,,=,8.142667504,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C)=C1c1ccc3[nH]ncc3c1C2,91,248.2,266.1419132,1,2,1,2,3.6518,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,568
3821,2652,16730987,21,Q92731,ERB,Homo sapiens,"(S)-6-cyclopropyl-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C5CC5,CHEMBL209623,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.7nM,partial agonist,69.00%,agonist,E2,,E2,,,,,EC50,=,5.8,nM,IC50,=,526,nM,=,8.113509275,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(C3CC3)=C1c1ccc3[nH]ncc3c1C2,69,272.222,292.1575633,1,2,2,2,4.0419,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1C1CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,569
3824,2654,16730987,11,P03372,ERA,Homo sapiens,"(S)-6-chloro-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)Cl,CHEMBL425246,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 470nM,partial agonist,42.00%,agonist,E2,,E2,,,,,EC50,=,152,nM,,,,,=,6.327902142,pIC50,,radiometric,CC[C@@]12CCC(=O)C(Cl)=C1c1ccc3[nH]ncc3c1C2,42,271.642,286.0872908,1,2,1,2,3.8282,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3825,2654,16730987,11,Q92731,ERB,Homo sapiens,"(S)-6-chloro-9a-ethyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)Cl,CHEMBL425246,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.7nM,partial agonist,70.00%,agonist,E2,,E2,,,,,EC50,=,1.5,nM,,,,,=,8.113509275,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(Cl)=C1c1ccc3[nH]ncc3c1C2,70,271.642,286.0872908,1,2,1,2,3.8282,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3828,2656,16730987,23,P03372,ERA,Homo sapiens,"(S)-9a-ethyl-6-phenyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)c5ccccc5,CHEMBL211349,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 46nM,partial agonist,37.00%,agonist,E2,,E2,,,,,EC50,=,72,nM,,,,,=,7.337242168,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(c3ccccc3)=C1c1ccc3[nH]ncc3c1C2,37,308.255,328.1575633,1,2,2,3,4.7891,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,571
3829,2656,16730987,23,Q92731,ERB,Homo sapiens,"(S)-9a-ethyl-6-phenyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)c5ccccc5,CHEMBL211349,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.4nM,partial agonist,54.00%,agonist,E2,,E2,,,,,EC50,=,0.8,nM,IC50,=,428,nM,=,8.853871964,pIC50,B,radiometric,CC[C@@]12CCC(=O)C(c3ccccc3)=C1c1ccc3[nH]ncc3c1C2,54,308.255,328.1575633,1,2,2,3,4.7891,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1C1CCCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,571
3885,2685,17439112,(S)-16f,P10275,AR,Homo sapiens,"(2S)-2-ethyl-1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC[C@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL390746,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 19nM,partial agonist,49.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,49,nM,IC50,>,10000,nM,=,7.721246399,pKi,B,radiometric,CC[C@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,49,366.176,380.095947,1,3,2,2,4.0866,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3886,2686,10230629,13,P10275,AR,Homo sapiens,"(6S,8R)-6-Ethyl-8-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1C[C@@H](C)Nc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL427957,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 23nM,partial agonist,30.00%,agonist,DHT,,DHT,,,,,EC50,=,66,nM,,,inactive,,=,7.638272164,pKi,B,radiometric,CC[C@H]1C[C@@H](C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,30,293.183,310.1292978,2,3,1,2,4.6569,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3887,2687,10230628,27,P10275,AR,Homo sapiens,"cis-5-Ethyl-7-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CC[C@H]1C[C@@H](C)Nc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL2112216,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 12nM,partial agonist,36.00%,agonist,DHT,,,,,,,EC50,=,27,nM,IC50,=,16,nM,=,7.920818754,pIC50,B,other,CC[C@H]1C[C@@H](C)Nc2cc3oc(=O)cc(C(F)(F)F)c3cc21,36,295.175,311.1133134,1,3,1,2,4.5095,42.24,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
3888,2688,10230629,14,P10275,AR,Homo sapiens,"(6S,8R)-6,8-Diethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1C[C@H](CC)c2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL7383,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9nM,partial agonist,47.00%,agonist,DHT,,DHT,,,,,EC50,=,32,nM,,,inactive,,=,8.045757491,pKi,B,radiometric,CC[C@H]1C[C@@H](CC)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,47,305.194,324.1449479,2,3,2,2,5.047,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
3892,2690,10230629,22,P10275,AR,Homo sapiens,"(7S,8R)-7-Ethyl-8-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1C)C(F)(F)F,CHEMBL7053,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11nM,agonist,89.00%,agonist,DHT,,DHT,,,,,EC50,=,9,nM,,,inactive,,=,7.958607315,pKi,B,radiometric,CC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,89,293.183,310.1292978,2,3,1,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3893,2691,10230629,24,P10275,AR,Homo sapiens,"(7S,8R)-7,8-Diethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1CC)C(F)(F)F,CHEMBL6959,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16nM,agonist,114.00%,agonist,DHT,,DHT,,,,,EC50,=,3,nM,,,inactive,,=,7.795880017,pKi,B,radiometric,CC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,114,305.194,324.1449479,2,3,2,2,4.732,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3894,2692,10230629,21,P10275,AR,Homo sapiens,"(R)-8-Ethyl-7,7-dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Nc2cc3nc(O)cc(c3cc2CC1(C)C)C(F)(F)F,CHEMBL6689,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 50nM,antagonist,90.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,42,nM,=,7.301029996,pKi,B,radiometric,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,90,305.194,324.1449479,2,3,1,2,4.732,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,586
3895,2693,10230629,26,P10275,AR,Homo sapiens,"(R)-7,7,8-Triethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Nc2cc3nc(O)cc(c3cc2CC1(CC)CC)C(F)(F)F,CHEMBL267471,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 42nM,partial antagonist,69.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,48,nM,=,7.37675071,pKi,B,radiometric,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(CC)CC,69,329.216,352.176248,2,3,3,2,5.5122,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
3896,2694,10230629,19,P10275,AR,Homo sapiens,"(7S,8R)-8-Ethyl-7-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Nc2cc3nc(O)cc(c3cc2C[C@@H]1C)C(F)(F)F,CHEMBL7455,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12nM,partial antagonist,40.00%,antagonist,DHT,,DHT,,,,,EC50,=,1668,nM,IC50,=,11,nM,=,7.920818754,pKi,B,radiometric,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@@H]1C,40,293.183,310.1292978,2,3,1,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
3897,2695,10230629,20,P10275,AR,Homo sapiens,"(7R,8R)-8-Ethyl-7-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@H]1Nc2cc3nc(O)cc(c3cc2C[C@H]1C)C(F)(F)F,CHEMBL7089,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11nM,partial antagonist,66.00%,antagonist,DHT,,DHT,,,,,EC50,=,2468,nM,IC50,=,15,nM,=,7.958607315,pKi,B,radiometric,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@H]1C,66,293.183,310.1292978,2,3,1,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
3898,2696,15911283,27,P04150,GR,Homo sapiens,"4',5'-diethyl-1-(4-fluorophenyl)-4a-methyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",CC[C@H]1OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1CC,CHEMBL370194,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6.6nM,agonist,75.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,24,nM,,,,,=,8.180456064,pIC50,B,radiometric,CC[C@H]1OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1CC,75,355.263,382.2056563,0,4,3,2,5.0513,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,agonist,agonist,agonist,91
3899,2697,15911283,19i,P04150,GR,Homo sapiens,"4',5'-diethyl-1-(4-fluorophenyl)-4a-methyl-(4'R,4aS,5'R)-spiro[4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",CC[C@H]1OC2(CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1CC,CHEMBL197312,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.5nM,partial agonist,32.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,19,nM,,,,,=,8.259637311,pIC50,B,radiometric,CC[C@H]1OC2(CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1CC,32,367.274,396.2213064,0,4,3,2,5.4414,36.28,C1CCC(C2CCC3CC4C(CCCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,95
3909,2700,10230628,23,P10275,AR,Homo sapiens,"cis-5-Ethyl-6-methyl-4-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",CC[C@@H]1[C@H](C)CNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL2112311,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 5nM,agonist,101.00%,agonist,DHT,,,,,,,EC50,=,7,nM,,,inactive,,=,8.301029996,pIC50,B,other,CC[C@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,101,295.175,311.1133134,1,3,1,2,4.367,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3910,2701,10340624,6l,P10275,AR,Homo sapiens,"Cis-6-Ethyl-7-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC[C@@H]1[C@H](C)CNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL2113261,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 27nM,agonist,89.00%,agonist,DHT,,DHT,,,,,EC50,=,7,nM,,,,,=,7.568636236,pKi,B,radiometric,CC[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@H]1C,89,293.183,310.1292978,2,3,1,2,4.5144,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
3964,2719,16730987,6,Q92731,ERB,Homo sapiens,"(R)-9a-ethyl-6-methyl-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one",CC[C@]12CCC(=O)C(=C1c3ccc4[nH]ncc4c3C2)C,CHEMBL379827,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4460nM,partial agonist,49.00%,agonist,E2,,E2,,,,,EC50,=,935,nM,,,,,=,5.350665141,pIC50,,radiometric,CC[C@]12CCC(=O)C(C)=C1c1ccc3[nH]ncc3c1C2,49,248.2,266.1419132,1,2,1,2,3.6518,45.75,CC1CCC2CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,568
3973,2722,21316964,(+/-)-11,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5-ethyl-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",CCc1c(cc(C)c2NC(C)(C)[C@H](O)[C@@H](C)c12)c3cccc4cc[nH]c34,CHEMBL1682421,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.7nM,agonist,169.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,16,nM,,,,,=,7.931814138,pKi,B,radiometric,CCc1c(-c2cccc3cc[nH]c23)cc(C)c2c1[C@H](C)[C@@H](O)C(C)(C)N2,169,320.266,348.2201635,3,2,2,3,5.37422,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
4004,2736,12954061,55a,P19793,RXRA,Homo sapiens,"5-{3-[3-tert-Butyl-2-(2,2-difluoro-ethoxy)-5-ethyl-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",CCc1cc(c(OCC(F)F)c(c1)C(C)(C)C)c2ccsc2\C=C\C(=C\C(=O)O)\C,CHEMBL129887,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,partial antagonist,61.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,15.5,nM,=,8.494850022,pKi,B,radiometric,CCc1cc(-c2ccsc2/C=C/C(C)=C/C(=O)O)c(OCC(F)F)c(C(C)(C)C)c1,61,406.324,434.1727222,1,3,8,2,6.963,46.53,C1CCC(C2CCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,129
4012,2737,12954061,55b,P19793,RXRA,Homo sapiens,"5-{3-[3-tert-Butyl-5-ethyl-2-(3-fluoro-propoxy)-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",CCc1cc(c(OCCCF)c(c1)C(C)(C)C)c2ccsc2\C=C\C(=C\C(=O)O)\C,CHEMBL339298,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9.9nM,antagonist,83.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,10.3,nM,=,8.004364805,pKi,B,radiometric,CCc1cc(-c2ccsc2/C=C/C(C)=C/C(=O)O)c(OCCCF)c(C(C)(C)C)c1,83,399.337,430.1977941,1,3,9,2,7.0575,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
4017,2738,17267219,7c,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-ethylquinolin-2(1H)-one",CCC1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL238123,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5.4nM,agonist,89.00%,agonist,DHT,,,,,,,EC50,=,12,nM,IC50,>,10000,nM,=,8.26760624,pIC50,B,radiometric,CCc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,89,338.166,352.1010324,1,2,4,2,4.0215,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
4049,2751,23276448,16a,P10827,TRA,Homo sapiens,N-[7-(3-Ethyl-4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acid,CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312277,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 710nM,agonist,96.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.148741651,pKi,,radiometric,CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3c2CCC3)ccc1O,96,346.233,369.1576228,3,4,6,2,3.95722,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
4050,2751,23276448,16a,P10828,TRB,Homo sapiens,N-[7-(3-Ethyl-4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acid,CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312277,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 53.6nM,agonist,99.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.27083521,pKi,B,radiometric,CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3c2CCC3)ccc1O,99,346.233,369.1576228,3,4,6,2,3.95722,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
4057,2754,17257838,11b,P10275,AR,Homo sapiens,"7-amino-6-ethyl-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCc1cc2C(=CC(=O)Nc2cc1N)C(F)(F)F,CHEMBL3706897,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,partial agonist,51.00%,agonist,DHT,,,,,,,EC50,=,593,nM,IC50,=,23,nM,=,7.698970004,pIC50,B,radiometric,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,51,245.139,256.0823476,2,2,1,2,2.6915,58.88,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
4058,2755,17257838,11g,P10275,AR,Homo sapiens,"6-ethyl-7-(methylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCc1cc2C(=CC(=O)Nc2cc1NC)C(F)(F)F,CHEMBL3706902,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 869nM,antagonist,98.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,504,nM,=,6.060980224,pIC50,,radiometric,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NC,98,257.15,270.0979977,2,2,2,2,3.151,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
4059,2756,17257838,11h,P10275,AR,Homo sapiens,"6-ethyl-7-(2,2,2-trifluoroethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CCc1cc2C(=CC(=O)Nc2cc1NCC(F)(F)F)C(F)(F)F,CHEMBL3706903,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 157nM,antagonist,91.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,216,nM,=,6.804100348,pIC50,,radiometric,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(F)(F)F,91,326.155,338.0853823,2,2,3,2,4.0835,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
4060,2757,21899328,20,P04150,GR,Homo sapiens,"[(5S)-2-[(4-Ethyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CCc1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911150,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.0nM,partial agonist,56.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,108,nM,IC50,=,27,nM,=,9,pKi,B,FPA,CCc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,56,432.379,456.161997,1,6,5,4,6.065,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
4062,2759,17553679,26,P04150,GR,Homo sapiens,"(Z)-5-(4-ethylbenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",CCc1ccc(\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24)cc1,CHEMBL3706953,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,partial agonist,54.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,207,nM,Efficacy,<,10%,,=,8.721246399,pKi,B,radiometric,CCc1ccc(/C=C2\Oc3ccc(O)c(OC)c3-c3ccc4c(c32)C(C)=CC(C)(C)N4)cc1,54,410.323,439.2147438,2,4,3,3,7.1281,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
4065,2760,11277515,2,P10276,RARA,Homo sapiens,"4-{(E)-4-[2-(4-Ethyl-phenyl)-6,6-dimethyl-cyclohex-1-enyl]-but-3-en-1-ynyl}-benzoic acid",CCc1ccc(cc1)C2=C(\C=C\C#Cc3ccc(cc3)C(=O)O)C(C)(C)CCC2,CHEMBL349935,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 136nM,antagonist,220.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,220,nM,=,6.866461092,pIC50,,radiometric,CCc1ccc(C2=C(/C=C/C#Cc3ccc(C(=O)O)cc3)C(C)(C)CCC2)cc1,220,356.295,384.2089301,1,1,4,2,6.5188,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,440
4066,2760,11277515,2,P10826,RARB,Homo sapiens,"4-{(E)-4-[2-(4-Ethyl-phenyl)-6,6-dimethyl-cyclohex-1-enyl]-but-3-en-1-ynyl}-benzoic acid",CCc1ccc(cc1)C2=C(\C=C\C#Cc3ccc(cc3)C(=O)O)C(C)(C)CCC2,CHEMBL349935,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,partial antagonist,40.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,40,nM,=,8.397940009,pIC50,B,radiometric,CCc1ccc(C2=C(/C=C/C#Cc3ccc(C(=O)O)cc3)C(C)(C)CCC2)cc1,40,356.295,384.2089301,1,1,4,2,6.5188,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,440
4160,2789,21963986,17,P04150,GR,Homo sapiens,"rac-2-((4-ethyl-1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",CCc1cccc2[nH]c(CC(O)(CC(C)(C)c3cc(F)ccc3OC)C(F)(F)F)cc12,CHEMBL1911645,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 28nM,agonist,90.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,88,nM,,,,,=,7.552841969,pIC50,B,FPA,CCc1cccc2[nH]c(CC(O)(CC(C)(C)c3cc(F)ccc3OC)C(F)(F)F)cc12,90,410.261,437.197792,2,2,7,3,6.0818,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
4165,2791,12954062,7c,P04150,GR,Homo sapiens,"5-[1-(2-Ethyl-phenyl)-meth-(Z)-ylidene]-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL415524,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 270nM,antagonist,86.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,77,nM,=,6.568636236,pKi,,radiometric,CCc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,86,385.312,411.1998427,1,2,2,3,7.553,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
4166,2791,12954062,7c,P06401,PR,Homo sapiens,"5-[1-(2-Ethyl-phenyl)-meth-(Z)-ylidene]-9-fluoro-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CCc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL415524,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.3nM,agonist,161.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2,nM,,,,,=,8.638272164,pKi,B,radiometric,CCc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,161,385.312,411.1998427,1,2,2,3,7.553,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
4170,2794,20382019,8g,P55055,LXRB,Homo sapiens,3-ethyl-4-(3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CCc1cnc2c(cccc2c1c3cccc(c3)c4cccc(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1098403,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.4nM,agonist,93.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,76,nM,,,,,=,8.619788758,pIC50,B,radiometric,CCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,93,435.341,455.1166845,0,3,4,4,6.5535,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
4174,2798,20350005,21,P55055,LXRB,Homo sapiens,3-Ethyl-2-[3'-(methylsulfonyl)biphenyl-4-yl]-5-(trifluoromethyl)-quinoxaline,CCc1nc2c(cccc2nc1c3ccc(cc3)c4cccc(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1089232,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 18nM,partial agonist,70.00%,agonist,1a,170nM,,,,,,EC50,=,2020,nM,,,,,=,7.744727495,pIC50,B,radiometric,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,70,437.337,456.1119335,0,4,4,4,5.9485,59.92,C1CCC(C2CCC(C3CCC4CCCCC4C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,137
4188,2800,20005711,7x,P55055,LXRB,Homo sapiens,"2-ethyl-3-(3-(3-(methylsulfonyl)benzyl)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCc1nc2c(cccn2c1c3cccc(Cc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL606756,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 79nM,partial agonist,48.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,1570,nM,,,,,=,7.102372909,pIC50,B,radiometric,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,48,437.337,458.1275836,0,4,5,4,5.5768,51.44,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4189,2800,20005711,7x,Q13133,LXRA,Homo sapiens,"2-ethyl-3-(3-(3-(methylsulfonyl)benzyl)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCc1nc2c(cccn2c1c3cccc(Cc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL606756,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 > 1000nM,partial agonist,30.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,3200,nM,,,,,>,6,pIC50,,radiometric,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,30,437.337,458.1275836,0,4,5,4,5.5768,51.44,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4190,2801,20005711,7e,P55055,LXRB,Homo sapiens,"2-ethyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCc1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611465,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 14nM,partial agonist,62.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,420,nM,,,,,=,7.853871964,pIC50,B,radiometric,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,62,441.325,460.1068481,0,5,5,4,5.7783,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4191,2801,20005711,7e,Q13133,LXRA,Homo sapiens,"2-ethyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CCc1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611465,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 217nM,partial agonist,58.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1220,nM,,,,,=,6.663540266,pIC50,,radiometric,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,58,441.325,460.1068481,0,5,5,4,5.7783,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4214,2813,9871534,19,P10275,AR,Homo sapiens,"(5bR,9aR)-1-Ethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CCN1C(=O)C=C(c2cc3[C@H]4CCCC[C@H]4Nc3cc12)C(F)(F)F,CHEMBL352456,,,,Ki = 194nM,antagonist,94.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,230,nM,=,6.71219827,pKi,,other,CCn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N[C@@H]1CCCC[C@H]31,94,317.205,336.1449479,1,3,1,2,4.4919,34.03,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,573
4216,2815,9873612,12a,P06401,PR,Homo sapiens,"11-Ethyl-1,3,3-trimethyl-4,11-dihydro-3H-pyrido[3,2-a]carbazole",CCn1c2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL91858,,cotransfection,-,Ki = 169nM,antagonist,94.00%,antagonist,,,,,,,,,,,,IC50,=,284,nM,=,6.772113295,pKi,,other,CCn1c2ccccc2c2ccc3c(c21)C(C)=CC(C)(C)N3,94,268.234,290.1782987,1,2,1,3,5.4218,16.96,C1CCC2C(C1)CC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,9
4217,2815,16821785,24,P06401,PR,Homo sapiens,"11-ethyl-1,3,3-trimethyl-4,11-dihydro-3H-pyrido[3,2-a]carbazole",CCn1c2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL91858,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.77,,,,progesterone,,,,,,,,,,,,,,,=,6.77,pKi,,radiometric,CCn1c2ccccc2c2ccc3c(c21)C(C)=CC(C)(C)N3,,268.234,290.1782987,1,2,1,3,5.4218,16.96,C1CCC2C(C1)CC1C3CCCCC3CCC21,,,antagonist,antagonist,9
4224,2819,19376703,16,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(1-(1-ethyl-1H-tetrazol-5-yl)ethyl)amino)-2-chlorobenzonitrile,CCn1nnnc1C(C)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL563716,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 16nM,agonist,122.00%,agonist,progesterone,,,,,,,EC50,=,0.6,nM,,,,,=,7.795880017,pIC50,B,FPA,CCn1nnnc1C(C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,122,383.157,400.0969999,0,6,6,3,4.63928,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
4227,2820,19321341,8,P04150,GR,Homo sapiens,"N,15-dimethyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",CN(C(=O)C1(C)CC2c3ccccc3C1c4ccccc24)c5nccs5,CHEMBL474965,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 82.5nM,partial agonist,67.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,1236,nM,,,,,=,7.083546051,pKi,B,FPA,CN(C(=O)C1(C)CC2c3ccccc3C1c1ccccc12)c1nccs1,67,340.322,360.1296343,0,3,2,3,4.7933,33.2,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
4244,2834,10673099,11,P03372,ERA,Homo sapiens,"(E)-3-[4-((7R,13S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-ylsulfanyl)-phenyl]-N,N-dimethyl-acrylamide",CN(C)C(=O)\C=C\c1ccc(S[C@@H]2Cc3cc(O)ccc3[C@H]4CC[C@]5(C)[C@@H](O)CC[C@H]5[C@H]24)cc1,CHEMBL1627356,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 94nM,agonist,104.00%,agonist,E2,,E2,2nM,,,,EC50,=,173,nM,,,inactive,,=,7.026872146,pIC50,B,radiometric,CN(C)C(=O)/C=C/c1ccc(S[C@@H]2Cc3cc(O)ccc3[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]32)cc1,104,442.39,477.233765,2,4,4,2,5.4814,60.77,C1CCC(CC2CC3CCCCC3C3CCC4CCCC4C23)CC1,agonist,agonist,agonist,agonist,220
4251,2839,24980053,21,P04150,GR,Homo sapiens,"(S)-N-(dimethylcarbamoyl)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CN(C)C(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5,CHEMBL3315056,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 110.5nM,partial agonist,55.00%,agonist,dexamethasone,,,,,,,EC50,=,8912,nM,,,,,=,6.956637722,pKi,,FPA,CN(C)C(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,55,515.351,546.2278483,1,6,4,3,4.4217,101.07,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,863
4254,284,19464171,20,Q03181,PPARB,Homo sapiens,"2-(4-(2-(but-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL501439,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 6nM,agonist,83.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,43,nM,,,,,=,8.22184875,pKi,B,radiometric,CC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,83,529.386,556.1531296,1,5,10,3,7.1799,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
4258,2841,21899328,48,P04150,GR,Homo sapiens,"rac-6-[9-[1,1-Dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-9H-xanthen-3-yl-N,N-dimethyl-3-phenylcarboxamide",CN(C)C(=O)c1ccc(cc1)c2ccc3C(c4ccccc4Oc3c2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911283,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 8.6nM,antagonist,89.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,610,nM,=,8.065501549,pKi,B,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(c2)Oc2ccccc2C3C(C)(C)C(=O)Nc2nncs2)cc1,89,472.4,498.1725617,1,6,5,4,5.8094,84.42,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
4259,2842,21899328,52,P04150,GR,Homo sapiens,"rac-6-[9-[1,1-Dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)-ethyl]-9H-xanthen-3-yl-N,N-dimethyl-3-pyridinecarboxamide",CN(C)C(=O)c1ccc(nc1)c2ccc3C(c4ccccc4Oc3c2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911284,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 4.1nM,antagonist,75.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,382,nM,IC50,=,162,nM,=,8.387216143,pKi,B,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(c2)Oc2ccccc2C3C(C)(C)C(=O)Nc2nncs2)nc1,75,474.396,499.1678107,1,7,5,4,5.2044,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
4260,2843,21899328,33,P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Dimethylamino)carbonyl]phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CN(C)C(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911270,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.74nM,partial agonist,58.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,89,nM,IC50,=,42.7,nM,=,8.759450752,pKi,B,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,58,474.396,499.1678107,1,7,5,4,5.2044,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
4261,2843,24980053,"6, BMS-776532",P04150,GR,Homo sapiens,"(S)-4-(5-(1-(1,3,4-thiadiazol-2-ylamino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-N,N-dimethylbenzamide",CN(C)C(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911270,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.9nM,partial agonist,32.00%,agonist,dexamethasone,,,,,,,EC50,=,242,nM,,,,,=,8.721246399,pKi,B,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,32,474.396,499.1678107,1,7,5,4,5.2044,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,agonist,partial agonist,"antagonist,agonist",partial agonist,956
4263,2844,21899328,34,P04150,GR,Homo sapiens,"[(5R)-2-[4-[(Dimethylamino)carbonyl]phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CN(C)C(=O)c1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911271,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 486nM,antagonist,104.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,1740,nM,=,6.313363731,pKi,,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,104,474.396,499.1678107,1,7,5,4,5.2044,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
4264,2845,21899328,"35, BMS-776532",P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Dimethylamino)carbonyl]-3-fluorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CN(C)C(=O)c1ccc(cc1F)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911272,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.94nM,partial agonist,32.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,242,nM,IC50,=,142.7,nM,=,8.71219827,pKi,B,FPA,CN(C)C(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1F,32,493.394,517.1583888,1,7,5,4,5.3435,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
4269,2849,21899328,53,P04150,GR,Homo sapiens,"rac-6-[9-[1,1-Dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)-ethyl]-9H-xanthen-3-yl-N,N-dimethyl-3-pyrimidinecarboxamide",CN(C)C(=O)c1cnc(nc1)c2ccc3C(c4ccccc4Oc3c2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911285,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 4.2nM,antagonist,76.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,596,nM,IC50,=,592,nM,=,8.37675071,pKi,B,FPA,CN(C)C(=O)c1cnc(-c2ccc3c(c2)Oc2ccccc2C3C(C)(C)C(=O)Nc2nncs2)nc1,76,476.392,500.1630596,1,8,5,4,4.5994,110.2,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
4324,2879,21899328,24,P04150,GR,Homo sapiens,"[(5S)-2-[4-(N,N-Dimethylphenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CN(C)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911154,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 3.8nM,antagonist,87.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,926,nM,IC50,=,242,nM,=,8.420216403,pKi,B,FPA,CN(C)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,87,446.386,471.172896,1,7,5,4,5.5686,80.24,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
4326,2880,15925510,7a,P06401,PR,Homo sapiens,"{4-[1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazol-4-yl]-phenyl}-dimethyl-amine",CN(C)c1ccc(cc1)C2CN(N=C2c3ccc(Cl)c(Cl)c3)S(=O)(=O)c4ccc(Cl)cc4,CHEMBL192314,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 7.4 ,antagonist,95.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,6.1,,=,7.4,pKi,B,FPA,CN(C)c1ccc(C2CN(S(=O)(=O)c3ccc(Cl)cc3)N=C2c2ccc(Cl)c(Cl)c2)cc1,95,488.698,507.0341809,0,4,5,3,5.9052,52.98,CC(C)(C1CCCCC1)C1CC(C2CCCCC2)C(C2CCCCC2)C1,antagonist,antagonist,antagonist,antagonist,1019
4329,2883,15925510,7b,P06401,PR,Homo sapiens,"{4-[(R)-1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazol-4-yl]-phenyl}-dimethyl-amine",CN(C)c1ccc(cc1)[C@@H]2CN(N=C2c3ccc(Cl)c(Cl)c3)S(=O)(=O)c4ccc(Cl)cc4,CHEMBL190264,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 7.0,antagonist,96.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,5.8,,=,7,pKi,,FPA,CN(C)c1ccc([C@@H]2CN(S(=O)(=O)c3ccc(Cl)cc3)N=C2c2ccc(Cl)c(Cl)c2)cc1,96,488.698,507.0341809,0,4,5,3,5.9052,52.98,CC(C)(C1CCCCC1)C1CC(C2CCCCC2)C(C2CCCCC2)C1,antagonist,antagonist,antagonist,antagonist,1019
4332,2885,9719599,2,P06401,PR,Homo sapiens,"(8S,11R,13R,14S,17S)-11-(4-Acetyl-phenyl)-17-hydroxy-17-(3-hydroxy-propyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,CHEMBL1908373,,cotransfection,-,Ki = 18nM,antagonist,95.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,2.2,nM,=,7.744727495,pKi,B,other,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,95,410.323,449.2929941,2,4,5,1,5.1557,60.77,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4333,2885,9873735,ZK-98299,P06401,PR,Homo sapiens,"11-(4-Dimethylamino-phenyl)-17-hydroxy-17-(3-hydroxy-propyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,CHEMBL1908373,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,antagonist,99.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,1.6,nM,=,7.744727495,pKi,B,radiometric,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,99,410.323,449.2929941,2,4,5,1,5.1557,60.77,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4334,2885,10743938,2,P06401,PR,Homo sapiens,"(8S,11R,13R,14S,17S)-11-(4-Acetyl-phenyl)-17-hydroxy-17-(3-hydroxy-propyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,CHEMBL1908373,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 18nM,antagonist,95.00%,antagonist,progesterone,,,,,,,,,inactive,,IC50,=,2.2,nM,=,7.744727495,pIC50,B,other,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,95,410.323,449.2929941,2,4,5,1,5.1557,60.77,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4335,2885,12781198,Onapristone,P06401,PR,Homo sapiens,"(8S,11R,13R,14S,17S)-11-(4-Acetyl-phenyl)-17-hydroxy-17-(3-hydroxy-propyl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,CHEMBL1908373,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,antagonist,95.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,2.2,nM,=,7.744727495,pKi,B,radiometric,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,95,410.323,449.2929941,2,4,5,1,5.1557,60.77,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4336,2886,17257838,10a,P10275,AR,Homo sapiens,"7-(dimethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-onec",CN(C)c1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706892,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 761nM,antagonist,88.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,1160,nM,=,6.118615343,pIC50,,radiometric,CN(C)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,88,245.139,256.0823476,1,2,1,2,2.6129,36.1,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
4337,2887,17034117,4c,P10275,AR,Homo sapiens,"6-N,N-dimethylamino-4-trifluoromethylquinolin-2(1H)-one",CN(C)c1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL217168,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 156nM,partial antagonist,72.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,34,nM,=,6.806875402,pKi,,radiometric,CN(C)c1ccc2nc(O)cc(C(F)(F)F)c2c1,72,245.139,256.0823476,1,3,1,2,3.0252,36.36,CC1CCC2CCCCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,651
4347,2892,18394907,44,P37231,PPARG,Homo sapiens,(S)-3-{4-[(E)-3-(Methyl-phenyl-amino)-propenyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(C\C=C\c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c3ccccc3,CHEMBL513904,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 2000nM,partial agonist,71.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,3700,nM,,,,,=,5.698970004,pIC50,,radiometric,CN(C/C=C/c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c1ccccc1,71,336.265,360.183778,1,3,8,3,4.5061,45.47,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,446
4348,2893,18394907,36,P37231,PPARG,Homo sapiens,(S)-3-{4-[(E)-3-(Methyl-pyridin-2-yl-amino)-propenyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(C\C=C\c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c3ccccn3,CHEMBL479001,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 12000nM,agonist,111.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,492,nM,,,,,=,4.920818754,pIC50,NB,radiometric,CN(C/C=C/c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c1ccccn1,111,338.261,361.179027,1,4,8,3,3.9011,58.36,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,agonist,agonist,agonist,446
4349,2894,18394907,32,P37231,PPARG,Homo sapiens,3-{4-[3-(Methyl-pyridin-2-yl-amino)-prop-1-ynyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(CC#Cc1ccc(CC(C(=O)O)n2cccc2)cc1)c3ccccn3,CHEMBL477940,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 53000nM,agonist,115.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,9000,nM,,,,,=,4.27572413,pIC50,NB,radiometric,CN(CC#Cc1ccc(CC(C(=O)O)n2cccc2)cc1)c1ccccn1,115,338.261,359.1633769,1,4,6,3,3.2394,58.36,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,agonist,agonist,agonist,446
4350,2895,18394907,33,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(Methyl-phenyl-amino)-prop-1-ynyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(CC#Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c3ccccc3,CHEMBL477941,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 12000nM,agonist,88.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,2000,nM,,,,,=,4.920818754,pIC50,NB,radiometric,CN(CC#Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c1ccccc1,88,336.265,358.1681279,1,3,6,3,3.8444,45.47,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,agonist,agonist,agonist,446
4351,2896,17267219,6e,P10275,AR,Homo sapiens,"6-(methyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237259,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.0nM,partial agonist,59.00%,agonist,DHT,,,,,,,EC50,=,9.8,nM,IC50,>,10000,nM,=,8.045757491,pIC50,B,radiometric,CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,59,314.144,324.0697323,1,2,2,2,3.5454,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
4353,2897,19019676,16b,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-methylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3c(F)cccc3F,CHEMBL464907,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.1,agonist,112.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.6,,,,,,=,7.1,pIC50,B,FPA,CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,112,496.262,515.1392088,3,6,7,3,2.6672,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
4363,2901,18394907,60,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(Methyl-phenyl-amino)-propyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c3ccccc3,CHEMBL514696,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 11000nM,partial agonist,57.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,3600,nM,,,,,=,4.958607315,pIC50,NB,radiometric,CN(CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c1ccccc1,57,336.265,362.1994281,1,3,9,3,4.4255,45.47,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,446
4364,2902,18394907,59,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(Methyl-pyridin-2-yl-amino)-propyl]-phenyl}-2-pyrrol-1-yl-propionic acid,CN(CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c3ccccn3,CHEMBL515972,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 28000nM,agonist,79.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,1200,nM,,,,,=,4.552841969,pIC50,NB,radiometric,CN(CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)c1ccccn1,79,338.261,363.194677,1,4,9,3,3.8205,58.36,C1CCC(CCCCC2CCC(CCC3CCCC3)CC2)CC1,agonist,agonist,agonist,agonist,446
4383,2910,12459017,39,P03372,ERA,Homo sapiens,"4-(2-{4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCN(CCO)CC4,CHEMBL347560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 395nM,partial agonist,60.00%,agonist,E2,,E2,1nM,,,,EC50,=,180,nM,IC50,=,30,nM,=,6.403402904,pKi,,radiometric,CN(CCCc1ccc(Cl)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCN(CCO)CC2)n1,60,489.797,525.2619011,3,9,12,3,3.0685,100.88,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,450
4384,2910,12459017,39,Q92731,ERB,Homo sapiens,"4-(2-{4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCN(CCO)CC4,CHEMBL347560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,antagonist,107.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,15,nM,=,7.823908741,pKi,B,radiometric,CN(CCCc1ccc(Cl)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCN(CCO)CC2)n1,107,489.797,525.2619011,3,9,12,3,3.0685,100.88,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,450
4399,2918,12459017,17,P03372,ERA,Homo sapiens,"4-[2-(4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino)-ethyl]-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCNCC4,CHEMBL153405,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 300nM,agonist,79.00%,agonist,E2,,E2,1nM,,,,EC50,=,180,nM,IC50,=,110,nM,=,6.522878745,pKi,,radiometric,CN(CCCc1ccc(Cl)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,79,449.776,481.2356863,3,8,10,3,3.3638,89.44,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,450
4400,2918,12459017,17,Q92731,ERB,Homo sapiens,"4-[2-(4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino)-ethyl]-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCNCC4,CHEMBL153405,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,antagonist,112.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,5,nM,=,7.823908741,pKi,B,radiometric,CN(CCCc1ccc(Cl)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,112,449.776,481.2356863,3,8,10,3,3.3638,89.44,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,450
4411,2922,12459017,21,P03372,ERA,Homo sapiens,"4-[2-(4-{[3-(4-Fluoro-phenyl)-propyl]-methyl-amino}-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino)-ethyl]-phenol",CN(CCCc1ccc(F)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCNCC4,CHEMBL150279,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 380nM,partial agonist,67.00%,agonist,E2,,E2,1nM,,,,EC50,=,200,nM,IC50,=,240,nM,=,6.420216403,pKi,,radiometric,CN(CCCc1ccc(F)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,67,433.321,465.2652369,3,8,10,3,2.8495,89.44,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,450
4412,2922,12459017,21,Q92731,ERB,Homo sapiens,"4-[2-(4-{[3-(4-Fluoro-phenyl)-propyl]-methyl-amino}-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino)-ethyl]-phenol",CN(CCCc1ccc(F)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCNCC4,CHEMBL150279,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,antagonist,98.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,15,nM,=,7.823908741,pKi,B,radiometric,CN(CCCc1ccc(F)cc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,98,433.321,465.2652369,3,8,10,3,2.8495,89.44,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,450
4440,2942,9836620,rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 6.52,agonist,no detail about the percentage act,,,,BRL49653,,,,,PEC50,=,6.27,,,,,,=,6.52,pKi,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4441,2942,10612594,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 7.33,agonist,no detail about the percentage act,,,,,,,,,PEC50,=,7.05,,,,,,=,7.33,pKi,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4442,2942,11405642,1,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 48nM,agonist,100.00%,agonist,reference compound (?),,,,,,,EC50,=,657,nM,,,,,=,7.318758763,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4443,2942,11720854,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 120nM,agonist,no detail about the percentage act,,,,BRL49653,,,,,EC50,=,43,nM,,,,,=,6.920818754,pKi,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4444,2942,12617924,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 131nM,agonist,no detail about the percentage act,,,,L-797773,5nM,,,,EC50,=,21,nM,,,,,=,6.882728704,pKi,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4445,2942,12657263,8,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 210nM,agonist,> 80%,agonist,,,L-797773,5nM,,,,EC50,=,10,nM,,,,,=,6.677780705,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4446,2942,12672231,2,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 440nM,agonist,no detail about the percentage act,,,,ragaglitazar,,,,,,,,,,,,,=,6.356547324,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,,,agonist,agonist,798
4447,2942,12729668,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 250nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,20,nM,,,,,=,6.602059991,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4448,2942,12873517,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 250nM,agonist,no detail about the percentage act,,,,L-797773,5nM,,,,EC50,=,20,nM,,,,,=,6.602059991,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4449,2942,15293980,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,40,nM,,,,,=,7.301029996,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4450,2942,15582409,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 70nM,agonist,100.00%,agonist,standard,,,,,,,EC50,=,268,nM,,,,,=,7.15490196,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4451,2942,15771468,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 250nM,agonist,100.00%,agonist,rosiglitazone,,,,,,,EC50,=,140,nM,,,,,=,6.602059991,pIC50,,FPA,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4452,2942,15863293,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 250nM,agonist,100.00%,agonist,Rosiglitazone,,,,,,,EC50,=,20,nM,,,,,=,6.602059991,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4453,2942,16137885,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,,Ki = 8nM,agonist,100.00%,agonist,Rosiglitazone,,Rosiglitazone,4nM,Kd = 5.58nM,,,EC50,=,5,nM,,,,,=,8.096910013,pKi,B,other,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4454,2942,16366601,1,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled rosiglitazone",IC50 = 92nM,agonist,no detail about the percentage act,,,,Rosiglitazone,10nM,,,,EC50,=,4150,nM,,,,,=,7.036212173,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4455,2942,16451087,1,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 92nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,220,nM,,,,,=,7.036212173,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4456,2942,16919947,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,Fluorescence polarization (FP) competition binding assay,IC50 = 90nM,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,7.045757491,pIC50,B,FPA,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,,,agonist,agonist,798
4457,2942,16970391,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 308nM,agonist,no detail about the percentage act,,,,2-methyl-2-(4- { 3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-propyl } -phenoxy)-propionic acid,,,,,EC50,=,67,nM,,,,,=,6.511449284,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4458,2942,16970391,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,no binding,,,,,,,,,,,,<,20% at 10uM,,,,,,,,NEG,NB,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,,,agonist,agonist,798
4459,2942,16973358,rosiglitazone,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 440nM,agonist,100.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,158,nM,,,,,=,6.356547324,pKi,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4460,2942,16979341,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 440nM,agonist,100.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,158,nM,,,,,=,6.356547324,pKi,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4461,2942,17005393,1,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 48nM,agonist,100.00%,agonist,ref agonist,,,,,,,EC50,=,657,nM,,,,,=,7.318758763,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4462,2942,17005394,"3, Rosigilitazone",P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 67nM,agonist,100.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,308,nM,,,,,=,7.173925197,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4463,2942,17129725,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 67nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,308,nM,,,,,=,7.173925197,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4464,2942,17292606,rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 256nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,35,nM,,,,,=,6.591760035,pIC50,,FPA,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4465,2942,18029178,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 67nM,agonist,no detail about the percentage act,,,,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl-ureido]-ethyl}-phenoxy)-2-methyl-butyric   acid",,,,,EC50,=,308,nM,,,,,=,7.173925197,pIC50,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4466,2942,18255290,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,agonist,100.00%,agonist,,,,,,,,EC50,=,4,nM,,,,,=,8.096910013,pKi,B,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4467,2942,18291645,Rosiglitazone,P37231,PPARG,Homo sapiens,"5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione",CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 > 5000nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,45,nM,,,,,>,5.301029996,pIC50,,FPA,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4468,2942,18394907,Rosiglitazone,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 274nM,agonist,84.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,223,nM,,,,,=,6.562249437,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,84,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4469,2942,19349176,RSG,P37231,PPARG,Homo sapiens,Rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 450nM,agonist,85.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,450,nM,,,,,=,6.346787486,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,85,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4470,2942,19507861,rosiglitazone,P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,agonist,100.00%,agonist,rosiglitazone,200nM,TZD3,,,,,EC50,=,20,nM,,,,,=,6.698970004,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4471,2942,19719236,"rosiglitazone, RSG",P37231,PPARG,Homo sapiens,rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H2]-radiolabeled nTZD11",IC50 = 250nM,,,,,,TZD3,,,,,,,,,,,,,=,6.602059991,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,,,agonist,agonist,798
4472,2942,20219371,rosiglitazone,P37231,PPARG,Homo sapiens,Rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,,,,Ki = 82nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,0.011,nM,,,,,=,7.086186148,pKi,B,other,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4473,2942,23294830,"rosiglitazone, RSG",P37231,PPARG,Homo sapiens,Rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 200nM,agonist,100.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,100,nM,,,,,=,6.698970004,pIC50,,radiometric,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,100,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,agonist,agonist,agonist,798
4474,2942,25978962,Rosiglitazone,P37231,PPARG,Homo sapiens,Rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,CHEMBL121,TR-FRET,,Fluorescence polarization (FP) competition binding assay,Ki = 27.11nM,agonist,no detail about the percentage act,,,,,,,,,IC50,=,75.52,nM,,,,,=,7.566870482,pKi,B,FPA,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,338.283,357.1147125,1,6,7,2,2.4909,71.53,CC1CC(C)C(CC2CCC(CCCCC3CCCCC3)CC2)C1,agonist,,agonist,agonist,798
4525,2952,12459017,31,P03372,ERA,Homo sapiens,"cis-4-(2-{4-[Methyl-(2-phenyl-cyclopropylmethyl)-amino]-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(C[C@@H]1C[C@@H]1c2ccccc2)c3nc(NCCc4ccc(O)cc4)nc(n3)N5CCNCC5,CHEMBL153395,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1240nM,partial agonist,70.00%,agonist,E2,,E2,1nM,,,,EC50,=,500,nM,IC50,=,565,nM,=,5.906578315,pKi,,radiometric,CN(C[C@@H]1C[C@@H]1c1ccccc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,70,426.334,459.2746587,3,8,9,3,2.8813,89.44,C1CCC(CCCC2CC(CCC3CC3C3CCCCC3)CC(C3CCCCC3)C2)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,402
4526,2952,12459017,31,Q92731,ERB,Homo sapiens,"cis-4-(2-{4-[Methyl-(2-phenyl-cyclopropylmethyl)-amino]-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(C[C@@H]1C[C@@H]1c2ccccc2)c3nc(NCCc4ccc(O)cc4)nc(n3)N5CCNCC5,CHEMBL153395,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 40nM,antagonist,93.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,20,nM,=,7.397940009,pKi,B,radiometric,CN(C[C@@H]1C[C@@H]1c1ccccc1)c1nc(NCCc2ccc(O)cc2)nc(N2CCNCC2)n1,93,426.334,459.2746587,3,8,9,3,2.8813,89.44,C1CCC(CCCC2CC(CCC3CC3C3CCCCC3)CC(C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,402
4529,2954,17034119,18,P55055,LXRB,Homo sapiens,(4-{[{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}(methyl)amino]methyl}phenyl)-acetic acid,CN(Cc1ccc(CC(=O)O)cc1)c2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F,CHEMBL214324,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 115nM,partial agonist,60.00%,agonist,T0901317,,,,,,,EC50,=,374,nM,,,,,=,6.93930216,pIC50,,radiometric,CN(Cc1ccc(CC(=O)O)cc1)c1cccc(-c2c(Cc3ccccc3)cnc3c(C(F)(F)F)cccc23)c1,60,513.369,540.2024628,1,3,8,5,7.7749,53.43,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,331
4564,2981,20469868,21a,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-methyl-N-phenyl-3-(trifluoromethyl)benzenesulfonamide,CN(c1ccccc1)S(=O)(=O)c2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1083487,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,partial agonist,29.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.2,,,,,,=,7.9,pIC50,B,FPA,CN(c1ccccc1)S(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,29,506.375,525.1134107,0,4,5,5,6.6755,55.2,CC(C)(CC1CCCCC1)C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,1134
4567,2982,19606870,15,P10275,AR,Homo sapiens,"16-[(3,5-Difluorophenyl)methylidene]-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one",CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cc(F)cc(F)c5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL556431,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 41nM,agonist,98.00%,agonist,R1869,100nM,methyltrienolone,,,,,EC50,=,8,nM,,,,,=,7.387216143,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cc(F)cc(F)c5)[C@@H]4O)[C@@H]3CC[C@@H]12,98,396.287,427.2322857,1,2,1,1,4.9584,40.54,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
4568,2983,19606870,14,P10275,AR,Homo sapiens,16-[(3-Fluorophenyl)methylidene]-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cccc(F)c5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL562471,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 27nM,partial agonist,65.00%,agonist,R1868,100nM,methyltrienolone,,,,,EC50,=,12,nM,,,,,=,7.568636236,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cccc(F)c5)[C@@H]4O)[C@@H]3CC[C@@H]12,65,377.289,409.2417075,1,2,1,1,4.8193,40.54,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,632
4569,2984,19606870,16,P10275,AR,Homo sapiens,16-(Phenylmethylidene)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5ccccc5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL560935,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 116nM,agonist,140.00%,agonist,R1870,100nM,methyltrienolone,,,,,EC50,=,26,nM,,,,,=,6.935542011,pIC50,,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5ccccc5)[C@@H]4O)[C@@H]3CC[C@@H]12,140,358.291,391.2511293,1,2,1,1,4.6802,40.54,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
4571,2986,19606870,20,P10275,AR,Homo sapiens,16-(Pyridin-3-ylmethylidene)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cccnc5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL562780,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 62nM,agonist,93.00%,agonist,R1874,100nM,methyltrienolone,,,,,EC50,=,62,nM,,,,,=,7.20760831,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cccnc5)[C@@H]4O)[C@@H]3CC[C@@H]12,93,360.287,392.2463783,1,3,1,1,4.0752,53.43,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
4572,2987,19606870,19,P10275,AR,Homo sapiens,16-(Pyridin-4-ylmethylidene)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5ccncc5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL556848,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 126nM,partial agonist,69.00%,agonist,R1873,100nM,methyltrienolone,,,,,EC50,=,138,nM,,,,,=,6.899629455,pIC50,,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5ccncc5)[C@@H]4O)[C@@H]3CC[C@@H]12,69,360.287,392.2463783,1,3,1,1,4.0752,53.43,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,632
4574,2989,19606870,22,P10275,AR,Homo sapiens,16-[(2-cyclopropylpyrimidin-5-yl)methylidene]-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cnc(nc5)C6CC6)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL551270,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 51nM,agonist,140.00%,agonist,R1876,100nM,methyltrienolone,,,,,EC50,=,26,nM,,,,,=,7.292429824,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cnc(C6CC6)nc5)[C@@H]4O)[C@@H]3CC[C@@H]12,140,398.316,433.2729274,1,4,2,1,4.3476,66.32,CC1CCC2C(CCC3C4CC(CC5CCC(C6CC6)CC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,630
4576,2990,19606870,21,P10275,AR,Homo sapiens,16-(Pyrimidin-5-ylmethylidene)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cncnc5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL551269,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 59nM,agonist,141.00%,agonist,R1875,100nM,methyltrienolone,,,,,EC50,=,17,nM,,,,,=,7.229147988,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](C/C(=C\c5cncnc5)[C@@H]4O)[C@@H]3CC[C@@H]12,141,362.283,393.2416272,1,4,1,1,3.4702,66.32,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
4577,2991,19606870,2,P10275,AR,Homo sapiens,"(4aR,4bS,6aS,7S,9aS,9bR,11aR)-7-hydroxy-1,4a,6a-trimethyl-4b,5,6,6a,7,8,9,9a,9b,10,11,11a-dodecahydro-1H-indeno[5,4-f]quinolin-2(4aH)-one",CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=CC1=O,CHEMBL559246,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,agonist,105.00%,agonist,R1864,100nM,methyltrienolone,,,,,EC50,=,5,nM,,,,,=,8.15490196,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CC[C@@H]12,105,274.214,303.2198292,1,2,0,0,2.9867,40.54,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
4578,2992,19606870,12,P10275,AR,Homo sapiens,16alpha-(3-Fluorobenzyl)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@]4(C)[C@@H](O)[C@H](Cc5cccc(F)c5)C[C@@H]34)[C@@]2(C)C=CC1=O,CHEMBL556229,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 23nM,partial agonist,40.00%,agonist,R1867,100nM,methyltrienolone,,,,,EC50,=,14,nM,,,,,=,7.638272164,pIC50,B,radiometric,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](O)[C@H](Cc5cccc(F)c5)C[C@H]4[C@@H]3CC[C@@H]12,40,377.289,411.2573575,1,2,2,1,4.5946,40.54,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,632
4589,3,17005393,15,P37231,PPARG,Homo sapiens,"3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((prop-2-ynyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",Cc1oc(nc1CCOc2ccc(CCC(=O)O)c3CN(CCc23)C(=O)OCC#C)c4ccccc4,CHEMBL223434,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,agonist,76.00%,agonist,ref agonist,,,,,,,EC50,=,77,nM,,,,,=,7.619788758,pIC50,B,radiometric,C#CCOC(=O)N1CCc2c(OCCc3nc(-c4ccccc4)oc3C)ccc(CCC(=O)O)c2C1,76,460.316,488.1947366,1,6,9,3,4.41662,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
4590,3,17005393,15,Q07869,PPARA,Homo sapiens,"3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((prop-2-ynyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",Cc1oc(nc1CCOc2ccc(CCC(=O)O)c3CN(CCc23)C(=O)OCC#C)c4ccccc4,CHEMBL223434,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8399nM,partial agonist,38.00%,agonist,ref agonist,,,,,,,EC50,=,2780,nM,,,,,=,5.075772419,pIC50,,radiometric,C#CCOC(=O)N1CCc2c(OCCc3nc(-c4ccccc4)oc3C)ccc(CCC(=O)O)c2C1,38,460.316,488.1947366,1,6,9,3,4.41662,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
4656,3024,17439112,10a,P10275,AR,Homo sapiens,"1,2,3,6-tetrahydro-1-methyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CN1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL227030,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 15nM,partial agonist,56.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,56,nM,IC50,>,10000,nM,=,7.823908741,pKi,B,radiometric,CN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,56,273.149,284.0772623,1,3,0,2,2.3755,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
4661,3029,19595590,20,P06401,PR,Homo sapiens,(S)-4-(benzyl(1-methylpyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CN1CC[C@@H](C1)N(Cc2ccccc2)c3ccc(C#N)c(Cl)c3,CHEMBL550270,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,partial agonist,58.00%,agonist,progesterone,,,,,,,EC50,=,1300,nM,,,,,=,7.397940009,pIC50,B,FPA,CN1CC[C@H](N(Cc2ccccc2)c2ccc(C#N)c(Cl)c2)C1,58,305.683,325.1345753,0,3,4,2,3.92238,30.27,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4662,303,16987661,4c,P04150,GR,Homo sapiens,"(4R)-4-[(1S,2S,5S,7R,9R,10R,11S,14R,15R,16S)-9,16-dihydroxy-5-[2-(4-{4-[(10S,11S,14S,15S,17R)-14-hydroxy-15-methyl-5-oxo-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-17-yl]phenyl}phenoxy)ethoxy]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanoic acid",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)c6ccc(OCCO[C@H]7CC[C@@]8(C)[C@@H](C7)C[C@@H](O)[C@H]9[C@@H]%10CC[C@H]([C@H](C)CCC(=O)O)[C@@]%10(C)[C@@H](O)C[C@H]89)cc6,CHEMBL384444,,GRAF (??GR linked to Alkaline Fosfatase??,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.5nM,partial antagonist,44.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,23.5,nM,=,8.602059991,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(-c4ccc(OCCO[C@H]5CC[C@]6(C)[C@H]7C[C@H](O)[C@@]8(C)[C@@H](CC[C@@H]8[C@H](C)CCC(=O)O)[C@@H]7[C@H](O)C[C@@H]6C5)cc4)cc3)C[C@@]21C,44,836.641,912.5540194,4,7,11,2,10.8729,133.52,CC1CCC2C(CCC3C4CCCC4CC(C4CCC(C5CCC(CCCCC6CCC7C(CCC8C9CCCC9CCC78)C6)CC5)CC4)C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,617
4663,3030,19926282,3,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-methylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CN1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL558664,,,,IC50 = 16nM,partial agonist,65.00%,agonist,,,,,,,,EC50,=,9,nM,,,,,=,7.795880017,pIC50,B,other,CN1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,65,374.688,393.1219599,0,3,4,2,4.94118,30.27,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4664,3031,19595590,12,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-methylpyrrolidin-3-yl)amino)benzonitrile,CN1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL568906,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 20nM,partial agonist,67.00%,agonist,progesterone,,,,,,,EC50,=,1.6,nM,,,,,=,7.698970004,pIC50,B,FPA,CN1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,67,341.136,359.095603,0,3,4,2,4.57578,30.27,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4666,3033,9871534,6,P10275,AR,Homo sapiens,"1,8-Dimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",CN1CCc2cc3C(=CC(=O)N(C)c3cc12)C(F)(F)F,CHEMBL162103,,,,Ki = 167nM,antagonist,94.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,197,nM,=,6.777283529,pKi,,other,CN1CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc21,94,269.161,282.0979977,0,3,0,2,2.5496,25.24,CC1CCC2CC3CCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,578
4667,3034,19616429,13,P06401,PR,Homo sapiens,"(S)-2-chloro-4-((2,4-difluorobenzyl)(1-methyl-5-oxopyrrolidin-3-yl)amino)benzonitrile",CN1C[C@H](CC1=O)N(Cc2ccc(F)cc2F)c3ccc(C#N)c(Cl)c3,CHEMBL564479,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 40nM,partial agonist,46.00%,agonist,progesterone,,,,,,,EC50,=,625,nM,,,,,=,7.397940009,pIC50,B,other,CN1C[C@@H](N(Cc2ccc(F)cc2F)c2ccc(C#N)c(Cl)c2)CC1=O,46,359.678,375.0949963,0,3,4,2,3.72718,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4668,3035,19616429,14,P06401,PR,Homo sapiens,"(S)-2-chloro-4-((2,3-difluorobenzyl)(1-methyl-5-oxopyrrolidin-3-yl)amino)benzonitrile",CN1C[C@H](CC1=O)N(Cc2cccc(F)c2F)c3ccc(C#N)c(Cl)c3,CHEMBL552284,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,53.00%,agonist,progesterone,,,,,,,EC50,=,35,nM,,,,,=,7.602059991,pIC50,B,other,CN1C[C@@H](N(Cc2cccc(F)c2F)c2ccc(C#N)c(Cl)c2)CC1=O,53,359.678,375.0949963,0,3,4,2,3.72718,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4669,3036,19616429,10,P06401,PR,Homo sapiens,2-Chloro-4-[[(3S)-1-methyl-5-oxo-3-pyrrolidinyl](phenylmethyl)amino]benzonitrile,CN1C[C@H](CC1=O)N(Cc2ccccc2)c3ccc(C#N)c(Cl)c3,CHEMBL562345,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 200nM,partial agonist,39.00%,agonist,progesterone,,,,,,,EC50,=,1365,nM,,,,,=,6.698970004,pIC50,,other,CN1C[C@@H](N(Cc2ccccc2)c2ccc(C#N)c(Cl)c2)CC1=O,39,321.682,339.1138399,0,3,4,2,3.44898,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4670,3037,19616429,15,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-methyl-5-oxopyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CN1C[C@H](CC1=O)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL565157,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,65.00%,agonist,progesterone,,,,,,,EC50,=,70,nM,,,,,=,7.602059991,pIC50,B,other,CN1C[C@@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)CC1=O,65,390.687,407.1012245,0,3,4,2,4.46778,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4671,3038,19616429,11,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-methyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,CN1C[C@H](CC1=O)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL551885,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,62.00%,agonist,progesterone,,,,,,,EC50,=,0.3,nM,,,,,=,7.602059991,pIC50,B,other,CN1C[C@@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)CC1=O,62,357.135,373.0748675,0,3,4,2,4.10238,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4672,3039,19616429,12,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-fluorobenzyl)(1-methyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,CN1C[C@H](CC1=O)N(Cc2ccccc2F)c3ccc(C#N)c(Cl)c3,CHEMBL563283,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 20nM,partial agonist,50.00%,agonist,progesterone,,,,,,,EC50,=,135,nM,,,,,=,7.698970004,pIC50,B,other,CN1C[C@@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)CC1=O,50,340.68,357.1044181,0,3,4,2,3.58808,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
4676,304,12036351,RU-486 (Mifepristone),P04150,GR,Homo sapiens,"11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one (RU-486)",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.24nM,antagonist,no detail about the percentage act,,,,dexamethasone,10nM,Kd = 2.5nM,,,,,,,IC50,=,2,nM,=,9.619788758,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4677,304,12824023,1 Mifepristone - RU-486,P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one (Mifepristone)",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,activity  induced  by  a  dose  o  fthe  GR  agonist  pre- dnisolone by a GR antagonist in rat hepatocytes,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.1nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,IC50,=,5,nM,=,8.958607315,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4678,304,15080982,1 RU-486 (Mifepristone),P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,whole cell GRAF functional assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,IC50,=,5,nM,=,9,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4679,304,15261265,1,P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,GRAF (inhibition of dexamethasone-induced ALP expression),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.1nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,IC50,=,4.8,nM,=,8.958607315,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4680,304,15293993,1,P04150,GR,Homo sapiens,"(2R,8S,13S,14S,17R)-2-(4-Dimethylamino-phenyl)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,GRAF (inhibition of dexamethasone-induced ALP expression),"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.1nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,IC50,=,0.44,nM,=,10,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4681,304,15456242,4 (Mifepristone),P04150,GR,Homo sapiens,"11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyloxy-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,luciferase reporter gene assay,Fluorescence polarization (FP) competition binding assay,IC50 = 2.2nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,7.8,nM,=,8.657577319,pIC50,B,FPA,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4682,304,16078847,1,P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,GRAF (inhibition of dexamethasone-induced ALP expression),"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,antagonist,no detail about the percentage act,,,,dexamethasone,10nM,,,,,,,,IC50,=,4.8,nM,=,8.958607315,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4683,304,16821781,RU-486,P04150,GR,Homo sapiens,mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,,PIC50 = 8.24,antagonist,no detail about the percentage act,,,,,,,,,,,,,PIC50,=,8.33,,=,8.24,pIC50,B,other,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4684,304,16987661,"1, RU-486",P04150,GR,Homo sapiens,mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,GRAF (??GR linked to Alkaline Fosfatase??,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.2nM,antagonist,101.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,10,nM,=,8.920818754,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,101,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4685,304,17070047,"1, mifepristone",P04150,GR,Homo sapiens,"(9S,11R,13S,14S,17S)-11-(4-dimethylamino-phenyl)-17-hydroxy-13-methyl-7-prop-1-ynyl-1,2,6,7,8,11,12,13,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,GRAF (??GR linked to Alkaline Fosfatase??,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.1nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,Ki,=,39,nM,=,8.958607315,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4686,304,17616395,5,P04150,GR,Homo sapiens,RU486,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.16,,4.00%,agonist,dexamethasone,,,,,,,PEC50,<,6,,,,,,=,8.16,pIC50,B,FPA,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,4,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4687,304,17822897,mifepristone,P04150,GR,Homo sapiens,mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.4nM,antagonist,no detail about the percentage act,,dexamethasone,,dexamethasone,,,,,,,,,Ki,=,1.2,nM,=,9.397940009,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4688,304,18038970,"4, RU-486",P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-ynyl)-1,2,7,8,11,12,13,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3(14H)-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.24,antagonist,99.70%,antagonist,dexamethasone,,,,,,,PEC50,<,5,,PIC50,=,8.33,,=,8.24,pIC50,B,FPA,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,99.7,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4689,304,18226897,Mifepristone,P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-ynyl)-1,2,7,8,11,12,13,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3(14H)-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.4nM,antagonist,no detail about the percentage act,,,,dexamethasone,,,,,,,,,Ki,=,1.2,nM,=,9.397940009,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4690,304,26218343,MIF,P04150,GR,Homo sapiens,mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,HEK293 cells transiently transfected with GREs controlling a luciferase ( luc ) reporter gene,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 0.299nM,antagonist,no detail about the percentage act,,,,dexamethasone,0.3nM,,,,,,,,IC50,=,0.298,nM,=,9.524328812,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4691,304,9719599,1,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,cotransfection,-,Ki = 1.1nM,antagonist,99.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,0.3,nM,=,8.958607315,pKi,B,other,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,99,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4692,304,9873612,1,P06401,PR,Homo sapiens,"(11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,cotransfection,-,Ki = 1.1nM,antagonist,99.00%,antagonist,,,,,,,,,,,,IC50,=,0.3,nM,=,8.958607315,pKi,B,other,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,99,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4693,304,11591515,mifepristone,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,PRE-luciferase,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.1nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,0.3,nM,=,8.958607315,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4694,304,12036351,RU-486 (Mifepristone),P06401,PR,Homo sapiens,"11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one (RU-486)",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 15nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,11.8,nM,=,7.823908741,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,,antagonist,antagonist,618
4695,304,12781197,Mifepristone,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.1nM,antagonist,99.00%,antagonist,progesterone,,dexamethasone,2.5nM,,,,,,,,IC50,=,0.3,nM,=,8.958607315,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,99,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4696,304,12781198,Mifepristone,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.1nM,antagonist,93.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,0.3,nM,=,8.958607315,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,93,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4697,304,15080982,RU-486,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,,,,,,progesterone,,,,,,,,,,,,,=,8.522878745,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4698,304,15261265,1,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.9nM,,,,,,dexamethasone,,,,,,,,,,,,,=,8.537602002,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4699,304,15293993,1,P06401,PR,Homo sapiens,"(2R,8S,13S,14S,17R)-2-(4-Dimethylamino-phenyl)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.64nM,,,,,,,,,,,,,,,,,,,=,9.193820026,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4700,304,15925510,RU-486 (Mifepristone),P06401,PR,Homo sapiens,"(11R,13S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 8.0,antagonist,100.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,9.6,,=,8,pKi,B,FPA,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,100,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
4701,304,16078847,1,P06401,PR,Homo sapiens,"(8S,11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.9nM,,,,,,,,,,,,,,,,,,,=,8.537602002,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4702,304,26218343,MIF,P06401,PR,Homo sapiens,mifepristone,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,CHEMBL1276308,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 0.998nM,,,,,,methyltrienolone,0.29nM,,,,,,,,,,,,=,9.000869459,pKi,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,,,antagonist,antagonist,618
4732,3043,9871534,26,P10275,AR,Homo sapiens,"(5bR,9aR)-1,5b,10-Trimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CN1[C@@H]2CCCC[C@]2(C)c3cc4C(=CC(=O)N(C)c4cc13)C(F)(F)F,CHEMBL163143,,,,Ki = 97nM,partial antagonist,72.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,53,nM,=,7.013228266,pKi,B,other,CN1c2cc3c(cc2[C@@]2(C)CCCC[C@@H]12)c(C(F)(F)F)cc(=O)n3C,72,329.216,350.160598,0,3,0,2,4.2074,25.24,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,573
4733,3044,9871534,29,P10275,AR,Homo sapiens,"(5bR,9aS)-1,9,9,10-Tetramethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CN1[C@H]2[C@H](CCCC2(C)C)c3cc4C(=CC(=O)N(C)c4cc13)C(F)(F)F,CHEMBL163142,,,,Ki = 59nM,antagonist,90.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,27,nM,=,7.229147988,pKi,B,other,CN1c2cc3c(cc2[C@H]2CCCC(C)(C)[C@H]21)c(C(F)(F)F)cc(=O)n3C,90,341.227,364.176248,0,3,0,2,4.6694,25.24,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,573
4734,3045,9871534,18,P10275,AR,Homo sapiens,"(5bR,9aR)-1,10-Dimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CN1[C@@H]2CCCC[C@@H]2c3cc4C(=CC(=O)N(C)c4cc13)C(F)(F)F,CHEMBL161892,,,,Ki = 10nM,partial antagonist,73.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,36,nM,=,8,pKi,B,other,CN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,73,317.205,336.1449479,0,3,0,2,4.0333,25.24,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,partial antagonist,antagonist,partial antagonist,573
4735,3046,10743937,22d,P10275,AR,Homo sapiens,"8-Bromo-1,2,2-trimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CN1c2cc3nc(Br)cc(c3cc2CCC1(C)C)C(F)(F)F,CHEMBL133167,,cotransfection,hAR transfected into COS-1 cells,Ki = 426nM,antagonist,93.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,72,nM,=,6.370590401,pKi,,other,CN1c2cc3nc(Br)cc(C(F)(F)F)c3cc2CCC1(C)C,93,357.088,372.0448953,0,2,0,2,5.1771,16.13,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
4736,3047,10743937,22f,P10275,AR,Homo sapiens,"8,8,9-Trimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-pyrido[3,2-g]quinoline-2-carbonitrile",CN1c2cc3nc(cc(c3cc2CCC1(C)C)C(F)(F)F)C#N,CHEMBL132427,,cotransfection,hAR transfected into COS-1 cells,Ki = 86nM,antagonist,94.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,45,nM,=,7.065501549,pKi,B,other,CN1c2cc3nc(C#N)cc(C(F)(F)F)c3cc2CCC1(C)C,94,303.202,319.1296322,0,3,0,2,4.28628,39.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
4737,3048,10743937,22b,P10275,AR,Homo sapiens,"8-Chloro-1,2,2-trimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CN1c2cc3nc(Cl)cc(c3cc2CCC1(C)C)C(F)(F)F,CHEMBL133289,,cotransfection,hAR transfected into COS-1 cells,Ki = 294nM,antagonist,87.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,251,nM,=,6.53165267,pKi,,other,CN1c2cc3nc(Cl)cc(C(F)(F)F)c3cc2CCC1(C)C,87,312.637,328.0954109,0,2,0,2,5.068,16.13,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
4738,3049,10743937,22c,P10275,AR,Homo sapiens,"8-Fluoro-1,2,2-trimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CN1c2cc3nc(F)cc(c3cc2CCC1(C)C)C(F)(F)F,CHEMBL133465,,cotransfection,hAR transfected into COS-1 cells,Ki = 96nM,antagonist,86.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,172,nM,=,7.017728767,pKi,B,other,CN1c2cc3nc(F)cc(C(F)(F)F)c3cc2CCC1(C)C,86,296.182,312.1249614,0,2,0,2,4.5537,16.13,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
4740,3050,10743937,22e,P10275,AR,Homo sapiens,"1,2,2-Trimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CN1c2cc3nccc(c3cc2CCC1(C)C)C(F)(F)F,CHEMBL132609,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,83.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,725,nM,>,6,pKi,,other,CN1c2cc3nccc(C(F)(F)F)c3cc2CCC1(C)C,83,277.184,294.1343832,0,2,0,2,4.4146,16.13,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
4752,3055,24980053,22,P04150,GR,Homo sapiens,"(S)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methyl-N-(methylcarbamoyl)propanamide",CNC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5,CHEMBL3315057,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 6.9nM,partial agonist,67.00%,agonist,dexamethasone,,,,,,,EC50,=,302,nM,,,,,=,8.161150909,pKi,B,FPA,CNC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,67,503.34,532.2121982,2,6,4,3,4.0795,109.86,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,863
4754,3056,21349714,(+/-)-8,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl methylcarbamate",CNC(=O)O[C@@H]1[C@@H](C)c2c(F)c(c(F)cc2NC1(C)C)c3cccc4c(Cl)c[nH]c34,CHEMBL1684341,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 157nM,agonist,157.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,21,nM,,,,,=,6.804100348,pKi,,radiometric,CNC(=O)O[C@@H]1[C@@H](C)c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC1(C)C,157,411.71,433.1368611,3,3,2,3,5.7987,66.15,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
4755,3057,21349714,(+/-)-7,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl methylcarbamate",CNC(=O)O[C@@H]1[C@@H](C)c2c(F)c(c(F)cc2NC1(C)C)c3cccc4cc[nH]c34,CHEMBL1684230,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 185nM,agonist,185.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,39,nM,,,,,=,6.732828272,pKi,,radiometric,CNC(=O)O[C@@H]1[C@@H](C)c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC1(C)C,185,376.257,399.1758334,3,3,2,3,5.1453,66.15,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
4760,3060,21899328,31,P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Methylamino)carbonyl)]phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CNC(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911268,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 9.17nM,antagonist,100.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,806,nM,=,8.037630664,pKi,B,FPA,CNC(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,100,462.385,485.1521606,2,7,5,4,4.8622,106.1,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
4761,3061,21899328,32,P04150,GR,Homo sapiens,"[(5S)-2-[4-[(Methylamino)carbonyl)]-3-fluorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CNC(=O)c1ccc(cc1F)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911269,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 5.48nM,antagonist,102.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,408,nM,=,8.261219442,pKi,B,FPA,CNC(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1F,102,481.383,503.1427388,2,7,5,4,5.0013,106.1,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
4796,3092,19162487,4i,P55055,LXRB,Homo sapiens,3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]-N-methylbenzamide,CNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461890,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,partial agonist,66.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,800,nM,,,,,=,8.045757491,pIC50,B,radiometric,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,66,383.729,402.1135055,1,3,4,4,6.01552,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
4797,3092,19932617,5a,P55055,LXRB,Homo sapiens,3-(3-(8-chloro-3-methylquinolin-4-yl)phenoxy)-N-methylbenzamide,CNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461890,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,partial agonist,66.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,800,nM,,,,,=,8.045757491,pIC50,B,radiometric,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,66,383.729,402.1135055,1,3,4,4,6.01552,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
4798,3092,19162487,4i,Q13133,LXRA,Homo sapiens,3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]-N-methylbenzamide,CNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461890,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 125nM,partial agonist,37.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,1306,nM,,,,,=,6.903089987,pIC50,,radiometric,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,37,383.729,402.1135055,1,3,4,4,6.01552,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
4799,3092,19932617,5a,Q13133,LXRA,Homo sapiens,3-(3-(8-chloro-3-methylquinolin-4-yl)phenoxy)-N-methylbenzamide,CNC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL461890,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 125nM,,,,,,,,,,,,,,,,,,,=,6.903089987,pIC50,,radiometric,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,,383.729,402.1135055,1,3,4,4,6.01552,51.22,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,partial agonist,280
4815,3100,20005711,7v,P55055,LXRB,Homo sapiens,"3-(3-(8-chloro-2-isopropylimidazo[1,2-a]pyridin-3-yl)phenoxy)-N-methylbenzenesulfonamide",CNS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(Cl)cccn34)C(C)C)c1,CHEMBL595917,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.5nM,partial agonist,61.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,530,nM,,,,,=,8.124938737,pIC50,B,radiometric,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,61,433.791,455.1070402,1,5,6,4,5.4785,72.7,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4816,3100,20005711,7v,Q13133,LXRA,Homo sapiens,"3-(3-(8-chloro-2-isopropylimidazo[1,2-a]pyridin-3-yl)phenoxy)-N-methylbenzenesulfonamide",CNS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(Cl)cccn34)C(C)C)c1,CHEMBL595917,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 239nM,partial agonist,46.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1610,nM,,,,,=,6.621602099,pIC50,,radiometric,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,46,433.791,455.1070402,1,5,6,4,5.4785,72.7,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
4821,3103,21257309,14a,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(6-methyl-1-(4-(methylamino)phenyl)-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",CNc1ccc(cc1)n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc23,CHEMBL1668071,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.7,agonist,119.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.6,,,,,,=,7.7,pIC50,B,FPA,CNc1ccc(-n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc32)cc1,119,458.397,491.2354963,3,6,8,4,5.07978,88.05,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
4822,3104,17257838,9a,P10275,AR,Homo sapiens,"7-(methylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706877,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 83nM,antagonist,79.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,30,nM,=,7.080921908,pIC50,B,radiometric,CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,79,233.128,242.0666976,2,2,1,2,2.5886,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
4824,3106,19606870,25,P10275,AR,Homo sapiens,16-{[(2-Methylamino)pyrimidin-5-yl]methylidene}-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CNc1ncc(\C=C\2/C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,CHEMBL563597,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 31nM,agonist,148.00%,agonist,R1879,100nM,methyltrienolone,,,,,EC50,=,5,nM,,,,,=,7.508638306,pIC50,B,radiometric,CNc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,148,388.301,422.2681763,2,5,2,1,3.5119,78.35,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
4838,3111,17705362,23,P04150,GR,Homo sapiens,"(Z)-5-(2'-(3'-((E)-1''-methoxyiminoethyl)thienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno-[3,4-f]quinoline",CO\N=C(/C)\c1ccsc1\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL397920,GRE activation agonist mode,,-,Ki = 1.1nM,partial agonist,40.00%,agonist,dexamethasone,,,,,,,EC50,=,0.1,nM,,,,,=,8.958607315,pKi,B,other,CO/N=C(\C)c1ccsc1/C=C1\Oc2ccc(O)c(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,40,460.385,488.1769784,2,7,4,3,6.9976,72.31,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,partial agonist,agonist,partial agonist,221
4845,3112,10052980,4,P19793,RXRA,Homo sapiens,"4-[[(E)-Methoxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",CO\N=C(/c1ccc(cc1)C(=O)O)\c2cc3c(cc2C)C(C)(C)CCC3(C)C,CHEMBL423465,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9nM,partial agonist,71.00%,agonist,ATRA,,,,,,,EC50,=,5,nM,,,,,=,8.045757491,pKi,B,radiometric,CO/N=C(\c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,71,350.268,379.2147438,1,3,4,2,5.44102,58.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,847
4846,3112,10052980,4,P28702,RXRB,Homo sapiens,"4-[[(E)-Methoxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",CO\N=C(/c1ccc(cc1)C(=O)O)\c2cc3c(cc2C)C(C)(C)CCC3(C)C,CHEMBL423465,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,agonist,90.00%,agonist,ATRA,,,,,,,EC50,=,10,nM,,,,,=,8.096910013,pKi,B,radiometric,CO/N=C(\c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,90,350.268,379.2147438,1,3,4,2,5.44102,58.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,847
4847,3112,10052980,4,P48443,RXRG,Homo sapiens,"4-[[(E)-Methoxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",CO\N=C(/c1ccc(cc1)C(=O)O)\c2cc3c(cc2C)C(C)(C)CCC3(C)C,CHEMBL423465,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,agonist,93.00%,agonist,ATRA,,,,,,,EC50,=,4,nM,,,,,=,8.096910013,pKi,B,radiometric,CO/N=C(\c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,93,350.268,379.2147438,1,3,4,2,5.44102,58.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,847
4848,3113,19376700,8c,P37231,PPARG,Homo sapiens,"(S)-2-(2-benzoylphenylamino)-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)propanoic acid",CO\N=C(/c1ccccc1)\c2ccc3N(CCOc4ccc(C[C@H](Nc5ccccc5C(=O)c6ccccc6)C(=O)O)cc4)CCC(C)(C)c3c2,CHEMBL555484,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 54nM,partial agonist,72.00%,agonist,Rosiglitazone,1000nM,rosiglitazone,,,,,EC50,=,14,nM,,,,,=,7.26760624,pIC50,B,radiometric,CO/N=C(\c1ccccc1)c1ccc2c(c1)C(C)(C)CCN2CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,72,638.489,681.3202715,2,7,14,5,7.9909,100.46,CC(C1CCCCC1)C1CCC2C(CCCC3CCC(CCCC4CCCCC4C(C)C4CCCCC4)CC3)CCCC2C1,agonist,partial agonist,agonist,partial agonist,856
4850,3115,19376700,8b,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(6-((methoxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)phenyl)-2-(2,2,2-trifluoroethoxy)propanoic acid",CO\N=C(/c1ccccc1)\c2ccc3N(CCOc4ccc(C[C@H](OCC(F)(F)F)C(=O)O)cc4)CCC(C)(C)c3c2,CHEMBL554562,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 33nM,agonist,100.00%,agonist,Rosiglitazone,1000nM,rosiglitazone,,,,,EC50,=,125,nM,,,,,=,7.48148606,pIC50,B,radiometric,CO/N=C(\c1ccccc1)c1ccc2c(c1)C(C)(C)CCN2CCOc1ccc(C[C@H](OCC(F)(F)F)C(=O)O)cc1,100,549.355,584.2498069,1,6,12,3,6.2267,80.59,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
4851,3116,21316964,(+/-)-13,P04150,GR,Homo sapiens,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-methyl oxime",CO\N=C\c1c(cc(C)c2NC(C)(C)[C@H](O)[C@@H](C)c12)c3cccc4cc[nH]c34,CHEMBL1682423,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.9nM,agonist,120.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.4,nM,,,,,=,8.161150909,pKi,B,radiometric,CO/N=C/c1c(-c2cccc3cc[nH]c23)cc(C)c2c1[C@H](C)[C@@H](O)C(C)(C)N2,120,350.272,377.2103271,3,4,3,3,4.79212,69.64,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
4852,3117,21324689,26,P04150,GR,Homo sapiens,"rac-5,7-difluoro-3-hydroxy-2,2-dimethyl-6-(3-methyl-1H-indol-7-yl)-2,3-dihydroquinolin-4(1H)-one O-methyl oxime",CO\N=C\1/C(O)C(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4c(C)c[nH]c34,CHEMBL1760023,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.8nM,agonist,83.00%,agonist,dexamethasone,,,,,,,EC50,=,3.9,nM,,,,,=,8.420216403,pKi,B,radiometric,CO/N=C1/c2c(cc(F)c(-c3cccc4c(C)c[nH]c34)c2F)NC(C)(C)C1O,83,364.246,385.1601834,3,4,2,3,4.33702,69.64,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,agonist,agonist,agonist,700
4856,3118,21324689,28,P04150,GR,Homo sapiens,"6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-3-hydroxy-2,2-dimethyl-2,3-dihydroquinolin-4(1H)-one O-methyl oxime",CO\N=C\1/C(O)C(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4c(Cl)c[nH]c34,CHEMBL1762211,IL-6 repression,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.7nM,partial agonist,57.00%,agonist,dexamethasone,,,,,,,IC50,=,22,nM,,,,,=,9.15490196,pKi,B,radiometric,CO/N=C1/c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC(C)(C)C1O,57,387.688,405.1055609,3,4,2,3,4.682,69.64,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,partial agonist,agonist,partial agonist,700
4859,3120,15026058,11,P04150,GR,Homo sapiens,"(E)-4-(10-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysen-5-yl)-but-2-enoic acid methyl ester",COC(=O)\C=C\CC1Oc2cccc(OC)c2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL46329,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.8nM,partial agonist,46.00%,agonist,dexamethasone,,,,,,,IC50,=,220,nM,,,,,=,8.107905397,pIC50,B,radiometric,COC(=O)/C=C/CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,46,378.278,405.1940083,1,5,4,2,5.5224,56.79,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
4862,3122,18255290,9,P37231,PPARG,Homo sapiens,"dimethyl 2-(4-(2-(6-((hydroxyimino)(phenyl)methyl)-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)benzyl)malonate",COC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)\C(=N/O)\c4ccccc4)cc1)C(=O)OC,CHEMBL252996,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10000nM,agonist,74.00%,agonist,,,,,,,,EC50,=,195,nM,,,,,=,5,pKi,NB,radiometric,COC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(/C(=N\O)c4ccccc4)ccc32)cc1)C(=O)OC,74,508.36,544.2573369,1,8,10,3,4.9846,97.66,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,partial agonist,agonist,partial agonist,854
4863,3123,18255290,8,P37231,PPARG,Homo sapiens,"dimethyl 2-(4-(2-(6-benzoyl-4,4-dimethyl-3,4-dihydroquinolin-1(2H)-yl)ethoxy)benzyl)malonate",COC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(ccc23)C(=O)c4ccccc4)cc1)C(=O)OC,CHEMBL252995,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10000nM,agonist,140.00%,agonist,,,,,,,,EC50,=,152,nM,,,,,=,5,pKi,NB,radiometric,COC(=O)C(Cc1ccc(OCCN2CCC(C)(C)c3cc(C(=O)c4ccccc4)ccc32)cc1)C(=O)OC,140,494.353,529.2464378,0,7,10,3,4.989,82.14,CC(C1CCCCC1)C1CCC2C(CCCC3CCCCC3)CCCC2C1,agonist,agonist,agonist,agonist,854
4864,3124,16876993,rac-38,P55055,LXRB,Homo sapiens,"methyl 1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-phenylpiperidine-2-carboxylate",COC(=O)C1(CCCCN1c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3ccccc3,CHEMBL383945,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,75.00%,agonist,T0901317,,,,,,,EC50,=,40,nM,,,,,=,7.522878745,pIC50,B,radiometric,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,75,440.234,461.1425629,1,4,4,2,5.0576,49.77,C1CCC(C2CCCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,151
4865,3124,16876993,rac-38,Q13133,LXRA,Homo sapiens,"methyl 1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-phenylpiperidine-2-carboxylate",COC(=O)C1(CCCCN1c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3ccccc3,CHEMBL383945,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,116.00%,agonist,T0901317,,,,,,,EC50,=,90,nM,,,,,=,7.22184875,pIC50,B,radiometric,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,116,440.234,461.1425629,1,4,4,2,5.0576,49.77,C1CCC(C2CCCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,151
4866,3125,16876993,rac-37,P55055,LXRB,Homo sapiens,"methyl 1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-phenylpyrrolidine-2-carboxylate",COC(=O)C1(CCCN1c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3ccccc3,CHEMBL384298,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,partial agonist,58.00%,agonist,T0901317,,,,,,,EC50,=,40,nM,,,,,=,7.522878745,pIC50,B,radiometric,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,58,428.223,447.1269128,1,4,4,2,4.6675,49.77,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
4867,3125,16876993,rac-37,Q13133,LXRA,Homo sapiens,"methyl 1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-phenylpyrrolidine-2-carboxylate",COC(=O)C1(CCCN1c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3ccccc3,CHEMBL384298,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,92.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,7.301029996,pIC50,B,radiometric,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,92,428.223,447.1269128,1,4,4,2,4.6675,49.77,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
4868,3126,25993269,20a,P03372,ERA,Homo sapiens,"Methyl 8-(4-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-yl-sulfonyloxy)phenylamino)-8-oxooctanoate",COC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)cc1,CHEMBL3589347,,,,Ki = 56.86nM,inverse agonist,-35.00%,agonist,E2,,,,,,,,,,,IC50,=,10800,nM,=,7.245193145,pKi,B,other,COC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)cc1,-35,586.428,621.2032527,3,9,13,3,5.4092,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,inverse agonist,antagonist,inverse agonist,1126
4869,3126,25993269,20a,Q92731,ERB,Homo sapiens,"Methyl 8-(4-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-yl-sulfonyloxy)phenylamino)-8-oxooctanoate",COC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)cc1,CHEMBL3589347,,,,Ki = 755.56nM,antagonist,76.00%,antagonist,E2,,,,,,,,,,,IC50,=,330,nM,=,6.121731042,pKi,,other,COC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)cc1,76,586.428,621.2032527,3,9,13,3,5.4092,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1126
4870,3127,25993269,20b,P03372,ERA,Homo sapiens,"Methyl8-(3-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-yl-sulfonyloxy)phenylamino)-8-oxooctanoate",COC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)c1,CHEMBL3589348,,,,Ki = 71.1nM,agonist,111.00%,agonist,E2,,,,,,,EC50,=,1,nM,,,,,=,7.148130399,pKi,B,other,COC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)c1,111,586.428,621.2032527,3,9,13,3,5.4092,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,agonist,agonist,agonist,1126
4871,3127,25993269,20b,Q92731,ERB,Homo sapiens,"Methyl8-(3-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-yl-sulfonyloxy)phenylamino)-8-oxooctanoate",COC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)c1,CHEMBL3589348,,,,Ki = 1416.67nM,antagonist,91.00%,antagonist,E2,,,,,,,,,,,,,,,=,5.848731303,pKi,,other,COC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)c1,91,586.428,621.2032527,3,9,13,3,5.4092,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
4875,313,16987661,2,P04150,GR,Homo sapiens,A-348441,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)CCO[C@H]6CC[C@@]7(C)[C@H](C[C@@H](O)[C@H]8[C@@H]9CC[C@H]([C@H](C)CCC(=O)O)[C@@]9(C)[C@@H](O)C[C@H]78)C6,CHEMBL219684,,GRAF (??GR linked to Alkaline Fosfatase??,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.1nM,antagonist,72.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,5,nM,=,8.958607315,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)CCO[C@H]4CC[C@]5(C)[C@H]6C[C@H](O)[C@@]7(C)[C@@H](CC[C@@H]7[C@H](C)CCC(=O)O)[C@@H]6[C@H](O)C[C@@H]5C4)cc3)C[C@@]21C,72,774.594,849.5543537,4,7,10,1,9.2633,127.53,CC1CCC2C(CCC3C4CCCC4CC(C4CCC(CCCCC5CCC6C(CCC7C8CCCC8CCC67)C5)CC4)C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,621
4883,3134,19926282,27,P06401,PR,Homo sapiens,(S)-methyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,COC(=O)N1CC[C@@H](C1)N(Cc2cc(F)ccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL591327,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 20nM,partial agonist,62.00%,agonist,progesterone,,,,,,,EC50,=,41,nM,,,,,=,7.698970004,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2cc(F)ccc2C)c2ccc(C#N)c(Cl)c2)C1,62,380.701,401.1306328,0,4,4,2,4.5065,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4884,3135,19926282,26,P06401,PR,Homo sapiens,"(S)-methyl 3-((3-chloro-4-cyanophenyl)(2,3-difluorobenzyl)amino)pyrrolidine-1-carboxylate",COC(=O)N1CC[C@@H](C1)N(Cc2cccc(F)c2F)c3ccc(C#N)c(Cl)c3,CHEMBL592745,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 20nM,partial agonist,51.00%,agonist,progesterone,,,,,,,EC50,=,137,nM,,,,,=,7.698970004,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2cccc(F)c2F)c2ccc(C#N)c(Cl)c2)C1,51,387.688,405.1055609,0,4,4,2,4.33718,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4886,3137,19926282,22,P06401,PR,Homo sapiens,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-(trifluoromethyl)benzyl)amino)pyrrolidine-1-carboxylate,COC(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL590853,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 12nM,partial agonist,66.00%,agonist,progesterone,,,,,,,EC50,=,8,nM,,,,,=,7.920818754,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,66,418.697,437.1117892,0,4,4,2,5.07778,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4887,3138,19926282,24,P06401,PR,Homo sapiens,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-methylbenzyl)amino)pyrrolidine-1-carboxylate,COC(=O)N1CC[C@@H](C1)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL592016,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 12nM,partial agonist,64.00%,agonist,progesterone,,,,,,,EC50,=,4,nM,,,,,=,7.920818754,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2ccccc2C)c2ccc(C#N)c(Cl)c2)C1,64,361.703,383.1400546,0,4,4,2,4.3674,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4888,3139,19926282,25,P06401,PR,Homo sapiens,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-chlorobenzyl)amino)pyrrolidine-1-carboxylate,COC(=O)N1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL592510,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 8nM,agonist,78.00%,agonist,progesterone,,,,,,,EC50,=,0.1,nM,,,,,=,8.096910013,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,78,385.145,403.0854322,0,4,4,2,4.71238,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
4891,3140,19926282,23,P06401,PR,Homo sapiens,(S)-methyl 3-((3-chloro-4-cyanophenyl)(2-fluorobenzyl)amino)pyrrolidine-1-carboxylate,COC(=O)N1CC[C@@H](C1)N(Cc2ccccc2F)c3ccc(C#N)c(Cl)c3,CHEMBL592289,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 12nM,partial agonist,51.00%,agonist,progesterone,,,,,,,EC50,=,165,nM,,,,,=,7.920818754,pIC50,B,other,COC(=O)N1CC[C@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)C1,51,368.69,387.1149827,0,4,4,2,4.19808,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
4959,3172,25435151,9,P55055,LXRB,Homo sapiens,methyl 1-(2-chlorophenyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-1H-pyrazole-3-carboxylate,COC(=O)c1cc(c2ccc(s2)c3cccc(c3)S(=O)(=O)C)n(n1)c4ccccc4Cl,CHEMBL3360968,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,partial agonist,68.00%,agonist,compound 3b,,,,,,,EC50,=,64,nM,,,,,=,8,pIC50,B,radiometric,COC(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,68,455.839,472.0318267,0,7,5,4,5.1113,78.26,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,139
4976,3183,21349714,22,P04150,GR,Homo sapiens,"methyl 4-(((3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yloxy)carbonyl)benzoate",COC(=O)c1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(NC2(C)C)cc(F)c(c3F)c4cccc5cc[nH]c45)cc1,CHEMBL1684355,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30nM,agonist,84.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,15,nM,,,,,=,7.522878745,pKi,B,radiometric,COC(=O)c1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(cc(F)c(-c4cccc5cc[nH]c45)c3F)NC2(C)C)cc1,84,492.332,519.1969628,3,5,4,4,6.8246,92.45,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
4991,3195,19853462,8b,P55055,LXRB,Homo sapiens,Methyl 3-{3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}benzoate,COC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL594884,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 435nM,partial agonist,56.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,3400,nM,,,,,=,6.361510743,pIC50,,radiometric,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,56,419.273,437.1238781,0,4,4,4,6.80792,48.42,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
4993,3196,19162487,4h,P55055,LXRB,Homo sapiens,Methyl 3-[3-(8-chloro-3-methylquinolin-4-yl)phenoxy]benzoate,COC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL541472,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 230nM,,,,T0901317,,T0901317,-,,,,,,,,,,,,=,6.638272164,pIC50,,radiometric,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,,385.721,403.0975211,0,4,4,4,6.44252,48.42,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,partial agonist,280
4994,3196,19853462,8d,P55055,LXRB,Homo sapiens,methyl 3-(3-(8-chloro-3-methylquinolin-4-yl)phenoxy)benzoate,COC(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(Cl)cccc34)c1,CHEMBL541472,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 231nM,partial agonist,45.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,1810,nM,,,,,=,6.63638802,pIC50,,radiometric,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,45,385.721,403.0975211,0,4,4,4,6.44252,48.42,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
4997,3197,19162487,4a,P55055,LXRB,Homo sapiens,Methyl 3-{3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}benzoate,COC(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL471608,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,,,,T0901317,,T0901317,-,,,,,,,,,,,,=,7.27572413,pIC50,B,radiometric,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,,491.339,513.1551782,0,4,6,5,8.0903,48.42,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,,,agonist,partial agonist,278
4998,3197,19853462,8a,P55055,LXRB,Homo sapiens,methyl 3-(3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)benzoate,COC(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL471608,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,partial agonist,61.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,895,nM,,,,,=,7.27572413,pIC50,B,radiometric,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,61,491.339,513.1551782,0,4,6,5,8.0903,48.42,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,278
5020,3203,20128594,"2, GSK-0660",Q03181,PPARB,Homo sapiens,methyl 3-(N-(2-methoxy-4-(phenylamino)phenyl)sulfamoyl)thiophene-2-carboxylate,COC(=O)c1sccc1S(=O)(=O)Nc2ccc(Nc3ccccc3)cc2OC,CHEMBL592652,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.8,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.5,,=,6.8,pIC50,,radiometric,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC,100,400.352,418.0657137,2,7,7,3,4.0877,93.73,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCC1,antagonist,antagonist,antagonist,antagonist,1166
5022,3204,16979341,12,P37231,PPARG,Homo sapiens,2-methoxy-2-methyl-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,COC(C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL222121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 1600nM,agonist,104.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,335,nM,,,,,=,5.795880017,pKi,,radiometric,COC(C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,104,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5023,3204,16979341,12,Q07869,PPARA,Homo sapiens,2-methoxy-2-methyl-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,COC(C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL222121,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4800nM,agonist,114.00%,agonist,GW2331,,GW2331,,,,,EC50,=,882,nM,,,,,=,5.318758763,pIC50,,radiometric,COC(C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,114,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5024,3205,16973358,14,P37231,PPARG,Homo sapiens,2-methoxy-2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,COC(C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL221850,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 560nM,agonist,116.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,232,nM,,,,,=,6.251811973,pKi,,radiometric,COC(C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,116,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5025,3205,16973358,14,Q07869,PPARA,Homo sapiens,2-methoxy-2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,COC(C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL221850,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 330nM,agonist,106.00%,agonist,GW2331,,GW2331,,,,,EC50,=,144,nM,,,,,=,6.48148606,pKi,,radiometric,COC(C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,106,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5026,3206,16973358,36,P37231,PPARG,Homo sapiens,3-(6-(4-(3-chlorophenoxy)-2-methylphenethoxy)pyridin-3-yl)-2-methoxypropanoic acid,COC(Cc1ccc(OCCc2ccc(Oc3cccc(Cl)c3)cc2C)nc1)C(=O)O,CHEMBL426878,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 15nM,agonist,95.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,50,nM,,,,,=,7.823908741,pKi,B,radiometric,COC(Cc1ccc(OCCc2ccc(Oc3cccc(Cl)c3)cc2C)nc1)C(=O)O,95,417.719,441.1343005,1,5,10,3,5.09932,77.88,C1CCC(CCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,404
5027,3206,16973358,36,Q07869,PPARA,Homo sapiens,3-(6-(4-(3-chlorophenoxy)-2-methylphenethoxy)pyridin-3-yl)-2-methoxypropanoic acid,COC(Cc1ccc(OCCc2ccc(Oc3cccc(Cl)c3)cc2C)nc1)C(=O)O,CHEMBL426878,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13nM,agonist,100.00%,agonist,GW2331,,GW2331,,,,,EC50,=,133,nM,,,,,=,7.886056648,pKi,B,radiometric,COC(Cc1ccc(OCCc2ccc(Oc3cccc(Cl)c3)cc2C)nc1)C(=O)O,100,417.719,441.1343005,1,5,10,3,5.09932,77.88,C1CCC(CCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,404
5028,3207,19349176,rac-3Aa,P37231,PPARG,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL521131,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 113nM,agonist,98.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,123,nM,,,,,=,6.946921557,pIC50,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,98,406.288,431.1732729,1,5,9,4,5.06682,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
5029,3207,19349176,rac-3Aa,Q07869,PPARA,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL521131,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 61nM,agonist,159.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,131,nM,,,,,=,7.214670165,pIC50,B,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,159,406.288,431.1732729,1,5,9,4,5.06682,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
5030,3208,19349176,rac-2Aa,P37231,PPARG,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519032,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 46nM,agonist,131.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,59,nM,,,,,=,7.337242168,pIC50,B,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,131,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5031,3208,19349176,rac-2Aa,Q07869,PPARA,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519032,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,agonist,168.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,103,nM,,,,,=,7.552841969,pIC50,B,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,168,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5032,3209,16979341,8,P37231,PPARG,Homo sapiens,2-methoxy-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL385106,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 348nM,agonist,98.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,280,nM,,,,,=,6.458420756,pKi,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,98,360.24,382.1528718,1,6,9,3,3.30862,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5033,3209,16979341,8,Q07869,PPARA,Homo sapiens,2-methoxy-3-(5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cn1)C(=O)O,CHEMBL385106,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3700nM,agonist,95.00%,agonist,GW2331,,GW2331,,,,,EC50,=,3140,nM,,,,,=,5.431798276,pIC50,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cn1)C(=O)O,95,360.24,382.1528718,1,6,9,3,3.30862,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5035,3210,16973358,12,P37231,PPARG,Homo sapiens,2-methoxy-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL373874,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 63nM,agonist,98.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,13,nM,,,,,=,7.200659451,pKi,B,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,98,360.24,382.1528718,1,6,9,3,3.30862,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5036,3210,16973358,12,Q07869,PPARA,Homo sapiens,2-methoxy-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL373874,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 180nM,agonist,95.00%,agonist,GW2331,,GW2331,,,,,EC50,=,83,nM,,,,,=,6.744727495,pKi,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,95,360.24,382.1528718,1,6,9,3,3.30862,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5037,3211,19349176,rac-3Ah,P37231,PPARG,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-o-tolyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3C)c4ccccc14)C(=O)O,CHEMBL483351,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 802nM,agonist,78.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,716,nM,,,,,=,6.095825632,pIC50,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3C)oc2C)c2ccccc12)C(=O)O,78,418.299,445.188923,1,5,9,4,5.37524,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
5038,3211,19349176,rac-3Ah,Q07869,PPARA,Homo sapiens,2-methoxy-3-(4-(2-(5-methyl-2-o-tolyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3C)c4ccccc14)C(=O)O,CHEMBL483351,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 432nM,agonist,114.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,123,nM,,,,,=,6.364516253,pIC50,,radiometric,COC(Cc1ccc(OCCc2nc(-c3ccccc3C)oc2C)c2ccccc12)C(=O)O,114,418.299,445.188923,1,5,9,4,5.37524,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
5039,3212,16737814,26,P37231,PPARG,Homo sapiens,2-methoxy-3-(1-((5-methyl-2-phenyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,COC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4)c1)C(=O)O,CHEMBL213902,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 318nM,partial agonist,62.00%,agonist,Edaglitazone,,,,,,,EC50,=,1100,nM,,,,,=,6.49757288,pIC50,,radiometric,COC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3)oc2C)c1)C(=O)O,62,368.263,390.1579572,1,5,7,4,4.29512,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
5040,3212,16737814,26,Q07869,PPARA,Homo sapiens,2-methoxy-3-(1-((5-methyl-2-phenyloxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,COC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccccc4)c1)C(=O)O,CHEMBL213902,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 363nM,partial agonist,73.00%,agonist,Farglitazar,,,,,,,EC50,=,350,nM,,,,,=,6.440093375,pIC50,,radiometric,COC(Cc1ccc2c(ccn2Cc2nc(-c3ccccc3)oc2C)c1)C(=O)O,73,368.263,390.1579572,1,5,7,4,4.29512,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,157
5044,3215,24239186,21,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL3094380,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 900nM,inverse agonist,-45.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,9000,nM,,,,,=,6.045757491,pIC50,,radiometric,COC(c1ccc(N(CC(F)(F)F)S(=O)(=O)c2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,-45,481.251,495.0550683,0,3,6,2,5.4105,46.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
5045,3216,9873735,29,P06401,PR,Homo sapiens,"8-Fluoro-5-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COC1Oc2cc(F)ccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL333167,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 80.5nM,antagonist,89.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,49,nM,=,7.09420412,pKi,B,radiometric,COC1Oc2cc(F)ccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,89,305.223,325.1478071,1,3,1,2,5.1375,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
5047,3218,9873735,27,P06401,PR,Homo sapiens,"9-Chloro-5-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COC1Oc2ccc(Cl)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL114553,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16.4nM,partial antagonist,73.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,57,nM,=,7.785156152,pKi,B,radiometric,COC1Oc2ccc(Cl)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,73,321.678,341.1182566,1,3,1,2,5.6518,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
5048,3219,9873735,25,P06401,PR,Homo sapiens,"9-Fluoro-5-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COC1Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL114435,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 38.4nM,antagonist,75.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,46,nM,=,7.415668776,pKi,B,radiometric,COC1Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,75,305.223,325.1478071,1,3,1,2,5.1375,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
5049,322,16987661,6h,P04150,GR,Homo sapiens,"(8S,11R,13S,14S,17S)-17-hydroxy-11-(4-methoxy-3-methyl-phenyl)-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",COc1ccc(cc1C)[C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC)[C@@H]4CCC5=CC(=O)CCC5=C24,CHEMBL222900,,GRAF (??GR linked to Alkaline Fosfatase??,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.1nM,antagonist,97.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,1.1,nM,=,10,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(OC)c(C)c3)C[C@@]21C,97,396.316,430.2507949,1,3,2,1,5.65752,46.53,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,antagonist,antagonist,antagonist,antagonist,618
5050,3220,9873735,23,P06401,PR,Homo sapiens,"5-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COC1Oc2ccccc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL112058,,cotransfection,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 400nM,antagonist,90.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,75,nM,=,6.397940009,pKi,,radiometric,COC1Oc2ccccc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,90,286.225,307.1572289,1,3,1,2,4.9984,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
5052,3221,19464171,26,Q03181,PPARB,Homo sapiens,"2-(4-(2-(4-methoxybut-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",COCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL503072,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 9nM,agonist,86.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,340,nM,,,,,=,8.045757491,pKi,B,radiometric,COCC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,86,557.396,586.1636943,1,6,11,3,6.8064,74.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
5054,3222,19464171,27,P37231,PPARG,Homo sapiens,"2-(4-(2-(5-methoxypent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",COCCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL511100,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 44nM,partial agonist,38.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,1400,nM,,,,,=,7.356547324,pKi,B,other,COCCC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,38,569.407,600.1793444,1,6,12,3,7.1965,74.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
5055,3222,19464171,27,Q03181,PPARB,Homo sapiens,"2-(4-(2-(5-methoxypent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",COCCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL511100,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4nM,agonist,96.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,470,nM,,,,,=,8.397940009,pKi,B,radiometric,COCCC#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,96,569.407,600.1793444,1,6,12,3,7.1965,74.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
5059,3224,19464171,9,Q03181,PPARB,Homo sapiens,"2-(4-(2-(3-methoxypropoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-2,3-dimethylphenoxy)acetic acid",COCCCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c(C)c3C,CHEMBL495817,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 8nM,agonist,88.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1900,nM,,,,,=,8.096910013,pKi,B,radiometric,COCCCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c(C)c1C,88,521.363,550.1636943,1,6,13,3,6.93114,74.22,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,336
5061,3225,19932617,7q,P55055,LXRB,Homo sapiens,4-(3-(3-(3-methoxypropylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,COCCCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL595804,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,partial agonist,48.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,274,nM,,,,,=,8.494850022,pIC50,B,radiometric,COCCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,48,491.361,515.1378139,0,5,8,4,6.83152,65.49,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
5065,3227,21414782,27,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-(2-methoxyethyl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",COCCN(c1cccc(c1C)c2ccc(Cl)cc2)S(=O)(=O)c3ccc(OC(C)C(=O)O)c(C)c3C,CHEMBL1760409,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.3,partial agonist,48.00%,agonist,,,,,,,,PEC50,=,6.3,,,,,,=,6.3,pIC50,,radiometric,COCCN(c1cccc(-c2ccc(Cl)cc2)c1C)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,48,501.818,531.1482364,1,5,10,3,5.62586,93.14,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
5068,3229,19595590,15,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-(2-methoxyethyl)pyrrolidin-3-yl)amino)benzonitrile,COCCN1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL560489,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 25nM,partial agonist,40.00%,agonist,progesterone,,,,,,,EC50,=,50,nM,,,,,=,7.602059991,pIC50,B,FPA,COCCN1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,40,381.157,403.1218177,0,4,7,2,4.59238,39.5,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
5080,3238,19464171,11,Q03181,PPARB,Homo sapiens,"2-(4-(2-(2-methoxyethoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-2,3-dimethylphenoxy)acetic acid",COCCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c(C)c3C,CHEMBL495818,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 11nM,agonist,95.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1700,nM,,,,,=,7.958607315,pKi,B,radiometric,COCCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c(C)c1C,95,509.352,536.1480442,1,6,12,3,6.54104,74.22,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,336
5093,3246,17553679,15,P04150,GR,Homo sapiens,"(Z)-5-(4-fluoro-2-((methoxymethoxy)methyl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COCOCc1cc(F)ccc1\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL3706942,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.6nM,antagonist,81.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,192,nM,IC50,=,0.4,nM,=,9.22184875,pKi,B,radiometric,COCOCc1cc(F)ccc1/C=C1\Oc2ccc(O)c(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,81,473.33,503.2108013,2,6,6,3,6.8253,69.18,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
5096,3247,19606870,11,P10275,AR,Homo sapiens,16alpha-(Methoxymethyl)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,COC[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,CHEMBL538877,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,partial agonist,43.00%,agonist,R1866,100nM,methyltrienolone,,,,,EC50,=,612,nM,,,,,=,7.619788758,pIC50,B,radiometric,COC[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,43,314.235,347.2460439,1,3,2,0,2.8592,49.77,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,615
5097,3248,15911283,30,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',5'-di(methoxymethyl)-4a-methyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",COC[C@H]1OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1COC,CHEMBL193703,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,partial agonist,62.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,8.3,nM,,,,,=,7.585026652,pIC50,B,radiometric,COC[C@H]1OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1COC,62,387.261,414.1954856,0,6,5,2,3.5241,54.74,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,91
5114,3258,17705362,9,P04150,GR,Homo sapiens,"(Z)-5-(2'-(3'-methoxymethylthienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline",COCc1ccsc1\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL395716,GRE activation agonist mode,,-,Ki = 0.2nM,partial agonist,58.00%,agonist,dexamethasone,,,,,,,EC50,=,0.2,nM,,,,,=,9.698970004,pKi,B,other,COCc1ccsc1/C=C1\Oc2ccc(O)c(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,58,434.367,461.1660793,2,6,4,3,6.7736,59.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,partial agonist,agonist,partial agonist,221
5122,3260,20584610,17,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Methoxy-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CON1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210910,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 3.7nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,24,nM,=,8.431798276,pKi,B,radiometric,CON1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,391.22,409.1249407,0,6,2,1,2.10728,82.87,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
5123,3261,15582409,1h,P37231,PPARG,Homo sapiens,(S)-2-Methoxy-3-{4-[5-(4-phenoxy-phenoxy)-pent-1-ynyl]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(cc1)C#CCCCOc2ccc(Oc3ccccc3)cc2)C(=O)O,CHEMBL182230,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7nM,agonist,77.00%,agonist,standard,,,,,,,EC50,=,239,nM,,,,,=,8.15490196,pIC50,B,radiometric,CO[C@@H](Cc1ccc(C#CCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,77,404.292,430.1780239,1,4,10,3,5.3317,64.99,C(CCCC1CCC(CC2CCCCC2)CC1)CCC1CCCCC1,agonist,agonist,agonist,agonist,1168
5125,3261,15582409,1h,Q07869,PPARA,Homo sapiens,(S)-2-Methoxy-3-{4-[5-(4-phenoxy-phenoxy)-pent-1-ynyl]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(cc1)C#CCCCOc2ccc(Oc3ccccc3)cc2)C(=O)O,CHEMBL182230,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 770nM,partial agonist,35.00%,agonist,standard,,,,,,,EC50,=,2622,nM,,,,,=,6.113509275,pIC50,,radiometric,CO[C@@H](Cc1ccc(C#CCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,35,404.292,430.1780239,1,4,10,3,5.3317,64.99,C(CCCC1CCC(CC2CCCCC2)CC1)CCC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1168
5126,3262,15582409,1g,P37231,PPARG,Homo sapiens,(S)-2-Methoxy-3-{4-[4-(4-phenoxy-phenoxy)-but-1-ynyl]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(cc1)C#CCCOc2ccc(Oc3ccccc3)cc2)C(=O)O,CHEMBL181656,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,partial agonist,74.00%,agonist,standard,,,,,,,EC50,=,103,nM,,,,,=,7.886056648,pIC50,B,radiometric,CO[C@@H](Cc1ccc(C#CCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,74,392.281,416.1623739,1,4,9,3,4.9416,64.99,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,468
5128,3262,15582409,1g,Q07869,PPARA,Homo sapiens,(S)-2-Methoxy-3-{4-[4-(4-phenoxy-phenoxy)-but-1-ynyl]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(cc1)C#CCCOc2ccc(Oc3ccccc3)cc2)C(=O)O,CHEMBL181656,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1154nM,partial agonist,33.00%,agonist,standard,,,,,,,EC50,=,1880,nM,,,,,=,5.937794191,pIC50,,radiometric,CO[C@@H](Cc1ccc(C#CCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,33,392.281,416.1623739,1,4,9,3,4.9416,64.99,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,468
5129,3263,15582409,1a,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(Biphenyl-4-yloxy)-propoxy]-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)c3ccccc3)cc1)C(=O)O,CHEMBL182884,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 21nM,agonist,84.00%,agonist,standard,,,,,,,EC50,=,154,nM,,,,,=,7.677780705,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(-c3ccccc3)cc2)cc1)C(=O)O,84,380.27,406.1780239,1,4,11,3,4.8436,64.99,C1CCC(CCCCCC2CCC(C3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,462
5131,3263,15582409,1a,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(Biphenyl-4-yloxy)-propoxy]-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)c3ccccc3)cc1)C(=O)O,CHEMBL182884,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 568nM,partial agonist,42.00%,agonist,standard,,,,,,,EC50,=,1100,nM,,,,,=,6.245651664,pIC50,,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(-c3ccccc3)cc2)cc1)C(=O)O,42,380.27,406.1780239,1,4,11,3,4.8436,64.99,C1CCC(CCCCCC2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,462
5132,3264,15582409,1f,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(4-Benzoyl-phenoxy)-propoxy]-3-chloro-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)C(=O)c3ccccc3)c(Cl)c1)C(=O)O,CHEMBL181644,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5nM,agonist,83.00%,agonist,standard,,,,,,,EC50,=,305,nM,,,,,=,8.301029996,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(C(=O)c3ccccc3)cc2)c(Cl)c1)C(=O)O,83,443.733,468.1339662,1,5,12,3,5.061,82.06,CC(C1CCCCC1)C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,903
5134,3264,15582409,1f,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(4-Benzoyl-phenoxy)-propoxy]-3-chloro-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)C(=O)c3ccccc3)c(Cl)c1)C(=O)O,CHEMBL181644,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 309nM,partial agonist,36.00%,agonist,standard,,,,,,,EC50,=,2713,nM,,,,,=,6.510041521,pIC50,,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(C(=O)c3ccccc3)cc2)c(Cl)c1)C(=O)O,36,443.733,468.1339662,1,5,12,3,5.061,82.06,CC(C1CCCCC1)C1CCC(CCCCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,903
5135,3265,15582409,1c,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(4-Benzoyl-phenoxy)-propoxy]-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)C(=O)c3ccccc3)cc1)C(=O)O,CHEMBL363532,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5nM,agonist,76.00%,agonist,standard,,,,,,,EC50,=,260,nM,,,,,=,8.301029996,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(C(=O)c3ccccc3)cc2)cc1)C(=O)O,76,408.28,434.1729386,1,5,12,3,4.4076,82.06,CC(C1CCCCC1)C1CCC(CCCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,903
5137,3265,15582409,1c,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(4-Benzoyl-phenoxy)-propoxy]-phenyl}-2-methoxy-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(cc2)C(=O)c3ccccc3)cc1)C(=O)O,CHEMBL363532,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 470nM,partial agonist,27.00%,agonist,standard,,,,,,,EC50,=,2870,nM,,,,,=,6.327902142,pIC50,,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(C(=O)c3ccccc3)cc2)cc1)C(=O)O,27,408.28,434.1729386,1,5,12,3,4.4076,82.06,CC(C1CCCCC1)C1CCC(CCCCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,903
5139,3266,15582409,1b,Q07869,PPARA,Homo sapiens,(S)-2-Methoxy-3-{4-[3-(4-phenoxy-phenoxy)-propoxy]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,CHEMBL181954,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2711nM,partial agonist,43.00%,agonist,standard,,,,,,,EC50,=,2816,nM,,,,,=,5.566870482,pIC50,,radiometric,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,43,396.269,422.1729386,1,5,12,3,4.9689,74.22,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,468
5140,3267,19349176,(S)-2Ac,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(2-(3,5-dimethylphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-methoxypropanoic acid",CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3cc(C)cc(C)c3)c4ccsc14)C(=O)O,CHEMBL484138,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8nM,partial agonist,61.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,11,nM,,,,,=,8.096910013,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3cc(C)cc(C)c3)oc2C)c2ccsc12)C(=O)O,61,438.355,465.160994,1,6,9,4,5.74516,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
5141,3268,19349176,(S)-2Ad,P37231,PPARG,Homo sapiens,(S)-3-(4-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-methoxypropanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(C)C)c4ccsc14)C(=O)O,CHEMBL484409,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,partial agonist,53.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(C)C)cc3)oc2C)c2ccsc12)C(=O)O,53,450.366,479.176644,1,6,10,4,6.25172,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
5142,3268,19349176,(S)-2Ad,Q07869,PPARA,Homo sapiens,(S)-3-(4-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-methoxypropanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(C)C)c4ccsc14)C(=O)O,CHEMBL484409,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 45nM,agonist,151.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,20,nM,,,,,=,7.346787486,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(C)C)cc3)oc2C)c2ccsc12)C(=O)O,151,450.366,479.176644,1,6,10,4,6.25172,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5143,3269,19349176,(S)-2Ab,P37231,PPARG,Homo sapiens,(S)-2-methoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccsc14)C(=O)O,CHEMBL484137,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 23nM,agonist,132.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,53,nM,,,,,=,7.638272164,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccsc12)C(=O)O,132,483.338,505.1170785,1,6,9,4,6.14712,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5144,3269,19349176,(S)-2Ab,Q07869,PPARA,Homo sapiens,(S)-2-methoxy-3-(4-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccc(cc3)C(F)(F)F)c4ccsc14)C(=O)O,CHEMBL484137,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,agonist,109.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,2,nM,,,,,=,7.27572413,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccc(C(F)(F)F)cc3)oc2C)c2ccsc12)C(=O)O,109,483.338,505.1170785,1,6,9,4,6.14712,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5146,3270,19349176,(S)-2Aa,P37231,PPARG,Homo sapiens,Aleglitazar,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519504,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 19nM,partial agonist,67.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,21,nM,,,,,=,7.721246399,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,67,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
5147,3270,19349176,(S)-2Aa,Q07869,PPARA,Homo sapiens,Aleglitazar,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL519504,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,agonist,156.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,50,nM,,,,,=,7.420216403,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,156,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5148,3271,19349176,(S)-4Aa,P37231,PPARG,Homo sapiens,(S)-2-methoxy-3-(7-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-4-yl)propanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4sccc14)C(=O)O,CHEMBL484330,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 11nM,agonist,159.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,33,nM,,,,,=,7.958607315,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2sccc12)C(=O)O,159,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5149,3271,19349176,(S)-4Aa,Q07869,PPARA,Homo sapiens,(S)-2-methoxy-3-(7-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-4-yl)propanoic acid,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4sccc14)C(=O)O,CHEMBL484330,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,agonist,174.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,157,nM,,,,,=,7.552841969,pIC50,B,radiometric,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2sccc12)C(=O)O,174,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5150,3272,16973358,(S)-14,P37231,PPARG,Homo sapiens,(S)-2-methoxy-2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CO[C@@](C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL222117,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 270nM,agonist,97.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,110,nM,,,,,=,6.568636236,pKi,,radiometric,CO[C@@](C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,97,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5151,3272,16973358,(S)-14,Q07869,PPARA,Homo sapiens,(S)-2-methoxy-2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CO[C@@](C)(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL222117,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 570nM,agonist,99.00%,agonist,GW2331,,GW2331,,,,,EC50,=,111,nM,,,,,=,6.244125144,pKi,,radiometric,CO[C@@](C)(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)nc1)C(=O)O,99,372.251,396.1685219,1,6,9,3,3.69872,94.68,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
5152,3273,19349176,(R)-3Aa,P37231,PPARG,Homo sapiens,(R)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL484329,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1570nM,partial agonist,31.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,122,nM,,,,,=,5.804100348,pIC50,,radiometric,CO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,31,406.288,431.1732729,1,5,9,4,5.06682,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
5153,3273,19349176,(R)-3Aa,Q07869,PPARA,Homo sapiens,(R)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)naphthalen-1-yl)propanoic acid,CO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccccc14)C(=O)O,CHEMBL484329,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 918nM,agonist,92.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,650,nM,,,,,=,6.037157319,pIC50,,radiometric,CO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccccc12)C(=O)O,92,406.288,431.1732729,1,5,9,4,5.06682,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,176
5154,3274,19349176,(R)-2Aa,P37231,PPARG,Homo sapiens,(R)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL482993,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1440nM,partial agonist,65.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,1210,nM,,,,,=,5.841637508,pIC50,,radiometric,CO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,65,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
5155,3274,19349176,(R)-2Aa,Q07869,PPARA,Homo sapiens,(R)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CO[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL482993,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4610nM,agonist,109.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,358,nM,,,,,=,5.336299075,pIC50,,radiometric,CO[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,109,414.333,437.1296938,1,6,9,4,5.12832,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5160,3278,15125928,8,P19793,RXRA,Homo sapiens,"(E)-3-[3-(3,5-Diisopropyl-2-methoxy-phenyl)-benzo[b]thiophen-5-yl]-but-2-enoic acid",COc1c(cc(cc1c2csc3ccc(cc23)\C(=C\C(=O)O)\C)C(C)C)C(C)C,CHEMBL314745,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 29.6nM,partial agonist,65.41%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,914,nM,,,,,=,7.528708289,pKi,B,radiometric,COc1c(-c2csc3ccc(/C(C)=C/C(=O)O)cc23)cc(C(C)C)cc1C(C)C,65.41,380.339,408.1759158,1,3,6,3,7.3116,46.53,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
5162,3279,12801232,12a,P19793,RXRA,Homo sapiens,"7-(3,5-Di-tert-butyl-2-methoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",COc1c(cc(cc1C(C)(C)C)C(C)(C)C)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL329334,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 1nM,partial agonist,65.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,36,nM,,,,,=,9,pKi,B,radiometric,COc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)(C)C)cc1C(C)(C)C,65,336.261,370.2507949,1,2,5,1,6.2806,46.53,C1CCCCC1,agonist,partial agonist,agonist,partial agonist,205
5165,3280,12801232,11a,P19793,RXRA,Homo sapiens,"7-(3,5-Diisopropyl-2-methoxy-phenyl)-3-methyl-octa-2,4,6-trienoic acid",COc1c(cc(cc1\C(=C/C=C/C(=C/C(=O)O)/C)\C)C(C)C)C(C)C,CHEMBL90824,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 1nM,agonist,83.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,2,nM,,,,,=,9,pKi,B,radiometric,COc1c(/C(C)=C\C=C\C(C)=C\C(=O)O)cc(C(C)C)cc1C(C)C,83,312.239,342.2194948,1,2,7,1,5.9324,46.53,C1CCCCC1,agonist,agonist,agonist,agonist,205
5171,3285,18442912,5f,P10275,AR,Homo sapiens,"trifluoromethyl 10-methoxy-4-methyl-2,5-dioxo-2,5-dihydro-1H-chromeno[3,4-f]quinoline-9-carboxylate",COc1c(ccc2OC(=O)c3c(ccc4NC(=O)C=C(C)c34)c12)C(=O)OC(F)(F)F,CHEMBL256769,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 10nM,agonist,97.00%,agonist,DHT,,,,,,,EC50,=,43,nM,IC50,>,10000,nM,=,8,pKi,B,radiometric,COc1c(C(=O)OC(F)(F)F)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,97,407.215,419.0616718,1,6,2,4,3.78132,98.6,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,agonist,agonist,agonist,agonist,636
5182,3290,18442912,9c,P10275,AR,Homo sapiens,"9-hydroxy-10-methoxy-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1c(O)ccc2OCc3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL427731,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5nM,agonist,118.00%,agonist,DHT,,,,,,,EC50,=,306,nM,IC50,=,19,nM,=,8.301029996,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,118,294.201,309.100108,2,4,1,3,3.11012,71.55,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,634
5183,3291,17553679,33,P04150,GR,Homo sapiens,"(Z)-5-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methylene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cc(F)cc4COCOc34)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706960,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.9nM,antagonist,88.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.2,nM,IC50,=,0.8,nM,=,9.045757491,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cc(F)cc4c1OCOC4)O2)C(C)=CC(C)(C)N3,88,461.319,487.1795012,2,6,2,3,6.5713,69.18,C1CCC2C(C1)CCCC2CC1CC2CCCCC2C2CCC3CCCCC3C12,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,24
5184,3292,17553679,28,P04150,GR,Homo sapiens,"5-[1-biphenyl-4-yl-meth-(Z)-ylidene]-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(cc3)c4ccccc4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706955,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.4nM,agonist,142.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,33,nM,Efficacy,<,10%,,=,8.356547324,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(-c4ccccc4)cc1)O2)C(C)=CC(C)(C)N3,142,458.367,487.2147438,2,4,3,4,8.2327,50.72,C1CCC(C2CCC(CC3CC4CCCCC4C4CCC5CCCCC5C34)CC2)CC1,agonist,agonist,agonist,agonist,155
5185,3293,17553679,27,P04150,GR,Homo sapiens,"(Z)-5-(4-isopropylbenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(cc3)C(C)C)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706954,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.9nM,partial agonist,37.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,455,nM,Efficacy,<,10%,,=,8.537602002,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(C(C)C)cc1)O2)C(C)=CC(C)(C)N3,37,422.334,453.2303939,2,4,3,3,7.6891,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
5186,3294,17553679,25,P04150,GR,Homo sapiens,"10-methoxy-2,2,4-trimethyl-5-[1-p-tolyl-meth-(Z)-ylidene]-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(C)cc3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706952,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,partial antagonist,55.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,38,nM,IC50,=,12,nM,=,8.721246399,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(C)cc1)O2)C(C)=CC(C)(C)N3,55,398.312,425.1990937,2,4,2,3,6.87412,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,222
5187,3295,17553679,24,P04150,GR,Homo sapiens,"(Z)-5-(4-chlorobenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(Cl)cc3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706951,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.7nM,partial agonist,70.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,43,nM,Efficacy,<,10%,,=,8.769551079,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(Cl)cc1)O2)C(C)=CC(C)(C)N3,70,421.754,445.1444713,2,4,2,3,7.2191,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,222
5188,3296,17553679,14,P04150,GR,Homo sapiens,"5-fluoro-2-((Z)-(9-hydroxy-10-methoxy-2,2,4-trimethyl-1,2-dihydro-4aH-chromeno[3,4-f]quinolin-5(12aH)-ylidene)methyl)benzaldehyde oxime",COc1c(O)ccc2O\C(=C/c3ccc(F)cc3\C=N\O)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706941,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,356,nM,IC50,=,0.1,nM,=,8.823908741,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(F)cc1/C=N/O)O2)C(C)=CC(C)(C)N3,92,447.316,472.1798355,3,6,3,3,6.5129,83.31,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,222
5189,3297,17553679,9,P04150,GR,Homo sapiens,"(Z)-5-fluoro-2-((9-hydroxy-10-methoxy-2,2,4-trimethyl-1,2-dihydro-4aH-chromeno[3,4-f]quinolin-5(12aH)-ylidene)methyl)-N,N-dimethylbenzamide",COc1c(O)ccc2O\C(=C/c3ccc(F)cc3C(=O)N(C)C)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706936,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.4nM,partial agonist,56.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.1,nM,IC50,=,11,nM,=,8.619788758,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(F)cc1C(=O)N(C)C)O2)C(C)=CC(C)(C)N3,56,471.338,500.2111356,2,5,3,3,6.4066,71.03,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,222
5190,3298,17553679,11,P04150,GR,Homo sapiens,"(Z)-(5-fluoro-2-((9-hydroxy-10-methoxy-2,2,4-trimethyl-1,2-dihydro-4aH-chromeno[3,4-f]quinolin-5(12aH)-ylidene)methyl)phenyl)(piperidin-1-yl)methanone",COc1c(O)ccc2O\C(=C/c3ccc(F)cc3C(=O)N4CCCCC4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706938,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.9nM,partial agonist,58.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.5,nM,Efficacy,<,10%,,=,9.045757491,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(F)cc1C(=O)N1CCCCC1)O2)C(C)=CC(C)(C)N3,58,507.371,540.2424358,2,5,3,3,7.3309,71.03,CC(C1CCCCC1)C1CCCCC1CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,partial agonist,agonist,partial agonist,870
5191,3299,17553679,13,P04150,GR,Homo sapiens,"(Z)-5-(4-fluoro-2-(hydroxymethyl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(F)cc3CO)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706940,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.5nM,partial antagonist,26.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,16,nM,IC50,=,89,nM,=,9.301029996,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(F)cc1CO)O2)C(C)=CC(C)(C)N3,26,433.309,459.1845865,3,5,3,3,6.1971,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,222
5200,3300,17553679,12,P04150,GR,Homo sapiens,"(Z)-5-(4-fluoro-2-(piperidin-1-ylsulfonyl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(F)cc3S(=O)(=O)N4CCCCC4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706939,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 94nM,partial antagonist,73.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,108,nM,IC50,=,6.6,nM,=,7.026872146,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(F)cc1S(=O)(=O)N1CCCCC1)O2)C(C)=CC(C)(C)N3,73,543.426,576.2094214,2,6,4,3,6.8794,88.1,CC(C)(C1CCCCC1)C1CCCCC1CC1CC2CCCCC2C2CCC3CCCCC3C12,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,1028
5201,3301,17553679,29,P04150,GR,Homo sapiens,"(Z)-5-(4-hydroxybenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccc(O)cc3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706956,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.1nM,antagonist,88.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,1.1,nM,IC50,=,0.4,nM,=,8.958607315,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccc(O)cc1)O2)C(C)=CC(C)(C)N3,88,402.3,427.1783583,3,5,2,3,6.2713,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
5203,3303,17553679,18,P04150,GR,Homo sapiens,"5-[1-biphenyl-3-yl-meth-(Z)-ylidene]-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(c3)c4ccccc4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706945,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7.2nM,antagonist,91.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,2.3,nM,=,8.142667504,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(-c4ccccc4)c1)O2)C(C)=CC(C)(C)N3,91,458.367,487.2147438,2,4,3,4,8.2327,50.72,C1CCC(C2CCCC(CC3CC4CCCCC4C4CCC5CCCCC5C34)C2)CC1,antagonist,antagonist,antagonist,antagonist,166
5204,3304,17553679,23,P04150,GR,Homo sapiens,"(Z)-5-(3-(pyridin-3-yl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(c3)c4cccnc4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706950,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,antagonist,93.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,0.7,nM,=,8.823908741,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(-c4cccnc4)c1)O2)C(C)=CC(C)(C)N3,93,460.363,488.2099928,2,5,3,4,7.6277,63.61,C1CCC(C2CCCC(CC3CC4CCCCC4C4CCC5CCCCC5C34)C2)CC1,antagonist,antagonist,antagonist,antagonist,166
5205,3305,17553679,22,P04150,GR,Homo sapiens,"(Z)-5-(3-(thiophen-3-yl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(c3)c4ccsc4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706949,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.1nM,antagonist,95.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,0.5,nM,=,8.508638306,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(-c4ccsc4)c1)O2)C(C)=CC(C)(C)N3,95,466.412,493.1711647,2,5,3,4,8.2942,50.72,C1CCC(C2CCCC(CC3CC4CCCCC4C4CCC5CCCCC5C34)C2)C1,antagonist,antagonist,antagonist,antagonist,165
5206,3306,17553679,17,P04150,GR,Homo sapiens,"(Z)-5-(3-(trifluoromethyl)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(c3)C(F)(F)F)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706944,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.7nM,antagonist,97.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,2.5,nM,=,8.568636236,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(C(F)(F)F)c1)O2)C(C)=CC(C)(C)N3,97,455.306,479.1708283,2,4,2,3,7.5845,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
5207,3307,17553679,16,P04150,GR,Homo sapiens,"10-methoxy-2,2,4-trimethyl-5-[1-m-tolyl-meth-(Z)-ylidene]-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(C)c3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706943,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.5nM,antagonist,97.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,0.2,nM,=,8.602059991,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(C)c1)O2)C(C)=CC(C)(C)N3,97,398.312,425.1990937,2,4,2,3,6.87412,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
5213,3309,17553679,36,P04150,GR,Homo sapiens,"(Z)-10-methoxy-2,2,4-trimethyl-5-((6-methylpyridin-2-yl)methylene)-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(C)n3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706962,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.6nM,antagonist,84.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.7,nM,IC50,=,1.1,nM,=,8.795880017,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(C)n1)O2)C(C)=CC(C)(C)N3,84,400.308,426.1943427,2,5,2,3,6.26912,63.61,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
5215,3310,17553679,19,P04150,GR,Homo sapiens,"(Z)-5-(3-hydroxybenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(O)c3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706946,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.4nM,partial antagonist,65.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,1.5,nM,IC50,=,4.7,nM,=,8.853871964,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(O)c1)O2)C(C)=CC(C)(C)N3,65,402.3,427.1783583,3,5,2,3,6.2713,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,222
5218,3311,17553679,20,P04150,GR,Homo sapiens,"(Z)-5-(3-(trifluoromethoxy)benzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(OC(F)(F)F)c3)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706947,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.1nM,antagonist,95.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,1.9,nM,=,8.387216143,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(OC(F)(F)F)c1)O2)C(C)=CC(C)(C)N3,95,471.305,495.1657429,2,5,3,3,7.4643,59.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
5219,3312,17553679,21,P04150,GR,Homo sapiens,"(Z)-5-(3-phenoxybenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3cccc(Oc4ccccc4)c3)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706948,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.6nM,antagonist,94.00%,antagonist,dexamethasone,,dexamethasone,,,,,Efficacy,<,10%,,IC50,=,1.9,nM,=,8.337242168,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1cccc(Oc4ccccc4)c1)O2)C(C)=CC(C)(C)N3,94,474.366,503.2096584,2,5,4,4,8.358,59.95,C1CCC(CC2CCCC(CC3CC4CCCCC4C4CCC5CCCCC5C34)C2)CC1,antagonist,antagonist,antagonist,antagonist,284
5220,3313,17553679,8,P04150,GR,Homo sapiens,"5-[1-biphenyl-2-yl-meth-(Z)-ylidene]-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3ccccc3c4ccccc4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL3706935,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.7nM,antagonist,92.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,4.5,nM,IC50,=,3.6,nM,=,8.173925197,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccccc1-c1ccccc1)O2)C(C)=CC(C)(C)N3,92,458.367,487.2147438,2,4,3,4,8.2327,50.72,C1CCC(C2CCCCC2CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,153
5221,3314,17553679,7,P04150,GR,Homo sapiens,"10-methoxy-2,2,4-trimethyl-5-[1-o-tolyl-meth-(Z)-ylidene]-2,4a,5,12a-tetrahydro-1H-6-oxa-1-aza-chrysen-9-ol",COc1c(O)ccc2O\C(=C/c3ccccc3C)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706934,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.7nM,antagonist,91.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,3.4,nM,IC50,=,0.4,nM,=,8.769551079,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccccc1C)O2)C(C)=CC(C)(C)N3,91,398.312,425.1990937,2,4,2,3,6.87412,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
5222,3315,17553679,6,P04150,GR,Homo sapiens,"(Z)-5-(2-chlorobenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccccc3Cl)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706933,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,partial antagonist,60.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,18,nM,IC50,=,24,nM,=,7.823908741,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccccc1Cl)O2)C(C)=CC(C)(C)N3,60,421.754,445.1444713,2,4,2,3,7.2191,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,222
5223,3316,17553679,5,P04150,GR,Homo sapiens,"(Z)-5-(2-fluorobenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1c(O)ccc2O\C(=C/c3ccccc3F)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706932,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.8nM,antagonist,89.00%,antagonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.6,nM,IC50,=,1.3,nM,=,9.096910013,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1ccccc1F)O2)C(C)=CC(C)(C)N3,89,405.299,429.1740218,2,4,2,3,6.7048,50.72,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,222
5224,3317,17553679,35,P04150,GR,Homo sapiens,"(Z)-2-((9-hydroxy-10-methoxy-2,2,4-trimethyl-1,2-dihydro-4aH-chromeno[3,4-f]quinolin-5(12aH)-ylidene)methyl)-N,N,5-trimethylfuran-3-carboxamide",COc1c(O)ccc2O\C(=C/c3oc(C)cc3C(=O)N(C)C)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL3706961,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.4nM,agonist,104.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,1.5,nM,IC50,=,4.9,nM,=,8.468521083,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1oc(C)cc1C(=O)N(C)C)O2)C(C)=CC(C)(C)N3,104,456.328,486.2154721,2,6,3,3,6.16892,84.17,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,221
5225,3318,17705362,22,P04150,GR,Homo sapiens,"(Z)-5-(2'-(3'-((E)-1''-hydroxyiminoethyl)thienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno-[3,4-f]quinoline",COc1c(O)ccc2O\C(=C/c3sccc3\C(=N\O)\C)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL397919,GRE activation agonist mode,,-,Ki = 0.6nM,partial agonist,35.00%,agonist,dexamethasone,,,,,,,EC50,=,5,nM,,,,,=,9.22184875,pKi,B,other,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1sccc1/C(C)=N/O)O2)C(C)=CC(C)(C)N3,35,448.374,474.1613283,3,7,3,3,6.8254,83.31,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,partial agonist,agonist,partial agonist,221
5229,3319,17553679,34,P04150,GR,Homo sapiens,"(Z)-(2-((9-hydroxy-10-methoxy-2,2,4-trimethyl-1,2-dihydro-4aH-chromeno[3,4-f]quinolin-5(12aH)-ylidene)methyl)thiophen-3-yl)(piperidin-1-yl)methanone",COc1c(O)ccc2O\C(=C/c3sccc3C(=O)N4CCCCC4)\c5c(ccc6NC(C)(C)C=C(C)c56)c12,CHEMBL243455,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.4nM,agonist,93.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.2,nM,IC50,=,4.1,nM,=,8.853871964,pKi,B,radiometric,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1sccc1C(=O)N1CCCCC1)O2)C(C)=CC(C)(C)N3,93,496.418,528.2082785,2,6,3,3,7.2533,71.03,CC(C1CCCCC1)C1CCCC1CC1CC2CCCCC2C2CCC3CCCCC3C12,"antagonist,agonist",agonist,"antagonist,agonist",agonist,861
5235,3320,17705362,20,P04150,GR,Homo sapiens,"(+/-)-(Z)-5-(2'-(3'-(1''-hydroxyethyl)thienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline",COc1c(O)ccc2O\C(=C/c3sccc3C(C)O)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL244537,,GRE activation antagonist mode,-,Ki = 1.2nM,antagonist,96.00%,antagonist,dexamethasone,,,,,,,,,,,,,,,=,8.920818754,pKi,B,other,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1sccc1C(C)O)O2)C(C)=CC(C)(C)N3,96,434.367,461.1660793,3,6,3,3,6.6805,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,,antagonist,,antagonist,221
5239,3321,17705362,15,P04150,GR,Homo sapiens,"(+/-)-(Z)-5-(2'-(3'-(1''-hydroxy-2'',2'',2''-trifluoroethyl)thienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline",COc1c(O)ccc2O\C(=C/c3sccc3C(O)C(F)(F)F)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL243656,,GRE activation antagonist mode,-,Ki = 1.4nM,antagonist,97.00%,antagonist,dexamethasone,,,,,,,,,,,,,,,=,8.853871964,pKi,B,other,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1sccc1C(O)C(F)(F)F)O2)C(C)=CC(C)(C)N3,97,491.361,515.1378139,3,6,3,3,7.2229,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,,antagonist,,antagonist,221
5243,3322,17705362,8,P04150,GR,Homo sapiens,"(Z)-5-(2'-(3'-hydroxymethylthienylmethylidene))1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline",COc1c(O)ccc2O\C(=C/c3sccc3CO)\c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL394369,GRE activation agonist mode,,-,Ki = 0.7nM,partial agonist,26.00%,agonist,dexamethasone,,,,,,,EC50,=,0.2,nM,,,,,=,9.15490196,pKi,B,other,COc1c(O)ccc2c1-c1ccc3c(c1/C(=C/c1sccc1CO)O2)C(C)=CC(C)(C)N3,26,422.356,447.1504293,3,6,3,3,6.1195,70.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)C1,agonist,partial agonist,agonist,partial agonist,221
5247,3323,18442912,5e,P10275,AR,Homo sapiens,"9-hydroxy-10-methoxy-4-methyl-1H-chromeno[3,4-f]quinoline-2,5-dione",COc1c(O)ccc2OC(=O)c3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL427898,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.0nM,agonist,117.00%,agonist,DHT,,,,,,,EC50,=,21,nM,IC50,>,10000,nM,=,8.397940009,pKi,B,radiometric,COc1c(O)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,117,310.2,323.0793725,2,5,1,4,2.81032,92.53,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,agonist,agonist,agonist,agonist,636
5288,3353,17267219,7i,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-methoxyquinolin-2(1H)-one",COC1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL393280,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 23nM,partial agonist,34.00%,agonist,DHT,,,,,,,EC50,=,35,nM,IC50,=,15,nM,=,7.638272164,pIC50,B,radiometric,COc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,34,342.154,354.0802969,1,3,4,2,3.4677,45.33,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
5291,3355,12781198,11s,P06401,PR,Homo sapiens,"9-Bromo-7-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cc(Br)cc2c1OCc3c2ccc4NC(C)(C)C=C(C)c34,CHEMBL294265,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 476nM,partial antagonist,45.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,43,nM,=,6.322393047,pKi,,radiometric,COc1cc(Br)cc2c1OCc1c-2ccc2c1C(C)=CC(C)(C)N2,45,366.129,385.067741,1,3,1,2,5.6245,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,partial antagonist,antagonist,partial antagonist,16
5292,3355,16821785,65,P06401,PR,Homo sapiens,"9-bromo-7-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",COc1cc(Br)cc2c1OCc3c2ccc4NC(C)(C)C=C(C)c34,CHEMBL294265,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.32,,,,progesterone,,,,,,,,,,,,,,,=,6.32,pKi,,radiometric,COc1cc(Br)cc2c1OCc1c-2ccc2c1C(C)=CC(C)(C)N2,,366.129,385.067741,1,3,1,2,5.6245,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,partial antagonist,16
5298,3360,21269824,7k,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-methoxybenzoic acid",COc1cc(ccc1NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)C(=O)O,CHEMBL1668245,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 740nM,partial agonist,32.00%,agonist,GW4064,,,,,,,EC50,=,10400,nM,,,,,=,6.13076828,pIC50,,radiometric,COc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,32,527.785,553.1579904,2,5,7,4,7.1018,93.45,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
5315,337,14592510,23b,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-[3,5-Di-tert-butyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-6-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C(=C(\C)/c1cc(cc(c1OCC(F)(F)F)C(C)(C)C)C(C)(C)C)\F,CHEMBL335242,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 4.1nM,antagonist,92.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,7.2.,nM,=,8.387216143,pKi,B,radiometric,CC(/C=C/C(F)=C(/C)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)(F)F)=C\C(=O)O,92,424.264,456.2287578,1,2,6,1,7.5103,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
5321,3372,8627601,13,P06401,PR,Homo sapiens,"Acetic acid 5-bromo-4-methoxy-2-(5,5,7-trimethyl-spiro[2.5]oct-7-en-4-ylmethyl)-phenyl ester",COc1cc(CC2C(C)(C)CC(=CC23CC3)C)c(OC(=O)C)cc1Br,CHEMBL50849,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 98nM,partial antagonist,26.00%,antagonist,,,,,,,,EC50,=,2117,nM,IC50,=,160,nM,=,7.008773924,pKi,B,radiometric,COc1cc(CC2C(C)(C)CC(C)=CC23CC3)c(OC(C)=O)cc1Br,26,380.132,406.1143568,0,3,4,1,5.6981,35.53,C1CCC(CC2CCCCC23CC3)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,257
5323,3373,15582409,1e,P37231,PPARG,Homo sapiens,(S)-2-Methoxy-3-{3-methoxy-4-[3-(4-phenoxy-phenoxy)-propoxy]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)c(OC)c1)C(=O)O,CHEMBL180504,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,agonist,87.00%,agonist,standard,,,,,,,EC50,=,185,nM,,,,,=,7.886056648,pIC50,B,radiometric,COc1cc(C[C@H](OC)C(=O)O)ccc1OCCCOc1ccc(Oc2ccccc2)cc1,87,424.279,452.1835032,1,6,13,3,4.9775,83.45,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,468
5325,3373,15582409,1e,Q07869,PPARA,Homo sapiens,(S)-2-Methoxy-3-{3-methoxy-4-[3-(4-phenoxy-phenoxy)-propoxy]-phenyl}-propionic acid,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)c(OC)c1)C(=O)O,CHEMBL180504,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1349nM,partial agonist,35.00%,agonist,standard,,,,,,,EC50,=,2152,nM,,,,,=,5.86998805,pIC50,,radiometric,COc1cc(C[C@H](OC)C(=O)O)ccc1OCCCOc1ccc(Oc2ccccc2)cc1,35,424.279,452.1835032,1,6,13,3,4.9775,83.45,C1CCC(CCCCCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,468
5347,338,12951091,3,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-6-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C(=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C)\F,CHEMBL111217,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 7.8nM,antagonist,87.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,6.8,nM,=,8.107905397,pKi,B,radiometric,CC(/C=C/C(F)=C(/C)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F)=C\C(=O)O,87,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
5348,338,14592510,23a,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-6-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C(=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C)\F,CHEMBL111217,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 7.8nM,antagonist,87.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,6.8,nM,=,8.107905397,pKi,B,radiometric,CC(/C=C/C(F)=C(/C)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F)=C\C(=O)O,87,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
5367,3387,21510635,"3, Candidachalcone",P03372,ERA,Homo sapiens,"(E)-1-(2,4-dihydroxy-3-((Z)-3-hydroxy-3-methylbut-1-enyl)-6-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one",COc1cc(O)c(\C=C/C(C)(C)O)c(O)c1C(=O)\C=C\c2ccc(O)cc2,CHEMBL1784260,,,Fluorescence polarization (FP) competition binding assay,IC50 = 80000nM,agonist,95.10%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,=,4.096910013,pIC50,NB,FPA,COc1cc(O)c(/C=C\C(C)(C)O)c(O)c1C(=O)/C=C/c1ccc(O)cc1,95.1,348.225,370.1416384,4,6,6,2,3.4922,107.22,CC(CCC1CCCCC1)C1CCCCC1,,agonist,,agonist,1139
5368,3388,21510635,"2, Tephrocandidin B",P03372,ERA,Homo sapiens,"2,3-Dihydro-7-hydroxy-8-[(Z)-3-hydroxy-3-methylbut-1-enyl-2-(4-hydroxyphenyl]-5-methoxychromen-4-one",COc1cc(O)c(\C=C/C(C)(C)O)c2OC(CC(=O)c12)c3ccc(O)cc3,CHEMBL1784259,,,Fluorescence polarization (FP) competition binding assay,IC50 = 1000000nM,agonist,86.10%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,=,3,pIC50,NB,FPA,COc1cc(O)c(/C=C\C(C)(C)O)c2c1C(=O)CC(c1ccc(O)cc1)O2,86.1,348.225,370.1416384,3,6,4,2,3.597,96.22,CC1CC(C2CCCCC2)CC2CCCCC12,,agonist,,agonist,663
5369,3389,21510635,"1, Tephrocandidin A",P03372,ERA,Homo sapiens,"(S,Z)-7-hydroxy-8-(3-hydroxy-3-methylbut-1-enyl)-5-methoxy-2-phenylchroman-4-one",COc1cc(O)c(\C=C/C(C)(C)O)c2O[C@@H](CC(=O)c12)c3ccccc3,CHEMBL1784258,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3500000nM,partial agonist,70.10%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,=,2.455931956,pIC50,NB,FPA,COc1cc(O)c(/C=C\C(C)(C)O)c2c1C(=O)C[C@@H](c1ccccc1)O2,70.1,332.226,354.1467238,2,5,4,2,3.8914,75.99,CC1CC(C2CCCCC2)CC2CCCCC12,,partial agonist,,partial agonist,663
5373,339,12954061,49,P19793,RXRA,Homo sapiens,"5-{2-[3,5-Diisopropyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopent-1-enyl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)(F)F)c(c1)C2=C(CCC2)\C=C\C(=C\C(=O)O)\C,CHEMBL337719,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.0nM,antagonist,79.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,2.3,nM,=,9,pKi,B,radiometric,CC(/C=C/C1=C(c2cc(C(C)C)cc(C(C)C)c2OCC(F)(F)F)CCC1)=C\C(=O)O,79,405.266,436.2225295,1,2,8,1,7.3991,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
5386,3394,23232056,"1, SR-9805",P51449,RORG,Homo sapiens,"3-(benzo[d][1,3]dioxol-5-yl)-1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one",COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c3ccc4OCOc4c3)c(OC)c1,CHEMBL2312113,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of [3H2]T0901317 from the ligand-binding domain (LBD) ,IC50 = 57nM,antagonist,95.00%,antagonist,DMSO,10000nM,T0901317,5nM,,,,,,,,IC50,=,76,nM,=,7.244125144,pIC50,B,radiometric,COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccc3c(c2)OCO3)c(OC)c1,95,410.276,441.2151377,1,6,6,2,4.1646,77.46,CC(CC(C1CCCCC1)C1CCC2CCCC2C1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1130
5387,3395,23232056,8,P51449,RORG,Homo sapiens,"1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(2-methoxyphenyl)propan-1-one",COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c3ccccc3OC)c(OC)c1,CHEMBL2312134,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of [3H2]T0901317 from the ligand-binding domain (LBD) ,IC50 = 106nM,antagonist,96.00%,antagonist,DMSO,10000nM,T0901317,5nM,,,,,,,,IC50,=,265,nM,=,6.974694135,pIC50,,radiometric,COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccccc2OC)c(OC)c1,96,394.277,427.2358732,1,5,7,2,4.4445,68.23,CC(CC(C1CCCCC1)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1140
5394,3399,16610787,1ab,Q92731,ERB,Homo sapiens,5-hydroxy-3-(4-hydroxyphenyl)-7-methoxy-4(3H)-quinazolinone,COc1cc(O)c2C(=O)N(C=Nc2c1)c3ccc(O)cc3,CHEMBL379213,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9525nM,partial agonist,47.00%,agonist,,,E1,11nM,,,,,,,,,,,,=,5.021135016,pIC50,,radiometric,COc1cc(O)c2c(=O)n(-c3ccc(O)cc3)cnc2c1,47,272.175,284.0797069,2,6,2,3,1.8055,84.58,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
5400,340,12954061,25b,P19793,RXRA,Homo sapiens,"5-{2-[2-(2,2-Difluoro-ethoxy)-3,5-diisopropyl-phenyl]-cyclopent-1-enyl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)C2=C(CCC2)\C=C\C(=C\C(=O)O)\C,CHEMBL340074,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.9nM,partial antagonist,38.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,5.1,nM,=,9.045757491,pKi,B,radiometric,CC(/C=C/C1=C(c2cc(C(C)C)cc(C(C)C)c2OCC(F)F)CCC1)=C\C(=O)O,38,386.268,418.2319513,1,2,9,1,7.1019,46.53,C1CCC(C2CCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,129
5415,3405,19349176,(S)-2Ae,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(2-(3,5-dimethoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-methoxypropanoic acid",CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3cc(OC)cc(OC)c3)c4ccsc14)C(=O)O,CHEMBL521007,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,44.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,23,nM,,,,,=,8.522878745,pIC50,B,radiometric,COc1cc(OC)cc(-c2nc(CCOc3ccc(C[C@H](OC)C(=O)O)c4sccc34)c(C)o2)c1,44,470.353,497.1508232,1,8,11,4,5.14552,100.25,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
5416,3405,19349176,(S)-2Ae,Q07869,PPARA,Homo sapiens,"(S)-3-(4-(2-(2-(3,5-dimethoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-methoxypropanoic acid",CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3cc(OC)cc(OC)c3)c4ccsc14)C(=O)O,CHEMBL521007,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 48nM,agonist,196.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,61,nM,,,,,=,7.318758763,pIC50,B,radiometric,COc1cc(OC)cc(-c2nc(CCOc3ccc(C[C@H](OC)C(=O)O)c4sccc34)c(C)o2)c1,196,470.353,497.1508232,1,8,11,4,5.14552,100.25,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
5450,342,12954061,40,P19793,RXRA,Homo sapiens,"5-[3',5'-Di-tert-butyl-2'-(3-fluoro-propoxy)-biphenyl-2-yl]-3-methyl-penta-2,4-dienoic acid",C\C(=C/C(=O)O)\C=C\c1ccccc1c2cc(cc(c2OCCCF)C(C)(C)C)C(C)(C)C,CHEMBL129976,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 20.9nM,antagonist,88.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,46.3,nM,=,7.679853714,pKi,B,radiometric,CC(/C=C/c1ccccc1-c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCCCF)=C\C(=O)O,88,415.314,452.2726733,1,2,8,2,7.7311,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
5458,3421,15115388,18,P04150,GR,Homo sapiens,"((R)-3,4-Difluoro-5-methoxy-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",COc1cc(cc(F)c1F)[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5,CHEMBL313062,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.9nM,agonist,76.60%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,14.4,nM,,,,,=,8.721246399,pIC50,B,radiometric,COc1cc([C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)cc(F)c1F,76.6,429.292,454.1868127,1,4,4,3,5.7777,47.28,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
5459,3421,15808489,2,P04150,GR,Homo sapiens,"(R)-(3,4-Difluoro-5-methoxy-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",COc1cc(cc(F)c1F)[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5,CHEMBL313062,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.9nM,agonist,77.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,14.4,nM,,,,,=,8.721246399,pIC50,B,radiometric,COc1cc([C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)cc(F)c1F,77,429.292,454.1868127,1,4,4,3,5.7777,47.28,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
5463,3422,15115388,16,P04150,GR,Homo sapiens,"((R)-4-Fluoro-3-methoxy-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",COc1cc(ccc1F)[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5,CHEMBL313400,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.9nM,partial agonist,66.70%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,31.3,nM,,,,,=,8.102372909,pIC50,B,radiometric,COc1cc([C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)ccc1F,66.7,410.294,436.1962345,1,4,4,3,5.6386,47.28,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
5481,343,12954061,39a,P19793,RXRA,Homo sapiens,"5-[2'-(2,2-Difluoro-ethoxy)-3',5'-diisopropyl-biphenyl-2-yl]-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)c2ccccc2\C=C\C(=C\C(=O)O)\C,CHEMBL130230,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 29.6nM,antagonist,81.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,79.9,nM,=,7.528708289,pKi,B,radiometric,CC(/C=C/c1ccccc1-c1cc(C(C)C)cc(C(C)C)c1OCC(F)F)=C\C(=O)O,81,398.279,428.2163013,1,2,9,2,7.2884,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
5494,3438,18513967,"14, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(4-methoxy-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",COc1ccc(c2cc(C)c3NC(C)(C)CC(C)c3c2Cl)c4[nH]ccc14,CHEMBL404640,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 110nM,antagonist,88.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,67,nM,=,6.958607315,pKi,,radiometric,COc1ccc(-c2cc(C)c3c(c2Cl)C(C)CC(C)(C)N3)c2[nH]ccc12,88,343.708,368.1655411,2,2,2,3,6.50302,37.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,antagonist,antagonist,antagonist,antagonist,37
5501,344,12954061,39b,P19793,RXRA,Homo sapiens,"5-[2'-(3-Fluoro-propoxy)-3',5'-diisopropyl-biphenyl-2-yl]-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCCCF)c(c1)c2ccccc2\C=C\C(=C\C(=O)O)\C,CHEMBL445634,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15.2nM,antagonist,87.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,49.6,nM,=,7.818156412,pKi,B,radiometric,CC(/C=C/c1ccccc1-c1cc(C(C)C)cc(C(C)C)c1OCCCF)=C\C(=O)O,87,391.292,424.2413731,1,2,10,2,7.3829,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
5506,3440,21899328,19,P04150,GR,Homo sapiens,"(5S)-2-(4-Methoxyphenyl)-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",COc1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911149,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,antagonist,96.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,105,nM,=,8.920818754,pKi,B,FPA,COc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,96,436.367,458.1412616,1,7,5,4,5.5112,86.23,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
5507,3441,21899328,18,P04150,GR,Homo sapiens,"[(5R)-2-(4-Methoxyphenyl)-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",COc1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911148,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 49.5nM,antagonist,93.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,4360,nM,=,7.305394801,pKi,B,FPA,COc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,93,436.367,458.1412616,1,7,5,4,5.5112,86.23,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
5519,3446,20735001,35,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(4-methoxybiphenyl-3-yl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)c4ccccc4,CHEMBL1254080,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 12nM,agonist,81.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,40,nM,,,,,=,7.920818754,pIC50,B,FPA,COc1ccc(-c2ccccc2)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,81,441.303,468.2024628,2,3,7,4,6.4423,58.14,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
5522,3447,20735001,36,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(2-methoxy-5-pyridin-3-ylphenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)c4ccncc4,CHEMBL1254173,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,78.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,30,nM,,,,,=,8.096910013,pIC50,B,FPA,COc1ccc(-c2ccncc2)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,78,443.299,469.1977117,2,4,7,4,5.8373,71.03,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
5525,3448,20735001,37,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(2-methoxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)c4cncnc4,CHEMBL1254174,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 27nM,agonist,81.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,50,nM,,,,,=,7.568636236,pIC50,B,FPA,COc1ccc(-c2cncnc2)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,81,445.295,470.1929607,2,5,7,4,5.2323,83.92,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
5528,3449,20735001,(R)-37,P04150,GR,Homo sapiens,"(R)-2-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(2-methoxy-5-(pyrimidin-5-yl)phenyl)-4-methylpentan-2-ol",COc1ccc(cc1C(C)(C)C[C@@](O)(Cc2cc3ccncc3[nH]2)C(F)(F)F)c4cncnc4,CHEMBL1254264,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,78.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,20,nM,,,,,=,8.096910013,pIC50,B,FPA,COc1ccc(-c2cncnc2)cc1C(C)(C)C[C@@](O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,78,445.295,470.1929607,2,5,7,4,5.2323,83.92,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
5534,345,12954061,44,P19793,RXRA,Homo sapiens,"5-{3-[3,5-Diisopropyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-pyridin-4-yl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)(F)F)c(c1)c2cnccc2\C=C\C(=C\C(=O)O)\C,CHEMBL130577,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 48.0nM,antagonist,89.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,271.2,nM,=,7.318758763,pKi,B,radiometric,CC(/C=C/c1ccncc1-c1cc(C(C)C)cc(C(C)C)c1OCC(F)(F)F)=C\C(=O)O,89,419.273,447.2021284,1,3,8,2,6.9806,59.42,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
5539,3450,16973358,33,P37231,PPARG,Homo sapiens,2-((6-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL221649,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 17nM,agonist,115.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,5,nM,,,,,=,7.769551079,pKi,B,radiometric,COc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)cc1,115,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
5540,3450,16973358,33,Q07869,PPARA,Homo sapiens,2-((6-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL221649,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 65nM,agonist,96.00%,agonist,GW2331,,GW2331,,,,,EC50,=,486,nM,,,,,=,7.187086643,pKi,B,radiometric,COc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)cc1,96,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
5541,3451,16979341,16,P37231,PPARG,Homo sapiens,2-((5-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221388,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 93nM,agonist,90.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,105,nM,,,,,=,7.031517051,pKi,B,radiometric,COc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)cc1,90,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
5542,3451,16979341,16,Q07869,PPARA,Homo sapiens,2-((5-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221388,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 840nM,agonist,95.00%,agonist,GW2331,,GW2331,,,,,EC50,=,437,nM,,,,,=,6.075720714,pIC50,,radiometric,COc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)cc1,95,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
5557,346,12954061,34,P19793,RXRA,Homo sapiens,"5-{2-[2-(3-Fluoro-propoxy)-3,5-diisopropyl-phenyl]-furan-3-yl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCCCF)c(c1)c2occc2\C=C\C(=C\C(=O)O)\C,CHEMBL335751,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.2nM,antagonist,77.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,11.6,nM,=,8.207608311,pKi,B,radiometric,CC(/C=C/c1ccoc1-c1cc(C(C)C)cc(C(C)C)c1OCCCF)=C\C(=O)O,77,383.269,414.2206377,1,3,10,2,6.9759,59.67,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
5576,3469,21257309,12d,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-methoxyphenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",COc1ccc(cc1)n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc23,CHEMBL1668067,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,partial agonist,63.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.8,pIC50,B,FPA,COc1ccc(-n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc32)cc1,63,460.389,492.2195119,2,6,8,4,5.04668,85.25,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
5580,347,12954061,61,P19793,RXRA,Homo sapiens,"(2E,4E)-5-{3-[3,5-Di-tert-butyl-2-(3,3-difluoro-propoxy)-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",C\C(=C/C(=O)O)\C=C\c1sccc1c2cc(cc(c2OCCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL335762,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.9nM,antagonist,93.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,8.7,nM,=,8.721246399,pKi,B,radiometric,CC(/C=C/c1sccc1-c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCCC(F)F)=C\C(=O)O,93,442.357,476.2196724,1,3,8,2,8.0882,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
5598,3477,22579420,APH 2,P37231,PPARG,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-(4-methoxystyryl)benzene-1,3-diol",COc1ccc(\C=C\c2cc(O)c(C\C=C(/C)\CCC=C(C)C)c(O)c2)cc1,CHEMBL2031856,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 630nM,partial agonist,66.00%,agonist,Troglitazone,,,,,,,EC50,=,14000,nM,,,,,=,6.200659451,pIC50,,other,COc1ccc(/C=C/c2cc(O)c(C/C=C(\C)CCC=C(C)C)c(O)c2)cc1,66,348.272,378.2194948,2,3,8,2,6.512,49.69,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
5599,3477,22579420,APH 2,Q07869,PPARA,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-(4-methoxystyryl)benzene-1,3-diol",COc1ccc(\C=C\c2cc(O)c(C\C=C(/C)\CCC=C(C)C)c(O)c2)cc1,CHEMBL2031856,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 2500nM,partial agonist,63.00%,agonist,Wy14643,,,,,,,EC50,=,19000,nM,,,,,=,5.602059991,pIC50,,other,COc1ccc(/C=C/c2cc(O)c(C/C=C(\C)CCC=C(C)C)c(O)c2)cc1,63,348.272,378.2194948,2,3,8,2,6.512,49.69,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
5605,348,12954061,31c,P19793,RXRA,Homo sapiens,"5-{3-[3,5-Diisopropyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)(F)F)c(c1)c2ccsc2\C=C\C(=C\C(=O)O)\C,CHEMBL132488,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.7nM,antagonist,87.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,10.4,nM,=,8.060480747,pKi,B,radiometric,CC(/C=C/c1sccc1-c1cc(C(C)C)cc(C(C)C)c1OCC(F)(F)F)=C\C(=O)O,87,425.322,452.1633004,1,3,8,2,7.6471,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
5610,3480,17553679,30,P04150,GR,Homo sapiens,"(Z)-5-(4-methoxybenzylidene)-10-methoxy-2,2,4-trimethyl-2,4a,5,12a-tetrahydro-1H-chromeno[3,4-f]quinolin-9-ol",COc1ccc(\C=C\2/Oc3ccc(O)c(OC)c3c4ccc5NC(C)(C)C=C(C)c5c24)cc1,CHEMBL3706957,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.7nM,agonist,133.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,133,nM,Efficacy,<,10%,,=,8.568636236,pKi,B,radiometric,COc1ccc(/C=C2\Oc3ccc(O)c(OC)c3-c3ccc4c(c32)C(C)=CC(C)(C)N4)cc1,133,414.311,441.1940083,2,5,3,3,6.5743,59.95,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
5625,349,12954061,31a,P19793,RXRA,Homo sapiens,"5-{3-[2-(2,2-Difluoro-ethoxy)-3,5-diisopropyl-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)c2ccsc2\C=C\C(=C\C(=O)O)\C,CHEMBL340555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.2nM,partial antagonist,42.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,11.4,nM,=,8.657577319,pKi,B,radiometric,CC(/C=C/c1sccc1-c1cc(C(C)C)cc(C(C)C)c1OCC(F)F)=C\C(=O)O,42,406.324,434.1727222,1,3,9,2,7.3499,46.53,C1CCC(C2CCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,129
5637,3494,18701276,7f,P37231,PPARG,Homo sapiens,"(S)-2-(4-fluoro-3-((3-(4-methoxybenzoyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3cc(O[C@@H](C)C(=O)O)ccc3F)c4nc(C)ccc24,CHEMBL509236,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,partial agonist,27.00%,agonist,Rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,8.397940009,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3cc(O[C@@H](C)C(=O)O)ccc3F)c3nc(C)ccc23)cc1,27,451.304,476.1747501,1,6,8,4,4.93204,90.65,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5639,3496,18701276,7c,P37231,PPARG,Homo sapiens,"(S)-2-(4-fluoro-3-((3-(4-methoxybenzoyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3cc(O[C@@H](C)C(=O)O)ccc3F)c4ncccc24,CHEMBL455127,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,partial agonist,43.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,8.301029996,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3cc(O[C@@H](C)C(=O)O)ccc3F)c3ncccc23)cc1,43,439.293,462.1591001,1,6,8,4,4.62362,90.65,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5641,3498,18701276,7h,P37231,PPARG,Homo sapiens,"(S)-2-(2-fluoro-5-((6-methoxy-3-(4-methoxybenzoyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3ccc(F)c(O[C@@H](C)C(=O)O)c3)c4nc(OC)ccc24,CHEMBL460072,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,partial agonist,29.00%,agonist,Rosiglitazone,,,,,,,EC50,=,1,nM,,,,,=,9,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3ccc(F)c(O[C@@H](C)C(=O)O)c3)c3nc(OC)ccc23)cc1,29,467.303,492.1696647,1,7,9,4,4.63222,99.88,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5642,3499,18701276,7d,P37231,PPARG,Homo sapiens,"(S)-2-(2-fluoro-5-((3-(4-methoxybenzoyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3ccc(F)c(O[C@@H](C)C(=O)O)c3)c4ncccc24,CHEMBL507477,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,47.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,8,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3ccc(F)c(O[C@@H](C)C(=O)O)c3)c3ncccc23)cc1,47,439.293,462.1591001,1,6,8,4,4.62362,90.65,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5647,350,12954061,31b,P19793,RXRA,Homo sapiens,"5-{3-[2-(3-Fluoro-propoxy)-3,5-diisopropyl-phenyl]-thiophen-2-yl}-3-methyl-penta-2,4-dienoic acid",CC(C)c1cc(C(C)C)c(OCCCF)c(c1)c2ccsc2\C=C\C(=C\C(=O)O)\C,CHEMBL131561,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.4nM,antagonist,79.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,6.8,nM,=,8.468521083,pKi,B,radiometric,CC(/C=C/c1sccc1-c1cc(C(C)C)cc(C(C)C)c1OCCCF)=C\C(=O)O,79,399.337,430.1977941,1,3,10,2,7.4444,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
5653,3501,18701276,7e,P37231,PPARG,Homo sapiens,"(S)-2-(3-((3-(4-methoxybenzoyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c4nc(C)ccc24,CHEMBL510180,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 16nM,partial agonist,35.00%,agonist,Rosiglitazone,,,,,,,EC50,=,9,nM,,,,,=,7.795880017,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3nc(C)ccc23)cc1,35,432.306,458.1841719,1,6,8,4,4.79294,90.65,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5654,3502,18701276,7b,P37231,PPARG,Homo sapiens,"(S)-2-(3-((3-(4-methoxybenzoyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",COc1ccc(cc1)C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c4ncccc24,CHEMBL455126,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 66nM,partial agonist,32.00%,agonist,Rosiglitazone,,,,,,,EC50,=,27,nM,,,,,=,7.180456064,pIC50,B,radiometric,COc1ccc(C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3ncccc23)cc1,32,420.295,444.1685219,1,6,8,4,4.48452,90.65,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5664,3508,15603954,24,P37231,PPARG,Homo sapiens,(S)-2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c4cc(OC(F)(F)F)ccc24,CHEMBL179330,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,,21.00%,agonist,Rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,9,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3cc(OC(F)(F)F)ccc32)cc1,21,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,,agonist,partial agonist,866
5665,3508,15863293,11,P37231,PPARG,Homo sapiens,(S)-2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c4cc(OC(F)(F)F)ccc24,CHEMBL179330,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,28.00%,agonist,Rosiglitazone,,,,,,,EC50,=,1,nM,,,,,=,8.698970004,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3cc(OC(F)(F)F)ccc32)cc1,28,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5666,3508,19507861,1,P37231,PPARG,Homo sapiens,(S)-2-(3-((1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl)methyl)phenoxy)propanoic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c4cc(OC(F)(F)F)ccc24,CHEMBL179330,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,partial agonist,36.00%,agonist,rosiglitazone,194nM,TZD3 ,,,,,EC50,=,2,nM,,,,,=,9,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3cc(OC(F)(F)F)ccc32)cc1,36,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5669,3509,15603954,25,P37231,PPARG,Homo sapiens,(R)-2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3cccc(O[C@H](C)C(=O)O)c3)c4cc(OC(F)(F)F)ccc24,CHEMBL359548,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3nM,partial agonist,34.00%,agonist,Rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,8.522878745,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3cccc(O[C@H](C)C(=O)O)c3)c3cc(OC(F)(F)F)ccc32)cc1,34,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5672,351,21316964,(+/-)-20,P04150,GR,Homo sapiens,"(+/-)-4-((3R,4S)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-5-yl)but-3-en-2-one",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(\C=C\C(=O)C)c12)c3cccc4cc[nH]c34,CHEMBL1682430,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10.4nM,agonist,168.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,112,nM,,,,,=,7.982966661,pKi,B,radiometric,CC(=O)/C=C/c1c(-c2cccc3cc[nH]c23)cc(C)c2c1[C@H](C)[C@@H](O)C(C)(C)N2,168,360.287,388.2150781,3,3,3,3,5.41402,65.12,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
5673,3510,15603954,22,P37231,PPARG,Homo sapiens,2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-2-methyl-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3ccccc3OC(C)(C)C(=O)O)c4cc(OC(F)(F)F)ccc24,CHEMBL361395,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,agonist,75.00%,agonist,Rosiglitazone,,,,,,,EC50,=,50,nM,,,,,=,9,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3ccccc3OC(C)(C)C(=O)O)c3cc(OC(F)(F)F)ccc32)cc1,75,515.314,541.1712222,1,6,8,4,6.37822,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,agonist,agonist,agonist,866
5674,3511,15603954,18,P37231,PPARG,Homo sapiens,2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3ccccc3OC(C)C(=O)O)c4cc(OC(F)(F)F)ccc24,CHEMBL181628,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,agonist,83.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,9,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3ccccc3OC(C)C(=O)O)c3cc(OC(F)(F)F)ccc32)cc1,83,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,agonist,agonist,agonist,866
5675,3512,15603954,20,P37231,PPARG,Homo sapiens,(S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3ccccc3O[C@@H](C)C(=O)O)c4cc(OC(F)(F)F)ccc24,CHEMBL181937,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,agonist,97.00%,agonist,Rosiglitazone,,,,,,,EC50,=,2,nM,,,,,=,8.698970004,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3ccccc3O[C@@H](C)C(=O)O)c3cc(OC(F)(F)F)ccc32)cc1,97,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,agonist,agonist,agonist,866
5676,3513,15603954,19,P37231,PPARG,Homo sapiens,(R)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc(cc1)C(=O)n2c(C)c(Cc3ccccc3O[C@H](C)C(=O)O)c4cc(OC(F)(F)F)ccc24,CHEMBL182100,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 23nM,partial agonist,47.00%,agonist,Rosiglitazone,,,,,,,EC50,=,21,nM,,,,,=,7.638272164,pIC50,B,radiometric,COc1ccc(C(=O)n2c(C)c(Cc3ccccc3O[C@H](C)C(=O)O)c3cc(OC(F)(F)F)ccc32)cc1,47,503.303,527.1555721,1,6,8,4,5.98812,86.99,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
5678,3515,23232056,6p,P51449,RORG,Homo sapiens,"1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-1-one",COc1ccc(cc1)C(CC(=O)N2CC(C)CC(C)C2)c3c(O)cc(OC)cc3OC,CHEMBL2312126,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of [3H2]T0901317 from the ligand-binding domain (LBD) ,IC50 = 96nM,antagonist,95.00%,antagonist,DMSO,10000nM,T0901317,5nM,,,,,,,,IC50,=,114,nM,=,7.017728767,pIC50,B,radiometric,COc1ccc(C(CC(=O)N2CC(C)CC(C)C2)c2c(O)cc(OC)cc2OC)cc1,95,394.277,427.2358732,1,5,7,2,4.4445,68.23,CC(CC(C1CCCCC1)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1140
5681,3518,17181172,35,P04150,GR,Homo sapiens,1-[2-hydroxy-4-(5-methoxy-2-methylphenyl)-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,COc1ccc(C)c(c1)C(C)(C)CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F,CHEMBL219561,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,17,nM,,,,,=,7.958607315,pIC50,B,FPA,COc1ccc(C)c(C(C)(C)CC(O)(Cn2ccc(=O)c3ccccc32)C(F)(F)F)c1,86,407.262,433.1864784,1,4,6,3,4.97982,51.46,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,agonist,agonist,agonist,807
5685,352,12781197,11,P06401,PR,Homo sapiens,"1-[9-Fluoro-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-aza-chrysen-(5Z)-ylidene]-propan-2-one",CC(=O)\C=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13,CHEMBL65227,,co-transaction assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 100nM,antagonist,91.00%,antagonist,progesterone,,dexamethasone,2.5nM,,,,,,,,IC50,=,124,nM,>,7,pKi,,radiometric,CC(=O)/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,91,329.245,349.1478071,1,3,1,2,5.4224,38.33,CC1CC2CCCCC2C2CCC3CCCCC3C12,antagonist,antagonist,antagonist,antagonist,515
5698,3529,11405642,9,P37231,PPARG,Homo sapiens,"5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)-benzamide",COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc3ccc(cc3)C(F)(F)F,CHEMBL24458,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 463nM,agonist,109.00%,agonist,reference compound (?),,,,,,,EC50,=,1090,nM,,,,,=,6.334419009,pIC50,,radiometric,COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,109,421.291,438.0861127,2,5,6,2,3.5381,84.5,CC1CC(C)C(CC2CCCC(C(C)CCC3CCCCC3)C2)C1,agonist,agonist,agonist,agonist,799
5699,3529,15293980,6,P37231,PPARG,Homo sapiens,"5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)-benzamide",COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc3ccc(cc3)C(F)(F)F,CHEMBL24458,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 330nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,800,nM,,,,,=,6.48148606,pIC50,,radiometric,COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,,421.291,438.0861127,2,5,6,2,3.5381,84.5,CC1CC(C)C(CC2CCCC(C(C)CCC3CCCCC3)C2)C1,agonist,,agonist,agonist,799
5700,3529,11405642,9,Q07869,PPARA,Homo sapiens,"5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)-benzamide",COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc3ccc(cc3)C(F)(F)F,CHEMBL24458,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 914nM,partial agonist,54.00%,agonist,reference compound (?),,,,,,,EC50,=,922,nM,,,,,=,6.039053804,pIC50,,radiometric,COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,54,421.291,438.0861127,2,5,6,2,3.5381,84.5,CC1CC(C)C(CC2CCCC(C(C)CCC3CCCCC3)C2)C1,agonist,partial agonist,agonist,partial agonist,799
5701,3529,15293980,6,Q07869,PPARA,Homo sapiens,"5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-methoxy-N-(4-trifluoromethyl-benzyl)-benzamide",COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc3ccc(cc3)C(F)(F)F,CHEMBL24458,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 230nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,1000,nM,,,,,=,6.638272164,pKi,,radiometric,COc1ccc(CC2SC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,,421.291,438.0861127,2,5,6,2,3.5381,84.5,CC1CC(C)C(CC2CCCC(C(C)CCC3CCCCC3)C2)C1,agonist,,agonist,partial agonist,799
5702,353,17267219,(+/-)-6x,P10275,AR,Homo sapiens,"(+/-)-6-((3-oxobutan-2-yl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F)C(=O)C,CHEMBL3706931,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.1nM,partial agonist,69.00%,agonist,DHT,,,,,,,EC50,=,5.8,nM,IC50,>,10000,nM,=,8.508638306,pIC50,B,radiometric,CC(=O)C(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,69,366.176,380.095947,1,3,4,2,3.8931,53.17,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
5706,3532,20005711,7t,P55055,LXRB,Homo sapiens,"3-(3-(8-chloro-2-isopropylimidazo[1,2-a]pyridin-3-yl)phenoxy)-N-(4-methoxybenzyl)-N-methylbenzenesulfonamide",COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(c3)c4c(nc5c(Cl)cccn45)C(C)C)c2)cc1,CHEMBL595915,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,partial agonist,48.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,890,nM,,,,,=,7.619788758,pIC50,B,radiometric,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,48,545.878,575.1645551,0,6,9,5,7.3997,73.14,CC(C)(CCC1CCCCC1)C1CCCC(CC2CCCC(C3CCC4CCCCC43)C2)C1,agonist,partial agonist,agonist,partial agonist,1216
5707,3532,20005711,7t,Q13133,LXRA,Homo sapiens,"3-(3-(8-chloro-2-isopropylimidazo[1,2-a]pyridin-3-yl)phenoxy)-N-(4-methoxybenzyl)-N-methylbenzenesulfonamide",COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(c3)c4c(nc5c(Cl)cccn45)C(C)C)c2)cc1,CHEMBL595915,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 71nM,partial agonist,47.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,930,nM,,,,,=,7.148741651,pIC50,B,radiometric,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,47,545.878,575.1645551,0,6,9,5,7.3997,73.14,CC(C)(CCC1CCCCC1)C1CCCC(CC2CCCC(C3CCC4CCCCC43)C2)C1,agonist,partial agonist,agonist,partial agonist,1216
5713,3537,10743937,14,P10275,AR,Homo sapiens,"(8,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-pyrido[3,2-g]quinolin-2-yl)-(4-methoxy-benzyl)-amine",COc1ccc(CNc2cc(c3cc4CCC(C)(C)Nc4cc3n2)C(F)(F)F)cc1,CHEMBL134117,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,partial antagonist,57.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,3217,nM,>,6,pKi,,other,COc1ccc(CNc2cc(C(F)(F)F)c3cc4c(cc3n2)NC(C)(C)CC4)cc1,57,391.267,415.187147,2,4,4,3,6.011,46.18,C1CCC(CCC2CCC3CC4CCCCC4CC3C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,308
5719,354,12781197,MPA,P06401,PR,Homo sapiens,"(6S,8S,10R,14S,15S)-17-Acetyl-6,10-dimethyl-13-(R)-methyl-17-(2-oxo-propyl)-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",C[C@H]1CC2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(CC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL292284,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,80.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,0.15,nM,,,,,=,9.468521083,pKi,B,radiometric,CC(=O)C[C@]1(C(C)=O)CC[C@H]2C3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,80,348.272,384.266445,0,3,3,0,5.3188,51.21,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
5745,3547,24656565,2,P04150,GR,Homo sapiens,"4-(5-fluoro-2-methoxyphenyl)-2,4-dimethyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(C)(O)Cc2cc3ccncc3[nH]2,CHEMBL3233269,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 230nM,partial agonist,35.00%,agonist,,,,,,,,IC50,>,2000,nM,,,,,=,6.638272164,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)CC(C)(O)Cc1cc2ccncc2[nH]1,35,331.241,356.1900063,2,3,6,3,4.372,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,,partial agonist,,partial agonist,420
5770,3553,17181172,24,P04150,GR,Homo sapiens,"1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-2,3-dihydro-1H-quinolin-4-one",COc1ccc(F)cc1C(C)(C)CC(O)(CN2CCC(=O)c3ccccc23)C(F)(F)F,CHEMBL219314,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,partial agonist,72.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,110,nM,,,,,=,8.397940009,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CN1CCC(=O)c2ccccc21)C(F)(F)F,72,414.249,439.1770565,1,4,6,2,4.8884,49.77,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,partial agonist,agonist,partial agonist,807
5782,3557,17181172,14,P04150,GR,Homo sapiens,"cis-1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-3,5-dimethylpiperidin-4-one",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C[C@@H](C)C(=O)[C@@H](C)C2)C(F)(F)F,CHEMBL216273,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,89.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,75,nM,,,,,=,8,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CN1C[C@H](C)C(=O)[C@H](C)C1)C(F)(F)F,89,390.227,419.2083567,1,4,6,1,3.9523,49.77,CC1CCC(CCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,808
5785,3558,17181172,19,P04150,GR,Homo sapiens,"2-[(trans-2,6-dimethylmorpholin-4-yl)methyl]-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C[C@H](C)O[C@@H](C)C2)C(F)(F)F,CHEMBL218830,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,partial agonist,41.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,>,2000,nM,,,,,=,6.958607315,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CN1C[C@H](C)O[C@@H](C)C1)C(F)(F)F,41,378.216,407.2083567,1,4,6,1,3.9046,41.93,C1CCC(CCCCC2CCCCC2)CC1,,partial agonist,,partial agonist,441
5788,3559,17181172,20,P04150,GR,Homo sapiens,"2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C[C@@H](C)O[C@@H](C)C2)C(F)(F)F,CHEMBL375348,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 38nM,partial agonist,72.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,270,nM,,,,,=,7.420216403,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CN1C[C@H](C)O[C@H](C)C1)C(F)(F)F,72,378.216,407.2083567,1,4,6,1,3.9046,41.93,C1CCC(CCCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,441
5791,356,26238323,12,P55055,LXRB,Homo sapiens,tert-butyl 2-hydroxy-6-((4-(N-methylacetamido)phenoxy)methyl)-3-(trifluoromethyl)benzoate,CN(C(=O)C)c1ccc(OCc2ccc(c(O)c2C(=O)OC(C)(C)C)C(F)(F)F)cc1,CHEMBL3609363,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 1700nM,agonist,76.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,260,nM,,,,,=,5.769551079,pKi,,FPA,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,76,415.238,439.1606575,1,5,5,2,4.928,76.07,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
5792,356,26238323,12,Q13133,LXRA,Homo sapiens,tert-butyl 2-hydroxy-6-((4-(N-methylacetamido)phenoxy)methyl)-3-(trifluoromethyl)benzoate,CN(C(=O)C)c1ccc(OCc2ccc(c(O)c2C(=O)OC(C)(C)C)C(F)(F)F)cc1,CHEMBL3609363,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 270nM,agonist,89.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,280,nM,,,,,=,6.568636236,pKi,,FPA,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,89,415.238,439.1606575,1,5,5,2,4.928,76.07,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
5793,3560,17616395,250,P04150,GR,Homo sapiens,(S)-5-amino-N-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide,COc1ccc(F)cc1C(C)(C)CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3)C(F)(F)F,CHEMBL235208,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.26,agonist,103.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.92,,,,,,=,8.26,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F,103,487.279,512.1846818,3,6,8,3,4.1324,102.4,CC(CCCCCC1CCCCC1)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,"agonist,partial agonist",1301
5794,3560,17616395,2500,P04150,GR,Homo sapiens,(S)-5-amino-N-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide,COc1ccc(F)cc1C(C)(C)CC(O)(CNC(=O)c2cnn(c2N)c3ccc(F)cc3)C(F)(F)F,CHEMBL235208,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.17,partial agonist,70.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.8,,,,,,=,8.17,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F,70,487.279,512.1846818,3,6,8,3,4.1324,102.4,CC(CCCCCC1CCCCC1)C1CCC(C2CCCCC2)C1,agonist,partial agonist,agonist,"agonist,partial agonist",1301
5799,3562,16112571,31,P04150,GR,Homo sapiens,5-[2-Benzyl-4-(5-fluoro-2-methoxy-phenyl)-2-hydroxy-4-methyl-pentylamino]-3H-isobenzofuran-1-one,COc1ccc(F)cc1C(C)(C)CC(O)(CNc2ccc3C(=O)OCc3c2)Cc4ccccc4,CHEMBL197100,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 81nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,610,nM,=,7.091514981,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(CNc1ccc2c(c1)COC2=O)Cc1ccccc1,100,433.309,463.2158867,2,5,9,3,5.2583,67.79,CC1CCC2CC(CCC(CCC3CCCCC3)CC3CCCCC3)CCC12,antagonist,antagonist,antagonist,antagonist,686
5821,3568,17692519,40,P04150,GR,Homo sapiens,"4-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-2,6-dimethylbenzonitrile",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc(C)c(C#N)c(C)c2)C(F)(F)F,CHEMBL236755,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,agonist,95.00%,agonist,dexamethasone,,,,,,,EC50,=,4,nM,,,,,=,7.958607315,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc(C)c(C#N)c(C)c1)C(F)(F)F,95,398.25,423.1821419,1,3,6,2,5.52662,53.25,C1CCC(CCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,441
5824,3569,17692519,26,P04150,GR,Homo sapiens,"2-(3,5-dimethylbenzyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc(C)cc(C)c2)C(F)(F)F,CHEMBL393392,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 55nM,partial agonist,55.00%,agonist,dexamethasone,,,,,,,EC50,=,280,nM,,,,,=,7.259637311,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc(C)cc(C)c1)C(F)(F)F,55,372.232,398.186893,1,2,6,2,5.65494,29.46,C1CCC(CCCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,441
5827,357,26238323,4,P55055,LXRB,Homo sapiens,tert-butyl 2-((4-(N-methylacetamido)phenoxy)methyl)-5-(trifluoromethyl)benzoate,CN(C(=O)C)c1ccc(OCc2ccc(cc2C(=O)OC(C)(C)C)C(F)(F)F)cc1,CHEMBL3609362,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 180nM,partial agonist,28.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,210,nM,,,,,=,6.744727495,pKi,,FPA,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,28,399.239,423.1657429,0,4,5,2,5.2224,55.84,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
5828,357,26238323,4,Q13133,LXRA,Homo sapiens,tert-butyl 2-((4-(N-methylacetamido)phenoxy)methyl)-5-(trifluoromethyl)benzoate,CN(C(=O)C)c1ccc(OCc2ccc(cc2C(=O)OC(C)(C)C)C(F)(F)F)cc1,CHEMBL3609362,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 870nM,partial agonist,27.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,310,nM,,,,,=,6.060480747,pKi,,FPA,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,27,399.239,423.1657429,0,4,5,2,5.2224,55.84,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
5829,3570,17692519,41,P04150,GR,Homo sapiens,"2-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-4,6-dimethylbenzonitrile",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc(C)cc(C)c2C#N)C(F)(F)F,CHEMBL392501,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,83.00%,agonist,dexamethasone,,,,,,,EC50,=,40,nM,,,,,=,8.096910013,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc(C)cc(C)c1C#N)C(F)(F)F,83,398.25,423.1821419,1,3,6,2,5.52662,53.25,C1CCC(CCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,441
5832,3571,17692519,33,P04150,GR,Homo sapiens,"2-(3-chloro-5-methylbenzyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc(C)cc(Cl)c2)C(F)(F)F,CHEMBL392499,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 46nM,agonist,79.00%,agonist,dexamethasone,,,,,,,EC50,=,125,nM,,,,,=,7.337242168,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc(C)cc(Cl)c1)C(F)(F)F,79,395.674,418.1322705,1,2,6,2,5.99992,29.46,C1CCC(CCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,441
5835,3572,17692519,34,P04150,GR,Homo sapiens,3-chloro-5-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)benzonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc(Cl)cc(c2)C#N)C(F)(F)F,CHEMBL235689,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 27nM,partial agonist,46.00%,agonist,dexamethasone,,,,,,,EC50,>,2000,nM,,,,,=,7.568636236,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc(Cl)cc(C#N)c1)C(F)(F)F,46,409.681,429.1118694,1,3,6,2,5.56318,53.25,C1CCC(CCCCC2CCCCC2)CC1,,partial agonist,,partial agonist,441
5844,3575,21963986,16,P04150,GR,Homo sapiens,rac-2-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-indole-4-carbonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3c(cccc3[nH]2)C#N)C(F)(F)F,CHEMBL1911644,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,91.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,8,nM,,,,,=,8.301029996,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C#N)cccc2[nH]1)C(F)(F)F,91,412.257,434.1617408,2,3,6,3,5.39108,69.04,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5847,3576,21963986,15,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((4-(trifluoromethyl)-1H-indol-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3c(cccc3[nH]2)C(F)(F)F)C(F)(F)F,CHEMBL1911549,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 160nM,partial agonist,70.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,290,nM,,,,,=,6.795880017,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C(F)(F)F)cccc2[nH]1)C(F)(F)F,70,455.244,477.1538765,2,2,6,3,6.5382,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
5850,3577,21963986,14,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((4-methyl-1H-indol-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3c(C)cccc3[nH]2)C(F)(F)F,CHEMBL1911548,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 30nM,agonist,91.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,6,nM,,,,,=,7.522878745,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cccc2[nH]1)C(F)(F)F,91,398.25,423.1821419,2,2,6,3,5.82782,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5853,3578,21963986,21,P04150,GR,Homo sapiens,rac-2-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-indole-5-carbonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ccc3[nH]2)C#N)C(F)(F)F,CHEMBL1911649,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,89.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,11,nM,,,,,=,8.096910013,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C#N)ccc2[nH]1)C(F)(F)F,89,412.257,434.1617408,2,3,6,3,5.39108,69.04,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5856,3579,21963986,20,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ccc3[nH]2)C(F)(F)F)C(F)(F)F,CHEMBL1911648,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 290nM,agonist,77.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,191,nM,,,,,=,6.537602002,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(F)(F)F)ccc2[nH]1)C(F)(F)F,77,455.244,477.1538765,2,2,6,3,6.5382,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5860,3580,21963986,19,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-methyl-1H-indol-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(C)ccc3[nH]2)C(F)(F)F,CHEMBL1911647,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 66nM,agonist,86.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,113,nM,,,,,=,7.180456064,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)ccc2[nH]1)C(F)(F)F,86,398.25,423.1821419,2,2,6,3,5.82782,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5865,3582,21963986,18,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-2-((5-fluoro-1H-indol-2-yl)methyl)-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(F)ccc3[nH]2)C(F)(F)F,CHEMBL1911646,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 24nM,agonist,84.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,78,nM,,,,,=,7.619788758,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(F)ccc2[nH]1)C(F)(F)F,84,405.237,427.15707,2,2,6,3,5.6585,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5868,3583,25516791,23,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)N4CCOCC4)C(F)(F)F,CHEMBL3358935,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,agonist,95.00%,agonist,dexamethasone,,,,,,,IC50,=,2,nM,,,,,=,8.698970004,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F,95,466.285,495.2145047,2,5,7,3,4.751,70.61,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
5869,3584,25516791,19,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)S(=O)(=O)C)C(F)(F)F,CHEMBL3358931,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 28nM,partial agonist,40.00%,agonist,dexamethasone,,,,,,,IC50,>,2000,nM,,,,,=,7.552841969,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F,40,464.311,488.1392911,2,5,7,3,4.3179,92.28,C1CCC(CCCCC2CC3CCCCC3C2)CC1,,partial agonist,,partial agonist,420
5874,3586,21963986,25,P04150,GR,Homo sapiens,rac-2-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-indole-6-carbonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccc(cc3[nH]2)C#N)C(F)(F)F,CHEMBL1911654,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 14nM,agonist,91.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,14,nM,,,,,=,7.853871964,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccc(C#N)cc2[nH]1)C(F)(F)F,91,412.257,434.1617408,2,3,6,3,5.39108,69.04,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5880,3588,21963986,23,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((6-methyl-1H-indol-2-yl)methyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccc(C)cc3[nH]2)C(F)(F)F,CHEMBL1911652,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 38nM,partial agonist,60.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,334,nM,,,,,=,7.420216403,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccc(C)cc2[nH]1)C(F)(F)F,60,398.25,423.1821419,2,2,6,3,5.82782,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
5883,3589,21963986,22,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-2-((6-fluoro-1H-indol-2-yl)methyl)-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccc(F)cc3[nH]2)C(F)(F)F,CHEMBL1911651,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 30nM,agonist,94.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,29,nM,,,,,=,7.522878745,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccc(F)cc2[nH]1)C(F)(F)F,94,405.237,427.15707,2,2,6,3,5.6585,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5886,359,25815138,9,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-2-phenylethanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)CCc4ccccc4)c(F)c2,CHEMBL3581531,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 110nM,inverse agonist,-64.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,310,nM,,,,,=,6.958607315,pIC50,,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)CCc3ccccc3)c(F)c2)CC1,-64,441.358,473.2148411,0,4,8,2,3.4212,60.93,CC(C)(CCC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1224
5896,3593,21963986,10,P04150,GR,Homo sapiens,"rac-1,1,1-trifluoro-2-((7-fluoro-1H-indol-2-yl)methyl)-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cccc(F)c3[nH]2)C(F)(F)F,CHEMBL1911544,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,agonist,75.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,36,nM,,,,,=,7.823908741,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cccc(F)c2[nH]1)C(F)(F)F,75,405.237,427.15707,2,2,6,3,5.6585,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5899,3594,20735001,1,P04150,GR,Homo sapiens,"2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F,CHEMBL1254651,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 21nM,agonist,87.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,6.6,nM,,,,,=,7.677780705,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F,87,386.239,409.1664919,2,2,6,3,5.5194,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5900,3594,21963986,2,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccccc3[nH]2)C(F)(F)F,CHEMBL1254651,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 22nM,agonist,87.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,7,nM,,,,,=,7.657577319,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F,87,386.239,409.1664919,2,2,6,3,5.5194,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5912,3597,24656565,5,P04150,GR,Homo sapiens,"3-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5-(5-fluoro-2-methoxyphenyl)-2,2,5-trimethylhexan-3-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(C)(C)C,CHEMBL3233272,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,87.00%,agonist,,,,,,,,IC50,=,36,nM,,,,,=,8.096910013,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(C)(C)C,87,367.274,398.2369565,2,3,6,3,5.3982,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5915,3598,24656565,4,P04150,GR,Homo sapiens,"3-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5-(5-fluoro-2-methoxyphenyl)-2,5-dimethylhexan-3-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(C)C,CHEMBL3233271,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,partial agonist,62.00%,agonist,,,,,,,,IC50,=,73,nM,,,,,=,8.045757491,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(C)C,62,355.263,384.2213064,2,3,7,3,5.0081,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
5918,3599,20735001,6,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1254734,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.4nM,agonist,92.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,9.8,nM,,,,,=,8.356547324,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,92,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5919,3599,24656565,1a,P04150,GR,Homo sapiens,"2-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1254734,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,agonist,92.00%,agonist,,,,,,,,IC50,=,10,nM,,,,,=,8.397940009,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,92,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5927,360,25815138,23,P51449,RORG,Homo sapiens,"N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-1-(3,5-dichlorophenyl)methanesulfonamide",CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4cc(Cl)cc(Cl)c4)c(F)c2,CHEMBL3581544,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 29nM,inverse agonist,-92.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,40,nM,,,,,=,7.537602002,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3cc(Cl)cc(Cl)c3)c(F)c2)CC1,-92,500.253,527.1212463,0,4,7,2,4.6855,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
5928,3600,24656565,7,P04150,GR,Homo sapiens,"2-cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C4CC4,CHEMBL3233274,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,agonist,87.00%,agonist,,,,,,,,IC50,=,47,nM,,,,,=,7.823908741,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C1CC1,87,355.263,382.2056563,2,3,7,3,4.7621,58.14,C1CCC(CCC(CC2CC3CCCCC3C2)C2CC2)CC1,agonist,agonist,agonist,agonist,417
5931,3601,24656565,8,P04150,GR,Homo sapiens,"2-cyclobutyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C4CCC4,CHEMBL3233275,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 17nM,partial agonist,34.00%,agonist,,,,,,,,IC50,=,260,nM,,,,,=,7.769551079,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C1CCC1,34,367.274,396.2213064,2,3,7,3,5.1522,58.14,C1CCC(CCC(CC2CC3CCCCC3C2)C2CCC2)CC1,agonist,partial agonist,agonist,partial agonist,418
5940,3604,20735001,13,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(thieno[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3s2)C(F)(F)F,CHEMBL1254907,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.0nM,agonist,90.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,2.8,nM,,,,,=,8.698970004,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2s1)C(F)(F)F,90,406.295,427.1229128,1,4,6,3,5.6478,42.35,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5946,3606,20735001,7,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cnccc3[nH]2)C(F)(F)F,CHEMBL1254735,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7.3nM,agonist,95.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,8.2,nM,,,,,=,8.13667714,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cnccc2[nH]1)C(F)(F)F,95,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5952,3608,24506830,22,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methoxy-phenyl)-4-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-6-ylmethyl)-pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cncnc3[nH]2)C(F)(F)F,CHEMBL3126954,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,agonist,82.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,10,nM,,,,,=,8.397940009,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cncnc2[nH]1)C(F)(F)F,82,390.231,411.1569898,2,4,6,3,4.3094,71.03,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5955,3609,20735001,8,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ncccc3[nH]2)C(F)(F)F,CHEMBL1254820,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 23nM,partial agonist,43.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,120,nM,,,,,=,7.638272164,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ncccc2[nH]1)C(F)(F)F,43,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
5958,361,25815138,21,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-1-(4-chlorophenyl)-N-cyclobutylmethanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4ccc(Cl)cc4)c(F)c2,CHEMBL3580673,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 37nM,inverse agonist,-97.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,33,nM,,,,,=,7.431798276,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccc(Cl)cc3)c(F)c2)CC1,-97,464.8,493.1602187,0,4,7,2,4.0321,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
5959,3610,24506830,32,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methoxy-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ncncc3[nH]2)C(F)(F)F,CHEMBL3126940,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,agonist,85.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,21,nM,,,,,=,8.045757491,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F,85,390.231,411.1569898,2,4,6,3,4.3094,71.03,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
5962,3611,17692519,38,P04150,GR,Homo sapiens,4-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1-naphthonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2ccc(C#N)c3ccccc23)C(F)(F)F,CHEMBL392500,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 21nM,agonist,92.00%,agonist,dexamethasone,,,,,,,EC50,=,70,nM,,,,,=,7.677780705,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1ccc(C#N)c2ccccc12)C(F)(F)F,92,422.272,445.1664919,1,3,6,3,6.06298,53.25,C1CCC(CCCCC2CCCC3CCCCC23)CC1,agonist,agonist,agonist,agonist,435
5968,3613,17692519,36,P04150,GR,Homo sapiens,3-chloro-4-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)benzonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2ccc(cc2Cl)C#N)C(F)(F)F,CHEMBL235063,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 17nM,partial agonist,60.00%,agonist,dexamethasone,,,,,,,EC50,=,20,nM,,,,,=,7.769551079,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1ccc(C#N)cc1Cl)C(F)(F)F,60,409.681,429.1118694,1,3,6,2,5.56318,53.25,C1CCC(CCCCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,441
5971,3614,17692519,35,P04150,GR,Homo sapiens,3-fluoro-4-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)benzonitrile,COc1ccc(F)cc1C(C)(C)CC(O)(Cc2ccc(cc2F)C#N)C(F)(F)F,CHEMBL400609,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 22nM,partial agonist,40.00%,agonist,dexamethasone,,,,,,,EC50,>,2000,nM,,,,,=,7.657577319,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1ccc(C#N)cc1F)C(F)(F)F,40,393.226,413.14142,1,3,6,2,5.04888,53.25,C1CCC(CCCCC2CCCCC2)CC1,,partial agonist,,partial agonist,441
5989,362,25815138,15,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-1-(4-fluorophenyl)methanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4ccc(F)cc4)c(F)c2,CHEMBL3581537,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 17nM,inverse agonist,-97.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,7,nM,,,,,=,7.769551079,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccc(F)cc3)c(F)c2)CC1,-97,448.345,477.1897692,0,4,7,2,3.5178,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
6019,363,25815138,19,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-1-(3-chlorophenyl)-N-cyclobutylmethanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4cccc(Cl)c4)c(F)c2,CHEMBL3581541,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 19nM,inverse agonist,-98.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,9,nM,,,,,=,7.721246399,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3cccc(Cl)c3)c(F)c2)CC1,-98,464.8,493.1602187,0,4,7,2,4.0321,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
6029,3633,17181172,21,P04150,GR,Homo sapiens,"1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-3,5-dimethyl-1H-pyridin-4-one",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C=C(C)C(=O)C(=C2)C)C(F)(F)F,CHEMBL219015,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 120nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,53,nM,,,,,=,6.920818754,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1cc(C)c(=O)c(C)c1)C(F)(F)F,87,390.227,415.1770565,1,4,6,2,4.27414,51.46,CC1CCC(CCCCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,808
6035,3635,17181172,29,P04150,GR,Homo sapiens,"1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-[1,6]naphthyridin-4-one",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C=CC(=O)c3cnccc23)C(F)(F)F,CHEMBL386916,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,partial agonist,72.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,35,nM,,,,,=,7.468521083,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc(=O)c2cnccc21)C(F)(F)F,72,416.245,438.1566554,1,5,6,3,4.2055,64.35,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,partial agonist,agonist,partial agonist,807
6038,3636,17181172,28,P04150,GR,Homo sapiens,"1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-[1,5]naphthyridin-4-one",COc1ccc(F)cc1C(C)(C)CC(O)(CN2C=CC(=O)c3ncccc23)C(F)(F)F,CHEMBL219140,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 77nM,agonist,78.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,56,nM,,,,,=,7.113509275,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc(=O)c2ncccc21)C(F)(F)F,78,416.245,438.1566554,1,5,6,3,4.2055,64.35,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,agonist,agonist,agonist,807
6047,3639,20735001,12,P04150,GR,Homo sapiens,"2-((1H-pyrrolo[3,2-b]pyridin-1-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)CC(O)(Cn2ccc3ncccc23)C(F)(F)F,CHEMBL1254994,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7.1nM,partial agonist,66.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,35,nM,,,,,=,8.148741651,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc2ncccc21)C(F)(F)F,66,388.235,410.1617408,1,4,6,3,4.8453,47.28,C1CCC(CCCCC2CCC3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,423
6050,364,25815138,13,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-1-(3-fluorophenyl)methanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4cccc(F)c4)c(F)c2,CHEMBL3581535,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 25nM,inverse agonist,-98.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,10,nM,,,,,=,7.602059991,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3cccc(F)c3)c(F)c2)CC1,-98,448.345,477.1897692,0,4,7,2,3.5178,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
6063,3644,21963986,(R)-21,P04150,GR,Homo sapiens,(R)-2-(4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-indole-5-carbonitrile,COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3cc(ccc3[nH]2)C#N)C(F)(F)F,CHEMBL1911650,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 1nM,agonist,90.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,3,nM,,,,,=,9,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2cc(C#N)ccc2[nH]1)C(F)(F)F,90,412.257,434.1617408,2,3,6,3,5.39108,69.04,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
6066,3645,21963986,(R)-2,P04150,GR,Homo sapiens,"(R)-2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3ccccc3[nH]2)C(F)(F)F,CHEMBL1911542,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,87.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,6,nM,,,,,=,8,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2ccccc2[nH]1)C(F)(F)F,87,386.239,409.1664919,2,2,6,3,5.5194,45.25,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
6070,3646,20735001,(R)-6,P04150,GR,Homo sapiens,"(R)-2-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1255080,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.4nM,agonist,93.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,6,nM,,,,,=,8.853871964,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,93,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
6073,3647,20735001,(R)-7,P04150,GR,Homo sapiens,"(R)-2-((1H-pyrrolo[3,2-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3cnccc3[nH]2)C(F)(F)F,CHEMBL1253819,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.4nM,agonist,93.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,2,nM,,,,,=,8.853871964,pIC50,B,FPA,COc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2cnccc2[nH]1)C(F)(F)F,93,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
6079,3649,20735001,(S)-6,P04150,GR,Homo sapiens,"(S)-2-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",COc1ccc(F)cc1C(C)(C)C[C@](O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1253818,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1700nM,agonist,86.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,430,nM,,,,,=,5.769551079,pIC50,,FPA,COc1ccc(F)cc1C(C)(C)C[C@](O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,86,388.235,410.1617408,2,3,6,3,4.9144,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
6102,366,25815138,17,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-1-(2-chlorophenyl)-N-cyclobutylmethanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4ccccc4Cl)c(F)c2,CHEMBL3581539,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 9nM,inverse agonist,-96.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,4,nM,,,,,=,8.045757491,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3Cl)c(F)c2)CC1,-96,464.8,493.1602187,0,4,7,2,4.0321,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
6104,3661,21349714,17,P04150,GR,Homo sapiens,"(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 3-chloro-4-methoxyphenylcarbamate",COc1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(F)c(c(F)cc3NC2(C)C)c4cccc5c(Cl)c[nH]c45)cc1Cl,CHEMBL1684350,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.7nM,agonist,116.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.8,nM,,,,,=,8.173925197,pKi,B,radiometric,COc1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(cc(F)c(-c4cccc5c(Cl)c[nH]c45)c3F)NC2(C)C)cc1Cl,116,535.228,559.1241035,3,4,4,4,8.3534,75.38,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
6105,3662,21349714,16,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 3-chloro-4-methoxyphenylcarbamate",COc1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(F)c(c(F)cc3NC2(C)C)c4cccc5cc[nH]c45)cc1Cl,CHEMBL1684349,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.6nM,agonist,119.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,11,nM,,,,,=,7.935542011,pKi,B,radiometric,COc1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(cc(F)c(-c4cccc5cc[nH]c45)c3F)NC2(C)C)cc1Cl,119,499.775,525.1630758,3,4,4,4,7.7,75.38,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
6110,3666,15771468,2,P37231,PPARG,Homo sapiens,((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)cc1,CHEMBL186179,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 190nM,agonist,82.00%,agonist,rosiglitazone,,,,,,,EC50,=,110,nM,,,,,=,6.721246399,pIC50,,FPA,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,82,488.326,516.1896512,1,7,11,4,5.36572,111.33,CC(CCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1,agonist,agonist,agonist,agonist,1180
6111,3666,18511276,1,P37231,PPARG,Homo sapiens,((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)cc1,CHEMBL186179,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 190nM,agonist,139.00%,agonist,ref agonist,,,,,,,EC50,=,40,nM,,,,,=,6.721246399,pIC50,,FPA,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,139,488.326,516.1896512,1,7,11,4,5.36572,111.33,CC(CCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1,agonist,agonist,agonist,agonist,1180
6112,3666,15771468,2,Q07869,PPARA,Homo sapiens,((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)cc1,CHEMBL186179,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 250nM,partial agonist,70.00%,agonist,GW2331,,,,,,,EC50,=,320,nM,,,,,=,6.602059991,pIC50,,FPA,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,70,488.326,516.1896512,1,7,11,4,5.36572,111.33,CC(CCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1,agonist,partial agonist,agonist,"partial agonist,agonist",1180
6113,3666,18511276,1,Q07869,PPARA,Homo sapiens,((4-Methoxy-phenoxycarbonyl)-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)cc1,CHEMBL186179,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 250nM,agonist,107.00%,agonist,ref agonist,,,,,,,EC50,=,1410,nM,,,,,=,6.602059991,pIC50,,FPA,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,107,488.326,516.1896512,1,7,11,4,5.36572,111.33,CC(CCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1,agonist,agonist,agonist,"partial agonist,agonist",1180
6119,367,25815138,11,P51449,RORG,Homo sapiens,N-(4-(4-Acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-1-(2-fluorophenyl)methanesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)Cc4ccccc4F)c(F)c2,CHEMBL3581533,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 10nM,inverse agonist,-98.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,3,nM,,,,,=,8,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3F)c(F)c2)CC1,-98,448.345,477.1897692,0,4,7,2,3.5178,60.93,CC(C)(CC1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1151
6122,3672,25993269,23d,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(4-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic acid,COc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)cc1,CHEMBL3589354,,,,Ki = 2384.62nM,partial antagonist,40.00%,antagonist,E2,,,,,,,,,,,IC50,=,115600,nM,=,5.622580818,pKi,,other,COc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)cc1,40,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1126
6123,3672,25993269,23d,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(4-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic acid,COc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)cc1,CHEMBL3589354,,,,Ki = 618.18nM,antagonist,137.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.20888505,pKi,,other,COc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)cc1,137,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
6126,3675,19932617,7r,P55055,LXRB,Homo sapiens,4-(3-(4-methoxy-3-(methylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,COc1ccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)cc1S(=O)(=O)C,CHEMBL607090,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.2nM,partial agonist,43.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,688,nM,,,,,=,8.086186148,pIC50,B,radiometric,COc1ccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,43,467.339,487.1065138,0,5,5,4,6.43342,65.49,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6128,3676,19853462,9a,P55055,LXRB,Homo sapiens,3-Benzyl-4-[3-(4-methoxyphenoxy)phenyl]-8-(trifluoromethyl)quinoline,COc1ccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL596233,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 287nM,partial agonist,38.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,612,nM,,,,,=,6.542118103,pIC50,,radiometric,COc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,38,463.329,485.1602636,0,3,6,5,8.3123,31.35,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,278
6130,3677,25815138,28,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-4-methoxybenzenesulfonamide,COc1ccc(cc1)S(=O)(=O)N(Cc2ccc(cc2F)N3CCN(CC3)C(=O)C)C4CCC4,CHEMBL3581549,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 120nM,inverse agonist,-52.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,3300,nM,,,,,=,6.920818754,pIC50,,radiometric,COc1ccc(S(=O)(=O)N(Cc2ccc(N3CCN(C(C)=O)CC3)cc2F)C2CCC2)cc1,-52,445.346,475.1941057,0,5,7,2,3.2462,70.16,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6133,368,25815138,22,P51449,RORG,Homo sapiens,"N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-3,5-dichloro-N-cyclobutylbenzenesulfonamide",CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4cc(Cl)cc(Cl)c4)c(F)c2,CHEMBL3581543,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 6nM,partial agonist,65.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,6,nM,,,,,=,8.22184875,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3cc(Cl)cc(Cl)c3)c(F)c2)CC1,65,488.242,513.1055963,0,4,6,2,4.5444,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6144,3688,22070604,42,P37231,PPARG,Homo sapiens,"(R)-2-(4-chloro-3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cc(O[C@H](C)C(=O)O)ccc4Cl)c5cc(ccc35)C(F)(F)F,CHEMBL1946953,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.1nM,partial agonist,26.00%,agonist,rosiglitazone,,,,,,,EC50,=,102,nM,,,,,=,8.040958608,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cc(O[C@H](C)C(=O)O)ccc4Cl)c4cc(C(F)(F)F)ccc43)noc2c1,26,542.748,561.0914477,1,8,7,5,5.5144,108.72,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6145,3689,22070604,53,P37231,PPARG,Homo sapiens,"(R)-2-(4-chloro-3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cc(O[C@H](C)C(=O)O)ccc4Cl)c5ccccc35,CHEMBL1947146,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13.7nM,partial agonist,50.00%,agonist,rosiglitazone,,,,,,,EC50,=,51.1,nM,,,,,=,7.863279433,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cc(O[C@H](C)C(=O)O)ccc4Cl)c4ccccc43)noc2c1,50,473.743,493.104063,1,8,7,5,4.4956,108.72,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6146,369,25815138,24,P51449,RORG,Homo sapiens,"N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-3,5-difluorobenzenesulfonamide",CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4cc(F)cc(F)c4)c(F)c2,CHEMBL3581545,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 49nM,partial agonist,43.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,14,nM,,,,,=,7.30980392,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3cc(F)cc(F)c3)c(F)c2)CC1,43,455.332,481.1646974,0,4,6,2,3.5158,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6147,3690,22070604,49,P37231,PPARG,Homo sapiens,"(R)-5-(4-chloro-3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cc(ccc4Cl)[C@@]5(C)OC(=O)NC5=O)c6cc(ccc36)C(F)(F)F,CHEMBL1947142,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.7nM,partial agonist,28.00%,agonist,rosiglitazone,,,,,,,EC50,=,17,nM,,,,,=,8.113509275,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cc([C@@]5(C)OC(=O)NC5=O)ccc4Cl)c4cc(C(F)(F)F)ccc43)noc2c1,28,568.766,586.0866966,1,9,5,5,5.1441,117.59,CC1CC(C)C(C2CCCC(CC3C(C)C(C4CCC5CCCCC54)C4CCCCC34)C2)C1,agonist,partial agonist,agonist,partial agonist,748
6148,3691,22070604,54,P37231,PPARG,Homo sapiens,"(R)-5-(4-chloro-3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cc(ccc4Cl)[C@@]5(C)OC(=O)NC5=O)c6ccccc36,CHEMBL1947147,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.9nM,partial agonist,26.00%,agonist,rosiglitazone,,,,,,,EC50,=,9.1,nM,,,,,=,8.004364805,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cc([C@@]5(C)OC(=O)NC5=O)ccc4Cl)c4ccccc43)noc2c1,26,499.761,518.099312,1,9,5,5,4.1253,117.59,CC1CC(C)C(C2CCCC(CC3C(C)C(C4CCC5CCCCC54)C4CCCCC34)C2)C1,agonist,partial agonist,agonist,partial agonist,748
6150,3693,22070604,37,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c5cc(ccc35)C(F)(F)F,CHEMBL1946755,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4.1nM,partial agonist,28.00%,agonist,rosiglitazone,,,,,,,EC50,=,103,nM,,,,,=,8.387216143,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4cc(C(F)(F)F)ccc43)noc2c1,28,542.748,561.0914477,1,8,7,5,5.5144,108.72,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6151,3694,22070604,38,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c5cc(OC(F)(F)F)ccc35,CHEMBL1946756,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.2nM,partial agonist,39.00%,agonist,rosiglitazone,,,,,,,EC50,=,11.4,nM,,,,,=,8.494850022,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4cc(OC(F)(F)F)ccc43)noc2c1,39,558.747,577.0863623,1,9,8,5,5.3942,117.95,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6152,3695,22070604,39,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-5-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c5ccc(cc35)C(F)(F)F,CHEMBL1946757,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.3nM,partial agonist,43.00%,agonist,rosiglitazone,,,,,,,EC50,=,83,nM,,,,,=,8.638272164,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4ccc(C(F)(F)F)cc43)noc2c1,43,542.748,561.0914477,1,8,7,5,5.5144,108.72,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6153,3696,22070604,40,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-5-(trifluoromethoxy)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c5ccc(OC(F)(F)F)cc35,CHEMBL1946758,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4.1nM,partial agonist,31.00%,agonist,rosiglitazone,,,,,,,EC50,=,13.2,nM,,,,,=,8.387216143,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4ccc(OC(F)(F)F)cc43)noc2c1,31,558.747,577.0863623,1,9,8,5,5.3942,117.95,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6154,3697,22070604,50,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",COc1ccc2c(noc2c1)N3C(=O)N(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c5ccccc35,CHEMBL1947143,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6.9nM,partial agonist,31.00%,agonist,rosiglitazone,,,,,,,EC50,=,28.1,nM,,,,,=,8.161150909,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4ccccc43)noc2c1,31,473.743,493.104063,1,8,7,5,4.4956,108.72,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6159,370,25815138,33,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-4-tert-butyl-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(cc4)C(C)(C)C)c(F)c2,CHEMBL3581554,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 18nM,inverse agonist,-55.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,120,nM,,,,,=,7.744727495,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(C(C)(C)C)cc3)c(F)c2)CC1,-55,465.38,501.2461412,0,4,6,2,4.5351,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6160,3700,22070604,47,P37231,PPARG,Homo sapiens,"(R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cccc(c4)[C@@]5(C)OC(=O)NC5=O)c6cc(ccc36)C(F)(F)F,CHEMBL1947140,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 93nM,partial agonist,45.00%,agonist,rosiglitazone,,,,,,,EC50,=,237,nM,,,,,=,7.031517051,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4cc(C(F)(F)F)ccc43)noc2c1,45,533.313,552.125669,1,9,5,5,4.4907,117.59,CC1CC(C)C(C2CCCC(CC3C(C)C(C4CCC5CCCCC54)C4CCCCC34)C2)C1,agonist,partial agonist,agonist,partial agonist,748
6161,3701,22070604,51,P37231,PPARG,Homo sapiens,"(R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",COc1ccc2c(noc2c1)N3C(=O)N(Cc4cccc(c4)[C@@]5(C)OC(=O)NC5=O)c6ccccc36,CHEMBL1947144,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 83.1nM,agonist,85.00%,agonist,rosiglitazone,,,,,,,EC50,=,360,nM,,,,,=,7.080398976,pIC50,B,radiometric,COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1,85,464.308,484.1382844,1,9,5,5,3.4719,117.59,CC1CC(C)C(C2CCCC(CC3C(C)C(C4CCC5CCCCC54)C4CCCCC34)C2)C1,agonist,agonist,agonist,agonist,748
6165,3705,16153845,36,P37231,PPARG,Homo sapiens,"1-(4-tert-Butyl-phenyl)-6-methoxy-3-(3-trifluoromethyl-phenoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid",COc1ccc2c(Oc3cccc(c3)C(F)(F)F)c(C(=O)O)n(c4ccc(cc4)C(C)(C)C)c2n1,CHEMBL372091,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,partial agonist,31.00%,agonist,maximal activation (no details),,,,,,,EC50,=,266,nM,,,,,=,7,pIC50,,radiometric,COc1ccc2c(Oc3cccc(C(F)(F)F)c3)c(C(=O)O)n(-c3ccc(C(C)(C)C)cc3)c2n1,31,461.29,484.1609919,1,5,5,4,6.8409,73.58,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
6170,3708,12781198,11h,P06401,PR,Homo sapiens,"9-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1ccc2OCc3c(ccc4NC(C)(C)C=C(C)c34)c2c1,CHEMBL65522,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 86nM,antagonist,76.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,170,nM,=,7.065501549,pKi,B,radiometric,COc1ccc2c(c1)-c1ccc3c(c1CO2)C(C)=CC(C)(C)N3,76,286.225,307.1572289,1,3,1,2,4.862,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
6171,3708,16821785,57,P06401,PR,Homo sapiens,"9-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",COc1ccc2OCc3c(ccc4NC(C)(C)C=C(C)c34)c2c1,CHEMBL65522,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 7.07,,,,progesterone,,,,,,,,,,,,,,,=,7.07,pKi,B,radiometric,COc1ccc2c(c1)-c1ccc3c(c1CO2)C(C)=CC(C)(C)N3,,286.225,307.1572289,1,3,1,2,4.862,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
6174,371,25815138,32,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-4-(trifluoromethyl)benzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(cc4)C(F)(F)F)c(F)c2,CHEMBL3581553,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 50nM,inverse agonist,-39.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,300,nM,,,,,=,7.301029996,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(C(F)(F)F)cc3)c(F)c2)CC1,-39,486.341,513.1709256,0,4,6,2,4.2564,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6186,3713,18722772,15,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(6-methoxy-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",COc1ccc2CN(CCc2c1)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL524829,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,partial agonist,48.00%,agonist,GW501516,,,,,,,PEC50,=,6.1,,,,,,=,8,pIC50,B,radiometric,COc1ccc2c(c1)CCN(S(=O)(=O)c1cccc(C(=O)Nc3ccc(Cl)cc3C(=O)O)c1)C2,48,479.792,500.0808851,2,5,6,3,4.0461,113.01,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
6203,3721,21510635,5,P03372,ERA,Homo sapiens,(+)-Pisatin,COc1ccc2[C@H]3Oc4cc5OCOc5cc4[C@@]3(O)COc2c1,CHEMBL1784262,,,Fluorescence polarization (FP) competition binding assay,IC50 > 5000000nM,partial agonist,36.20%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,>,2.301029996,pIC50,NB,FPA,COc1ccc2c(c1)OC[C@]1(O)c3cc4c(cc3O[C@H]21)OCO4,36.2,300.181,314.0790382,1,6,1,2,2.1376,66.38,C1CC2CC3CC4C5CCCCC5CCC4C3CC2C1,,partial agonist,,partial agonist,2
6204,3722,12781198,11l,P06401,PR,Homo sapiens,"8-Methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1ccc2c(OCc3c2ccc4NC(C)(C)C=C(C)c34)c1,CHEMBL303293,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 357nM,antagonist,85.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,193,nM,=,6.447331784,pKi,,radiometric,COc1ccc2c(c1)OCc1c-2ccc2c1C(C)=CC(C)(C)N2,85,286.225,307.1572289,1,3,1,2,4.862,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
6205,3722,16821785,59,P06401,PR,Homo sapiens,"8-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline",COc1ccc2c(OCc3c2ccc4NC(C)(C)C=C(C)c34)c1,CHEMBL303293,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.45,,,,progesterone,,,,,,,,,,,,,,,=,6.45,pKi,,radiometric,COc1ccc2c(c1)OCc1c-2ccc2c1C(C)=CC(C)(C)N2,,286.225,307.1572289,1,3,1,2,4.862,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,,,antagonist,antagonist,16
6217,373,25815138,20,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-4-chloro-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(Cl)cc4)c(F)c2,CHEMBL3581542,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 92nM,inverse agonist,-63.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,190,nM,,,,,=,7.036212173,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(Cl)cc3)c(F)c2)CC1,-63,452.789,479.1445686,0,4,6,2,3.891,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6220,3732,15603954,7,P37231,PPARG,Homo sapiens,3-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-benzoic acid,COc1ccc2c(c1)c(Cc3cccc(c3)C(=O)O)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL181219,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 208nM,partial agonist,33.00%,agonist,Rosiglitazone,,,,,,,EC50,=,280,nM,,,,,=,6.681936665,pIC50,,radiometric,COc1ccc2c(c1)c(Cc1cccc(C(=O)O)c1)c(C)n2C(=O)c1ccc(Cl)cc1,33,413.731,433.1080858,1,4,5,4,5.58922,68.53,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
6221,3733,15603954,16,P37231,PPARG,Homo sapiens,2-{3-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-phenoxy}-2-methyl-propionic acid,COc1ccc2c(c1)c(Cc3cccc(OC(C)(C)C(=O)O)c3)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL181141,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 45nM,partial agonist,59.00%,agonist,Rosiglitazone,,,,,,,EC50,=,19,nM,,,,,=,7.346787486,pIC50,B,radiometric,COc1ccc2c(c1)c(Cc1cccc(OC(C)(C)C(=O)O)c1)c(C)n2C(=O)c1ccc(Cl)cc1,59,465.763,491.1499506,1,5,7,4,6.13302,77.76,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
6222,3734,15603954,13,P37231,PPARG,Homo sapiens,2-{3-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc2c(c1)c(Cc3cccc(OC(C)C(=O)O)c3)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL359476,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 49nM,partial agonist,42.00%,agonist,Rosiglitazone,,,,,,,EC50,=,19,nM,,,,,=,7.30980392,pIC50,B,radiometric,COc1ccc2c(c1)c(Cc1cccc(OC(C)C(=O)O)c1)c(C)n2C(=O)c1ccc(Cl)cc1,42,453.752,477.1343005,1,5,7,4,5.74292,77.76,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
6225,3737,15603954,15,P37231,PPARG,Homo sapiens,2-{2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-phenoxy}-2-methyl-propionic acid,COc1ccc2c(c1)c(Cc3ccccc3OC(C)(C)C(=O)O)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL179604,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 79nM,agonist,86.00%,agonist,Rosiglitazone,,,,,,,EC50,=,12,nM,,,,,=,7.102372909,pIC50,B,radiometric,COc1ccc2c(c1)c(Cc1ccccc1OC(C)(C)C(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,86,465.763,491.1499506,1,5,7,4,6.13302,77.76,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,agonist,agonist,agonist,866
6226,3738,15603954,12,P37231,PPARG,Homo sapiens,2-{2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc2c(c1)c(Cc3ccccc3OC(C)C(=O)O)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL367360,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 84nM,agonist,97.00%,agonist,Rosiglitazone,,,,,,,EC50,=,14,nM,,,,,=,7.075720714,pIC50,B,radiometric,COc1ccc2c(c1)c(Cc1ccccc1OC(C)C(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,97,453.752,477.1343005,1,5,7,4,5.74292,77.76,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,agonist,agonist,agonist,866
6227,3739,15603954,9,P37231,PPARG,Homo sapiens,{2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-ylmethyl]-phenoxy}-acetic acid,COc1ccc2c(c1)c(Cc3ccccc3OCC(=O)O)c(C)n2C(=O)c4ccc(Cl)cc4,CHEMBL181087,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 333nM,partial agonist,50.00%,agonist,Rosiglitazone,,,,,,,EC50,=,191,nM,,,,,=,6.477555766,pIC50,,radiometric,COc1ccc2c(c1)c(Cc1ccccc1OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,50,441.741,463.1186505,1,5,7,4,5.35442,77.76,CC(C1CCCCC1)C1CC(CC2CCCCC2)C2CCCCC21,agonist,partial agonist,agonist,partial agonist,866
6228,374,25815138,29,P51449,RORG,Homo sapiens,"N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-2,4-dichloro-N-cyclobutylbenzenesulfonamide",CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(Cl)cc4Cl)c(F)c2,CHEMBL3581550,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 76nM,inverse agonist,-37.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,220,nM,,,,,=,7.119186408,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(Cl)cc3Cl)c(F)c2)CC1,-37,488.242,513.1055963,0,4,6,2,4.5444,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6234,3742,18722772,25,Q03181,PPARB,Homo sapiens,2-(3-(5-methoxy-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,COc1ccc2c(ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(C)cc4C(=O)O)c1,CHEMBL525552,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.8,partial agonist,31.00%,agonist,GW501516,,,,,,,PEC50,=,6.3,,,,,,=,6.8,pIC50,,radiometric,COc1ccc2c(ccn2S(=O)(=O)c2cccc(C(=O)Nc3ccc(C)cc3C(=O)O)c2)c1,31,444.339,464.1042074,2,6,6,4,4.14582,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6237,3743,18722772,32,Q03181,PPARB,Homo sapiens,2-(3-(5-methoxy-4-methyl-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,COc1ccc2c(ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(C)cc4C(=O)O)c1C,CHEMBL496743,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.7,partial agonist,33.00%,agonist,GW501516,,,,,,,PEC50,=,7.9,,,,,,=,7.7,pIC50,B,radiometric,COc1ccc2c(ccn2S(=O)(=O)c2cccc(C(=O)Nc3ccc(C)cc3C(=O)O)c2)c1C,33,456.35,478.1198574,2,6,6,4,4.45424,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6240,3744,18722772,34,Q03181,PPARB,Homo sapiens,5-chloro-2-(3-(5-methoxy-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,COc1ccc2c(ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O)c1,CHEMBL497789,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,partial agonist,29.00%,agonist,GW501516,,,,,,,PEC50,=,6.8,,,,,,=,7.9,pIC50,B,radiometric,COc1ccc2c(ccn2S(=O)(=O)c2cccc(C(=O)Nc3ccc(Cl)cc3C(=O)O)c2)c1,29,467.781,484.0495849,2,6,6,4,4.4908,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6243,3745,18722772,36,Q03181,PPARB,Homo sapiens,5-chloro-2-(3-(5-methoxy-4-methyl-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,COc1ccc2c(ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O)c1C,CHEMBL522577,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,35.00%,agonist,GW501516,,,,,,,PEC50,=,7.8,,,,,,=,7.8,pIC50,B,radiometric,COc1ccc2c(ccn2S(=O)(=O)c2cccc(C(=O)Nc3ccc(Cl)cc3C(=O)O)c2)c1C,35,479.792,498.065235,2,6,6,4,4.79922,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6245,3746,18513967,"20, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(6-methoxy-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",COc1ccc2cc[nH]c2c1c3cc(C)c4NC(C)(C)CC(C)c4c3Cl,CHEMBL253745,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,partial agonist,60.00%,agonist,dexamethasone,,,,,,,EC50,=,48,nM,,,,,=,8.823908741,pKi,B,radiometric,COc1ccc2cc[nH]c2c1-c1cc(C)c2c(c1Cl)C(C)CC(C)(C)N2,60,343.708,368.1655411,2,2,2,3,6.50302,37.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,partial agonist,agonist,partial agonist,37
6250,3747,18722772,28,Q03181,PPARB,Homo sapiens,2-(3-(6-methoxy-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,COc1ccc2ccn(c2c1)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(C)cc4C(=O)O,CHEMBL496116,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.5,partial agonist,35.00%,agonist,GW501516,,,,,,,PEC50,=,7,,,,,,=,7.5,pIC50,B,radiometric,COc1ccc2ccn(S(=O)(=O)c3cccc(C(=O)Nc4ccc(C)cc4C(=O)O)c3)c2c1,35,444.339,464.1042074,2,6,6,4,4.14582,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6253,3748,18722772,35,Q03181,PPARB,Homo sapiens,5-chloro-2-(3-(6-methoxy-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,COc1ccc2ccn(c2c1)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL497991,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,partial agonist,32.00%,agonist,GW501516,,,,,,,PEC50,=,7,,,,,,=,7.9,pIC50,B,radiometric,COc1ccc2ccn(S(=O)(=O)c3cccc(C(=O)Nc4ccc(Cl)cc4C(=O)O)c3)c2c1,32,467.781,484.0495849,2,6,6,4,4.4908,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6256,375,25815138,14,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-4-fluorobenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(F)cc4)c(F)c2,CHEMBL3581536,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 220nM,inverse agonist,-37.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,>,10000,nM,,,,,=,6.657577319,pIC50,,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(F)cc3)c(F)c2)CC1,-37,436.334,463.1741192,0,4,6,2,3.3767,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,,inverse agonist,,inverse agonist,1066
6257,3750,15863293,4,P37231,PPARG,Homo sapiens,(S)-2-{3-[1-(6-Methoxy-quinolin-3-yl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,COc1ccc2ncc(cc2c1)n3c(C)c(Cc4cccc(O[C@@H](C)C(=O)O)c4)c5cc(OC(F)(F)F)ccc35,CHEMBL365387,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 29nM,partial agonist,32.00%,agonist,Rosiglitazone,,,,,,,EC50,=,49,nM,,,,,=,7.537602002,pIC50,B,radiometric,COc1ccc2ncc(-n3c(C)c(Cc4cccc(O[C@@H](C)C(=O)O)c4)c4cc(OC(F)(F)F)ccc43)cc2c1,32,525.333,550.1715566,1,6,8,5,6.83702,82.81,C1CCC(CC2CC(C3CCC4CCCCC4C3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,232
6258,3751,18442912,5b,P10275,AR,Homo sapiens,"9-methoxy-4-methyl-1H-chromeno[3,4-f]quinoline-2,5-dione",COc1ccc2OC(=O)c3c(ccc4NC(=O)C=C(C)c34)c2c1,CHEMBL258397,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 610nM,partial antagonist,62.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,48,nM,=,6.214670165,pKi,,radiometric,COc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1,62,294.201,307.0844579,1,4,1,4,3.10472,72.3,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,antagonist,partial antagonist,antagonist,partial antagonist,636
6266,3756,16973358,34,P37231,PPARG,Homo sapiens,2-((6-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL426550,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 7nM,agonist,93.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,2,nM,,,,,=,8.15490196,pKi,B,radiometric,COc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)c1,93,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
6267,3756,16973358,34,Q07869,PPARA,Homo sapiens,2-((6-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL426550,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 215nM,agonist,104.00%,agonist,GW2331,,GW2331,,,,,EC50,=,90,nM,,,,,=,6.66756154,pKi,,radiometric,COc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)c1,104,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
6268,3757,16979341,18,P37231,PPARG,Homo sapiens,2-((5-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221438,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 20nM,agonist,93.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,5,nM,,,,,=,7.698970004,pKi,B,radiometric,COc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)c1,93,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
6269,3757,16979341,18,Q07869,PPARA,Homo sapiens,2-((5-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,COc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221438,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1200nM,agonist,98.00%,agonist,GW2331,,GW2331,,,,,EC50,=,1570,nM,,,,,=,5.920818754,pIC50,,radiometric,COc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)c1,98,412.272,438.1790866,1,7,9,3,3.85142,103.91,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
6272,3759,24755427,41,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(3-methoxyphenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",COc1cccc(c1)n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cccc23,CHEMBL3261418,,,Fluorescence polarization (FP) competition binding assay,IC50 = 6.9nM,partial agonist,62.00%,agonist,dexamethasone,,,,,,,IC50,=,41,nM,,,,,=,8.161150909,pIC50,B,FPA,COc1cccc(-n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cccc32)c1,62,448.378,478.2038618,2,6,8,4,4.73826,85.25,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
6273,376,25815138,31,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-4-(trifluoromethoxy)benzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(OC(F)(F)F)cc4)c(F)c2,CHEMBL3581552,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 290nM,inverse agonist,-82.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,160,nM,,,,,=,6.537602002,pIC50,,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(OC(F)(F)F)cc3)c(F)c2)CC1,-82,502.34,529.1658402,0,5,7,2,4.1362,70.16,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6277,3763,9784110,19,P06401,PR,Homo sapiens,"5-[1-(3-Methoxy-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc(\C=C\2/Oc3ccccc3c4ccc5NC(C)(C)C=C(C)c5c24)c1,CHEMBL139631,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 53.3nM,partial antagonist,70.00%,antagonist,progesterone,,progesterone,,,,,EC50,>,10000,nM,IC50,=,425,nM,=,7.273272791,pKi,B,radiometric,COc1cccc(/C=C2\Oc3ccccc3-c3ccc4c(c32)C(C)=CC(C)(C)N4)c1,70,370.302,395.188529,1,3,2,3,6.8601,30.49,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,222
6286,3769,26048793,26,P37231,PPARG,Homo sapiens,"3-fluoro-4-(3-(2-methoxy-6-(trifluoromethyl)benzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)benzoic acid",COc1cccc(c1C(=O)c2nc(c3CCCCn23)c4ccc(cc4F)C(=O)O)C(F)(F)F,CHEMBL3596278,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 9100nM,inverse agonist,-96.00%,agonist,,,,,,,,EC50,=,670,nM,,,,,=,5.040958608,pIC50,,other,COc1cccc(C(F)(F)F)c1C(=O)c1nc(-c2ccc(C(=O)O)cc2F)c2n1CCCC2,-96,444.255,462.1202699,1,5,5,3,4.9821,81.42,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
6287,377,25815138,30,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-4-(difluoromethoxy)benzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccc(OC(F)F)cc4)c(F)c2,CHEMBL3581551,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 31nM,inverse agonist,-75.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,150,nM,,,,,=,7.508638306,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccc(OC(F)F)cc3)c(F)c2)CC1,-75,483.342,511.175262,0,5,8,2,3.839,70.16,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,inverse agonist,agonist,inverse agonist,1066
6297,3778,26048793,23,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-methoxybenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",COc1cccc(Cl)c1C(=O)c2nc(c3CCCCn23)c4ccc(cc4F)C(=O)O,CHEMBL3596275,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 5500nM,inverse agonist,-98.00%,agonist,,,,,,,,EC50,=,240,nM,,,,,=,5.259637311,pIC50,,other,COc1cccc(Cl)c1C(=O)c1nc(-c2ccc(C(=O)O)cc2F)c2n1CCCC2,-98,410.703,428.093913,1,5,5,3,4.6167,81.42,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
6299,378,25815138,27,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-3-cyano-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4cccc(c4)C#N)c(F)c2,CHEMBL3581548,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 280nM,inverse agonist,-29.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,>,10000,nM,,,,,=,6.552841969,pIC50,,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3cccc(C#N)c3)c(F)c2)CC1,-29,443.354,470.1787899,0,5,6,2,3.10928,84.72,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,,inverse agonist,,inverse agonist,1066
6304,3784,25993269,23e,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(3-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,COc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)c1,CHEMBL3589355,,,,Ki = 4428.57nM,antagonist,87.00%,antagonist,E2,,,,,,,EC50,=,1160,nM,,,,,=,5.353736486,pKi,,other,COc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)c1,87,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
6305,3784,25993269,23e,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(3-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,COc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)c1,CHEMBL3589355,,,,Ki = 81.53nM,agonist,100.00%,agonist,E2,,,,,,,EC50,=,1100,nM,,,,,=,7.088682558,pKi,B,other,COc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)c1,100,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,agonist,agonist,"agonist,antagonist",1126
6306,3784,25993269,23e,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(3-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,COc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)c1,CHEMBL3589355,,,,Ki = 81.53nM,antagonist,100.00%,antagonist,E2,,,,,,,EC50,=,1100,nM,,,,,=,7.088682558,pKi,B,other,COc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)c1,100,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,"agonist,antagonist",1126
6310,3787,25815138,25,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-3-methoxybenzenesulfonamide,COc1cccc(c1)S(=O)(=O)N(Cc2ccc(cc2F)N3CCN(CC3)C(=O)C)C4CCC4,CHEMBL3581546,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 36nM,partial agonist,54.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,26,nM,,,,,=,7.443697499,pIC50,B,radiometric,COc1cccc(S(=O)(=O)N(Cc2ccc(N3CCN(C(C)=O)CC3)cc2F)C2CCC2)c1,54,445.346,475.1941057,0,5,7,2,3.2462,70.16,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6312,3789,20469868,23d,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-3-(methyloxy)benzenesulfonamide,COc1cccc(c1)S(=O)(=O)Nc2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1084013,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,79.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.6,,,,,,=,7.8,pIC50,B,FPA,COc1cccc(S(=O)(=O)Nc2ccc(-c3ccc4c(cnn4-c4ccc(F)cc4)c3)c(C(F)(F)F)c2)c1,79,522.374,541.1083253,1,5,6,5,6.6598,73.22,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,agonist,agonist,agonist,agonist,1119
6315,379,25815138,18,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-3-chloro-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4cccc(Cl)c4)c(F)c2,CHEMBL3581540,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 22nM,partial agonist,53.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,50,nM,,,,,=,7.657577319,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3cccc(Cl)c3)c(F)c2)CC1,53,452.789,479.1445686,0,4,6,2,3.891,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6317,3791,18442912,15a,P10275,AR,Homo sapiens,"10-methoxy-4-(trifluoromethyl)-1H-isochromeno[3,4-f]quinoline-2,6-dione",COc1cccc2C(=O)Oc3c(ccc4NC(=O)C=C(c34)C(F)(F)F)c12,CHEMBL403219,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 50nM,partial agonist,33.00%,agonist,DHT,,,,,,,EC50,=,90,nM,IC50,>,10000,nM,=,7.301029996,pKi,B,radiometric,COc1cccc2c(=O)oc3c(ccc4[nH]c(=O)cc(C(F)(F)F)c43)c12,33,351.195,361.0561925,1,4,1,4,3.8151,72.3,CC1CCC2C(CCC3C4CCCCC4C(C)CC23)C1,agonist,partial agonist,agonist,partial agonist,635
6328,380,25815138,12,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-3-fluorobenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4cccc(F)c4)c(F)c2,CHEMBL3581534,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 65nM,partial agonist,46.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,41,nM,,,,,=,7.187086643,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3cccc(F)c3)c(F)c2)CC1,46,436.334,463.1741192,0,4,6,2,3.3767,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6361,381,25815138,3,P51449,RORG,Homo sapiens,N-(4-(4-Acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccccc4)c(F)c2,CHEMBL3581529,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 250nM,partial agonist,35.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,69,nM,,,,,=,6.602059991,pIC50,,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccccc3)c(F)c2)CC1,35,417.336,445.183541,0,4,6,2,3.2376,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6382,3818,18442912,18a,P10275,AR,Homo sapiens,"10-methoxy-4-(trifluoromethyl)-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1cccc2OCc3c(ccc4NC(=O)C=C(c34)C(F)(F)F)c12,CHEMBL401629,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 11nM,partial agonist,67.00%,agonist,DHT,,,,,,,EC50,=,20,nM,IC50,>,10000,nM,=,7.958607315,pKi,B,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1CO2,67,335.196,347.0769279,1,3,1,3,4.1149,51.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,634
6383,3819,18442912,17b,P10275,AR,Homo sapiens,"10-methoxy-4-(trifluoromethyl)-1H-isochromeno[3,4-f]quinolin-2(6H)-one",COc1cccc2COc3c(ccc4NC(=O)C=C(c34)C(F)(F)F)c12,CHEMBL402136,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 27nM,partial antagonist,68.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,78,nM,=,7.568636236,pKi,B,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1OC2,68,335.196,347.0769279,1,3,1,3,4.1149,51.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,antagonist,partial antagonist,antagonist,partial antagonist,634
6384,382,25815138,16,P51449,RORG,Homo sapiens,N-(4-(4-acetylpiperazin-1-yl)-2-fluorobenzyl)-2-chloro-N-cyclobutylbenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccccc4Cl)c(F)c2,CHEMBL3581538,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 55nM,partial agonist,33.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,47,nM,,,,,=,7.259637311,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccccc3Cl)c(F)c2)CC1,33,452.789,479.1445686,0,4,6,2,3.891,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6385,3820,18442912,9f,P10275,AR,Homo sapiens,"10-methoxy-4,5-dimethyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1cccc2OC(C)c3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL253744,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 250nM,partial antagonist,63.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,62,nM,=,6.602059991,pKi,,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(C)O2,63,290.213,307.1208434,1,3,1,3,3.96552,51.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,antagonist,partial antagonist,antagonist,partial antagonist,634
6386,3821,18442912,9d,P10275,AR,Homo sapiens,"5-hydroxy-10-methoxy-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1cccc2OC(O)c3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL258190,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1300nM,agonist,93.00%,agonist,DHT,,,,,,,EC50,=,208,nM,IC50,>,10000,nM,=,5.886056648,pKi,,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(O)O2,93,294.201,309.100108,2,4,1,3,2.89542,71.55,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,agonist,agonist,agonist,634
6387,3822,18442912,9e,P10275,AR,Homo sapiens,"5,10-dimethoxy-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COC1Oc2cccc(OC)c2c3ccc4NC(=O)C=C(C)c4c13,CHEMBL253746,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2346nM,partial antagonist,49.00%,antagonist,DHT,,,,,,,EC50,=,184,nM,IC50,=,19,nM,=,5.629671992,pKi,,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(OC)O2,49,306.212,323.115758,1,4,2,3,3.54952,60.55,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,634
6388,3823,18442912,9a,P10275,AR,Homo sapiens,"10-methoxy-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",COc1cccc2OCc3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL256947,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 59nM,partial agonist,70.00%,agonist,DHT,,,,,,,EC50,=,50,nM,IC50,>,10000,nM,=,7.229147988,pKi,B,radiometric,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,70,278.202,293.1051933,1,3,1,3,3.40452,51.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,634
6389,3824,11728194,27,P04150,GR,Homo sapiens,"5-Isopropyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(C(C)C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL141282,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 9.0nM,agonist,81.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,146,nM,,,,,=,8.045757491,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(C(C)C)O2)C(C)=CC(C)(C)N3,81,322.258,349.2041791,1,3,2,2,6.0591,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,agonist,agonist,agonist,16
6401,383,25815138,10,P51449,RORG,Homo sapiens,N-(4-(4-Acetylpiperazin-1-yl)-2-fluorobenzyl)-N-cyclobutyl-2-fluorobenzenesulfonamide,CC(=O)N1CCN(CC1)c2ccc(CN(C3CCC3)S(=O)(=O)c4ccccc4F)c(F)c2,CHEMBL3581532,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 76nM,partial agonist,46.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,63,nM,,,,,=,7.119186408,pIC50,B,radiometric,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)c3ccccc3F)c(F)c2)CC1,46,436.334,463.1741192,0,4,6,2,3.3767,60.93,CC(C)(C1CCCCC1)C(CC1CCC(C2CCCCC2)CC1)C1CCC1,agonist,partial agonist,agonist,partial agonist,1066
6408,3833,11728194,32,P04150,GR,Homo sapiens,"5-Benzyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(C3CCCC3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL337112,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.1nM,partial agonist,34.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,38,nM,,,,,=,8.677780705,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(C1CCCC1)O2)C(C)=CC(C)(C)N3,34,346.28,375.2198292,1,3,2,2,6.5933,30.49,C1CCC2C(C1)CC(C1CCCC1)C1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,17
6416,3837,11728194,29,P04150,GR,Homo sapiens,"5-Isobutyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC(C)C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL137982,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 9.5nM,partial agonist,61.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,223,nM,,,,,=,8.022276395,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(CC(C)C)O2)C(C)=CC(C)(C)N3,61,334.269,363.2198292,1,3,3,2,6.4492,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
6422,384,19926282,30,P06401,PR,Homo sapiens,(S)-4-((1-acetylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)-2-chlorobenzonitrile,CC(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL590611,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 30nM,agonist,78.00%,agonist,progesterone,,,,,,,EC50,=,35,nM,,,,,=,7.522878745,pIC50,B,other,CC(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,78,402.698,421.1168746,0,3,4,2,4.85788,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
6423,3840,15026058,10d,P04150,GR,Homo sapiens,"5-(3,3-Difluoro-allyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(CC=C(F)F)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL50118,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,partial agonist,60.00%,agonist,dexamethasone,,,,,,,IC50,=,76,nM,,,,,=,8.677780705,pIC50,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(CC=C(F)F)O2)C(C)=CC(C)(C)N3,60,360.254,383.1696854,1,3,3,2,6.5736,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
6433,3845,11520196,17,P04150,GR,Homo sapiens,"5-(3,5-Dichloro-phenyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cc(Cl)cc(Cl)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL419158,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7.1nM,agonist,94.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,16,nM,,,,,=,8.148741651,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cc(Cl)cc(Cl)c1)O2)C(C)=CC(C)(C)N3,94,429.197,451.1105843,1,3,2,3,7.7582,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,"agonist,partial agonist",61
6434,3845,11520196,22,P04150,GR,Homo sapiens,"5-(3,5-Dichloro-phenyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cc(Cl)cc(Cl)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL419158,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.3nM,partial agonist,70.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,1.3,nM,,,,,=,8.48148606,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cc(Cl)cc(Cl)c1)O2)C(C)=CC(C)(C)N3,70,429.197,451.1105843,1,3,2,3,7.7582,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",61
6435,3845,11520196,21,P04150,GR,Homo sapiens,"5-(3,5-Dichloro-phenyl)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cc(Cl)cc(Cl)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL419158,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 95nM,,,,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,,,,,,,,,=,7.022276395,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cc(Cl)cc(Cl)c1)O2)C(C)=CC(C)(C)N3,,429.197,451.1105843,1,3,2,3,7.7582,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,,,agonist,"agonist,partial agonist",61
6439,3846,11520196,11,P06401,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-(3-trifluoromethyl-phenyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cccc(c3)C(F)(F)F)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL95644,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,32,nM,,,,,=,7.958607315,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cccc(C(F)(F)F)c1)O2)C(C)=CC(C)(C)N3,87,427.296,451.1759137,1,3,2,3,7.4702,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
6444,3847,11520196,12,P04150,GR,Homo sapiens,"Dimethyl-carbamic acid 3-(10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysen-5-yl)-phenyl ester",COc1cccc2OC(c3cccc(OC(=O)N(C)C)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL317578,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.4nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,26,nM,,,,,=,8.619788758,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cccc(OC(=O)N(C)C)c1)O2)C(C)=CC(C)(C)N3,92,440.329,470.2205574,1,5,3,3,6.5118,60.03,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
6449,3848,11520196,13,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-(3-methylsulfanylmethoxy-phenyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cccc(OCSC)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL97206,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.0nM,agonist,97.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,16,nM,,,,,=,8.397940009,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cccc(OCSC)c1)O2)C(C)=CC(C)(C)N3,97,430.379,459.1868148,1,5,5,3,7.1507,39.72,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
6450,3848,11728194,5,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-(3-methylsulfanylmethoxy-phenyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3cccc(OCSC)c3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL97206,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.0nM,agonist,95.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,9,nM,,,,,=,8.397940009,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1cccc(OCSC)c1)O2)C(C)=CC(C)(C)N3,95,430.379,459.1868148,1,5,5,3,7.1507,39.72,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,61
6456,3849,11520196,20,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3ccccc3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL99046,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.1nM,agonist,77.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,30,nM,,,,,=,8.677780705,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1ccccc1)O2)C(C)=CC(C)(C)N3,77,358.291,383.188529,1,3,2,3,6.4514,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,"agonist,partial agonist",61
6457,3849,11520196,10,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3ccccc3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL99046,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.7nM,partial agonist,62.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,51,nM,,,,,=,8.327902142,pKi,B,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1ccccc1)O2)C(C)=CC(C)(C)N3,62,358.291,383.188529,1,3,2,3,6.4514,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",61
6458,3849,11520196,19,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-phenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(c3ccccc3)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL99046,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 240nM,,,,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,,,,,,,,,=,6.619788758,pKi,,radiometric,COc1cccc2c1-c1ccc3c(c1C(c1ccccc1)O2)C(C)=CC(C)(C)N3,,358.291,383.188529,1,3,2,3,6.4514,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,,,agonist,"agonist,partial agonist",61
6474,3854,15026058,30 (-)-anti,P04150,GR,Homo sapiens,"(S)-10-Methoxy-2,2,4-trimethyl-5-((R)-3-methyl-cyclohex-2-enyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2O[C@@H]([C@@H]3CCCC(=C3)C)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL46325,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.7nM,partial agonist,40.00%,agonist,dexamethasone,,,,,,,IC50,=,40,nM,,,,,=,9.15490196,pIC50,B,radiometric,COc1cccc2c1-c1ccc3c(c1[C@H]([C@H]1C=C(C)CCC1)O2)C(C)=CC(C)(C)N3,40,370.302,401.2354792,1,3,2,2,7.1495,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,61
6475,3854,15026058,30 (-)-anti,P06401,PR,Homo sapiens,"(S)-10-Methoxy-2,2,4-trimethyl-5-((R)-3-methyl-cyclohex-2-enyl)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2O[C@@H]([C@@H]3CCCC(=C3)C)c4c(ccc5NC(C)(C)C=C(C)c45)c12,CHEMBL46325,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 710nM,partial agonist,61.00%,agonist,progesterone,,,,,,,,,,,IC50,=,241,nM,=,6.148741651,pIC50,,radiometric,COc1cccc2c1-c1ccc3c(c1[C@H]([C@H]1C=C(C)CCC1)O2)C(C)=CC(C)(C)N3,61,370.302,401.2354792,1,3,2,2,7.1495,30.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial agonist,antagonist,partial agonist,61
6483,3859,18722772,11,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(5-methoxy-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",COc1cccc2CN(CCc12)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL520827,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,partial agonist,53.00%,agonist,GW501516,,,,,,,PEC50,=,5.9,,,,,,=,7.9,pIC50,B,radiometric,COc1cccc2c1CCN(S(=O)(=O)c1cccc(C(=O)Nc3ccc(Cl)cc3C(=O)O)c1)C2,53,479.792,500.0808851,2,5,6,3,4.0461,113.01,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
6485,386,24980053,13,P04150,GR,Homo sapiens,"(S)-4-(5-(1-acetamido-2-methyl-1-oxopropan-2-yl)-9-fluoro-5H-chromeno[2,3-b]pyridin-2-yl)-N,N-dimethylbenzamide",CN(C)C(=O)c1ccc(cc1)c2ccc3[C@H](c4cccc(F)c4Oc3n2)C(C)(C)C(=O)NC(=O)C,CHEMBL3315050,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 69.4nM,partial agonist,55.00%,agonist,dexamethasone,,,,,,,EC50,=,1046,nM,,,,,=,7.15864053,pKi,B,FPA,CC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N(C)C)cc3)nc2Oc2c(F)cccc21,55,449.312,475.1907345,1,5,4,3,4.516,88.6,C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,98
6489,3861,18722772,22,Q03181,PPARB,Homo sapiens,2-(3-(4-methoxy-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,COc1cccc2c1ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(C)cc4C(=O)O,CHEMBL525366,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,partial agonist,44.00%,agonist,GW501516,,,,,,,PEC50,=,7.4,,,,,,=,8,pIC50,B,radiometric,COc1cccc2c1ccn2S(=O)(=O)c1cccc(C(=O)Nc2ccc(C)cc2C(=O)O)c1,44,444.339,464.1042074,2,6,6,4,4.14582,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6492,3862,18722772,33,Q03181,PPARB,Homo sapiens,5-chloro-2-(3-(4-methoxy-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,COc1cccc2c1ccn2S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL496744,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.2,partial agonist,49.00%,agonist,GW501516,,,,,,,PEC50,=,6.8,,,,,,=,8.2,pIC50,B,radiometric,COc1cccc2c1ccn2S(=O)(=O)c1cccc(C(=O)Nc2ccc(Cl)cc2C(=O)O)c1,49,467.781,484.0495849,2,6,6,4,4.4908,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6495,3863,18722772,31,Q03181,PPARB,Homo sapiens,2-(3-(7-methoxy-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,COc1cccc2ccn(c12)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(C)cc4C(=O)O,CHEMBL523594,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.3,partial agonist,37.00%,agonist,GW501516,,,,,,,PEC50,=,6.2,,,,,,=,7.3,pIC50,B,radiometric,COc1cccc2ccn(S(=O)(=O)c3cccc(C(=O)Nc4ccc(C)cc4C(=O)O)c3)c12,37,444.339,464.1042074,2,6,6,4,4.14582,114.7,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
6499,3865,18442912,5c,P10275,AR,Homo sapiens,"10-methoxy-4-methyl-1H-chromeno[3,4-f]quinoline-2,5-dione",COc1cccc2OC(=O)c3c(ccc4NC(=O)C=C(C)c34)c12,CHEMBL450933,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 28nM,partial agonist,72.00%,agonist,DHT,,,,,,,EC50,=,11,nM,IC50,>,10000,nM,=,7.552841969,pKi,B,radiometric,COc1cccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,72,294.201,307.0844579,1,4,1,4,3.10472,72.3,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,agonist,partial agonist,agonist,partial agonist,636
6509,387,24980053,14,P04150,GR,Homo sapiens,"(S)-N-acetyl-2-(9-fluoro-2-(4-(pyrrolidine-1-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCCC5,CHEMBL3315051,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 2.5nM,partial agonist,67.00%,agonist,dexamethasone,,,,,,,EC50,=,27,nM,,,,,=,8.602059991,pKi,B,FPA,CC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCCC4)cc3)nc2Oc2c(F)cccc21,67,473.334,501.2063846,1,5,4,3,5.0502,88.6,CC(C1CCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,819
6533,388,24980053,15,P04150,GR,Homo sapiens,"(S)-N-acetyl-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5,CHEMBL3315052,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 5.9nM,agonist,76.00%,agonist,dexamethasone,,,,,,,EC50,=,14,nM,,,,,=,8.229147988,pKi,B,FPA,CC(=O)NC(=O)C(C)(C)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,76,489.333,517.2012992,1,6,4,3,4.2866,97.83,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,863
6551,3887,19349176,rac-2Ag,P37231,PPARG,Homo sapiens,2-methoxy-3-(4-(2-(2-(2-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3OC)c4ccsc14)C(=O)O,CHEMBL519802,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 916nM,partial agonist,64.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,1615,nM,,,,,=,6.038104526,pIC50,,radiometric,COc1ccccc1-c1nc(CCOc2ccc(CC(OC)C(=O)O)c3sccc23)c(C)o1,64,442.343,467.1402585,1,7,10,4,5.13692,91.02,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
6552,3887,19349176,rac-2Ag,Q07869,PPARA,Homo sapiens,2-methoxy-3-(4-(2-(2-(2-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3OC)c4ccsc14)C(=O)O,CHEMBL519802,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 294nM,agonist,101.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,435,nM,,,,,=,6.53165267,pIC50,,radiometric,COc1ccccc1-c1nc(CCOc2ccc(CC(OC)C(=O)O)c3sccc23)c(C)o1,101,442.343,467.1402585,1,7,10,4,5.13692,91.02,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
6553,3888,12954062,7f,P04150,GR,Homo sapiens,"9-Fluoro-5-[1-(2-methoxy-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL335996,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 277nM,antagonist,81.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,90,nM,=,6.557520231,pKi,,radiometric,COc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,81,389.3,413.1791072,1,3,2,3,6.9992,30.49,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
6554,3888,12954062,7f,P06401,PR,Homo sapiens,"9-Fluoro-5-[1-(2-methoxy-phenyl)-meth-(Z)-ylidene]-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL335996,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.8nM,agonist,154.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.93,nM,,,,,=,8.420216403,pKi,B,radiometric,COc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,154,389.3,413.1791072,1,3,2,3,6.9992,30.49,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
6568,3898,25993269,24e,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Methoxyphenyl Ester,COc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5,CHEMBL3589697,,,,Ki > 5000nM,antagonist,164.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,COc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)NO)cc1)=C2c1ccc(O)cc1,164,600.435,636.2141517,4,9,14,3,5.0446,160.49,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
6569,3898,25993269,24e,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Methoxyphenyl Ester,COc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5,CHEMBL3589697,,,,Ki = 2833.33nM,partial antagonist,74.00%,antagonist,E2,,,,,,,EC50,=,23,nM,,,,,=,5.54770284,pKi,,other,COc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)NO)cc1)=C2c1ccc(O)cc1,74,600.435,636.2141517,4,9,14,3,5.0446,160.49,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,partial antagonist,agonist,partial antagonist,1126
6570,3899,25993269,23i,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(2-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,COc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589359,,,,Ki = 158.97nM,agonist,104.00%,antagonist,E2,,,,,,,EC50,=,16,nM,,,,,=,6.798684826,pKi,,other,COc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,104,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
6571,3899,25993269,23i,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(2-methoxyphenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,COc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589359,,,,Ki = 95.24nM,antagonist,78.00%,antagonist,E2,,,,,,,EC50,=,1800,nM,IC50,=,290,nM,=,7.021180613,pKi,B,other,COc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,78,586.428,621.2032527,3,8,14,3,5.6238,148.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,1126
6584,3906,19606870,23,P10275,AR,Homo sapiens,16-[(2-Methoxypyrimidin-5-yl)methylidene]-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,COc1ncc(\C=C\2/C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,CHEMBL559878,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 11nM,agonist,158.00%,agonist,R1877,100nM,methyltrienolone,,,,,EC50,=,2,nM,,,,,=,7.958607315,pIC50,B,radiometric,COc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,158,390.293,423.2521919,1,5,2,1,3.4788,75.55,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
6593,3912,19926282,14,P06401,PR,Homo sapiens,(S)-4-(benzyl(1-(methylsulfonyl)pyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2)c3ccc(C#N)c(Cl)c3,CHEMBL591072,,,,IC50 = 63nM,partial agonist,53.00%,agonist,,,,,,,,EC50,=,843,nM,,,,,=,7.200659451,pIC50,B,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2)c2ccc(C#N)c(Cl)c2)C1,53,369.748,389.0964756,0,4,5,2,3.25218,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
6594,3913,19926282,19,P06401,PR,Homo sapiens,(S)-4-((2-bromobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)-2-chlorobenzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2Br)c3ccc(C#N)c(Cl)c3,CHEMBL592017,,,,IC50 = 5nM,agonist,87.00%,agonist,,,,,,,,EC50,=,3,nM,,,,,=,8.301029996,pIC50,B,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2Br)c2ccc(C#N)c(Cl)c2)C1,87,449.652,467.0069876,0,4,5,2,4.01468,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
6595,3914,19926282,16,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-cyanobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2C#N)c3ccc(C#N)c(Cl)c3,CHEMBL590835,,,,IC50 = 100nM,partial agonist,53.00%,agonist,,,,,,,,EC50,=,1130,nM,,,,,=,7,pIC50,,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C#N)c2ccc(C#N)c(Cl)c2)C1,53,395.766,414.0917245,0,5,5,2,3.12386,88.2,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
6596,3915,19926282,8,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-(methylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL591092,,,,IC50 = 13nM,agonist,82.00%,agonist,,,,,,,,EC50,=,11,nM,,,,,=,7.886056648,pIC50,B,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,82,438.753,457.0838602,0,4,5,2,4.27098,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
6597,3916,19926282,18,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL602745,,,,IC50 = 6nM,agonist,88.00%,agonist,,,,,,,,EC50,=,1,nM,,,,,=,8.22184875,pIC50,B,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,88,405.201,423.0575032,0,4,5,2,3.90558,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
6598,3917,19926282,17,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-fluorobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2F)c3ccc(C#N)c(Cl)c3,CHEMBL584422,,,,IC50 = 20nM,partial agonist,66.00%,agonist,,,,,,,,EC50,=,36,nM,,,,,=,7.698970004,pIC50,B,other,CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2F)c2ccc(C#N)c(Cl)c2)C1,66,388.746,407.0870537,0,4,5,2,3.39128,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
6600,3919,20469868,20b,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]methanesulfonamide,CS(=O)(=O)Nc1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1084360,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 8.0,antagonist,80.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.8,,=,8,pIC50,B,FPA,CS(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,80,434.309,449.0821106,1,4,4,4,5.2219,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,107
6638,3936,20382019,8q,P55055,LXRB,Homo sapiens,"4-(2',4'-difluoro-5'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline",CS(=O)(=O)c1cc(c(F)cc1F)c2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F,CHEMBL1097140,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.9nM,agonist,76.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,565,nM,,,,,=,8.30980392,pIC50,B,radiometric,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c(F)cc1F,76,449.315,463.0665408,0,3,3,4,6.2693,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
6640,3937,20382019,8p,P55055,LXRB,Homo sapiens,4-(4'-fluoro-3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1cc(ccc1F)c2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F,CHEMBL1097160,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.6nM,agonist,76.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,512,nM,,,,,=,8.585026652,pIC50,B,radiometric,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)ccc1F,76,430.317,445.0759626,0,3,3,4,6.1302,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
6642,3938,19962892,26,P55055,LXRB,Homo sapiens,4-(3-(3-chloro-5-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline-3-carboxamide,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)N)c1,CHEMBL602446,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 62nM,,,,,,T0901317,,,,,,,,,,,,,=,7.20760831,pIC50,B,radiometric,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,,504.788,520.0471403,1,5,5,4,5.8687,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
6643,3938,20350005,26,P55055,LXRB,Homo sapiens,4-(3-(3-chloro-5-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline-3-carboxamide,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)N)c1,CHEMBL602446,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 61nM,agonist,84.00%,agonist,1a,170nM,,,,,,EC50,=,1700,nM,,,,,=,7.214670165,pIC50,B,radiometric,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,84,504.788,520.0471403,1,5,5,4,5.8687,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
6644,3938,19962892,26,Q13133,LXRA,Homo sapiens,4-(3-(3-chloro-5-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline-3-carboxamide,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)N)c1,CHEMBL602446,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1772nM,,,,,,T0901317,,,,,,,,,,,,,=,5.751536282,pIC50,,radiometric,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,,504.788,520.0471403,1,5,5,4,5.8687,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,partial agonist,280
6645,3938,20350005,26,Q13133,LXRA,Homo sapiens,4-(3-(3-chloro-5-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline-3-carboxamide,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)N)c1,CHEMBL602446,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1770nM,partial agonist,36.00%,agonist,1a,140nM,,,,,,EC50,=,5100,nM,,,,,=,5.752026734,pIC50,,radiometric,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,36,504.788,520.0471403,1,5,5,4,5.8687,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6656,3944,20382019,8f,P55055,LXRB,Homo sapiens,3-benzyl-4-(4'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1ccc(cc1)c2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F,CHEMBL1098402,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 109nM,partial agonist,44.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,3300,nM,,,,,=,6.962573502,pIC50,,radiometric,CS(=O)(=O)c1ccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,44,495.396,517.1323346,0,3,5,5,7.5819,47.03,C1CCC(CC2CCC3CCCCC3C2C2CCCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,237
6660,395,17533125,2t,P37231,PPARG,Homo sapiens,N-((S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propyl)-acetamide,CC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1)Nc4ccccc4C(=O)c5ccccc5,CHEMBL230259,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 6.86,partial agonist,54.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,6.86,pKi,,radiometric,CC(=O)NC[C@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)Nc1ccccc1C(=O)c1ccccc1,54,538.413,573.2627566,2,6,13,5,6.66182,93.46,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,,partial agonist,,partial agonist,881
6672,396,24685544,28,P51449,RORG,Homo sapiens,N-((4'-((N-isobutyl-1-phenylmethylsulfonamido)methyl)biphenyl-4-yl)methyl)acetamide,CC(C)CN(Cc1ccc(cc1)c2ccc(CNC(=O)C)cc2)S(=O)(=O)Cc3ccccc3,CHEMBL3263717,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 1000nM,inverse agonist,-78.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,2700,nM,,,,,=,6,pIC50,,radiometric,CC(=O)NCc1ccc(-c2ccc(CN(CC(C)C)S(=O)(=O)Cc3ccccc3)cc2)cc1,-78,432.375,464.2133639,1,3,10,3,4.9777,66.48,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
6676,3963,25435151,3a,P55055,LXRB,Homo sapiens,"1-(2,4-difluorobenzyl)-6-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(c1)c2ccc(s2)C3=CC(=C(C#N)C(=O)N3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360960,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,agonist,100.00%,agonist,compound 3b,,,,,,,EC50,=,2,nM,,,,,=,7.958607315,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,100,535.41,550.0444254,0,6,5,4,5.86428,79.93,CC1CCCC(C2CCC(C3CCCCC3)C2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,737
6677,3963,25435151,3a,Q13133,LXRA,Homo sapiens,"1-(2,4-difluorobenzyl)-6-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(c1)c2ccc(s2)C3=CC(=C(C#N)C(=O)N3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360960,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,agonist,100.00%,agonist,compound 3b,,,,,,,EC50,=,4,nM,,,,,=,7.958607315,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,100,535.41,550.0444254,0,6,5,4,5.86428,79.93,CC1CCCC(C2CCC(C3CCCCC3)C2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,737
6678,3964,25435151,6,P55055,LXRB,Homo sapiens,5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1-(2-(trifluoromethyl)phenyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3c4ccccc4C(F)(F)F)C(F)(F)F,CHEMBL3360965,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 16nM,agonist,85.00%,agonist,compound 3b,,,,,,,EC50,=,68,nM,,,,,=,7.795880017,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,85,502.376,516.040089,0,5,4,4,6.7089,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,139
6679,3964,25435151,6,Q13133,LXRA,Homo sapiens,5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1-(2-(trifluoromethyl)phenyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3c4ccccc4C(F)(F)F)C(F)(F)F,CHEMBL3360965,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 240nM,partial agonist,39.00%,agonist,compound 3b,,,,,,,EC50,=,120,nM,,,,,=,6.619788758,pIC50,,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,39,502.376,516.040089,0,5,4,4,6.7089,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,139
6680,3965,25435151,7,P55055,LXRB,Homo sapiens,1-(2-chlorophenyl)-5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(cc2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360966,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,partial agonist,61.00%,agonist,compound 3b,,,,,,,EC50,=,49,nM,,,,,=,7.886056648,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,61,460.779,476.0573111,0,4,4,4,6.282,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,140
6681,3965,25435151,7,Q13133,LXRA,Homo sapiens,1-(2-chlorophenyl)-5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(cc2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360966,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 180nM,partial agonist,30.00%,agonist,compound 3b,,,,,,,EC50,=,220,nM,,,,,=,6.744727495,pIC50,,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,30,460.779,476.0573111,0,4,4,4,6.282,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,140
6682,3966,25435151,5,P55055,LXRB,Homo sapiens,1-(2-chlorophenyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360964,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,agonist,90.00%,agonist,compound 3b,,,,,,,EC50,=,110,nM,,,,,=,7.920818754,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,90,468.824,482.013732,0,5,4,4,6.3435,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,139
6683,3966,25435151,5,Q13133,LXRA,Homo sapiens,1-(2-chlorophenyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360964,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 68nM,partial agonist,65.00%,agonist,compound 3b,,,,,,,EC50,=,140,nM,,,,,=,7.167491087,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,65,468.824,482.013732,0,5,4,4,6.3435,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,139
6684,3967,25435151,4,P55055,LXRB,Homo sapiens,"1-(2,4-difluorobenzyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazole",CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360963,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7nM,agonist,92.00%,agonist,compound 3b,,,,,,,EC50,=,14,nM,,,,,=,8.15490196,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,92,483.378,498.0495108,0,5,5,4,6.0274,51.96,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,245
6685,3967,25435151,4,Q13133,LXRA,Homo sapiens,"1-(2,4-difluorobenzyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazole",CS(=O)(=O)c1cccc(c1)c2ccc(s2)c3cc(nn3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360963,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,agonist,98.00%,agonist,compound 3b,,,,,,,EC50,=,18,nM,,,,,=,7.698970004,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,98,483.378,498.0495108,0,5,5,4,6.0274,51.96,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,245
6688,3969,25435151,13,P55055,LXRB,Homo sapiens,2-(2-chlorophenyl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-4-(trifluoromethyl)-1H-imidazole,CS(=O)(=O)c1cccc(c1)c2ccc(cc2)n3cc(nc3c4ccccc4Cl)C(F)(F)F,CHEMBL3360970,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,agonist,76.00%,agonist,compound 3b,,,,,,,EC50,=,61,nM,,,,,=,7.958607315,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(-n3cc(C(F)(F)F)nc3-c3ccccc3Cl)cc2)c1,76,460.779,476.0573111,0,4,4,4,6.282,51.96,C1CCC(C2CCC(C3CCCC3C3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,140
6693,3970,20345102,13,P55055,LXRB,Homo sapiens,N-(2-chloro-6-fluorobenzyl)-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)cyclopropanesulfonamide,CS(=O)(=O)c1cccc(c1)c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C4CC4)cc2,CHEMBL1093840,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.2,agonist,90.00%,agonist,Compound 2,,,,,,,PEC50,=,7.7,,,,,,=,8.2,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C3CC3)cc2)c1,90,484.852,507.0741061,0,4,8,3,5.044,71.52,CC(C)(C1CC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,agonist,agonist,agonist,921
6694,3971,20345102,12,P55055,LXRB,Homo sapiens,N-(2-chloro-6-fluorobenzyl)-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide,CS(=O)(=O)c1cccc(c1)c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c4ccccc4)cc2,CHEMBL1093554,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.3,agonist,120.00%,agonist,Compound 2,,,,,,,PEC50,=,9,,,,,,=,8.3,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,120,520.885,543.0741061,0,4,8,4,5.9407,71.52,CC(C)(C1CCCCC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,agonist,agonist,agonist,1068
6695,3972,20345102,11,P55055,LXRB,Homo sapiens,N-(2-chloro-4-fluorobenzyl)-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide,CS(=O)(=O)c1cccc(c1)c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c4ccccc4)cc2,CHEMBL1091034,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.4,agonist,100.00%,agonist,Compound 2,,,,,,,PEC50,=,8.5,,,,,,=,8.4,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,100,520.885,543.0741061,0,4,8,4,5.9407,71.52,CC(C)(C1CCCCC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,agonist,agonist,agonist,1068
6696,3973,20382019,8e,P55055,LXRB,Homo sapiens,3-benzyl-4-(3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1cccc(c1)c2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F,CHEMBL1098401,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.5nM,agonist,112.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,100,nM,,,,,=,8.823908741,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,112,495.396,517.1323346,0,3,5,5,7.5819,47.03,C1CCC(CC2CCC3CCCCC3C2C2CCCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,237
6698,3974,25435151,8,P55055,LXRB,Homo sapiens,1-(2-chlorophenyl)-5-(3'-(methylsulfonyl)biphenyl-3-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2cccc(c2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360967,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 31nM,agonist,95.00%,agonist,compound 3b,,,,,,,EC50,=,230,nM,,,,,=,7.508638306,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,95,460.779,476.0573111,0,4,4,4,6.282,51.96,C1CCC(C2CCCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,161
6699,3974,25435151,8,Q13133,LXRA,Homo sapiens,1-(2-chlorophenyl)-5-(3'-(methylsulfonyl)biphenyl-3-yl)-3-(trifluoromethyl)-1H-pyrazole,CS(=O)(=O)c1cccc(c1)c2cccc(c2)c3cc(nn3c4ccccc4Cl)C(F)(F)F,CHEMBL3360967,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 300nM,partial agonist,66.00%,agonist,compound 3b,,,,,,,EC50,=,320,nM,,,,,=,6.522878745,pIC50,,radiometric,CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,66,460.779,476.0573111,0,4,4,4,6.282,51.96,C1CCC(C2CCCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,161
6700,3975,20382019,8a,P55055,LXRB,Homo sapiens,4-(3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1cccc(c1)c2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F,CHEMBL1095714,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.4nM,partial agonist,73.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,525,nM,,,,,=,8.356547324,pIC50,B,radiometric,CS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,73,411.319,427.0853844,0,3,3,4,5.9911,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,162
6704,3977,20005711,7h,P55055,LXRB,Homo sapiens,"3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-2-phenyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(cccn34)C(F)(F)F)c5ccccc5)c1,CHEMBL611734,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.2nM,partial agonist,64.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,570,nM,,,,,=,8.142667504,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,64,489.369,508.1068481,0,5,5,5,6.8829,60.67,C1CCC(CC2CCCC(C3C4CCCCC4CC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,271
6705,3977,20005711,7h,Q13133,LXRA,Homo sapiens,"3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-2-phenyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(cccn34)C(F)(F)F)c5ccccc5)c1,CHEMBL611734,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 91nM,partial agonist,54.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1110,nM,,,,,=,7.040958608,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,54,489.369,508.1068481,0,5,5,5,6.8829,60.67,C1CCC(CC2CCCC(C3C4CCCCC4CC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,271
6706,3978,20005711,7o,P55055,LXRB,Homo sapiens,"2-((1H-imidazol-1-yl)methyl)-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(cccn34)C(F)(F)F)n5ccnc5)c1,CHEMBL608531,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,81.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,850,nM,,,,,=,7.522878745,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,81,481.35,498.0973461,0,7,5,5,5.4016,78.49,C1CCC(CC2CCCC(C3C4CCCCC4CC3C3CCCC3)C2)CC1,agonist,agonist,agonist,agonist,270
6707,3978,20005711,7o,Q13133,LXRA,Homo sapiens,"2-((1H-imidazol-1-yl)methyl)-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(nc4c(cccn34)C(F)(F)F)n5ccnc5)c1,CHEMBL608531,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 365nM,agonist,79.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1700,nM,,,,,=,6.437707136,pIC50,,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,79,481.35,498.0973461,0,7,5,5,5.4016,78.49,C1CCC(CC2CCCC(C3C4CCCCC4CC3C3CCCC3)C2)CC1,agonist,agonist,agonist,agonist,270
6717,3983,19962892,16,P55055,LXRB,Homo sapiens,4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline-3-carboxamide,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)N)c1,CHEMBL591582,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 18nM,agonist,85.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,1600,nM,,,,,=,7.744727495,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,85,469.335,486.0861127,1,5,5,4,5.2153,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
6719,3984,19962892,33,P55055,LXRB,Homo sapiens,8-chloro-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)quinoline-3-carboxamide,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(cnc4c(Cl)cccc34)C(=O)N)c1,CHEMBL593267,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 16nM,partial agonist,72.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,630,nM,,,,,=,7.795880017,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,72,435.783,452.0597557,1,5,5,4,4.8499,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6720,3984,19962892,33,Q13133,LXRA,Homo sapiens,8-chloro-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)quinoline-3-carboxamide,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(cnc4c(Cl)cccc34)C(=O)N)c1,CHEMBL593267,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 543nM,partial agonist,57.00%,agonist,T0901317,140nM,T0901317,,,,,EC50,=,3000,nM,,,,,=,6.26520017,pIC50,,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,57,435.783,452.0597557,1,5,5,4,4.8499,99.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6729,3989,20005711,7m,P55055,LXRB,Homo sapiens,"3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-2-(piperidin-1-ylmethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(CN4CCCCC4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL612006,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 69nM,partial agonist,56.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,204,nM,,,,,=,7.161150909,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,56,503.376,529.1646974,0,6,6,4,6.2018,63.91,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,277
6730,3989,20005711,7m,Q13133,LXRA,Homo sapiens,"3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-2-(piperidin-1-ylmethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(CN4CCCCC4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL612006,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 > 1000nM,partial agonist,45.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,920,nM,,,,,>,6,pIC50,,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,45,503.376,529.1646974,0,6,6,4,6.2018,63.91,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,277
6732,3990,20005711,7n,P55055,LXRB,Homo sapiens,"3-((3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)thiazolidine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(CN4CCSC4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL612007,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.0nM,partial agonist,62.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,32,nM,,,,,=,8.698970004,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,62,511.421,533.1054682,0,7,6,4,5.7222,63.91,C1CCC(CC2CCCC(C3C(CC4CCCC4)CC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,275
6733,3990,20005711,7n,Q13133,LXRA,Homo sapiens,"3-((3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methyl)thiazolidine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(CN4CCSC4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL612007,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,partial agonist,64.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,64,511.421,533.1054682,0,7,6,4,5.7222,63.91,C1CCC(CC2CCCC(C3C(CC4CCCC4)CC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,275
6734,3991,19932617,7d,P55055,LXRB,Homo sapiens,3-benzyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL592506,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.92nM,agonist,78.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,11,nM,,,,,=,9.036212173,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,78,511.395,533.1272492,0,4,6,5,7.7072,56.26,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
6736,3992,19932617,7f,P55055,LXRB,Homo sapiens,3-benzyl-8-chloro-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)quinoline,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(Cl)cccc35)c1,CHEMBL606539,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.2nM,agonist,85.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,30,nM,,,,,=,8.920818754,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)c1,85,477.843,499.1008922,0,4,6,5,7.3418,56.26,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
6738,3993,20005711,7i,P55055,LXRB,Homo sapiens,"2-benzyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL611735,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.81nM,agonist,88.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,20,nM,,,,,=,9.091514981,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,88,501.38,522.1224982,0,5,6,5,6.8067,60.67,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,277
6739,3993,20005711,7i,Q13133,LXRA,Homo sapiens,"2-benzyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)nc5c(cccn35)C(F)(F)F)c1,CHEMBL611735,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.9nM,partial agonist,62.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,144,nM,,,,,=,8.229147988,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,62,501.38,522.1224982,0,5,6,5,6.8067,60.67,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,277
6740,3994,19932617,7e,P55055,LXRB,Homo sapiens,4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F)c1,CHEMBL593241,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.8nM,partial agonist,44.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,214,nM,,,,,=,8.552841969,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,44,427.318,443.080299,0,4,4,4,6.1164,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6742,3995,19932617,7h,P55055,LXRB,Homo sapiens,8-chloro-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)quinoline,CS(=O)(=O)c1cccc(Oc2cccc(c2)c3ccnc4c(Cl)cccc34)c1,CHEMBL593471,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.2nM,partial agonist,45.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,382,nM,,,,,=,8.142667504,pIC50,B,radiometric,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(Cl)cccc34)c2)c1,45,393.766,409.0539421,0,4,4,4,5.751,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
6752,4,19464171,10,P37231,PPARG,Homo sapiens,"2-(2,3-dimethyl-4-(2-(prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#C)ccc1OCC(=O)O,CHEMBL524063,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 300nM,partial agonist,40.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,3000,nM,,,,,=,6.522878745,pKi,,other,C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c(C)c1C,40,493.353,516.1218295,1,5,10,3,6.52784,64.99,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,336
6753,4,19464171,10,Q03181,PPARB,Homo sapiens,"2-(2,3-dimethyl-4-(2-(prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#C)ccc1OCC(=O)O,CHEMBL524063,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4nM,agonist,86.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,54,nM,,,,,=,8.397940009,pKi,B,radiometric,C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c(C)c1C,86,493.353,516.1218295,1,5,10,3,6.52784,64.99,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,336
6754,4,19464171,10,Q07869,PPARA,Homo sapiens,"2-(2,3-dimethyl-4-(2-(prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#C)ccc1OCC(=O)O,CHEMBL524063,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 210nM,partial agonist,48.00%,agonist,GW2433,,GW2433,10nM,,,,EC50,=,6100,nM,,,,,=,6.677780705,pKi,,radiometric,C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c(C)c1C,48,493.353,516.1218295,1,5,10,3,6.52784,64.99,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,336
6773,4008,10743937,11a,P10275,AR,Homo sapiens,"2,2-Dimethyl-8-methylsulfanyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CSc1cc(c2cc3CCC(C)(C)Nc3cc2n1)C(F)(F)F,CHEMBL134242,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,95.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,751,nM,>,6,pKi,,other,CSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,95,309.251,326.1064542,1,3,1,2,5.1122,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
6780,4012,12954062,7g,P04150,GR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(2-methylsulfanyl-phenyl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CSc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL422444,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 386nM,antagonist,98.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,=,860,nM,=,6.413412695,pKi,,radiometric,CSc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,98,405.368,429.1562636,1,3,2,3,7.7125,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,222
6781,4012,12954062,7g,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-[1-(2-methylsulfanyl-phenyl)-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CSc1ccccc1\C=C\2/Oc3ccc(F)cc3c4ccc5NC(C)(C)C=C(C)c5c24,CHEMBL422444,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.59nM,agonist,132.00%,agonist,progesterone,,progesterone,,,,,EC50,=,6.2,nM,,,,,=,9.229147988,pKi,B,radiometric,CSc1ccccc1/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,132,405.368,429.1562636,1,3,2,3,7.7125,21.26,C1CCC(CC2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,agonist,agonist,agonist,222
6787,4016,17267219,(S)-8d,P10275,AR,Homo sapiens,"(S)-6-((1-chloropropan-2-yl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",C[C@@H](CCl)N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL235347,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.8nM,agonist,87.00%,agonist,DHT,,,,,,,EC50,=,3.6,nM,IC50,>,10000,nM,=,8.008773924,pIC50,B,radiometric,C[C@@H](CCl)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,87,373.619,386.06206,1,2,4,2,4.5429,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
6816,4031,17267219,(R)-8a,P10275,AR,Homo sapiens,"(R)-6-((2,2,2-trifluoroethyl)(1,1,1-trifluoropropan-2-yl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",C[C@@H](N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F)C(F)(F)F,CHEMBL235127,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.2nM,agonist,86.00%,agonist,DHT,,,,,,,EC50,=,2.3,nM,IC50,>,10000,nM,=,8.036212173,pIC50,B,radiometric,C[C@@H](N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,86,395.16,406.072767,1,2,3,2,4.8664,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
6820,4035,22070604,32,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-chlorobenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",C[C@@H](Oc1cc(CN2C(=O)N(c3ccc(cc23)C(F)(F)F)c4noc5cc(Cl)ccc45)ccc1Cl)C(=O)O,CHEMBL1946570,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 68nM,partial agonist,32.00%,agonist,rosiglitazone,,,,,,,EC50,=,200,nM,,,,,=,7.167491087,pIC50,B,radiometric,C[C@@H](Oc1cc(Cn2c(=O)n(-c3noc4cc(Cl)ccc34)c3ccc(C(F)(F)F)cc32)ccc1Cl)C(=O)O,32,550.191,565.0419106,1,7,6,5,6.1592,99.49,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6821,4036,22070604,36,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(5-chlorobenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",C[C@@H](Oc1cc(CN2C(=O)N(c3ccc(cc23)C(F)(F)F)c4noc5ccc(Cl)cc45)ccc1Cl)C(=O)O,CHEMBL1946754,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 35.4nM,partial agonist,36.00%,agonist,rosiglitazone,,,,,,,EC50,=,120,nM,,,,,=,7.450996738,pIC50,B,radiometric,C[C@@H](Oc1cc(Cn2c(=O)n(-c3noc4ccc(Cl)cc34)c3ccc(C(F)(F)F)cc32)ccc1Cl)C(=O)O,36,550.191,565.0419106,1,7,6,5,6.1592,99.49,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
6827,4040,10212133,18,P06401,PR,Homo sapiens,"(4S,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL35429,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.3nM,agonist,122.00%,agonist,progesterone,,progesterone,,,,,EC50,=,4.5,nM,,,,,=,8.886056648,pKi,B,radiometric,C[C@@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1ccc(Cl)cc1)Oc1ccccc1-3,122,381.733,403.1339066,1,3,1,3,6.3655,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
6830,4041,10212133,24,P06401,PR,Homo sapiens,"(4S,5S)-2,2,4-Trimethyl-5-(3-trifluoromethyl-phenyl)-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5cccc(c5)C(F)(F)F)c3c12,CHEMBL36065,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16.6nM,agonist,93.00%,agonist,progesterone,,progesterone,,,,,EC50,=,14,nM,,,,,=,7.779891912,pKi,B,radiometric,C[C@@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1cccc(C(F)(F)F)c1)Oc1ccccc1-3,93,415.285,437.1602636,1,3,1,3,6.7309,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
6833,4042,10212133,22,P06401,PR,Homo sapiens,"(4S,5S)-5-(3-Fluoro-phenyl)-2,2,4-trimethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5cccc(F)c5)c3c12,CHEMBL36564,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.6nM,agonist,106.00%,agonist,progesterone,,progesterone,,,,,EC50,=,6.3,nM,,,,,=,8.585026652,pKi,B,radiometric,C[C@@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1cccc(F)c1)Oc1ccccc1-3,106,365.278,387.1634572,1,3,1,3,5.8512,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
6836,4043,10212133,20,P06401,PR,Homo sapiens,"(4S,5S)-2,2,4-Trimethyl-5-phenyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccccc5)c3c12,CHEMBL284475,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.6nM,agonist,92.00%,agonist,progesterone,,progesterone,,,,,EC50,=,10,nM,,,,,=,8.180456064,pKi,B,radiometric,C[C@@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1ccccc1)Oc1ccccc1-3,92,346.28,369.172879,1,3,1,3,5.7121,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
6842,4046,10212133,9,P06401,PR,Homo sapiens,"(4R,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",C[C@@H]1CC(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL36076,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 91nM,partial agonist,58.00%,agonist,progesterone,,progesterone,,,,,EC50,=,48,nM,IC50,=,3100,nM,=,7.040958608,pKi,B,radiometric,C[C@@H]1CC(C)(C)Nc2ccc3c(c21)[C@H](c1ccc(Cl)cc1)Oc1ccccc1-3,58,365.734,389.1546421,1,2,1,3,7.1865,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,61
6843,4047,15911283,39,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4',4a,6'-tetramethyl-(4aS,6'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1CC(C)(C)O[C@@]2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL195967,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,partial agonist,59.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,25,nM,,,,,=,8.677780705,pIC50,B,radiometric,C[C@@H]1CC(C)(C)O[C@@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,59,355.263,382.2056563,0,4,1,2,5.0513,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
6844,4048,15911283,38,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4',4a,6'-tetramethyl-(4aS,6'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1CC(C)(C)O[C@]2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL195654,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.2nM,partial agonist,44.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,12,nM,,,,,=,8.657577319,pIC50,B,radiometric,C[C@@H]1CC(C)(C)O[C@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,44,355.263,382.2056563,0,4,1,2,5.0513,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
6861,4055,15911283,33,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a-dimethyl-(4'R,4aS,5'S)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1CCO[C@@]2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL380790,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 18nM,partial agonist,46.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.48,nM,,,,,=,7.744727495,pIC50,B,radiometric,C[C@@H]1CCO[C@@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,46,331.241,354.1743562,0,4,1,2,4.2727,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
6862,4056,17887661,(+/-)4d,P10275,AR,Homo sapiens,"rac-6-(trans-2,5-dimethylpyrrolidin-1-yl)-4-trifluoromethyl-1H-quinolin-2-one",C[C@@H]1CC[C@@H](C)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL243251,Luciferase reporter gene assay,,,Ki = 43nM,agonist,88.00%,agonist,DHT,,,,,,,EC50,=,48,nM,,,,,=,7.366531544,pKi,B,other,C[C@@H]1CC[C@@H](C)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,88,293.183,310.1292978,1,2,1,2,3.9241,36.1,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,604
6863,4057,17887661,4f,P10275,AR,Homo sapiens,"6-((2R,5R)-2-chloromethyl-5-methylpyrrolidin-1-yl)-4-trifluoromethyl-1H-quinolin-2-one",C[C@@H]1CC[C@H](CCl)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL395992,Luciferase reporter gene assay,,,Ki = 10nM,agonist,101.00%,agonist,DHT,,,,,,,EC50,=,12,nM,,,,,=,8,pKi,B,other,C[C@@H]1CC[C@H](CCl)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,101,328.636,344.0903255,1,2,2,2,4.143,36.1,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,604
6864,4058,17887661,4e,P10275,AR,Homo sapiens,"6-((2R,5R)-2-hydroxymethyl-5-methylpyrrolidin-1-yl)-4-trifluoromethyl-1H-quinolin-2-one",C[C@@H]1CC[C@H](CO)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL243252,Luciferase reporter gene assay,,,Ki = 70nM,partial agonist,71.00%,agonist,DHT,,,,,,,EC50,=,21,nM,,,,,=,7.15490196,pKi,B,other,C[C@@H]1CC[C@H](CO)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,71,309.182,326.1242124,2,3,2,2,2.8965,56.33,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,604
6865,4059,17887661,6a,P10275,AR,Homo sapiens,"6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethyl-1Hquinolin-",C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL467888,Luciferase reporter gene assay,,,Ki = 1.5nM,agonist,109.00%,agonist,DHT,,,,,,,EC50,=,7.1,nM,,,,,=,8.823908741,pKi,B,other,C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,109,378.187,394.1115971,2,3,2,2,3.8274,56.33,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,604
6867,4060,17887661,6b,P10275,AR,Homo sapiens,"6-[(2R,5R)-2-methyl-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethyl-1Hquinolin-",C[C@@H]1CC[C@H]([C@H](O)C(F)(F)F)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL2113293,Luciferase reporter gene assay,,,Ki = 7.6nM,agonist,111.00%,agonist,DHT,,,,,,,EC50,=,8.4,nM,,,,,=,8.119186408,pKi,B,other,C[C@@H]1CC[C@H]([C@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,111,378.187,394.1115971,2,3,2,2,3.8274,56.33,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,604
6868,4061,10230629,8,P10275,AR,Homo sapiens,"(R)-8-Methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@@H]1CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL267141,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7nM,partial antagonist,37.00%,antagonist,DHT,,DHT,,,,,EC50,=,21,nM,IC50,=,19,nM,=,8.15490196,pKi,B,radiometric,C[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,37,269.161,282.0979977,2,3,0,2,3.7058,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
6873,4064,15925510,9c,P06401,PR,Homo sapiens,"(R)-1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole",C[C@@H]1CN(N=C1c2ccc(Cl)c(Cl)c2)S(=O)(=O)c3ccc(Cl)cc3,CHEMBL192859,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 5.7,partial antagonist,48.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,5.3,,=,5.7,pKi,,FPA,C[C@@H]1CN(S(=O)(=O)c2ccc(Cl)cc2)N=C1c1ccc(Cl)c(Cl)c1,48,390.614,401.9763317,0,3,3,2,4.6915,49.74,CC(C)(C1CCCCC1)C1CCC(C2CCCCC2)C1,antagonist,partial antagonist,antagonist,partial antagonist,1021
6874,4065,9871534,11,P10275,AR,Homo sapiens,"(S)-3-Methyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@@H]1CNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL349229,,,,Ki = 17nM,partial agonist,43.00%,agonist,DHT,,,,,,,EC50,=,62,nM,,,inactive,,=,7.769551079,pKi,B,other,C[C@@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc21,43,257.15,268.0823476,2,3,0,2,3.4882,45.15,CC1CCC2CC3CCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,578
6875,4066,10340624,6n,P10275,AR,Homo sapiens,"Cis-7-Methyl-4-trifluoromethyl-6-(3,3,3-trifluoro-propyl)-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@@H]1CNc2cc3nc(O)cc(c3cc2[C@@H]1CCC(F)(F)F)C(F)(F)F,CHEMBL2113247,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,47.00%,antagonist,DHT,,DHT,,,,,EC50,=,82,nM,IC50,=,63,nM,>,6,pKi,,radiometric,C[C@@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2[C@@H]1CCC(F)(F)F,47,362.188,378.1166825,2,3,2,2,5.4469,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
6876,4067,17439112,(R)-16e,P10275,AR,Homo sapiens,"(2R-)-(-)-1,2,3,6-tetrahydro-2-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",C[C@@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL224263,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.1nM,agonist,82.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,82,nM,IC50,>,10000,nM,=,8.148741651,pKi,B,radiometric,C[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,82,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
6877,4068,15911283,32 (table 1),P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,6'-trimethyl-(4'R,4aS,6'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1C[C@@H](C)OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL365546,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.4nM,partial agonist,58.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.5,nM,,,,,=,8.075720714,pIC50,B,radiometric,C[C@@H]1C[C@@H](C)OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,58,343.252,368.1900063,0,4,1,2,4.6612,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
6878,4068,15911283,32 (table 2),P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,6'-trimethyl-(4'R,4aS,6'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1C[C@@H](C)OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL365546,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.4nM,partial agonist,58.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.5,nM,,,,,=,8.075720714,pIC50,B,radiometric,C[C@@H]1C[C@@H](C)OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,58,343.252,368.1900063,0,4,1,2,4.6612,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
6879,4069,15911283,25,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,6'-trimethyl-(4'R,4aS,6'R)-spiro[4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1C[C@@H](C)OC2(CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL195451,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.3nM,partial agonist,27.00%,agonist,dexamethasone,,dexamethasone,,,,,,,,,,,,,=,8.080921908,pIC50,B,radiometric,C[C@@H]1C[C@@H](C)OC2(CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,27,355.263,382.2056563,0,4,1,2,5.0513,36.28,C1CCC(C2CCC3CC4C(CCCC45CCCCC5)CC32)CC1,,partial agonist,,partial agonist,96
6885,4073,15999989,2,P04150,GR,Homo sapiens,"(8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.10,,,,,,,,,,,,,,,PIC50,<,5,,=,8.1,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
6886,4073,16644222,dexamethasone,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,,,-,RBA = 100,agonist,100.00%,agonist,dexamethasone,,,,,,,,,,,,,,,=,100,RBA,,other,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,agonist,agonist,agonist,615
6887,4073,16821781,2,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,,,,PIC50 = 8.1 ,agonist,102.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.3,,PIC50,<,5,,=,8.1,pIC50,B,other,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,102,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6888,4073,17181172,1a,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,100.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,0.51,nM,,,,,=,8.522878745,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6889,4073,17616395,2,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.12,agonist,102.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.27,,,,,,=,8.12,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,102,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6890,4073,17692519,dex,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,100.00%,agonist,dexamethasone,,,,,,,EC50,=,0.5,nM,,,,,=,8.522878745,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6891,4073,18038970,"2, dexamethasone",P04150,GR,Homo sapiens,"(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,13,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3(9H,10H,14H)-one",C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,102.00%,agonist,dexamethasone,,,,,,,PEC50,=,8.3,,PIC50,<,5,,=,8.1,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,102,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6892,4073,19321341,dex,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.1nM,agonist,100.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,2.5,nM,,,,,=,8.958607315,pKi,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6893,4073,20047280,dex,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.2nM,agonist,100.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,4.5,nM,,,,,=,8.920818754,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6894,4073,20727743,DEX,P04150,GR,Homo sapiens,dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,7.9,pIC50,B,radiometric,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
6895,4073,20735001,dexamethasone,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.4nM,agonist,100.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,0.51,nM,,,,,=,8.468521083,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6896,4073,21073190,"1, dex",P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 1.1nM,agonist,100.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,2.5,nM,,,,,=,8.958607315,pKi,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6897,4073,21257309,3,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,99.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.4,,,,,,=,7.9,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,99,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6898,4073,21963986,Dexamethasone,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,100.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,0.51,nM,,,,,=,8.522878745,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6899,4073,23916594,Dex,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.2nM,agonist,100.00%,agonist,dexamethasone,,,,,,,EC50,=,4.5,nM,,,,,=,8.920818754,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6900,4073,24011644,Dexamethasone,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,Gal4 luciferase reporter gene assays,,-,Ki = 1.1nM,agonist,100.00%,agonist,dexamethasone,,,,,,,EC50,=,4.2,nM,,,,,=,8.958607315,pKi,B,other,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6901,4073,24215891,dex,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.5nM,agonist,96.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,0.5,nM,,,,,=,8.455931956,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,96,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6902,4073,24446728,dex,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.69nM,,,,,,dexamethasone,,,,,,,,,,,,,=,9.161150909,pKi,B,radiometric,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
6903,4073,24656565,Dexamethasone,P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,100.00%,agonist,,,,,,,,IC50,=,0.5,nM,,,,,=,8.522878745,pIC50,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6904,4073,24980053,"1, Dex",P04150,GR,Homo sapiens,Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL384467,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,agonist,100.00%,agonist,dexamethasone,,,,,,,EC50,=,4.5,nM,,,,,=,8.920818754,pKi,B,FPA,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,100,363.235,392.1999022,3,5,2,0,1.8957,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
6926,4074,19606870,10,P10275,AR,Homo sapiens,16alpha-(Methyl)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,C[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,CHEMBL538137,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 31nM,partial agonist,54.00%,agonist,R1865,100nM,methyltrienolone,,,,,EC50,=,119,nM,,,,,=,7.508638306,pIC50,B,radiometric,C[C@@H]1C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,54,286.225,317.2354792,1,2,0,0,3.2327,40.54,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,615
6934,4081,9871534,8,P10275,AR,Homo sapiens,"(R)-2,8-Dimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@@H]1Cc2cc3C(=CC(=O)N(C)c3cc2N1)C(F)(F)F,CHEMBL163366,,,,Ki = 9nM,partial agonist,66.00%,agonist,DHT,,,,,,,EC50,=,20,nM,,,inactive,,=,8.045757491,pKi,B,other,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N1,66,269.161,282.0979977,1,3,0,2,2.9138,34.03,CC1CCC2CC3CCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,578
6935,4082,9871534,7,P10275,AR,Homo sapiens,"(R)-2-Methyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@@H]1Cc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL351465,,,,Ki = 10nM,partial antagonist,55.00%,antagonist,DHT,,,,,,,EC50,=,168,nM,IC50,=,7,nM,=,8,pKi,B,other,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,55,257.15,268.0823476,2,3,0,2,3.3157,45.15,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,578
6936,4083,10230629,17,P10275,AR,Homo sapiens,"(7R,8R)-7,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1C)C(F)(F)F,CHEMBL7058,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,partial antagonist,41.00%,antagonist,DHT,,DHT,,,,,EC50,=,34,nM,IC50,=,74,nM,=,7.823908741,pKi,B,radiometric,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,41,281.172,296.1136478,2,3,0,2,3.9518,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
6956,4095,10212133,15b,P06401,PR,Homo sapiens,"(3S,4R,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysen-3-ol",C[C@H]1[C@H](O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL35431,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 500nM,partial antagonist,69.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,3200,nM,>,6.301029996,pKi,,radiometric,C[C@@H]1c2c(ccc3c2[C@H](c2ccc(Cl)cc2)Oc2ccccc2-3)NC(C)(C)[C@H]1O,69,381.733,405.1495567,2,3,1,3,6.1573,41.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,partial antagonist,antagonist,partial antagonist,61
6977,4106,20047280,46,P04150,GR,Homo sapiens,"(R)-1-(4-Fluorophenyl)-2-((5aR,6S)-1-(4-fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)propan-2-ol",C[C@@](O)(Cc1ccc(F)cc1)[C@H]2CCCC3=Cc4c(ncn4C[C@]23C)c5ccc(F)cc5,CHEMBL569100,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,partial agonist,63.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,760,nM,,,,,=,7.958607315,pIC50,B,FPA,C[C@@](O)(Cc1ccc(F)cc1)[C@H]1CCCC2=Cc3c(-c4ccc(F)cc4)ncn3C[C@@]21C,63,406.306,434.21697,1,3,4,3,6.0254,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,318
6979,4108,20047280,31,P04150,GR,Homo sapiens,"(S)-1-(4-Chlorophenyl)-1-((5aR,6S)-1-(4-fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(ncn3C[C@]12C)c4ccc(F)cc4)c5ccc(Cl)cc5,CHEMBL567027,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,partial agonist,35.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,697,nM,,,,,=,8.698970004,pIC50,B,FPA,C[C@@](O)(c1ccc(Cl)cc1)[C@H]1CCCC2=Cc3c(-c4ccc(F)cc4)ncn3C[C@@]21C,35,410.75,436.1717694,1,3,3,3,6.4537,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
6980,4109,20047280,39,P04150,GR,Homo sapiens,"(S)-1-(5-Chlorothiophen-2-yl)-1-((5aR,6S)-1-(4-fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)-ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(ncn3C[C@]12C)c4ccc(F)cc4)c5ccc(Cl)s5,CHEMBL572330,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,partial agonist,59.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,253,nM,,,,,=,8.397940009,pIC50,B,FPA,C[C@@](O)(c1ccc(Cl)s1)[C@H]1CCCC2=Cc3c(-c4ccc(F)cc4)ncn3C[C@@]21C,59,418.795,442.1281903,1,4,3,3,6.5152,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
6984,4111,15115388,21,P04150,GR,Homo sapiens,"1-((S)-4-Fluoro-phenyl)-1-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL311662,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.5nM,agonist,102.00%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,2.2,nM,,,,,=,8.602059991,pIC50,B,radiometric,C[C@@](O)(c1ccc(F)cc1)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,102,394.295,420.2013199,1,3,3,3,5.8041,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
6985,4111,20047280,27,P04150,GR,Homo sapiens,"(S)-1-(4-fluorophenyl)-1-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL311662,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.5nM,agonist,79.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,57,nM,,,,,=,8.602059991,pIC50,B,FPA,C[C@@](O)(c1ccc(F)cc1)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,79,394.295,420.2013199,1,3,3,3,5.8041,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
6996,4119,15115388,25,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-1-thiophen-3-yl-ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4)c5ccsc5,CHEMBL310570,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.8nM,agonist,96.80%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,1,nM,,,,,=,9.096910013,pIC50,B,radiometric,C[C@@](O)(c1ccsc1)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,96.8,383.342,408.1671626,1,4,3,3,5.7265,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,agonist,agonist,"agonist,partial agonist",88
6997,4119,15808489,4,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-1-thiophen-3-yl-ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4)c5ccsc5,CHEMBL310570,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.8nM,agonist,97.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.96,nM,,,,,=,9.096910013,pIC50,B,radiometric,C[C@@](O)(c1ccsc1)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,97,383.342,408.1671626,1,4,3,3,5.7265,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,agonist,agonist,"agonist,partial agonist",88
6998,4119,20047280,41,P04150,GR,Homo sapiens,"(S)-1-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)-1-(thiophen-3-yl)ethanol",C[C@](O)([C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4)c5ccsc5,CHEMBL310570,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.8nM,partial agonist,69.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,36,nM,,,,,=,9.096910013,pIC50,B,FPA,C[C@@](O)(c1ccsc1)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,69,383.342,408.1671626,1,4,3,3,5.7265,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",88
7012,4123,19321341,13a-(R),P04150,GR,Homo sapiens,"(15R)-8-cyano-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",C[C@]1(CC2(C#N)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL473801,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 0.9nM,partial agonist,53.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,243.1,nM,,,,,=,9.045757491,pKi,B,FPA,C[C@@]1(C(=O)Nc2nccs2)CC2(C#N)c3ccccc3C1c1ccccc12,53,354.329,371.1092332,1,4,2,3,4.44678,65.78,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
7016,4124,19321341,2a-(R),P04150,GR,Homo sapiens,"(15R)-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",C[C@]1(CC2c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL514646,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.3nM,partial agonist,41.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,114.9,nM,,,,,=,8.886056648,pKi,B,FPA,C[C@@]1(C(=O)Nc2nccs2)CC2c3ccccc3C1c1ccccc12,41,328.311,346.1139842,1,3,2,3,4.769,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
7053,414,24239186,31,P51449,RORG,Homo sapiens,"N-(5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)sulfamoyl)-4-methylthiazol-2-yl)acetamide",CC(=O)Nc1nc(C)c(s1)S(=O)(=O)Nc2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL3094388,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 2000nM,inverse agonist,-88.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,911,nM,,,,,=,5.698970004,pIC50,,radiometric,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,-88,464.304,477.0251672,3,6,5,2,3.52292,108.39,CC(C)(CC1CCCCC1)C1CCCC1,agonist,inverse agonist,agonist,inverse agonist,1132
7089,4157,17267219,(R)-8c,P10275,AR,Homo sapiens,"(R)-6-((1-chloropropan-2-yl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",C[C@H](CCl)N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL394194,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5.4nM,agonist,87.00%,agonist,DHT,,,,,,,EC50,=,3.7,nM,IC50,>,10000,nM,=,8.26760624,pIC50,B,radiometric,C[C@H](CCl)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,87,373.619,386.06206,1,2,4,2,4.5429,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
7101,4161,17267219,(S)-8b,P10275,AR,Homo sapiens,"(S)-6-((2,2,2-trifluoroethyl)(1,1,1-trifluoropropan-2-yl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",C[C@H](N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F)C(F)(F)F,CHEMBL235128,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 112nM,partial agonist,27.00%,agonist,DHT,,,,,,,EC50,=,50,nM,IC50,=,20,nM,=,6.950781977,pIC50,,radiometric,C[C@H](N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,27,395.16,406.072767,1,2,3,2,4.8664,36.1,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
7107,4163,15006411,56,P19793,RXRA,Homo sapiens,"(E)-3-[7-(3,5-Di-tert-butyl-2-ethoxy-phenyl)-benzofuran-2-yl]-but-2-enoic acid",C[C@H](NC(=O)[C@H](Cc1ccccc1)NP(=O)(O)O)C(=O)NCC(=O)N,CHEMBL2372524,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 19nM,partial antagonist,64.00%,antagonist,,,ATRA,,,,,EC50,=,86,nM,IC50,=,20,nM,=,7.721246399,pKi,B,radiometric,C[C@H](NC(=O)[C@H](Cc1ccccc1)NP(=O)(O)O)C(=O)NCC(N)=O,64,351.15,372.119871,6,4,9,1,-1.6138,170.85,C1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,205
7110,4164,19464171,25,P37231,PPARG,Homo sapiens,"(S)-2-(4-(2-(4-hydroxypent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",C[C@H](O)C#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL502521,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 79nM,agonist,99.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,3300,nM,,,,,=,7.102372909,pKi,B,other,C[C@H](O)C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,99,557.396,586.1636943,2,6,10,3,6.5408,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
7111,4164,19464171,25,Q03181,PPARB,Homo sapiens,"(S)-2-(4-(2-(4-hydroxypent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",C[C@H](O)C#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL502521,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 6nM,agonist,99.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1200,nM,,,,,=,8.22184875,pKi,B,radiometric,C[C@H](O)C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,99,557.396,586.1636943,2,6,10,3,6.5408,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
7113,4165,19926282,41,P06401,PR,Homo sapiens,"2-chloro-4-((2,5-dichlorobenzyl)((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)amino)benzonitrile",C[C@H](O)C(=O)N1CC[C@@H](C1)N(Cc2cc(Cl)ccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL590593,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 50nM,partial agonist,37.00%,agonist,progesterone,,,,,,,EC50,=,341,nM,,,,,=,7.301029996,pIC50,B,other,C[C@H](O)C(=O)N1CC[C@H](N(Cc2cc(Cl)ccc2Cl)c2ccc(C#N)c(Cl)c2)C1,37,432.609,451.0621099,1,4,5,2,4.50678,67.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
7114,4166,19926282,38,P06401,PR,Homo sapiens,2-chloro-4-(((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,C[C@H](O)C(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL605078,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 63nM,partial agonist,47.00%,agonist,progesterone,,,,,,,EC50,=,208,nM,,,,,=,7.200659451,pIC50,B,other,C[C@H](O)C(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,47,430.708,451.1274393,1,4,5,2,4.21878,67.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
7115,4167,15115388,26,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-ethanol",C[C@H](O)[C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4,CHEMBL420767,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8.8nM,partial agonist,52.90%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,14.3,nM,,,,,=,8.055517328,pIC50,B,radiometric,C[C@H](O)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,52.9,303.231,326.1794416,1,3,2,2,4.1381,38.05,C1CCC(C2CCC3CC4CCCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,97
7120,4169,10212133,17,P06401,PR,Homo sapiens,"(4R,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL34015,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 31.3nM,agonist,102.00%,agonist,progesterone,,progesterone,,,,,EC50,=,5.3,nM,,,,,=,7.504455662,pKi,B,radiometric,C[C@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1ccc(Cl)cc1)Oc1ccccc1-3,102,381.733,403.1339066,1,3,1,3,6.3655,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
7122,417,9784110,MPA,P04150,GR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.2nM,agonist,157.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,10,nM,,,,,=,7.879426069,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,157,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7123,417,10212133,MPA,P04150,GR,Homo sapiens,"Acetic acid (6S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.2nM,,,,,,dexamethasone,,,,,,,,,,,,,=,7.879426069,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
7124,417,12954062,MPA,P04150,GR,Homo sapiens,"Acetic acid (6S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.2nM,agonist,157.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,10,nM,,,,,=,7.879426069,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,157,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7125,417,9464360,MPA,P06401,PR,Homo sapiens,"Acetic acid (6S,8R,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,2.9,nM,IC50,>,10000,nM,=,9.468521083,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,agonist,agonist,615
7126,417,9784110,MPA,P06401,PR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,80.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.15,nM,IC50,>,10000,nM,=,9.468521083,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,80,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7127,417,9873735,MPA,P06401,PR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,80.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.15,nM,,,,,=,9.468521083,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,80,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7128,417,10212133,MPA,P06401,PR,Homo sapiens,"Acetic acid (6S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,80.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.15,nM,,,,,=,9.468521083,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,80,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7129,417,11859003,MPA,P06401,PR,Homo sapiens,"Acetic acid (6S,10R,13S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,alkaline phosphatase assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10.8nM,agonist,no detail about the percentage act,,,,R5020,3nM,,,,EC50,=,0.12,nM,,,,,=,7.966576245,pIC50,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,agonist,agonist,615
7130,417,12954062,3 (MPA),P06401,PR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.34nM,agonist,80.00%,agonist,progesterone,,progesterone,,,,,EC50,=,0.15,nM,,,,,=,9.468521083,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,80,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7131,417,16821785,74,P06401,PR,Homo sapiens,"acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 9.47,,,,progesterone,,,,,,,,,,,,,,,=,9.47,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
7132,417,18553958,MPA,P06401,PR,Homo sapiens,medroxyprogesterone acetate,C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,-,,-,Ki = 1.4nM,agonist,98.00%,agonist,progesterone,,,,,,,EC50,=,0.5,nM,,,,,=,8.853871964,pKi,B,other,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,98,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7133,417,20510622,Progesterone,P06401,PR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5.1nM,agonist,no detail about the percentage act,,,,progesterone,5nM,,,,EC50,=,15.2,nM,IC50,>,10000,nM,=,8.292429824,pIC50,B,radiometric,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,,394.324,429.2667794,1,3,2,1,5.4065,40.54,CC1CCC2C(CCC3C4CCCC4CC(C4CCCCC4)C23)C1,agonist,,agonist,agonist,618
7134,417,9784110,MPA,P10275,AR,Homo sapiens,"Acetic acid (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.9nM,agonist,159.00%,agonist,DHT,,DHT,,,,,EC50,=,6.1,nM,,,,,=,8.537602002,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,159,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7135,417,10212133,MPA,P10275,AR,Homo sapiens,"Acetic acid (6S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.9nM,,,,,,DHT,,,,,,,,,,,,,=,8.537602002,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,"agonist,antagonist",agonist,615
7136,417,12954062,MPA,P10275,AR,Homo sapiens,"Acetic acid (6S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester",C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(=O)C)C(=O)C)[C@@]4(C)CCC(=O)C=C14,CHEMBL717,reporter,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 2.9nM,agonist,159.00%,agonist,DHT,,DHT,,,,,IC50,=,6.1,nM,IC50,=,6.1,nM,=,8.537602002,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,159,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,"antagonist,agonist",agonist,"agonist,antagonist",agonist,615
7138,4170,10212133,23,P06401,PR,Homo sapiens,"(4R,5S)-2,2,4-Trimethyl-5-(3-trifluoromethyl-phenyl)-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5cccc(c5)C(F)(F)F)c3c12,CHEMBL286158,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 123nM,partial agonist,66.00%,agonist,progesterone,,progesterone,,,,,EC50,=,16,nM,,,,,=,6.910094889,pKi,,radiometric,C[C@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1cccc(C(F)(F)F)c1)Oc1ccccc1-3,66,415.285,437.1602636,1,3,1,3,6.7309,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,partial agonist,agonist,partial agonist,601
7141,4171,10212133,21,P06401,PR,Homo sapiens,"(4R,5S)-5-(3-Fluoro-phenyl)-2,2,4-trimethyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5cccc(F)c5)c3c12,CHEMBL35525,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 28nM,agonist,114.00%,agonist,progesterone,,progesterone,,,,,EC50,=,8.7,nM,,,,,=,7.552841969,pKi,B,radiometric,C[C@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1cccc(F)c1)Oc1ccccc1-3,114,365.278,387.1634572,1,3,1,3,5.8512,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
7144,4172,10212133,19,P06401,PR,Homo sapiens,"(4R,5S)-2,2,4-Trimethyl-5-phenyl-1,2,4,5-tetrahydro-6-oxa-1-aza-chrysen-3-one",C[C@H]1C(=O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccccc5)c3c12,CHEMBL285705,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 28.6nM,agonist,103.00%,agonist,progesterone,,progesterone,,,,,EC50,=,9,nM,,,,,=,7.543633967,pKi,B,radiometric,C[C@H]1C(=O)C(C)(C)Nc2ccc3c(c21)[C@H](c1ccccc1)Oc1ccccc1-3,103,346.28,369.172879,1,3,1,3,5.7121,38.33,CC1CCC2CCC3C4CCCCC4CC(C4CCCCC4)C3C2C1,agonist,agonist,agonist,agonist,601
7149,4175,10212133,8,P06401,PR,Homo sapiens,"(4S,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",C[C@H]1CC(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL286822,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 10.1nM,partial agonist,39.00%,agonist,progesterone,,progesterone,,,,,EC50,=,39,nM,,,,,=,7.995678626,pKi,B,radiometric,C[C@H]1CC(C)(C)Nc2ccc3c(c21)[C@H](c1ccc(Cl)cc1)Oc1ccccc1-3,39,365.734,389.1546421,1,2,1,3,7.1865,21.26,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,agonist,partial agonist,agonist,partial agonist,61
7159,418,15911262,4,P55055,LXRB,Homo sapiens,"2,6-dimethyl-13-methylcarbonyloxy-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 2,6-dimethyl-13-methylcarbonyloxy-(2S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic anhydride",CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL191965,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,54.00%,agonist,,,Methyl-AA,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,54,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,partial agonist,agonist,partial agonist,1195
7160,418,16125384,1,P55055,LXRB,Homo sapiens,"2,6-dimethyl-13-methylcarbonyloxy-(2S)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 2,6-dimethyl-13-methylcarbonyloxy-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(14),10,12-triene-6-carboxylic anhydride",CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL191965,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,agonist,no detail about the percentage act,,maximal inhibition (no details),,,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,,agonist,partial agonist,1195
7161,418,15911262,4,Q13133,LXRA,Homo sapiens,"2,6-dimethyl-13-methylcarbonyloxy-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 2,6-dimethyl-13-methylcarbonyloxy-(2S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic anhydride",CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL191965,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,60.00%,agonist,,,Methyl-AA,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,60,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,partial agonist,agonist,partial agonist,1195
7162,418,16125384,1,Q13133,LXRA,Homo sapiens,"2,6-dimethyl-13-methylcarbonyloxy-(2S)-tricyclo[8.4.0.02,7]tetradeca-1(10),11,13-triene-6-carboxylic 2,6-dimethyl-13-methylcarbonyloxy-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(14),10,12-triene-6-carboxylic anhydride",CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)C4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL191965,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,10,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,,agonist,partial agonist,1195
7171,4184,15911283,34,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a-dimethyl-(4'S,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@H]1CCO[C@]2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL193986,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 21nM,partial agonist,35.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.53,nM,,,,,=,7.677780705,pIC50,B,radiometric,C[C@H]1CCO[C@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,35,331.241,354.1743562,0,4,1,2,4.2727,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
7172,4185,17887661,4c,P10275,AR,Homo sapiens,"6-(cis-2,5-dimethylpyrrolidin-1-yl)-4-trifluoromethyl-1H-quinolin-2-one",C[C@@H]1CC[C@H](C)N1c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL244896,Luciferase reporter gene assay,,,Ki = 19nM,agonist,101.00%,agonist,DHT,,,,,,,EC50,=,2.6,nM,,,,,=,7.721246399,pKi,B,other,C[C@H]1CC[C@@H](C)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,101,293.183,310.1292978,1,2,1,2,3.9241,36.1,CC1CCC2CC(C3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,604
7173,4186,9871534,23,P10275,AR,Homo sapiens,"(5bR,7S,9aR)-1,7,10-Trimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",C[C@H]1CC[C@@H]2[C@H](C1)c3cc4C(=CC(=O)N(C)c4cc3N2C)C(F)(F)F,CHEMBL161980,,,,Ki = 78nM,antagonist,89.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,54,nM,=,7.107905397,pKi,B,other,C[C@H]1CC[C@@H]2[C@H](C1)c1cc3c(C(F)(F)F)cc(=O)n(C)c3cc1N2C,89,329.216,350.160598,0,3,0,2,4.2793,25.24,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,573
7174,4187,9871534,22,P10275,AR,Homo sapiens,"(5bR,7S,9aR)-1,7-Dimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",C[C@H]1CC[C@H]2Nc3cc4N(C)C(=O)C=C(c4cc3[C@H]2C1)C(F)(F)F,CHEMBL165803,,,,Ki = 94nM,antagonist,77.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,48,nM,=,7.026872146,pKi,B,other,C[C@H]1CC[C@H]2Nc3cc4c(cc3[C@H]2C1)c(C(F)(F)F)cc(=O)n4C,77,317.205,336.1449479,1,3,0,2,4.255,34.03,CC1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,573
7175,4188,9871534,21,P10275,AR,Homo sapiens,"(5bR,7S,9aR)-7-Methyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",C[C@H]1CC[C@H]2Nc3cc4nc(O)cc(c4cc3[C@H]2C1)C(F)(F)F,CHEMBL166212,,,,Ki = 23nM,partial agonist,53.00%,agonist,DHT,,,,,,,EC50,=,64,nM,,,inactive,,=,7.638272164,pKi,B,other,C[C@H]1CC[C@H]2Nc3cc4nc(O)cc(C(F)(F)F)c4cc3[C@H]2C1,53,305.194,322.1292978,2,3,0,2,4.6569,45.15,CC1CCC2CC3C(CC2C1)CC1CCCCC13,agonist,partial agonist,agonist,partial agonist,573
7177,419,16124770,13,P55055,LXRB,Homo sapiens,acetyl Podocarpic acid anhydride,CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)[C@@]4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL506838,HTFR assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,agonist,85.00%,agonist,maximal inhibition (no details),,Methyl-AA,,,,,EC50,<,3,nM,,,,,=,9,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,85,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,1195
7178,419,16124770,13,Q13133,LXRA,Homo sapiens,acetyl Podocarpic acid anhydride,CC(=O)Oc1ccc2CC[C@H]3[C@](C)(CCC[C@]3(C)c2c1)C(=O)OC(=O)[C@@]4(C)CCC[C@@]5(C)[C@H]4CCc6ccc(OC(=O)C)cc56,CHEMBL506838,HTFR assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,50.00%,agonist,maximal inhibition (no details),,Methyl-AA,,,,,EC50,=,1,nM,,,,,=,8.698970004,pIC50,B,radiometric,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,50,568.411,614.3243538,0,7,4,2,7.3278,95.97,CC(CC(C)C1CCCC2C3CCCCC3CCC12)C1CCCC2C3CCCCC3CCC12,agonist,partial agonist,agonist,partial agonist,1195
7184,4192,15925510,9b,P06401,PR,Homo sapiens,"(S)-1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-4-methyl-4,5-dihydro-1H-pyrazole",C[C@H]1CN(N=C1c2ccc(Cl)c(Cl)c2)S(=O)(=O)c3ccc(Cl)cc3,CHEMBL364712,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 7.7,partial antagonist,51.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,7.6,,=,7.7,pKi,B,FPA,C[C@H]1CN(S(=O)(=O)c2ccc(Cl)cc2)N=C1c1ccc(Cl)c(Cl)c1,51,390.614,401.9763317,0,3,3,2,4.6915,49.74,CC(C)(C1CCCCC1)C1CCC(C2CCCCC2)C1,antagonist,partial antagonist,antagonist,partial antagonist,1021
7187,4194,10340624,6m,P10275,AR,Homo sapiens,"Trans-7-Methyl-4-trifluoromethyl-6-(3,3,3-trifluoro-propyl)-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@H]1CNc2cc3nc(O)cc(c3cc2C1CCC(F)(F)F)C(F)(F)F,CHEMBL281945,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,partial antagonist,72.00%,antagonist,DHT,,DHT,,,,,EC50,=,13,nM,IC50,=,61,nM,=,8.698970004,pKi,B,radiometric,C[C@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2C1CCC(F)(F)F,72,362.188,378.1166825,2,3,2,2,5.4469,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
7188,4195,17439112,(S)-16e,P10275,AR,Homo sapiens,"(2S-)-(-)-1,2,3,6-tetrahydro-2-methyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",C[C@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL227088,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5.7nM,partial agonist,58.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,58,nM,IC50,>,10000,nM,=,8.244125144,pKi,B,radiometric,C[C@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,58,354.165,366.0802969,1,3,1,2,3.6965,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
7189,4196,10230629,12,P10275,AR,Homo sapiens,"(6S,8R)-6,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@@H]1C[C@H](C)c2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL268326,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6nM,partial antagonist,52.00%,antagonist,DHT,,DHT,,,,,EC50,=,59,nM,IC50,=,15,nM,=,8.22184875,pKi,B,radiometric,C[C@H]1C[C@@H](C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,52,281.172,296.1136478,2,3,0,2,4.2668,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
7190,4197,15911283,36,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,6'-trimethyl-(4'R,4aS,6'S)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@@H]1C[C@H](C)O[C@@]2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL362988,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.1nM,partial agonist,64.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,26,nM,,,,,=,8.508638306,pIC50,B,radiometric,C[C@H]1C[C@@H](C)O[C@]2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,64,343.252,368.1900063,0,4,1,2,4.6612,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
7192,4198,15911283,35,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,6'-trimethyl-(4'S,4aS,6'S)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro-4'H-[1,3]dioxane)]",C[C@H]1C[C@H](C)OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O1,CHEMBL434183,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.1nM,partial agonist,60.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,13,nM,,,,,=,8.148741651,pIC50,B,radiometric,C[C@H]1C[C@H](C)OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O1,60,343.252,368.1900063,0,4,1,2,4.6612,36.28,C1CCC(C2CCC3CC4C(CCC45CCCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,92
7224,4207,10230629,16,P10275,AR,Homo sapiens,"(7S,8R)-7,8-Dimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@H]1Cc2cc3c(cc(O)nc3cc2N[C@@H]1C)C(F)(F)F,CHEMBL6983,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 22nM,partial antagonist,66.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,33,nM,=,7.657577319,pKi,B,radiometric,C[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,66,281.172,296.1136478,2,3,0,2,3.9518,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
7225,4208,9871534,15,P10275,AR,Homo sapiens,"(R)-1,2,3,3,8-Pentamethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@H]1N(C)c2cc3N(C)C(=O)C=C(c3cc2C1(C)C)C(F)(F)F,CHEMBL349631,,,,Ki = 33nM,antagonist,82.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,5,nM,=,7.48148606,pKi,B,other,C[C@H]1N(C)c2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,82,305.194,324.1449479,0,3,0,2,3.6732,25.24,CC1CCC2CC3CCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,578
7226,4209,9871534,14,P10275,AR,Homo sapiens,"(R)-2,3,3,8-Tetramethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@H]1Nc2cc3N(C)C(=O)C=C(c3cc2C1(C)C)C(F)(F)F,CHEMBL351519,,,,Ki = 9nM,partial agonist,34.00%,agonist,DHT,,,,,,,EC50,=,380,nM,IC50,=,22,nM,=,8.045757491,pKi,B,other,C[C@H]1Nc2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,34,293.183,310.1292978,1,3,0,2,3.6489,34.03,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,578
7228,421,9464360,progesterone,P04150,GR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30.5nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,>,1000,nM,=,7.515700161,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,,partial antagonist,615
7229,421,9784110,progesterone,P04150,GR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30.5nM,partial antagonist,39.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,>,1000,nM,=,7.515700161,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,39,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,partial antagonist,,partial antagonist,615
7230,421,10212133,prog,P04150,GR,Homo sapiens,"(10R,13S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30.5nM,,,,,,dexamethasone,,,,,,,,,,,,,=,7.515700161,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,,partial antagonist,615
7231,421,12954062,progesterone,P04150,GR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30.5nM,partial antagonist,39.00%,antagonist,dexamethasone,,dexamethasone,,,,,,,,,IC50,>,1000,nM,=,7.515700161,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,39,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,partial antagonist,,partial antagonist,615
7232,421,8523400,progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,,radiometric binding assay monitoring the displacement of (Z)-[125I]-17a-(2-iodovinyl)-19-nortestosterone from the ligand-binding domain (LBD) ,IC50 = 17nM,,,,,,,,,,,,,,,,,,,=,7.769551079,pIC50,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
7233,421,9464360,Progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103, ,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,0.15,nM,IC50,>,10000,nM,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,agonist,agonist,615
7234,421,9784110,progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,reporter gene assay,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,100.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.9,nM,IC50,>,10000,nM,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7235,421,9873735,progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,cotransfection,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,100.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.9,nM,,,,,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7236,421,10212133,prog,P06401,PR,Homo sapiens,"(10R,13S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,100.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.9,nM,,,,,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7237,421,10743938,Progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,CV-1 cells ??reporter gene assay,,-,IC50 = 3.5nM,agonist,100.00%,agonist,progesterone,,,,,,,EC50,=,2.9,nM,,,,,=,8.455931956,pIC50,B,other,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7238,421,11859003,P4,P06401,PR,Homo sapiens,"(10R,13S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,alkaline phosphatase assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.5nM,agonist,no detail about the percentage act,,,,R5020,3nM,,,,EC50,=,0.92,nM,,,,,=,8.455931956,pIC50,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,agonist,agonist,615
7239,421,12781197,Progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,100.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,2.9,nM,,,,,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7240,421,12954062,progesterone,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,100.00%,agonist,progesterone,,progesterone,,,,,EC50,=,2.9,nM,,,,,=,8.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7241,421,16821785,73,P06401,PR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.46,,,,progesterone,,,,,,,,,,,,,,,=,8.46,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,agonist,agonist,615
7242,421,18553958,progesterone,P06401,PR,Homo sapiens,progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,-,,-,Ki = 3.4nM,agonist,100.00%,agonist,progesterone,,,,,,,EC50,=,0.5,nM,,,,,=,8.468521083,pKi,B,other,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,100,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7243,421,9464360,progesterone,P10275,AR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.5nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,37,nM,=,8.070581074,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,antagonist,,antagonist,partial antagonist,615
7244,421,9784110,progesterone,P10275,AR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.5nM,partial antagonist,46.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,37,nM,=,8.070581074,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,46,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,antagonist,partial antagonist,antagonist,partial antagonist,615
7245,421,10212133,Prog,P10275,AR,Homo sapiens,"(10R,13S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.5nM,,,,,,DHT,,,,,,,,,,,,,=,8.070581074,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,antagonist,partial antagonist,615
7246,421,12954062,progesterone,P10275,AR,Homo sapiens,"(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 8.5nM,partial antagonist,46.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,37,nM,=,8.070581074,pKi,B,radiometric,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,46,352.26,386.2457096,0,4,2,0,4.6552,60.44,CC1CCC2C(CCC3C4CCCC4CCC23)C1,antagonist,partial antagonist,antagonist,partial antagonist,615
7247,421,20510622,Progesterone,P10275,AR,Homo sapiens,Progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled DHT",Ki = 35nM,,,,,,DHT,5nM,,,,,,,,,,,,=,7.455931956,pKi,B,radiometric,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,,284.229,314.2245802,0,2,1,0,4.7235,34.14,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,antagonist,partial antagonist,615
7248,4210,9871534,10,P10275,AR,Homo sapiens,"(2R,3R)-2,3,8-Trimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@H]1Nc2cc3N(C)C(=O)C=C(c3cc2[C@H]1C)C(F)(F)F,CHEMBL348918,,,,Ki = 10nM,partial agonist,37.00%,agonist,DHT,,,,,,,EC50,=,15,nM,IC50,=,9182,nM,=,8,pKi,B,other,C[C@H]1Nc2cc3c(cc2[C@H]1C)c(C(F)(F)F)cc(=O)n3C,37,281.172,296.1136478,1,3,0,2,3.4748,34.03,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,578
7249,4211,9871534,13,P10275,AR,Homo sapiens,"(R)-2,3,3-Trimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@H]1Nc2cc3nc(O)cc(c3cc2C1(C)C)C(F)(F)F,CHEMBL165219,,,,Ki = 21nM,partial agonist,35.00%,agonist,DHT,,,,,,,EC50,=,99,nM,IC50,=,48,nM,=,7.677780705,pKi,B,other,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C1(C)C,35,281.172,296.1136478,2,3,0,2,4.0508,45.15,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,578
7250,4212,10230629,18,P10275,AR,Homo sapiens,"(R)-7,7,8-Trimethyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",C[C@H]1Nc2cc3nc(O)cc(c3cc2CC1(C)C)C(F)(F)F,CHEMBL267907,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 82nM,antagonist,78.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,24,nM,=,7.086186148,pKi,B,radiometric,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,78,293.183,310.1292978,2,3,0,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,586
7251,4213,9871534,9,P10275,AR,Homo sapiens,"(2R,3R)-2,3-Dimethyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",C[C@H]1Nc2cc3nc(O)cc(c3cc2[C@H]1C)C(F)(F)F,CHEMBL162569,,,,Ki = 6nM,agonist,81.00%,agonist,DHT,,,,,,,EC50,=,5,nM,,,inactive,,=,8.22184875,pKi,B,other,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2[C@H]1C,81,269.161,282.0979977,2,3,0,2,3.8767,45.15,CC1CCC2CC3CCCC3CC2C1,agonist,agonist,agonist,agonist,578
7253,4214,15911283,26,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4',4a,5'-trimethyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@H]1OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1C,CHEMBL194012,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,partial agonist,30.00%,agonist,dexamethasone,,dexamethasone,,,,,,,,,,,,,=,7.619788758,pIC50,B,radiometric,C[C@H]1OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1C,30,331.241,354.1743562,0,4,1,2,4.2711,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,,partial agonist,,partial agonist,91
7262,4220,16125384,13,P55055,LXRB,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid ((1R,2R,3R,5S)-2,6,6-trimethyl-bicyclo[3.1.1]hept-3-yl)-amide",C[C@H]1[C@@H](C[C@@H]2C[C@H]1C2(C)C)NC(=O)[C@@]3(C)CCC[C@@]4(C)[C@H]3CCc5ccc(O)cc45,CHEMBL382942,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,agonist,78.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.698970004,pIC50,,radiometric,C[C@H]1[C@H](NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)C[C@@H]2C[C@H]1C2(C)C,78,370.302,409.2980795,2,2,2,1,5.5894,49.33,CC(CC1CC2CC(C2)C1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,923
7265,4222,21316964,(+/-)-26,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5-chloro-8-fluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(F)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1682436,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.0nM,agonist,126.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,89,nM,,,,,=,8.096910013,pKi,B,radiometric,C[C@H]1c2c(Cl)c(-c3cccc4cc[nH]c34)cc(F)c2NC(C)(C)[C@@H]1O,126,338.684,358.1248192,3,2,1,3,5.2959,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7266,4223,21316964,(+/-)-29,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-8-chloro-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(Cl)c(F)c(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1682439,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.0nM,agonist,139.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,1.3,nM,,,,,=,9,pKi,B,radiometric,C[C@H]1c2c(F)c(-c3cccc4cc[nH]c34)c(F)c(Cl)c2NC(C)(C)[C@@H]1O,139,357.682,376.1153973,3,2,1,3,5.435,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7267,4224,21316964,(+/-)-28,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7,8-trifluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(F)c(F)c(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1682438,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.0nM,agonist,156.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,16,nM,,,,,=,8.301029996,pKi,B,radiometric,C[C@H]1c2c(F)c(-c3cccc4cc[nH]c34)c(F)c(F)c2NC(C)(C)[C@@H]1O,156,341.227,360.1449479,3,2,1,3,4.9207,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7268,4225,21316964,(+/-)-30,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-dichloro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2cc(Cl)c(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1682440,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 157nM,agonist,100.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,480,nM,,,,,=,6.804100348,pKi,,radiometric,C[C@H]1c2c(cc(Cl)c(-c3cccc4cc[nH]c34)c2Cl)NC(C)(C)[C@@H]1O,100,355.139,374.0952686,3,2,1,3,5.8102,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7269,4226,21349714,(+/-)-11,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl cyclohexylcarbamate",C[C@@H]1[C@@H](OC(=O)NC2CCCCC2)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5c(Cl)c[nH]c45,CHEMBL1684344,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 89nM,agonist,89.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,70,nM,,,,,=,7.050609993,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)NC1CCCCC1,89,471.765,501.1994613,3,3,3,3,7.5016,66.15,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7272,4227,21349714,(+/-)-9,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl benzylcarbamate",C[C@@H]1[C@@H](OC(=O)NCc2ccccc2)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5c(Cl)c[nH]c45,CHEMBL1684342,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 87nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,17,nM,,,,,=,7.060480747,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)NCc1ccccc1,87,483.776,509.1681612,3,3,4,4,7.3691,66.15,CC(CCC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1145
7275,4228,21349714,20,P04150,GR,Homo sapiens,"(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 4-cyanophenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc(cc2)C#N)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5c(Cl)c[nH]c45,CHEMBL1684353,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.7nM,agonist,125.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.1,nM,,,,,=,7.863279433,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccc(C#N)cc1,125,497.783,520.1477601,3,4,3,4,7.56308,89.94,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7276,4229,21349714,14,P04150,GR,Homo sapiens,"(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl phenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccccc2)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5c(Cl)c[nH]c45,CHEMBL1684347,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7.6nM,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.6,nM,,,,,=,8.119186408,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccccc1,130,471.765,495.1525111,3,3,3,4,7.6914,66.15,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7278,4230,21316964,(+/-)-31,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1682441,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.5nM,agonist,138.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.6,nM,,,,,=,8.602059991,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1O,138,322.229,342.1543697,3,2,1,3,4.7816,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7279,4230,21349714,(+/-)-4,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1682441,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.5nM,agonist,138.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.6,nM,,,,,=,8.602059991,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1O,138,322.229,342.1543697,3,2,1,3,4.7816,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7283,4232,21349714,19,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 4-cyanophenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc(cc2)C#N)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684352,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16.1nM,agonist,84.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,21,nM,,,,,=,7.793174124,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccc(C#N)cc1,84,462.33,486.1867324,3,4,3,4,6.90968,89.94,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7284,4233,21349714,21,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 4-chlorophenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc(Cl)cc2)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684354,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 70nM,agonist,136.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,178,nM,,,,,=,7.15490196,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccc(Cl)cc1,136,471.765,495.1525111,3,3,3,4,7.6914,66.15,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7285,4234,21349714,23,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 4-(dimethylamino)phenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc(cc2)N(C)C)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684356,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.1nM,agonist,112.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,3.5,nM,,,,,=,8.292429824,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccc(N(C)C)cc1,112,474.341,504.2336826,3,4,4,4,7.104,69.39,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7286,4235,21349714,18,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl benzo[d][1,3]dioxol-5-ylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc3OCOc3c2)C(C)(C)Nc4cc(F)c(c(F)c14)c5cccc6cc[nH]c56,CHEMBL1684351,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12.2nM,agonist,98.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,18,nM,,,,,=,7.913640169,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccc2c(c1)OCO2,98,480.321,505.1813127,3,5,3,4,6.7667,84.61,CC(CC1CCC2CCCC2C1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,933
7287,4236,21349714,(+/-)-25,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 3-cyanophenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2cccc(c2)C#N)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684358,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13.7nM,agonist,114.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,24,nM,,,,,=,7.863279433,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1cccc(C#N)c1,114,462.33,486.1867324,3,4,3,4,6.90968,89.94,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7290,4237,21349714,13,P04150,GR,Homo sapiens,"(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl phenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccccc2)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684346,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.2nM,agonist,194.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,105,nM,,,,,=,8.207608311,pKi,B,radiometric,C[C@H]1c2c(cc(F)c(-c3cccc4cc[nH]c34)c2F)NC(C)(C)[C@@H]1OC(=O)Nc1ccccc1,194,436.312,461.1914835,3,3,3,4,7.038,66.15,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7291,4238,10212133,16b,P06401,PR,Homo sapiens,"(3R,4S,5S)-5-(4-Chloro-phenyl)-2,2,4-trimethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysen-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2ccc3c4ccccc4O[C@@H](c5ccc(Cl)cc5)c3c12,CHEMBL34035,,reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 500nM,antagonist,91.00%,antagonist,progesterone,,progesterone,,,,,,,,,IC50,=,460,nM,>,6.301029996,pKi,,radiometric,C[C@H]1c2c(ccc3c2[C@H](c2ccc(Cl)cc2)Oc2ccccc2-3)NC(C)(C)[C@@H]1O,91,381.733,405.1495567,2,3,1,3,6.1573,41.49,C1CCC(C2CC3CCCCC3C3CCC4CCCCC4C23)CC1,antagonist,antagonist,antagonist,antagonist,61
7292,4239,21316964,(+/-)-27,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-7,8-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(F)c(F)c(cc12)c3cccc4cc[nH]c34,CHEMBL1682437,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.4nM,agonist,193.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,11,nM,,,,,=,8.619788758,pKi,B,radiometric,C[C@H]1c2cc(-c3cccc4cc[nH]c34)c(F)c(F)c2NC(C)(C)[C@@H]1O,193,322.229,342.1543697,3,2,1,3,4.7816,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7327,4265,17267219,bicalutamide,P10275,AR,Homo sapiens,(R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL63560,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 151nM,antagonist,85.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,162,nM,=,6.821023053,pIC50,,radiometric,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,85,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,1304
7328,4265,17887661,bicalutamide,P10275,AR,Homo sapiens,(R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL63560,,Luciferase reporter gene assay,,Ki = 70nM,antagonist,76.00%,antagonist,DHT,,,,,,,,,,,IC50,=,128,nM,=,7.15490196,pKi,B,other,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,76,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,1304
7329,4265,18303829,bicalutamide,P10275,AR,Homo sapiens,(R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL63560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 0.29,,,,,,DHT,2nM,,,,,,,,,,,,=,0.29,RBA,,radiometric,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,,,antagonist,antagonist,1304
7330,4265,18571420,"6, (R)- bicalutamide (Casodex)",P10275,AR,Homo sapiens,N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL63560,,SC-3 growth-inhibitory activity ,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 49nM,antagonist,no detail about the percentage act,,,,testosterone,1nM,,,,,,,,IC50,=,4900,nM,=,7.30980392,pKi,B,radiometric,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,antagonist,,antagonist,antagonist,1304
7331,4265,22746350,1,P10275,AR,Homo sapiens,(R)-bicalutamide,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,CHEMBL63560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.92,,13.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.92,pIC50,,radiometric,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,13.5,416.267,430.0610408,2,5,5,2,2.87958,107.26,CC(CCC(C)(C)C1CCCCC1)CC1CCCCC1,,,antagonist,antagonist,1304
7339,4268,16125384,26,Q13133,LXRA,Homo sapiens,"1-Adamantan-1-yl-3-((1S,4aS,10aR)-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-propane-1,3-dione",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)CC(=O)C45CC6CC(CC(C6)C4)C5,CHEMBL194866,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1670nM,partial agonist,69.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,5.777283529,pIC50,,radiometric,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,69,380.317,418.2871805,0,2,4,1,6.4416,34.14,CC(CCC1CCCC2C3CCCCC3CCC12)C12CC3CC(CC(C3)C1)C2,,partial agonist,,partial agonist,1114
7340,4269,16125384,17,P55055,LXRB,Homo sapiens,"(Dodecahydro-carbazol-9-yl)-((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)N4C5CCCCC5C6CCCCC46,CHEMBL370175,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 190nM,agonist,139.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.721246399,pIC50,,radiometric,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,139,394.324,435.3137296,1,2,1,1,6.3623,40.54,CC(C1CCCC2C3CCCCC3CCC12)C1C2CCCCC2C2CCCCC21,,agonist,,agonist,830
7341,4269,16125384,17,Q13133,LXRA,Homo sapiens,"(Dodecahydro-carbazol-9-yl)-((1S,4aS,10aR)-6-hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)N4C5CCCCC5C6CCCCC46,CHEMBL370175,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 300nM,agonist,430.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.522878745,pIC50,,radiometric,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,430,394.324,435.3137296,1,2,1,1,6.3623,40.54,CC(C1CCCC2C3CCCCC3CCC12)C1C2CCCCC2C2CCCCC21,,agonist,,agonist,830
7342,427,23294830,28,P37231,PPARG,Homo sapiens,"N-(3-Acetyl-5-chloro-4-(5-chloropyridin-3-yloxy)-phenyl)-2,4-dichlorobenzenesulfonamide",CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc(Cl)c1Oc3cncc(Cl)c3,CHEMBL2331773,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 12nM,agonist,80.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,30,nM,,,,,=,7.920818754,pIC50,B,radiometric,CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc(Cl)c1Oc1cncc(Cl)c1,80,494.098,503.9271886,1,5,6,3,6.4909,85.36,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,agonist,agonist,agonist,1167
7343,4270,16125384,21,P55055,LXRB,Homo sapiens,"((1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-(4-phenyl-piperidin-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCC(CC4)c5ccccc5,CHEMBL194733,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 180nM,agonist,95.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.744727495,pIC50,,radiometric,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,95,366.314,401.2718647,0,1,2,2,6.1031,20.31,CC(C1CCC(C2CCCCC2)CC1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,836
7344,4270,16125384,21,Q13133,LXRA,Homo sapiens,"((1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-(4-phenyl-piperidin-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCC(CC4)c5ccccc5,CHEMBL194733,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,agonist,92.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.698970004,pIC50,,radiometric,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,92,366.314,401.2718647,0,1,2,2,6.1031,20.31,CC(C1CCC(C2CCCCC2)CC1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,836
7345,4271,16125384,22,P55055,LXRB,Homo sapiens,"2,6-dimethyl-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(14),10,12-trien-6-yl-spiro[1H-indene-1,4'-(hexahydropyridine)]-1-ylmethanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCC5(CC4)C=Cc6ccccc56,CHEMBL197265,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 500nM,agonist,275.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.301029996,pIC50,,radiometric,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,275,390.336,425.2718647,0,1,1,2,6.2841,20.31,CC(C1CCC2(CC1)CCC1CCCCC12)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,817
7346,4271,16125384,22,Q13133,LXRA,Homo sapiens,"2,6-dimethyl-(2S,6S,7R)-tricyclo[8.4.0.02,7]tetradeca-1(14),10,12-trien-6-yl-spiro[1H-indene-1,4'-(hexahydropyridine)]-1-ylmethanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCC5(CC4)C=Cc6ccccc56,CHEMBL197265,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 750nM,agonist,175.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.124938737,pIC50,,radiometric,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,175,390.336,425.2718647,0,1,1,2,6.2841,20.31,CC(C1CCC2(CC1)CCC1CCCCC12)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,817
7347,4272,16125384,23,P55055,LXRB,Homo sapiens,"((1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-(3-phenyl-piperidin-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCCC(C4)c5ccccc5,CHEMBL196340,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 370nM,agonist,111.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.431798276,pIC50,,radiometric,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,111,366.314,401.2718647,0,1,2,2,6.1031,20.31,CC(C1CCCC(C2CCCCC2)C1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,909
7348,4272,16125384,23,Q13133,LXRA,Homo sapiens,"((1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthren-1-yl)-(3-phenyl-piperidin-1-yl)-methanone",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)N4CCCC(C4)c5ccccc5,CHEMBL196340,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 360nM,agonist,144.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.443697499,pIC50,,radiometric,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,144,366.314,401.2718647,0,1,2,2,6.1031,20.31,CC(C1CCCC(C2CCCCC2)C1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,909
7353,4275,16125384,14,P55055,LXRB,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid adamantan-1-ylamide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NC45CC6CC(CC(C6)C4)C5,CHEMBL199255,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 170nM,agonist,81.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.769551079,pIC50,,radiometric,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,81,370.302,407.2824294,2,2,2,1,5.4875,49.33,CC(CC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,916
7354,4275,16125384,14,Q13133,LXRA,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid adamantan-1-ylamide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NC45CC6CC(CC(C6)C4)C5,CHEMBL199255,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 140nM,agonist,130.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.853871964,pIC50,,radiometric,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,130,370.302,407.2824294,2,2,2,1,5.4875,49.33,CC(CC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,916
7359,4278,16125384,18,P55055,LXRB,Homo sapiens,"(1S,4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCC4(CCCCC4)c5ccccc5,CHEMBL372612,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,agonist,90.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,7.698970004,pIC50,B,radiometric,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,90,406.335,445.2980795,2,2,4,2,6.4208,49.33,CC(CCC1(C2CCCCC2)CCCCC1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,1089
7360,4278,16125384,18,Q13133,LXRA,Homo sapiens,"(1S,4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCC4(CCCCC4)c5ccccc5,CHEMBL372612,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 50nM,agonist,164.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,7.301029996,pIC50,B,radiometric,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,164,406.335,445.2980795,2,2,4,2,6.4208,49.33,CC(CCC1(C2CCCCC2)CCCCC1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,1089
7361,4279,16125384,19,P55055,LXRB,Homo sapiens,"(1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)NCC4(CCCCC4)c5ccccc5,CHEMBL194353,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 130nM,partial agonist,40.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.886056648,pIC50,,radiometric,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,40,390.336,429.3031649,1,1,4,2,6.7152,29.1,CC(CCC1(C2CCCCC2)CCCCC1)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1089
7362,4279,16125384,19,Q13133,LXRA,Homo sapiens,"(1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (1-phenyl-cyclohexylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccccc23)C(=O)NCC4(CCCCC4)c5ccccc5,CHEMBL194353,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,agonist,98.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.698970004,pIC50,,radiometric,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,98,390.336,429.3031649,1,1,4,2,6.7152,29.1,CC(CCC1(C2CCCCC2)CCCCC1)C1CCCC2C3CCCCC3CCC12,,agonist,,agonist,1089
7363,428,23294830,37,P37231,PPARG,Homo sapiens,"N-(3-Acetyl-4-(quinolin-3-yloxy)phenyl)-2,4-dichlorobenzenesulfonamide",CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc3cnc4ccccc4c3,CHEMBL2338475,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 30nM,partial agonist,42.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,60,nM,,,,,=,7.522878745,pIC50,B,radiometric,CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1,42,471.236,486.0207834,1,5,6,4,6.3373,85.36,CC(C)(CC1CCC(CC2CCC3CCCCC3C2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1157
7364,4280,16124770,15,P55055,LXRB,Homo sapiens,"(1S,4aS,10aR)-6-Hydroxy-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (adamantan-1-ylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCC45CC6CC(CC(C6)C4)C5,CHEMBL194642,HTFR assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 190nM,partial agonist,25.00%,agonist,maximal inhibition (no details),,Methyl-AA,,,,,EC50,>,50000,nM,,,,,=,6.721246399,pIC50,,radiometric,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,25,382.313,421.2980795,2,2,3,1,5.7351,49.33,CC(CCC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,,,partial agonist,1082
7365,4280,16125384,10,P55055,LXRB,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (adamantan-1-ylmethyl)-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCC45CC6CC(CC(C6)C4)C5,CHEMBL194642,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 190nM,partial agonist,50.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.721246399,pIC50,,radiometric,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,50,382.313,421.2980795,2,2,3,1,5.7351,49.33,CC(CCC12CC3CC(CC(C3)C1)C2)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1082
7368,4281,16125384,8,P55055,LXRB,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid phenethyl-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCCc4ccccc4,CHEMBL196145,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2220nM,partial agonist,28.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,5.653647026,pIC50,,radiometric,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,28,346.28,377.2354792,2,2,4,2,4.7614,49.33,CC(CCCC1CCCCC1)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1208
7369,4281,16125384,8,Q13133,LXRA,Homo sapiens,"(4S,4aR)-6-Hydroxy-4a-methyl-1-(S)-methyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid phenethyl-amide",C[C@@]1(CCC[C@@]2(C)[C@H]1CCc3ccc(O)cc23)C(=O)NCCc4ccccc4,CHEMBL196145,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2930nM,partial agonist,40.00%,agonist,,,,,,,,,,,,,,,,=,5.53313238,pIC50,,radiometric,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,40,346.28,377.2354792,2,2,4,2,4.7614,49.33,CC(CCCC1CCCCC1)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1208
7370,4282,19321341,13b-(S),P04150,GR,Homo sapiens,"(15S)-8-cyano-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",C[C@@]1(CC2(C#N)c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL473802,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 37.8nM,partial agonist,66.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,836.8,nM,,,,,=,7.4225082,pKi,B,FPA,C[C@]1(C(=O)Nc2nccs2)CC2(C#N)c3ccccc3C1c1ccccc12,66,354.329,371.1092332,1,4,2,3,4.44678,65.78,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
7371,4283,19321341,2b-(S),P04150,GR,Homo sapiens,"(15S)-15-methyl-N-(1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",C[C@@]1(CC2c3ccccc3C1c4ccccc24)C(=O)Nc5nccs5,CHEMBL474576,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 26.2nM,partial agonist,45.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,543.5,nM,,,,,=,7.581698709,pKi,B,FPA,C[C@]1(C(=O)Nc2nccs2)CC2c3ccccc3C1c1ccccc12,45,328.311,346.1139842,1,3,2,3,4.769,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
7411,4297,9925725,2,P10275,AR,Homo sapiens,"(9R,10S,11S,13S,17S)-9-Fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",C[C@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,CHEMBL302870,luciferase reporter gene assay,luciferase reporter gene assay,-,Ki = 4nM,agonist,128.00%,agonist,DHT,,,,,,,EC50,=,128,nM,,,inactive,,=,8.397940009,pKi,B,other,C[C@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,128,307.215,336.210073,2,3,0,0,3.3322,57.53,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7414,4299,17439112,1,P10275,AR,Homo sapiens,fluoxymesterone,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,CHEMBL1445,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 5.7nM,agonist,124.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,124,nM,IC50,>,10000,nM,=,8.244125144,pKi,B,radiometric,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,124,307.215,336.210073,2,3,0,0,3.3322,57.53,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,agonist,agonist,615
7426,4308,22070604,52,P37231,PPARG,Homo sapiens,"(R)-5-(3-((3-(6-chlorobenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",C[C@@]1(OC(=O)NC1=O)c2cccc(CN3C(=O)N(c4ccccc34)c5noc6cc(Cl)ccc56)c2,CHEMBL1947145,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 49.1nM,agonist,101.00%,agonist,rosiglitazone,,,,,,,EC50,=,102,nM,,,,,=,7.308918508,pIC50,B,radiometric,C[C@]1(c2cccc(Cn3c(=O)n(-c4noc5cc(Cl)ccc45)c4ccccc43)c2)OC(=O)NC1=O,101,471.751,488.0887473,1,8,4,5,4.1167,108.36,CC1CC(C)C(C2CCCC(CC3C(C)C(C4CCC5CCCCC54)C4CCCCC34)C2)C1,agonist,agonist,agonist,agonist,748
7447,432,21899328,26,P04150,GR,Homo sapiens,"[(5S)-2-(4-Acetylphenyl)-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(=O)c1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911156,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.9nM,partial antagonist,72.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,75.4,nM,IC50,=,31,nM,=,8.537602002,pKi,B,FPA,CC(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,72,448.378,470.1412616,1,7,5,4,5.7052,94.07,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,956
7463,4325,9871534,24,P10275,AR,Homo sapiens,"(5bR,9aR)-5b-Methyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",C[C@]12CCCC[C@H]1Nc3cc4nc(O)cc(c4cc23)C(F)(F)F,CHEMBL351447,,,,Ki = 21nM,partial agonist,60.00%,agonist,DHT,,,,,,,EC50,=,25,nM,,,inactive,,=,7.677780705,pKi,B,other,C[C@]12CCCC[C@H]1Nc1cc3nc(O)cc(C(F)(F)F)c3cc12,60,305.194,322.1292978,2,3,0,2,4.585,45.15,CC1CCC2CC3C(CC2C1)CC1CCCCC13,agonist,partial agonist,agonist,partial agonist,573
7471,4328,1548683,estradiol,P03372,ERA,Homo sapiens,"(estradiol)13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled estradiol",IC50 = 3nM,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,8.522878745,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7472,4328,2909731,estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled estradiol",IC50 = 3nM,,,,,,,,,,,,,,,,,,,=,8.522878745,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7473,4328,10447957,17-beta-estradiol,P03372,ERA,Homo sapiens,"(S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.9nM,,,,,,E2,5.7nM,,,,,,,,,,,,=,8.229147988,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7474,4328,10447957,17-beta-estradiol,P03372,ERA,Homo sapiens,"(S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,5.7nM,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7475,4328,10673099,17b-estradiol,P03372,ERA,Homo sapiens,"(8R,9S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,agonist,100.00%,agonist,E2,,E2,2nM,,,,EC50,=,0.007,nM,,,inactive,,=,8.522878745,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
7476,4328,11459665,raloxifene,P03372,ERA,Homo sapiens,"(R)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.22nM,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,9.657577319,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7477,4328,11906280,17-beta-estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,0.02,nM,,,,,=,7.619788758,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7478,4328,12749898,4 (estradiol (E2)),P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,,,,,,E2,2nM,,,,,,,,,,,,=,9,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7479,4328,12824043,17b-E2,P03372,ERA,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,-,IC50 = 3.2nM,,,,,,,,,,,,,,,,,,,=,8.494850022,pIC50,B,other,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7480,4328,12825935,1 (17-beta-estradiol),P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,agonist,no detail about the percentage act,,,,E2,8nM,,,,,,,,,,,,=,7.552841969,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7481,4328,15006374,beta-estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.3nM,agonist,100.00%,agonist,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,agonist,agonist,agonist,15
7482,4328,15081034,17-beta-E2,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 =  19nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,0.67,nM,,,,,=,7.721246399,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7483,4328,15084115,e-2,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7484,4328,15203155,estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7485,4328,15203156,estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.8nM,,,,,,E2,,,,,,,,,,,,,=,9.096910013,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7486,4328,15225686,17-beta-estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,,,,,,E2,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7487,4328,15341953,17-beta-estradiol,P03372,ERA,Homo sapiens,"(S)-(S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,,,E2,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7488,4328,15658851,1,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 28nM,,,,,,E2,8nM,,,,,,,,,,,,=,7.552841969,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7489,4328,15664843,estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7490,4328,15745820,estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7491,4328,15771467,17 beta-estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKi = 8.7,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,8.7,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7492,4328,15828819,E2,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7493,4328,15876535,E2,P03372,ERA,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,,,,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7494,4328,15993065,estradiol,P03372,ERA,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7495,4328,16098741,1,P03372,ERA,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,,,,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7496,4328,16190762,estradiol (E2),P03372,ERA,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,10nM,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7497,4328,16219463,1,P03372,ERA,Homo sapiens,17beta-Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.75nM,,,,,,E2,0.5nM,,,,,,,,,,,,=,9.124938737,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7498,4328,16412638,Estradiol,P03372,ERA,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 240nM,,,,,,,,,,,,,,,,,,,=,6.619788758,pIC50,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7499,4328,16610787,"(+)-3,17-beta-estradiol",P03372,ERA,Homo sapiens,"(+)-3,17-beta-estradiol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,agonist,no detail about the percentage act,,,,E1,11nM,,,,EC50,=,0.59,nM,,,,,=,8,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7500,4328,16777408,estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.3nM,,,,,,,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7501,4328,16884312,estradiol,P03372,ERA,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,10nM,Kd = 0.2nM,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7502,4328,17049855,E2,P03372,ERA,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,E2,,,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7503,4328,17149865,E2,P03372,ERA,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.2nM,,,,,,E2,,,,,,,,,,,,,=,8.920818754,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7504,4328,17188490,"4, estradiol",P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,,,E2,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7505,4328,17289385,estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.0nM,,,,,,E2,,,,,,,,,,,,,=,9,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7506,4328,17448656,estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.4nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,0.75,nM,,,,,=,8.853871964,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7507,4328,17482813,1,P03372,ERA,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,,,,,,,,,,,,,,,,,,,=,8.494850022,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7508,4328,17890084,estradiol,P03372,ERA,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.4nM,agonist,100.00%,agonist,E2,,E2,,,,,EC50,=,0.75,nM,,,,,=,8.853871964,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
7509,4328,18722117,Estradiol,P03372,ERA,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,,,,,,E2,,,,,,,,,,,,,=,8.698970004,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7510,4328,19356928,E2,P03372,ERA,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.627nM,,,,,,,,,,,,,,,,,,,=,9.202732459,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7511,4328,19705860,estradiol,P03372,ERA,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,RBA = 100,,,,,,ES2,1 nM,,estradiol,2.9 nM,,,,,,,,,=,100,RBA,,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7512,4328,21510635,E2,P03372,ERA,Homo sapiens,17beta-Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,IC50 = 18nM,agonist,100.00%,agonist,E2,100nM,estradiol,,,,,,,,,,,,,=,7.744727495,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,agonist,agonist,agonist,15
7513,4328,22464681,E2,P03372,ERA,Homo sapiens,17-beta-Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,RBA = 100,,,,,,ES2,1nM,,E2,2.22nM,,,,,,,,,=,100,RBA,,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7514,4328,23043242,E2,P03372,ERA,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",RBA = 100,,,,,,E2,5nM,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7515,4328,25027938,E2,P03372,ERA,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,-,RBA = 100,,,,,,,,,,,,,,,,,,,=,100,RBA,,other,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7516,4328,25369367,1,P03372,ERA,Homo sapiens,17beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.7nM,,,,,,estrogen,,,,,,,,,,,,,=,8.244125144,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,agonist,agonist,15
7517,4328,25559213,estradiol,P03372,ERA,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assays in HEC-1 cells,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,agonist,100.00%,agonist,,,estradiol,,Kd = 0.2nM,,,EC50,=,0.16,nM,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
7522,4328,1548683,estradiol,Q92731,ERB,Homo sapiens,"(estradiol)13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled estradiol",IC50 = 3nM,,,,,,,,,,,,,,,,,,,=,8.522878745,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7523,4328,10673099,17b-estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,,,,,,,,,,,,,,,,,,,=,8.397940009,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7524,4328,11459665,raloxifene,Q92731,ERB,Homo sapiens,"(R)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 10nM,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,8,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7525,4328,11906280,17-beta-estradiol,Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,0.07,nM,,,,,=,7.619788758,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,"agonist,antagonist",agonist,15
7526,4328,12749898,4 (estradiol (E2)),Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,,,,,,E2,4.8nM,,,,,,,,,,,,=,8.698970004,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7527,4328,12824043,17b-E2,Q92731,ERB,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,-,IC50 = 3.6nM,,,,,,,,,,,,,,,,,,,=,8.443697499,pIC50,B,other,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7528,4328,12825935,1 (17-beta-estradiol),Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,agonist,no detail about the percentage act,,,,E2,8nM,,,,,,,,,,,,=,7.619788758,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7529,4328,15006374,B-estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.1nM,agonist,100.00%,agonist,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,agonist,"agonist,antagonist",agonist,15
7530,4328,15081034,17-beta-E2,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 =  11nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,0.48,nM,,,,,=,7.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,"agonist,antagonist",agonist,15
7531,4328,15084115,e-2,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.1nM,,,,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7532,4328,15203155,estradiol,Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,,,,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7533,4328,15203156,estradiol,Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 45nM,,,,,,E2,,,,,,,,,,,,,=,7.346787486,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7534,4328,15225686,17-beta-estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,,,,,,E2,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7535,4328,15341953,17-beta-estradiol,Q92731,ERB,Homo sapiens,"(S)-(S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,,,E2,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7536,4328,15658851,1,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,ERE assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,antagonist,no detail about the percentage act,,,,E2,8nM,,,,,,,,IC50,=,98,nM,=,7.619788758,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,antagonist,,"agonist,antagonist",agonist,15
7537,4328,15664843,estradiol,Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,,,,,,E2,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7538,4328,15745820,estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,,,,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7539,4328,15771467,17 beta-estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKi = 8.5,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,8.5,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7540,4328,15828819,E2,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7541,4328,15876535,E2,Q92731,ERB,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,,,,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7542,4328,15993065,estradiol,Q92731,ERB,Homo sapiens,"13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,,,,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7543,4328,16098741,1,Q92731,ERB,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,,,,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7544,4328,16190762,estradiol (E2),Q92731,ERB,Homo sapiens,"(13S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,10nM,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7545,4328,16219463,1,Q92731,ERB,Homo sapiens,17beta-Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.18nM,,,,,,E2,0.5nM,,,,,,,,,,,,=,8.928117993,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7546,4328,16412638,Estradiol,Q92731,ERB,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,,,,,,,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7547,4328,16777408,estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.1nM,,,,,,,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7548,4328,16884312,estradiol,Q92731,ERB,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,,,,,,E2,10nM,Kd = 0.5nM,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7549,4328,17049855,E2,Q92731,ERB,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,E2,,,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7550,4328,17149865,E2,Q92731,ERB,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.4nM,,,,,,,,,,,,,,,,,,,=,8.853871964,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7551,4328,17188490,"4, estradiol",Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,,,E2,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7552,4328,17289385,estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.0nM,,,,,,E2,,,,,,,,,,,,,=,9,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7553,4328,17448656,estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.2nM,partial agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,2.1,nM,,,,,=,8.920818754,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,"agonist,antagonist",agonist,15
7554,4328,17482813,1,Q92731,ERB,Homo sapiens,17-beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.6nM,,,,,,,,,,,,,,,,,,,=,8.443697499,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7555,4328,17890084,estradiol,Q92731,ERB,Homo sapiens,"(8R,9S,13S,14S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.2nM,agonist,100.00%,agonist,E2,,E2,,,,,EC50,=,2.1,nM,,,,,=,8.920818754,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,"agonist,antagonist",agonist,15
7556,4328,18722117,Estradiol,Q92731,ERB,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,,,,,,E2,,,,,,,,,,,,,=,8.698970004,pKi,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7557,4328,19356928,E2,Q92731,ERB,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.316nM,,,,,,,,,,,,,,,,,,,=,9.500312917,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7558,4328,19705860,estradiol,Q92731,ERB,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,RBA = 100,,,,,,ES2,1 nM,,estradiol,3.2 nM,,,,,,,,,=,100,RBA,,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7559,4328,22464681,E2,Q92731,ERB,Homo sapiens,17-beta-Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,RBA = 100,,,,,,ES2,1nM,,E2,3.3nM,,,,,,,,,=,100,RBA,,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7560,4328,23043242,E2,Q92731,ERB,Homo sapiens,estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",RBA = 100,,,,,,E2,5nM,,,,,,,,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7561,4328,25027938,E2,Q92731,ERB,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,-,RBA = 100,,,,,,,,,,,,,,,,,,,=,100,RBA,,other,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7562,4328,25369367,1,Q92731,ERB,Homo sapiens,17beta-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.6nM,,,,,,estrogen,,,,,,,,,,,,,=,8.251811973,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,"agonist,antagonist",agonist,15
7563,4328,25559213,estradiol,Q92731,ERB,Homo sapiens,Estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL135,reporter gene assays in HEC-1 cells,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 100,agonist,100.00%,agonist,,,estradiol,,kd = 0.5nM,,,EC50,=,0.38,nM,,,,,=,100,RBA,,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,100,248.196,272.17763,2,2,0,1,3.6092,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,"agonist,antagonist",agonist,15
7565,433,21899328,28,P04150,GR,Homo sapiens,"[(5S)-2-(4-Acetyl-3-fluorophenyl)-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(=O)c1ccc(cc1F)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911158,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 6.0nM,antagonist,91.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,134,nM,=,8.22184875,pKi,B,FPA,CC(=O)c1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1F,91,467.376,488.1318398,1,7,5,4,5.8443,94.07,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
7582,4340,10673099,ICI-182780,P03372,ERA,Homo sapiens,"(7R,13S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL1358,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6nM,antagonist,100.00%,antagonist,E2,,E2,2nM,,,,,,inactive,,IC50,=,0.47,nM,=,8.22184875,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,100,559.406,606.3166075,2,3,14,1,8.6826,63.52,C1CCC2C(C1)CCC1C3CCCC3CCC21,antagonist,antagonist,antagonist,antagonist,15
7583,4340,12672240,ICI-182780,P03372,ERA,Homo sapiens,"13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL1358,,,radiometric binding assay monitoring the displacement of [3H]-17beta-estradiol from the ligand-binding domain (LBD) ,Ki = 1.04nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,8.982966661,pKi,B,radiometric,CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,,358.291,387.2198292,1,3,8,3,5.7017,32.7,C1CCC(CC(C2CCCCC2)C2CCCCC2)CC1,,,antagonist,antagonist,324
7584,4340,15993065,Fulvestrant,P03372,ERA,Homo sapiens,"(7R,8R,9S,13S,14S,17S)-13-Methyl-7-[9-(4,4,5,5,5-pentafluoro-pentane-1-sulfinyl)-nonyl]-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL1358,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8.0nM,,,,,,E2,,,,,,,,,,,,,=,8.096910013,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,,559.406,606.3166075,2,3,14,1,8.6826,63.52,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,antagonist,antagonist,15
7585,4340,16806917,ICI-182780,P03372,ERA,Homo sapiens,"(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL1358,,,,RBA = 138,,,,,,,,,,,,,,,,,,,=,138,RBA,,other,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,,559.406,606.3166075,2,3,14,1,8.6826,63.52,C1CCC2C(C1)CCC1C3CCCC3CCC21,,,antagonist,antagonist,15
7586,4340,26407012,2,P03372,ERA,Homo sapiens,Fulvestrant,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,CHEMBL1358,,MCF-7 cell assay,Fluorescence polarization (FP) competition binding assay,PIC50 = 9.09,down regulator,no detail about the percentage act,,,,,,,,,,,,,PIC50,=,10.2,,=,9.09,pIC50,B,FPA,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,,559.406,606.3166075,2,3,14,1,8.6826,63.52,C1CCC2C(C1)CCC1C3CCCC3CCC21,antagonist,,antagonist,antagonist,15
7594,4343,10673099,10,P03372,ERA,Homo sapiens,"(E)-3-[4-((7R,13S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-ylsulfanyl)-phenyl]-acrylic acid",C[C@]12CC[C@H]3[C@@H]([C@@H](Cc4cc(O)ccc34)Sc5ccc(\C=C\C(=O)O)cc5)[C@@H]1CC[C@@H]2O,CHEMBL1628170,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 46nM,agonist,104.00%,agonist,E2,,E2,2nM,,,,EC50,=,13,nM,,,inactive,,=,7.337242168,pIC50,B,radiometric,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](Sc4ccc(/C=C/C(=O)O)cc4)[C@H]3[C@@H]1CC[C@@H]2O,104,420.36,450.1864804,3,4,4,2,5.4778,77.76,C1CCC(CC2CC3CCCCC3C3CCC4CCCC4C23)CC1,agonist,agonist,agonist,agonist,220
7605,4350,16309907,22,P03372,ERA,Homo sapiens,"(3S,10R,13S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL440283,ER transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 210nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,26,nM,,,,,=,6.677780705,pIC50,,radiometric,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,2,2,0,0,3.671,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7606,4350,17890084,12,P03372,ERA,Homo sapiens,"(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL440283,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 180nM,agonist,91.00%,agonist,E2,,E2,,,,,EC50,=,26,nM,,,,,=,6.744727495,pIC50,,radiometric,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,91,260.207,290.2245802,2,2,0,0,3.671,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
7609,4350,16309907,22,Q92731,ERB,Homo sapiens,"(3S,10R,13S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL440283,ER transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 10nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,6,nM,,,,,=,8,pIC50,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,2,2,0,0,3.671,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,,agonist,agonist,15
7610,4350,17890084,12,Q92731,ERB,Homo sapiens,"(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL440283,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.9nM,agonist,77.00%,agonist,E2,,E2,,,,,EC50,=,5.6,nM,,,,,=,8.004364805,pIC50,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,77,260.207,290.2245802,2,2,0,0,3.671,40.46,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
7635,436,21349714,(+/-)-24,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 4-acetylphenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2ccc(cc2)C(=O)C)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684357,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.9nM,agonist,155.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,16,nM,,,,,=,8.537602002,pKi,B,radiometric,CC(=O)c1ccc(NC(=O)O[C@@H]2[C@@H](C)c3c(cc(F)c(-c4cccc5cc[nH]c45)c3F)NC2(C)C)cc1,155,476.333,503.2020482,3,4,4,4,7.2406,83.22,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7647,4361,9871534,Dihydrotestosterone,P10275,AR,Homo sapiens,"(S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,,,,Ki = 2nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,6,nM,,,inactive,,=,8.698970004,pKi,B,other,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7648,4361,9925725,1b,P10275,AR,Homo sapiens,"(10S,13S,17S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,luciferase reporter gene assay,luciferase reporter gene assay,-,Ki = 3nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,100,nM,,,inactive,,=,8.522878745,pKi,B,other,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7649,4361,10077001,DHT,P10275,AR,Homo sapiens,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C, ZINC03814360,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,agonist,no detail about the percentage act,,ATRA,,,,,,,IC50,=,0.001,nM,,,,,=,7,pIC50,,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,"agonist,antagonist",agonist,615
7650,4361,10230628,Dihydrotestosterone,P10275,AR,Homo sapiens,"(S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 4nM,agonist,100.00%,agonist,DHT,,,,,,,,,inactive,,IC50,=,157,nM,=,8.397940009,pIC50,B,other,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,antagonist,agonist,"agonist,antagonist",agonist,615
7651,4361,10230629,Dihydrotetosterone,P10275,AR,Homo sapiens,"(S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,agonist,100.00%,agonist,DHT,,DHT,,,,,EC50,=,6,nM,,,inactive,,=,8.698970004,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7652,4361,10340624,DHT,P10275,AR,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,agonist,100.00%,agonist,DHT,,DHT,,,,,EC50,=,6,nM,,,,,=,8.698970004,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7653,4361,17034117,DHT,P10275,AR,Homo sapiens,dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.2nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,5.1,nM,IC50,>,10000,nM,=,9.698970004,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7654,4361,17181141,DHT,P10275,AR,Homo sapiens,dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.3nM,agonist,100.00%,agonist,DHT,,DHT,,,,,EC50,=,2.8,nM,,,,,=,9.522878745,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7655,4361,17267219,DHT,P10275,AR,Homo sapiens,dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.2nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,5.1,nM,IC50,>,10000,nM,=,9.698970004,pIC50,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7656,4361,17439112,DHT,P10275,AR,Homo sapiens,dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.3nM,agonist,100.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,100,nM,IC50,>,10000,nM,=,9.522878745,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7657,4361,17887661,dihydrotestosterone,P10275,AR,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-dodecahydro-2H-cyclopenta[a]phenanthren-3(4H,9H,14H)-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,Luciferase reporter gene assay,,,Ki = 70nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,5.1,nM,,,,,=,7.15490196,pKi,B,other,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7658,4361,18442912,Dihydrotestosterone,P10275,AR,Homo sapiens,Dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.20nM,agonist,100.00%,agonist,DHT,,,,,,,EC50,=,5.1,nM,IC50,>,10000,nM,=,9.698970004,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7659,4361,19606870,"1, DHT",P10275,AR,Homo sapiens,Dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,agonist,100.00%,agonist,R1881,100nM,methyltrienolone,,,,,EC50,=,2,nM,,,,,=,9,pIC50,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,100,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7660,4361,20510622,DHT,P10275,AR,Homo sapiens,"(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[alpha]phenanthren-3(2H)-one",C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled DHT",Ki = 4.7nM,,,,,,DHT,5nM,,,,,,,,,,,,=,8.327902142,pKi,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,"agonist,antagonist",agonist,615
7661,4361,21036041,2,P10275,AR,Homo sapiens,dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,,,,,,R1881,,,,,,,,,,,,,=,8,pIC50,B,FPA,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,,,"agonist,antagonist",agonist,615
7662,4361,22094279,DHT,P10275,AR,Homo sapiens,Dihydrotestosterone,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,CHEMBL27769,Luciferase reporter gene assay,luciferase reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,agonist,no detail about the percentage act,,,,mibolerone,3nM,,,,EC50,=,6.2,nM,IC50,>,10000,nM,=,8.677780705,pIC50,B,radiometric,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,,260.207,290.2245802,1,2,0,0,3.9591,37.3,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,"agonist,antagonist",agonist,615
7680,4371,20584610,21,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Cyclopropanecarbonyl-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C(=O)C5CC5,CHEMBL1209906,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 36nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,69,nM,=,7.443697499,pKi,B,radiometric,C[C@]12CN(C(=O)C3CC3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,427.253,447.1405908,0,5,2,1,2.48248,90.71,CC(C1CC1)C1CC2CC(C1)C1C(C)C(C3CCCCC3)C(C)C21,antagonist,antagonist,antagonist,antagonist,813
7681,4372,20584610,29,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid(4-fluoro-phenyl)-amide",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C(=O)Nc5ccc(F)cc5,CHEMBL1210034,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 29nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,39,nM,=,7.537602002,pKi,B,radiometric,C[C@]12CN(C(=O)Nc3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,496.291,516.142068,1,5,2,2,3.91708,102.74,CC(CC1CCCCC1)C1CC2CC(C1)C1C(C)C(C3CCCCC3)C(C)C21,antagonist,antagonist,antagonist,antagonist,1004
7682,4373,20584610,28,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid phenylamide",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C(=O)Nc5ccccc5,CHEMBL1209972,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 40nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,16,nM,=,7.397940009,pKi,B,radiometric,C[C@]12CN(C(=O)Nc3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,477.293,498.1514898,1,5,2,2,3.77798,102.74,CC(CC1CCCCC1)C1CC2CC(C1)C1C(C)C(C3CCCCC3)C(C)C21,antagonist,antagonist,antagonist,antagonist,1004
7683,4374,20584610,22,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Benzoyl-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C(=O)c5ccccc5,CHEMBL1209970,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 23nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,54,nM,=,7.638272164,pKi,B,radiometric,C[C@]12CN(C(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,463.286,483.1405908,0,5,2,2,3.38628,90.71,CC(C1CCCCC1)C1CC2CC(C1)C1C(C)C(C3CCCCC3)C(C)C21,antagonist,antagonist,antagonist,antagonist,841
7684,4375,20584610,16,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Hydroxy-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CN(O)C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210909,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 37nM,antagonist,97.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,182,nM,=,7.431798276,pKi,B,radiometric,C[C@]12CN(O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,97,379.209,395.1092907,1,6,1,1,1.93508,93.87,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
7685,4376,20584610,33,P10275,AR,Homo sapiens,"4-[(1S,2S,6R,7R)-9-(4-Fluoro-benzenesulfonyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl]-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)S(=O)(=O)c5ccc(F)cc5,CHEMBL1208805,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 32nM,antagonist,100.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,54,nM,=,7.494850022,pKi,B,radiometric,C[C@]12CN(S(=O)(=O)c3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,100,518.339,537.0981546,0,6,3,2,3.07388,107.78,CC1C(C2CCCCC2)C(C)C2C3CC(CC(C(C)(C)C4CCCCC4)C3)C12,antagonist,antagonist,antagonist,antagonist,537
7686,4377,20584610,32,P10275,AR,Homo sapiens,"4-[(1R,2R,6S,7S)-3,5-dioxo-9-(phenylsulfonyl)-11-oxa-4,9-diazatricyclo[5.3.1.0 2,6]undec-4-yl]-2-(trifluoromethyl)benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)S(=O)(=O)c5ccccc5,CHEMBL1210090,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 12nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,99,nM,=,7.920818754,pKi,B,radiometric,C[C@]12CN(S(=O)(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,499.341,519.1075764,0,6,3,2,2.93478,107.78,CC1C(C2CCCCC2)C(C)C2C3CC(CC(C(C)(C)C4CCCCC4)C3)C12,antagonist,antagonist,antagonist,antagonist,537
7687,4378,20584610,34,P10275,AR,Homo sapiens,"4-[(1S,2S,6R,7R)-1,7-Dimethyl-3,5-dioxo-9-(pyridine-2-sulfonyl)-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl]-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)S(=O)(=O)c5ccccn5,CHEMBL1210091,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 93nM,antagonist,98.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,170,nM,=,7.031517051,pKi,B,radiometric,C[C@]12CN(S(=O)(=O)c3ccccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,98,501.337,520.1028254,0,7,3,2,2.32978,120.67,CC1C(C2CCCCC2)C(C)C2C3CC(CC(C(C)(C)C4CCCCC4)C3)C12,antagonist,antagonist,antagonist,antagonist,537
7688,4379,20584610,30,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Methanesulfonyl-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)S(=O)(=O)C,CHEMBL1210035,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 56nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,205,nM,=,7.251811973,pKi,B,radiometric,C[C@]12CN(S(C)(=O)=O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,439.286,457.0919263,0,6,2,1,1.50548,107.78,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
7690,4380,20584610,38,P10275,AR,Homo sapiens,"4-[(1S,2S,6R,7R)-9-(6-Chloro-pyrimidin-4-yl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl]-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)c5cc(Cl)ncn5,CHEMBL1210152,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 3.5nM,antagonist,98.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,11,nM,=,8.455931956,pKi,B,radiometric,C[C@]12CN(c3cc(Cl)ncn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,98,474.721,491.0972017,0,7,2,2,3.19388,99.42,CC1C(C2CCCCC2)C(C)C2C3CC(C4CCCCC4)CC(C3)C12,antagonist,antagonist,antagonist,antagonist,533
7691,4381,20584610,35,P10275,AR,Homo sapiens,"3-[(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-9-yl]-benzamide",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)c5cccc(c5)C(=O)N,CHEMBL1210783,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 9.0nM,antagonist,98.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,7.4,nM,=,8.045757491,pKi,B,radiometric,C[C@]12CN(c3cccc(C(N)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,98,477.293,498.1514898,1,6,3,2,2.84938,116.73,CC1C(C2CCCCC2)C(C)C2C3CC(C4CCCCC4)CC(C3)C12,antagonist,antagonist,antagonist,antagonist,533
7692,4382,20584610,37,P10275,AR,Homo sapiens,"4-[(1S,2S,6R,7R)-9-(3-Methanesulfonyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl]-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)c5cccc(c5)S(=O)(=O)C,CHEMBL1210151,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 9.4nM,antagonist,96.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,7.4,nM,=,8.026872146,pKi,B,radiometric,C[C@]12CN(c3cccc(S(C)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,96,511.352,533.1232265,0,7,3,2,3.15398,107.78,CC1C(C2CCCCC2)C(C)C2C3CC(C4CCCCC4)CC(C3)C12,antagonist,antagonist,antagonist,antagonist,533
7693,4383,20584610,36,P10275,AR,Homo sapiens,"3-[(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-9-yl]-benzenesulfonamide",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)c5cccc(c5)S(=O)(=O)N,CHEMBL1210150,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 22nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,37,nM,=,7.657577319,pKi,B,radiometric,C[C@]12CN(c3cccc(S(N)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,513.348,534.1184754,1,7,3,2,2.39788,133.8,CC1C(C2CCCCC2)C(C)C2C3CC(C4CCCCC4)CC(C3)C12,antagonist,antagonist,antagonist,antagonist,533
7694,4384,20584610,39,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-1,7-Dimethyl-3,5-dioxo-9-pyrimidin-2-yl-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CN(C[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)c5ncccn5,CHEMBL1210214,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 6.1nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,31,nM,=,8.214670165,pKi,B,radiometric,C[C@]12CN(c3ncccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,439.268,457.1361741,0,7,2,2,2.54048,99.42,CC1C(C2CCCCC2)C(C)C2C3CC(C4CCCCC4)CC(C3)C12,antagonist,antagonist,antagonist,antagonist,533
7695,4385,20584610,6c,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-1,7-Dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",C[C@]12CNC[C@](C)(O1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1208812,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 21nM,antagonist,98.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,128,nM,=,7.677780705,pKi,B,radiometric,C[C@]12CNC[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,98,363.21,379.114376,1,5,1,1,1.83348,82.43,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
7697,4386,11520196,prednisolone,P04150,GR,Homo sapiens,"11,17-Dihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.4nM,agonist,95.00%,agonist,dexamethasone,,dexamethasone,,Kl = 1.5nM,,,IC50,=,3.8,nM,,,,,=,8.619788758,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,95,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7698,4386,11728194,prednisolone,P04150,GR,Homo sapiens,"11,17-Dihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.4nM,agonist,97.00%,agonist,dexamethasone,,dexamethasone,,0.9nM,,,EC50,=,3.3,nM,,,,,=,8.619788758,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,97,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7699,4386,15115388,prednisolone,P04150,GR,Homo sapiens,"(R)-11,17-Dihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13.8nM,agonist,106.00%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,4.5,nM,,,,,=,7.860120914,pIC50,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,106,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7700,4386,15808489,Prednisolone,P04150,GR,Homo sapiens,"(8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13.8nM,agonist,102.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,4.5,nM,,,,,=,7.860120914,pIC50,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,102,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7701,4386,17553679,prednisolone,P04150,GR,Homo sapiens,prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation agonist mode (using  an MMTV:luciferase reporter),GRE activation antagonist mode (using  an MMTV:luciferase reporter),radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.3,nM,Efficacy,<,10%,,=,8.27572413,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,130,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7702,4386,18513967,1,P04150,GR,Homo sapiens,prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,agonist,130.00%,agonist,dexamethasone,,,,,,,EC50,=,5.3,nM,,,,,=,8.27572413,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,130,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7703,4386,19019676,1,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,81.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.9,pIC50,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,81,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7704,4386,19321341,pred,P04150,GR,Homo sapiens,prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 1.5nM,agonist,97.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,15.8,nM,,,,,=,8.823908741,pKi,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,97,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7705,4386,20427184,2,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,94.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,3,nM,,,,,=,8.15490196,pIC50,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,94,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7706,4386,20735001,prednisolone,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,agonist,91.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,6.6,nM,,,,,=,7.823908741,pIC50,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,91,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7707,4386,21073190,"2, pred",P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 1.5nM,agonist,97.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,15.8,nM,,,,,=,8.823908741,pKi,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,97,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7708,4386,21115247,1,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.3nM,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.3,nM,,,,,=,8.27572413,pIC50,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,130,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7709,4386,21316964,1,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,agonist,129.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.3,nM,,,,,=,8.27572413,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,129,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7710,4386,21349714,1,P04150,GR,Homo sapiens,prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,agonist,130.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.3,nM,,,,,=,8.27572413,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,130,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7711,4386,21899328,"2, pred",P04150,GR,Homo sapiens,prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.5nM,agonist,97.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,73.9,nM,IC50,=,21,nM,=,8.823908741,pKi,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,97,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,"antagonist,agonist",agonist,"agonist,antagonist",agonist,615
7712,4386,21963986,Pred,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,agonist,96.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,7,nM,,,,,=,7.823908741,pIC50,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,96,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7713,4386,24446728,prednisolone,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.14nM,agonist,no detail about the percentage act,,,,dexamethasone,,,,,IC50,=,7.26,nM,,,,,=,8.943095149,pKi,B,radiometric,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,,"agonist,antagonist",agonist,615
7714,4386,24656565,Pred,P04150,GR,Homo sapiens,Prednisolone,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,agonist,91.00%,agonist,,,,,,,,IC50,=,6,nM,,,,,=,7.823908741,pIC50,B,FPA,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,91,332.226,360.193674,3,5,2,0,1.5576,94.83,CC1CCC2C(CCC3C4CCCC4CCC23)C1,agonist,agonist,"agonist,antagonist",agonist,615
7737,4388,15911283,prednisolone,P04150,GR,Homo sapiens,"11,17-Dihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,CHEMBL131,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13.8nM,agonist,102.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,4.5,nM,,,,,=,7.860120914,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC21OCCO1,102,307.219,326.1430561,0,4,1,2,3.4941,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,agonist,agonist,"agonist,partial agonist",91
7738,4388,15911283,13,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methylspiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CCC24OCCO4)c5ccc(F)cc5,CHEMBL371311,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 73nM,partial agonist,69.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,28,nM,,,,,=,7.13667714,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC21OCCO1,69,307.219,326.1430561,0,4,1,2,3.4941,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",91
7741,4389,15911283,31,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4',5'-diphenyl-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C[C@]12Cc3cnn(c3C=C1CCC24O[C@@H]([C@H](O4)c5ccccc5)c6ccccc6)c7ccc(F)cc7,CHEMBL195990,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,67.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,10,nM,,,,,=,8,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC21O[C@H](c2ccccc2)[C@@H](c2ccccc2)O1,67,451.351,478.2056563,0,4,3,4,6.9767,36.28,C1CCC(C2CCC3CC4C(CCC45CC(C4CCCCC4)C(C4CCCCC4)C5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,90
7742,439,9873612,5c,P06401,PR,Homo sapiens,"1-(2,2,4-Trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-8-yl)-ethanone",CC(=O)c1ccc2c(Cc3cc4NC(C)(C)C=C(C)c4cc23)c1,CHEMBL93345,,cotransfection,-,Ki = 176nM,antagonist,75.00%,antagonist,,,,,,,,,,,,IC50,=,164,nM,=,6.754487332,pKi,,other,CC(=O)c1ccc2c(c1)Cc1cc3c(cc1-2)C(C)=CC(C)(C)N3,75,282.237,303.1623143,1,2,1,2,5.0678,29.1,C1CCC2CC3C(CC2C1)CC1CCCCC13,antagonist,antagonist,antagonist,antagonist,28
7743,439,16821785,3,P06401,PR,Homo sapiens,"1-(2,2,4-trimethyl-2,10-dihydro-1H-indeno[1,2-g]quinolin-8-yl)ethanone",CC(=O)c1ccc2c(Cc3cc4NC(C)(C)C=C(C)c4cc23)c1,CHEMBL93345,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 6.75,,,,progesterone,,,,,,,,,,,,,,,=,6.75,pKi,,radiometric,CC(=O)c1ccc2c(c1)Cc1cc3c(cc1-2)C(C)=CC(C)(C)N3,,282.237,303.1623143,1,2,1,2,5.0678,29.1,C1CCC2CC3C(CC2C1)CC1CCCCC13,,,antagonist,antagonist,28
7752,4404,15115388,32,P04150,GR,Homo sapiens,"(S)-3-Cyclopropyl-1-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-propan-1-ol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)CCC4CC4)c5ccc(F)cc5,CHEMBL312399,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.5nM,agonist,84.80%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,8.6,nM,,,,,=,8.823908741,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)CCC1CC1,84.8,351.275,380.2263918,1,3,5,2,5.3084,38.05,C1CCC(C2CCC3CC4C(CCCC5CC5)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,99
7753,4405,15115388,34,P04150,GR,Homo sapiens,"(S)-2-(4-Fluoro-phenyl)-1-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-ethanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)Cc4ccc(F)cc4)c5ccc(F)cc5,CHEMBL82546,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.8nM,agonist,80.70%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,3.2,nM,,,,,=,8.552841969,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)Cc1ccc(F)cc1,80.7,394.295,420.2013199,1,3,4,3,5.5,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,318
7754,4405,15808489,3,P04150,GR,Homo sapiens,"(S)-2-(4-Fluoro-phenyl)-1-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-ethanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)Cc4ccc(F)cc4)c5ccc(F)cc5,CHEMBL82546,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.6nM,agonist,81.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,3.2,nM,,,,,=,8.337242168,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)Cc1ccc(F)cc1,81,394.295,420.2013199,1,3,4,3,5.5,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,318
7755,4406,15115388,33,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-2-phenyl-ethanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)Cc4ccccc4)c5ccc(F)cc5,CHEMBL310420,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4.2nM,partial agonist,65.40%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,13.9,nM,,,,,=,8.37675071,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)Cc1ccccc1,65.4,375.297,402.2107417,1,3,4,3,5.3609,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,318
7756,4407,15808489,9,P04150,GR,Homo sapiens,"(R)-(2,5-Dichloro-thiophen-3-yl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cc(Cl)sc4Cl)c5ccc(F)cc5,CHEMBL194077,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10.2nM,partial agonist,65.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,31,nM,,,,,=,7.991399828,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1cc(Cl)sc1Cl,65,442.237,462.0735679,1,4,3,3,6.8592,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
7757,4408,15808489,14,P04150,GR,Homo sapiens,"(R)-Benzo[b]thiophen-2-yl-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cc5ccccc5s4)c6ccc(F)cc6,CHEMBL195972,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 29.1nM,partial agonist,66.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,19,nM,,,,,=,7.536107011,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1cc2ccccc2s1,66,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CC6CCCCC6C5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,82
7758,4408,17467988,13,P04150,GR,Homo sapiens,"(R)-benzo[b]thiophen-2-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cc5ccccc5s4)c6ccc(F)cc6,CHEMBL195972,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 29.1nM,partial agonist,66.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,19,nM,,,,,=,7.536107011,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1cc2ccccc2s1,66,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CC6CCCCC6C5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,82
7759,4409,15115388,15,P04150,GR,Homo sapiens,"((R)-4-Chloro-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(Cl)cc4)c5ccc(F)cc5,CHEMBL81111,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,77.50%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,1.9,nM,,,,,=,8.045757491,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(Cl)cc1,77.5,398.739,422.1561193,1,3,3,3,6.1443,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
7762,4410,15808489,10,P04150,GR,Homo sapiens,"(R)-(5-Chloro-thiophen-2-yl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(Cl)s4)c5ccc(F)cc5,CHEMBL193404,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.6nM,agonist,82.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,13,nM,,,,,=,8.119186408,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(Cl)s1,82,406.784,428.1125402,1,4,3,3,6.2058,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,88
7764,4411,15115388,11,P04150,GR,Homo sapiens,"((R)-4-Fluoro-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL79807,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6.2nM,partial agonist,67.50%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,9.7,nM,,,,,=,8.207608311,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(F)cc1,67.5,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7765,4411,15808489,1,P04150,GR,Homo sapiens,"(R)-(4-Fluoro-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL79807,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.3nM,partial agonist,67.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,9.7,nM,,,,,=,8.27572413,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(F)cc1,67,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7766,4411,17467988,6,P04150,GR,Homo sapiens,"(R)-(4-fluorophenyl)((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL79807,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.3nM,partial agonist,67.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,9.7,nM,,,,,=,8.27572413,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(F)cc1,67,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7770,4412,15808489,12,P04150,GR,Homo sapiens,"(R)-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-(6-fluoro-pyridin-3-yl)-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(F)nc4)c5ccc(F)cc5,CHEMBL362914,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13.6nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,13,nM,,,,,=,7.866461092,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(F)nc1,86,384.28,407.1809188,1,4,3,3,5.025,50.94,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
7771,4413,15115388,14,P04150,GR,Homo sapiens,"(R)-4-{[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-hydroxy-methyl}-phenol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccc(O)cc4)c5ccc(F)cc5,CHEMBL81397,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9.5nM,agonist,76.50%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,19.5,nM,,,,,=,8.022276395,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccc(O)cc1,76.5,379.285,404.1900063,2,4,3,3,5.1965,58.28,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
7772,4414,15115388,13,P04150,GR,Homo sapiens,"(R)-3-{[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-hydroxy-methyl}-phenol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cccc(O)c4)c5ccc(F)cc5,CHEMBL309909,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24.9nM,partial agonist,65.70%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,54.2,nM,,,,,=,7.603800653,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1cccc(O)c1,65.7,379.285,404.1900063,2,4,3,3,5.1965,58.28,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7774,4415,15115388,10,P04150,GR,Homo sapiens,"[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-(R)-phenyl-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccccc4)c5ccc(F)cc5,CHEMBL81591,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8.4nM,partial agonist,61.30%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,2.9,nM,,,,,=,8.075720714,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccccc1,61.3,363.286,388.1950916,1,3,3,3,5.4909,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7778,4416,15115388,12,P04150,GR,Homo sapiens,"((R)-2-Fluoro-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccccc4F)c5ccc(F)cc5,CHEMBL310365,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7.2nM,partial agonist,45.00%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,2.7,nM,,,,,=,8.142667504,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccccc1F,45,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7779,4417,15808489,8,P04150,GR,Homo sapiens,"(R)-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-thiophen-2-yl-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cccs4)c5ccc(F)cc5,CHEMBL196347,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.1nM,partial agonist,54.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,37,nM,,,,,=,8.148741651,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1cccs1,54,371.331,394.1515126,1,4,3,3,5.5524,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
7780,4418,15808489,11,P04150,GR,Homo sapiens,"(R)-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-pyridin-4-yl-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccncc4)c5ccc(F)cc5,CHEMBL365818,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 23.2nM,partial agonist,68.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,38,nM,,,,,=,7.634512015,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccncc1,68,365.282,389.1903406,1,4,3,3,4.8859,50.94,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7781,4419,15808489,7,P04150,GR,Homo sapiens,"(R)-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-furan-3-yl-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4cocc4)c5ccc(F)cc5,CHEMBL371376,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.9nM,partial agonist,57.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,2.7,nM,,,,,=,8.537602002,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccoc1,57,355.263,378.1743562,1,4,3,3,5.0839,51.19,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
7782,442,21349714,(+/-)-26,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5,7-difluoro-6-(1H-indol-7-yl)-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl 3-acetylphenylcarbamate",C[C@@H]1[C@@H](OC(=O)Nc2cccc(c2)C(=O)C)C(C)(C)Nc3cc(F)c(c(F)c13)c4cccc5cc[nH]c45,CHEMBL1684359,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9.4nM,agonist,98.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,29,nM,,,,,=,8.026872146,pKi,B,radiometric,CC(=O)c1cccc(NC(=O)O[C@@H]2[C@@H](C)c3c(cc(F)c(-c4cccc5cc[nH]c45)c3F)NC2(C)C)c1,98,476.333,503.2020482,3,4,4,4,7.2406,83.22,CC(CC1CCCCC1)CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,1042
7785,4420,17467988,10,P04150,GR,Homo sapiens,"(R)-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)(thiophen-3-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4ccsc4)c5ccc(F)cc5,CHEMBL233390,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.1nM,agonist,81.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,1,nM,,,,,=,8.292429824,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1ccsc1,81,371.331,394.1515126,1,4,3,3,5.5524,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,88
7786,4421,15808489,15,P04150,GR,Homo sapiens,"(R)-Benzo[b]thiophen-3-yl-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL363179,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.1nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,18,nM,,,,,=,8.292429824,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1csc2ccccc12,86,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,84
7787,4421,17467988,16,P04150,GR,Homo sapiens,"(R)-benzo[b]thiophen-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL363179,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.1nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,18,nM,,,,,=,8.292429824,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@@H](O)c1csc2ccccc12,86,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,84
7789,4422,15115388,20,P04150,GR,Homo sapiens,"((S)-4-Fluoro-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL311034,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20.4nM,partial agonist,48.50%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,15.5,nM,,,,,=,7.690369833,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@H](O)c1ccc(F)cc1,48.5,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7790,4422,17467988,7,P04150,GR,Homo sapiens,"(S)-(4-fluorophenyl)((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL311034,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10.4nM,partial agonist,48.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,16.5,nM,,,,,=,7.982966661,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@H](O)c1ccc(F)cc1,48,382.284,406.1856698,1,3,3,3,5.63,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7794,4423,15808489,13,P04150,GR,Homo sapiens,"(S)-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-(6-fluoro-pyridin-3-yl)-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@H](O)c4ccc(F)nc4)c5ccc(F)cc5,CHEMBL364015,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.1nM,agonist,76.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,21,nM,,,,,=,8.040958608,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@H](O)c1ccc(F)nc1,76,384.28,407.1809188,1,4,3,3,5.025,50.94,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
7795,4424,15808489,16,P04150,GR,Homo sapiens,"(S)-Benzo[b]thiophen-3-yl-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL372684,IL-6 production assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.5nM,agonist,94.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,6,nM,,,,,=,8.823908741,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@H](O)c1csc2ccccc12,94,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,84
7796,4424,17467988,17,P04150,GR,Homo sapiens,"(S)-benzo[b]thiophen-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CCC[C@@H]2[C@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL372684,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.5nM,agonist,94.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,6,nM,,,,,=,8.823908741,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@H](O)c1csc2ccccc12,94,419.375,444.1671626,1,4,3,4,6.7056,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCCC4CC32)CC1,agonist,agonist,agonist,agonist,84
7801,4429,17467988,14,P04150,GR,Homo sapiens,"(R)-benzo[b]thiophen-2-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4cc5ccccc5s4)c6ccc(F)cc6,CHEMBL232606,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 69.1nM,partial agonist,34.00%,agonist,dexamethasone,,dexamethasone,,,,,,,,,,,,,=,7.160521953,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1cc2ccccc2s1,34,407.364,430.1515126,1,4,3,4,6.3155,38.05,C1CCC(C2CCC3CC4C(CC5CC6CCCCC6C5)CCC4CC32)CC1,,partial agonist,,partial agonist,81
7802,443,19349176,"Farglitazar, GW-2570",P37231,PPARG,Homo sapiens,2-(S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,CC(=O)c1ccccc1N[C@@H](Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C(=O)O,CHEMBL474295,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,agonist,252.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,5,nM,,,,,=,9,pIC50,B,radiometric,CC(=O)c1ccccc1N[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)C(=O)O,252,456.328,484.199822,2,6,11,4,5.58192,101.66,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,411
7803,443,19349176,"Farglitazar, GW-2570",Q07869,PPARA,Homo sapiens,2-(S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,CC(=O)c1ccccc1N[C@@H](Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C(=O)O,CHEMBL474295,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 633nM,agonist,100.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,284,nM,,,,,=,6.19859629,pIC50,,radiometric,CC(=O)c1ccccc1N[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1)C(=O)O,100,456.328,484.199822,2,6,11,4,5.58192,101.66,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,411
7804,4430,17467988,8,P04150,GR,Homo sapiens,"(R)-(4-fluorophenyl)((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL233217,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 17.4nM,partial agonist,26.00%,agonist,dexamethasone,,dexamethasone,,,,,,,,,,,,,=,7.759450752,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1ccc(F)cc1,26,370.273,392.1700198,1,3,3,3,5.2399,38.05,C1CCC(CC2CCC3CC4C(CCC4C4CCCCC4)CC23)CC1,,partial agonist,,partial agonist,229
7806,4432,17467988,22,P04150,GR,Homo sapiens,"(R)-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)(naphthalen-1-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4cccc5ccccc45)c6ccc(F)cc6,CHEMBL439386,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,agonist,80.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,48,nM,,,,,=,8.301029996,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1cccc2ccccc12,80,399.319,424.1950916,1,3,3,4,6.254,38.05,C1CCC(C2CCC3CC4C(CC5CCCC6CCCCC65)CCC4CC32)CC1,agonist,agonist,agonist,agonist,89
7807,4433,17467988,11,P04150,GR,Homo sapiens,"(R)-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)(thiophen-3-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4ccsc4)c5ccc(F)cc5,CHEMBL393194,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.0nM,agonist,77.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,21,nM,,,,,=,8.096910013,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1ccsc1,77,359.32,380.1358625,1,4,3,3,5.1623,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCC4CC32)CC1,agonist,agonist,agonist,agonist,87
7808,4434,17467988,24,P04150,GR,Homo sapiens,"(R)-benzofuran-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4coc5ccccc45)c6ccc(F)cc6,CHEMBL236202,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.3nM,agonist,83.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,3,nM,,,,,=,8.638272164,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1coc2ccccc12,83,391.296,414.1743562,1,4,3,4,5.847,51.19,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCC4CC32)CC1,agonist,agonist,agonist,agonist,83
7809,4435,17467988,18,P04150,GR,Homo sapiens,"(R)-benzo[b]thiophen-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL233789,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,partial agonist,71.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5,nM,,,,,=,8.677780705,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@@H](O)c1csc2ccccc12,71,407.364,430.1515126,1,4,3,4,6.3155,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,83
7811,4437,17467988,9,P04150,GR,Homo sapiens,"(S)-(4-fluorophenyl)((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@H](O)c4ccc(F)cc4)c5ccc(F)cc5,CHEMBL233389,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12.0nM,partial agonist,58.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,6,nM,,,,,=,7.920818754,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@H](O)c1ccc(F)cc1,58,370.273,392.1700198,1,3,3,3,5.2399,38.05,C1CCC(CC2CCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,229
7813,4439,17467988,23,P04150,GR,Homo sapiens,"(S)-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)(naphthalen-1-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@H](O)c4cccc5ccccc45)c6ccc(F)cc6,CHEMBL236201,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6.4nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,33,nM,,,,,=,8.193820026,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@H](O)c1cccc2ccccc12,87,399.319,424.1950916,1,3,3,4,6.254,38.05,C1CCC(C2CCC3CC4C(CC5CCCC6CCCCC65)CCC4CC32)CC1,agonist,agonist,agonist,agonist,89
7815,4440,17467988,12,P04150,GR,Homo sapiens,"(S)-((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)(thiophen-3-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@H](O)c4ccsc4)c5ccc(F)cc5,CHEMBL411825,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,agonist,80.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,2.1,nM,,,,,=,7.552841969,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@H](O)c1ccsc1,80,359.32,380.1358625,1,4,3,3,5.1623,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCC4CC32)CC1,agonist,agonist,agonist,agonist,87
7816,4441,17467988,25,P04150,GR,Homo sapiens,"(S)-benzofuran-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@H](O)c4coc5ccccc45)c6ccc(F)cc6,CHEMBL392376,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.9nM,agonist,78.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5,nM,,,,,=,8.408935393,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@H](O)c1coc2ccccc12,78,391.296,414.1743562,1,4,3,4,5.847,51.19,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCC4CC32)CC1,agonist,agonist,agonist,agonist,83
7817,4442,17467988,19,P04150,GR,Homo sapiens,"(S)-benzo[b]thiophen-3-yl((4aR,5S)-1-(4-fluorophenyl)-4a-methyl-1,4,4a,5,6,7-hexahydrocyclopenta[f]indazol-5-yl)methanol",C[C@]12Cc3cnn(c3C=C1CC[C@@H]2[C@H](O)c4csc5ccccc45)c6ccc(F)cc6,CHEMBL233588,IL-6 inhibition ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.1nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,10,nM,,,,,=,8.508638306,pIC50,B,radiometric,C[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CC[C@@H]2[C@H](O)c1csc2ccccc12,92,407.364,430.1515126,1,4,3,4,6.3155,38.05,C1CCC(C2CCC3CC4C(CC5CCC6CCCCC65)CCC4CC32)CC1,agonist,agonist,agonist,agonist,83
7825,445,23953070,"8d, diastereomer 4",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C(c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426623,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 24nM,agonist,100.00%,agonist,dexamethasone,,,,,,,EC50,=,20,nM,,,,,=,7.619788758,pKi,B,FPA,CC(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,100,437.374,457.1372595,1,6,6,5,5.4228,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,agonist,agonist,agonist,966
7826,445,23953070,"8a, diastereomer 1",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C(c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426623,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 44nM,,,,dexamethasone,,,,,,,EC50,>,100,nM,,,,,=,7.356547324,pKi,B,FPA,CC(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,,437.374,457.1372595,1,6,6,5,5.4228,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,,,agonist,agonist,966
7834,4456,20047280,48,P04150,GR,Homo sapiens,"(R)-1-Cyclohexyl-1-((5aR,6S)-1-(4-fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)ethanol",C[C@@](O)(C1CCCCC1)[C@H]2CCCC3=Cc4c(ncn4C[C@]23C)c5ccc(F)cc5,CHEMBL572212,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.1nM,partial agonist,30.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,470,nM,,,,,=,8.508638306,pIC50,B,FPA,C[C@]12Cn3cnc(-c4ccc(F)cc4)c3C=C1CCC[C@@H]2[C@](C)(O)C1CCCCC1,30,375.297,408.2576919,1,3,3,2,6.2239,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,248
7836,4458,10743937,12a,P10275,AR,Homo sapiens,"8-Methanesulfinyl-2,2-dimethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",C[S+]([O-])c1cc(c2cc3CCC(C)(C)Nc3cc2n1)C(F)(F)F,CHEMBL134209,,cotransfection,hAR transfected into COS-1 cells,Ki = 20nM,antagonist,98.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,63,nM,=,7.698970004,pKi,B,other,C[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,98,325.25,342.1013688,1,3,1,2,4.1277,47.98,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
7839,446,23953070,"8b, diastereomer 2",P04150,GR,Homo sapiens,"(3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC([C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426624,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 0.59nM,agonist,76.00%,agonist,dexamethasone,,,,,,,EC50,=,27,nM,,,,,=,9.229147988,pKi,B,FPA,CC(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,76,437.374,457.1372595,1,6,6,5,5.4228,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,agonist,agonist,agonist,966
7840,446,23953070,"8c, diastereomer 3",P04150,GR,Homo sapiens,"(3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC([C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426624,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 0.48nM,agonist,122.00%,agonist,dexamethasone,,,,,,,EC50,=,0.1,nM,,,,,=,9.318758763,pKi,B,FPA,CC(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,122,437.374,457.1372595,1,6,6,5,5.4228,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,agonist,agonist,agonist,966
7852,4463,21414782,26,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-(cyclopropylmethyl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CC(Oc1ccc(c(C)c1C)S(=O)(=O)N(CC2CC2)c3cccc(c3C)c4ccc(Cl)cc4)C(=O)O,CHEMBL1760408,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.1,partial agonist,53.00%,agonist,,,,,,,,PEC50,=,6.1,,,,,,=,6.1,pIC50,,radiometric,Cc1c(-c2ccc(Cl)cc2)cccc1N(CC1CC1)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,53,497.83,527.1533217,1,4,9,3,6.38946,83.91,CC(C)(C1CCCCC1)C(CC1CC1)C1CCCC(C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,1060
7855,4464,21414782,25,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-(cyclobutylmethyl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CC(Oc1ccc(c(C)c1C)S(=O)(=O)N(CC2CCC2)c3cccc(c3C)c4ccc(Cl)cc4)C(=O)O,CHEMBL1760407,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.0,partial agonist,59.00%,agonist,,,,,,,,PEC50,=,6.3,,,,,,=,6,pIC50,,radiometric,Cc1c(-c2ccc(Cl)cc2)cccc1N(CC1CCC1)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,59,509.841,541.1689718,1,4,9,3,6.77956,83.91,CC(C)(C1CCCCC1)C(CC1CCC1)C1CCCC(C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,1062
7858,4465,21414782,28,Q03181,PPARB,Homo sapiens,"2-(4-(N-(4'-chloro-2-methylbiphenyl-3-yl)-N-(4,4,4-trifluorobutyl)sulfamoyl)-2,3-dimethylphenoxy)propanoic acid",CC(Oc1ccc(c(C)c1C)S(=O)(=O)N(CCCC(F)(F)F)c2cccc(c2C)c3ccc(Cl)cc3)C(=O)O,CHEMBL1760410,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,pIC50 = 5.9,partial agonist,56.00%,agonist,,,,,,,,PEC50,=,5.7,,,,,,=,5.9,pIC50,,radiometric,Cc1c(-c2ccc(Cl)cc2)cccc1N(CCCC(F)(F)F)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C,56,554.824,583.1407064,1,4,10,3,7.32196,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1164
7868,447,17391964,32,P55055,LXRB,Homo sapiens,2-{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)-methyl]phenyl}propanoic acid,CC(C(=O)O)c1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL374804,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 2.6nM,agonist,97.00%,agonist,T0901317,,T0901317,,,,,EC50,=,58,nM,,,,,=,8.585026652,pIC50,B,radiometric,CC(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,97,529.368,554.1817273,2,4,8,5,7.9518,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
7872,4471,21316964,(+/-)-23,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(1H-indol-7-yl)-2,2,4,7,8-pentamethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)c(C)c(cc12)c3cccc4cc[nH]c34,CHEMBL1682433,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 38.3nM,agonist,165.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,205,nM,,,,,=,7.416801226,pKi,B,radiometric,Cc1c(-c2cccc3cc[nH]c23)cc2c(c1C)NC(C)(C)[C@H](O)[C@H]2C,165,308.255,334.2045135,3,2,1,3,5.12024,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7883,448,24980053,17,P04150,GR,Homo sapiens,"(S)-N-(2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanoyl)cyclopropanecarboxamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)NC(=O)C6CC6,CHEMBL3315054,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 8.5nM,partial agonist,67.00%,agonist,dexamethasone,,,,,,,EC50,=,177,nM,,,,,=,8.070581074,pKi,B,FPA,CC(C)(C(=O)NC(=O)C1CC1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,67,513.355,543.2169493,1,6,5,3,4.6767,97.83,CC(CC(C)C1CC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,agonist,partial agonist,agonist,partial agonist,1190
7897,4490,19664922,11,P06401,PR,Homo sapiens,"2-chloro-9-(2-chlorophenyl)-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine-3-carbonitrile",Cc1c(C#N)c(Cl)nc2c3C(CC(=O)Nc3sc12)c4ccccc4Cl,CHEMBL570708,reporter gene assay (CV-1),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.3,agonist,116.00%,agonist,progesterone,,,,,,,PEC50,=,9.1,,,,,,=,7.3,pIC50,B,FPA,Cc1c(C#N)c(Cl)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl,116,377.191,386.9999883,1,4,1,3,5.2573,65.78,CC1CC2CC3CCCCC3C2C(C2CCCCC2)C1,agonist,agonist,agonist,agonist,501
7909,4496,19664922,6,P06401,PR,Homo sapiens,"2-Amino-9-(2-chloro-phenyl)-4-methyl-7-oxo-6,7,8,9-tetrahydro-thieno[2,3-b:4,5-b']dipyridine-3-carbonitrile",Cc1c(C#N)c(N)nc2c3C(CC(=O)Nc3sc12)c4ccccc4Cl,CHEMBL578413,reporter gene assay (CV-1),,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.7,agonist,80.00%,agonist,progesterone,,,,,,,PEC50,=,6.2,,,,,,=,6.7,pIC50,,FPA,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl,80,355.745,368.0498597,2,5,1,3,4.1861,91.8,CC1CC2CC3CCCCC3C2C(C2CCCCC2)C1,agonist,agonist,agonist,agonist,501
7911,4497,19664922,8b,P06401,PR,Homo sapiens,"2-Amino-9-(2-fluoro-phenyl)-4-methyl-7-oxo-6,7,8,9-tetrahydro-thieno[2,3-b:4,5-b']dipyridine-3-carbonitrile",Cc1c(C#N)c(N)nc2c3C(CC(=O)Nc3sc12)c4ccccc4F,CHEMBL577997,reporter gene assay (CV-1),,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.2,partial agonist,47.00%,agonist,progesterone,,,,,,,PEC50,=,5.4,,,,,,=,6.2,pIC50,,FPA,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1F,47,339.29,352.0794103,2,5,1,3,3.6718,91.8,CC1CC2CC3CCCCC3C2C(C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,501
7912,4498,19664922,9,P06401,PR,Homo sapiens,"(S)-2-Amino-9-(2-chloro-phenyl)-4-methyl-7-oxo-6,7,8,9-tetrahydro-thieno[2,3-b:4,5-b']dipyridine-3-carbonitrile",Cc1c(C#N)c(N)nc2c3[C@H](CC(=O)Nc3sc12)c4ccccc4Cl,CHEMBL569353,reporter gene assay (CV-1),,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.8,agonist,83.00%,agonist,progesterone,,,,,,,PEC50,=,6.7,,,,,,=,6.8,pIC50,,FPA,Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)C[C@@H]3c1ccccc1Cl,83,355.745,368.0498597,2,5,1,3,4.1861,91.8,CC1CC2CC3CCCCC3C2C(C2CCCCC2)C1,agonist,agonist,agonist,agonist,501
7919,45,15006411,67,P19793,RXRA,Homo sapiens,"(Z)-3-{7-[2-(2,2-Difluoro-ethoxy)-3,5-diisopropyl-phenyl]-benzofuran-2-yl}-2-fluoro-but-2-enoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)c2cccc3cc(oc23)\C(=C(/F)\C(=O)O)\C,CHEMBL41422,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 101nM,partial antagonist,62.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,22,nM,=,6.995678626,pKi,,radiometric,C/C(=C(/F)C(=O)O)c1cc2cccc(-c3cc(C(C)C)cc(C(C)C)c3OCC(F)F)c2o1,62,433.276,460.186144,1,3,8,3,7.7756,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,partial antagonist,antagonist,partial antagonist,138
7922,450,24980053,24,P04150,GR,Homo sapiens,"(S)-N-(cyclobutylcarbamoyl)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)NC(=O)NC6CCC6,CHEMBL3315059,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 8.7nM,agonist,87.00%,agonist,dexamethasone,,,,,,,EC50,=,676,nM,,,,,=,8.060480747,pKi,B,FPA,CC(C)(C(=O)NC(=O)NC1CCC1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,87,539.373,572.2434984,2,6,5,3,5.0022,109.86,CC(CC(C)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21)CC1CCC1,agonist,agonist,agonist,agonist,1229
7930,4504,17616395,18D1,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-carboxamide",Cc1c(cnn1c2ccccc2)C(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL392319,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.12,antagonist,87.00%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,PIC50,=,6.2,,=,8.12,pIC50,B,FPA,Cc1c(C(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,87,443.299,471.2133618,2,4,6,3,4.88822,67.15,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,antagonist,antagonist,antagonist,antagonist,1247
7931,4504,17616395,18D1E1,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-carboxamide",Cc1c(cnn1c2ccccc2)C(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL392319,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.03,antagonist,93.00%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,,,,,=,8.03,pIC50,B,FPA,Cc1c(C(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,93,443.299,471.2133618,2,4,6,3,4.88822,67.15,CC(CCCCC1CCCC2CCCCC12)C1CCC(C2CCCCC2)C1,,antagonist,antagonist,antagonist,1247
7934,4507,9836620,Troglitazone,P37231,PPARG,Homo sapiens,"5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione",Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,CHEMBL408,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 7.33,agonist,no detail about the percentage act,,,,BRL49653,,,,,PEC50,=,7.05,,,,,,=,7.33,pKi,B,radiometric,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,,414.333,441.160994,2,6,5,2,4.37426,84.86,CC1CC(C)C(CC2CCC(CCC3CCC4CCCCC4C3)CC2)C1,agonist,,agonist,agonist,791
7935,4507,10612594,Troglitazone,P37231,PPARG,Homo sapiens,"5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione",Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,CHEMBL408,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 6.52,agonist,no detail about the percentage act,,,,,,,,,PEC50,=,6.27,,,,,,=,6.52,pKi,,radiometric,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,,414.333,441.160994,2,6,5,2,4.37426,84.86,CC1CC(C)C(CC2CCC(CCC3CCC4CCCCC4C3)CC2)C1,agonist,,agonist,agonist,791
7936,4507,11405642,2,P37231,PPARG,Homo sapiens,"5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione",Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,CHEMBL408,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1285nM,agonist,79.00%,agonist,reference compound (?),,,,,,,EC50,=,2235,nM,,,,,=,5.891096872,pIC50,,radiometric,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,79,414.333,441.160994,2,6,5,2,4.37426,84.86,CC1CC(C)C(CC2CCC(CCC3CCC4CCCCC4C3)CC2)C1,agonist,agonist,agonist,agonist,791
7937,4507,17005393,3,P37231,PPARG,Homo sapiens,troglitazone,Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,CHEMBL408,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1285nM,agonist,79.00%,agonist,ref agonist,,,,,,,EC50,=,2235,nM,,,,,=,5.891096872,pIC50,,radiometric,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,79,414.333,441.160994,2,6,5,2,4.37426,84.86,CC1CC(C)C(CC2CCC(CCC3CCC4CCCCC4C3)CC2)C1,agonist,agonist,agonist,agonist,791
7938,4507,22579420,Troglitazone,P37231,PPARG,Homo sapiens,Troglitazone,Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,CHEMBL408,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 300nM,agonist,100.00%,agonist,Troglitazone,,,,,,,EC50,=,400,nM,,,,,=,6.522878745,pIC50,,other,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,100,414.333,441.160994,2,6,5,2,4.37426,84.86,CC1CC(C)C(CC2CCC(CCC3CCC4CCCCC4C3)CC2)C1,agonist,agonist,agonist,agonist,791
7942,4509,20079636,7d,P37231,PPARG,Homo sapiens,"4'-((2,3-dimethyl-5-(3-phenylpropylcarbamoyl)-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid",Cc1c(C)n(Cc2ccc(cc2)c3ccccc3C(=O)O)c4ccc(cc14)C(=O)NCCCc5ccccc5,CHEMBL602670,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 18nM,partial agonist,37.00%,agonist,rosiglitazone,,,,,,,EC50,=,22,nM,,,,,=,7.744727495,pIC50,B,radiometric,Cc1c(C)n(Cc2ccc(-c3ccccc3C(=O)O)cc2)c2ccc(C(=O)NCCCc3ccccc3)cc12,37,484.385,516.2412929,2,3,9,5,7.03424,71.33,CC(CCCCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1254
7945,451,24980053,32,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(4-(pyrrolidine-1-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCCC5)C(=O)NC(=O)N,CHEMBL3315064,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 0.7nM,agonist,98.00%,agonist,dexamethasone,,,,,,,EC50,=,5.3,nM,,,,,=,9.15490196,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCCC4)cc3)nc2Oc2c(F)cccc21,98,475.33,502.2016336,2,5,4,3,4.5824,114.62,CC(C1CCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,819
7947,4510,20079636,7c,P37231,PPARG,Homo sapiens,"4'-((5-(benzylcarbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid",Cc1c(C)n(Cc2ccc(cc2)c3ccccc3C(=O)O)c4ccc(cc14)C(=O)NCc5ccccc5,CHEMBL602469,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 41nM,partial agonist,28.00%,agonist,rosiglitazone,,,,,,,EC50,=,47,nM,,,,,=,7.387216143,pIC50,B,radiometric,Cc1c(C)n(Cc2ccc(-c3ccccc3C(=O)O)cc2)c2ccc(C(=O)NCc3ccccc3)cc12,28,460.363,488.2099928,2,3,7,5,6.60164,71.33,CC(CCC1CCCCC1)C1CCC2C(CC3CCC(C4CCCCC4)CC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,1129
7964,4518,21316964,(+/-)-21,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-7-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)c(Cl)c(cc12)c3cccc4cc[nH]c34,CHEMBL1682431,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.8nM,agonist,134.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,36,nM,,,,,=,8.744727495,pKi,B,radiometric,Cc1c(Cl)c(-c2cccc3cc[nH]c23)cc2c1NC(C)(C)[C@H](O)[C@H]2C,134,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7966,4519,18722772,18,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(7-chloro-8-methyl-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",Cc1c(Cl)ccc2CCN(Cc12)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL496933,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,54.00%,agonist,GW501516,,,,,,,PEC50,=,6.5,,,,,,=,7.8,pIC50,B,radiometric,Cc1c(Cl)ccc2c1CN(S(=O)(=O)c1cccc(C(=O)Nc3ccc(Cl)cc3C(=O)O)c1)CC2,54,499.246,518.0469981,2,4,5,3,4.99932,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
7968,452,24980053,35,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(nc4)C(=O)N5CCCC5)C(=O)NC(=O)N,CHEMBL3315067,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 2.0nM,partial agonist,53.00%,agonist,dexamethasone,,,,,,,EC50,=,112.6,nM,,,,,=,8.698970004,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCCC4)nc3)nc2Oc2c(F)cccc21,53,477.326,503.1968825,2,6,4,3,3.9774,127.51,CC(C1CCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,819
7972,4522,21316964,(+/-)-22,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-7-fluoro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)c(F)c(cc12)c3cccc4cc[nH]c34,CHEMBL1682432,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.9nM,agonist,162.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,40,nM,,,,,=,9.045757491,pKi,B,radiometric,Cc1c(F)c(-c2cccc3cc[nH]c23)cc2c1NC(C)(C)[C@H](O)[C@H]2C,162,315.242,338.1794416,3,2,1,3,4.95092,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
7982,453,24980053,26,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)NC(=O)N,CHEMBL3315061,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 2.1nM,partial agonist,74.00%,agonist,dexamethasone,,,,,,,EC50,=,5.5,nM,,,,,=,8.677780705,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,74,491.329,518.1965482,2,6,4,3,3.8188,123.85,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,863
7999,454,24980053,36,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(6-(morpholine-4-carbonyl)pyridin-3-yl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(nc4)C(=O)N5CCOCC5)C(=O)NC(=O)N,CHEMBL3315068,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 7.3nM,partial agonist,55.00%,agonist,dexamethasone,,,,,,,EC50,=,142.9,nM,,,,,=,8.13667714,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)nc3)nc2Oc2c(F)cccc21,55,493.325,519.1917972,2,7,4,3,3.2138,136.74,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,863
8012,455,24980053,34,P04150,GR,Homo sapiens,"N-carbamoyl-2-((S)-9-fluoro-2-(4-((S)-3-fluoropyrrolidine-1-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CC[C@H](F)C5)C(=O)NC(=O)N,CHEMBL3315066,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,agonist,94.00%,agonist,dexamethasone,,,,,,,EC50,=,1.3,nM,,,,,=,8.920818754,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CC[C@H](F)C4)cc3)nc2Oc2c(F)cccc21,94,494.328,520.1922118,2,5,4,3,4.5304,114.62,CC(C1CCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,819
8029,456,24980053,33,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-methyl-2-(2-(4-(pyrrolidine-1-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)propanamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)N5CCCC5)C(=O)NC(=O)N,CHEMBL3315065,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.9nM,agonist,87.00%,agonist,dexamethasone,,,,,,,EC50,=,49.3,nM,,,,,=,8.721246399,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCCC4)cc3)ccc21,87,456.332,484.2110554,2,5,4,3,4.4433,114.62,CC(C1CCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,819
8046,457,24980053,31,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-methyl-2-(2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)propanamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)NC(=O)N,CHEMBL3315063,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.5nM,agonist,79.00%,agonist,dexamethasone,,,,,,,EC50,=,11,nM,,,,,=,8.823908741,pKi,B,FPA,CC(C)(C(=O)NC(N)=O)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCOCC4)cc3)ccc21,79,472.331,500.20597,2,6,4,3,3.6797,123.85,CC(C1CCCCC1)C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,agonist,agonist,agonist,863
8061,458,23953070,7a,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(thiophen-3-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5ccsc5,CHEMBL2426643,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 11nM,partial agonist,68.00%,agonist,,,,,,,,EC50,=,73,nM,,,,,=,7.958607315,pKi,B,FPA,CC(C)(C(=O)Nc1ccsc1)C(c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,68,445.393,469.1624116,1,4,6,5,7.0229,46.92,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8076,459,23953070,6g,P04150,GR,Homo sapiens,"rac-3-cyclopentyl-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(thiazol-2-yl)propanamide",CC(C)(C(C1CCCC1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nccs5,CHEMBL2426640,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 21nM,partial agonist,47.00%,agonist,,,,,,,,EC50,=,82,nM,,,,,=,7.677780705,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)C(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C1CCCC1,47,435.378,462.1889607,1,5,6,4,6.5598,59.81,CC(CC1CCCC1)CC(C1CCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,962
8096,460,23953070,6h,P04150,GR,Homo sapiens,"rac-3-cyclohexyl-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(thiazol-2-yl)propanamide",CC(C)(C(C1CCCCC1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nccs5,CHEMBL2426641,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 18nM,partial agonist,55.00%,agonist,,,,,,,,EC50,=,66,nM,,,,,=,7.744727495,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)C(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C1CCCCC1,55,447.389,476.2046108,1,5,6,4,6.9499,59.81,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8134,462,21073190,16,P04150,GR,Homo sapiens,"rac-3-(2-Fluoro-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc(O)c(F)c2)C(=O)Nc3nccs3,CHEMBL1801009,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.6nM,agonist,77.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,51.1,nM,,,,,=,9.22184875,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc(O)c(F)c1,77,351.297,370.1151271,2,4,5,3,4.7846,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,970
8155,463,21073190,12,P04150,GR,Homo sapiens,"rac-3-(4-Hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc(O)cc2)C(=O)Nc3nccs3,CHEMBL1801013,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 2.5nM,partial agonist,63.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,61.4,nM,,,,,=,8.602059991,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc(O)cc1,63,332.299,352.1245489,2,4,5,3,4.6455,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
8178,4640,19464171,12,Q03181,PPARB,Homo sapiens,"2-(4-(2-(cyanomethoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-2,3-dimethylphenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#N)ccc1OCC(=O)O,CHEMBL522238,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 16nM,agonist,89.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1100,nM,,,,,=,7.795880017,pKi,B,radiometric,Cc1c(OCC(=O)O)ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#N)c1C,89,495.349,517.1170785,1,6,10,3,6.41822,88.78,C1CCC(CCC2CCC(CC3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,336
8181,4641,19464171,16,Q03181,PPARB,Homo sapiens,"2-(2,3-dimethyl-4-(2-((tetrahydrofuran-2-yl)methoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC4CCCO4)ccc1OCC(=O)O,CHEMBL501980,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 70nM,agonist,84.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,7100,nM,,,,,=,7.15490196,pKi,B,radiometric,Cc1c(OCC(=O)O)ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC2CCCO2)c1C,84,533.374,562.1636943,1,6,11,3,7.07364,74.22,C1CCC(CCC2CCC(CC3CCCCC3)C(CCC3CCCC3)C2)CC1,agonist,agonist,agonist,agonist,337
8190,4644,19464171,14,Q03181,PPARB,Homo sapiens,"2-(2,3-dimethyl-4-(2-(pyridin-3-ylmethoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCc4cccnc4)ccc1OCC(=O)O,CHEMBL502518,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 36nM,agonist,78.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,2900,nM,,,,,=,7.443697499,pKi,B,radiometric,Cc1c(OCC(=O)O)ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCc2cccnc2)c1C,78,543.393,569.1483786,1,6,11,4,7.48984,77.88,C1CCC(CCC2CCC(CC3CCCCC3)C(CCC3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,338
8193,4645,19464171,15,Q03181,PPARB,Homo sapiens,"2-(2,3-dimethyl-4-(2-(pyridin-4-ylmethoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1c(C)c(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCc4ccncc4)ccc1OCC(=O)O,CHEMBL501979,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 47nM,agonist,76.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,4100,nM,,,,,=,7.327902142,pKi,B,radiometric,Cc1c(OCC(=O)O)ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCc2ccncc2)c1C,76,543.393,569.1483786,1,6,11,4,7.48984,77.88,C1CCC(CCC2CCC(CC3CCCCC3)C(CCC3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,338
8196,4647,15863293,7,P37231,PPARG,Homo sapiens,(S)-2-{4-Chloro-3-[1-(6-chloro-benzo[d]isoxazol-3-yl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,C[C@H](Oc1ccc(Cl)c(Oc2c(C)n(c3noc4cc(Cl)ccc34)c5ccc(OC(F)(F)F)cc25)c1)C(=O)O,CHEMBL363805,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5nM,partial agonist,31.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3,nM,,,,,=,8.301029996,pIC50,B,radiometric,Cc1c(Oc2cc(O[C@@H](C)C(=O)O)ccc2Cl)c2cc(OC(F)(F)F)ccc2n1-c1noc2cc(Cl)ccc12,31,564.194,580.0415763,1,7,7,5,7.92972,95.95,C1CCC(CC2CC(C3CCC4CCCCC43)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,231
8197,4647,19507861,2,P37231,PPARG,Homo sapiens,(2S)-2-(4-chloro-3-(1-(6-chlorobenzo[d]isoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yloxy)phenoxy)propanoic acid,C[C@H](Oc1ccc(Cl)c(Oc2c(C)n(c3noc4cc(Cl)ccc34)c5ccc(OC(F)(F)F)cc25)c1)C(=O)O,CHEMBL363805,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6nM,partial agonist,31.00%,agonist,rosiglitazone,195nM,TZD3,,,,,EC50,=,3,nM,,,,,=,8.22184875,pIC50,B,radiometric,Cc1c(Oc2cc(O[C@@H](C)C(=O)O)ccc2Cl)c2cc(OC(F)(F)F)ccc2n1-c1noc2cc(Cl)ccc12,31,564.194,580.0415763,1,7,7,5,7.92972,95.95,C1CCC(CC2CC(C3CCC4CCCCC43)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,231
8199,4649,18701276,12h,P37231,PPARG,Homo sapiens,"(S)-2-(2-chloro-5-((3-(4-chlorophenoxy)-2-methyl-6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",C[C@H](Oc1cc(Cn2c(C)c(Oc3ccc(Cl)cc3)c4ccc(nc24)C(F)(F)F)ccc1Cl)C(=O)O,CHEMBL517436,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 22nM,partial agonist,26.00%,agonist,Rosiglitazone,,,,,,,EC50,=,23,nM,,,,,=,7.657577319,pIC50,B,radiometric,Cc1c(Oc2ccc(Cl)cc2)c2ccc(C(F)(F)F)nc2n1Cc1ccc(Cl)c(O[C@@H](C)C(=O)O)c1,26,520.185,538.0673971,1,5,7,4,7.36282,73.58,C1CCC(CC2CC(CC3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,256
8200,465,24011644,6,P04150,GR,Homo sapiens,"3-(1H-indol-5-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3[nH]ccc3c2)C(=O)Nc4nccs4,CHEMBL2426152,AP-1 repression,,-,Ki = 7nM,partial agonist,61.00%,agonist,dexamethasone,,,,,,,EC50,=,230,nM,,,,,=,8.15490196,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc2[nH]ccc2c1,61,354.329,375.1405333,2,3,5,4,5.4212,57.78,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2CCCC2C1,agonist,partial agonist,agonist,partial agonist,965
8206,4655,18701276,12a,Q03181,PPARB,Homo sapiens,"(S)-2-(4-chloro-3-((3-(4-chlorophenoxy)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenoxy)propanoic acid",C[C@H](Oc1ccc(Cl)c(Cn2c(C)c(Oc3ccc(Cl)cc3)c4cccnc24)c1)C(=O)O,CHEMBL452054,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 25nM,partial agonist,36.00%,agonist,Rosiglitazone,,,,,,,EC50,=,36,nM,,,,,=,7.602059991,pIC50,B,radiometric,Cc1c(Oc2ccc(Cl)cc2)c2cccnc2n1Cc1cc(O[C@@H](C)C(=O)O)ccc1Cl,36,451.18,470.0800125,1,5,7,4,6.34402,73.58,C1CCC(CC2CC(CC3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,256
8207,4656,18701276,12b,P37231,PPARG,Homo sapiens,"(S)-2-(3-((3-(4-chlorophenoxy)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-4-fluorophenoxy)propanoic acid",C[C@H](Oc1ccc(F)c(Cn2c(C)c(Oc3ccc(Cl)cc3)c4cccnc24)c1)C(=O)O,CHEMBL509369,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 54nM,agonist,156.00%,agonist,Rosiglitazone,,,,,,,EC50,=,156,nM,,,,,=,7.26760624,pIC50,B,radiometric,Cc1c(Oc2ccc(Cl)cc2)c2cccnc2n1Cc1cc(O[C@@H](C)C(=O)O)ccc1F,156,434.725,454.109563,1,5,7,4,5.82972,73.58,C1CCC(CC2CC(CC3CCCCC3)C3CCCCC23)CC1,agonist,agonist,agonist,agonist,256
8208,4657,18701276,12c,P37231,PPARG,Homo sapiens,"(S)-2-(5-((3-(4-chlorophenoxy)-2-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-2-fluorophenoxy)propanoic acid",C[C@H](Oc1cc(Cn2c(C)c(Oc3ccc(Cl)cc3)c4cccnc24)ccc1F)C(=O)O,CHEMBL455130,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 106nM,agonist,140.00%,agonist,Rosiglitazone,,,,,,,EC50,=,140,nM,,,,,=,6.974694135,pIC50,,radiometric,Cc1c(Oc2ccc(Cl)cc2)c2cccnc2n1Cc1ccc(F)c(O[C@@H](C)C(=O)O)c1,140,434.725,454.109563,1,5,7,4,5.82972,73.58,C1CCC(CC2CC(CC3CCCCC3)C3CCCCC23)CC1,agonist,agonist,agonist,agonist,256
8209,4658,15863293,5,P37231,PPARG,Homo sapiens,(S)-2-{3-[1-(6-Chloro-benzo[d]isoxazol-3-yl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid,C[C@H](Oc1cccc(Oc2c(C)n(c3noc4cc(Cl)ccc34)c5ccc(OC(F)(F)F)cc25)c1)C(=O)O,CHEMBL192646,COS-1 cell-based transactivation assay (TA) using transiently co-transfected pcDNA3-PPAR/GAL4 chimer and pUAS(5X)-tk-luc reporter vectors,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 33nM,partial agonist,26.00%,agonist,Rosiglitazone,,,,,,,EC50,=,195,nM,,,,,=,7.48148606,pIC50,B,radiometric,Cc1c(Oc2cccc(O[C@@H](C)C(=O)O)c2)c2cc(OC(F)(F)F)ccc2n1-c1noc2cc(Cl)ccc12,26,528.741,546.0805486,1,7,7,5,7.27632,95.95,C1CCC(CC2CC(C3CCC4CCCCC43)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,231
8210,4659,17616395,17D2E2,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-sulfonamide",Cc1c(cnn1c2ccccc2)S(=O)(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL391874,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.52,partial antagonist,67.00%,antagonist,dexamethasone,,,,,,,PEC50,<,6,,,,,,=,7.52,pIC50,B,FPA,Cc1c(S(=O)(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,67,479.354,507.1803474,2,5,7,3,4.43672,84.22,CC(C)(CCCCC1CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,,partial antagonist,,partial antagonist,1298
8211,4659,17616395,17D1,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-sulfonamide",Cc1c(cnn1c2ccccc2)S(=O)(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL391874,,,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.8,,,,,,,,,,,,,,,,,,,=,6.8,pIC50,,FPA,Cc1c(S(=O)(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,,479.354,507.1803474,2,5,7,3,4.43672,84.22,CC(C)(CCCCC1CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,,,,partial antagonist,1298
8212,4659,17616395,17D2,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-sulfonamide",Cc1c(cnn1c2ccccc2)S(=O)(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL391874,,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.46,,,,,,,,,,,,,,,,,,,=,7.46,pIC50,B,FPA,Cc1c(S(=O)(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,,479.354,507.1803474,2,5,7,3,4.43672,84.22,CC(C)(CCCCC1CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,,,,partial antagonist,1298
8213,4659,17616395,17D2E1,P04150,GR,Homo sapiens,"5-methyl-1-phenyl-N-(3,3,3-trifluoro-2-hydroxy-2-((1-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)propyl)-1H-pyrazole-4-sulfonamide",Cc1c(cnn1c2ccccc2)S(=O)(=O)NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F,CHEMBL391874,,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.29,,,,,,,,,,,,,,,,,,,=,7.29,pIC50,B,FPA,Cc1c(S(=O)(=O)NCC(O)(CC2(C)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccccc1,,479.354,507.1803474,2,5,7,3,4.43672,84.22,CC(C)(CCCCC1CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,,,,partial antagonist,1298
8221,4664,10743937,7a,P10275,AR,Homo sapiens,"8-Bromo-2,2,4,10-tetramethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1CC(C)(C)Nc2c(C)c3nc(Br)cc(c3cc12)C(F)(F)F,CHEMBL134056,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,82.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,785,nM,>,6,pKi,,other,Cc1c2c(cc3c(C(F)(F)F)cc(Br)nc13)C(C)CC(C)(C)N2,82,369.099,386.0605453,1,2,0,2,6.02222,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
8222,4665,10743937,5b,P10275,AR,Homo sapiens,"8-Chloro-2,2,4,10-tetramethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1CC(C)(C)Nc2c(C)c3nc(Cl)cc(c3cc12)C(F)(F)F,CHEMBL131963,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,partial antagonist,60.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,675,nM,>,6,pKi,,other,Cc1c2c(cc3c(C(F)(F)F)cc(Cl)nc13)C(C)CC(C)(C)N2,60,324.648,342.1110609,1,2,0,2,5.91312,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
8223,4666,10743937,6b,P10275,AR,Homo sapiens,"8-Fluoro-2,2,4,10-tetramethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1CC(C)(C)Nc2c(C)c3nc(F)cc(c3cc12)C(F)(F)F,CHEMBL133825,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,partial antagonist,68.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,1448,nM,>,6,pKi,,other,Cc1c2c(cc3c(C(F)(F)F)cc(F)nc13)C(C)CC(C)(C)N2,68,308.193,326.1406115,1,2,0,2,5.39882,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,31
8225,4668,10743937,8a,P10275,AR,Homo sapiens,"2,2,4,10-Tetramethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-pyrido[3,2-g]quinoline",CC1CC(C)(C)Nc2c(C)c3nccc(c3cc12)C(F)(F)F,CHEMBL133054,,cotransfection,hAR transfected into COS-1 cells,Ki > 1000nM,antagonist,99.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,244,nM,>,6,pKi,,other,Cc1c2c(cc3c(C(F)(F)F)ccnc13)C(C)CC(C)(C)N2,99,289.195,308.1500333,1,2,0,2,5.25972,24.92,C1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,31
8228,4670,21324689,15,P04150,GR,Homo sapiens,"5,7-difluoro-2,2-dimethyl-6-(3-methyl-1H-indol-7-yl)-2,3-dihydroquinolin-4(1H)-one O-tert-butyl oxime",Cc1c[nH]c2c(cccc12)c3c(F)cc4NC(C)(C)C\C(=N/OC(C)(C)C)\c4c3F,CHEMBL1762202,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.2nM,agonist,97.00%,agonist,dexamethasone,,,,,,,EC50,=,5,nM,,,,,=,8.657577319,pKi,B,radiometric,Cc1c[nH]c2c(-c3c(F)cc4c(c3F)/C(=N/OC(C)(C)C)CC(C)(C)N4)cccc12,97,384.28,411.2122189,2,3,2,3,6.53492,49.41,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,agonist,agonist,agonist,700
8232,4671,21324689,22,P04150,GR,Homo sapiens,"5,7-difluoro-2,2-dimethyl-6-(3-methyl-1H-indol-7-yl)-2,3-dihydroquinolin-4(1H)-one O-1-hydroxy-2-methylpropan-2-yl oxime",Cc1c[nH]c2c(cccc12)c3c(F)cc4NC(C)(C)C\C(=N/OC(C)(C)CO)\c4c3F,CHEMBL1762209,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.8nM,agonist,77.00%,agonist,dexamethasone,,,,,,,EC50,=,19,nM,,,,,=,9.096910013,pKi,B,radiometric,Cc1c[nH]c2c(-c3c(F)cc4c(c3F)/C(=N/OC(C)(C)CO)CC(C)(C)N4)cccc12,77,400.279,427.2071335,3,4,4,3,5.50732,69.64,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,agonist,agonist,agonist,700
8236,4672,21324689,17,P04150,GR,Homo sapiens,"5,7-difluoro-2,2-dimethyl-6-(3-methyl-1H-indol-7-yl)-2,3-dihydroquinolin-4(1H)-one O-isopropyl oxime",CC(C)O\N=C\1/CC(C)(C)Nc2cc(F)c(c(F)c12)c3cccc4c(C)c[nH]c34,CHEMBL1762204,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.7nM,partial agonist,67.00%,agonist,dexamethasone,,,,,,,EC50,=,0.6,nM,,,,,=,8.568636236,pKi,B,radiometric,Cc1c[nH]c2c(-c3c(F)cc4c(c3F)/C(=N/OC(C)C)CC(C)(C)N4)cccc12,67,372.269,397.1965689,2,3,3,3,6.14482,49.41,CC1CCCC2CCC(C3CCCC4CCCC43)CC12,agonist,partial agonist,agonist,partial agonist,700
8246,4676,18513967,"7, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(1H-indol-3-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3c[nH]c4ccccc34,CHEMBL404496,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 24nM,partial antagonist,60.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,10,nM,=,7.619788758,pKi,B,radiometric,Cc1cc(-c2c[nH]c3ccccc23)c(Cl)c2c1NC(C)(C)CC2C,60,315.698,338.1549764,2,1,1,3,6.49442,27.82,C1CCC2CC(C3CCC4CCCCC43)CCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,34
8254,468,24011644,13,P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nccs5,CHEMBL2426137,Gal4 luciferase reporter gene assays,,-,Ki = 3nM,partial agonist,74.00%,agonist,dexamethasone,,,,,,,EC50,=,103,nM,,,,,=,8.522878745,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,74,447.389,470.1576606,1,5,6,5,6.3937,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8255,468,24011644,"13, enantiomer 2",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nccs5,CHEMBL2426137,Gal4 luciferase reporter gene assays,,-,Ki = 1nM,partial agonist,69.00%,agonist,dexamethasone,,,,,,,EC50,=,60,nM,,,,,=,9,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,69,447.389,470.1576606,1,5,6,5,6.3937,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8256,468,24011644,"13, enantiomer 1",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nccs5,CHEMBL2426137,Gal4 luciferase reporter gene assays,,-,Ki = 4nM,,,,dexamethasone,,,,,,,EC50,>,10000,nM,,,,,=,8.397940009,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,,447.389,470.1576606,1,5,6,5,6.3937,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,,,agonist,partial agonist,966
8270,4687,18513967,"16, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(5-chloro-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cc(Cl)cc4cc[nH]c34,CHEMBL438885,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 24nM,antagonist,94.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,53,nM,=,7.619788758,pKi,B,radiometric,Cc1cc(-c2cc(Cl)cc3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,94,351.151,372.1160041,2,1,1,3,7.14782,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,antagonist,antagonist,antagonist,antagonist,37
8272,4688,18513967,"19, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(4,5-difluoro-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cc(F)c(F)c4cc[nH]c34,CHEMBL429842,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.8nM,agonist,127.00%,agonist,dexamethasone,,,,,,,EC50,=,76,nM,,,,,=,8.744727495,pKi,B,radiometric,Cc1cc(-c2cc(F)c(F)c3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,127,353.694,374.1361328,2,1,1,3,6.77262,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8276,4689,18513967,"18, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(5-fluoro-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cc(F)cc4cc[nH]c34,CHEMBL403274,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.8nM,agonist,88.00%,agonist,dexamethasone,,,,,,,EC50,=,9.2,nM,,,,,=,9.096910013,pKi,B,radiometric,Cc1cc(-c2cc(F)cc3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,88,334.696,356.1455546,2,1,1,3,6.63352,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8278,469,24011644,23,P04150,GR,Homo sapiens,"3-(1-(2,4-difluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4F)C(=O)Nc5nccs5,CHEMBL2426146,Gal4 luciferase reporter gene assays,,-,Ki = 2nM,partial agonist,73.00%,agonist,dexamethasone,,,,,,,EC50,=,78,nM,,,,,=,8.698970004,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3F)ncn2c1,73,466.387,488.1482388,1,5,6,5,6.5328,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8288,4694,18513967,"15, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(4-chloro-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3ccc(Cl)c4cc[nH]c34,CHEMBL404879,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 131nM,antagonist,78.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,12,nM,=,6.882728704,pKi,,radiometric,Cc1cc(-c2ccc(Cl)c3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,78,351.151,372.1160041,2,1,1,3,7.14782,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,antagonist,antagonist,antagonist,antagonist,37
8290,4695,18513967,"17, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(4-fluoro-1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3ccc(F)c4cc[nH]c34,CHEMBL257152,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.3nM,agonist,190.00%,agonist,dexamethasone,,,,,,,EC50,=,46,nM,,,,,=,8.886056648,pKi,B,radiometric,Cc1cc(-c2ccc(F)c3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,190,334.696,356.1455546,2,1,1,3,6.63352,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8306,47,12951091,2,P19793,RXRA,Homo sapiens,"(2E,4Z,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-5-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C(/F)\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL110921,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 8.2nM,agonist,270.00%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,259,nM,IC50,=,8712.8,nM,=,8.086186148,pKi,B,radiometric,C/C(=C/C(F)=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,270,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,"antagonist,agonist",agonist,"antagonist,agonist","agonist,antagonist",205
8307,47,12951091,2,P19793,RXRA,Homo sapiens,"(2E,4Z,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-5-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C(/F)\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL110921,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 8.2nM,agonist,100.00%,antagonist,LGD1069,,9-Cis-RA,,,,,EC50,=,259,nM,IC50,=,8712.8,nM,=,8.086186148,pKi,B,radiometric,C/C(=C/C(F)=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,270,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,"antagonist,agonist",antagonist,"antagonist,agonist","agonist,antagonist",205
8309,4700,18513967,"8, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(1H-indol-4-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4[nH]ccc34,CHEMBL258193,GRE activation agonist mode,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.4nM,partial agonist,34.00%,agonist,dexamethasone,,,,,,,EC50,=,433,nM,IC50,=,1.8,nM,=,8.356547324,pKi,B,radiometric,Cc1cc(-c2cccc3[nH]ccc23)c(Cl)c2c1NC(C)(C)CC2C,34,315.698,338.1549764,2,1,1,3,6.49442,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,37
8311,4701,18513967,"13, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-2,2,4,8-tetramethyl-6-(3-methyl-1H-indol-7-yl)-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4c(C)c[nH]c34,CHEMBL256787,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11nM,agonist,82.00%,agonist,dexamethasone,,,,,,,EC50,=,7.5,nM,,,,,=,7.958607315,pKi,B,radiometric,Cc1cc(-c2cccc3c(C)c[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,82,327.709,352.1706265,2,1,1,3,6.80284,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8313,4702,21316964,(+/-)-18,P04150,GR,Homo sapiens,"(+/-)-3-((3R,4S)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-5-yl)acrylonitrile",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(\C=C\C#N)c12)c3cccc4cc[nH]c34,CHEMBL1682428,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 16.6nM,agonist,120.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,5.7,nM,,,,,=,7.779891912,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(/C=C/C#N)c2c1NC(C)(C)[C@H](O)[C@H]2C,120,346.284,371.1997624,3,3,2,3,5.3486,71.84,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8314,4703,21316964,(+/-)-12,P04150,GR,Homo sapiens,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde oxime",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(\C=N\O)c12)c3cccc4cc[nH]c34,CHEMBL1682422,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 319nM,agonist,160.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,105,nM,,,,,=,6.496209317,pKi,,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(/C=N/O)c2c1NC(C)(C)[C@H](O)[C@H]2C,160,338.261,363.194677,4,4,2,3,4.61992,80.64,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8315,4704,21316964,(+/-)-15,P04150,GR,Homo sapiens,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-tert-butyl oxime",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(\C=N\OC(C)(C)C)c12)c3cccc4cc[nH]c34,CHEMBL1682425,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6.0nM,agonist,122.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,34,nM,,,,,=,8.22184875,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(/C=N/OC(C)(C)C)c2c1NC(C)(C)[C@H](O)[C@H]2C,122,386.305,419.2572773,3,4,3,3,5.96082,69.64,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8316,4705,21316964,(+/-)-16,P04150,GR,Homo sapiens,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-phenyl oxime",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(\C=N\OCc3ccccc3)c12)c4cccc5cc[nH]c45,CHEMBL1682426,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,127.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,3.7,nM,,,,,=,8.455931956,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(/C=N/OCc2ccccc2)c2c1NC(C)(C)[C@H](O)[C@H]2C,127,422.338,453.2416272,3,4,5,4,6.36252,69.64,C1CCC(CCCCC2C3CCCCC3CCC2C2CCCC3CCCC32)CC1,agonist,agonist,agonist,agonist,414
8318,4706,21316964,(+/-)-19,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbonitrile",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c3cccc4cc[nH]c34)c(C#N)c12,CHEMBL1682429,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.3nM,agonist,173.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,9.6,nM,,,,,=,8.886056648,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(C#N)c2c1NC(C)(C)[C@H](O)[C@H]2C,173,322.262,345.1841124,3,3,1,3,4.6835,71.84,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8320,4707,21316964,(+/-)-10,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(1H-indol-7-yl)-2,2,4,5,8-pentamethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(C)c12)c3cccc4cc[nH]c34,CHEMBL1682420,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.2nM,agonist,97.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.9,nM,,,,,=,8.920818754,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(C)c2c1NC(C)(C)[C@H](O)[C@H]2C,97,308.255,334.2045135,3,2,1,3,5.12024,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8321,4708,21115247,8,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,4,8-pentamethyl-1,2-dihydroquinolin-3(4H)-one",Cc1cc(c(Cl)c2c1NC(C)(C)C(=O)C2(C)C)c3cccc4cc[nH]c34,CHEMBL1644755,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.5nM,agonist,106.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,95,nM,,,,,=,8.346787486,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)C(=O)C2(C)C,106,343.708,366.149891,2,2,1,3,5.84752,44.89,CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,646
8326,4710,21115247,7,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2-dihydroquinolin-3(4H)-one",CC1C(=O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644754,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.8nM,agonist,77.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,235,nM,,,,,=,8.236572006,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)C(=O)C2C,77,331.697,352.134241,2,2,1,3,5.67342,44.89,CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,646
8330,4712,21115247,13,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,4,8-pentamethyl-1,2,3,4-tetrahydroquinolin-3-ol",Cc1cc(c(Cl)c2c1NC(C)(C)C(O)C2(C)C)c3cccc4cc[nH]c34,CHEMBL1644761,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 16nM,agonist,157.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,105,nM,,,,,=,7.795880017,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)C(O)C2(C)C,157,343.708,368.1655411,3,2,1,3,5.63932,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8333,4713,21115247,(-)12,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetra hydroquinolin-3-ol",CC1C(O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644760,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.9nM,agonist,133.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,0.8,nM,,,,,=,9.045757491,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)C(O)C2C,133,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,"agonist,partial agonist",37
8334,4713,21115247,(+)12,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",CC1C(O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644760,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 85nM,partial agonist,48.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,483,nM,,,,,=,7.070581074,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)C(O)C2C,48,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,partial agonist,agonist,"agonist,partial agonist",37
8339,4715,18513967,(-)-9,P04150,GR,Homo sapiens,"(-)-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL258191,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.3nM,agonist,89.00%,agonist,dexamethasone,,,,,,,EC50,=,12,nM,,,,,=,9.522878745,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,89,315.698,338.1549764,2,1,1,3,6.49442,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8340,4715,18513967,"9, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL258191,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.6nM,agonist,110.00%,agonist,dexamethasone,,,,,,,EC50,=,20,nM,,,,,=,9.22184875,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,110,315.698,338.1549764,2,1,1,3,6.49442,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8341,4715,21115247,3,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL258191,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.6nM,agonist,110.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,20,nM,,,,,=,9.22184875,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)CC2C,110,315.698,338.1549764,2,1,1,3,6.49442,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8348,4716,21115247,22,P04150,GR,Homo sapiens,"(3S,4S)-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@H](O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644765,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,71.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,307,nM,,,,,=,8,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)[C@@H](O)[C@H]2C,71,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,partial agonist,agonist,partial agonist,37
8351,4717,21115247,12,P04150,GR,Homo sapiens,"(3R,4S)-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644759,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.7nM,agonist,144.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.1,nM,,,,,=,8.769551079,pIC50,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)[C@H](O)[C@H]2C,144,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8352,4717,21316964,(+/-)-3,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34,CHEMBL1644759,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.7nM,agonist,144.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.1,nM,,,,,=,8.769551079,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(Cl)c2c1NC(C)(C)[C@H](O)[C@H]2C,144,331.697,354.149891,3,2,1,3,5.46522,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8355,4718,21316964,(+/-)-9,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-5-fluoro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(c(F)c12)c3cccc4cc[nH]c34,CHEMBL1682419,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.3nM,agonist,123.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,56,nM,,,,,=,8.638272164,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)c(F)c2c1NC(C)(C)[C@H](O)[C@H]2C,123,315.242,338.1794416,3,2,1,3,4.95092,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8356,4719,21316964,(+/-)-8,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinolin-3-ol",C[C@@H]1[C@@H](O)C(C)(C)Nc2c(C)cc(cc12)c3cccc4cc[nH]c34,CHEMBL1682418,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 9.0nM,agonist,161.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,108,nM,,,,,=,8.045757491,pKi,B,radiometric,Cc1cc(-c2cccc3cc[nH]c23)cc2c1NC(C)(C)[C@H](O)[C@H]2C,161,296.244,320.1888634,3,2,1,3,4.81182,48.05,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
8358,4720,18513967,"11, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-2,2,4,8-tetramethyl-6-(1-methyl-1H-indol-7-yl)-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4ccn(C)c34,CHEMBL427899,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 79nM,partial agonist,63.00%,agonist,dexamethasone,,,,,,,EC50,=,191,nM,,,,,=,7.102372909,pKi,B,radiometric,Cc1cc(-c2cccc3ccn(C)c23)c(Cl)c2c1NC(C)(C)CC2C,63,327.709,352.1706265,1,2,1,3,6.50482,16.96,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,partial agonist,agonist,partial agonist,37
8386,4734,17267219,9,P10275,AR,Homo sapiens,"6-(isobutyl(2,2,2-trifluoroethyl)amino)-4-methylquinolin-2(1H)-one",CC(C)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(C)c2c1,CHEMBL235346,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,partial agonist,71.00%,agonist,DHT,,,,,,,EC50,=,3.2,nM,IC50,>,10000,nM,=,7.920818754,pIC50,B,radiometric,Cc1cc(=O)[nH]c2ccc(N(CC(C)C)CC(F)(F)F)cc12,71,293.183,312.1449479,1,2,4,2,3.86122,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
8387,4735,17267219,7b,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-methylquinolin-2(1H)-one",CC1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL238122,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.4nM,agonist,93.00%,agonist,DHT,,,,,,,EC50,=,0.8,nM,IC50,>,10000,nM,=,8.853871964,pIC50,B,radiometric,Cc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,93,326.155,338.0853823,1,2,3,2,3.76752,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
8388,4736,18442912,9b,P10275,AR,Homo sapiens,"10-(hydroxymethyl)-4-methyl-1H-chromeno[3,4-f]quinolin-2(5H)-one",CC1=CC(=O)Nc2ccc3c(COc4cccc(CO)c34)c12,CHEMBL257151,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 26nM,agonist,156.00%,agonist,DHT,,,,,,,EC50,=,12,nM,IC50,>,10000,nM,=,7.585026652,pKi,B,radiometric,Cc1cc(=O)[nH]c2ccc3c(c12)COc1cccc(CO)c1-3,156,278.202,293.1051933,2,3,1,3,2.88822,62.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,agonist,agonist,agonist,634
8389,4737,18442912,5d,P10275,AR,Homo sapiens,"tert-butyl 4-methyl-2,5-dioxo-2,5-dihydro-1H-chromeno[3,4-f]quinoline-10-carboxylate",CC1=CC(=O)Nc2ccc3c(C(=O)Oc4cccc(C(=O)OC(C)(C)C)c34)c12,CHEMBL401711,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 8.7nM,agonist,132.00%,agonist,DHT,,,,,,,EC50,=,1.1,nM,IC50,>,10000,nM,=,8.060480747,pKi,B,radiometric,Cc1cc(=O)[nH]c2ccc3c4c(C(=O)OC(C)(C)C)cccc4oc(=O)c3c12,132,358.244,377.1263227,1,5,1,4,4.05142,89.37,CC1CCC2C(CCC3C4CCCCC4CC(C)C23)C1,agonist,agonist,agonist,agonist,636
8396,4742,10743938,12,P06401,PR,Homo sapiens,"4-Methyl-5-(2,2,4,4-tetramethyl-3-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-thiophene-2-carbonitrile",Cc1cc(C#N)sc1c2ccc3NC(C)(C)C(=O)C(C)(C)c3c2,CHEMBL132889,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 3.9nM,partial antagonist,73.00%,antagonist,progesterone,,,,,,,EC50,=,350,nM,IC50,=,10,nM,=,8.408935393,pIC50,B,other,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)(C)C(=O)C(C)(C)N2,73,304.289,324.1296343,1,4,1,2,4.646,52.89,CC1CCC2CCC(C3CCCC3)CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,643
8397,4742,16821785,49,P06401,PR,Homo sapiens,"4-methyl-5-(2,2,4,4-tetramethyl-3-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carbonitrile",Cc1cc(C#N)sc1c2ccc3NC(C)(C)C(=O)C(C)(C)c3c2,CHEMBL132889,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKI = 8.41,,,,progesterone,,,,,,,,,,,,,,,=,8.41,pKi,B,radiometric,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)(C)C(=O)C(C)(C)N2,,304.289,324.1296343,1,4,1,2,4.646,52.89,CC1CCC2CCC(C3CCCC3)CC2C1,,,"antagonist,agonist",partial antagonist,643
8399,4744,18513967,"3, racemic",P04150,GR,Homo sapiens,"racemic-4-methyl-5-(2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carbonitrile",CC1CC(C)(C)Nc2ccc(cc12)c3sc(cc3C)C#N,CHEMBL134260,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 43nM,antagonist,97.00%,antagonist,dexamethasone,,,,,,,,,,,IC50,=,73,nM,=,7.366531544,pKi,B,radiometric,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)CC(C)(C)N2,97,276.279,296.1347196,1,3,1,2,5.2929,35.82,C1CCC2CC(C3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,36
8400,4744,10743938,7,P06401,PR,Homo sapiens,"4-Methyl-5-(2,2,4-trimethyl-1,2,3,4-tetrahydro-quinolin-6-yl)-thiophene-2-carbonitrile",CC1CC(C)(C)Nc2ccc(cc12)c3sc(cc3C)C#N,CHEMBL134260,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 6.2nM,antagonist,80.00%,antagonist,progesterone,,,,,,,EC50,=,2290,nM,IC50,=,31,nM,=,8.207608311,pIC50,B,other,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)CC(C)(C)N2,80,276.279,296.1347196,1,3,1,2,5.2929,35.82,C1CCC2CC(C3CCCC3)CCC2C1,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,36
8401,4744,18513967,"3, racemic",P06401,PR,Homo sapiens,"racemic-4-methyl-5-(2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carbonitrile",CC1CC(C)(C)Nc2ccc(cc12)c3sc(cc3C)C#N,CHEMBL134260,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.4nM,,,,,,,,,,,,,,,,,,,=,8.075720714,pKi,B,radiometric,Cc1cc(C#N)sc1-c1ccc2c(c1)C(C)CC(C)(C)N2,,276.279,296.1347196,1,3,1,2,5.2929,35.82,C1CCC2CC(C3CCCC3)CCC2C1,,,"antagonist,agonist",antagonist,36
8404,4746,20128594,15,Q03181,PPARB,Homo sapiens,4-chloro-3-methyl-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide,Cc1cc(ccc1Cl)C(=O)NCCS(=O)(=O)c2ccc(cn2)C(F)(F)F,CHEMBL609901,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.9,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.6,,=,6.9,pIC50,,radiometric,Cc1cc(C(=O)NCCS(=O)(=O)c2ccc(C(F)(F)F)cn2)ccc1Cl,100,392.701,406.0365756,1,4,5,2,3.26592,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
8406,4747,21269824,7i,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-methylbenzoic acid",Cc1cc(ccc1NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)C(=O)O,CHEMBL1615150,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20nM,partial agonist,51.00%,agonist,GW4064,,,,,,,EC50,=,500,nM,,,,,=,7.698970004,pIC50,B,radiometric,Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,51,511.786,537.1630758,2,4,6,4,7.40162,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
8410,4750,19783444,17b,P37231,PPARG,Homo sapiens,2-(5-Methyl-isoxazol-3-yl)-3-{4-[3-(5-methyl-2-phenyloxazol-4-yl)-propyl]-phenyl}-propionic acid,Cc1onc(c1)C(Cc2ccc(CCCc3nc(oc3C)c4ccccc4)cc2)C(=O)O,CHEMBL604491,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14000nM,partial agonist,42.00%,agonist,darglitazone,,,,,,,EC50,=,1900,nM,,,,,=,4.853871964,pIC50,NB,radiometric,Cc1cc(C(Cc2ccc(CCCc3nc(-c4ccccc4)oc3C)cc2)C(=O)O)no1,42,404.296,430.1892573,1,5,9,4,5.53264,89.36,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
8411,4751,19783444,17c,P37231,PPARG,Homo sapiens,2-(3-Methyl-isoxazol-5-yl)-3-{4-[3-(5-methyl-2-phenyloxazol-4-yl)-propyl]-phenyl}-propionic acid,Cc1cc(on1)C(Cc2ccc(CCCc3nc(oc3C)c4ccccc4)cc2)C(=O)O,CHEMBL603538,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1600nM,partial agonist,56.00%,agonist,darglitazone,,,,,,,EC50,=,3800,nM,,,,,=,5.795880017,pIC50,,radiometric,Cc1cc(C(Cc2ccc(CCCc3nc(-c4ccccc4)oc3C)cc2)C(=O)O)on1,56,404.296,430.1892573,1,5,9,4,5.53264,89.36,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
8412,4752,20427184,"27, (-)-Enantiomer",P04150,GR,Homo sapiens,"2,2,2-trifluoro-1-(4-fluoro-3-methylphenyl)-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",Cc1cc(ccc1F)C(O)(c2ccc3c(cnn3c4ccc(F)cc4)c2)C(F)(F)F,CHEMBL1094514,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 59nM,agonist,87.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,93,nM,,,,,=,7.229147988,pIC50,B,FPA,Cc1cc(C(O)(c2ccc3c(cnn3-c3ccc(F)cc3)c2)C(F)(F)F)ccc1F,87,403.245,418.1104542,1,3,3,4,5.41032,38.05,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
8417,4757,20345102,15,P55055,LXRB,Homo sapiens,"N-(2-chloro-6-fluorobenzyl)-2,4,6-trimethyl-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc2ccc(cc2)c3cccc(c3)S(=O)(=O)C)Cc4c(F)cccc4Cl,CHEMBL1093523,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,50.00%,agonist,Compound 2,,,,,,,PEC50,=,7.8,,,,,,=,7.8,pIC50,B,radiometric,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c(C)c1,50,556.918,585.1210563,0,4,8,4,6.86596,71.52,CC(C)(C1CCCCC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,1068
8436,4770,24755427,46,P04150,GR,Homo sapiens,"rac-2,4,6-trimethyl-N-(1,1,1-trifluoro-3-(1-(4-fluorophenyl)-1H-indazol-4-yloxy)propan-2-yl)benzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)NC(COc2cccc3c2cnn3c4ccc(F)cc4)C(F)(F)F,CHEMBL3261423,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.8nM,partial agonist,73.00%,agonist,dexamethasone,,,,,,,IC50,=,14,nM,,,,,=,8.420216403,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC(COc2cccc3c2cnn3-c2ccc(F)cc2)C(F)(F)F)c(C)c1,73,498.352,521.1396255,1,5,7,4,5.37806,73.22,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
8443,4773,24215891,16,P04150,GR,Homo sapiens,"N-(3-(7-cyano-5-methyl-1H-indol-3-yl)-1,1,1-trifluoropropan-2-yl)-2,4,6-trimethylbenzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)NC(Cc2c[nH]c3c(cc(C)cc23)C#N)C(F)(F)F,CHEMBL3093453,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,85.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,15,nM,,,,,=,8.301029996,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC(Cc2c[nH]c3c(C#N)cc(C)cc23)C(F)(F)F)c(C)c1,85,427.322,449.1384826,2,3,5,3,4.72516,85.75,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1240
8446,4774,24215891,15,P04150,GR,Homo sapiens,"N-(3-(7-cyano-1H-indol-3-yl)-1,1,1-trifluoropropan-2-yl)-2,4,6-trimethylbenzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)NC(Cc2c[nH]c3c(cccc23)C#N)C(F)(F)F,CHEMBL3093452,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,partial agonist,70.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,45,nM,,,,,=,8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC(Cc2c[nH]c3c(C#N)cccc23)C(F)(F)F)c(C)c1,70,415.311,435.1228325,2,3,5,3,4.41674,85.75,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1240
8461,4779,24215891,9,P04150,GR,Homo sapiens,"2,4,6-trimethyl-N-(1,1,1-trifluoro-3-(5-methyl-1H-indol-3-yl)propan-2-yl)benzenesulfonamide",Cc1ccc2[nH]cc(CC(NS(=O)(=O)c3c(C)cc(C)cc3C)C(F)(F)F)c2c1,CHEMBL3093446,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,partial agonist,60.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,210,nM,,,,,=,8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC(Cc2c[nH]c3ccc(C)cc23)C(F)(F)F)c(C)c1,60,401.304,424.1432336,2,2,5,3,4.85348,61.96,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1240
8464,478,24011644,15,P04150,GR,Homo sapiens,"2,2-dimethyl-3-phenyl-3-(3-phenylimidazo[1,5-a]pyridin-7-yl)-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3c(ncc3c2)c4ccccc4)C(=O)Nc5nccs5,CHEMBL2426139,Gal4 luciferase reporter gene assays,,-,Ki = 5nM,agonist,no detail about the percentage act,,dexamethasone,,,,,,,EC50,=,360,nM,,,,,=,8.301029996,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccn2c(-c3ccccc3)ncc2c1,,428.391,452.1670824,1,5,6,5,6.2546,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,,agonist,partial agonist,966
8465,478,24011644,"15, enantiomer 1",P04150,GR,Homo sapiens,"2,2-dimethyl-3-phenyl-3-(3-phenylimidazo[1,5-a]pyridin-7-yl)-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3c(ncc3c2)c4ccccc4)C(=O)Nc5nccs5,CHEMBL2426139,Gal4 luciferase reporter gene assays,,-,Ki = 11nM,partial agonist,30.00%,agonist,dexamethasone,,,,,,,EC50,>,10000,nM,,,,,=,7.958607315,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccn2c(-c3ccccc3)ncc2c1,30,428.391,452.1670824,1,5,6,5,6.2546,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,,partial agonist,agonist,partial agonist,966
8472,4782,24215891,6,P04150,GR,Homo sapiens,"2,4,6-trimethyl-N-(1,1,1-trifluoro-3-(1H-indol-3-yl)propan-2-yl)benzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)NC(Cc2c[nH]c3ccccc23)C(F)(F)F,CHEMBL3093443,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,partial agonist,30.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,>,2000,nM,,,,,=,7.823908741,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC(Cc2c[nH]c3ccccc23)C(F)(F)F)c(C)c1,30,389.293,410.1275836,2,2,5,3,4.54506,61.96,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,,partial agonist,,partial agonist,1240
8484,4786,24215891,19,P04150,GR,Homo sapiens,"2,4,6-trimethyl-N-(1,1,1-trifluoro-3-(1H-pyrrolo[3,2-b]pyridin-1-yl)propan-2-yl)benzenesulfonamide",Cc1cc(C)c(c(C)c1)S(=O)(=O)NC(Cn2ccc3ncccc23)C(F)(F)F,CHEMBL3093455,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 340nM,partial agonist,36.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,>,2000,nM,,,,,=,6.468521083,pIC50,,FPA,Cc1cc(C)c(S(=O)(=O)NC(Cn2ccc3ncccc32)C(F)(F)F)c(C)c1,36,391.289,411.1228325,1,4,5,3,3.87096,63.99,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,,partial agonist,,partial agonist,1240
8488,4788,21257309,12b,P04150,GR,Homo sapiens,"(R)-N-(2-(1-(4-fluorophenyl)-6-methyl-1H-indazol-4-ylamino)propyl)-2,4,6-trimethylbenzenesulfonamide",C[C@H](CNS(=O)(=O)c1c(C)cc(C)cc1C)Nc2cc(C)cc3c2cnn3c4ccc(F)cc4,CHEMBL1668065,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,119.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.4,,,,,,=,7.9,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)NC[C@@H](C)Nc2cc(C)cc3c2cnn3-c2ccc(F)cc2)c(C)c1,119,451.377,480.1995254,2,5,7,4,5.17718,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8490,479,24011644,9,P04150,GR,Homo sapiens,"3-(imidazo[1,5-a]pyridin-7-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3cncc3c2)C(=O)Nc4nccs4,CHEMBL2426155,AP-1 repression,,-,Ki = 18nM,partial agonist,39.00%,agonist,dexamethasone,,,,,,,EC50,=,1200,nM,,,,,=,7.744727495,pKi,B,other,CC(C)(C(=O)Nc1nccs1)C(c1ccccc1)c1ccn2cncc2c1,39,356.325,376.1357823,1,5,5,4,4.5876,59.29,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2CCCC2C1,agonist,partial agonist,agonist,partial agonist,965
8491,4790,24755427,43,P04150,GR,Homo sapiens,"(S)-N-(4-(1-(4-fluorophenyl)-1H-indazol-4-yl)butan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CCc1cccc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261420,,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.6nM,agonist,76.00%,agonist,dexamethasone,,,,,,,IC50,=,23,nM,,,,,=,8.337242168,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CCc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1,76,437.37,465.1886264,1,4,7,4,5.38946,63.99,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8493,4792,21257309,12e,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-cyanophenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(cc3)C#N)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668068,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,partial agonist,68.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.3,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(C#N)cc2)c(C)c1,68,458.397,487.2041962,2,6,7,4,4.90976,99.81,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
8494,4793,21257309,12a,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-fluorophenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668064,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,96.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.4,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(F)cc2)c(C)c1,96,451.377,480.1995254,2,5,7,4,5.17718,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8495,4794,21257309,14b,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-(isopropylamino)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CC(C)Nc1ccc(cc1)n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc23,CHEMBL1668072,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,89.00%,agonist,,,dexamethasone,,,,,PEC50,=,8,,,,,,=,7.9,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(NC(C)C)cc2)c(C)c1,89,482.419,519.2667964,3,6,9,4,5.85838,88.05,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8496,4795,21257309,14c,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-(cyclopropylamino)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(NC4CC4)cc3)NS(=O)(=O)c5c(C)cc(C)cc5C,CHEMBL1668073,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,79.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.1,,,,,,=,8.1,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(NC3CC3)cc2)c(C)c1,79,482.419,517.2511464,3,6,9,4,5.61238,88.05,CC(C)(CCCCC1CCCC2C1CCC2C1CCC(CC2CC2)CC1)C1CCCCC1,agonist,agonist,agonist,agonist,1289
8497,4796,21257309,14d,P04150,GR,Homo sapiens,"(S)-2-(4-(6-methyl-4-(2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)acetamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(NCC(=O)N)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668074,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,89.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.2,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(NCC(N)=O)cc2)c(C)c1,89,500.414,534.2413099,4,7,10,4,3.93528,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8498,4797,21257309,14f,P04150,GR,Homo sapiens,"(S)-2-(4-(6-methyl-4-((S)-2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)propanamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(N[C@@H](C)C(=O)N)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668076,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,partial agonist,38.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.8,,,,,,=,7.5,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(N[C@@H](C)C(N)=O)cc2)c(C)c1,38,512.425,548.25696,4,7,10,4,4.32378,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
8499,4798,21257309,14e,P04150,GR,Homo sapiens,"(R)-2-(4-(6-methyl-4-((S)-2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)propanamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(N[C@H](C)C(=O)N)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668075,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.6,agonist,110.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.8,,,,,,=,7.6,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(N[C@H](C)C(N)=O)cc2)c(C)c1,110,512.425,548.25696,4,7,10,4,4.32378,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8500,4799,21257309,12f,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(6-methyl-1-(4-(methylsulfonyl)phenyl)-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3ccc(cc3)S(=O)(=O)C)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668069,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,agonist,81.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.9,,,,,,=,7.5,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2ccc(S(C)(=O)=O)cc2)c(C)c1,81,508.455,540.1864975,2,7,8,4,4.44158,110.16,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8502,48,12951091,4,P19793,RXRA,Homo sapiens,"(2E,4Z,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-4-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C(=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C)\F,CHEMBL326673,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 4.8nM,agonist,107.00%,agonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,4842.1,nM,=,8.318758763,pKi,B,radiometric,C/C(=C/C=C(F)/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,107,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,antagonist,agonist,antagonist,"agonist,antagonist",205
8503,48,12951091,4,P19793,RXRA,Homo sapiens,"(2E,4Z,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-4-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C(=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C)\F,CHEMBL326673,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 4.8nM,agonist,100.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,4842.1,nM,=,8.318758763,pKi,B,radiometric,C/C(=C/C=C(F)/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,107,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,antagonist,antagonist,antagonist,"agonist,antagonist",205
8504,480,23953070,6i,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-(pyridin-4-yl)-N-(thiazol-2-yl)propanamide",CC(C)(C(c1ccncc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nccs5,CHEMBL2426642,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 12nM,partial agonist,60.00%,agonist,,,,,,,,EC50,=,389,nM,,,,,=,7.920818754,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)C(c1ccncc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,60,449.385,471.1529095,1,6,6,5,5.8129,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8505,4800,21257309,12c,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(3-fluorophenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(F)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668066,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,92.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.6,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(F)c2)c(C)c1,92,451.377,480.1995254,2,5,7,4,5.17718,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8506,4801,21257309,14l,P04150,GR,Homo sapiens,"N-((2S)-1-(1-(3-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)N4CCCC(CO)C4)NS(=O)(=O)c5c(C)cc(C)cc5C,CHEMBL1668082,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.6,partial agonist,51.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.6,,,,,,=,7.6,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(N3CCCC(CO)C3)c2)c(C)c1,51,534.451,575.2930112,3,7,9,4,5.24678,99.49,CC(C)(CCCCC1CCCC2C1CCC2C1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1290
8507,4801,21257309,"14l1, isomer1",P04150,GR,Homo sapiens,"N-((2S)-1-(1-(3-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)N4CCCC(CO)C4)NS(=O)(=O)c5c(C)cc(C)cc5C,CHEMBL1668082,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.6,partial agonist,41.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.2,,,,,,=,7.6,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(N3CCCC(CO)C3)c2)c(C)c1,41,534.451,575.2930112,3,7,9,4,5.24678,99.49,CC(C)(CCCCC1CCCC2C1CCC2C1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1290
8508,4801,21257309,"14l2, isomer 2",P04150,GR,Homo sapiens,"N-((2S)-1-(1-(3-(3-(hydroxymethyl)piperidin-1-yl)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)N4CCCC(CO)C4)NS(=O)(=O)c5c(C)cc(C)cc5C,CHEMBL1668082,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,partial agonist,37.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.5,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(N3CCCC(CO)C3)c2)c(C)c1,37,534.451,575.2930112,3,7,9,4,5.24678,99.49,CC(C)(CCCCC1CCCC2C1CCC2C1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1290
8509,4802,21257309,14g,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(3-(isopropylamino)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CC(C)Nc1cccc(c1)n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cc(C)cc23,CHEMBL1668077,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.2,agonist,129.00%,agonist,,,dexamethasone,,,,,PEC50,=,9.3,,,,,,=,8.2,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(NC(C)C)c2)c(C)c1,129,482.419,519.2667964,3,6,9,4,5.85838,88.05,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8510,4803,21257309,14h,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(3-(cyclopropylamino)phenyl)-6-methyl-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(NC4CC4)c3)NS(=O)(=O)c5c(C)cc(C)cc5C,CHEMBL1668078,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,127.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.9,,,,,,=,8.1,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(NC3CC3)c2)c(C)c1,127,482.419,517.2511464,3,6,9,4,5.61238,88.05,CC(C)(CCCCC1CCCC2C1CCC2C1CCCC(CC2CC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1291
8511,4804,21257309,14i,P04150,GR,Homo sapiens,"(S)-2-(3-(6-methyl-4-(2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)acetamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(NCC(=O)N)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668079,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,agonist,110.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.6,,,,,,=,7.9,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(NCC(N)=O)c2)c(C)c1,110,500.414,534.2413099,4,7,10,4,3.93528,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8512,4805,21257309,14k,P04150,GR,Homo sapiens,"(S)-2-(3-(6-methyl-4-((S)-2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)propanamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(N[C@@H](C)C(=O)N)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668081,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.3,agonist,125.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.8,,,,,,=,8.3,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(N[C@@H](C)C(N)=O)c2)c(C)c1,125,512.425,548.25696,4,7,10,4,4.32378,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8513,4806,21257309,14j,P04150,GR,Homo sapiens,"(R)-2-(3-(6-methyl-4-((S)-2-(2,4,6-trimethylphenylsulfonamido)propylamino)-1H-indazol-1-yl)phenylamino)propanamide",C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(N[C@H](C)C(=O)N)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL1668080,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,106.00%,agonist,,,dexamethasone,,,,,PEC50,=,8.7,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cc(C)cc3c2cnn3-c2cccc(N[C@H](C)C(N)=O)c2)c(C)c1,106,512.425,548.25696,4,7,10,4,4.32378,131.14,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8514,4807,24755427,13,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(8-methylquinolin-5-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1ccc(C)c2ncccc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3261174,,,Fluorescence polarization (FP) competition binding assay,IC50 = 18nM,partial agonist,59.00%,agonist,dexamethasone,,,,,,,IC50,=,1.1,nM,,,,,=,7.744727495,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2ccc(C)c3ncccc23)c(C)c1,59,370.328,397.1823981,2,4,6,3,4.24738,71.09,CC(C)(CCCCC1CCCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1299
8518,481,21073190,19,P04150,GR,Homo sapiens,"(S)-3-(3-Bromo-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)c(Br)c2)C(=O)Nc3nccs3,CHEMBL1801006,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.4nM,agonist,83.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,40.1,nM,,,,,=,9.397940009,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc(O)c(Br)c1,83,412.203,430.0350609,2,4,5,3,5.408,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,970
8521,4810,24755427,9,P04150,GR,Homo sapiens,"(S)-N-(1-(1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2[nH]ncc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3261170,,,Fluorescence polarization (FP) competition binding assay,IC50 = 42nM,partial agonist,57.00%,agonist,dexamethasone,,,,,,,IC50,=,0.76,nM,,,,,=,7.37675071,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3[nH]ncc23)c(C)c1,57,348.302,372.161997,3,4,6,3,3.26706,86.88,CC(C)(CCCCC1CCCC2CCCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1296
8522,4811,24755427,36,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-chlorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(Cl)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261413,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.4nM,agonist,99.00%,agonist,dexamethasone,,,,,,,IC50,=,3.7,nM,,,,,=,8.468521083,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(Cl)cc2)c(C)c1,99,455.821,482.1543248,2,5,7,4,5.38306,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8523,4812,24755427,37,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-fluoro-3-methylphenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(F)c(C)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261414,,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.1nM,agonist,77.00%,agonist,dexamethasone,,,,,,,IC50,=,14,nM,,,,,=,8.387216143,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)c(C)c2)c(C)c1,77,451.377,480.1995254,2,5,7,4,5.17718,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8524,4813,24755427,30,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261407,,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.9nM,agonist,89.00%,agonist,dexamethasone,,,,,,,IC50,=,1.5,nM,,,,,=,8.30980392,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1,89,439.366,466.1838753,2,5,7,4,4.86876,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8525,4814,24755427,31,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(6-fluoropyridin-3-yl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(F)nc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261408,,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.3nM,agonist,91.00%,agonist,dexamethasone,,,,,,,IC50,=,2.3,nM,,,,,=,8.638272164,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)nc2)c(C)c1,91,441.362,467.1791243,2,6,7,4,4.26376,88.91,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8526,4815,24755427,40,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(3-fluorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3cccc(F)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261417,,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.0nM,agonist,80.00%,agonist,dexamethasone,,,,,,,IC50,=,6.1,nM,,,,,=,8.397940009,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2cccc(F)c2)c(C)c1,80,439.366,466.1838753,2,5,7,4,4.86876,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8527,4816,24755427,33,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(1-phenyl-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccccc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261410,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.5nM,agonist,88.00%,agonist,dexamethasone,,,,,,,IC50,=,1.5,nM,,,,,=,8.455931956,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccccc2)c(C)c1,88,420.368,448.1932971,2,5,7,4,4.72966,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8528,4817,24755427,35,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(1-(pyridin-3-yl)-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3cccnc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261412,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.6nM,agonist,94.00%,agonist,dexamethasone,,,,,,,IC50,=,2.6,nM,,,,,=,8.251811973,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2cccnc2)c(C)c1,94,422.364,449.1885461,2,6,7,4,4.12466,88.91,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8529,4818,24755427,34,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(1-(pyrimidin-5-yl)-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3cncnc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261411,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.3nM,partial agonist,67.00%,agonist,dexamethasone,,,,,,,IC50,=,6.9,nM,,,,,=,8.27572413,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2cncnc2)c(C)c1,67,424.36,450.1837951,2,7,7,4,3.51966,101.8,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1294
8530,4819,24755427,14,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(2-methylquinolin-5-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2nc(C)ccc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3261175,,,Fluorescence polarization (FP) competition binding assay,IC50 = 160nM,partial agonist,56.00%,agonist,dexamethasone,,,,,,,IC50,=,2.2,nM,,,,,=,6.795880017,pIC50,,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3nc(C)ccc23)c(C)c1,56,370.328,397.1823981,2,4,6,3,4.24738,71.09,CC(C)(CCCCC1CCCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1299
8531,482,21073190,20,P04150,GR,Homo sapiens,"(S)-3-(3-cyano-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)c(c2)C#N)C(=O)Nc3nccs3,CHEMBL1801005,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.9nM,partial agonist,74.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,506,nM,,,,,=,9.045757491,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc(O)c(C#N)c1,74,358.317,377.1197978,2,5,5,3,4.51718,86.01,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
8534,4820,24755427,10,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(quinolin-5-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2ncccc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3261171,,,Fluorescence polarization (FP) competition binding assay,IC50 = 75nM,agonist,88.00%,agonist,dexamethasone,,,,,,,IC50,=,1.8,nM,,,,,=,7.124938737,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3ncccc23)c(C)c1,88,358.317,383.166748,2,4,6,3,3.93896,71.09,CC(C)(CCCCC1CCCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1299
8537,4823,24755427,29,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-yloxy)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",C[C@@H](COc1cccc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261406,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.2nM,agonist,93.00%,agonist,dexamethasone,,,,,,,IC50,=,60,nM,,,,,=,8.283996656,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)COc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1,93,441.358,467.1678909,1,5,7,4,4.83566,73.22,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8539,4825,24755427,7,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(quinolin-5-yloxy)propan-2-yl)benzenesulfonamide",C[C@@H](COc1cccc2ncccc12)NS(=O)(=O)c3c(C)cc(C)cc3C,CHEMBL3261168,,,Fluorescence polarization (FP) competition binding assay,IC50 = 240nM,partial agonist,71.00%,agonist,dexamethasone,,,,,,,IC50,=,0.96,nM,,,,,=,6.619788758,pIC50,,FPA,Cc1cc(C)c(S(=O)(=O)N[C@@H](C)COc2cccc3ncccc23)c(C)c1,71,360.309,384.1507636,1,4,6,3,3.90586,68.29,CC(C)(CCCCC1CCCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1299
8549,4828,24755427,39,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-ylamino)-3-methylbutan-2-yl)-2,4,6-trimethylbenzenesulfonamide",CC(C)[C@@H](CNc1cccc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261416,,,Fluorescence polarization (FP) competition binding assay,IC50 = 35nM,agonist,83.00%,agonist,dexamethasone,,,,,,,IC50,=,12,nM,,,,,=,7.455931956,pIC50,B,FPA,Cc1cc(C)c(S(=O)(=O)N[C@H](CNc2cccc3c2cnn3-c2ccc(F)cc2)C(C)C)c(C)c1,83,463.388,494.2151755,2,5,8,4,5.50486,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
8552,483,21073190,17,P04150,GR,Homo sapiens,"(S)-3-(3-Fluoro-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)c(F)c2)C(=O)Nc3nccs3,CHEMBL1801008,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.7nM,agonist,79.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,15.9,nM,,,,,=,9.15490196,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc(O)c(F)c1,79,351.297,370.1151271,2,4,5,3,4.7846,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,970
8569,484,21073190,13,P04150,GR,Homo sapiens,"(S)-3-(4-Hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)cc2)C(=O)Nc3nccs3,CHEMBL1801012,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,partial agonist,63.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,40.9,nM,,,,,=,8.920818754,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc(O)cc1,63,332.299,352.1245489,2,4,5,3,4.6455,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
8570,484,21899328,5,P04150,GR,Homo sapiens,"(S)-3-(4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)cc2)C(=O)Nc3nccs3,CHEMBL1801012,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,,21.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,372,nM,,,,,=,8.920818754,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc(O)cc1,21,332.299,352.1245489,2,4,5,3,4.6455,62.22,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,,agonist,partial agonist,970
8585,4843,25435151,3c,P55055,LXRB,Homo sapiens,"2-(4-(5-(5-cyano-1-(2,4-difluorobenzyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridin-2-yl)thiophen-2-yl)-3-methylphenyl)acetic acid",Cc1cc(CC(=O)O)ccc1c2ccc(s2)C3=CC(=C(C#N)C(=O)N3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360962,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,113.00%,agonist,compound 3b,,,,,,,EC50,=,320,nM,,,,,=,8.045757491,pIC50,B,radiometric,Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,113,527.365,544.0880045,1,5,6,4,6.3963,83.09,CC1CCCC(C2CCC(C3CCCCC3)C2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,737
8586,4843,25435151,3c,Q13133,LXRA,Homo sapiens,"2-(4-(5-(5-cyano-1-(2,4-difluorobenzyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridin-2-yl)thiophen-2-yl)-3-methylphenyl)acetic acid",Cc1cc(CC(=O)O)ccc1c2ccc(s2)C3=CC(=C(C#N)C(=O)N3Cc4ccc(F)cc4F)C(F)(F)F,CHEMBL3360962,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 36nM,agonist,96.00%,agonist,compound 3b,,,,,,,EC50,=,570,nM,,,,,=,7.443697499,pIC50,B,radiometric,Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,96,527.365,544.0880045,1,5,6,4,6.3963,83.09,CC1CCCC(C2CCC(C3CCCCC3)C2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,737
8595,4847,19464171,13,Q03181,PPARB,Homo sapiens,"2-(2,3-dimethyl-4-(2-((5-methylisoxazol-3-yl)methoxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)phenoxy)acetic acid",Cc1onc(COc2cc(COc3ccc(cc3)C(F)(F)F)ccc2Sc4ccc(OCC(=O)O)c(C)c4C)c1,CHEMBL526371,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 35nM,agonist,95.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,2200,nM,,,,,=,7.455931956,pKi,B,radiometric,Cc1cc(COc2cc(COc3ccc(C(F)(F)F)cc3)ccc2Sc2ccc(OCC(=O)O)c(C)c2C)no1,95,547.381,573.1432932,1,7,11,4,7.39126,91.02,C1CCC(CCC2CCC(CC3CCCCC3)C(CCC3CCCC3)C2)CC1,agonist,agonist,agonist,agonist,337
8600,485,23953070,(3S)-5d,P04150,GR,Homo sapiens,"(S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nccs5,CHEMBL2426665,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 6.0nM,agonist,94.00%,agonist,dexamethasone,,,,,,,EC50,=,7.6,nM,,,,,=,8.22184875,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,94,447.389,470.1576606,1,5,6,5,6.4179,59.81,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,agonist,agonist,agonist,966
8603,4851,24755427,20,P04150,GR,Homo sapiens,"(S)-2,4-dichloro-6-methyl-N-(1-(quinolin-5-yloxy)propan-2-yl)benzenesulfonamide",C[C@@H](COc1cccc2ncccc12)NS(=O)(=O)c3c(C)cc(Cl)cc3Cl,CHEMBL3261398,,,Fluorescence polarization (FP) competition binding assay,IC50 = 220nM,partial agonist,64.00%,agonist,dexamethasone,,,,,,,not active (,<,50% inhibition) at 10 ?M,,,,,,=,6.657577319,pIC50,,FPA,Cc1cc(Cl)cc(Cl)c1S(=O)(=O)N[C@@H](C)COc1cccc2ncccc12,64,407.193,424.0415188,1,4,6,3,4.59582,68.29,CC(C)(CCCCC1CCCC2CCCCC21)C1CCCCC1,,partial agonist,,partial agonist,1299
8606,4854,12781198,12d,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4,7-tetramethyl-2,3,4,5-tetrahydro-1H-6-oxa-1-aza-chrysene",CC1CC(C)(C)Nc2ccc3c(COc4c(C)cc(F)cc34)c12,CHEMBL65054,,hPR cotransfection assay in CV-1 cells,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 391nM,antagonist,89.00%,antagonist,progesterone,,,,,,,,,,,EC50,=,637,nM,=,6.407823243,pKi,,radiometric,Cc1cc(F)cc2c1OCc1c-2ccc2c1C(C)CC(C)(C)N2,89,289.224,311.1685425,1,2,0,2,5.39122,21.26,C1CCC2C(C1)CCC1C3CCCCC3CCC21,antagonist,antagonist,antagonist,antagonist,16
8657,4878,23276448,31,P10827,TRA,Homo sapiens,N-{7-[4-Hydroxy-3-(1-hydroxy-2-phenylethyl)phenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(c3)C(O)Cc4ccccc4,CHEMBL2312265,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6751nM,partial agonist,61.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,5.170631892,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(C(O)Cc3ccccc3)c1)CCC2,61,434.298,461.1838376,4,5,8,3,4.67092,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8658,4878,23276448,31,P10828,TRB,Homo sapiens,N-{7-[4-Hydroxy-3-(1-hydroxy-2-phenylethyl)phenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(c3)C(O)Cc4ccccc4,CHEMBL2312265,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 124nM,partial agonist,68.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.906578315,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(C(O)Cc3ccccc3)c1)CCC2,68,434.298,461.1838376,4,5,8,3,4.67092,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8659,4879,23276448,16b,P10827,TRA,Homo sapiens,N-[7-(4-Hydroxy-3-isobutylphenoxy)-6-methylindan-4-yl]malonamic acid,CC(C)Cc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312278,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1431nM,agonist,96.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,5.844360366,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CC(C)C)c1)CCC2,96,370.255,397.188923,3,4,7,2,4.59332,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
8660,4879,23276448,16b,P10828,TRB,Homo sapiens,N-[7-(4-Hydroxy-3-isobutylphenoxy)-6-methylindan-4-yl]malonamic acid,CC(C)Cc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312278,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 39.9nM,agonist,109.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.399027104,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CC(C)C)c1)CCC2,109,370.255,397.188923,3,4,7,2,4.59332,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
8661,488,23953070,(3R)-5d,P04150,GR,Homo sapiens,"(R)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide",CC(C)([C@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nccs5,CHEMBL2426644,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 7.9nM,partial agonist,59.00%,agonist,dexamethasone,,,,,,,EC50,=,435,nM,,,,,=,8.102372909,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,59,447.389,470.1576606,1,5,6,5,6.4179,59.81,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8662,4880,23276448,16c,P10827,TRA,Homo sapiens,N-{7-[4-Hydroxy-3-(3-methylbutyl)phenoxy]-6-methylindan-4-yl}malonamic acid,CC(C)CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312279,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 503nM,agonist,94.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.298432015,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCC(C)C)c1)CCC2,94,382.266,411.204573,3,4,8,2,4.98342,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
8663,4880,23276448,16c,P10828,TRB,Homo sapiens,N-{7-[4-Hydroxy-3-(3-methylbutyl)phenoxy]-6-methylindan-4-yl}malonamic acid,CC(C)CCc1cc(Oc2c(C)cc(NC(=O)CC(=O)O)c3CCCc23)ccc1O,CHEMBL2312279,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 31.7nM,agonist,94.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.498940738,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCC(C)C)c1)CCC2,94,382.266,411.204573,3,4,8,2,4.98342,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,agonist,,agonist,253
8664,4881,23276448,16d,P10827,TRA,Homo sapiens,N-{7-[3-(2-Cyclohexylethyl)-4-hydroxyphenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCC4CCCCC4)c3,CHEMBL2312280,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 429nM,partial agonist,48.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.367542708,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCC3CCCCC3)c1)CCC2,48,418.299,451.2358732,3,4,8,2,5.90772,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8665,4881,23276448,16d,P10828,TRB,Homo sapiens,N-{7-[3-(2-Cyclohexylethyl)-4-hydroxyphenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCC4CCCCC4)c3,CHEMBL2312280,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 17.0nM,partial agonist,73.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.769551079,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCC3CCCCC3)c1)CCC2,73,418.299,451.2358732,3,4,8,2,5.90772,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8669,4883,23276448,35e,P10828,TRB,Homo sapiens,N-(7-{3-[2-(4-Chlorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(Cl)cc4)c3,CHEMBL2312272,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 40nM,partial agonist,40.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.397940009,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(Cl)cc3)c1)CCC2,40,453.752,479.1499506,3,4,8,3,5.83342,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8670,4884,23276448,35b,P10827,TRA,Homo sapiens,"N-(7-{3-[2-(3,4-Difluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)c(F)c4)c3,CHEMBL2312269,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 186nM,partial agonist,45.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.730487056,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)c(F)c3)c1)CCC2,45,456.295,481.1700793,3,4,8,3,5.45822,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8671,4884,23276448,35b,P10828,TRB,Homo sapiens,"N-(7-{3-[2-(3,4-Difluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)c(F)c4)c3,CHEMBL2312269,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6nM,agonist,101.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.22184875,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)c(F)c3)c1)CCC2,101,456.295,481.1700793,3,4,8,3,5.45822,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,343
8672,4885,23276448,32b,P10827,TRA,Homo sapiens,N-(7-{3-[2-(4-Fluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)cc4)c3,CHEMBL2312264,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 228nM,partial agonist,67.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.642065153,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)cc3)c1)CCC2,67,437.297,463.1795012,3,4,8,3,5.31912,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8673,4885,23276448,32b,P10828,TRB,Homo sapiens,N-(7-{3-[2-(4-Fluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)cc4)c3,CHEMBL2312264,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.2nM,agonist,90.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.086186148,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)cc3)c1)CCC2,90,437.297,463.1795012,3,4,8,3,5.31912,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,343
8674,4886,23276448,35a,P10827,TRA,Homo sapiens,"N-(7-{3-[2-(2,4-Difluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)cc4F)c3,CHEMBL2312268,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 201nM,partial agonist,49.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.696803943,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)cc3F)c1)CCC2,49,456.295,481.1700793,3,4,8,3,5.45822,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8675,4886,23276448,35a,P10828,TRB,Homo sapiens,"N-(7-{3-[2-(2,4-Difluorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(F)cc4F)c3,CHEMBL2312268,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12nM,partial agonist,73.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.920818754,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(F)cc3F)c1)CCC2,73,456.295,481.1700793,3,4,8,3,5.45822,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8677,4887,23276448,40c,P10828,TRB,Homo sapiens,N-(7-{4-Hydroxy-3-[2-(4-hydroxyphenyl)ethyl]phenoxy}-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccc(O)cc4)c3,CHEMBL2312275,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 57.6nM,partial agonist,44.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.239577517,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccc(O)cc3)c1)CCC2,44,434.298,461.1838376,4,5,8,3,4.88562,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8679,4888,23276448,35d,P10828,TRB,Homo sapiens,N-(7-{3-[2-(3-Chlorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4cccc(Cl)c4)c3,CHEMBL2312271,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 41nM,partial agonist,41.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.387216143,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3cccc(Cl)c3)c1)CCC2,41,453.752,479.1499506,3,4,8,3,5.83342,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8680,4889,23276448,40b,P10827,TRA,Homo sapiens,N-(7-{4-Hydroxy-3-[2-(3-hydroxyphenyl)ethyl]phenoxy}-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4cccc(O)c4)c3,CHEMBL2312274,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 10000nM,partial agonist,53.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,>,5,pKi,NB,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3cccc(O)c3)c1)CCC2,53,434.298,461.1838376,4,5,8,3,4.88562,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8681,4889,23276448,40b,P10828,TRB,Homo sapiens,N-(7-{4-Hydroxy-3-[2-(3-hydroxyphenyl)ethyl]phenoxy}-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4cccc(O)c4)c3,CHEMBL2312274,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 81.3nM,partial agonist,50.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.089909454,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3cccc(O)c3)c1)CCC2,50,434.298,461.1838376,4,5,8,3,4.88562,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8683,489,21073190,29,P04150,GR,Homo sapiens,(S)-2-(3-Hydroxy-9H-xanthen-9-yl)-2-methyl-N-(thiazol-2-yl)-propanamide,CC(C)([C@H]1c2ccccc2Oc3cc(O)ccc13)C(=O)Nc4nccs4,CHEMBL1800984,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.3nM,agonist,81.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,17.5,nM,,,,,=,9.522878745,pKi,B,FPA,CC(C)(C(=O)Nc1nccs1)[C@H]1c2ccccc2Oc2cc(O)ccc21,81,348.298,366.1038134,2,5,3,3,4.7512,71.45,CC(CC1CCCC1)CC1C2CCCCC2CC2CCCCC21,agonist,agonist,agonist,agonist,959
8686,4890,23276448,32a,P10827,TRA,Homo sapiens,N-[7-(4-Hydroxy-3-phenethylphenoxy)-6-methylindan-4-yl]malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccccc4)c3,CHEMBL2312263,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1638nM,partial agonist,52.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,5.785686103,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccccc3)c1)CCC2,52,418.299,445.188923,3,4,8,3,5.18002,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8687,4890,23276448,32a,P10828,TRB,Homo sapiens,N-[7-(4-Hydroxy-3-phenethylphenoxy)-6-methylindan-4-yl]malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccccc4)c3,CHEMBL2312263,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 40.2nM,agonist,86.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.395773947,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccccc3)c1)CCC2,86,418.299,445.188923,3,4,8,3,5.18002,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,343
8689,4891,23276448,35c,P10828,TRB,Homo sapiens,N-(7-{3-[2-(2-Chlorophenyl)ethyl]-4-hydroxyphenoxy}-6-methylindan-4-yl)malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccccc4Cl)c3,CHEMBL2312270,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30nM,partial agonist,35.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.522878745,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccccc3Cl)c1)CCC2,35,453.752,479.1499506,3,4,8,3,5.83342,95.86,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8690,4892,23276448,"40a, KTA-574",P10827,TRA,Homo sapiens,N-(7-{4-Hydroxy-3-[2-(2-hydroxyphenyl)ethyl]phenoxy}-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccccc4O)c3,CHEMBL2312273,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 10000nM,partial agonist,66.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,>,5,pKi,NB,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccccc3O)c1)CCC2,66,434.298,461.1838376,4,5,8,3,4.88562,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,343
8691,4892,23276448,"40a, KTA-574",P10828,TRB,Homo sapiens,N-(7-{4-Hydroxy-3-[2-(2-hydroxyphenyl)ethyl]phenoxy}-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CCc4ccccc4O)c3,CHEMBL2312273,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 53.5nM,agonist,81.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.271646218,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(CCc3ccccc3O)c1)CCC2,81,434.298,461.1838376,4,5,8,3,4.88562,116.09,C1CCC(CCC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,343
8692,4893,23276448,26,P10827,TRA,Homo sapiens,"N-{7-[4-Hydroxy-3-(6-oxo-1,6-dihydropyridazin-3-methyl)phenoxy]-6-methylindan-4-yl}malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CC4=NNC(=O)C=C4)c3,CHEMBL2312262,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 91.8nM,partial agonist,73.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.037157319,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(Cc3ccc(=O)[nH]n3)c1)CCC2,73,426.279,449.1586855,4,6,7,3,3.06892,141.61,CC1CCC(CC2CCCC(CC3CCCC4CCCC43)C2)CC1,,partial agonist,,partial agonist,749
8693,4893,23276448,26,P10828,TRB,Homo sapiens,"N-{7-[4-Hydroxy-3-(6-oxo-1,6-dihydropyridazin-3-methyl)phenoxy]-6-methylindan-4-yl}malonamic acid",Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(CC4=NNC(=O)C=C4)c3,CHEMBL2312262,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 14.1nM,agonist,79.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.850780887,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(Cc3ccc(=O)[nH]n3)c1)CCC2,79,426.279,449.1586855,4,6,7,3,3.06892,141.61,CC1CCC(CC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,749
8694,4894,23276448,22,P10827,TRA,Homo sapiens,N-{7-[3-(4-Fluorobenzyl)-4-hydroxyphenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(Cc4ccc(F)cc4)c3,CHEMBL2312281,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 30.5nM,agonist,115.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,7.515700161,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(Cc3ccc(F)cc3)c1)CCC2,115,425.286,449.1638511,3,4,7,3,5.12472,95.86,C1CCC(CC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,287
8695,4894,23276448,22,P10828,TRB,Homo sapiens,N-{7-[3-(4-Fluorobenzyl)-4-hydroxyphenoxy]-6-methylindan-4-yl}malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)c(Cc4ccc(F)cc4)c3,CHEMBL2312281,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.7nM,agonist,92.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.431798276,pKi,B,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)c(Cc3ccc(F)cc3)c1)CCC2,92,425.286,449.1638511,3,4,7,3,5.12472,95.86,C1CCC(CC2CCCC(CC3CCCC4CCCC43)C2)CC1,,agonist,,agonist,287
8696,4895,23276448,13,P10827,TRA,Homo sapiens,N-[7-(4-Hydroxyphenoxy)-6-methylindan-4-yl]malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)cc3,CHEMBL2312276,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 10000nM,agonist,47.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,>,5,pKi,NB,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)cc1)CCC2,47,322.211,341.1263227,3,4,5,2,3.39482,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,partial agonist,,partial agonist,253
8697,4895,23276448,13,P10828,TRB,Homo sapiens,N-[7-(4-Hydroxyphenoxy)-6-methylindan-4-yl]malonamic acid,Cc1cc(NC(=O)CC(=O)O)c2CCCc2c1Oc3ccc(O)cc3,CHEMBL2312276,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1662nM,partial agonist,62.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,5.779368981,pKi,,radiometric,Cc1cc(NC(=O)CC(=O)O)c2c(c1Oc1ccc(O)cc1)CCC2,62,322.211,341.1263227,3,4,5,2,3.39482,95.86,C1CCC(CC2CCCC3CCCC32)CC1,,partial agonist,,partial agonist,253
8704,4899,21257309,19c,P04150,GR,Homo sapiens,(S)-N-isopropyl-3-(6-methyl-4-(2-(1-methylethylsulfonamido)propylamino)-1H-indazol-1-yl)benzamide,CC(C)NC(=O)c1cccc(c1)n2ncc3c(NC[C@H](C)NS(=O)(=O)C(C)C)cc(C)cc23,CHEMBL1668085,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.4,agonist,88.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.4,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C(C)C)c2cnn(-c3cccc(C(=O)NC(C)C)c3)c2c1,88,438.363,471.2304109,3,6,9,3,3.60032,105.12,C1CCC(C2CCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,111
8706,49,12951091,5,P19793,RXRA,Homo sapiens,"(2Z,4E,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-2-fluoro-3-methyl-octa-2,4,6-trienoic acid",C\C(=C(\F)/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL325592,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 10.6nM,antagonist,92.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,3.4,nM,=,7.974694135,pKi,B,radiometric,C/C(=C/C=C/C(C)=C(\F)C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,92,405.266,438.2381796,1,2,7,1,7.2131,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
8707,490,23953070,6f,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-4-phenyl-N-(1,3,4-thiadiazol-2-yl)butanamide",CC(C)(C(Cc1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426639,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 1.1nM,partial agonist,37.00%,agonist,,,,,,,,EC50,=,705,nM,,,,,=,8.958607315,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)C(Cc1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,37,461.396,485.1685596,1,6,7,5,6.0073,72.7,CC(CC1CCCC1)CC(CC1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,972
8708,4900,21257309,20d,P04150,GR,Homo sapiens,N-((R)-1-amino-1-oxopropan-2-yl)-3-(4-((S)-2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)-N-methylbenzamide,C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)N(C)[C@H](C)C(=O)N)NS(=O)(=O)C4CC4,CHEMBL1668090,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,agonist,111.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.5,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)N(C)[C@H](C)C(N)=O)c3)c2c1,111,480.38,512.2205745,3,7,10,3,2.16192,139.42,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CC1,agonist,agonist,agonist,agonist,1292
8710,4902,21257309,20e,P04150,GR,Homo sapiens,(S)-1-(3-(4-((S)-2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)benzoyl)pyrrolidine-2-carboxamide,C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)N4CCC[C@H]4C(=O)N)NS(=O)(=O)C5CC5,CHEMBL1668091,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.8,agonist,76.00%,agonist,,,dexamethasone,,,,,PEC50,=,5.4,,,,,,=,6.8,pIC50,,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)N4CCC[C@H]4C(N)=O)c3)c2c1,76,492.391,524.2205745,3,7,9,3,2.30602,139.42,CC(C1CCCC1)C1CCCC(C2CCC3C(CCCCC(C)(C)C4CC4)CCCC32)C1,agonist,agonist,agonist,agonist,823
8711,4903,21257309,19d,P04150,GR,Homo sapiens,(S)-3-(4-(2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)-N-isopropylbenzamide,CC(C)NC(=O)c1cccc(c1)n2ncc3c(NC[C@H](C)NS(=O)(=O)C4CC4)cc(C)cc23,CHEMBL1668086,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,110.00%,agonist,,,dexamethasone,,,,,PEC50,=,7.9,,,,,,=,7.8,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)NC(C)C)c3)c2c1,110,438.363,469.2147609,3,6,9,3,3.35432,105.12,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CC1,agonist,agonist,agonist,agonist,1292
8712,4904,21257309,20a,P04150,GR,Homo sapiens,(S)-N-(2-amino-2-oxoethyl)-3-(4-(2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)benzamide,C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)NCC(=O)N)NS(=O)(=O)C4CC4,CHEMBL1668087,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.1,agonist,95.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.7,,,,,,=,8.1,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)NCC(N)=O)c3)c2c1,95,456.358,484.1892744,4,7,10,3,1.43122,148.21,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CC1,agonist,agonist,agonist,agonist,1292
8713,4905,21257309,20b,P04150,GR,Homo sapiens,N-((S)-1-amino-1-oxopropan-2-yl)-3-(4-((S)-2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)benzamide,C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)N[C@@H](C)C(=O)N)NS(=O)(=O)C4CC4,CHEMBL1668088,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.4,agonist,114.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.7,,,,,,=,7.4,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)N[C@@H](C)C(N)=O)c3)c2c1,114,468.369,498.2049244,4,7,10,3,1.81972,148.21,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CC1,agonist,agonist,agonist,agonist,1292
8714,4906,21257309,20c,P04150,GR,Homo sapiens,N-((R)-1-amino-1-oxopropan-2-yl)-3-(4-((S)-2-(cyclopropanesulfonamido)propylamino)-6-methyl-1H-indazol-1-yl)benzamide,C[C@@H](CNc1cc(C)cc2c1cnn2c3cccc(c3)C(=O)N[C@H](C)C(=O)N)NS(=O)(=O)C4CC4,CHEMBL1668089,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.5,agonist,116.00%,agonist,,,dexamethasone,,,,,PEC50,=,6.9,,,,,,=,7.5,pIC50,B,FPA,Cc1cc(NC[C@H](C)NS(=O)(=O)C2CC2)c2cnn(-c3cccc(C(=O)N[C@H](C)C(N)=O)c3)c2c1,116,468.369,498.2049244,4,7,10,3,1.81972,148.21,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CC1,agonist,agonist,agonist,agonist,1292
8715,4907,21257309,19a,P04150,GR,Homo sapiens,(S)-N-isopropyl-3-(6-methyl-4-(2-(methylsulfonamido)propylamino)-1H-indazol-1-yl)benzamide,CC(C)NC(=O)c1cccc(c1)n2ncc3c(NC[C@H](C)NS(=O)(=O)C)cc(C)cc23,CHEMBL1668083,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 6.9,partial agonist,49.00%,agonist,,,dexamethasone,,,,,PEC50,=,5.7,,,,,,=,6.9,pIC50,,FPA,Cc1cc(NC[C@H](C)NS(C)(=O)=O)c2cnn(-c3cccc(C(=O)NC(C)C)c3)c2c1,49,414.341,443.1991108,3,6,8,3,2.82172,105.12,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
8737,4919,15006374,11,P03372,ERA,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-5-methyl-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Cc1cc(O)cc2O[C@@H]([C@@H](C(=O)c12)c3ccc(O)cc3)c4ccc(OCCN5CCCCC5)cc4,CHEMBL30950,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 14nM,partial antagonist,46.00%,antagonist,,,E2,,,,,,,,,,,,,=,7.853871964,pIC50,B,radiometric,Cc1cc(O)cc2c1C(=O)[C@@H](c1ccc(O)cc1)[C@@H](c1ccc(OCCN3CCCCC3)cc1)O2,46,442.321,473.2202231,2,6,6,3,5.37112,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,partial antagonist,,partial antagonist,493
8738,4919,15006374,11,Q92731,ERB,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-5-methyl-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Cc1cc(O)cc2O[C@@H]([C@@H](C(=O)c12)c3ccc(O)cc3)c4ccc(OCCN5CCCCC5)cc4,CHEMBL30950,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 546nM,partial antagonist,46.00%,antagonist,,,E2,,,,,,,,,,,,,=,6.262807357,pIC50,,radiometric,Cc1cc(O)cc2c1C(=O)[C@@H](c1ccc(O)cc1)[C@@H](c1ccc(OCCN3CCCCC3)cc1)O2,46,442.321,473.2202231,2,6,6,3,5.37112,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,partial antagonist,,partial antagonist,493
8777,494,24011644,14,P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nncs5,CHEMBL2426138,Gal4 luciferase reporter gene assays,,-,Ki = 3nM,agonist,no detail about the percentage act,,dexamethasone,,,,,,,EC50,=,262,nM,,,,,=,8.522878745,pKi,B,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,,449.385,471.1529095,1,6,6,5,5.7887,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,,agonist,partial agonist,966
8778,494,24011644,"14, enantiomer 2",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nncs5,CHEMBL2426138,Gal4 luciferase reporter gene assays,,-,Ki = 2nM,partial agonist,65.00%,agonist,dexamethasone,,,,,,,EC50,=,118,nM,,,,,=,8.698970004,pKi,B,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,65,449.385,471.1529095,1,6,6,5,5.7887,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8779,494,24011644,"14 , enantiomer 1",P04150,GR,Homo sapiens,"3-(1-(4-fluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4)C(=O)Nc5nncs5,CHEMBL2426138,Gal4 luciferase reporter gene assays,,-,Ki = 6nM,,,,dexamethasone,,,,,,,EC50,>,10000,nM,,,,,=,8.22184875,pKi,B,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3)ncn2c1,,449.385,471.1529095,1,6,6,5,5.7887,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,,,agonist,partial agonist,966
8808,495,24011644,24,P04150,GR,Homo sapiens,"3-(1-(2,4-difluorophenyl)imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(ncn3c2)c4ccc(F)cc4F)C(=O)Nc5nncs5,CHEMBL2426147,Gal4 luciferase reporter gene assays,,-,Ki = 1nM,partial agonist,61.00%,agonist,dexamethasone,,,,,,,EC50,=,117,nM,,,,,=,9,pKi,B,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(-c3ccc(F)cc3F)ncn2c1,61,468.383,489.1434877,1,6,6,5,5.9278,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8825,4959,17543524,12,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2cc(C)c(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL236500,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2600nM,partial agonist,27.00%,agonist,compound 2b,,,,,,,EC50,=,1100,nM,,,,,=,5.585026652,pIC50,,radiometric,Cc1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)cc(C(C)C)c1O,27,530.063,555.0255972,3,4,8,2,5.90922,95.86,C1CCC(CC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,268
8896,4982,21414782,2,Q03181,PPARB,Homo sapiens,2-(4-(N-isopentyl-N-(4'-(trifluoromethyl)biphenyl-3-yl)sulfamoyl)-2-methylphenoxy)acetic acid,CC(C)CCN(c1cccc(c1)c2ccc(cc2)C(F)(F)F)S(=O)(=O)c3ccc(OCC(=O)O)c(C)c3,CHEMBL1760266,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,pIC50 = 5.9,agonist,75.00%,agonist,,,,,,,,PEC50,=,6.8,,,,,,=,5.9,pIC50,,radiometric,Cc1cc(S(=O)(=O)N(CCC(C)C)c2cccc(-c3ccc(C(F)(F)F)cc3)c2)ccc1OCC(=O)O,75,507.36,535.1640287,1,4,10,3,6.38562,83.91,CC(C)(CC1CCCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1164
8919,4991,12699745,7k GW-501516,Q03181,PPARB,Homo sapiens,{2-Methyl-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid,Cc1cc(SCc2sc(nc2C)c3ccc(cc3)C(F)(F)F)ccc1OCC(=O)O,CHEMBL38943,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,1,nM,,,,,=,9,pIC50,B,radiometric,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,,435.363,453.0680201,1,5,7,3,6.20144,59.42,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,321
8920,4991,17512197,GW-501516,Q03181,PPARB,Homo sapiens,2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid,Cc1cc(SCc2sc(nc2C)c3ccc(cc3)C(F)(F)F)ccc1OCC(=O)O,CHEMBL38943,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.6nM,agonist,no detail about the percentage act,,,,2-(4-(3-(4-acetyl-3-hydroxy-2  propyl- phenoxy)propoxy)phenoxy)acetic acid,50nM,,,,EC50,=,4,nM,,,,,=,8.585026652,pIC50,B,radiometric,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,,435.363,453.0680201,1,5,7,3,6.20144,59.42,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,321
8921,4991,18722772,GW1516,Q03181,PPARB,Homo sapiens,2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid,Cc1cc(SCc2sc(nc2C)c3ccc(cc3)C(F)(F)F)ccc1OCC(=O)O,CHEMBL38943,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.3,agonist,98.00%,agonist,GW501516,,,,,,,PEC50,=,8.5,,,,,,=,8.3,pIC50,B,radiometric,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,98,435.363,453.0680201,1,5,7,3,6.20144,59.42,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
8922,4991,21414782,1,Q03181,PPARB,Homo sapiens,2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid,Cc1cc(SCc2sc(nc2C)c3ccc(cc3)C(F)(F)F)ccc1OCC(=O)O,CHEMBL38943,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.3,agonist,98.00%,agonist,,,,,,,,PEC50,=,8.5,,,,,,=,8.3,pIC50,B,radiometric,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,98,435.363,453.0680201,1,5,7,3,6.20144,59.42,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
8928,4993,15115388,17,P04150,GR,Homo sapiens,"((R)-4-Fluoro-3-methyl-phenyl)-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-methanol",Cc1cc(ccc1F)[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5,CHEMBL83110,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6.7nM,agonist,82.10%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,10.2,nM,,,,,=,8.173925197,pIC50,B,radiometric,Cc1cc([C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)ccc1F,82.1,394.295,420.2013199,1,3,3,3,5.93842,38.05,C1CCC(CC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,agonist,agonist,agonist,248
8929,4994,21073190,25,P04150,GR,Homo sapiens,"(S)-3-(4-Hydroxy-3-methylphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",Cc1cc(ccc1O)[C@H](c2ccccc2)C(C)(C)C(=O)Nc3nncs3,CHEMBL1800983,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 2.2nM,partial agonist,53.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,28.6,nM,,,,,=,8.657577319,pKi,B,FPA,Cc1cc([C@H](c2ccccc2)C(C)(C)C(=O)Nc2nncs2)ccc1O,53,346.306,367.1354479,2,5,5,3,4.34892,75.11,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
8939,4998,17257838,11a,P10275,AR,Homo sapiens,"7-amino-6-methyl-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",Cc1cc2C(=CC(=O)Nc2cc1N)C(F)(F)F,CHEMBL3706896,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 30nM,antagonist,75.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,76,nM,=,7.522878745,pIC50,B,radiometric,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,75,233.128,242.0666976,2,2,0,2,2.43752,58.88,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
8940,4999,17257838,11f,P10275,AR,Homo sapiens,"7-(isobutylamino)-6-methyl-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)CNc1cc2NC(=O)C=C(c2cc1C)C(F)(F)F,CHEMBL3706901,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 650nM,antagonist,83.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,301,nM,=,6.187086643,pIC50,,radiometric,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(C)C,83,281.172,298.1292978,2,2,3,2,3.92322,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
8941,5,19464171,19,P37231,PPARG,Homo sapiens,"2-(4-(2-(prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OC(=O)COc1ccc(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#C)c4CCCCc14,CHEMBL495990,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 1200nM,partial agonist,43.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,4900,nM,,,,,=,5.920818754,pKi,,other,C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,43,517.375,542.1374796,1,5,10,3,6.7898,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,partial agonist,agonist,partial agonist,334
8942,5,19464171,19,Q03181,PPARB,Homo sapiens,"2-(4-(2-(prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OC(=O)COc1ccc(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#C)c4CCCCc14,CHEMBL495990,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7nM,agonist,87.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,52,nM,,,,,=,8.15490196,pKi,B,radiometric,C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,87,517.375,542.1374796,1,5,10,3,6.7898,64.99,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
8947,50,14592510,34d,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[4-(2,2-Difluoro-ethoxy)-3',5'-difluoro-5-isopropyl-biphenyl-3-yl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2cc(F)cc(F)c2,CHEMBL337393,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 2.6nM,antagonist,92.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,4.6,nM,=,8.585026652,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2cc(F)cc(F)c2)cc(C(C)C)c1OCC(F)F,92,436.275,462.1818076,1,2,9,2,7.3895,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
8950,500,23953070,5e,P04150,GR,Homo sapiens,"rac-3-(1-(4-chlorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(cnn3c4ccc(Cl)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426645,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 18nM,partial agonist,55.00%,agonist,dexamethasone,,,,,,,EC50,=,256,nM,,,,,=,7.744727495,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(cnn2-c2ccc(Cl)cc2)c1,55,465.84,487.123359,1,6,6,5,6.3272,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
8964,5006,21963986,28,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-methyl-4-(5-methyl-2,3-dihydrobenzofuran-7-yl)pentan-2-ol",Cc1cc2CCOc2c(c1)C(C)(C)CC(O)(Cc3cc4ccccc4[nH]3)C(F)(F)F,CHEMBL1911657,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,95.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,7,nM,,,,,=,8,pIC50,B,FPA,Cc1cc2c(c(C(C)(C)CC(O)(Cc3cc4ccccc4[nH]3)C(F)(F)F)c1)OCC2,95,391.263,417.1915637,2,2,5,3,5.61502,45.25,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
8970,5007,10052980,3,P19793,RXRA,Homo sapiens,"4-[[(E)-Hydroxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",Cc1cc2c(cc1\C(=N\O)\c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL162334,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6nM,partial agonist,66.00%,agonist,ATRA,,,,,,,EC50,=,7,nM,,,,,=,8.22184875,pKi,B,radiometric,Cc1cc2c(cc1/C(=N/O)c1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C,66,338.257,365.1990937,2,3,3,2,5.26882,69.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,847
8971,5007,10052980,3,P28702,RXRB,Homo sapiens,"4-[[(E)-Hydroxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",Cc1cc2c(cc1\C(=N\O)\c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL162334,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5nM,agonist,81.00%,agonist,ATRA,,,,,,,EC50,=,14,nM,,,,,=,8.301029996,pKi,B,radiometric,Cc1cc2c(cc1/C(=N/O)c1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C,81,338.257,365.1990937,2,3,3,2,5.26882,69.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,847
8972,5007,10052980,3,P48443,RXRG,Homo sapiens,"4-[[(E)-Hydroxyimino]-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid",Cc1cc2c(cc1\C(=N\O)\c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL162334,CV-1 cells transfected with an expression vector foreach of the RAR and RXR subtypes and a luciferase reportergene,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5nM,agonist,76.00%,agonist,ATRA,,,,,,,EC50,=,7,nM,,,,,=,8.301029996,pKi,B,radiometric,Cc1cc2c(cc1/C(=N/O)c1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C,76,338.257,365.1990937,2,3,3,2,5.26882,69.89,CC(C1CCCCC1)C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,847
9007,5017,12801232,4,P19793,RXRA,Homo sapiens,"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid",Cc1cc2c(cc1C3(CC3)c4ccc(cn4)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL288436,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 18nM,partial agonist,70.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,11,nM,,,,,=,7.744727495,pKi,B,radiometric,Cc1cc2c(cc1C1(c3ccc(C(=O)O)cn3)CC1)C(C)(C)CCC2(C)C,70,334.269,363.2198292,1,2,3,2,5.51712,50.19,C1CCC(C2(C3CCC4CCCCC4C3)CC2)CC1,agonist,partial agonist,"agonist,antagonist","partial agonist,agonist",45
9008,5017,14592510,1,P19793,RXRA,Homo sapiens,"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid",Cc1cc2c(cc1C3(CC3)c4ccc(cn4)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL288436,CV-1 cellscotransfected with the luciferase reporter plasmid ,,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 12.9nM,agonist,75.00%,agonist,,,9-Cis-RA,,,,,EC50,=,17,nM,,,,,=,7.88941029,pKi,B,radiometric,Cc1cc2c(cc1C1(c3ccc(C(=O)O)cn3)CC1)C(C)(C)CCC2(C)C,75,334.269,363.2198292,1,2,3,2,5.51712,50.19,C1CCC(C2(C3CCC4CCCCC4C3)CC2)CC1,agonist,agonist,"agonist,antagonist","partial agonist,agonist",45
9009,5017,15006411,LG100268,P19793,RXRA,Homo sapiens,"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid",Cc1cc2c(cc1C3(CC3)c4ccc(cn4)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL288436,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,partial agonist,70.00%,agonist,,,ATRA,,,,,EC50,=,11,nM,IC50,=,0,nM,=,7.744727495,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,70,386.268,420.2476014,1,2,7,1,6.9159,46.53,C1CCCCC1,"antagonist,agonist",partial agonist,"agonist,antagonist","partial agonist,agonist",205
9014,5018,19791803,20,P19793,RXRA,Homo sapiens,"2-Fluoro-4-(1-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)vinyl)benzoic Acid",Cc1cc2c(cc1Cc3ccc(C(=O)O)c(F)c3)C(C)(C)CCC2(C)C,CHEMBL583996,RAR/RARE-agonist activity assay (Caco-2 human colon cancer cells),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12nM,partial agonist,26.00%,agonist,All-trans RA,1000nM,9cRA,10nM,,,,EC50,=,43,nM,,,,,=,7.920818754,pKi,B,radiometric,Cc1cc2c(cc1Cc1ccc(C(=O)O)c(F)c1)C(C)(C)CCC2(C)C,26,327.249,354.1995083,1,1,3,2,5.77212,37.3,C1CCC(CC2CCC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,242
9015,5019,19791803,16,P19793,RXRA,Homo sapiens,"4-(1-(1,2,3,4-Tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)vinyl)-2-nitrobenzoic Acid",Cc1cc2c(cc1Cc3ccc(C(=O)O)c(c3)[N+](=O)[O-])C(C)(C)CCC2(C)C,CHEMBL583410,RAR/RARE-agonist activity assay (Caco-2 human colon cancer cells),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 81nM,partial agonist,35.00%,agonist,All-trans RA,1000nM,9cRA,10nM,,,,EC50,=,200,nM,,,,,=,7.091514981,pKi,B,radiometric,Cc1cc2c(cc1Cc1ccc(C(=O)O)c([N+](=O)[O-])c1)C(C)(C)CCC2(C)C,35,354.256,381.1940083,1,3,4,2,5.54122,80.44,C1CCC(CC2CCC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,242
9023,5022,12954061,4,P19793,RXRA,Homo sapiens,"4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-benzoic acid",Cc1cc2c(cc1S(=O)(=O)c3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL118307,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,84.00%,antagonist,ATRA,,9-Cis-RA,,,,,,,,,IC50,=,8,nM,=,8.522878745,pKi,B,radiometric,Cc1cc2c(cc1S(=O)(=O)c1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C,84,360.305,386.1551803,1,3,3,2,4.87502,71.44,CC(C)(C1CCCCC1)C1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,1015
9031,5023,12954061,2,P19793,RXRA,Homo sapiens,"4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylsulfanyl)-benzoic acid",Cc1cc2c(cc1Sc3ccc(cc3)C(=O)O)C(C)(C)CCC2(C)C,CHEMBL118693,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18nM,partial agonist,70.00%,agonist,ATRA,,9-Cis-RA,,,,,EC50,=,11,nM,,,,,=,7.744727495,pKi,B,radiometric,Cc1cc2c(cc1Sc1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C,70,328.307,354.1653511,1,2,3,2,6.19342,37.3,C1CCC(CC2CCC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,242
9036,5024,25516791,11,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1,CHEMBL3358923,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 22nM,partial agonist,71.00%,agonist,dexamethasone,,,,,,,IC50,=,170,nM,,,,,=,7.657577319,pIC50,B,FPA,Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1,71,384.247,408.1824763,2,2,5,3,5.52264,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9044,5028,18513967,"12, racemic",P04150,GR,Homo sapiens,"racemic-5-chloro-2,2,4,8-tetramethyl-6-(2-methyl-1H-indol-7-yl)-1,2,3,4-tetrahydroquinoline",CC1CC(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc(C)[nH]c34,CHEMBL443847,GRE activation agonist mode,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 90nM,partial agonist,57.00%,agonist,dexamethasone,,,,,,,EC50,=,531,nM,,,,,=,7.045757491,pKi,B,radiometric,Cc1cc2cccc(-c3cc(C)c4c(c3Cl)C(C)CC(C)(C)N4)c2[nH]1,57,327.709,352.1706265,2,1,1,3,6.80284,27.82,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,partial agonist,agonist,partial agonist,37
9048,5030,16338239,14,P10827,TRA,Homo sapiens,"6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethylquinoline-2-carboxylic acid",CC(C)c1cc(Oc2c(C)cc3nc(ccc3c2C)C(=O)O)ccc1O,CHEMBL203555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,agonist,95.00%,agonist,T3,,,,,,,EC50,=,83,nM,,,,,=,6.698970004,pIC50,,radiometric,Cc1cc2nc(C(=O)O)ccc2c(C)c1Oc1ccc(O)c(C(C)C)c1,95,330.234,351.1470582,2,4,4,3,5.17114,79.65,C1CCC(CC2CCC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,242
9049,5030,17467994,52,P10827,TRA,Homo sapiens,"6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethylquinoline-2-carboxylic acid",CC(C)c1cc(Oc2c(C)cc3nc(ccc3c2C)C(=O)O)ccc1O,CHEMBL203555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.70,,,,,,,,,,,,,,,,,,,=,6.7,pIC50,,radiometric,Cc1cc2nc(C(=O)O)ccc2c(C)c1Oc1ccc(O)c(C(C)C)c1,,330.234,351.1470582,2,4,4,3,5.17114,79.65,C1CCC(CC2CCC3CCCCC3C2)CC1,,,agonist,agonist,242
9050,5030,16338239,14,P10828,TRB,Homo sapiens,"6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethylquinoline-2-carboxylic acid",CC(C)c1cc(Oc2c(C)cc3nc(ccc3c2C)C(=O)O)ccc1O,CHEMBL203555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 15nM,agonist,96.00%,agonist,T3,,,,,,,EC50,=,49,nM,,,,,=,7.823908741,pIC50,B,radiometric,Cc1cc2nc(C(=O)O)ccc2c(C)c1Oc1ccc(O)c(C(C)C)c1,96,330.234,351.1470582,2,4,4,3,5.17114,79.65,C1CCC(CC2CCC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,242
9051,5030,17467994,52,P10828,TRB,Homo sapiens,"6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethylquinoline-2-carboxylic acid",CC(C)c1cc(Oc2c(C)cc3nc(ccc3c2C)C(=O)O)ccc1O,CHEMBL203555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.82,,,,,,,,,,,,,,,,,,,=,7.82,pIC50,B,radiometric,Cc1cc2nc(C(=O)O)ccc2c(C)c1Oc1ccc(O)c(C(C)C)c1,,330.234,351.1470582,2,4,4,3,5.17114,79.65,C1CCC(CC2CCC3CCCCC3C2)CC1,,,agonist,agonist,242
9058,5034,21899328,17,P04150,GR,Homo sapiens,"[(5S)-2-[(4-Methyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",Cc1ccc(cc1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911147,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.5nM,antagonist,94.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,2214,nM,IC50,=,260,nM,=,8.602059991,pKi,B,FPA,Cc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1,94,420.368,442.1463469,1,6,4,4,5.81102,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
9059,5035,20382019,8l,P55055,LXRB,Homo sapiens,3-methyl-4-(4'-methyl-3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,Cc1ccc(cc1S(=O)(=O)C)c2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F,CHEMBL1098850,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,agonist,110.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,175,nM,,,,,=,8.494850022,pIC50,B,radiometric,Cc1ccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,110,435.341,455.1166845,0,3,3,4,6.60794,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
9061,5036,16973358,27,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-p-tolyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL221184,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 23nM,agonist,96.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,22,nM,,,,,=,7.638272164,pKi,B,radiometric,Cc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)cc1,96,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9062,5036,16973358,27,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-p-tolyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1ccc(cc1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL221184,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 31nM,agonist,84.00%,agonist,GW2331,,GW2331,,,,,EC50,=,23,nM,,,,,=,7.508638306,pKi,B,radiometric,Cc1ccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)cc1,84,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9066,5039,24755427,38,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(1-p-tolyl-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(C)cc3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261415,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.9nM,agonist,85.00%,agonist,dexamethasone,,,,,,,IC50,=,4.5,nM,,,,,=,8.408935393,pIC50,B,FPA,Cc1ccc(-n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cccc32)cc1,85,432.379,462.2089472,2,5,7,4,5.03808,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
9097,5053,25516791,37,P04150,GR,Homo sapiens,"5-methyl-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",Cc1ccc(c(c1)C(=O)N)C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)S(=O)(=O)C)C(F)(F)F,CHEMBL3358948,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,agonist,92.00%,agonist,dexamethasone,,,,,,,IC50,=,45,nM,,,,,=,6.958607315,pIC50,,FPA,Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1,92,471.331,497.159612,3,5,7,3,3.57752,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9100,5057,11277515,1,P10276,RARA,Homo sapiens,"4-[(E)-4-(6,6-Dimethyl-2-p-tolyl-cyclohex-1-enyl)-but-3-en-1-ynyl]-benzoic acid",Cc1ccc(cc1)C2=C(\C=C\C#Cc3ccc(cc3)C(=O)O)C(C)(C)CCC2,CHEMBL349018,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 148nM,antagonist,210.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,210,nM,=,6.829738285,pIC50,,radiometric,Cc1ccc(C2=C(/C=C/C#Cc3ccc(C(=O)O)cc3)C(C)(C)CCC2)cc1,210,344.284,370.1932801,1,1,3,2,6.26482,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,440
9103,5058,11277515,4,P10276,RARA,Homo sapiens,"4-[(E)-4-(3,3-Dimethyl-6-p-tolyl-cyclohexa-1,5-dienyl)-but-3-en-1-ynyl]-benzoic acid",Cc1ccc(cc1)C2=CCC(C)(C)C=C2\C=C\C#Cc3ccc(cc3)C(=O)O,CHEMBL350485,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 252nM,antagonist,129.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,129,nM,=,6.598599459,pIC50,,radiometric,Cc1ccc(C2=CCC(C)(C)C=C2/C=C/C#Cc2ccc(C(=O)O)cc2)cc1,129,344.284,368.17763,1,1,3,2,6.04082,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,440
9104,5058,11277515,4,P10826,RARB,Homo sapiens,"4-[(E)-4-(3,3-Dimethyl-6-p-tolyl-cyclohexa-1,5-dienyl)-but-3-en-1-ynyl]-benzoic acid",Cc1ccc(cc1)C2=CCC(C)(C)C=C2\C=C\C#Cc3ccc(cc3)C(=O)O,CHEMBL350485,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,partial antagonist,35.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,35,nM,=,7.27572413,pIC50,B,radiometric,Cc1ccc(C2=CCC(C)(C)C=C2/C=C/C#Cc2ccc(C(=O)O)cc2)cc1,35,344.284,368.17763,1,1,3,2,6.04082,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,440
9105,5058,11277515,4,P13631,RARG,Homo sapiens,"4-[(E)-4-(3,3-Dimethyl-6-p-tolyl-cyclohexa-1,5-dienyl)-but-3-en-1-ynyl]-benzoic acid",Cc1ccc(cc1)C2=CCC(C)(C)C=C2\C=C\C#Cc3ccc(cc3)C(=O)O,CHEMBL350485,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,CV-1 cellscotransfected with the luciferase reporter plasmid dMTV-TREp-LUC,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 31nM,partial antagonist,40.00%,antagonist,,,TTNPB,10nM,,,,,,,,IC50,=,4,nM,=,7.508638306,pIC50,B,radiometric,Cc1ccc(C2=CCC(C)(C)C=C2/C=C/C#Cc2ccc(C(=O)O)cc2)cc1,40,344.284,368.17763,1,1,3,2,6.04082,37.3,C1CCC(CCCCC2CCCCC2C2CCCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,440
9108,506,23953070,5t,P04150,GR,Homo sapiens,"rac-3-(1-cycloheptyl-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(cnn3C4CCCCCC4)c2)C(=O)Nc5nncs5,CHEMBL2426633,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 12nM,agonist,160.00%,agonist,dexamethasone,,,,,,,EC50,=,188,nM,,,,,=,7.920818754,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccc2c(cnn2C2CCCCCC2)c1,160,442.398,473.2249316,1,6,6,4,6.5799,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCCC2)C1,agonist,agonist,agonist,agonist,967
9116,5064,15115388,35,P04150,GR,Homo sapiens,"(S)-1-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-2-p-tolyl-ethanol",Cc1ccc(C[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)cc1,CHEMBL419479,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.4nM,partial agonist,66.80%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,11.4,nM,,,,,=,8.468521083,pIC50,B,radiometric,Cc1ccc(C[C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)cc1,66.8,387.308,416.2263918,1,3,4,3,5.66932,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,318
9129,5069,25516791,9,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((3-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2[nH]c3cnccc3c2C)C(F)(F)F,CHEMBL3358921,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,agonist,93.00%,agonist,dexamethasone,,,,,,,IC50,=,5,nM,,,,,=,8.045757491,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F,93,384.247,408.1824763,2,2,5,3,5.52264,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9132,5070,25516791,10,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((4-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3c(C)cncc3[nH]2)C(F)(F)F,CHEMBL3358922,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,agonist,91.00%,agonist,dexamethasone,,,,,,,IC50,=,59,nM,,,,,=,7.958607315,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F,91,384.247,408.1824763,2,2,5,3,5.52264,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9134,5071,25516791,13,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)c4ccccc4)C(F)(F)F,CHEMBL3358925,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 26nM,agonist,96.00%,agonist,dexamethasone,,,,,,,IC50,=,2,nM,,,,,=,7.585026652,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F,96,444.302,470.1981263,2,2,6,4,6.88122,48.91,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9136,5072,24506830,20,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(3-phenyl-7H-pyrrolo[2,3-c]pyridazin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(nnc3[nH]2)c4ccccc4)C(F)(F)F,CHEMBL3126952,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,agonist,96.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,6,nM,,,,,=,7.886056648,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)nnc2[nH]1)C(F)(F)F,96,446.298,471.1933753,2,3,6,4,6.27622,61.8,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9139,5073,25516791,18,P04150,GR,Homo sapiens,"2-(4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxamide",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)C(=O)N)C(F)(F)F,CHEMBL3358930,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,partial agonist,54.00%,agonist,dexamethasone,,,,,,,IC50,=,300,nM,,,,,=,8.15490196,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F,54,414.253,437.1726399,3,3,6,3,4.31312,92,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9141,5074,25516791,15,P04150,GR,Homo sapiens,"2-((5-(dimethylamino)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methylpentan-2-ol",CN(C)c1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1,CHEMBL3358927,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,87.00%,agonist,dexamethasone,,,,,,,IC50,=,38,nM,,,,,=,8,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F,87,410.265,437.2090254,2,3,6,3,5.28022,52.15,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9143,5075,25516791,14,P04150,GR,Homo sapiens,"2-((5-amino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methylpentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(N)ncc3[nH]2)C(F)(F)F,CHEMBL3358926,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,91.00%,agonist,dexamethasone,,,,,,,IC50,=,37,nM,,,,,=,8.15490196,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F,91,386.243,409.1777252,3,3,5,3,4.79642,74.93,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9145,5076,25516791,17,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cc(ncc3[nH]2)N4CCOCC4)C(F)(F)F,CHEMBL3358929,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,94.00%,agonist,dexamethasone,,,,,,,IC50,=,3,nM,,,,,=,8.522878745,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F,94,450.286,479.21959,2,4,6,3,5.05082,61.38,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9147,5077,25516791,16,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-2-((5-isopropoxy-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-4-methylpentan-2-ol",CC(C)Oc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1,CHEMBL3358928,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,96.00%,agonist,dexamethasone,,,,,,,IC50,=,3,nM,,,,,=,8,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F,96,424.268,452.208691,2,3,7,3,6.00142,58.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9149,5078,20735001,33,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1254079,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,89.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,38,nM,,,,,=,8,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,89,372.236,394.1668262,2,2,5,3,5.21422,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9150,5078,25516791,8,P04150,GR,Homo sapiens,"2-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methylpentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ccncc3[nH]2)C(F)(F)F,CHEMBL1254079,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,89.00%,agonist,dexamethasone,,,,,,,IC50,=,38,nM,,,,,=,8,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,89,372.236,394.1668262,2,2,5,3,5.21422,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9161,5081,24506830,19,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(1Hpyrrolo[2,3-d]pyridazin-2-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3cnncc3[nH]2)C(F)(F)F,CHEMBL3126951,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,89.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,5,nM,,,,,=,8.522878745,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cnncc2[nH]1)C(F)(F)F,89,374.232,395.1620752,2,3,5,3,4.60922,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9164,5082,24506830,24b,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(2-phenyl-5H-pyrrolo[2,3-b]pyrazin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(cnc3[nH]2)c4ccccc4)C(F)(F)F,CHEMBL3126933,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,agonist,82.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,170,nM,,,,,=,7.958607315,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(-c3ccccc3)cnc2[nH]1)C(F)(F)F,82,446.298,471.1933753,2,3,6,4,6.27622,61.8,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9167,5083,24506830,27,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(2-phenyl-5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(ncc3[nH]2)c4ccccc4)C(F)(F)F,CHEMBL3126935,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,93.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,8,nM,,,,,=,8.301029996,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(-c3ccccc3)ncc2[nH]1)C(F)(F)F,93,446.298,471.1933753,2,3,6,4,6.27622,61.8,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9170,5084,24506830,28,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(2-pyridin-3-yl-5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(ncc3[nH]2)c4cccnc4)C(F)(F)F,CHEMBL3126936,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,12,nM,,,,,=,8.301029996,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(-c3cccnc3)ncc2[nH]1)C(F)(F)F,92,448.294,472.1886243,2,4,6,4,5.67122,74.69,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9173,5085,24506830,26,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-2-(2-isopropyl-5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-4-methyl-pentan-2-ol",CC(C)c1ncc2[nH]c(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)cc2n1,CHEMBL3126934,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 26nM,partial agonist,50.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,560,nM,,,,,=,7.585026652,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(C(C)C)ncc2[nH]1)C(F)(F)F,50,410.265,437.2090254,2,3,6,3,5.73262,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9176,5086,24506830,29,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(2-pyrrolidin-1-yl-5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(ncc3[nH]2)N4CCCC4)C(F)(F)F,CHEMBL3126937,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 18nM,agonist,76.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,130,nM,,,,,=,7.744727495,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(N3CCCC3)ncc2[nH]1)C(F)(F)F,76,436.283,464.2199244,2,4,6,3,5.20942,65.04,C1CCC(CCCCC2CC3CCC(C4CCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,415
9179,5087,24506830,30,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(2-morpholin-4-yl-5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(ncc3[nH]2)N4CCOCC4)C(F)(F)F,CHEMBL3126938,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,84.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,15,nM,,,,,=,8.301029996,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(N3CCOCC3)ncc2[nH]1)C(F)(F)F,84,452.282,480.214839,2,5,6,3,4.44582,74.27,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
9182,5088,24506830,31,P04150,GR,Homo sapiens,"rac-2-[2-(1,1-Dioxo-1lambda6-thiomorpholin-4-yl)-5H-pyrrolo[3,2-d]-pyrimidin-6-ylmethyl]-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nc(ncc3[nH]2)N4CCS(=O)(=O)CC4)C(F)(F)F,CHEMBL3126939,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,84.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,19,nM,,,,,=,8.096910013,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nc(N3CCS(=O)(=O)CC3)ncc2[nH]1)C(F)(F)F,84,500.348,528.1818246,2,6,6,3,3.84402,99.18,CC1(C)CCC(C2CCC3CC(CCCCC4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,736
9189,5090,24506830,21,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3ncncc3[nH]2)C(F)(F)F,CHEMBL3126953,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,partial agonist,74.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,19,nM,,,,,=,8.096910013,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F,74,374.232,395.1620752,2,3,5,3,4.60922,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9192,5091,24506830,18,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-c]pyridazin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)CC(O)(Cc2cc3nnccc3[nH]2)C(F)(F)F,CHEMBL3126950,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,85.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,16,nM,,,,,=,8.15490196,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2nnccc2[nH]1)C(F)(F)F,85,374.232,395.1620752,2,3,5,3,4.60922,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9195,5092,17181172,33,P04150,GR,Homo sapiens,1-[4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,Cc1ccc(F)cc1C(C)(C)CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F,CHEMBL216173,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,partial agonist,66.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,34,nM,,,,,=,8,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F,66,398.25,421.1664919,1,3,5,3,5.11032,42.23,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,partial agonist,agonist,partial agonist,807
9201,5094,24506830,(R)-21,P04150,GR,Homo sapiens,"(R)-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3ncncc3[nH]2)C(F)(F)F,CHEMBL3126949,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,partial agonist,72.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,13,nM,,,,,=,8.301029996,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2ncncc2[nH]1)C(F)(F)F,72,374.232,395.1620752,2,3,5,3,4.60922,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9204,5095,24506830,(R)-18,P04150,GR,Homo sapiens,"(R)-1,1,1-Trifluoro-4-(5-fluoro-2-methyl-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-c]pyridazin-6-ylmethyl)-pentan-2-ol",Cc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc2cc3nnccc3[nH]2)C(F)(F)F,CHEMBL3126948,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,9,nM,,,,,=,8.397940009,pIC50,B,FPA,Cc1ccc(F)cc1C(C)(C)C[C@@](O)(Cc1cc2nnccc2[nH]1)C(F)(F)F,86,374.232,395.1620752,2,3,5,3,4.60922,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
9210,5097,19926282,29,P06401,PR,Homo sapiens,(S)-isopropyl 3-((3-chloro-4-cyanophenyl)(5-fluoro-2-methylbenzyl)amino)pyrrolidine-1-carboxylate,CC(C)OC(=O)N1CC[C@@H](C1)N(Cc2cc(F)ccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL601055,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 50nM,partial agonist,44.00%,agonist,progesterone,,,,,,,EC50,=,233,nM,,,,,=,7.301029996,pIC50,B,other,Cc1ccc(F)cc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)OC(C)C)C1,44,404.723,429.1619329,0,4,5,2,5.2851,56.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
9211,5098,19926282,40,P06401,PR,Homo sapiens,2-chloro-4-((5-fluoro-2-methylbenzyl)((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)amino)benzonitrile,C[C@H](O)C(=O)N1CC[C@@H](C1)N(Cc2cc(F)ccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL585848,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 79nM,partial agonist,35.00%,agonist,progesterone,,,,,,,EC50,=,183,nM,,,,,=,7.102372909,pIC50,B,other,Cc1ccc(F)cc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)[C@H](C)O)C1,35,392.712,415.1462829,1,4,5,2,3.6475,67.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
9216,51,14592510,34f,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[4-(2,2-Difluoro-ethoxy)-4'-fluoro-5-isopropyl-biphenyl-3-yl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2ccc(F)cc2,CHEMBL133915,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 0.8nM,antagonist,94.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,2.2,nM,=,9.096910013,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2ccc(F)cc2)cc(C(C)C)c1OCC(F)F,94,417.277,444.1912294,1,2,9,2,7.2504,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
9219,510,24011644,16,P04150,GR,Homo sapiens,"2,2-dimethyl-3-phenyl-3-(3-phenylimidazo[1,5-a]pyridin-7-yl)-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3c(ncc3c2)c4ccccc4)C(=O)Nc5nncs5,CHEMBL2426140,Gal4 luciferase reporter gene assays,,-,Ki = 899nM,agonist,no detail about the percentage act,,dexamethasone,,,,,,,EC50,=,2000,nM,,,,,=,6.046240308,pKi,,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccn2c(-c3ccccc3)ncc2c1,,430.387,453.1623314,1,6,6,5,5.6496,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,,agonist,partial agonist,966
9220,510,24011644,"16, enantiomer 2",P04150,GR,Homo sapiens,"2,2-dimethyl-3-phenyl-3-(3-phenylimidazo[1,5-a]pyridin-7-yl)-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3c(ncc3c2)c4ccccc4)C(=O)Nc5nncs5,CHEMBL2426140,Gal4 luciferase reporter gene assays,,-,Ki = 254nM,partial agonist,43.00%,agonist,dexamethasone,,,,,,,EC50,=,613,nM,,,,,=,6.595166283,pKi,,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccn2c(-c3ccccc3)ncc2c1,43,430.387,453.1623314,1,6,6,5,5.6496,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9221,510,24011644,"16, enantiomer 1",P04150,GR,Homo sapiens,"2,2-dimethyl-3-phenyl-3-(3-phenylimidazo[1,5-a]pyridin-7-yl)-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccn3c(ncc3c2)c4ccccc4)C(=O)Nc5nncs5,CHEMBL2426140,Gal4 luciferase reporter gene assays,,-,Ki = 1122nM,,,,dexamethasone,,,,,,,EC50,>,10000,nM,,,,,=,5.950007143,pKi,,other,CC(C)(C(=O)Nc1nncs1)C(c1ccccc1)c1ccn2c(-c3ccccc3)ncc2c1,,430.387,453.1623314,1,6,6,5,5.6496,72.18,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,,,agonist,partial agonist,966
9234,5106,18722772,3,Q03181,PPARB,Homo sapiens,"2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)-5-methylbenzoic acid",Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3)c(c1)C(=O)O,CHEMBL485087,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,partial agonist,51.00%,agonist,GW501516,,,,,,,PEC50,=,6.7,,,,,,=,7.9,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)N3CCc4ccccc4C3)c2)c(C(=O)O)c1,51,428.34,450.1249428,2,4,5,3,3.69252,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
9237,5107,18722772,21,Q03181,PPARB,Homo sapiens,2-(3-(4-bromo-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4c(Br)cccc34)c(c1)C(=O)O,CHEMBL495905,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,partial agonist,45.00%,agonist,GW501516,,,,,,,PEC50,=,7.9,,,,,,=,8,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4c(Br)cccc43)c2)c(C(=O)O)c1,45,496.233,512.0041547,2,5,5,4,4.89972,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9240,5108,18722772,20,Q03181,PPARB,Homo sapiens,5-methyl-2-(3-(4-methyl-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4c(C)cccc34)c(c1)C(=O)O,CHEMBL495904,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.2,partial agonist,42.00%,agonist,GW501516,,,,,,,PEC50,=,7.7,,,,,,=,8.2,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4c(C)cccc43)c2)c(C(=O)O)c1,42,428.34,448.1092927,2,5,5,4,4.44564,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9243,5109,18722772,23,Q03181,PPARB,Homo sapiens,5-methyl-2-(3-(5-methyl-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4cc(C)ccc34)c(c1)C(=O)O,CHEMBL498171,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,partial agonist,34.00%,agonist,GW501516,,,,,,,PEC50,=,7.5,,,,,,=,8,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4cc(C)ccc43)c2)c(C(=O)O)c1,34,428.34,448.1092927,2,5,5,4,4.44564,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9247,5110,18722772,24,Q03181,PPARB,Homo sapiens,2-(3-(5-chloro-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4cc(Cl)ccc34)c(c1)C(=O)O,CHEMBL498172,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.7,partial agonist,27.00%,agonist,GW501516,,,,,,,PEC50,=,7.3,,,,,,=,7.7,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4cc(Cl)ccc43)c2)c(C(=O)O)c1,27,451.782,468.0546703,2,5,5,4,4.79062,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9250,5111,18722772,26,Q03181,PPARB,Homo sapiens,5-methyl-2-(3-(6-methyl-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4ccc(C)cc34)c(c1)C(=O)O,CHEMBL522575,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,partial agonist,37.00%,agonist,GW501516,,,,,,,PEC50,=,7.3,,,,,,=,8,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4ccc(C)cc43)c2)c(C(=O)O)c1,37,428.34,448.1092927,2,5,5,4,4.44564,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9253,5112,18722772,27,Q03181,PPARB,Homo sapiens,2-(3-(6-chloro-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4ccc(Cl)cc34)c(c1)C(=O)O,CHEMBL496733,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.2,partial agonist,33.00%,agonist,GW501516,,,,,,,PEC50,=,6.7,,,,,,=,7.2,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4ccc(Cl)cc43)c2)c(C(=O)O)c1,33,451.782,468.0546703,2,5,5,4,4.79062,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9256,5113,18722772,29,Q03181,PPARB,Homo sapiens,5-methyl-2-(3-(7-methyl-1H-indol-1-ylsulfonyl)benzamido)benzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4cccc(C)c34)c(c1)C(=O)O,CHEMBL522224,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.4,partial agonist,47.00%,agonist,GW501516,,,,,,,PEC50,=,7.1,,,,,,=,8.4,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4cccc(C)c43)c2)c(C(=O)O)c1,47,428.34,448.1092927,2,5,5,4,4.44564,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9259,5114,18722772,30,Q03181,PPARB,Homo sapiens,2-(3-(7-chloro-1H-indol-1-ylsulfonyl)benzamido)-5-methylbenzoic acid,Cc1ccc(NC(=O)c2cccc(c2)S(=O)(=O)n3ccc4cccc(Cl)c34)c(c1)C(=O)O,CHEMBL496534,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,45.00%,agonist,GW501516,,,,,,,PEC50,=,6.8,,,,,,=,7.8,pIC50,B,radiometric,Cc1ccc(NC(=O)c2cccc(S(=O)(=O)n3ccc4cccc(Cl)c43)c2)c(C(=O)O)c1,45,451.782,468.0546703,2,5,5,4,4.79062,105.47,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,1038
9263,5117,17181172,34,P04150,GR,Homo sapiens,1-[2-hydroxy-4-(2-hydroxy-5-methylphenyl)-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,Cc1ccc(O)c(c1)C(C)(C)CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F,CHEMBL384081,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,93.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,5.6,nM,,,,,=,8.096910013,pIC50,B,FPA,Cc1ccc(O)c(C(C)(C)CC(O)(Cn2ccc(=O)c3ccccc32)C(F)(F)F)c1,93,395.251,419.1708283,2,4,5,3,4.67682,62.46,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,agonist,agonist,agonist,807
9291,513,21073190,24,P04150,GR,Homo sapiens,"(S)-3-(3-Bromo-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)c(Br)c2)C(=O)Nc3nncs3,CHEMBL1800982,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.4nM,agonist,87.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,12.7,nM,,,,,=,9.397940009,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc(O)c(Br)c1,87,414.199,431.0303099,2,5,5,3,4.803,75.11,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,970
9309,514,21073190,23,P04150,GR,Homo sapiens,"(S)-3-(3-Fluoro-4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)c(F)c2)C(=O)Nc3nncs3,CHEMBL1800981,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.7nM,partial agonist,70.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,21.2,nM,,,,,=,9.15490196,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc(O)c(F)c1,70,353.293,371.110376,2,5,5,3,4.1796,75.11,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
9315,5143,18809325,1c,P37231,PPARG,Homo sapiens,p-tolyl 2-phenylethenesulfonate,Cc1ccc(OS(=O)(=O)\C=C\c2ccccc2)cc1,CHEMBL469939,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49648",IC50 = 407nM,partial agonist,31.30%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,6.390405591,pIC50,,radiometric,Cc1ccc(OS(=O)(=O)/C=C/c2ccccc2)cc1,31.3,260.229,274.0663653,0,3,4,2,3.37452,43.37,CC(C)(CCC1CCCCC1)CC1CCCCC1,,partial agonist,,partial agonist,1220
9316,5144,25993269,24b,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Tolyl Ester,Cc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5)cc1,CHEMBL3589694,,,,Ki > 5000nM,antagonist,116.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,Cc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)=C3c2ccc(O)cc2)cc1,116,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
9317,5144,25993269,24b,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Tolyl Ester,Cc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5)cc1,CHEMBL3589694,,,,Ki > 5000nM,antagonist,95.00%,antagonist,E2,,,,,,,EC50,=,38,nM,,,,,>,5.301029996,pKi,,other,Cc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)=C3c2ccc(O)cc2)cc1,95,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
9318,5145,25993269,23b,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(p-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)cc1,CHEMBL3589352,,,,Ki = 182.35nM,partial antagonist,36.00%,antagonist,E2,,,,,,,,,,,IC50,=,1080,nM,=,6.739094232,pKi,,other,Cc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)cc1,36,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1126
9319,5145,25993269,23b,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(p-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)cc1,CHEMBL3589352,,,,Ki = 87.32nM,antagonist,111.00%,antagonist,E2,,,,,,,EC50,=,520,nM,,,,,=,7.058886273,pKi,B,other,Cc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)cc1,111,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
9327,515,21073190,22,P04150,GR,Homo sapiens,"(S)-3-(4-Hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)cc2)C(=O)Nc3nncs3,CHEMBL1801004,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 1.2nM,partial agonist,69.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,20.3,nM,,,,,=,8.920818754,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc(O)cc1,69,334.295,353.1197978,2,5,5,3,4.0405,75.11,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
9328,515,23953070,4,P04150,GR,Homo sapiens,"(S)-3-(4-hydroxyphenyl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc(O)cc2)C(=O)Nc3nncs3,CHEMBL1801004,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 1.1nM,partial agonist,28.80%,agonist,dexamethasone,,,,,,,EC50,=,526,nM,,,,,=,8.958607315,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc(O)cc1,28.8,334.295,353.1197978,2,5,5,3,4.0405,75.11,CC(CC1CCCC1)CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,970
9334,5152,24239186,6,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccc(cc1)S(=O)(=O)N(CC(F)(F)F)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F,CHEMBL3094368,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 51nM,inverse agonist,-100.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,20,nM,,,,,=,7.292429824,pIC50,B,radiometric,Cc1ccc(S(=O)(=O)N(CC(F)(F)F)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,-100,481.251,495.0550683,1,3,5,2,5.06482,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
9338,5156,26321361,5,P51449,RORG,Homo sapiens,"2,6-difluoro-N-(1-tosyl-1,2,3,4-tetrahydroquinolin-7-yl)benzamide",Cc1ccc(cc1)S(=O)(=O)N2CCCc3ccc(NC(=O)c4c(F)cccc4F)cc23,CHEMBL3617294,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 110nM,inverse agonist,-95.00%,agonist,,,28-hydroxycholesterol,,,,,EC50,=,150,nM,,,,,=,6.958607315,pIC50,,radiometric,Cc1ccc(S(=O)(=O)N2CCCc3ccc(NC(=O)c4c(F)cccc4F)cc32)cc1,-95,422.327,442.1162699,1,3,4,3,4.66702,66.48,CC(CC1CCC2CCCC(C(C)(C)C3CCCCC3)C2C1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,950
9339,5157,15125923,11f,P03372,ERA,Homo sapiens,"1-[4-(2-Pyrrolidin-1-yl-ethoxy)-phenyl]-2-(toluene-4-sulfonyl)-1,2,3,4-tetrahydro-isoquinolin-6-ol",Cc1ccc(cc1)S(=O)(=O)N2CCc3cc(O)ccc3C2c4ccc(OCCN5CCCC5)cc4,CHEMBL330307,,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24.8nM,partial antagonist,66.00%,antagonist,E2,,E2,0.5nM,,,,,,,,IC50,=,29.8,nM,=,7.605548319,pIC50,B,radiometric,Cc1ccc(S(=O)(=O)N2CCc3cc(O)ccc3C2c2ccc(OCCN3CCCC3)cc2)cc1,66,460.385,492.2082785,1,5,7,3,4.51162,70.08,CC(C)(C1CCCCC1)C1CCC2CCCCC2C1C1CCC(CCCC2CCCC2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,1017
9343,516,23953070,(3S)-5a,P04150,GR,Homo sapiens,"(S)-3-(1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc3[nH]ncc3c2)C(=O)Nc4nncs4,CHEMBL2426658,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 2.7nM,partial agonist,41.00%,agonist,dexamethasone,,,,,,,EC50,=,208,nM,,,,,=,8.568636236,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc2[nH]ncc2c1,41,358.321,377.1310312,2,5,5,4,4.2112,83.56,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2CCCC2C1,agonist,partial agonist,agonist,partial agonist,965
9348,5164,20047280,38,P04150,GR,Homo sapiens,"(S)-1-((5aR,6S)-1-(4-Fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)-1-(5-methylthiophen-2-yl)-ethanol",Cc1ccc(s1)[C@@](C)(O)[C@H]2CCCC3=Cc4c(ncn4C[C@]23C)c5ccc(F)cc5,CHEMBL572329,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.5nM,partial agonist,47.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,272,nM,,,,,=,8.823908741,pIC50,B,FPA,Cc1ccc([C@@](C)(O)[C@H]2CCCC3=Cc4c(-c5ccc(F)cc5)ncn4C[C@@]32C)s1,47,395.353,422.1828127,1,4,3,3,6.17022,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
9349,5165,22070604,35,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(6-methylbenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",C[C@@H](Oc1cc(CN2C(=O)N(c3ccc(cc23)C(F)(F)F)c4noc5cc(C)ccc45)ccc1Cl)C(=O)O,CHEMBL1946753,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14.2nM,partial agonist,37.00%,agonist,rosiglitazone,,,,,,,EC50,=,77.5,nM,,,,,=,7.847711656,pIC50,B,radiometric,Cc1ccc2c(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4cc(C(F)(F)F)ccc43)noc2c1,37,526.749,545.096533,1,7,6,5,5.81422,99.49,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
9354,5167,18038970,55D1E1,P04150,GR,Homo sapiens,"1,1,1-trifluoro-3-[(2-methyl-5-quinolinyl)amino]-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol",Cc1ccc2c(NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F)cccc2n1,CHEMBL238360,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.3,partial agonist,37.20%,agonist,dexamethasone,,,,,,,PEC50,=,8.02,,PIC50,=,7.11,,=,8.3,pIC50,B,FPA,Cc1ccc2c(NCC(O)(CC3(C)CCCc4ccccc43)C(F)(F)F)cccc2n1,37.2,401.282,428.2075481,2,3,5,3,5.93282,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,989
9355,5167,18038970,55D2E1,P04150,GR,Homo sapiens,"1,1,1-trifluoro-3-[(2-methyl-5-quinolinyl)amino]-2-[(1-methyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-2-propanol",Cc1ccc2c(NCC(O)(CC3(C)CCCc4ccccc34)C(F)(F)F)cccc2n1,CHEMBL238360,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.04,partial agonist,60.50%,agonist,dexamethasone,,,,,,,PEC50,=,7.14,,,,,,=,8.04,pIC50,B,FPA,Cc1ccc2c(NCC(O)(CC3(C)CCCc4ccccc43)C(F)(F)F)cccc2n1,60.5,401.282,428.2075481,2,3,5,3,5.93282,45.15,C(CCC1CCCC2CCCCC12)CC1CCCC2CCCCC12,agonist,partial agonist,"antagonist,agonist",partial agonist,989
9356,5168,22070604,34,P37231,PPARG,Homo sapiens,"(R)-2-(2-chloro-5-((3-(5-methylbenzo[d]isoxazol-3-yl)-2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenoxy)propanoic acid",C[C@@H](Oc1cc(CN2C(=O)N(c3ccc(cc23)C(F)(F)F)c4noc5ccc(C)cc45)ccc1Cl)C(=O)O,CHEMBL1946572,COS-1 cells transiently co-transfected with aGAL4-responsive reporter,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11.2nM,partial agonist,53.00%,agonist,rosiglitazone,,,,,,,EC50,=,3000,nM,,,,,=,7.950781977,pIC50,B,radiometric,Cc1ccc2onc(-n3c(=O)n(Cc4ccc(Cl)c(O[C@H](C)C(=O)O)c4)c4cc(C(F)(F)F)ccc43)c2c1,53,526.749,545.096533,1,7,6,5,5.81422,99.49,CC1C(CC2CCCCC2)C2CCCCC2C1C1CCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,655
9358,517,23953070,(3S)-5c,P04150,GR,Homo sapiens,"(S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nc5nncs5,CHEMBL2426662,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 5.1nM,agonist,106.00%,agonist,dexamethasone,,,,,,,EC50,=,5.8,nM,,,,,=,8.292429824,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,106,449.385,471.1529095,1,6,6,5,5.8129,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,agonist,agonist,agonist,966
9366,5172,21899328,16,P04150,GR,Homo sapiens,"[(5S)-2-[(3-Methyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",Cc1cccc(c1)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911146,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 24.0nM,antagonist,101.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,1559,nM,=,7.619788758,pKi,B,FPA,Cc1cccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)c1,101,420.368,442.1463469,1,6,4,4,5.81102,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
9367,5173,16973358,28,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-m-tolyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL374448,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 16nM,agonist,130.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,5,nM,,,,,=,7.795880017,pKi,B,radiometric,Cc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)c1,130,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9368,5173,16973358,28,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-m-tolyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)cn3)n2,CHEMBL374448,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 277nM,agonist,86.00%,agonist,GW2331,,GW2331,,,,,EC50,=,134,nM,,,,,=,6.557520231,pKi,,radiometric,Cc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)cn3)c(C)o2)c1,86,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9369,5174,16979341,19,P37231,PPARG,Homo sapiens,2-((5-(2-(5-methyl-2-m-tolyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221489,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 43nM,agonist,93.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,12,nM,,,,,=,7.366531544,pKi,B,radiometric,Cc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)c1,93,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9370,5174,16979341,19,Q07869,PPARA,Homo sapiens,2-((5-(2-(5-methyl-2-m-tolyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1cccc(c1)c2oc(C)c(CCOc3ccc(CC4(CCCO4)C(=O)O)nc3)n2,CHEMBL221489,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1100nM,agonist,93.00%,agonist,GW2331,,GW2331,,,,,EC50,=,867,nM,,,,,=,5.958607315,pIC50,,radiometric,Cc1cccc(-c2nc(CCOc3ccc(CC4(C(=O)O)CCCO4)nc3)c(C)o2)c1,93,396.273,422.1841719,1,6,8,3,4.15124,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9371,5175,24755427,32,P04150,GR,Homo sapiens,"(S)-2,4,6-trimethyl-N-(1-(1-m-tolyl-1H-indazol-4-ylamino)propan-2-yl)benzenesulfonamide",C[C@@H](CNc1cccc2c1cnn2c3cccc(C)c3)NS(=O)(=O)c4c(C)cc(C)cc4C,CHEMBL3261409,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.8nM,agonist,84.00%,agonist,dexamethasone,,,,,,,IC50,=,6.6,nM,,,,,=,8.420216403,pIC50,B,FPA,Cc1cccc(-n2ncc3c(NC[C@H](C)NS(=O)(=O)c4c(C)cc(C)cc4C)cccc32)c1,84,432.379,462.2089472,2,5,7,4,5.03808,76.02,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCCCC1,agonist,agonist,agonist,agonist,1294
9381,518,23953070,(3S)-5h,P04150,GR,Homo sapiens,"(S)-2,2-dimethyl-3-phenyl-3-(1-(pyridin-3-yl)-1H-indazol-5-yl)-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H](c1ccccc1)c2ccc3c(cnn3c4cccnc4)c2)C(=O)Nc5nncs5,CHEMBL2426648,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 0.9nM,partial agonist,57.00%,agonist,dexamethasone,,,,,,,EC50,=,132,nM,,,,,=,9.045757491,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2cccnc2)c1,57,432.383,454.1575803,1,7,6,5,5.0688,85.59,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9386,5184,25993269,23p,P03372,ERA,Homo sapiens,"(exo-rac)-8-(4-(6-(2,6-Dimethylphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid",Cc1cccc(C)c1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589366,,,,Ki > 5000nM,antagonist,127.00%,antagonist,E2,,,,,,,EC50,=,320,nM,,,,,>,5.301029996,pKi,,other,Cc1cccc(C)c1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,127,582.44,619.2239881,3,7,13,3,6.23204,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
9387,5184,25993269,23p,Q92731,ERB,Homo sapiens,"(exo-rac)-8-(4-(6-(2,6-Dimethylphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid",Cc1cccc(C)c1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589366,,,,Ki = 971.43nM,antagonist,87.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.012588489,pKi,,other,Cc1cccc(C)c1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,87,582.44,619.2239881,3,7,13,3,6.23204,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
9395,519,24980053,27,P04150,GR,Homo sapiens,"(S)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@@H]1c2ccc(nc2Oc3c(F)cccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)Nc6nncs6,CHEMBL3315062,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 1.6nM,partial agonist,58.00%,agonist,dexamethasone,,,,,,,EC50,=,10.8,nM,,,,,=,8.795880017,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,58,533.415,559.1689535,1,8,5,4,5.1141,106.54,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,agonist,partial agonist,agonist,partial agonist,958
9410,5198,22579420,Wy14643,Q07869,PPARA,Homo sapiens,"2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid",Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C,CHEMBL295416,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 10110nM,agonist,100.00%,agonist,Wy14643,,,,,,,EC50,=,130,nM,,,,,=,4.995248844,pIC50,NB,other,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C,100,309.693,323.0495254,2,5,5,2,3.66714,75.11,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
9411,5199,18809325,1d,P37231,PPARG,Homo sapiens,m-tolyl 2-phenylethenesulfonate,Cc1cccc(OS(=O)(=O)\C=C\c2ccccc2)c1,CHEMBL467711,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49649",IC50 = 1187nM,partial agonist,33.20%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,5.925549281,pIC50,,radiometric,Cc1cccc(OS(=O)(=O)/C=C/c2ccccc2)c1,33.2,260.229,274.0663653,0,3,4,2,3.37452,43.37,CC(C)(CCC1CCCCC1)CC1CCCCC1,,partial agonist,,partial agonist,1220
9415,52,14592510,34b,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[4-(2,2-Difluoro-ethoxy)-3'-fluoro-5-isopropyl-biphenyl-3-yl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2cccc(F)c2,CHEMBL130232,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 1.0nM,antagonist,91.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,3.9,nM,=,9,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2cccc(F)c2)cc(C(C)C)c1OCC(F)F,91,417.277,444.1912294,1,2,9,2,7.2504,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
9419,5200,25993269,24c,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 3-Tolyl Ester,Cc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5)c1,CHEMBL3589695,,,,Ki = 4428.57nM,antagonist,115.00%,antagonist,E2,,,,,,,,,,,,,,,=,5.353736486,pKi,,other,Cc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)=C3c2ccc(O)cc2)c1,115,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
9420,5200,25993269,24c,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 3-Tolyl Ester,Cc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5)c1,CHEMBL3589695,,,,Ki > 5000nM,partial antagonist,48.00%,antagonist,E2,,,,,,,EC50,=,54,nM,IC50,=,613,nM,>,5.301029996,pKi,,other,Cc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)=C3c2ccc(O)cc2)c1,48,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,1126
9421,5201,25993269,23c,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(m-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)c1,CHEMBL3589353,,,,Ki = 80.52nM,partial antagonist,43.00%,antagonist,E2,,,,,,,,,,,,,,,=,7.094096234,pKi,B,other,Cc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)c1,43,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,partial antagonist,,partial antagonist,1126
9422,5201,25993269,23c,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(m-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5)c1,CHEMBL3589353,,,,Ki = 67.73nM,antagonist,87.00%,antagonist,E2,,,,,,,,,,,,,,,=,7.169218924,pKi,B,other,Cc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(NC(=O)CCCCCCC(=O)O)cc2)=C3c2ccc(O)cc2)c1,87,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
9427,5205,17391964,22,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzoyl-8-methylquinolin-4-yl)phenyl]-amino}methyl)phenyl]acetic acid,Cc1cccc2c(c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(cnc12)C(=O)c5ccccc5,CHEMBL387484,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 5.5nM,agonist,75.00%,agonist,T0901317,,T0901317,,,,,EC50,=,61,nM,,,,,=,8.259637311,pIC50,B,radiometric,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(C(=O)c3ccccc3)cnc12,75,460.363,486.1943427,2,4,8,5,6.68042,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
9429,5206,17391964,23,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzyl-8-methylquinolin-4-yl)phenyl]amino}-methyl)phenyl]acetic acid,Cc1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(NCc5ccc(CC(=O)O)cc5)c4,CHEMBL225828,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 5.0nM,agonist,97.00%,agonist,T0901317,,T0901317,,,,,EC50,=,90,nM,,,,,=,8.301029996,pIC50,B,radiometric,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,97,444.364,472.2150781,2,3,8,5,7.04022,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,331
9436,521,21899328,23,P04150,GR,Homo sapiens,"[(5S)-alpha,alpha-Dimethyl-2-[(4-hydroxyl)phenyl]-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@@H]1c2ccccc2Oc3nc(ccc13)c4ccc(O)cc4)C(=O)Nc5nncs5,CHEMBL1911153,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 5.7nM,antagonist,96.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,201,nM,=,8.244125144,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccccc2Oc2nc(-c3ccc(O)cc3)ccc21,96,424.356,444.1256115,2,7,4,4,5.2082,97.23,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
9443,5213,21899328,15,P04150,GR,Homo sapiens,"[(5S)-2-[(2-Methyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",Cc1ccccc1c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911145,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 10.5nM,antagonist,101.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,1556,nM,=,7.978810701,pKi,B,FPA,Cc1ccccc1-c1ccc2c(n1)Oc1ccccc1[C@@H]2C(C)(C)C(=O)Nc1nncs1,101,420.368,442.1463469,1,6,4,4,5.81102,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
9451,5217,24506830,40,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-4-(2-methyl-phenyl)-pentan-2-ol",Cc1ccccc1C(C)(C)CC(O)(Cc2cc3ncncc3[nH]2)C(F)(F)F,CHEMBL3126943,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,partial agonist,69.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,44,nM,,,,,=,7.886056648,pIC50,B,FPA,Cc1ccccc1C(C)(C)CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F,69,355.234,377.171497,2,3,5,3,4.47012,61.8,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
9454,5218,17181172,32,P04150,GR,Homo sapiens,1-[2-hydroxy-4-methyl-4-o-tolyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,Cc1ccccc1C(C)(C)CC(O)(CN2C=CC(=O)c3ccccc23)C(F)(F)F,CHEMBL425970,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 22nM,partial agonist,63.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,61,nM,,,,,=,7.657577319,pIC50,B,FPA,Cc1ccccc1C(C)(C)CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F,63,379.252,403.1759137,1,3,5,3,4.97122,42.23,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,partial agonist,agonist,partial agonist,807
9464,5223,19616429,17,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-isopropyl-5-oxopyrrolidin-3-yl)(2-methylbenzyl)amino)benzonitrile,CC(C)N1C[C@H](CC1=O)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL551541,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 20nM,partial agonist,71.00%,agonist,progesterone,,,,,,,EC50,=,2,nM,,,,,=,7.698970004,pIC50,B,other,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CC(=O)N(C(C)C)C1,71,357.715,381.1607901,0,3,5,2,4.536,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
9465,5224,19926282,39,P06401,PR,Homo sapiens,2-chloro-4-(((S)-1-((S)-2-hydroxypropanoyl)pyrrolidin-3-yl)(2-methylbenzyl)amino)benzonitrile,C[C@H](O)C(=O)N1CC[C@@H](C1)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL600466,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 32nM,partial agonist,60.00%,agonist,progesterone,,,,,,,EC50,=,3,nM,,,,,=,7.494850022,pIC50,B,other,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C(=O)[C@H](C)O)C1,60,373.714,397.1557047,1,4,5,2,3.5084,67.57,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
9466,5225,19595590,21,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-methylbenzyl)(1-methylpyrrolidin-3-yl)amino)benzonitrile,CN1CC[C@@H](C1)N(Cc2ccccc2C)c3ccc(C#N)c(Cl)c3,CHEMBL557534,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 50nM,partial agonist,73.00%,agonist,progesterone,,,,,,,EC50,=,200,nM,,,,,=,7.301029996,pIC50,B,FPA,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(C)C1,73,317.694,339.1502254,0,3,4,2,4.2308,30.27,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
9467,5226,19926282,20,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-methylbenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile,Cc1ccccc1CN([C@H]2CCN(C2)S(=O)(=O)C)c3ccc(C#N)c(Cl)c3,CHEMBL601500,,,,IC50 = 16nM,agonist,77.00%,agonist,,,,,,,,EC50,=,25,nM,,,,,=,7.795880017,pIC50,B,other,Cc1ccccc1CN(c1ccc(C#N)c(Cl)c1)[C@H]1CCN(S(C)(=O)=O)C1,77,381.759,403.1121256,0,4,5,2,3.5606,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,agonist,agonist,agonist,323
9471,5229,25993269,24d,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Tolyl Ester,Cc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5,CHEMBL3589696,,,,Ki > 5000nM,antagonist,126.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,Cc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)NO)cc1)=C2c1ccc(O)cc1,126,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
9472,5229,25993269,24d,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Tolyl Ester,Cc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)NO)cc5,CHEMBL3589696,,,,Ki = 2125.0nM,antagonist,94.00%,antagonist,E2,,,,,,,EC50,=,203,nM,,,,,=,5.672641066,pKi,,other,Cc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)NO)cc1)=C2c1ccc(O)cc1,94,584.436,620.2192371,4,8,13,3,5.34442,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
9477,5230,25993269,23f,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(o-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589356,,,,Ki = 104.02nM,partial antagonist,43.00%,antagonist,E2,,,,,,,,,,,IC50,=,460,nM,=,6.982883151,pKi,,other,Cc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,43,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1126
9478,5230,25993269,23f,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(o-tolyloxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,Cc1ccccc1OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(NC(=O)CCCCCCC(=O)O)cc5,CHEMBL3589356,,,,Ki = 91.89nM,antagonist,117.00%,antagonist,E2,,,,,,,EC50,=,380,nM,,,,,=,7.036731748,pKi,B,other,Cc1ccccc1OS(=O)(=O)C1CC2OC1C(c1ccc(NC(=O)CCCCCCC(=O)O)cc1)=C2c1ccc(O)cc1,117,570.429,605.2083381,3,7,13,3,5.92362,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
9485,5235,20345102,14,P55055,LXRB,Homo sapiens,N-(2-chloro-6-fluorobenzyl)-2-methyl-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide,Cc1ccccc1S(=O)(=O)N(Cc2ccc(cc2)c3cccc(c3)S(=O)(=O)C)Cc4c(F)cccc4Cl,CHEMBL1091976,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.9,agonist,120.00%,agonist,Compound 2,,,,,,,PEC50,=,8.5,,,,,,=,7.9,pIC50,B,radiometric,Cc1ccccc1S(=O)(=O)N(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)Cc1c(F)cccc1Cl,120,532.896,557.0897562,0,4,8,4,6.24912,71.52,CC(C)(C1CCCCC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,agonist,agonist,agonist,1068
9496,5245,25686852,4g,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methylpyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1ccnc(n1)N2C[C@@H](Cc3ccc(OCCc4nc(oc4C)c5ccccc5)cc3)[C@H](C2)C(=O)O,CHEMBL3398449,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 450nM,partial agonist,49.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,630,nM,,,,,=,6.346787486,pIC50,,FPA,Cc1ccnc(N2C[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@@H](C(=O)O)C2)n1,49,468.343,498.2267054,1,7,9,4,4.74964,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,186
9497,5245,25686852,4g,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methylpyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1ccnc(n1)N2C[C@@H](Cc3ccc(OCCc4nc(oc4C)c5ccccc5)cc3)[C@H](C2)C(=O)O,CHEMBL3398449,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3980nM,agonist,93.00%,agonist,GW2331,1000nM,,,,,,EC50,=,170,nM,,,,,=,5.400116928,pIC50,,FPA,Cc1ccnc(N2C[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@@H](C(=O)O)C2)n1,93,468.343,498.2267054,1,7,9,4,4.74964,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
9500,5247,20047280,37,P04150,GR,Homo sapiens,"(S)-1-((5aR,6S)-1-(4-Fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)-1-(3-methylthiophen-2-yl)-ethanol",Cc1ccsc1[C@@](C)(O)[C@H]2CCCC3=Cc4c(ncn4C[C@]23C)c5ccc(F)cc5,CHEMBL567028,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,partial agonist,26.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,380,nM,,,,,=,8.698970004,pIC50,B,FPA,Cc1ccsc1[C@@](C)(O)[C@H]1CCCC2=Cc3c(-c4ccc(F)cc4)ncn3C[C@@]21C,26,395.353,422.1828127,1,4,3,3,6.17022,38.05,C1CCC(C2CCC3CC4C(CC5CCCC5)CCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,88
9504,525,21073190,30,P04150,GR,Homo sapiens,"(S)-2-(3-Hydroxy-9H-xanthen-9-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@H]1c2ccccc2Oc3cc(O)ccc13)C(=O)Nc4nncs4,CHEMBL1800985,AP-1 repression,,Fluorescence polarization (FP) competition binding assay,Ki = 0.8nM,agonist,82.00%,agonist,dexamethasone,2.5nM,,,,,,EC50,=,7.8,nM,,,,,=,9.096910013,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2cc(O)ccc21,82,350.294,367.0990624,2,6,3,3,4.1462,84.34,CC(CC1CCCC1)CC1C2CCCCC2CC2CCCCC21,agonist,agonist,agonist,"agonist,partial agonist",959
9505,525,21899328,6,P04150,GR,Homo sapiens,"(S)-2-(3-hydroxy-9H-xanthen-9-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)([C@H]1c2ccccc2Oc3cc(O)ccc13)C(=O)Nc4nncs4,CHEMBL1800985,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,Ki = 0.8nM,partial agonist,46.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,85.7,nM,,,,,=,9.096910013,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2cc(O)ccc21,46,350.294,367.0990624,2,6,3,3,4.1462,84.34,CC(CC1CCCC1)CC1C2CCCCC2CC2CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",959
9526,5259,23953070,7d,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(5-methylthiazol-2-yl)-3-phenylpropanamide",Cc1cnc(NC(=O)C(C)(C)C(c2ccccc2)c3ccc4c(cnn4c5ccc(F)cc5)c3)s1,CHEMBL2426627,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 11nM,partial agonist,48.00%,agonist,,,,,,,,EC50,=,49,nM,,,,,=,7.958607315,pKi,B,FPA,Cc1cnc(NC(=O)C(C)(C)C(c2ccccc2)c2ccc3c(cnn3-c3ccc(F)cc3)c2)s1,48,459.4,484.1733106,1,5,6,5,6.72632,59.81,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9527,526,21899328,45,P04150,GR,Homo sapiens,"[(5S)-2-[4-(3,3-Difluoro-1-pyrrolidinylcarbonyl)-3-chlorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(C(=O)N5CCC(F)(F)C5)c(Cl)c4)C(=O)Nc6nncs6,CHEMBL1911282,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 3.08nM,partial agonist,44.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,165,nM,IC50,=,129.7,nM,=,8.511449284,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCC(F)(F)C4)c(Cl)c3)ccc21,44,571.867,595.1256447,1,7,5,4,6.6372,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCC4)CC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,957
9529,5260,19321341,3,P04150,GR,Homo sapiens,"15-methyl-N-(5-methyl-1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c5ccccc35)s1,CHEMBL474770,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 12.7nM,partial agonist,30.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,609.8,nM,,,,,=,7.896196279,pKi,B,FPA,Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c2ccccc23)s1,30,340.322,360.1296343,1,3,2,3,5.07742,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
9530,5260,19321341,"3a, isomer A",P04150,GR,Homo sapiens,"15-methyl-N-(5-methyl-1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c5ccccc35)s1,CHEMBL474770,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 4.1nM,partial agonist,32.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,345,nM,,,,,=,8.387216143,pKi,B,FPA,Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c2ccccc23)s1,32,340.322,360.1296343,1,3,2,3,5.07742,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
9531,5260,19321341,"3b, isomer B",P04150,GR,Homo sapiens,"15-methyl-N-(5-methyl-1,3-thiazol-2-yl)tetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c5ccccc35)s1,CHEMBL474770,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 187nM,partial agonist,31.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,972.5,nM,,,,,=,6.728158393,pKi,,FPA,Cc1cnc(NC(=O)C2(C)CC3c4ccccc4C2c2ccccc23)s1,31,340.322,360.1296343,1,3,2,3,5.07742,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
9534,5261,20382019,8o,P55055,LXRB,Homo sapiens,"4-(2',4'-difluoro-5'-(methylsulfonyl)biphenyl-3-yl)-3-methyl-8-(trifluoromethyl)quinoline",Cc1cnc2c(cccc2c1c3cccc(c3)c4cc(c(F)cc4F)S(=O)(=O)C)C(F)(F)F,CHEMBL1097159,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.3nM,agonist,81.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,195,nM,,,,,=,8.48148606,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cc(S(C)(=O)=O)c(F)cc2F)c1,81,461.326,477.0821909,0,3,3,4,6.57772,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
9536,5262,20382019,8n,P55055,LXRB,Homo sapiens,4-(4'-fluoro-3'-(methylsulfonyl)biphenyl-3-yl)-3-methyl-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(c3)c4ccc(F)c(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1097158,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.7nM,agonist,80.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,161,nM,,,,,=,8.769551079,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2ccc(F)c(S(C)(=O)=O)c2)c1,80,442.328,459.0916127,0,3,3,4,6.43862,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
9540,5264,20382019,8c,P55055,LXRB,Homo sapiens,3-methyl-4-(3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(c3)c4cccc(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1094741,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.8nM,agonist,94.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,284,nM,,,,,=,8.744727495,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,94,423.33,441.1010345,0,3,3,4,6.29952,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
9542,5265,18023179,37,P55055,LXRB,Homo sapiens,2-(5-((3-(3-methyl-8-(trifluoromethyl)quinolin-4-yl)phenyl)methylamino)naphthalen-1-yl)acetic acid,Cc1cnc2c(cccc2c1c3cccc(CNc4cccc5c(CC(=O)O)cccc45)c3)C(F)(F)F,CHEMBL442437,Gal4 luciferase reporter gene assays,,-,IC50 = 10nM,partial agonist,51.00%,agonist,T0901317,,,,,,,EC50,=,4167,nM,,,,,=,8,pIC50,B,other,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,51,477.336,500.1711626,2,3,6,5,7.62142,62.22,C1CCC2C(C1)CCCC2CCC1CCCC(C2CCCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,25
9543,5265,18023179,37,Q13133,LXRA,Homo sapiens,2-(5-((3-(3-methyl-8-(trifluoromethyl)quinolin-4-yl)phenyl)methylamino)naphthalen-1-yl)acetic acid,Cc1cnc2c(cccc2c1c3cccc(CNc4cccc5c(CC(=O)O)cccc45)c3)C(F)(F)F,CHEMBL442437,Gal4 luciferase reporter gene assays,,-,IC50 = 211nM,partial agonist,47.00%,agonist,T0901317,,,,,,,EC50,=,7866,nM,,,,,=,6.675717545,pIC50,,other,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,47,477.336,500.1711626,2,3,6,5,7.62142,62.22,C1CCC2C(C1)CCCC2CCC1CCCC(C2CCCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,25
9544,5266,17391964,17,P55055,LXRB,Homo sapiens,{4-[({3-[3-methyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl}acetic acid,Cc1cnc2c(cccc2c1c3cccc(NCc4ccc(CC(=O)O)cc4)c3)C(F)(F)F,CHEMBL389859,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 4.3nM,agonist,89.00%,agonist,T0901317,,T0901317,,,,,EC50,=,100,nM,,,,,=,8.366531544,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,89,429.292,450.1555126,2,3,6,4,6.46822,62.22,C1CCC(CCC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,332
9546,5267,19932617,7t,P55055,LXRB,Homo sapiens,4-(3-(3-chloro-5-(methylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cc(Cl)cc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594176,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.0nM,agonist,89.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,445,nM,,,,,=,8.522878745,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(Cl)cc(S(C)(=O)=O)c2)c1,89,474.782,491.0569767,0,4,4,4,7.07822,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9548,5268,19932617,7s,P55055,LXRB,Homo sapiens,4-(3-(3-fluoro-5-(methylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cc(F)cc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594175,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.9nM,agonist,79.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,90,nM,,,,,=,8.721246399,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(F)cc(S(C)(=O)=O)c2)c1,79,458.327,475.0865273,0,4,4,4,6.56392,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9550,5269,19853462,5g,P55055,LXRB,Homo sapiens,(4-{3-[3-Methyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)methanol,Cc1cnc2c(cccc2c1c3cccc(Oc4ccc(CO)cc4)c3)C(F)(F)F,CHEMBL595125,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 31nM,partial agonist,48.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,1370,nM,,,,,=,7.508638306,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(CO)cc2)c1,48,391.263,409.1289635,1,3,4,4,6.51362,42.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9552,527,21899328,44,P04150,GR,Homo sapiens,"[(5S)-2-[4-(3,3-Difluoro-1-pyrrolidinylcarbonyl)-3-fluorophenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(C(=O)N5CCC(F)(F)C5)c(F)c4)C(=O)Nc6nncs6,CHEMBL1911281,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.53nM,partial agonist,43.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,192,nM,IC50,=,99.3,nM,=,8.596879479,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCC(F)(F)C4)c(F)c3)ccc21,43,555.412,579.1551953,1,7,5,4,6.1229,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCC4)CC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,957
9553,5270,19932617,7a,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(4-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4ccc(cc4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL593884,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 42nM,partial agonist,30.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,1550,nM,,,,,=,7.37675071,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(S(C)(=O)=O)cc2)c1,30,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9555,5271,19853462,5f,P55055,LXRB,Homo sapiens,3-{3-[3-Methyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)methanol,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(CO)c4)c3)C(F)(F)F,CHEMBL595118,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,partial agonist,69.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,233,nM,,,,,=,8.677780705,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,69,391.263,409.1289635,1,3,4,4,6.51362,42.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9556,5271,19932617,6a,P55055,LXRB,Homo sapiens,(3-(3-(3-methyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)phenyl)methanol,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(CO)c4)c3)C(F)(F)F,CHEMBL595118,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,73.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,1510,nM,,,,,=,8.522878745,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,73,391.263,409.1289635,1,3,4,4,6.51362,42.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9559,5272,19932617,7k,P55055,LXRB,Homo sapiens,4-(3-(3-(isopropylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,CC(C)S(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL595113,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.8nM,partial agonist,49.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,56,nM,,,,,=,8.744727495,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,49,463.351,485.1272492,0,4,5,4,7.20342,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9561,5273,19932617,7m,P55055,LXRB,Homo sapiens,4-(3-(3-(isobutylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,CC(C)CS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL595345,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.1nM,partial agonist,55.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,592,nM,,,,,=,8.091514981,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CC(C)C)c2)c1,55,475.362,499.1428993,0,4,6,4,7.45102,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9563,5274,19932617,7p,P55055,LXRB,Homo sapiens,2-methyl-4-(3-(3-(3-methyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)phenylsulfonyl)butan-2-ol,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)CCC(C)(C)O)c3)C(F)(F)F,CHEMBL604582,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.2nM,partial agonist,62.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,962,nM,,,,,=,8.086186148,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)(C)O)c2)c1,62,503.372,529.153464,1,5,7,4,6.95602,76.49,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9565,5275,19932617,7n,P55055,LXRB,Homo sapiens,4-(3-(3-(isopentylsulfonyl)phenoxy)phenyl)-3-methyl-8-(trifluoromethyl)quinoline,CC(C)CCS(=O)(=O)c1cccc(Oc2cccc(c2)c3c(C)cnc4c(cccc34)C(F)(F)F)c1,CHEMBL594174,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,partial agonist,56.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,1030,nM,,,,,=,7.886056648,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)C)c2)c1,56,487.373,513.1585494,0,4,7,4,7.84112,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9567,5276,19932617,7o,P55055,LXRB,Homo sapiens,3-(3-(3-(3-methyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)phenylsulfonyl)propan-1-ol,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)CCCO)c3)C(F)(F)F,CHEMBL593472,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.4nM,partial agonist,68.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,70,nM,,,,,=,8.853871964,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,68,479.35,501.1221638,1,5,7,4,6.17742,76.49,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
9569,5277,19932617,7b,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.0nM,agonist,78.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,31,nM,,,,,=,9,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,78,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9570,5277,19962892,15,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,,,,,,T0901317,,,,,,,,,,,,,=,9,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
9571,5277,20005711,5a,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.0nM,agonist,78.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,31,nM,,,,,=,9,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,78,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9572,5277,20006495,5a,P55055,LXRB,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.0nM,,,,,,T0901317,,,,,,,,,,,,,=,9,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
9573,5277,19932617,7b,Q13133,LXRA,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.4nM,,,,,,,,,,,,,,,,,,,=,8.619788758,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
9574,5277,19962892,15,Q13133,LXRA,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,,,,,,T0901317,,,,,,,,,,,,,=,8.698970004,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
9575,5277,20005711,5a,Q13133,LXRA,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.4nM,agonist,75.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,183,nM,,,,,=,8.619788758,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,75,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9576,5277,20006495,5a,Q13133,LXRA,Homo sapiens,3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,Cc1cnc2c(cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL595689,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.4nM,,,,,,T0901317,,,,,,,,,,,,,=,8.619788758,pIC50,B,radiometric,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,439.329,457.0959491,0,4,4,4,6.42482,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,,,agonist,agonist,280
9581,528,21899328,43,P04150,GR,Homo sapiens,"[(5S)-2-[3-Fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(C(=O)N5CCCC5)c(F)c4)C(=O)Nc6nncs6,CHEMBL1911280,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.96nM,partial agonist,39.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,177,nM,IC50,=,205,nM,=,8.707743929,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCCC4)c(F)c3)ccc21,39,517.416,543.1740389,1,7,5,4,5.8777,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCC4)CC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,957
9584,5281,19162487,4p,P55055,LXRB,Homo sapiens,8-Chloro-3-methyl-4-{3-[3-(morpholin-4-ylcarbonyl)phenoxy]phenyl}quinoline,Cc1cnc2c(Cl)cccc2c1c3cccc(Oc4cccc(c4)C(=O)N5CCOCC5)c3,CHEMBL460198,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7nM,partial agonist,46.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,572,nM,,,,,=,8.15490196,pIC50,B,radiometric,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,46,435.761,458.1397203,0,4,4,4,6.12832,51.66,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3CCCC4CCCCC43)C2)C1,agonist,partial agonist,agonist,partial agonist,897
9585,5281,19162487,4p,Q13133,LXRA,Homo sapiens,8-Chloro-3-methyl-4-{3-[3-(morpholin-4-ylcarbonyl)phenoxy]phenyl}quinoline,Cc1cnc2c(Cl)cccc2c1c3cccc(Oc4cccc(c4)C(=O)N5CCOCC5)c3,CHEMBL460198,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 158nM,partial agonist,33.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,1237,nM,,,,,=,6.801342913,pIC50,,radiometric,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,33,435.761,458.1397203,0,4,4,4,6.12832,51.66,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3CCCC4CCCCC43)C2)C1,agonist,partial agonist,agonist,partial agonist,897
9588,5283,19853462,5i,P55055,LXRB,Homo sapiens,2-{3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]phenyl}-propan-2-ol,Cc1cnc2c(Cl)cccc2c1c3cccc(Oc4cccc(c4)C(C)(C)O)c3,CHEMBL606157,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.5nM,agonist,84.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,108,nM,,,,,=,8.602059991,pIC50,B,radiometric,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(C)(C)O)c2)c1,84,381.733,403.1339066,1,3,4,4,6.88332,42.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9590,5284,19853462,5h,P55055,LXRB,Homo sapiens,{3-[3-(8-Chloro-3-methylquinolin-4-yl)phenoxy]phenyl}-methanol,Cc1cnc2c(Cl)cccc2c1c3cccc(Oc4cccc(CO)c4)c3,CHEMBL596047,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,agonist,75.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,938,nM,,,,,=,7.920818754,pIC50,B,radiometric,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,75,357.711,375.1026065,1,3,4,4,6.14822,42.35,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9592,5285,19932617,7g,P55055,LXRB,Homo sapiens,8-chloro-3-methyl-4-(3-(3-(methylsulfonyl)phenoxy)phenyl)quinoline,Cc1cnc2c(Cl)cccc2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3,CHEMBL595782,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.1nM,agonist,103.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,44,nM,,,,,=,8.958607315,pIC50,B,radiometric,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,103,405.777,423.0695921,0,4,4,4,6.05942,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,280
9595,5287,25978072,12a,P04150,GR,Homo sapiens,"6-(2,4-Dimethyl-2H-pyrazol-3-yl)-2,2,4,4-tetramethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",Cc1cnn(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)c4CCCc24,CHEMBL3582115,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 28nM,antagonist,79.00%,antagonist,,,,,,,,,,,,IC50,=,128,nM,=,7.552841969,pKi,B,radiometric,Cc1cnn(C)c1-c1cc2c(c3c1CCC3)NC(C)(C)C(=O)C2(C)C,79,310.251,337.2154125,1,4,1,2,3.93502,46.92,CC1CCC2C(C1)CC(C1CCCC1)C1CCCC21,antagonist,antagonist,antagonist,antagonist,558
9598,5289,23953070,7e,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(4-methylthiazol-2-yl)-3-phenylpropanamide",Cc1csc(NC(=O)C(C)(C)C(c2ccccc2)c3ccc4c(cnn4c5ccc(F)cc5)c3)n1,CHEMBL2426628,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 14nM,partial agonist,74.00%,agonist,,,,,,,,EC50,=,29,nM,,,,,=,7.853871964,pKi,B,FPA,Cc1csc(NC(=O)C(C)(C)C(c2ccccc2)c2ccc3c(cnn3-c3ccc(F)cc3)c2)n1,74,459.4,484.1733106,1,5,6,5,6.72632,59.81,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9599,529,21899328,40,P04150,GR,Homo sapiens,"[(5S)-2-[3-Fluoro-4-(1-piperidinylcarbonyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(C(=O)N5CCCCC5)c(F)c4)C(=O)Nc6nncs6,CHEMBL1911277,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.68nM,antagonist,94.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,203.6,nM,=,8.774690718,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCCCC4)c(F)c3)ccc21,94,529.427,557.189689,1,7,5,4,6.2678,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,antagonist,antagonist,antagonist,antagonist,958
9618,53,14592510,34a,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[4-(2,2-Difluoro-ethoxy)-2'-fluoro-5-isopropyl-biphenyl-3-yl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2ccccc2F,CHEMBL422088,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 2.3nM,antagonist,91.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,3.1,nM,=,8.638272164,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2ccccc2F)cc(C(C)C)c1OCC(F)F,91,417.277,444.1912294,1,2,9,2,7.2504,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
9621,530,21899328,39,P04150,GR,Homo sapiens,"[(5S)-alpha,alpha-Dimethyl-2-[4-(1-piperidinylcarbonyl)phenyl]-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)N5CCCCC5)C(=O)Nc6nncs6,CHEMBL1911276,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.3nM,antagonist,76.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,273,nM,IC50,=,167.1,nM,=,8.886056648,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCCCC4)cc3)ccc21,76,510.429,539.1991108,1,7,5,4,6.1287,97.31,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,958
9634,531,21899328,42,P04150,GR,Homo sapiens,"[(5S)-2-[3-Fluoro-4-(1-morpholinylcarbonyl)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]-pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(C(=O)N5CCOCC5)c(F)c4)C(=O)Nc6nncs6,CHEMBL1911279,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.70nM,partial agonist,62.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,78.9,nM,IC50,=,34.4,nM,=,8.568636236,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCOCC4)c(F)c3)ccc21,62,533.415,559.1689535,1,8,5,4,5.1141,106.54,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,958
9635,5310,12459017,43,P03372,ERA,Homo sapiens,"4-(2-{4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-[4-(2-methyl-thiazol-4-ylmethyl)-piperazin-1-yl]-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCN(Cc5csc(C)n5)CC4,CHEMBL434502,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 650nM,agonist,81.00%,agonist,E2,,E2,1nM,,,,EC50,=,150,nM,IC50,=,150,nM,=,6.187086643,pKi,,radiometric,Cc1nc(CN2CCN(c3nc(NCCc4ccc(O)cc4)nc(N(C)CCCc4ccc(Cl)cc4)n3)CC2)cs1,81,555.905,592.2499565,2,10,12,4,5.04132,93.54,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCC(CC4CCCC4)CC3)C2)CC1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,451
9636,5310,12459017,43,Q92731,ERB,Homo sapiens,"4-(2-{4-{[3-(4-Chloro-phenyl)-propyl]-methyl-amino}-6-[4-(2-methyl-thiazol-4-ylmethyl)-piperazin-1-yl]-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",CN(CCCc1ccc(Cl)cc1)c2nc(NCCc3ccc(O)cc3)nc(n2)N4CCN(Cc5csc(C)n5)CC4,CHEMBL434502,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 25nM,antagonist,98.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,5,nM,=,7.602059991,pKi,B,radiometric,Cc1nc(CN2CCN(c3nc(NCCc4ccc(O)cc4)nc(N(C)CCCc4ccc(Cl)cc4)n3)CC2)cs1,98,555.905,592.2499565,2,10,12,4,5.04132,93.54,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCC(CC4CCCC4)CC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,451
9638,5312,19321341,5,P04150,GR,Homo sapiens,"N-(4,5-dimethyl-1,3-thiazol-2-yl)-15-methyltetracyclo[6.6.2.0^{2,7}.0^{9,14}]hexadeca-2,4,6,9(14),10,12-hexaene-15-carboxamide",Cc1nc(NC(=O)C2(C)CC3c4ccccc4C2c5ccccc35)sc1C,CHEMBL514455,reporter gene assay (AP-1 repression),,Fluorescence polarization (FP) competition binding assay,Ki = 22.6nM,partial agonist,42.00%,agonist,dexamethasone,2.5nM,dexamethasone,,,,,EC50,=,922.6,nM,,,,,=,7.645891561,pKi,B,FPA,Cc1nc(NC(=O)C2(C)CC3c4ccccc4C2c2ccccc23)sc1C,42,352.333,374.1452843,1,3,2,3,5.38584,41.99,CC(CC1CCCC1)C1CC2C3CCCCC3C1C1CCCCC21,agonist,partial agonist,agonist,partial agonist,951
9647,5317,20005711,6a,P55055,LXRB,Homo sapiens,2-methyl-1-(3-(3-(methylsulfonyl)phenoxy)phenyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole,Cc1nc2c(cccc2n1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594757,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.0nM,partial agonist,49.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,162,nM,,,,,=,8.15490196,pIC50,B,radiometric,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,49,429.314,446.0911981,0,5,4,4,5.54852,61.19,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
9648,5317,20006495,6a,P55055,LXRB,Homo sapiens,2-methyl-1-(3-(3-(methylsulfonyl)phenoxy)phenyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole,Cc1nc2c(cccc2n1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594757,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.0nM,,,,,,T0901317,,,,,,,,,,,,,=,8.15490196,pIC50,B,radiometric,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,429.314,446.0911981,0,5,4,4,5.54852,61.19,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,,,agonist,partial agonist,276
9649,5317,20005711,6a,Q13133,LXRA,Homo sapiens,2-methyl-1-(3-(3-(methylsulfonyl)phenoxy)phenyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole,Cc1nc2c(cccc2n1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594757,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 128nM,partial agonist,42.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,640,nM,,,,,=,6.89279003,pIC50,,radiometric,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,42,429.314,446.0911981,0,5,4,4,5.54852,61.19,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
9650,5317,20006495,6a,Q13133,LXRA,Homo sapiens,2-methyl-1-(3-(3-(methylsulfonyl)phenoxy)phenyl)-4-(trifluoromethyl)-1H-benzo[d]imidazole,Cc1nc2c(cccc2n1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL594757,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 111nM,,,,,,T0901317,,,,,,,,,,,,,=,6.954677021,pIC50,,radiometric,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,,429.314,446.0911981,0,5,4,4,5.54852,61.19,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,,,agonist,partial agonist,276
9655,532,21899328,41,P04150,GR,Homo sapiens,"[(5S)-alpha,alpha-Dimethyl-2-[4-(1-morpholinylcarbonyl)phenyl]-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)N5CCOCC5)C(=O)Nc6nncs6,CHEMBL1911278,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.60nM,partial agonist,70.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,39.2,nM,IC50,=,28.6,nM,=,8.585026652,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCOCC4)cc3)ccc21,70,514.417,541.1783753,1,8,5,4,4.975,106.54,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCC(C(C)C4CCCCC4)CC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,958
9666,5325,20005711,7a,P55055,LXRB,Homo sapiens,"2-methyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",Cc1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL605314,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 49nM,partial agonist,37.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,840,nM,,,,,=,7.30980392,pIC50,B,radiometric,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,37,429.314,446.0911981,0,5,4,4,5.52432,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
9676,533,21899328,29a,P04150,GR,Homo sapiens,"4-[(5S)-5-[1,1-Dimethyl-2-oxo-2-(1,3,4-thiadiazol-2-ylamino)-ethyl]-5H-[1]benzopyrano[2,3-b]pyridin-2-yl]benzoic acid",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)O)C(=O)Nc5nncs5,CHEMBL1911159,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 15.4nM,partial antagonist,46.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,>,5000,nM,=,7.812479279,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)O)cc3)ccc21,46,452.366,472.1205261,2,7,5,4,5.2008,114.3,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,,partial antagonist,,partial antagonist,956
9685,5334,16610787,1av,P03372,ERA,Homo sapiens,"5,7-dihydroxy-3-(4-hydroxyphenyl)-2-methyl-3H-quinazolin-4-one",CC1=Nc2cc(O)cc(O)c2C(=O)N1c3ccc(O)cc3,CHEMBL205577,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 33248nM,partial agonist,33.00%,agonist,,,E1,11nM,,,,,,,,,,,,=,4.478234474,pIC50,NB,radiometric,Cc1nc2cc(O)cc(O)c2c(=O)n1-c1ccc(O)cc1,33,272.175,284.0797069,3,6,1,3,1.81092,95.58,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
9689,5336,19606870,24,P10275,AR,Homo sapiens,16-[(2-Methylpyrimidin-5-yl)methylidene]-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,CN1[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C\C(=C/c5cnc(C)nc5)\[C@@H]4O)[C@@]2(C)C=CC1=O,CHEMBL549375,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 43nM,agonist,137.00%,agonist,R1878,100nM,methyltrienolone,,,,,EC50,=,8,nM,,,,,=,7.366531544,pIC50,B,radiometric,Cc1ncc(/C=C2\C[C@H]3[C@@H]4CC[C@H]5N(C)C(=O)C=C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2O)cn1,137,374.294,407.2572773,1,4,1,1,3.77862,66.32,CC1CCC2C(CCC3C4CC(CC5CCCCC5)CC4CCC23)C1,agonist,agonist,agonist,agonist,632
9693,534,21899328,30,P04150,GR,Homo sapiens,"[(5S)-2-[4-(Aminocarbonyl)-phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano-[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccc(cc4)C(=O)N)C(=O)Nc5nncs5,CHEMBL1911160,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 2.5nM,antagonist,100.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,201.5,nM,=,8.602059991,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccc(C(N)=O)cc3)ccc21,100,450.374,471.1365105,2,7,5,4,4.6015,120.09,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
9696,5342,25978072,12b,P04150,GR,Homo sapiens,"6-(3,5-Dimethyl-3H-imidazol-4-yl)-2,2,4,4-tetramethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",Cc1ncn(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)c4CCCc24,CHEMBL3582116,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 69nM,partial antagonist,63.00%,antagonist,,,,,,,,,,,,IC50,=,150,nM,=,7.161150909,pKi,B,radiometric,Cc1ncn(C)c1-c1cc2c(c3c1CCC3)NC(C)(C)C(=O)C2(C)C,63,310.251,337.2154125,1,4,1,2,3.93502,46.92,CC1CCC2C(C1)CC(C1CCCC1)C1CCCC21,antagonist,partial antagonist,antagonist,partial antagonist,558
9704,535,21899328,14,P04150,GR,Homo sapiens,"[(5S)-2-Phenyl-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)([C@H]1c2ccccc2Oc3nc(ccc13)c4ccccc4)C(=O)Nc5nncs5,CHEMBL1911144,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 7.1nM,antagonist,101.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,>,10000,nM,IC50,=,187,nM,=,8.148741651,pKi,B,FPA,CC(C)(C(=O)Nc1nncs1)[C@H]1c2ccccc2Oc2nc(-c3ccccc3)ccc21,101,408.357,428.1306969,1,6,4,4,5.5026,77,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,antagonist,antagonist,antagonist,antagonist,956
9715,536,23953070,7b,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(2H-1,2,3-triazol-2-yl)propanamide",CC(C)(C(c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2)C(=O)Nn5nccn5,CHEMBL2426625,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 11nM,partial agonist,73.00%,agonist,,,,,,,,EC50,=,17,nM,,,,,=,7.958607315,pKi,B,FPA,CC(C)(C(=O)Nn1nccn1)C(c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,73,431.325,454.1917376,1,6,6,5,4.6845,77.63,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9728,5366,24755427,50,P04150,GR,Homo sapiens,"(S)-N-(1-(1-(4-cyanophenyl)-1H-indazol-4-ylamino)propan-2-yl)-1-cyclopentyl-3,5-dimethyl-1H-pyrazole-4-sulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(cc3)C#N)NS(=O)(=O)c4c(C)nn(C5CCCC5)c4C,CHEMBL3261427,,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.7nM,agonist,87.00%,agonist,dexamethasone,,,,,,,IC50,=,16,nM,,,,,=,8.327902142,pIC50,B,FPA,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(C#N)cc1,87,486.411,517.2259942,2,8,8,4,4.60452,117.63,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCC(C2CCCC2)C1,agonist,agonist,agonist,agonist,1293
9729,5367,24755427,47,P04150,GR,Homo sapiens,"(S)-1-cyclopentyl-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(F)cc3)NS(=O)(=O)c4c(C)nn(C5CCCC5)c4C,CHEMBL3261424,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.8nM,agonist,87.00%,agonist,dexamethasone,,,,,,,IC50,=,9.7,nM,,,,,=,8.420216403,pIC50,B,FPA,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)cc1,87,479.391,510.2213235,2,7,8,4,4.87194,93.84,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCC(C2CCCC2)C1,agonist,agonist,agonist,agonist,1293
9730,5368,24755427,48,P04150,GR,Homo sapiens,"(S)-1-cyclopentyl-N-(1-(1-(6-fluoropyridin-3-yl)-1H-indazol-4-ylamino)propan-2-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide",C[C@@H](CNc1cccc2c1cnn2c3ccc(F)nc3)NS(=O)(=O)c4c(C)nn(C5CCCC5)c4C,CHEMBL3261425,,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.0nM,agonist,88.00%,agonist,dexamethasone,,,,,,,IC50,=,7.2,nM,,,,,=,8.522878745,pIC50,B,FPA,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1,88,481.387,511.2165724,2,8,8,4,4.26694,106.73,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCC(C2CCCC2)C1,agonist,agonist,agonist,agonist,1293
9733,5370,24755427,51,P04150,GR,Homo sapiens,"(S)-1-cyclopentyl-3,5-dimethyl-N-(1-(1-(pyrimidin-5-yl)-1H-indazol-4-ylamino)propan-2-yl)-1H-pyrazole-4-sulfonamide",C[C@@H](CNc1cccc2c1cnn2c3cncnc3)NS(=O)(=O)c4c(C)nn(C5CCCC5)c4C,CHEMBL3261428,,,Fluorescence polarization (FP) competition binding assay,IC50 = 5.7nM,agonist,76.00%,agonist,dexamethasone,,,,,,,IC50,=,43,nM,,,,,=,8.244125144,pIC50,B,FPA,Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1cncnc1,76,464.385,494.2212432,2,9,8,4,3.52284,119.62,CC(C)(CCCCC1CCCC2C(C3CCCCC3)CCC12)C1CCC(C2CCCC2)C1,agonist,agonist,agonist,agonist,1293
9767,538,17391964,33,P55055,LXRB,Homo sapiens,2-{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl}-2-methylpropanoic acid,CC(C)(C(=O)O)c1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL225884,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 3.8nM,agonist,86.00%,agonist,T0901317,,T0901317,,,,,EC50,=,78,nM,,,,,=,8.420216403,pIC50,B,radiometric,CC(C)(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,86,541.379,568.1973774,2,4,8,5,8.1259,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
9793,5386,19376703,34,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4,5-dimethyl-4H-1,2,4-triazol-3-yl)-2-methylpropyl)amino)-2-chlorobenzonitrile",CC(C)C(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnc(C)n3C,CHEMBL563070,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 398nM,partial agonist,61.00%,agonist,progesterone,,,,,,,EC50,=,1665,nM,,,,,=,6.400116928,pIC50,,FPA,Cc1nnc(C(C(C)C)N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)n1C,61,405.183,427.1330511,0,5,6,3,5.7059,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
9794,5387,19376703,32,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(4,5-dimethyl-4H-1,2,4-triazol-3-yl)ethyl)amino)-2-chlorobenzonitrile",CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnc(C)n3C,CHEMBL549554,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 63nM,agonist,119.00%,agonist,progesterone,,,,,,,EC50,=,4.5,nM,,,,,=,7.200659451,pIC50,B,FPA,Cc1nnc(C(C)N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)n1C,119,381.161,399.101751,0,5,5,3,5.0698,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
9795,5388,19376703,8,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)amino)-2-chlorobenzonitrile",CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3oc(C)nn3,CHEMBL559581,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 32nM,agonist,80.00%,agonist,progesterone,,,,,,,EC50,=,14,nM,,,,,=,7.494850022,pIC50,B,FPA,Cc1nnc(C(C)N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)o1,80,371.142,386.0701165,0,5,5,3,5.3243,65.95,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
9796,5389,23953070,7f,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)-3-phenylpropanamide",Cc1nnc(NC(=O)C(C)(C)C(c2ccccc2)c3ccc4c(cnn4c5ccc(F)cc5)c3)s1,CHEMBL2426629,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 21nM,partial agonist,56.00%,agonist,,,,,,,,EC50,=,141,nM,,,,,=,7.677780705,pKi,B,FPA,Cc1nnc(NC(=O)C(C)(C)C(c2ccccc2)c2ccc3c(cnn3-c3ccc(F)cc3)c2)s1,56,461.396,485.1685596,1,6,6,5,6.12132,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2C(CCC2C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,966
9804,5391,16112571,24,P04150,GR,Homo sapiens,"4-(5-Fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanoic acid (4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-amide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cc(F)ccc3O)C(F)(F)F)cc12,CHEMBL196374,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,agonist,87.00%,agonist,dexamethasone,,,,,,,EC50,=,10,nM,,,inactive,,=,8.397940009,pIC50,B,FPA,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cc(F)ccc3O)C(F)(F)F)cc12,87,448.243,468.1308346,3,6,5,3,3.94092,112.66,CC(CCCC1CCCCC1)CC1CCC2C(C)CCCC2C1,agonist,agonist,agonist,agonist,1219
9805,5391,20727743,3,P04150,GR,Homo sapiens,"4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-N-(4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-2-(trifluoromethyl)pentanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cc(F)ccc3O)C(F)(F)F)cc12,CHEMBL196374,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.5,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,8.5,pIC50,B,radiometric,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cc(F)ccc3O)C(F)(F)F)cc12,,448.243,468.1308346,3,6,5,3,3.94092,112.66,CC(CCCC1CCCCC1)CC1CCC2C(C)CCCC2C1,,,agonist,agonist,1219
9810,5392,17181172,"2a, ZK-216348",P04150,GR,Homo sapiens,"4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-N-(4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-2-(trifluoromethyl)pentanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cccc4CCOc34)C(F)(F)F)cc12,CHEMBL216272,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,80.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,59,nM,,,,,=,8.522878745,pIC50,B,FPA,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cccc4c3OCC4)C(F)(F)F)cc12,80,453.267,476.1559065,2,6,5,3,4.03112,101.66,CC(CCCC1CCCC2CCCC12)CC1CCC2C(C)CCCC2C1,agonist,agonist,agonist,agonist,1196
9811,5392,20727743,1,P04150,GR,Homo sapiens,"4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-N-(4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-2-(trifluoromethyl)pentanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cccc4CCOc34)C(F)(F)F)cc12,CHEMBL216272,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.7,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,7.7,pIC50,B,radiometric,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC(C)(C)c3cccc4c3OCC4)C(F)(F)F)cc12,,453.267,476.1559065,2,6,5,3,4.03112,101.66,CC(CCCC1CCCC2CCCC12)CC1CCC2C(C)CCCC2C1,,,agonist,agonist,1196
9818,5394,16821781,55,P04150,GR,Homo sapiens,"3,3,3-trifluoro-2-hydroxy-2-{[1-(1-methylethyl)-1,2,3,4-tetrahydro-1-naphthalenyl]methyl}-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)propanamide",CC(C)C1(CC(O)(C(=O)Nc2ccc3C(=O)ON=C(C)c3c2)C(F)(F)F)CCCc4ccccc14,CHEMBL214336,MMTV agonim,MMTV antagonim,,PIC50 = 8.32,partial agonist,43.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.73,,PIC50,=,6.89,,=,8.32,pIC50,B,other,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3(C(C)C)CCCc4ccccc43)C(F)(F)F)cc12,43,461.29,488.192292,2,5,5,3,5.04872,92.43,CC(CCC1CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1123
9824,5397,16821781,58,P04150,GR,Homo sapiens,"2-[(1-cyclobutyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)propanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC3(CCCc4ccccc34)C5CCC5)C(F)(F)F)cc12,CHEMBL210185,MMTV agonim,MMTV antagonim,,PIC50 = 8.02,partial agonist,27.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.76,,PIC50,=,6.78,,=,8.02,pIC50,B,other,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3(C4CCC4)CCCc4ccccc43)C(F)(F)F)cc12,27,473.301,500.192292,2,5,5,3,5.19282,92.43,CC(CCC1(C2CCC2)CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1084
9825,5398,18038970,7,P04150,GR,Homo sapiens,"2-((1-cyclopentyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)propanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC3(CCCc4ccccc34)C5CCCC5)C(F)(F)F)cc12,CHEMBL235365,MMTV agonim,MMTV antagonim,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.09,partial agonist,39.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.75,,PIC50,=,7.27,,=,8.09,pIC50,B,FPA,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3(C4CCCC4)CCCc4ccccc43)C(F)(F)F)cc12,39,485.312,514.2079421,2,5,5,3,5.58292,92.43,CC(CCC1(C2CCCC2)CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1085
9826,5399,16821781,61,P04150,GR,Homo sapiens,"2-[(1-cyclohexyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)propanamide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC3(CCCc4ccccc34)C5CCCCC5)C(F)(F)F)cc12,CHEMBL383890,MMTV agonim,MMTV antagonim,,PIC50 = 8.07,partial agonist,34.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.68,,PIC50,=,6.7,,=,8.07,pIC50,B,other,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3(C4CCCCC4)CCCc4ccccc43)C(F)(F)F)cc12,34,497.323,528.2235921,2,5,5,3,5.97302,92.43,CC(CCC1(C2CCCCC2)CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1088
9828,54,14592510,34e,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[2-(2,2-Difluoro-ethoxy)-5-furan-2-yl-3-isopropyl-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2occc2,CHEMBL130317,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 3.0nM,antagonist,89.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,3.6,nM,=,8.522878745,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2ccco2)cc(C(C)C)c1OCC(F)F,89,390.256,416.1799158,1,3,9,2,6.7043,59.67,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
9837,5403,16112571,27,P04150,GR,Homo sapiens,"2-Cyclohexylmethyl-4-(5-fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-pentanoic acid (4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-amide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(CC3CCCCC3)CC(C)(C)c4cc(F)ccc4O)cc12,CHEMBL195962,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,130,nM,=,8.15490196,pIC50,B,FPA,Cc1noc(=O)c2ccc(NC(=O)C(O)(CC3CCCCC3)CC(C)(C)c3cc(F)ccc3O)cc12,100,463.315,496.2373504,3,6,7,3,5.34902,112.66,CC(CC1CCC2C(C)CCCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,948
9867,5419,16112571,29,P04150,GR,Homo sapiens,"2-Benzyl-4-(5-fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-pentanoic acid (4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)-amide",CC1=NOC(=O)c2ccc(NC(=O)C(O)(Cc3ccccc3)CC(C)(C)c4cc(F)ccc4O)cc12,CHEMBL372102,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,120,nM,=,8.096910013,pIC50,B,FPA,Cc1noc(=O)c2ccc(NC(=O)C(O)(Cc3ccccc3)CC(C)(C)c3cc(F)ccc3O)cc12,100,463.315,490.1904002,3,6,7,4,4.62132,112.66,CC(CC1CCC2C(C)CCCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,948
9875,5421,16821781,60,P04150,GR,Homo sapiens,"2-[(1-cyclopentyl-1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-3,3,3-trifluoro-2-hydroxy-N-(4-methyl-1-oxo-1H-2,3-benzoxazin-6-yl)propanamide",CC1=NOC(=O)c2ccc(NC(=O)[C@](O)(C[C@]3(CCCc4ccccc34)C5CCCC5)C(F)(F)F)cc12,CHEMBL208996,MMTV agonim,MMTV antagonim,,PIC50 = 8.09,partial agonist,39.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.75,,PIC50,=,7.27,,=,8.09,pIC50,B,other,Cc1noc(=O)c2ccc(NC(=O)[C@](O)(C[C@@]3(C4CCCC4)CCCc4ccccc43)C(F)(F)F)cc12,39,485.312,514.2079421,2,5,5,3,5.58292,92.43,CC(CCC1(C2CCCC2)CCCC2CCCCC21)CC1CCC2C(C)CCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1085
9876,5422,25978072,"3d, QCA-1093",P04150,GR,Homo sapiens,"6-(3,5-Dimethylisoxazol-4-yl)-2,2,4,4-tetramethyl-2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-3-one",Cc1onc(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)c4CCCc24,CHEMBL3582112,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 15nM,antagonist,96.00%,antagonist,,,,,,,,,,,,IC50,=,30,nM,=,7.823908741,pKi,B,radiometric,Cc1noc(C)c1-c1cc2c(c3c1CCC3)NC(C)(C)C(=O)C2(C)C,96,312.243,338.1994281,1,4,1,2,4.49794,55.13,CC1CCC2C(C1)CC(C1CCCC1)C1CCCC21,antagonist,antagonist,antagonist,antagonist,558
9882,5423,25978072,3e,P04150,GR,Homo sapiens,"6-(3,5-dimethylisoxazol-4-yl)-2,2,4,4-tetramethyl-1,2,7,8,9,10-hexahydrobenzo[h]quinolin-3(4H)-one",Cc1onc(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)c4CCCCc24,CHEMBL3582113,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 106nM,partial antagonist,70.00%,antagonist,,,,,,,,,,,,IC50,=,167,nM,=,6.974694135,pKi,,radiometric,Cc1noc(C)c1-c1cc2c(c3c1CCCC3)NC(C)(C)C(=O)C2(C)C,70,324.254,352.2150781,1,4,1,2,4.88804,55.13,CC1CCC2C(C1)CC(C1CCCC1)C1CCCCC21,antagonist,partial antagonist,antagonist,partial antagonist,559
9883,5424,25978072,3f,P04150,GR,Homo sapiens,"4-(3,5-dimethylisoxazol-4-yl)-6,6,8,8-tetramethyl-8,9-dihydro-[1,3]dioxolo[4,5-h]quinolin-7(6H)-one",Cc1onc(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)c4OCOc24,CHEMBL3582114,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 55nM,antagonist,88.00%,antagonist,,,,,,,,,,,,IC50,=,77,nM,=,7.259637311,pKi,B,radiometric,Cc1noc(C)c1-c1cc2c(c3c1OCO3)NC(C)(C)C(=O)C2(C)C,88,320.219,342.1579572,1,6,1,2,3.73794,73.59,CC1CCC2C(C1)CC(C1CCCC1)C1CCCC21,antagonist,antagonist,antagonist,antagonist,558
9886,5425,25978072,3b,P04150,GR,Homo sapiens,"7-chloro-6-(3,5-dimethylisoxazol-4-yl)-2,2,4,4-tetramethyl-1,2-dihydroquinolin-3(4H)-one",Cc1onc(C)c1c2cc3c(NC(C)(C)C(=O)C3(C)C)cc2Cl,CHEMBL3582110,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 151nM,antagonist,98.00%,antagonist,,,,,,,,,,,,IC50,<,30,nM,=,6.821023053,pKi,,radiometric,Cc1noc(C)c1-c1cc2c(cc1Cl)NC(C)(C)C(=O)C2(C)C,98,311.663,332.1291556,1,4,1,2,4.66264,55.13,CC1CCC2CCC(C3CCCC3)CC2C1,,antagonist,,antagonist,643
9889,5426,24685544,18,P51449,RORG,Homo sapiens,"N-((5-(3,5-dimethylisoxazol-4-yl)thiophen-2-yl)methyl)-N-isobutyl-1-phenylmethanesulfonamide",CC(C)CN(Cc1ccc(s1)c2c(C)onc2C)S(=O)(=O)Cc3ccccc3,CHEMBL3263707,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 2000nM,inverse agonist,-50.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,7500,nM,,,,,=,5.698970004,pIC50,,radiometric,Cc1noc(C)c1-c1ccc(CN(CC(C)C)S(=O)(=O)Cc2ccccc2)s1,-50,392.376,418.1384847,0,5,8,3,5.00794,63.41,CC(C)(CCC1CCC(C2CCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1197
9890,5427,25978072,3a,P04150,GR,Homo sapiens,"6-(3,5-dimethylisoxazol-4-yl)-2,2,4,4-tetramethyl-1,2-dihydroquinolin-3(4H)-one",Cc1onc(C)c1c2ccc3NC(C)(C)C(=O)C(C)(C)c3c2,CHEMBL3582109,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",Ki = 16nM,antagonist,96.00%,antagonist,,,,,,,,,,,,IC50,=,37,nM,=,7.795880017,pKi,B,radiometric,Cc1noc(C)c1-c1ccc2c(c1)C(C)(C)C(=O)C(C)(C)N2,96,276.21,298.1681279,1,4,1,2,4.00924,55.13,CC1CCC2CCC(C3CCCC3)CC2C1,antagonist,antagonist,antagonist,antagonist,643
9916,5441,17005393,6,P37231,PPARG,Homo sapiens,3-[4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-(isopropoxycarbonylamino-methyl)-phenyl]-propionic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)ccc1CCC(=O)O,CHEMBL220622,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 47nM,agonist,92.00%,agonist,ref agonist,,,,,,,EC50,=,19,nM,,,,,=,7.327902142,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,92,508.36,542.2416868,2,6,12,4,6.59032,110.89,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,387
9917,5441,17005394,33,P37231,PPARG,Homo sapiens,3-[4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-(isopropoxycarbonylamino-methyl)-phenyl]-propionic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)ccc1CCC(=O)O,CHEMBL220622,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 47nM,agonist,92.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,19,nM,,,,,=,7.327902142,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,92,508.36,542.2416868,2,6,12,4,6.59032,110.89,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,387
9918,5441,17005393,6,Q07869,PPARA,Homo sapiens,3-[4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-(isopropoxycarbonylamino-methyl)-phenyl]-propionic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)ccc1CCC(=O)O,CHEMBL220622,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3489nM,partial agonist,52.00%,agonist,ref agonist,,,,,,,EC50,=,845,nM,,,,,=,5.457299031,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,52,508.36,542.2416868,2,6,12,4,6.59032,110.89,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,387
9919,5441,17005394,33,Q07869,PPARA,Homo sapiens,3-[4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-(isopropoxycarbonylamino-methyl)-phenyl]-propionic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ccccc4)ccc1CCC(=O)O,CHEMBL220622,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3489nM,partial agonist,52.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,845,nM,,,,,=,5.457299031,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,52,508.36,542.2416868,2,6,12,4,6.59032,110.89,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,387
9920,5442,17005394,37,P37231,PPARG,Homo sapiens,3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-[(pyrazin-2-yloxycarbonylamino)-methyl]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)Oc3cnccn3)c2)c4ccc(cc4)c5ccccc5,CHEMBL374344,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,agonist,84.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,2,nM,,,,,=,7.585026652,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)Oc2cnccn2)c1,84,548.385,578.2165347,2,8,12,5,6.03432,136.67,CC(CCC1CCCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)C1)CC1CCCCC1,agonist,agonist,agonist,agonist,1184
9921,5442,17005394,37,Q07869,PPARA,Homo sapiens,3-{4-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-2-[(pyrazin-2-yloxycarbonylamino)-methyl]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)Oc3cnccn3)c2)c4ccc(cc4)c5ccccc5,CHEMBL374344,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 449nM,partial agonist,68.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,198,nM,,,,,=,6.347753659,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)Oc2cnccn2)c1,68,548.385,578.2165347,2,8,12,5,6.03432,136.67,CC(CCC1CCCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)C1)CC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1184
9922,5443,17005393,17,P37231,PPARG,Homo sapiens,"5-[2-(2-biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-8-(2-carboxy-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 2,2-dimethyl-propyl ester",Cc1oc(nc1CCOc2ccc(CCC(=O)O)c3CN(CCc23)C(=O)OCC(C)(C)C)c4ccc(cc4)c5ccccc5,CHEMBL387373,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 33nM,partial agonist,56.00%,agonist,ref agonist,,,,,,,EC50,=,9,nM,,,,,=,7.48148606,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c2c1CCN(C(=O)OCC(C)(C)C)C2,56,556.404,596.288637,1,6,10,4,7.49652,102.1,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCCC54)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,149
9924,5444,19349176,(S)-3Ff,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy)naphthalen-1-yl)-2-(2,2,2-trifluoroethoxy)propanoic acid",Cc1oc(nc1CCOc2ccc(C[C@H](OCC(F)(F)F)C(=O)O)c3ccccc23)c4ccc(cc4)c5ccccc5,CHEMBL508299,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8nM,agonist,96.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,38,nM,,,,,=,8.096910013,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(C[C@H](OCC(F)(F)F)C(=O)O)c2ccccc12,96,547.359,575.1919577,1,5,11,5,7.66632,81.79,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCCC54)C3)CC2)CC1,agonist,agonist,agonist,agonist,149
9925,5444,19349176,(S)-3Ff,Q07869,PPARA,Homo sapiens,"(S)-3-(4-(2-(2-(biphenyl-4-yl)-5-methyloxazol-4-yl)ethoxy)naphthalen-1-yl)-2-(2,2,2-trifluoroethoxy)propanoic acid",Cc1oc(nc1CCOc2ccc(C[C@H](OCC(F)(F)F)C(=O)O)c3ccccc23)c4ccc(cc4)c5ccccc5,CHEMBL508299,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 429nM,agonist,79.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,987,nM,,,,,=,6.367542708,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(C[C@H](OCC(F)(F)F)C(=O)O)c2ccccc12,79,547.359,575.1919577,1,5,11,5,7.66632,81.79,C1CCC(C2CCC(C3CCC(CCCC4CCCC5CCCCC54)C3)CC2)CC1,agonist,agonist,agonist,agonist,149
9926,5445,11405642,8,P37231,PPARG,Homo sapiens,2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccc(cc3)c4ccccc4,CHEMBL25259,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 548nM,agonist,123.00%,agonist,reference compound (?),,,,,,,EC50,=,882,nM,,,,,=,6.261219442,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,123,430.31,457.188923,1,5,9,4,6.18052,81.79,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,387
9927,5445,15293980,12,P37231,PPARG,Homo sapiens,2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccc(cc3)c4ccccc4,CHEMBL25259,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 550nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,880,nM,,,,,=,6.259637311,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,,430.31,457.188923,1,5,9,4,6.18052,81.79,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,,agonist,agonist,387
9928,5445,11405642,8,Q07869,PPARA,Homo sapiens,2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccc(cc3)c4ccccc4,CHEMBL25259,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 174nM,agonist,92.00%,agonist,reference compound (?),,,,,,,EC50,=,149.5,nM,,,,,=,6.759450752,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,92,430.31,457.188923,1,5,9,4,6.18052,81.79,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,387
9929,5445,15293980,12,Q07869,PPARA,Homo sapiens,2-{4-[2-(2-Biphenyl-4-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccc(cc3)c4ccccc4,CHEMBL25259,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 170nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,150,nM,,,,,=,6.769551079,pKi,,radiometric,Cc1oc(-c2ccc(-c3ccccc3)cc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,,430.31,457.188923,1,5,9,4,6.18052,81.79,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,,agonist,agonist,387
9930,5446,17005394,35,P37231,PPARG,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-(4-(pyrimidin-2-yl)phenyl)oxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ncccn4)ccc1CCC(=O)O,CHEMBL223128,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,85.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,4,nM,,,,,=,7.301029996,pIC50,B,radiometric,Cc1oc(-c2ccc(-c3ncccn3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,85,512.352,544.2321847,2,8,12,4,5.38032,136.67,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,387
9931,5446,17005394,35,Q07869,PPARA,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-(4-(pyrimidin-2-yl)phenyl)oxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(cc3)c4ncccn4)ccc1CCC(=O)O,CHEMBL223128,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9940nM,partial agonist,37.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,900,nM,,,,,=,5.002613616,pIC50,,radiometric,Cc1oc(-c2ccc(-c3ncccn3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,37,512.352,544.2321847,2,8,12,4,5.38032,136.67,C1CCC(CCCC2CCC(C3CCC(C4CCCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,387
9933,5447,11405642,7,Q07869,PPARA,Homo sapiens,2-(4-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-phenoxy)-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccc(Br)cc3,CHEMBL65458,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 242nM,partial agonist,58.00%,agonist,reference compound (?),,,,,,,EC50,=,61.9,nM,,,,,=,6.616184634,pIC50,,radiometric,Cc1oc(-c2ccc(Br)cc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,58,438.148,459.0681349,1,5,8,3,5.27602,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
9934,5448,16973358,35,P37231,PPARG,Homo sapiens,2-((6-(2-(2-(4-cyanophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(cc4)C#N,CHEMBL217907,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 334nM,agonist,96.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,28,nM,,,,,=,6.476253533,pKi,,radiometric,Cc1oc(-c2ccc(C#N)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,96,410.28,433.1637708,1,7,8,3,3.7145,118.47,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9935,5448,16973358,35,Q07869,PPARA,Homo sapiens,2-((6-(2-(2-(4-cyanophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(cc4)C#N,CHEMBL217907,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 314nM,agonist,167.00%,agonist,GW2331,,GW2331,,,,,EC50,=,31,nM,,,,,=,6.503070352,pKi,,radiometric,Cc1oc(-c2ccc(C#N)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,167,410.28,433.1637708,1,7,8,3,3.7145,118.47,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9936,5449,19349176,(S)-2Gd,P37231,PPARG,Homo sapiens,(S)-2-(cyclopropylmethoxy)-3-(4-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CC(C)c1ccc(cc1)c2oc(C)c(CCOc3ccc(C[C@H](OCC4CC4)C(=O)O)c5sccc35)n2,CHEMBL485188,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,partial agonist,56.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,10,nM,,,,,=,8.301029996,pIC50,B,radiometric,Cc1oc(-c2ccc(C(C)C)cc2)nc1CCOc1ccc(C[C@H](OCC2CC2)C(=O)O)c2sccc12,56,486.399,519.2079442,1,6,12,4,7.03192,81.79,C1CCC(C2CCC(CCCC3CCC(CCCCC4CC4)C4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,198
9937,5449,19349176,(S)-2Gd,Q07869,PPARA,Homo sapiens,(S)-2-(cyclopropylmethoxy)-3-(4-(2-(2-(4-isopropylphenyl)-5-methyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CC(C)c1ccc(cc1)c2oc(C)c(CCOc3ccc(C[C@H](OCC4CC4)C(=O)O)c5sccc35)n2,CHEMBL485188,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 37nM,agonist,122.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,16,nM,,,,,=,7.431798276,pIC50,B,radiometric,Cc1oc(-c2ccc(C(C)C)cc2)nc1CCOc1ccc(C[C@H](OCC2CC2)C(=O)O)c2sccc12,122,486.399,519.2079442,1,6,12,4,7.03192,81.79,C1CCC(C2CCC(CCCC3CCC(CCCCC4CC4)C4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,198
9939,5450,16973358,31,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(cc4)C(F)(F)F,CHEMBL221641,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 94nM,agonist,95.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,6,nM,,,,,=,7.026872146,pKi,B,radiometric,Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,95,453.267,476.1559065,1,6,8,3,4.86162,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9940,5450,16973358,31,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(cc4)C(F)(F)F,CHEMBL221641,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 21nM,agonist,143.00%,agonist,GW2331,,GW2331,,,,,EC50,=,11,nM,,,,,=,7.677780705,pKi,B,radiometric,Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,143,453.267,476.1559065,1,6,8,3,4.86162,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9941,5451,16737814,28,P37231,PPARG,Homo sapiens,2-isopropoxy-3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CC(C)OC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL210017,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 139nM,agonist,82.00%,agonist,Edaglitazone,,,,,,,EC50,=,160,nM,,,,,=,6.8569852,pIC50,,radiometric,Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1Cn1ccc2cc(CC(OC(C)C)C(=O)O)ccc21,82,461.29,486.1766419,1,5,8,4,6.09252,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
9943,5451,16737814,28,Q07869,PPARA,Homo sapiens,2-isopropoxy-3-(1-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1H-indol-5-yl)propanoic acid,CC(C)OC(Cc1ccc2c(ccn2Cc3nc(oc3C)c4ccc(cc4)C(F)(F)F)c1)C(=O)O,CHEMBL210017,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 61nM,agonist,134.00%,agonist,Farglitazar,,,,,,,EC50,=,20,nM,,,,,=,7.214670165,pIC50,B,radiometric,Cc1oc(-c2ccc(C(F)(F)F)cc2)nc1Cn1ccc2cc(CC(OC(C)C)C(=O)O)ccc21,134,461.29,486.1766419,1,5,8,4,6.09252,77.49,C1CCC(C2CCC(CC3CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,157
9944,5452,16973358,29,P37231,PPARG,Homo sapiens,2-((6-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(Cl)cc4,CHEMBL221474,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 52nM,agonist,89.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,42,nM,,,,,=,7.283996656,pKi,B,radiometric,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,89,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9945,5452,16973358,29,Q07869,PPARA,Homo sapiens,2-((6-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccc(Cl)cc4,CHEMBL221474,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 14nM,agonist,87.00%,agonist,GW2331,,GW2331,,,,,EC50,=,10,nM,,,,,=,7.853871964,pKi,B,radiometric,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,87,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9946,5453,16979341,17,P37231,PPARG,Homo sapiens,2-((5-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)nc2)c4ccc(Cl)cc4,CHEMBL375370,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 300nM,agonist,81.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,130,nM,,,,,=,6.522878745,pKi,,radiometric,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)nc1,81,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9947,5453,16979341,17,Q07869,PPARA,Homo sapiens,2-((5-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)nc2)c4ccc(Cl)cc4,CHEMBL375370,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 150nM,agonist,122.00%,agonist,GW2331,,GW2331,,,,,EC50,=,48,nM,,,,,=,6.823908741,pIC50,,radiometric,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)nc1,122,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9960,546,17267219,6k,P10275,AR,Homo sapiens,"6-((3,3-dimethylbutyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CC(C)(C)CCN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237473,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 243nM,partial agonist,69.00%,agonist,DHT,,,,,,,EC50,=,81,nM,IC50,>,10000,nM,=,6.614393726,pIC50,,radiometric,CC(C)(C)CCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,69,374.199,394.1479826,1,2,4,2,5.3518,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
9961,5460,17005394,34,P37231,PPARG,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(Oc4ccccc4)cc3)ccc1CCC(=O)O,CHEMBL373685,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,80.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,2,nM,,,,,=,7.301029996,pIC50,B,radiometric,Cc1oc(-c2ccc(Oc3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,80,524.359,558.2366014,2,7,13,4,6.71562,120.12,C1CCC(CCCC2CCC(C3CCC(CC4CCCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,389
9962,5460,17005394,34,Q07869,PPARA,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccc(Oc4ccccc4)cc3)ccc1CCC(=O)O,CHEMBL373685,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 516nM,partial agonist,46.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,78,nM,,,,,=,6.287350298,pIC50,,radiometric,Cc1oc(-c2ccc(Oc3ccccc3)cc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,46,524.359,558.2366014,2,7,13,4,6.71562,120.12,C1CCC(CCCC2CCC(C3CCC(CC4CCCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,389
9969,5463,16973358,32,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4cccc(c4)C(F)(F)F,CHEMBL221525,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 100nM,agonist,81.00%,agonist,GW2331,,GW2331,,,,,EC50,=,8,nM,,,,,=,7,pKi,,radiometric,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,81,453.267,476.1559065,1,6,8,3,4.86162,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9970,5464,16876993,22,P55055,LXRB,Homo sapiens,"1,1,1,3,3,3-hexafluoro-2-(4-(((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)(2,2,2-trifluoroethyl)amino)phenyl)propan-2-ol",Cc1oc(nc1CN(CC(F)(F)F)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3cccc(c3)C(F)(F)F,CHEMBL215042,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,agonist,83.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,7.698970004,pIC50,B,radiometric,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,83,564.241,580.1020164,1,4,6,3,7.54992,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
9971,5464,16876993,22,Q13133,LXRA,Homo sapiens,"1,1,1,3,3,3-hexafluoro-2-(4-(((5-methyl-2-(3-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)(2,2,2-trifluoroethyl)amino)phenyl)propan-2-ol",Cc1oc(nc1CN(CC(F)(F)F)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3cccc(c3)C(F)(F)F,CHEMBL215042,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,130.00%,agonist,T0901317,,,,,,,EC50,=,700,nM,,,,,=,7.886056648,pIC50,B,radiometric,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,130,564.241,580.1020164,1,4,6,3,7.54992,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
9972,5465,16973358,30,P37231,PPARG,Homo sapiens,2-((6-(2-(2-(3-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4cccc(Cl)c4,CHEMBL425639,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 11nM,agonist,103.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,4,nM,,,,,=,7.958607315,pKi,B,radiometric,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,103,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9973,5465,16973358,30,Q07869,PPARA,Homo sapiens,2-((6-(2-(2-(3-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4cccc(Cl)c4,CHEMBL425639,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 99nM,agonist,117.00%,agonist,GW2331,,GW2331,,,,,EC50,=,46,nM,,,,,=,7.004364805,pKi,B,radiometric,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,117,419.715,442.1295495,1,6,8,3,4.49622,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
9976,5467,16876993,19,P55055,LXRB,Homo sapiens,"2-(4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(2,2,2-trifluoroethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",Cc1oc(nc1CN(CC(F)(F)F)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3cccc(Cl)c3,CHEMBL386603,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 50nM,agonist,89.00%,agonist,T0901317,,,,,,,EC50,=,30,nM,,,,,=,7.301029996,pIC50,B,radiometric,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,89,530.689,546.0756594,1,4,6,3,7.18452,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
9977,5467,16876993,19,Q13133,LXRA,Homo sapiens,"2-(4-(((2-(3-chlorophenyl)-5-methyloxazol-4-yl)methyl)(2,2,2-trifluoroethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",Cc1oc(nc1CN(CC(F)(F)F)c2ccc(cc2)C(O)(C(F)(F)F)C(F)(F)F)c3cccc(Cl)c3,CHEMBL386603,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,117.00%,agonist,T0901317,,,,,,,EC50,=,1000,nM,,,,,=,7.522878745,pIC50,B,radiometric,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,117,530.689,546.0756594,1,4,6,3,7.18452,49.5,C1CCC(CCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,321
9978,5468,18394907,40,P37231,PPARG,Homo sapiens,(S)-3-{4-[(E)-3-(5-Methyl-2-phenyl-oxazol-4-yl)-propenyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1C\C=C\c2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL479002,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 255nM,agonist,87.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,102,nM,,,,,=,6.59345982,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1C/C=C/c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,87,388.297,412.1786926,1,4,8,4,5.57582,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
9979,5468,18394907,40,Q07869,PPARA,Homo sapiens,(S)-3-{4-[(E)-3-(5-Methyl-2-phenyl-oxazol-4-yl)-propenyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1C\C=C\c2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL479002,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 912nM,partial agonist,44.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,623,nM,,,,,=,6.040005162,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1C/C=C/c1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,44,388.297,412.1786926,1,4,8,4,5.57582,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
9980,5469,18394907,41,P37231,PPARG,Homo sapiens,(R)-3-{4-[(E)-3-(5-Methyl-2-phenyl-oxazol-4-yl)-propenyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1C\C=C\c2ccc(C[C@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL477094,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 2600nM,agonist,100.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,2600,nM,,,,,=,5.585026652,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1C/C=C/c1ccc(C[C@H](C(=O)O)n2cccc2)cc1,100,388.297,412.1786926,1,4,8,4,5.57582,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
9981,547,17267219,6j,P10275,AR,Homo sapiens,"6-(neopentyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CC(C)(C)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237472,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,agonist,81.00%,agonist,DHT,,,,,,,EC50,=,1.8,nM,IC50,>,10000,nM,=,7.920818754,pIC50,B,radiometric,CC(C)(C)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,81,362.188,380.1323325,1,2,3,2,4.9617,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
9982,5470,18394907,30,P37231,PPARG,Homo sapiens,2-Biphenyl-4-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]-phenyl}-propionic acid,Cc1oc(nc1CC#Cc2ccc(CC(C(=O)O)c3ccc(cc3)c4ccccc4)cc2)c5ccccc5,CHEMBL476896,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 2200nM,partial agonist,44.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,2500,nM,,,,,=,5.657577319,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CC#Cc1ccc(CC(C(=O)O)c2ccc(-c3ccccc3)cc2)cc1,44,470.378,497.1990937,1,3,7,5,7.32212,63.33,C1CCC(C2CCC(CCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,171
9983,5471,18394907,31,P37231,PPARG,Homo sapiens,2-Biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]-phenyl}-propionic acid,Cc1oc(nc1CC#Cc2ccc(CC(C(=O)O)c3cccc(c3)c4ccccc4)cc2)c5ccccc5,CHEMBL476897,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 2800nM,partial agonist,51.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,13000,nM,,,,,=,5.552841969,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CC#Cc1ccc(CC(C(=O)O)c2cccc(-c3ccccc3)c2)cc1,51,470.378,497.1990937,1,3,7,5,7.32212,63.33,C1CCC(C2CCCC(CCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,197
9984,5472,18394907,29,P37231,PPARG,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]-phenyl}-2-pyridin-3-yl-propionic acid,Cc1oc(nc1CC#Cc2ccc(CC(C(=O)O)c3cccnc3)cc2)c4ccccc4,CHEMBL478726,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 26000nM,partial agonist,34.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,4500,nM,,,,,=,4.585026652,pIC50,NB,radiometric,Cc1oc(-c2ccccc2)nc1CC#Cc1ccc(CC(C(=O)O)c2cccnc2)cc1,34,400.308,422.1630426,1,4,6,4,5.05012,76.22,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,350
9986,5473,18394907,28,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CC#Cc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL478725,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 293nM,agonist,116.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,173,nM,,,,,=,6.53313238,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CC#Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,116,388.297,410.1630426,1,4,6,4,4.91412,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
9987,5473,18394907,28,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-prop-1-ynyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CC#Cc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL478725,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 330nM,partial agonist,50.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,1000,nM,,,,,=,6.48148606,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CC#Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,50,388.297,410.1630426,1,4,6,4,4.91412,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
9990,5475,18394907,56,P37231,PPARG,Homo sapiens,2-Biphenyl-4-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3ccc(cc3)c4ccccc4)cc2)c5ccccc5,CHEMBL478335,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 587nM,partial agonist,54.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,1800,nM,,,,,=,6.231361899,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2ccc(-c3ccccc3)cc2)cc1,54,470.378,501.2303939,1,3,10,5,7.90322,63.33,C1CCC(C2CCC(CCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,171
9991,5476,18394907,57,P37231,PPARG,Homo sapiens,2-Biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3cccc(c3)c4ccccc4)cc2)c5ccccc5,CHEMBL477298,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 2800nM,partial agonist,39.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,4000,nM,,,,,=,5.552841969,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2cccc(-c3ccccc3)c2)cc1,39,470.378,501.2303939,1,3,10,5,7.90322,63.33,C1CCC(C2CCCC(CCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,197
9992,5476,18394907,57,Q07869,PPARA,Homo sapiens,2-Biphenyl-3-yl-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3cccc(c3)c4ccccc4)cc2)c5ccccc5,CHEMBL477298,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 > 3300nM,partial agonist,74.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,5000,nM,,,,,>,5.48148606,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2cccc(-c3ccccc3)c2)cc1,74,470.378,501.2303939,1,3,10,5,7.90322,63.33,C1CCC(C2CCCC(CCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,197
9993,5477,18394907,58,P37231,PPARG,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-phenyl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3ccccc3)cc2)c4ccccc4,CHEMBL477318,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 4000nM,partial agonist,57.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,3900,nM,,,,,=,5.397940009,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2ccccc2)cc1,57,398.312,425.1990937,1,3,9,4,6.23622,63.33,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,350
9994,5477,18394907,58,Q07869,PPARA,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-phenyl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3ccccc3)cc2)c4ccccc4,CHEMBL477318,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 1900nM,partial agonist,28.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,2300,nM,,,,,=,5.721246399,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2ccccc2)cc1,28,398.312,425.1990937,1,3,9,4,6.23622,63.33,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,350
9995,5478,18394907,55,P37231,PPARG,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyridin-3-yl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3cccnc3)cc2)c4ccccc4,CHEMBL515181,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 22000nM,partial agonist,63.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,3900,nM,,,,,=,4.657577319,pIC50,NB,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2cccnc2)cc1,63,400.308,426.1943427,1,4,9,4,5.63122,76.22,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,350
9996,5479,19783444,17a,P37231,PPARG,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyridin-3-yl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3ccsc3)cc2)c4ccccc4,CHEMBL593087,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1600nM,agonist,82.00%,agonist,darglitazone,,,,,,,EC50,=,399,nM,,,,,=,5.795880017,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2ccsc2)cc1,82,406.357,431.1555147,1,4,9,4,6.29772,63.33,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
9997,5479,19783444,17a,Q07869,PPARA,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyridin-3-yl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)c3ccsc3)cc2)c4ccccc4,CHEMBL593087,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 676nM,partial agonist,59.00%,agonist,GW9578,,,,,,,EC50,=,685,nM,,,,,=,6.170053304,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)c2ccsc2)cc1,59,406.357,431.1555147,1,4,9,4,6.29772,63.33,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
9999,5480,19783444,17d,P37231,PPARG,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrazol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)n3cccn3)cc2)c4ccccc4,CHEMBL605088,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 320nM,agonist,80.00%,agonist,darglitazone,,,,,,,EC50,=,228,nM,,,,,=,6.494850022,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)n2cccn2)cc1,80,390.293,415.1895917,1,5,9,4,4.89022,81.15,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10000,5480,19783444,17d,Q07869,PPARA,Homo sapiens,3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrazol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(CC(C(=O)O)n3cccn3)cc2)c4ccccc4,CHEMBL605088,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 877nM,partial agonist,70.00%,agonist,GW9578,,,,,,,EC50,=,2600,nM,,,,,=,6.057000407,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)n2cccn2)cc1,70,390.293,415.1895917,1,5,9,4,4.89022,81.15,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10001,5481,19783444,17i,P37231,PPARG,Homo sapiens,"3-(4-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)phenyl)-2-(2H-1,2,3-triazol-2-yl)propanoic acid",Cc1oc(nc1CCCc2ccc(CC(C(=O)O)n3nccn3)cc2)c4ccccc4,CHEMBL593796,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 5nM,agonist,88.00%,agonist,darglitazone,,,,,,,EC50,=,15,nM,,,,,=,8.301029996,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)n2nccn2)cc1,88,392.289,416.1848406,1,6,9,4,4.28522,94.04,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10002,5481,19783444,17i,Q07869,PPARA,Homo sapiens,"3-(4-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)phenyl)-2-(2H-1,2,3-triazol-2-yl)propanoic acid",Cc1oc(nc1CCCc2ccc(CC(C(=O)O)n3nccn3)cc2)c4ccccc4,CHEMBL593796,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,partial agonist,64.00%,agonist,GW9578,,,,,,,EC50,=,182,nM,,,,,=,7.619788758,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(CC(C(=O)O)n2nccn2)cc1,64,392.289,416.1848406,1,6,9,4,4.28522,94.04,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10003,5482,18394907,53,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL477095,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 185nM,agonist,94.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,140,nM,,,,,=,6.732828272,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,94,388.297,414.1943427,1,4,9,4,5.49522,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10004,5482,18394907,53,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL477095,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 529nM,partial agonist,52.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,1600,nM,,,,,=,6.276544328,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,52,388.297,414.1943427,1,4,9,4,5.49522,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10005,5483,19783444,17e,P37231,PPARG,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrazol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3cccn3)cc2)c4ccccc4,CHEMBL593801,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 145nM,agonist,91.00%,agonist,darglitazone,,,,,,,EC50,=,65,nM,,,,,=,6.838631998,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2cccn2)cc1,91,390.293,415.1895917,1,5,9,4,4.89022,81.15,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10006,5483,19783444,17e,Q07869,PPARA,Homo sapiens,(S)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrazol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3cccn3)cc2)c4ccccc4,CHEMBL593801,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 899nM,partial agonist,65.00%,agonist,GW9578,,,,,,,EC50,=,874,nM,,,,,=,6.046240308,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2cccn2)cc1,65,390.293,415.1895917,1,5,9,4,4.89022,81.15,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10007,5484,19783444,17j,P37231,PPARG,Homo sapiens,"(S)-3-(4-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)phenyl)-2-(2H-1,2,3-triazol-2-yl)propanoic acid",Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3nccn3)cc2)c4ccccc4,CHEMBL594034,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3nM,agonist,103.00%,agonist,darglitazone,,,,,,,EC50,=,13,nM,,,,,=,8.522878745,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2nccn2)cc1,103,392.289,416.1848406,1,6,9,4,4.28522,94.04,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10008,5484,19783444,17j,Q07869,PPARA,Homo sapiens,"(S)-3-(4-(3-(5-methyl-2-phenyloxazol-4-yl)propyl)phenyl)-2-(2H-1,2,3-triazol-2-yl)propanoic acid",Cc1oc(nc1CCCc2ccc(C[C@@H](C(=O)O)n3nccn3)cc2)c4ccccc4,CHEMBL594034,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 34nM,agonist,90.00%,agonist,GW9578,,,,,,,EC50,=,61,nM,,,,,=,7.468521083,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@@H](C(=O)O)n2nccn2)cc1,90,392.289,416.1848406,1,6,9,4,4.28522,94.04,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10009,5485,18394907,54,P37231,PPARG,Homo sapiens,(R)-3-{4-[3-(5-Methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCCc2ccc(C[C@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL478334,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 3100nM,partial agonist,64.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,2300,nM,,,,,=,5.508638306,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCCc1ccc(C[C@H](C(=O)O)n2cccc2)cc1,64,388.297,414.1943427,1,4,9,4,5.49522,68.26,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10015,549,17257838,13g,P10275,AR,Homo sapiens,"6-(neopentylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)(C)CNc1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL3706911,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 56nM,partial antagonist,72.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,27,nM,=,7.251811973,pIC50,B,radiometric,CC(C)(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,72,281.172,298.1292978,2,2,2,2,4.0049,44.89,CC1CCC2CCCCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,651
10016,5490,18394907,66,P37231,PPARG,Homo sapiens,(S)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethylamino]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCNc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL477323,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 1600nM,agonist,103.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,480,nM,,,,,=,5.795880017,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCNc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,103,390.293,415.1895917,2,5,9,4,4.97452,80.29,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10020,5492,19201606,4e,Q07869,PPARA,Homo sapiens,"2-(5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2ccc(cc2)c3nn(nc3CC(=O)O)c4ccccc4)c5ccccc5,CHEMBL489507,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3350nM,partial agonist,29.00%,agonist,muraglitazar,,-,-,,,,EC50,=,4140,nM,,,,,=,5.474955193,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(-c2nn(-c3ccccc3)nc2CC(=O)O)cc1,29,456.332,480.1797552,1,7,9,5,5.14632,103.27,C1CCC(C2CCC(CCCC3CCC(C4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,175
10025,5495,16973358,8,P37231,PPARG,Homo sapiens,3-methyl-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CC(C)C(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL374323,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 8800nM,agonist,87.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,1280,nM,,,,,=,5.055517328,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C(=O)O)C(C)C)cn1,87,368.263,394.1892573,1,5,9,3,4.56582,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10026,5495,16973358,8,Q07869,PPARA,Homo sapiens,3-methyl-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)butanoic acid,CC(C)C(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL374323,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4100nM,agonist,93.00%,agonist,GW2331,,GW2331,,,,,EC50,=,426,nM,,,,,=,5.387216143,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C(=O)O)C(C)C)cn1,93,368.263,394.1892573,1,5,9,3,4.56582,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10027,5496,16973358,11,P37231,PPARG,Homo sapiens,"2,2-dimethyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid",Cc1oc(nc1CCOc2ccc(CC(C)(C)C(=O)O)cn2)c3ccccc3,CHEMBL387133,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 5100nM,partial agonist,72.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,984,nM,,,,,=,5.292429824,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C)(C)C(=O)O)cn1,72,356.252,380.1736072,1,5,8,3,4.31982,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10028,5496,16973358,11,Q07869,PPARA,Homo sapiens,"2,2-dimethyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid",Cc1oc(nc1CCOc2ccc(CC(C)(C)C(=O)O)cn2)c3ccccc3,CHEMBL387133,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 6800nM,agonist,112.00%,agonist,GW2331,,GW2331,,,,,EC50,=,534,nM,,,,,=,5.167491087,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C)(C)C(=O)O)cn1,112,356.252,380.1736072,1,5,8,3,4.31982,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10034,5499,16973358,5,P37231,PPARG,Homo sapiens,2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL218117,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 2100nM,agonist,113.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,268,nM,,,,,=,5.677780705,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C)C(=O)O)cn1,113,344.241,366.1579572,1,5,8,3,3.92972,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10035,5499,16973358,5,Q07869,PPARA,Homo sapiens,2-methyl-3-(6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)propanoic acid,CC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL218117,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3000nM,agonist,93.00%,agonist,GW2331,,GW2331,,,,,EC50,=,287,nM,,,,,=,5.522878745,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(C)C(=O)O)cn1,93,344.241,366.1579572,1,5,8,3,3.92972,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10039,55,14592510,34c,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[2-(2,2-Difluoro-ethoxy)-3-isopropyl-5-thiophen-2-yl-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c1OCC(F)F)c2cccs2,CHEMBL130374,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 0.8nM,antagonist,91.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,1.9,nM,=,9.096910013,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(-c2cccs2)cc(C(C)C)c1OCC(F)F,91,406.324,432.1570721,1,3,9,2,7.1728,46.53,C1CCC(C2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,129
10042,550,17257838,9f,P10275,AR,Homo sapiens,"7-(neopentylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)(C)CNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706882,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 134nM,antagonist,88.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,98,nM,=,6.872895202,pIC50,,radiometric,CC(C)(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,88,281.172,298.1292978,2,2,2,2,4.0049,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
10043,5500,16973358,9,P37231,PPARG,Homo sapiens,4-methyl-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)pentanoic acid,CC(C)CC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL222107,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 360nM,agonist,104.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,1650,nM,,,,,=,6.443697499,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(CC(C)C)C(=O)O)cn1,104,380.274,408.2049074,1,5,10,3,4.95592,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10044,5500,16973358,9,Q07869,PPARA,Homo sapiens,4-methyl-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)pentanoic acid,CC(C)CC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)nc1)C(=O)O,CHEMBL222107,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 430nM,agonist,98.00%,agonist,GW2331,,GW2331,,,,,EC50,=,1720,nM,,,,,=,6.366531544,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(CC(C)C)C(=O)O)cn1,98,380.274,408.2049074,1,5,10,3,4.95592,85.45,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,388
10068,5513,19349176,rac-2Da,P37231,PPARG,Homo sapiens,2-isobutoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CC(C)COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL483341,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,63.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,4,nM,,,,,=,8.522878745,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(OCC(C)C)C(=O)O)c2sccc12,63,450.366,479.176644,1,6,11,4,6.15452,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,partial agonist,agonist,partial agonist,173
10069,5513,19349176,rac-2Da,Q07869,PPARA,Homo sapiens,2-isobutoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,CC(C)COC(Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O,CHEMBL483341,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 239nM,agonist,181.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,48,nM,,,,,=,6.621602099,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC(OCC(C)C)C(=O)O)c2sccc12,181,450.366,479.176644,1,6,11,4,6.15452,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
10073,5515,16973358,16,P37231,PPARG,Homo sapiens,1-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)cyclopropanecarboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CC3)C(=O)O)cn2)c4ccccc4,CHEMBL219005,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 7980nM,agonist,80.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,1010,nM,,,,,=,5.097997109,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CC2)cn1,80,356.252,378.1579572,1,5,8,3,4.07382,85.45,C1CCC(C2CCC(CCCC3CCC(CC4CC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,178
10074,5516,16973358,17,P37231,PPARG,Homo sapiens,1-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)cyclobutanecarboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCC3)C(=O)O)cn2)c4ccccc4,CHEMBL220708,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 394nM,agonist,93.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,125,nM,,,,,=,6.404503778,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCC2)cn1,93,368.263,392.1736072,1,5,8,3,4.46392,85.45,C1CCC(C2CCC(CCCC3CCC(CC4CCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,179
10075,5516,16973358,17,Q07869,PPARA,Homo sapiens,1-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)cyclobutanecarboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCC3)C(=O)O)cn2)c4ccccc4,CHEMBL220708,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 633nM,agonist,94.00%,agonist,GW2331,,GW2331,,,,,EC50,=,238,nM,,,,,=,6.19859629,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCC2)cn1,94,368.263,392.1736072,1,5,8,3,4.46392,85.45,C1CCC(C2CCC(CCCC3CCC(CC4CCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,179
10078,5518,16973358,21,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydro-2H-pyran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL220533,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 81nM,agonist,103.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,209,nM,,,,,=,7.091514981,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCCO2)cn1,103,396.273,422.1841719,1,6,8,3,4.23292,94.68,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,291
10079,5518,16973358,21,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydro-2H-pyran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL220533,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 78nM,agonist,96.00%,agonist,GW2331,,GW2331,,,,,EC50,=,228,nM,,,,,=,7.107905397,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCCO2)cn1,96,396.273,422.1841719,1,6,8,3,4.23292,94.68,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,291
10082,552,17439112,10e,P10275,AR,Homo sapiens,"1-(2,2-dimethylpropyl)-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC(C)(C)N1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL375907,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 48nM,partial agonist,62.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,62,nM,IC50,>,10000,nM,=,7.318758763,pKi,B,radiometric,CC(C)(C)N1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,62,309.182,326.1242124,1,3,0,2,3.5442,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
10083,5520,16973358,19,P37231,PPARG,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL386957,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 38nM,agonist,89.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,12,nM,,,,,=,7.420216403,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,89,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10084,5520,16973358,19,Q07869,PPARA,Homo sapiens,2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL386957,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 78nM,agonist,106.00%,agonist,GW2331,,GW2331,,,,,EC50,=,48,nM,,,,,=,7.107905397,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)cn1,106,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10085,5521,16979341,13,P37231,PPARG,Homo sapiens,2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)nc2)c4ccccc4,CHEMBL220655,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 210nM,agonist,88.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,41,nM,,,,,=,6.677780705,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)nc1,88,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10086,5521,16979341,13,Q07869,PPARA,Homo sapiens,2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(CC3(CCCO3)C(=O)O)nc2)c4ccccc4,CHEMBL220655,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1600nM,agonist,90.00%,agonist,GW2331,,GW2331,,,,,EC50,=,226,nM,,,,,=,5.795880017,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2(C(=O)O)CCCO2)nc1,90,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10088,5523,18511276,17a,P37231,PPARG,Homo sapiens,"3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257180,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3036nM,partial agonist,52.00%,agonist,ref agonist,,,,,,,EC50,=,1120,nM,,,,,=,5.517698233,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)cc1,52,484.338,518.2416868,1,6,10,3,5.69352,102.1,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,291
10089,5523,18511276,17a,Q07869,PPARA,Homo sapiens,"3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257180,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1170nM,agonist,104.00%,agonist,ref agonist,,,,,,,EC50,=,28,nM,,,,,=,5.931814138,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)cc1,104,484.338,518.2416868,1,6,10,3,5.69352,102.1,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,291
10090,5524,18511276,25a,P37231,PPARG,Homo sapiens,rac-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257165,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1250nM,agonist,82.00%,agonist,ref agonist,,,,,,,EC50,=,257,nM,,,,,=,5.903089987,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2CN(C(=O)OCC(C)C)CCC2C(=O)O)cc1,82,484.338,520.2573369,1,6,10,3,5.62932,102.1,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,291
10091,5524,18511276,25a,Q07869,PPARA,Homo sapiens,rac-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257165,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 215nM,agonist,115.00%,agonist,ref agonist,,,,,,,EC50,=,5,nM,,,,,=,6.66756154,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2CN(C(=O)OCC(C)C)CCC2C(=O)O)cc1,115,484.338,520.2573369,1,6,10,3,5.62932,102.1,C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,291
10092,5525,9836620,AD-7057,P37231,PPARG,Homo sapiens,"5-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione",Cc1oc(nc1CCOc2ccc(CC3SC(=O)NC3=O)cc2)c4ccccc4,CHEMBL59132,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 7.57,agonist,no detail about the percentage act,,,,BRL49653,,,,,PEC50,=,7.95,,,,,,=,7.57,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2SC(=O)NC2=O)cc1,,388.319,408.1143781,1,6,7,3,4.16562,81.43,CC1CC(C)C(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,,agonist,partial agonist,795
10093,5525,11405642,10a,P37231,PPARG,Homo sapiens,"5-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione",Cc1oc(nc1CCOc2ccc(CC3SC(=O)NC3=O)cc2)c4ccccc4,CHEMBL59132,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,partial agonist,61.00%,agonist,reference compound (?),,,,,,,EC50,=,8,nM,,,,,=,7.853871964,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2SC(=O)NC2=O)cc1,61,388.319,408.1143781,1,6,7,3,4.16562,81.43,CC1CC(C)C(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,795
10094,5525,11405642,10a,Q07869,PPARA,Homo sapiens,"5-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione",Cc1oc(nc1CCOc2ccc(CC3SC(=O)NC3=O)cc2)c4ccccc4,CHEMBL59132,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4086nM,partial agonist,30.00%,agonist,reference compound (?),,,,,,,EC50,=,2751,nM,,,,,=,5.388701638,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC2SC(=O)NC2=O)cc1,30,388.319,408.1143781,1,6,7,3,4.16562,81.43,CC1CC(C)C(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,795
10095,5526,17005394,17,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((3-phenylpropanamido)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)CCc3ccccc3)c2)c4ccccc4,CHEMBL223349,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 161nM,partial agonist,52.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,1019,nM,,,,,=,6.793174124,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)CCc2ccccc2)c1,52,480.35,512.2311221,2,5,13,4,5.53772,101.66,CC(CCC1CCCCC1)CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1,agonist,partial agonist,agonist,partial agonist,1153
10096,5526,17005394,17,Q07869,PPARA,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((3-phenylpropanamido)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)CCc3ccccc3)c2)c4ccccc4,CHEMBL223349,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4962nM,partial agonist,32.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,2801,nM,,,,,=,5.30434324,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)CCc2ccccc2)c1,32,480.35,512.2311221,2,5,13,4,5.53772,101.66,CC(CCC1CCCCC1)CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1,agonist,partial agonist,agonist,partial agonist,1153
10099,5528,17005394,19,P37231,PPARG,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccccc3)ccc1CCC(=O)O,CHEMBL219824,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,partial agonist,72.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,8,nM,,,,,=,7.585026652,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,72,436.294,466.2103867,2,6,11,3,4.92332,110.89,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10100,5528,17005394,19,Q07869,PPARA,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(oc2C)c3ccccc3)ccc1CCC(=O)O,CHEMBL219824,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 146nM,partial agonist,51.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,70,nM,,,,,=,6.835647144,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,51,436.294,466.2103867,2,6,11,3,4.92332,110.89,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10101,5529,17005394,15,P37231,PPARG,Homo sapiens,3-(2-((benzyloxycarbonyl)methyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)OCc3ccccc3)c2)c4ccccc4,CHEMBL441554,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 91nM,partial agonist,65.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,115,nM,,,,,=,7.040958608,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OCc2ccccc2)c1,65,484.338,514.2103867,2,6,12,4,5.71512,110.89,CC(CCC1CCCCC1)CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1,agonist,partial agonist,agonist,partial agonist,1153
10102,5529,17005394,15,Q07869,PPARA,Homo sapiens,3-(2-((benzyloxycarbonyl)methyl)-4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)OCc3ccccc3)c2)c4ccccc4,CHEMBL441554,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 441nM,partial agonist,54.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,515,nM,,,,,=,6.355561411,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OCc2ccccc2)c1,54,484.338,514.2103867,2,6,12,4,5.71512,110.89,CC(CCC1CCCCC1)CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1,agonist,partial agonist,agonist,partial agonist,1153
10104,5530,17005394,36,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-(((pyrazin-2-yloxy)carbonyl)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)Oc3cnccn3)c2)c4ccccc4,CHEMBL223350,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 17nM,partial agonist,70.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,7,nM,,,,,=,7.769551079,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)Oc2cnccn2)c1,70,476.319,502.1852346,2,8,11,4,4.36732,136.67,CC(CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1)CC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1185
10105,5530,17005394,36,Q07869,PPARA,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-(((pyrazin-2-yloxy)carbonyl)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNC(=O)Oc3cnccn3)c2)c4ccccc4,CHEMBL223350,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 53nM,partial agonist,60.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,35,nM,,,,,=,7.27572413,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)Oc2cnccn2)c1,60,476.319,502.1852346,2,8,11,4,4.36732,136.67,CC(CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1)CC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1185
10106,5531,17005394,18,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((phenylmethylsulfonamido)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNS(=O)(=O)Cc3ccccc3)c2)c4ccccc4,CHEMBL219773,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 72nM,partial agonist,56.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,527,nM,,,,,=,7.142667504,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNS(=O)(=O)Cc2ccccc2)c1,56,504.394,534.1824577,2,6,13,4,4.90832,118.73,CC(C)(CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1)CC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1227
10107,5531,17005394,18,Q07869,PPARA,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-((phenylmethylsulfonamido)methyl)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(CCC(=O)O)c(CNS(=O)(=O)Cc3ccccc3)c2)c4ccccc4,CHEMBL219773,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3390nM,partial agonist,33.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,2940,nM,,,,,=,5.469800302,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c(CNS(=O)(=O)Cc2ccccc2)c1,33,504.394,534.1824577,2,6,13,4,4.90832,118.73,CC(C)(CCC1CCCC(CCCC2CCC(C3CCCCC3)C2)C1)CC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1227
10108,5532,17005393,16,P37231,PPARG,Homo sapiens,"3-(2-(isobutoxycarbonyl)-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",CC(C)COC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccccc4)ccc(CCC(=O)O)c2C1,CHEMBL446365,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 17nM,partial agonist,66.00%,agonist,ref agonist,,,,,,,EC50,=,8,nM,,,,,=,7.769551079,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c2c1CCN(C(=O)OCC(C)C)C2,66,472.327,506.2416868,1,6,10,3,5.43942,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
10109,5532,17005393,16,Q07869,PPARA,Homo sapiens,"3-(2-(isobutoxycarbonyl)-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-1,2,3,4-tetrahydroisoquinolin-8-yl)propanoic acid",CC(C)COC(=O)N1CCc2c(OCCc3nc(oc3C)c4ccccc4)ccc(CCC(=O)O)c2C1,CHEMBL446365,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3415nM,partial agonist,40.00%,agonist,ref agonist,,,,,,,EC50,=,1715,nM,,,,,=,5.466609292,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC(=O)O)c2c1CCN(C(=O)OCC(C)C)C2,40,472.327,506.2416868,1,6,10,3,5.43942,102.1,C1CCC(C2CCC(CCCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,176
10110,5533,18511276,14a,P37231,PPARG,Homo sapiens,"3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257345,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,agonist,95.00%,agonist,ref agonist,,,,,,,EC50,=,74,nM,,,,,=,6.958607315,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)cc1,95,496.349,532.2573369,1,6,11,3,6.08362,102.1,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,350
10111,5533,18511276,14a,Q07869,PPARA,Homo sapiens,"3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257345,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 255nM,agonist,95.00%,agonist,ref agonist,,,,,,,EC50,=,56,nM,,,,,=,6.59345982,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)cc1,95,496.349,532.2573369,1,6,11,3,6.08362,102.1,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,350
10112,5534,18511276,22a,P37231,PPARG,Homo sapiens,rac-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257164,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 450nM,agonist,79.00%,agonist,ref agonist,,,,,,,EC50,=,263,nM,,,,,=,6.346787486,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC2CN(C(=O)OCC(C)C)CCC2C(=O)O)cc1,79,496.349,534.2729869,1,6,11,3,6.01942,102.1,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,350
10113,5534,18511276,22a,Q07869,PPARA,Homo sapiens,rac-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(CCc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)C1)C(=O)O,CHEMBL257164,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 711nM,agonist,101.00%,agonist,ref agonist,,,,,,,EC50,=,44,nM,,,,,=,6.148130399,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CCC2CN(C(=O)OCC(C)C)CCC2C(=O)O)cc1,101,496.349,534.2729869,1,6,11,3,6.01942,102.1,C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,350
10114,5535,25686852,5e,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(CC[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398459,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 90nM,partial agonist,62.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,160,nM,,,,,=,7.045757491,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,62,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,1036
10115,5535,25686852,5e,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(CC[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398459,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 480nM,agonist,77.00%,agonist,GW2331,1000nM,,,,,,EC50,=,10,nM,,,,,=,6.318758763,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,77,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1036
10117,5536,25686852,5g,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4R)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(CC[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398461,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3250nM,agonist,89.00%,agonist,GW2331,1000nM,,,,,,EC50,=,980,nM,,,,,=,5.488116639,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CC[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,89,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1036
10118,5537,17292606,2l,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)((5-(2-chlorophenyl)furan-2-yl)methyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3oc(cc3)c4ccccc4Cl)cc2)c5ccccc5,CHEMBL397120,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 280nM,agonist,77.00%,agonist,Rosiglitazone,,,,,,,EC50,=,267,nM,,,,,=,6.552841969,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(-c3ccccc3Cl)o2)cc1,77,527.814,556.1764997,1,6,12,5,7.27172,88.94,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,196
10119,5537,17292606,2l,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)((5-(2-chlorophenyl)furan-2-yl)methyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3oc(cc3)c4ccccc4Cl)cc2)c5ccccc5,CHEMBL397120,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1800nM,partial agonist,55.00%,agonist,GW2331,,,,,,,EC50,=,871,nM,,,,,=,5.744727495,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(-c3ccccc3Cl)o2)cc1,55,527.814,556.1764997,1,6,12,5,7.27172,88.94,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,196
10120,5538,17292606,2h,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-(benzyloxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc(OCc4ccccc4)cc3)cc2)c5ccccc5,CHEMBL394948,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 284nM,agonist,82.00%,agonist,Rosiglitazone,,,,,,,EC50,=,221,nM,,,,,=,6.54668166,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(OCc3ccccc3)cc2)cc1,82,528.394,562.2467722,1,6,14,5,6.93732,85.03,C1CCC(CCC2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,agonist,agonist,agonist,352
10121,5538,17292606,2h,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-(benzyloxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc(OCc4ccccc4)cc3)cc2)c5ccccc5,CHEMBL394948,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1050nM,agonist,106.00%,agonist,GW2331,,,,,,,EC50,=,189,nM,,,,,=,5.978810701,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(OCc3ccccc3)cc2)cc1,106,528.394,562.2467722,1,6,14,5,6.93732,85.03,C1CCC(CCC2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,agonist,agonist,agonist,352
10122,5539,17292606,2g,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc(Oc4ccccc4)cc3)cc2)c5ccccc5,CHEMBL247925,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 227nM,partial agonist,70.00%,agonist,Rosiglitazone,,,,,,,EC50,=,52,nM,,,,,=,6.643974143,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(Oc3ccccc3)cc2)cc1,70,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,293
10123,5539,17292606,2g,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc(Oc4ccccc4)cc3)cc2)c5ccccc5,CHEMBL247925,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 970nM,partial agonist,59.00%,agonist,GW2331,,,,,,,EC50,=,35,nM,,,,,=,6.013228266,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc(Oc3ccccc3)cc2)cc1,59,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,293
10125,5540,17292606,2e,P37231,PPARG,Homo sapiens,"2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzo[d][1,3]dioxol-5-ylmethyl)amino)acetic acid",Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc4OCOc4c3)cc2)c5ccccc5,CHEMBL247720,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 3290nM,partial agonist,72.00%,agonist,Rosiglitazone,,,,,,,EC50,=,307,nM,,,,,=,5.482804102,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc3c(c2)OCO3)cc1,72,472.327,500.1947366,1,7,11,4,5.08702,94.26,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC5CCCC5C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,192
10126,5540,17292606,2e,Q07869,PPARA,Homo sapiens,"2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzo[d][1,3]dioxol-5-ylmethyl)amino)acetic acid",Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc4OCOc4c3)cc2)c5ccccc5,CHEMBL247720,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1800nM,agonist,77.00%,agonist,GW2331,,,,,,,EC50,=,128,nM,,,,,=,5.744727495,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc3c(c2)OCO3)cc1,77,472.327,500.1947366,1,7,11,4,5.08702,94.26,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC5CCCC5C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,192
10127,5541,17292606,2j,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-2-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc4ccccc4c3)cc2)c5ccccc5,CHEMBL396696,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1210nM,partial agonist,29.00%,agonist,Rosiglitazone,,,,,,,EC50,=,1210,nM,,,,,=,5.91721463,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc3ccccc3c2)cc1,29,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC5CCCCC5C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,193
10128,5541,17292606,2j,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-2-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccc4ccccc4c3)cc2)c5ccccc5,CHEMBL396696,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 680nM,partial agonist,39.00%,agonist,GW2331,,,,,,,EC50,=,618,nM,,,,,=,6.167491087,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccc3ccccc3c2)cc1,39,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCC(CCCC4CCC5CCCCC5C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,193
10129,5542,17292606,2f,P37231,PPARG,Homo sapiens,2-((3-phenoxybenzyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3cccc(Oc4ccccc4)c3)cc2)c5ccccc5,CHEMBL395191,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 480nM,agonist,78.00%,agonist,Rosiglitazone,,,,,,,EC50,=,391,nM,,,,,=,6.318758763,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2cccc(Oc3ccccc3)c2)cc1,78,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,296
10130,5542,17292606,2f,Q07869,PPARA,Homo sapiens,2-((3-phenoxybenzyl)(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3cccc(Oc4ccccc4)c3)cc2)c5ccccc5,CHEMBL395191,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 88nM,agonist,107.00%,agonist,GW2331,,,,,,,EC50,=,4,nM,,,,,=,7.055517328,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2cccc(Oc3ccccc3)c2)cc1,107,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCCC(CCCC3CCC(CCCC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,296
10131,5543,17292606,2i,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-1-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3cccc4ccccc34)cc2)c5ccccc5,CHEMBL247926,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 767nM,partial agonist,63.00%,agonist,Rosiglitazone,,,,,,,EC50,=,840,nM,,,,,=,6.115204636,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2cccc3ccccc23)cc1,63,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCC(CCCC4CCCC5CCCCC54)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,195
10132,5543,17292606,2i,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-1-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3cccc4ccccc34)cc2)c5ccccc5,CHEMBL247926,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 140nM,agonist,90.00%,agonist,GW2331,,,,,,,EC50,=,21,nM,,,,,=,6.853871964,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2cccc3ccccc23)cc1,90,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCC(CCCC4CCCC5CCCCC54)CC3)C2)CC1,agonist,agonist,agonist,agonist,195
10133,5544,15771468,1,P37231,PPARG,Homo sapiens,(Benzyl-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccccc3)cc2)c4ccccc4,CHEMBL371120,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 4800nM,agonist,111.00%,agonist,rosiglitazone,,,,,,,EC50,=,1500,nM,,,,,=,5.318758763,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccccc2)cc1,111,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,"agonist,partial agonist",411
10134,5544,17292606,2a,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccccc3)cc2)c4ccccc4,CHEMBL371120,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1770nM,partial agonist,28.00%,agonist,Rosiglitazone,,,,,,,EC50,=,3600,nM,,,,,=,5.752026734,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccccc2)cc1,28,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",411
10135,5544,15771468,1,Q07869,PPARA,Homo sapiens,(Benzyl-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-amino)-acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccccc3)cc2)c4ccccc4,CHEMBL371120,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 = 1400nM,agonist,103.00%,agonist,GW2331,,,,,,,EC50,=,20,nM,,,,,=,5.853871964,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccccc2)cc1,103,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,agonist,agonist,agonist,411
10136,5544,17292606,2a,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CC(=O)O)Cc3ccccc3)cc2)c4ccccc4,CHEMBL371120,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1400nM,,24.00%,agonist,GW2331,,,,,,,EC50,=,4020,nM,,,,,=,5.853871964,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CC(=O)O)Cc2ccccc2)cc1,24,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)CC1,agonist,,agonist,agonist,411
10138,5546,17292606,2d,P37231,PPARG,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(2-(benzyloxy)ethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CCOCc3ccccc3)CC(=O)O)cc2)c4ccccc4,CHEMBL394968,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4560nM,partial agonist,41.00%,agonist,Rosiglitazone,,,,,,,EC50,=,1180,nM,,,,,=,5.341035157,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CCOCc2ccccc2)CC(=O)O)cc1,41,468.339,500.2311221,1,6,14,4,5.37492,85.03,C(CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CCC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1181
10139,5546,17292606,2d,Q07869,PPARA,Homo sapiens,2-((4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(2-(benzyloxy)ethyl)amino)acetic acid,Cc1oc(nc1CCOc2ccc(CN(CCOCc3ccccc3)CC(=O)O)cc2)c4ccccc4,CHEMBL394968,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 1800nM,partial agonist,56.00%,agonist,GW2331,,,,,,,EC50,=,726,nM,,,,,=,5.744727495,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(CN(CCOCc2ccccc2)CC(=O)O)cc1,56,468.339,500.2311221,1,6,14,4,5.37492,85.03,C(CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CCC1CCCCC1,agonist,partial agonist,agonist,partial agonist,1181
10156,5552,11720854,4e,P37231,PPARG,Homo sapiens,(S)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 6.9nM,agonist,no detail about the percentage act,,,,BRL49653,,,,,EC50,=,4.7,nM,,,,,=,8.161150909,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,,agonist,agonist,189
10157,5552,11720854,ent-4e,P37231,PPARG,Homo sapiens,(S)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 51nM,agonist,no detail about the percentage act,,,,BRL49653,,,,,EC50,=,20,nM,,,,,=,7.292429824,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,,agonist,agonist,189
10158,5552,18394907,7,P37231,PPARG,Homo sapiens,(S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(1H-pyrrol-1-yl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 29nM,agonist,115.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,26,nM,,,,,=,7.537602002,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,115,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10161,5552,11720854,4e,Q07869,PPARA,Homo sapiens,(S)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 560nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,3600,nM,,,,,=,6.251811973,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,,agonist,partial agonist,189
10162,5552,11720854,ent-4e,Q07869,PPARA,Homo sapiens,(S)-3-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-pyrrol-1-yl-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2600nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,1300,nM,,,,,=,5.585026652,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,,agonist,partial agonist,189
10163,5552,18394907,7,Q07869,PPARA,Homo sapiens,(S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(1H-pyrrol-1-yl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](C(=O)O)n3cccc3)cc2)c4ccccc4,CHEMBL104850,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 = 697nM,partial agonist,64.00%,agonist,GW9578,,TZD3,5nM,,,,EC50,=,684,nM,,,,,=,6.156767222,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,64,392.285,416.1736072,1,5,9,4,4.94142,77.49,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,189
10165,5554,17533125,2q,P37231,PPARG,Homo sapiens,(S)-N-(2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propyl)cyclopropanecarboxamide,Cc1oc(nc1CCOc2ccc(C[C@@H](CNC(=O)C3CC3)Nc4ccccc4C(=O)c5ccccc5)cc2)c6ccccc6,CHEMBL230731,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 7.26,partial agonist,59.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,7.26,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](CNC(=O)C2CC2)Nc2ccccc2C(=O)c2ccccc2)cc1,59,562.435,599.2784067,2,6,14,5,7.05192,93.46,CC(CCC(CC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1C(C)C1CCCCC1)C1CC1,,partial agonist,,partial agonist,1280
10169,5558,17533125,2o,P37231,PPARG,Homo sapiens,N-((S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propyl)-2-methyl-succinamic acid,CC(CC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1)Nc4ccccc4C(=O)c5ccccc5)C(=O)O,CHEMBL398185,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 6.04,agonist,92.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,6.04,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](CNC(=O)CC(C)C(=O)O)Nc2ccccc2C(=O)c2ccccc2)cc1,92,606.444,645.283886,3,7,16,5,6.75272,130.76,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,881
10173,5560,17533125,2n,P37231,PPARG,Homo sapiens,2-{4-[2-((S)-2-(2-benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propylcarbamoyl)-ethyl]-phenylsulfanyl}-2-methyl-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@@H](CNC(=O)CCc3ccc(SC(C)(C)C(=O)O)cc3)Nc4ccccc4C(=O)c5ccccc5)cc2)c6ccccc6,CHEMBL230804,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 6.6,agonist,80.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,6.6,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](CNC(=O)CCc2ccc(SC(C)(C)C(=O)O)cc2)Nc2ccccc2C(=O)c2ccccc2)cc1,80,734.599,781.3185572,3,8,19,6,9.23002,130.76,CC(CCC1CCCCC1)CCC(CC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1C(C)C1CCCCC1,,agonist,,agonist,1156
10177,5564,17533125,2i,P37231,PPARG,Homo sapiens,(S)-2-(3-aminophenoxy)-N-(2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propyl)acetamide,Cc1oc(nc1CCOc2ccc(C[C@@H](CNC(=O)COc3cccc(N)c3)Nc4ccccc4C(=O)c5ccccc5)cc2)c6ccccc6,CHEMBL266742,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 6.72,partial agonist,48.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,6.72,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](CNC(=O)COc2cccc(N)c2)Nc2ccccc2C(=O)c2ccccc2)cc1,48,640.485,680.2998704,3,8,16,6,7.30312,128.71,CC(CCC1CCCCC1)CCC(CC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1C(C)C1CCCCC1,,partial agonist,,partial agonist,1156
10179,5566,17533125,2g,P37231,PPARG,Homo sapiens,(S)-N-(2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propyl)-3-(2-(dimethylamino)ethoxy)benzamide,CN(C)CCOc1cccc(c1)C(=O)NC[C@H](Cc2ccc(OCCc3nc(oc3C)c4ccccc4)cc2)Nc5ccccc5C(=O)c6ccccc6,CHEMBL267996,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKI = 7,partial agonist,55.00%,agonist,no detail ,,BRL-49653,,,,,,,,,,,,,=,7,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H](CNC(=O)c2cccc(OCCN(C)C)c2)Nc2ccccc2C(=O)c2ccccc2)cc1,55,676.518,722.3468206,2,8,18,6,7.89612,105.93,CC(CCC(CC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1)CC1CCCCC1C(C)C1CCCCC1)C1CCCCC1,,partial agonist,,partial agonist,1281
10187,5571,25686852,3j,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398443,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 80nM,agonist,105.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,640,nM,,,,,=,7.096910013,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,105,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1031
10188,5571,25686852,3k,P37231,PPARG,Homo sapiens,"cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398443,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 80nM,agonist,93.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,30,nM,,,,,=,7.096910013,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,93,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1031
10189,5571,25686852,3j,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398443,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 610nM,agonist,125.00%,agonist,GW2331,1000nM,,,,,,EC50,=,1,nM,,,,,=,6.214670165,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,125,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1031
10190,5571,25686852,3k,Q07869,PPARA,Homo sapiens,"cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)cc2)c5ccccc5,CHEMBL3398443,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 180nM,agonist,98.00%,agonist,GW2331,1000nM,,,,,,EC50,=,5,nM,,,,,=,6.744727495,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,98,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1031
10193,5573,25686852,4m,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(benzo[d]oxazol-2-yl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4oc5ccccc5n4)cc2)c6ccccc6,CHEMBL3398453,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 590nM,partial agonist,52.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,2080,nM,,,,,=,6.229147988,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nc4ccccc4o3)C[C@@H]2C(=O)O)cc1,52,494.357,523.210721,1,7,9,5,5.79242,101.83,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CC6CCCCC6C5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,183
10194,5573,25686852,4m,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-1-(benzo[d]oxazol-2-yl)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4oc5ccccc5n4)cc2)c6ccccc6,CHEMBL3398453,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2190nM,partial agonist,44.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2480,nM,,,,,=,5.659555885,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nc4ccccc4o3)C[C@@H]2C(=O)O)cc1,44,494.357,523.210721,1,7,9,5,5.79242,101.83,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CC6CCCCC6C5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,183
10195,5574,25686852,4h,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)cc2)c5ccccc5,CHEMBL255930,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 30nM,agonist,107.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,50,nM,,,,,=,7.522878745,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)cc1,107,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10196,5574,25686852,4i,P37231,PPARG,Homo sapiens,"(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)cc2)c5ccccc5,CHEMBL255930,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 20nM,agonist,85.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,30,nM,,,,,=,7.698970004,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)cc1,85,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10197,5574,25686852,4h,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)cc2)c5ccccc5,CHEMBL255930,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 740nM,agonist,110.00%,agonist,GW2331,1000nM,,,,,,EC50,=,30,nM,,,,,=,6.13076828,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)cc1,110,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10198,5574,25686852,4i,Q07869,PPARA,Homo sapiens,"(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)cc2)c5ccccc5,CHEMBL255930,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 960nM,agonist,108.00%,agonist,GW2331,1000nM,,,,,,EC50,=,90,nM,,,,,=,6.017728767,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)cc1,108,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10201,5576,25686852,4f,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ncccn4)cc2)c5ccccc5,CHEMBL3398448,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 2040nM,partial agonist,67.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,1060,nM,,,,,=,5.690369833,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3ncccn3)C[C@@H]2C(=O)O)cc1,67,456.332,484.2110554,1,7,9,4,4.44122,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,186
10202,5576,25686852,4f,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ncccn4)cc2)c5ccccc5,CHEMBL3398448,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,partial agonist,58.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2910,nM,,,,,>,5,pIC50,NB,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2CN(c3ncccn3)C[C@@H]2C(=O)O)cc1,58,456.332,484.2110554,1,7,9,4,4.44122,101.58,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,186
10215,5581,9836620,20,P37231,PPARG,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 9.47,agonist,no detail about the percentage act,,,,BRL49653,,,,,PEC50,=,9.47,,,,,,=,9.47,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,881
10216,5581,9836621,2,P37231,PPARG,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 8.94,agonist,no detail about the percentage act,,,,,,,,,PEC50,=,9.47,,,,,,=,8.94,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,881
10217,5581,9836622,2,P37231,PPARG,Homo sapiens,2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,,,radiometric binding assay monitoring the displacement of a radioligand from the ligand-binding domain (LBD) ,PKi = 8.94,agonist,no detail about the percentage act,,,,,,,,,PEC50,=,9.47,,,,,,=,8.94,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,881
10218,5581,11720854,Farglitazar,P37231,PPARG,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.1nM,agonist,no detail about the percentage act,,,,BRL49653,,,,,EC50,=,0.34,nM,,,,,=,8.958607315,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,agonist,881
10219,5581,17005393,5,P37231,PPARG,Homo sapiens,farglitazar,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 25nM,agonist,83.00%,agonist,ref agonist,,,,,,,EC50,=,5,nM,,,,,=,7.602059991,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,83,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,881
10220,5581,17292606,GI 262570,P37231,PPARG,Homo sapiens,(S)-2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 217nM,agonist,99.00%,agonist,Rosiglitazone,,,,,,,EC50,=,0.6,nM,,,,,=,6.663540266,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,99,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,881
10223,5581,9836620,20,Q07869,PPARA,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",PKi = 5.92,,,,,,,,,,,PEC50,=,6.34,,,,,,=,5.92,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,partial agonist,881
10224,5581,9836621,2,Q07869,PPARA,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PKi = 6.31,agonist,no detail about the percentage act,,,,,,,,,PEC50,=,6.34,,,,,,=,6.31,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,partial agonist,881
10225,5581,11720854,Rosiglitazone,Q07869,PPARA,Homo sapiens,(S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki > 3000nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,450,nM,,,,,>,5.522878745,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,,agonist,partial agonist,881
10226,5581,17005393,5,Q07869,PPARA,Homo sapiens,farglitazar,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1217nM,partial agonist,66.00%,agonist,ref agonist,,,,,,,EC50,=,345,nM,,,,,=,5.914709422,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,66,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,881
10227,5581,17292606,GI 262570,Q07869,PPARA,Homo sapiens,(S)-2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL107367,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2870nM,partial agonist,59.00%,agonist,GW2331,,,,,,,EC50,=,321,nM,,,,,=,5.542118103,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,59,516.383,546.2154721,2,6,12,5,6.61032,101.66,CC(C1CCCCC1)C1CCCCC1CCCC1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,881
10231,5583,19349176,(S)-2Fa,P37231,PPARG,Homo sapiens,"(S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-(2,2,2-trifluoroethoxy)propanoic acid",Cc1oc(nc1CCOc2ccc(C[C@H](OCC(F)(F)F)C(=O)O)c3sccc23)c4ccccc4,CHEMBL484607,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,agonist,119.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,151,nM,,,,,=,8.522878745,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](OCC(F)(F)F)C(=O)O)c2sccc12,119,483.338,505.1170785,1,6,10,4,6.06082,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
10232,5583,19349176,(S)-2Fa,Q07869,PPARA,Homo sapiens,"(S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)-2-(2,2,2-trifluoroethoxy)propanoic acid",Cc1oc(nc1CCOc2ccc(C[C@H](OCC(F)(F)F)C(=O)O)c3sccc23)c4ccccc4,CHEMBL484607,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,179.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,555,nM,,,,,=,7.22184875,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](OCC(F)(F)F)C(=O)O)c2sccc12,179,483.338,505.1170785,1,6,10,4,6.06082,81.79,C1CCC(C2CCC(CCCC3CCCC4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,173
10233,5584,19349176,(S)-2Ga,P37231,PPARG,Homo sapiens,(S)-2-(cyclopropylmethoxy)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@H](OCC3CC3)C(=O)O)c4sccc24)c5ccccc5,CHEMBL484001,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,agonist,79.00%,agonist,Edaglitazone,,Edaglitazone,,,,,EC50,=,32,nM,,,,,=,8.698970004,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](OCC2CC2)C(=O)O)c2sccc12,79,450.366,477.160994,1,6,11,4,5.90852,81.79,C1CCC(C2CCC(CCCC3CCC(CCCCC4CC4)C4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,198
10234,5584,19349176,(S)-2Ga,Q07869,PPARA,Homo sapiens,(S)-2-(cyclopropylmethoxy)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid,Cc1oc(nc1CCOc2ccc(C[C@H](OCC3CC3)C(=O)O)c4sccc24)c5ccccc5,CHEMBL484001,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 21nM,agonist,108.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,27,nM,,,,,=,7.677780705,pIC50,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](OCC2CC2)C(=O)O)c2sccc12,108,450.366,477.160994,1,6,11,4,5.90852,81.79,C1CCC(C2CCC(CCCC3CCC(CCCCC4CC4)C4CCCC34)C2)CC1,agonist,agonist,agonist,agonist,198
10245,5589,16973358,(S)-19,P37231,PPARG,Homo sapiens,(S)-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(C[C@@]3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL221123,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 6nM,agonist,93.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,14,nM,,,,,=,8.22184875,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@]2(C(=O)O)CCCO2)cn1,93,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10246,5589,16973358,(S)-19,Q07869,PPARA,Homo sapiens,(S)-2-((6-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-3-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(C[C@@]3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL221123,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 32nM,agonist,89.00%,agonist,GW2331,,GW2331,,,,,EC50,=,165,nM,,,,,=,7.494850022,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@]2(C(=O)O)CCCO2)cn1,89,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10248,5590,16979341,(S)-13,P37231,PPARG,Homo sapiens,(S)-2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(C[C@@]3(CCCO3)C(=O)O)nc2)c4ccccc4,CHEMBL218487,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 43nM,agonist,98.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,26,nM,,,,,=,7.366531544,pKi,B,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@]2(C(=O)O)CCCO2)nc1,98,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10249,5590,16979341,(S)-13,Q07869,PPARA,Homo sapiens,(S)-2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ccc(C[C@@]3(CCCO3)C(=O)O)nc2)c4ccccc4,CHEMBL218487,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 340nM,agonist,97.00%,agonist,GW2331,,GW2331,,,,,EC50,=,100,nM,,,,,=,6.468521083,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@]2(C(=O)O)CCCO2)nc1,97,384.262,408.1685219,1,6,8,3,3.84282,94.68,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10250,5591,19201606,2e,P37231,PPARG,Homo sapiens,5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrazole-4-carboxylic acid,Cc1oc(nc1CCOc2ccc(Cc3c(cnn3c4ccccc4)C(=O)O)cc2)c5ccccc5,CHEMBL473953,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1670nM,partial agonist,39.00%,agonist,muraglitazar,,-,-,,,,EC50,=,490,nM,,,,,=,5.777283529,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2c(C(=O)O)cnn2-c2ccccc2)cc1,39,454.336,479.1845063,1,6,9,5,5.74622,90.38,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4C4CCCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,181
10254,5593,19201606,1d,P37231,PPARG,Homo sapiens,4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrrole-3-carboxylic acid,Cc1oc(nc1CCOc2ccc(Cc3cn(cc3C(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL514328,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 890nM,partial agonist,72.00%,agonist,muraglitazar,,-,-,,,,EC50,=,4200,nM,,,,,=,6.050609993,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2cn(-c3ccccc3)cc2C(=O)O)cc1,72,452.34,478.1892573,1,5,9,5,6.35122,77.49,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,186
10256,5594,19201606,1c,P37231,PPARG,Homo sapiens,1-methyl-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1H-pyrrole-3-carboxylic acid,Cc1oc(nc1CCOc2ccc(Cc3cn(C)cc3C(=O)O)cc2)c4ccccc4,CHEMBL474158,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3820nM,agonist,84.00%,agonist,muraglitazar,,-,-,,,,EC50,=,1570,nM,,,,,=,5.417936637,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2cn(C)cc2C(=O)O)cc1,84,392.285,416.1736072,1,5,8,4,4.89902,77.49,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10258,5595,19201606,2d,P37231,PPARG,Homo sapiens,3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrazole-4-carboxylic acid,Cc1oc(nc1CCOc2ccc(Cc3nn(cc3C(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL514007,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2160nM,agonist,90.00%,agonist,muraglitazar,,-,-,,,,EC50,=,752,nM,,,,,=,5.665546249,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2nn(-c3ccccc3)cc2C(=O)O)cc1,90,454.336,479.1845063,1,6,9,5,5.74622,90.38,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10260,5596,19201606,4a,P37231,PPARG,Homo sapiens,"5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2ccc(Cc3nn(nc3C(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL474947,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 712nM,agonist,87.00%,agonist,muraglitazar,,-,-,,,,EC50,=,9270,nM,,,,,=,6.147520006,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2nn(-c3ccccc3)nc2C(=O)O)cc1,87,456.332,480.1797552,1,7,9,5,5.14122,103.27,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10261,5596,19201606,4a,Q07869,PPARA,Homo sapiens,"5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2ccc(Cc3nn(nc3C(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL474947,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2770nM,partial agonist,52.00%,agonist,muraglitazar,,-,-,,,,EC50,=,6150,nM,,,,,=,5.557520231,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2nn(-c3ccccc3)nc2C(=O)O)cc1,52,456.332,480.1797552,1,7,9,5,5.14122,103.27,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,186
10262,5597,19201606,4f,P37231,PPARG,Homo sapiens,"2-(5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2ccc(Cc3nn(nc3CC(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL491142,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,86.00%,agonist,muraglitazar,,-,-,,,,EC50,=,13,nM,,,,,=,8.15490196,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2nn(-c3ccccc3)nc2CC(=O)O)cc1,86,468.343,494.1954053,1,7,10,5,5.07012,103.27,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10263,5597,19201606,4f,Q07869,PPARA,Homo sapiens,"2-(5-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2ccc(Cc3nn(nc3CC(=O)O)c4ccccc4)cc2)c5ccccc5,CHEMBL491142,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 54nM,agonist,118.00%,agonist,muraglitazar,,-,-,,,,EC50,=,11,nM,,,,,=,7.26760624,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc(Cc2nn(-c3ccccc3)nc2CC(=O)O)cc1,118,468.343,494.1954053,1,7,10,5,5.07012,103.27,C1CCC(C2CCC(CCCC3CCC(CC4CCC(C5CCCCC5)C4)CC3)C2)CC1,agonist,agonist,agonist,agonist,186
10266,5599,11405642,6,P37231,PPARG,Homo sapiens,2-Methyl-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenoxy}-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccccc3,CHEMBL66206,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3017nM,partial agonist,55.00%,agonist,reference compound (?),,,,,,,EC50,=,2059,nM,,,,,=,5.52042469,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,55,358.244,381.1576228,1,5,8,3,4.51352,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10267,5599,11405642,6,Q07869,PPARA,Homo sapiens,2-Methyl-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenoxy}-propionic acid,Cc1oc(nc1CCOc2ccc(OC(C)(C)C(=O)O)cc2)c3ccccc3,CHEMBL66206,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1445nM,partial agonist,69.00%,agonist,reference compound (?),,,,,,,EC50,=,711,nM,,,,,=,5.840132153,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(OC(C)(C)C(=O)O)cc1,69,358.244,381.1576228,1,5,8,3,4.51352,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10269,56,12801232,12d,P19793,RXRA,Homo sapiens,"7-[3,5-Di-tert-butyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)(F)F)C(C)(C)C)C(C)(C)C,CHEMBL92487,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 27nM,antagonist,93.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,8,nM,=,7.568636236,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)(F)F,93,405.266,438.2381796,1,2,6,1,7.2131,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
10274,5601,11405642,5,P37231,PPARG,Homo sapiens,2-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenoxy}-propionic acid,CC(Oc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1)C(=O)O,CHEMBL64972,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3120nM,partial agonist,42.00%,agonist,reference compound (?),,,,,,,EC50,=,2751,nM,,,,,=,5.505845406,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(OC(C)C(=O)O)cc1,42,346.233,367.1419728,1,5,8,3,4.12342,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10275,5601,11405642,5,Q07869,PPARA,Homo sapiens,2-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenoxy}-propionic acid,CC(Oc1ccc(OCCc2nc(oc2C)c3ccccc3)cc1)C(=O)O,CHEMBL64972,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2033nM,partial agonist,65.00%,agonist,reference compound (?),,,,,,,EC50,=,625,nM,,,,,=,5.691862621,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(OC(C)C(=O)O)cc1,65,346.233,367.1419728,1,5,8,3,4.12342,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10277,5602,11405642,4,Q07869,PPARA,Homo sapiens,{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenoxy}-acetic acid,Cc1oc(nc1CCOc2ccc(OCC(=O)O)cc2)c3ccccc3,CHEMBL294807,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10596nM,partial agonist,28.00%,agonist,reference compound (?),,,,,,,EC50,=,2751,nM,,,,,=,4.97485805,pIC50,NB,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ccc(OCC(=O)O)cc1,28,334.222,353.1263227,1,5,8,3,3.73492,81.79,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10278,5603,25686852,1d,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4R)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(cc2)[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398427,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 4470nM,partial agonist,33.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,4180,nM,,,,,=,5.349692477,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc([C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,33,484.338,512.1947366,1,6,8,4,5.57052,102.1,CC(CC1CCCCC1)C1CCC(C2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,1024
10280,5604,25686852,2f,P37231,PPARG,Homo sapiens,"(+/-)-cis-2-((3R,4R)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidin-3-yl)acetic acid",Cc1oc(nc1CCOc2ccc(cc2)[C@@H]3CN(C[C@@H]3CC(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398435,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 8310nM,partial agonist,33.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,4180,nM,,,,,=,5.080398976,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc([C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2CC(=O)O)cc1,33,496.349,526.2103867,1,6,9,4,5.96062,102.1,CC(CC1CCCCC1)C1CCC(C2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,1024
10283,5605,25686852,1f,P37231,PPARG,Homo sapiens,"(+/-)-trans-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(cc2)[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398429,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 5860nM,agonist,99.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,10,nM,,,,,=,5.232102384,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc([C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,99,484.338,512.1947366,1,6,8,4,5.57052,102.1,CC(CC1CCCCC1)C1CCC(C2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,agonist,agonist,agonist,1024
10284,5605,25686852,1f,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4S)-4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2ccc(cc2)[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398429,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2860nM,partial agonist,58.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2580,nM,,,,,=,5.543633967,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1ccc([C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)cc1,58,484.338,512.1947366,1,6,8,4,5.57052,102.1,CC(CC1CCCCC1)C1CCC(C2CCC(CCCC3CCC(C4CCCCC4)C3)CC2)C1,agonist,partial agonist,agonist,partial agonist,1024
10285,5606,19201606,3d,P37231,PPARG,Homo sapiens,"5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(c2)c3nn(nc3C(=O)O)c4ccccc4)c5ccccc5,CHEMBL474551,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 670nM,partial agonist,39.00%,agonist,muraglitazar,,-,-,,,,EC50,=,2190,nM,,,,,=,6.173925197,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(-c2nn(-c3ccccc3)nc2C(=O)O)c1,39,444.321,466.1641052,1,7,8,5,5.21742,103.27,C1CCC(C2CCC(CCCC3CCCC(C4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,185
10286,5606,19201606,3d,Q07869,PPARA,Homo sapiens,"5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(c2)c3nn(nc3C(=O)O)c4ccccc4)c5ccccc5,CHEMBL474551,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1610nM,partial agonist,45.00%,agonist,muraglitazar,,-,-,,,,EC50,=,4020,nM,,,,,=,5.793174124,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(-c2nn(-c3ccccc3)nc2C(=O)O)c1,45,444.321,466.1641052,1,7,8,5,5.21742,103.27,C1CCC(C2CCC(CCCC3CCCC(C4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,185
10287,5607,19201606,3e,P37231,PPARG,Homo sapiens,"2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2cccc(c2)c3nn(nc3CC(=O)O)c4ccccc4)c5ccccc5,CHEMBL491750,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,agonist,985.00%,agonist,muraglitazar,,-,-,,,,EC50,=,560,nM,,,,,=,7.468521083,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(-c2nn(-c3ccccc3)nc2CC(=O)O)c1,985,456.332,480.1797552,1,7,9,5,5.14632,103.27,C1CCC(C2CCC(CCCC3CCCC(C4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,185
10288,5607,19201606,3e,Q07869,PPARA,Homo sapiens,"2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2cccc(c2)c3nn(nc3CC(=O)O)c4ccccc4)c5ccccc5,CHEMBL491750,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 280nM,partial agonist,72.00%,agonist,muraglitazar,,-,-,,,,EC50,=,390,nM,,,,,=,6.552841969,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(-c2nn(-c3ccccc3)nc2CC(=O)O)c1,72,456.332,480.1797552,1,7,9,5,5.14632,103.27,C1CCC(C2CCC(CCCC3CCCC(C4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,185
10291,5609,18511276,31a,P37231,PPARG,Homo sapiens,"2-(1-(isobutoxycarbonyl)-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid",CC(C)COC(=O)N1CCC(=C(C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2)CC(=O)O,CHEMBL403432,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 49nM,agonist,116.00%,agonist,ref agonist,,,,,,,EC50,=,18,nM,,,,,=,7.30980392,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2=C(CC(=O)O)CCN(C(=O)OCC(C)C)C2)c1,116,484.338,518.2416868,1,6,10,3,5.99812,102.1,C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,202
10292,5609,18511276,31a,Q07869,PPARA,Homo sapiens,"2-(1-(isobutoxycarbonyl)-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid",CC(C)COC(=O)N1CCC(=C(C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2)CC(=O)O,CHEMBL403432,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 130nM,agonist,82.00%,agonist,ref agonist,,,,,,,EC50,=,6,nM,,,,,=,6.886056648,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2=C(CC(=O)O)CCN(C(=O)OCC(C)C)C2)c1,82,484.338,518.2416868,1,6,10,3,5.99812,102.1,C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,202
10294,5610,18511276,31b,P37231,PPARG,Homo sapiens,"2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid",Cc1oc(nc1CCOc2cccc(c2)C3=C(CC(=O)O)CCN(C3)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL255309,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,agonist,110.00%,agonist,ref agonist,,,,,,,EC50,=,46,nM,,,,,=,7.468521083,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2=C(CC(=O)O)CCN(C(=O)Oc3ccccc3)C2)c1,110,508.36,538.2103867,1,6,9,4,6.40452,102.1,CC(CC1CCCCC1)C1CCCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1033
10295,5610,18511276,31b,Q07869,PPARA,Homo sapiens,"2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid",Cc1oc(nc1CCOc2cccc(c2)C3=C(CC(=O)O)CCN(C3)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL255309,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 16nM,agonist,87.00%,agonist,ref agonist,,,,,,,EC50,=,4,nM,,,,,=,7.795880017,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2=C(CC(=O)O)CCN(C(=O)Oc3ccccc3)C2)c1,87,508.36,538.2103867,1,6,9,4,6.40452,102.1,CC(CC1CCCCC1)C1CCCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1033
10297,5611,18511276,21a,Q07869,PPARA,Homo sapiens,rac-1-(isobutoxycarbonyl)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C(=O)O,CHEMBL258428,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 7620nM,partial agonist,67.00%,agonist,ref agonist,,,,,,,EC50,=,209,nM,,,,,=,5.118045029,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2CN(C(=O)OCC(C)C)CCC2C(=O)O)c1,67,472.327,506.2416868,1,6,9,3,5.55422,102.1,C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,202
10298,5612,18511276,32a,P37231,PPARG,Homo sapiens,rac-2-(1-(isobutoxycarbonyl)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)piperidin-4-yl)acetic acid,CC(C)COC(=O)N1CCC(CC(=O)O)C(C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL255097,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3089nM,agonist,75.00%,agonist,ref agonist,,,,,,,EC50,=,490,nM,,,,,=,5.510182092,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2CN(C(=O)OCC(C)C)CCC2CC(=O)O)c1,75,484.338,520.2573369,1,6,10,3,5.94432,102.1,C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,202
10299,5612,18511276,32a,Q07869,PPARA,Homo sapiens,rac-2-(1-(isobutoxycarbonyl)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)piperidin-4-yl)acetic acid,CC(C)COC(=O)N1CCC(CC(=O)O)C(C1)c2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL255097,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 15000nM,partial agonist,48.00%,agonist,ref agonist,,,,,,,EC50,=,580,nM,,,,,>,4.823908741,pIC50,NB,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2CN(C(=O)OCC(C)C)CCC2CC(=O)O)c1,48,484.338,520.2573369,1,6,10,3,5.94432,102.1,C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,202
10300,5613,18511276,32b,P37231,PPARG,Homo sapiens,rac-2-(3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)piperidin-4-yl)acetic acid,Cc1oc(nc1CCOc2cccc(c2)C3CN(CCC3CC(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL445942,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 7692nM,partial agonist,29.00%,agonist,ref agonist,,,,,,,EC50,=,1290,nM,,,,,=,5.113960724,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2CN(C(=O)Oc3ccccc3)CCC2CC(=O)O)c1,29,508.36,540.2260367,1,6,9,4,6.35072,102.1,CC(CC1CCCCC1)C1CCCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1033
10301,5613,18511276,32b,Q07869,PPARA,Homo sapiens,rac-2-(3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)piperidin-4-yl)acetic acid,Cc1oc(nc1CCOc2cccc(c2)C3CN(CCC3CC(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL445942,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 8120nM,partial agonist,62.00%,agonist,ref agonist,,,,,,,EC50,=,170,nM,,,,,=,5.090443971,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C2CN(C(=O)Oc3ccccc3)CCC2CC(=O)O)c1,62,508.36,540.2260367,1,6,9,4,6.35072,102.1,CC(CC1CCCCC1)C1CCCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1033
10302,5614,18511276,13a,P37231,PPARG,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL256134,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 4510nM,partial agonist,37.00%,agonist,ref agonist,,,,,,,EC50,=,3860,nM,,,,,=,5.345823458,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)c1,37,484.338,518.2416868,1,6,10,3,5.69352,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,295
10303,5614,18511276,13a,Q07869,PPARA,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(=C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL256134,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 2560nM,partial agonist,66.00%,agonist,ref agonist,,,,,,,EC50,=,235,nM,,,,,=,5.591760035,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=C(C(=O)O)CCN(C(=O)OCC(C)C)C2)c1,66,484.338,518.2416868,1,6,10,3,5.69352,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,295
10306,5616,18511276,13b,P37231,PPARG,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=C(CCN(C3)c4nccc(n4)C(F)(F)F)C(=O)O)c2)c5ccccc5,CHEMBL255271,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1384nM,partial agonist,65.00%,agonist,ref agonist,,,,,,,EC50,=,644,nM,,,,,=,5.85886391,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=C(C(=O)O)CCN(c3nccc(C(F)(F)F)n3)C2)c1,65,537.348,564.19844,1,7,9,4,5.91432,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,191
10307,5616,18511276,13b,Q07869,PPARA,Homo sapiens,"3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,5,6-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=C(CCN(C3)c4nccc(n4)C(F)(F)F)C(=O)O)c2)c5ccccc5,CHEMBL255271,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1328nM,partial agonist,37.00%,agonist,ref agonist,,,,,,,EC50,=,89,nM,,,,,=,5.876801925,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=C(C(=O)O)CCN(c3nccc(C(F)(F)F)n3)C2)c1,37,537.348,564.19844,1,7,9,4,5.91432,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,191
10308,5617,18511276,33a,P37231,PPARG,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(C(=O)O)C(=C1)Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL256358,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 130nM,agonist,132.00%,agonist,ref agonist,,,,,,,EC50,=,9,nM,,,,,=,6.886056648,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(C(=O)OCC(C)C)CCC2C(=O)O)c1,132,484.338,518.2416868,1,6,10,3,5.89702,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
10309,5617,18511276,33a,Q07869,PPARA,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",CC(C)COC(=O)N1CCC(C(=O)O)C(=C1)Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2,CHEMBL256358,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 861nM,agonist,114.00%,agonist,ref agonist,,,,,,,EC50,=,10,nM,,,,,=,6.064996849,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(C(=O)OCC(C)C)CCC2C(=O)O)c1,114,484.338,518.2416868,1,6,10,3,5.89702,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
10310,5618,18511276,33c,P37231,PPARG,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=CN(CCC3C(=O)O)C(=O)OCc4ccccc4)c2)c5ccccc5,CHEMBL401534,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 133nM,agonist,118.00%,agonist,ref agonist,,,,,,,EC50,=,24,nM,,,,,=,6.876148359,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(C(=O)OCc3ccccc3)CCC2C(=O)O)c1,118,520.371,552.2260367,1,6,10,4,6.44122,102.1,CC(CCC1CCCCC1)C1CCCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1143
10311,5618,18511276,33c,Q07869,PPARA,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=CN(CCC3C(=O)O)C(=O)OCc4ccccc4)c2)c5ccccc5,CHEMBL401534,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 654nM,agonist,125.00%,agonist,ref agonist,,,,,,,EC50,=,16,nM,,,,,=,6.184422252,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(C(=O)OCc3ccccc3)CCC2C(=O)O)c1,125,520.371,552.2260367,1,6,10,4,6.44122,102.1,CC(CCC1CCCCC1)C1CCCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1143
10312,5619,18511276,33b,P37231,PPARG,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=CN(CCC3C(=O)O)c4nccc(n4)C(F)(F)F)c2)c5ccccc5,CHEMBL255872,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 287nM,agonist,100.00%,agonist,ref agonist,,,,,,,EC50,=,14,nM,,,,,=,6.542118103,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(c3nccc(C(F)(F)F)n3)CCC2C(=O)O)c1,100,537.348,564.19844,1,7,9,4,6.11782,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,191
10313,5619,18511276,33b,Q07869,PPARA,Homo sapiens,"rac-5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydropyridine-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC3=CN(CCC3C(=O)O)c4nccc(n4)C(F)(F)F)c2)c5ccccc5,CHEMBL255872,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1078nM,agonist,85.00%,agonist,ref agonist,,,,,,,EC50,=,23,nM,,,,,=,5.967381239,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2=CN(c3nccc(C(F)(F)F)n3)CCC2C(=O)O)c1,85,537.348,564.19844,1,7,9,4,6.11782,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,191
10319,5622,18511276,24a,P37231,PPARG,Homo sapiens,rac-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL258212,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 6030nM,partial agonist,58.00%,agonist,ref agonist,,,,,,,EC50,=,1070,nM,,,,,=,5.219682688,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2CN(C(=O)OCC(C)C)CCC2C(=O)O)c1,58,484.338,520.2573369,1,6,10,3,5.62932,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,295
10320,5622,18511276,24a,Q07869,PPARA,Homo sapiens,rac-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(isobutoxycarbonyl)piperidine-4-carboxylic acid,CC(C)COC(=O)N1CCC(C(Cc2cccc(OCCc3nc(oc3C)c4ccccc4)c2)C1)C(=O)O,CHEMBL258212,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1370nM,agonist,101.00%,agonist,ref agonist,,,,,,,EC50,=,18,nM,,,,,=,5.863279433,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC2CN(C(=O)OCC(C)C)CCC2C(=O)O)c1,101,484.338,520.2573369,1,6,10,3,5.62932,102.1,C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,295
10321,5623,25686852,5b,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398456,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 210nM,agonist,126.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,630,nM,,,,,=,6.677780705,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,126,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1037
10322,5623,25686852,5b,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398456,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1060nM,agonist,113.00%,agonist,GW2331,1000nM,,,,,,EC50,=,8,nM,,,,,=,5.974694135,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,113,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1037
10323,5624,25686852,5c,P37231,PPARG,Homo sapiens,"(+/-)-trans-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398457,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 520nM,partial agonist,45.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,1170,nM,,,,,=,6.283996656,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,45,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1037
10324,5624,25686852,5c,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenethyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(CC[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398457,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,partial agonist,30.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2600,nM,,,,,>,5,pIC50,NB,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CC[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,30,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1037
10325,5625,17292606,1i,P37231,PPARG,Homo sapiens,2-(((1H-indol-2-yl)methyl)(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cc4ccccc4[nH]3)c2)c5ccccc5,CHEMBL396694,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 540nM,partial agonist,58.00%,agonist,Rosiglitazone,,,,,,,EC50,=,759,nM,,,,,=,6.26760624,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cc3ccccc3[nH]2)c1,58,466.347,495.2158064,2,5,11,5,5.83962,91.59,C1CCC(C2CCC(CCCC3CCCC(CCCC4CC5CCCCC5C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,199
10326,5625,17292606,1i,Q07869,PPARA,Homo sapiens,2-(((1H-indol-2-yl)methyl)(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cc4ccccc4[nH]3)c2)c5ccccc5,CHEMBL396694,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 246nM,partial agonist,62.00%,agonist,GW2331,,,,,,,EC50,=,197,nM,,,,,=,6.609064893,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cc3ccccc3[nH]2)c1,62,466.347,495.2158064,2,5,11,5,5.83962,91.59,C1CCC(C2CCC(CCCC3CCCC(CCCC4CC5CCCCC5C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,199
10327,5626,17292606,1f,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-(benzyloxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc(OCc4ccccc4)cc3)c2)c5ccccc5,CHEMBL394947,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 183nM,partial agonist,59.00%,agonist,Rosiglitazone,,,,,,,EC50,=,412,nM,,,,,=,6.73754891,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc(OCc3ccccc3)cc2)c1,59,528.394,562.2467722,1,6,14,5,6.93732,85.03,C1CCC(CCC2CCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,353
10328,5626,17292606,1f,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-(benzyloxy)benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc(OCc4ccccc4)cc3)c2)c5ccccc5,CHEMBL394947,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 387nM,partial agonist,56.00%,agonist,GW2331,,,,,,,EC50,=,324,nM,,,,,=,6.412289035,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc(OCc3ccccc3)cc2)c1,56,528.394,562.2467722,1,6,14,5,6.93732,85.03,C1CCC(CCC2CCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,353
10329,5627,17292606,1d,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc(Oc4ccccc4)cc3)c2)c5ccccc5,CHEMBL246272,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 230nM,partial agonist,73.00%,agonist,Rosiglitazone,,,,,,,EC50,=,67,nM,,,,,=,6.638272164,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc(Oc3ccccc3)cc2)c1,73,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,294
10330,5627,17292606,1d,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(4-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc(Oc4ccccc4)cc3)c2)c5ccccc5,CHEMBL246272,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,partial agonist,67.00%,agonist,GW2331,,,,,,,EC50,=,30,nM,,,,,=,6.958607315,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc(Oc3ccccc3)cc2)c1,67,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,294
10331,5628,17292606,1h,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-2-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc4ccccc4c3)c2)c5ccccc5,CHEMBL394967,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 145nM,partial agonist,49.00%,agonist,Rosiglitazone,,,,,,,EC50,=,1390,nM,,,,,=,6.838631998,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc3ccccc3c2)c1,49,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCCC(CCCC4CCC5CCCCC5C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,200
10332,5628,17292606,1h,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-2-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccc4ccccc4c3)c2)c5ccccc5,CHEMBL394967,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 149nM,partial agonist,65.00%,agonist,GW2331,,,,,,,EC50,=,313,nM,,,,,=,6.826813732,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccc3ccccc3c2)c1,65,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCCC(CCCC4CCC5CCCCC5C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,200
10333,5629,17292606,1e,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(3-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cccc(Oc4ccccc4)c3)c2)c5ccccc5,CHEMBL245656,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 110nM,agonist,90.00%,agonist,Rosiglitazone,,,,,,,EC50,=,359,nM,,,,,=,6.958607315,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cccc(Oc3ccccc3)c2)c1,90,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,297
10334,5629,17292606,1e,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(3-phenoxybenzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cccc(Oc4ccccc4)c3)c2)c5ccccc5,CHEMBL245656,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 83nM,agonist,95.00%,agonist,GW2331,,,,,,,EC50,=,62,nM,,,,,=,7.080921908,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cccc(Oc3ccccc3)c2)c1,95,516.383,548.2311221,1,6,13,5,7.15062,85.03,C1CCC(CC2CCCC(CCCC3CCCC(CCCC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,297
10336,5630,17292606,1g,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-1-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cccc4ccccc34)c2)c5ccccc5,CHEMBL429823,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 67nM,agonist,115.00%,agonist,Rosiglitazone,,,,,,,EC50,=,36,nM,,,,,=,7.173925197,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cccc3ccccc23)c1,115,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCCC(CCCC4CCCC5CCCCC54)C3)C2)CC1,agonist,agonist,agonist,agonist,201
10337,5630,17292606,1g,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(naphthalen-1-ylmethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3cccc4ccccc34)c2)c5ccccc5,CHEMBL429823,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,agonist,85.00%,agonist,GW2331,,,,,,,EC50,=,5,nM,,,,,=,7.468521083,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2cccc3ccccc23)c1,85,476.362,506.2205574,1,5,11,5,6.51152,75.8,C1CCC(C2CCC(CCCC3CCCC(CCCC4CCCC5CCCCC54)C3)C2)CC1,agonist,agonist,agonist,agonist,201
10338,5631,17292606,1a,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccccc3)c2)c4ccccc4,CHEMBL246270,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 240nM,agonist,82.00%,agonist,Rosiglitazone,,,,,,,EC50,=,295,nM,,,,,=,6.619788758,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccccc2)c1,82,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,413
10339,5631,17292606,1a,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(benzyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CC(=O)O)Cc3ccccc3)c2)c4ccccc4,CHEMBL246270,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 90nM,partial agonist,72.00%,agonist,GW2331,,,,,,,EC50,=,22,nM,,,,,=,7.045757491,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CC(=O)O)Cc2ccccc2)c1,72,428.318,456.2049074,1,5,11,4,5.35832,75.8,C1CCC(CCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,413
10340,5632,17292606,1c,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(3-phenylpropyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CCCc3ccccc3)CC(=O)O)c2)c4ccccc4,CHEMBL428748,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 773nM,partial agonist,43.00%,agonist,Rosiglitazone,,,,,,,EC50,=,901,nM,,,,,=,6.111820506,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CCCc2ccccc2)CC(=O)O)c1,43,452.34,484.2362075,1,5,13,4,5.79092,75.8,C1CCC(CCCCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,470
10341,5632,17292606,1c,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(3-phenylpropyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CCCc3ccccc3)CC(=O)O)c2)c4ccccc4,CHEMBL428748,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 51nM,partial agonist,62.00%,agonist,GW2331,,,,,,,EC50,=,47,nM,,,,,=,7.292429824,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CCCc2ccccc2)CC(=O)O)c1,62,452.34,484.2362075,1,5,13,4,5.79092,75.8,C1CCC(CCCCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,470
10342,5633,17292606,1b,P37231,PPARG,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(phenethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CCc3ccccc3)CC(=O)O)c2)c4ccccc4,CHEMBL246473,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 134nM,agonist,102.00%,agonist,Rosiglitazone,,,,,,,EC50,=,108,nM,,,,,=,6.872895202,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CCc2ccccc2)CC(=O)O)c1,102,440.329,470.2205574,1,5,12,4,5.40082,75.8,C1CCC(CCCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,454
10343,5633,17292606,1b,Q07869,PPARA,Homo sapiens,2-((3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)(phenethyl)amino)acetic acid,Cc1oc(nc1CCOc2cccc(CN(CCc3ccccc3)CC(=O)O)c2)c4ccccc4,CHEMBL246473,Luciferase reporter gene assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 75nM,agonist,82.00%,agonist,GW2331,,,,,,,EC50,=,44,nM,,,,,=,7.124938737,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(CN(CCc2ccccc2)CC(=O)O)c1,82,440.329,470.2205574,1,5,12,4,5.40082,75.8,C1CCC(CCCCC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)CC1,agonist,agonist,agonist,agonist,454
10346,5635,25686852,3d,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398438,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 1330nM,partial agonist,27.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,1250,nM,,,,,=,5.876148359,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,27,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1032
10347,5635,25686852,3e,P37231,PPARG,Homo sapiens,"cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398438,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 490nM,partial agonist,44.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,2000,nM,,,,,=,6.30980392,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,44,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1032
10348,5635,25686852,3d,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398438,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 220nM,agonist,165.00%,agonist,GW2331,1000nM,,,,,,EC50,=,10,nM,,,,,=,6.657577319,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,165,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1032
10349,5635,25686852,3e,Q07869,PPARA,Homo sapiens,"cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398438,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 70nM,agonist,130.00%,agonist,GW2331,1000nM,,,,,,EC50,=,4,nM,,,,,=,7.15490196,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,130,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1032
10350,5636,25686852,4b,P37231,PPARG,Homo sapiens,"(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenylpyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL3398444,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 80nM,partial agonist,29.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,3440,nM,,,,,=,7.096910013,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3ccccc3)C[C@@H]2C(=O)O)c1,29,452.34,482.2205574,1,5,9,4,5.65122,75.8,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10351,5636,25686852,4a,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenylpyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL3398444,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 220nM,,24.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,3410,nM,,,,,=,6.657577319,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3ccccc3)C[C@@H]2C(=O)O)c1,24,452.34,482.2205574,1,5,9,4,5.65122,75.8,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,,agonist,partial agonist,190
10352,5636,25686852,4a,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenylpyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL3398444,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,agonist,107.00%,agonist,GW2331,1000nM,,,,,,EC50,=,20,nM,,,,,=,7.397940009,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3ccccc3)C[C@@H]2C(=O)O)c1,107,452.34,482.2205574,1,5,9,4,5.65122,75.8,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10353,5636,25686852,4b,Q07869,PPARA,Homo sapiens,"(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenylpyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL3398444,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 70nM,agonist,152.00%,agonist,GW2331,1000nM,,,,,,EC50,=,50,nM,,,,,=,7.15490196,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3ccccc3)C[C@@H]2C(=O)O)c1,152,452.34,482.2205574,1,5,9,4,5.65122,75.8,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10354,5637,25686852,4d,P37231,PPARG,Homo sapiens,"cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)c2)c5ccccc5,CHEMBL3398446,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 40nM,agonist,75.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,2500,nM,,,,,=,7.397940009,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)c1,75,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10355,5637,25686852,4d,Q07869,PPARA,Homo sapiens,"cis-(3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@@H]3CN(C[C@@H]3C(=O)O)c4nccc(n4)C(F)(F)F)c2)c5ccccc5,CHEMBL3398446,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 20nM,agonist,107.00%,agonist,GW2331,1000nM,,,,,,EC50,=,14,nM,,,,,=,7.698970004,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2CN(c3nccc(C(F)(F)F)n3)C[C@@H]2C(=O)O)c1,107,525.337,552.19844,1,7,9,4,5.46002,101.58,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10358,5639,25686852,3h,P37231,PPARG,Homo sapiens,"(+/-)-trans-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398441,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 3630nM,partial agonist,59.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,6170,nM,,,,,=,5.440093375,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,59,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1032
10359,5639,25686852,3h,Q07869,PPARA,Homo sapiens,"(+/-)-trans-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398441,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3090nM,partial agonist,74.00%,agonist,GW2331,1000nM,,,,,,EC50,=,2590,nM,,,,,=,5.510041521,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,74,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1032
10362,5640,25686852,6b,Q07869,PPARA,Homo sapiens,"(+/-)-trans-2-((3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidin-3-yl)acetic acid",Cc1oc(nc1CCOc2cccc(C[C@H]3CN(C[C@@H]3CC(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398463,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 3090nM,partial agonist,44.00%,agonist,GW2331,1000nM,,,,,,EC50,=,850,nM,,,,,=,5.510041521,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2CC(=O)O)c1,44,508.36,540.2260367,1,6,10,4,6.03572,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1032
10364,5641,25686852,3f,Q07869,PPARA,Homo sapiens,"cis-(3S,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@H]3CN(C[C@H]3C(=O)O)C(=O)Oc4ccccc4)c2)c5ccccc5,CHEMBL3398439,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 660nM,agonist,93.00%,agonist,GW2331,1000nM,,,,,,EC50,=,950,nM,,,,,=,6.180456064,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2CN(C(=O)Oc3ccccc3)C[C@H]2C(=O)O)c1,93,496.349,526.2103867,1,6,9,4,5.64562,102.1,CC(CC1CCCCC1)C1CCC(CC2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,agonist,agonist,agonist,1032
10366,5642,25686852,4c,Q07869,PPARA,Homo sapiens,"cis-(3S,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenylpyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(C[C@H]3CN(C[C@H]3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL3398445,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 320nM,agonist,75.00%,agonist,GW2331,1000nM,,,,,,EC50,=,680,nM,,,,,=,6.494850022,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2CN(c3ccccc3)C[C@H]2C(=O)O)c1,75,452.34,482.2205574,1,5,9,4,5.65122,75.8,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10373,5646,19201606,1b,P37231,PPARG,Homo sapiens,4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrrole-3-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3cn(cc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL474157,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 160nM,agonist,82.00%,agonist,muraglitazar,,-,-,,,,EC50,=,550,nM,,,,,=,6.795880017,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2cn(-c3ccccc3)cc2C(=O)O)c1,82,452.34,478.1892573,1,5,9,5,6.35122,77.49,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10375,5647,19201606,2c,P37231,PPARG,Homo sapiens,4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrazole-3-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3cn(nc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL474149,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 70nM,partial agonist,65.00%,agonist,muraglitazar,,-,-,,,,EC50,=,156,nM,,,,,=,7.15490196,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2cn(-c3ccccc3)nc2C(=O)O)c1,65,454.336,479.1845063,1,6,9,5,5.74622,90.38,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10377,5648,19201606,1a,P37231,PPARG,Homo sapiens,1-methyl-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1H-pyrrole-3-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3cn(C)cc3C(=O)O)c2)c4ccccc4,CHEMBL473961,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1670nM,partial agonist,72.00%,agonist,muraglitazar,,-,-,,,,EC50,=,2370,nM,,,,,=,5.777283529,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2cn(C)cc2C(=O)O)c1,72,392.285,416.1736072,1,5,8,4,4.89902,77.49,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,187
10378,5648,19201606,1a,Q07869,PPARA,Homo sapiens,1-methyl-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1H-pyrrole-3-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3cn(C)cc3C(=O)O)c2)c4ccccc4,CHEMBL473961,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 5920nM,partial agonist,26.00%,agonist,muraglitazar,,-,-,,,,EC50,=,1470,nM,,,,,=,5.227678293,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2cn(C)cc2C(=O)O)c1,26,392.285,416.1736072,1,5,8,4,4.89902,77.49,C1CCC(C2CCC(CCCC3CCCC(CC4CCCC4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,187
10379,5649,19201606,2a,P37231,PPARG,Homo sapiens,3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrazole-4-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3nn(cc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL473952,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 140nM,agonist,76.00%,agonist,muraglitazar,,-,-,,,,EC50,=,23,nM,,,,,=,6.853871964,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nn(-c3ccccc3)cc2C(=O)O)c1,76,454.336,479.1845063,1,6,9,5,5.74622,90.38,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10380,5649,19201606,2a,Q07869,PPARA,Homo sapiens,3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-pyrazole-4-carboxylic acid,Cc1oc(nc1CCOc2cccc(Cc3nn(cc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL473952,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 70nM,partial agonist,26.00%,agonist,muraglitazar,,-,-,,,,EC50,=,11,nM,,,,,=,7.15490196,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nn(-c3ccccc3)cc2C(=O)O)c1,26,454.336,479.1845063,1,6,9,5,5.74622,90.38,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10382,5650,19201606,3a,P37231,PPARG,Homo sapiens,"5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(Cc3nn(nc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL515106,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 69nM,partial agonist,70.00%,agonist,muraglitazar,,-,-,,,,EC50,=,3790,nM,,,,,=,7.161150909,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nn(-c3ccccc3)nc2C(=O)O)c1,70,456.332,480.1797552,1,7,9,5,5.14122,103.27,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10383,5650,19201606,3a,Q07869,PPARA,Homo sapiens,"5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazole-4-carboxylic acid",Cc1oc(nc1CCOc2cccc(Cc3nn(nc3C(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL515106,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 69nM,partial agonist,30.00%,agonist,muraglitazar,,-,-,,,,EC50,=,1900,nM,,,,,=,7.161150909,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nn(-c3ccccc3)nc2C(=O)O)c1,30,456.332,480.1797552,1,7,9,5,5.14122,103.27,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10385,5651,19201606,3f,Q07869,PPARA,Homo sapiens,"2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid",Cc1oc(nc1CCOc2cccc(Cc3nn(nc3CC(=O)O)c4ccccc4)c2)c5ccccc5,CHEMBL491751,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 85nM,agonist,83.00%,agonist,muraglitazar,,-,-,,,,EC50,=,6,nM,,,,,=,7.070581074,pIC50,B,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nn(-c3ccccc3)nc2CC(=O)O)c1,83,468.343,494.1954053,1,7,10,5,5.07012,103.27,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,agonist,agonist,agonist,190
10386,5652,19201606,3c,P37231,PPARG,Homo sapiens,"4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-phenyl-1H-1,2,3-triazole-5-carboxylic acid",Cc1oc(nc1CCOc2cccc(Cc3nnn(c4ccccc4)c3C(=O)O)c2)c5ccccc5,CHEMBL474548,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 = 1480nM,partial agonist,49.00%,agonist,muraglitazar,,-,-,,,,EC50,=,9270,nM,,,,,=,5.829738285,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc(Cc2nnn(-c3ccccc3)c2C(=O)O)c1,49,456.332,480.1797552,1,7,9,5,5.14122,103.27,C1CCC(C2CCC(CCCC3CCCC(CC4CCC(C5CCCCC5)C4)C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,190
10388,5653,25686852,1b,P37231,PPARG,Homo sapiens,"(+/-)-cis-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(c2)[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398425,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 > 10000nM,partial agonist,35.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,5650,nM,,,,,>,5,pIC50,NB,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc([C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,35,484.338,512.1947366,1,6,8,4,5.57052,102.1,CC(CC1CCCCC1)C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1026
10389,5653,25686852,1b,Q07869,PPARA,Homo sapiens,"(+/-)-cis-(3R,4R)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidine-3-carboxylic acid",Cc1oc(nc1CCOc2cccc(c2)[C@@H]3CN(C[C@@H]3C(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398425,Gal4 luciferase reporter gene assays,,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,partial agonist,52.00%,agonist,GW2331,1000nM,,,,,,EC50,=,1650,nM,,,,,>,5,pIC50,NB,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc([C@@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2C(=O)O)c1,52,484.338,512.1947366,1,6,8,4,5.57052,102.1,CC(CC1CCCCC1)C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1026
10392,5655,25686852,2d,P37231,PPARG,Homo sapiens,"(+/-)-trans-2-((3R,4S)-4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-1-(phenoxycarbonyl)pyrrolidin-3-yl)acetic acid",Cc1oc(nc1CCOc2cccc(c2)[C@H]3CN(C[C@@H]3CC(=O)O)C(=O)Oc4ccccc4)c5ccccc5,CHEMBL3398433,Gal4 luciferase reporter gene assays,,fluorescence polarization (FP) ligand binding assay,IC50 = 1820nM,partial agonist,51.00%,agonist,rosiglitazone,1000nM,,,,,,EC50,=,14600,nM,,,,,=,5.739928612,pIC50,,FPA,Cc1oc(-c2ccccc2)nc1CCOc1cccc([C@H]2CN(C(=O)Oc3ccccc3)C[C@@H]2CC(=O)O)c1,51,496.349,526.2103867,1,6,9,4,5.96062,102.1,CC(CC1CCCCC1)C1CCC(C2CCCC(CCCC3CCC(C4CCCCC4)C3)C2)C1,agonist,partial agonist,agonist,partial agonist,1026
10394,5656,16979341,20,P37231,PPARG,Homo sapiens,2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyrazin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2cnc(CC3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL221490,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 160nM,agonist,102.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,156,nM,,,,,=,6.795880017,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1cnc(CC2(C(=O)O)CCCO2)cn1,102,386.258,409.1637708,1,7,8,3,3.23782,107.57,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,182
10396,5657,16979341,21,P37231,PPARG,Homo sapiens,2-((2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyrimidin-5-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ncc(CC3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL385974,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H]-radiolabeled Darglitazone from the ligand-binding domain (LBD) ,Ki = 2300nM,partial agonist,56.00%,agonist,darglitazone,,darglitazone,,,,,EC50,=,2500,nM,,,,,=,5.638272164,pKi,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ncc(CC2(C(=O)O)CCCO2)cn1,56,386.258,409.1637708,1,7,8,3,3.23782,107.57,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,182
10397,5657,16979341,21,Q07869,PPARA,Homo sapiens,2-((2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyrimidin-5-yl)methyl)-tetrahydrofuran-2-carboxylic acid,Cc1oc(nc1CCOc2ncc(CC3(CCCO3)C(=O)O)cn2)c4ccccc4,CHEMBL385974,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7300nM,partial agonist,58.00%,agonist,GW2331,,GW2331,,,,,EC50,>,10000,nM,,,,,=,5.13667714,pIC50,,radiometric,Cc1oc(-c2ccccc2)nc1CCOc1ncc(CC2(C(=O)O)CCCO2)cn1,58,386.258,409.1637708,1,7,8,3,3.23782,107.57,C1CCC(C2CCC(CCCC3CCC(CC4CCCC4)CC3)C2)CC1,,partial agonist,,partial agonist,182
10398,5658,18394907,75,P37231,PPARG,Homo sapiens,3-(4-{[Methyl-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-amino]-methyl}-phenyl)-2-pyrrol-1-yl-propionic acid,CN(Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1)Cc3nc(oc3C)c4ccccc4,CHEMBL516129,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled Darglitazone",IC50 > 100000nM,agonist,77.00%,agonist,darglitazone,,TZD4,2.5nM,,,,EC50,=,7000,nM,,,,,>,4,pIC50,NB,radiometric,Cc1oc(-c2ccccc2)nc1CN(C)Cc1ccc(C[C@@H](C(=O)O)n2cccc2)cc1,77,402.304,429.2052417,1,5,9,4,4.95192,71.5,C1CCC(C2CCC(CCCC3CCC(CCC4CCCC4)CC3)C2)CC1,agonist,agonist,agonist,agonist,189
10450,5678,17005394,38,P37231,PPARG,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-morpholinothiazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(sc2C)N3CCOCC3)ccc1CCC(=O)O,CHEMBL223351,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 22nM,partial agonist,57.00%,agonist,2-methyl-2-(4-{3-[propyl-(5-pyridin-2-yl-thiophene-2-sulfonyl)-amino]-pro- pyl}-phenoxy)-propionic acid,,,,,,,EC50,=,28,nM,,,,,=,7.657577319,pIC50,B,radiometric,Cc1sc(N2CCOCC2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,57,458.346,491.2090068,2,8,11,2,3.56142,110.22,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10451,5678,17005394,38,Q07869,PPARA,Homo sapiens,3-(2-((isopropoxycarbonyl)methyl)-4-(2-(5-methyl-2-morpholinothiazol-4-yl)ethoxy)phenyl)propanoic acid,CC(C)OC(=O)NCc1cc(OCCc2nc(sc2C)N3CCOCC3)ccc1CCC(=O)O,CHEMBL223351,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1495nM,partial agonist,37.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,986,nM,,,,,=,5.825358807,pIC50,,radiometric,Cc1sc(N2CCOCC2)nc1CCOc1ccc(CCC(=O)O)c(CNC(=O)OC(C)C)c1,37,458.346,491.2090068,2,8,11,2,3.56142,110.22,C1CCC(CCCC2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,388
10459,5682,10673099,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride,Cl.Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL1116,MCF-7 transient transfection assay,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,antagonist,100.00%,antagonist,E2,,E2,2nM,,,,,,inactive,,IC50,=,0.72,nM,=,8.698970004,pIC50,B,radiometric,Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,100,481.831,509.1427571,2,6,7,4,6.497,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,antagonist,antagonist,antagonist,914
10460,5682,16250633,1,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone hydrochloride,Cl.Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL1116,,,-,Ki = 0.37nM,,,,,,,,,,,,,,,,,,,=,9.431798276,pKi,B,other,Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,481.831,509.1427571,2,6,7,4,6.497,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
10497,57,12801232,12c,P19793,RXRA,Homo sapiens,"7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL42314,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,84.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,8,nM,=,8.522878745,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,84,386.268,420.2476014,1,2,7,1,6.9159,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
10498,57,12951091,1,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL42314,,,radiometric binding assay monitoring the displacement of [3H]-(9 cis)-RA from the ligand-binding domain (LBD) ,Ki = 2.7nM,,,,,,9-Cis-RA,,,,,,,,,,,,,=,8.568636236,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,,386.268,420.2476014,1,2,7,1,6.9159,46.53,C1CCCCC1,,,antagonist,antagonist,205
10499,57,14592510,3,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL42314,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 1.5nM,antagonist,84.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,6,nM,=,8.823908741,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCC(F)F,84,386.268,420.2476014,1,2,7,1,6.9159,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
10500,57,15006411,LG101506,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL42314,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,84.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,8,nM,=,8.522878745,pKi,B,radiometric,Cc1cc2c(cc1C1(c3ccc(C(=O)O)cn3)CC1)C(C)(C)CCC2(C)C,84,334.269,363.2198292,1,2,3,2,5.51712,50.19,C1CCC(C2(C3CCC4CCCCC4C3)CC2)CC1,antagonist,antagonist,antagonist,antagonist,45
10515,5709,9871534,5,P10275,AR,Homo sapiens,"8-Methyl-5-trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",CN1C(=O)C=C(c2cc3CCNc3cc12)C(F)(F)F,CHEMBL162503,,,,Ki = 61nM,partial antagonist,67.00%,antagonist,DHT,,,,,,,,,inactive,,IC50,=,56,nM,=,7.214670165,pKi,B,other,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NCC3,67,257.15,268.0823476,1,3,0,2,2.5253,34.03,CC1CCC2CC3CCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,578
10517,5710,9871534,17,P10275,AR,Homo sapiens,"(5bR,9aR)-1-Methyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CN1C(=O)C=C(c2cc3[C@H]4CCCC[C@H]4Nc3cc12)C(F)(F)F,CHEMBL163425,,,,Ki = 4nM,partial agonist,61.00%,agonist,DHT,,,,,,,EC50,=,10,nM,,,inactive,,=,8.397940009,pKi,B,other,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N[C@@H]1CCCC[C@H]31,61,305.194,322.1292978,1,3,0,2,4.009,34.03,CC1CCC2CC3C(CC2C1)CC1CCCCC13,agonist,partial agonist,agonist,partial agonist,573
10518,5711,9871534,25,P10275,AR,Homo sapiens,"(5bR,9aR)-1,5b-Dimethyl-4-trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",CN1C(=O)C=C(c2cc3c(N[C@@H]4CCCC[C@]34C)cc12)C(F)(F)F,CHEMBL422196,,,,Ki = 9nM,partial agonist,36.00%,agonist,DHT,,,,,,,EC50,=,33,nM,,,inactive,,=,8.045757491,pKi,B,other,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N[C@@H]1CCCC[C@]31C,36,317.205,336.1449479,1,3,0,2,4.1831,34.03,CC1CCC2CC3C(CC2C1)CC1CCCCC13,agonist,partial agonist,agonist,partial agonist,573
10537,5719,19394832,41,Q13133,LXRA,Homo sapiens,{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}-[(1-methyl-1H-indol-2-yl)methyl]amine,Cn1c(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc6ccccc16,CHEMBL551981,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 39nM,partial agonist,53.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,10180,nM,,,,,=,7.408935393,pIC50,B,radiometric,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,53,495.378,521.2078825,1,3,6,6,8.6152,29.85,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CC4CCCCC4C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,238
10538,5719,19394832,41,Q13133,LXRA,Homo sapiens,{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}-[(1-methyl-1H-indol-2-yl)methyl]amine,Cn1c(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc6ccccc16,CHEMBL551981,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1123nM,,13.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,13500,nM,,,,,=,5.949620244,pIC50,,radiometric,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,13,495.378,521.2078825,1,3,6,6,8.6152,29.85,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CC4CCCCC4C3)C2)CC1,agonist,,agonist,partial agonist,238
10541,5720,19394832,37,Q13133,LXRA,Homo sapiens,3-(3-Benzyl-8-chlorocinnolin-4-yl)phenyl][(1-methyl-1H-indol-2-yl)methyl]amine,Cn1c(CNc2cccc(c2)c3c(Cc4ccccc4)nnc5c(Cl)cccc35)cc6ccccc16,CHEMBL550847,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,partial agonist,35.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,2780,nM,,,,,=,7.619788758,pIC50,B,radiometric,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,35,463.822,488.1767745,1,4,6,6,7.6448,42.74,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CC4CCCCC4C3)C2)CC1,agonist,partial agonist,agonist,partial agonist,238
10542,5720,19394832,37,Q13133,LXRA,Homo sapiens,3-(3-Benzyl-8-chlorocinnolin-4-yl)phenyl][(1-methyl-1H-indol-2-yl)methyl]amine,Cn1c(CNc2cccc(c2)c3c(Cc4ccccc4)nnc5c(Cl)cccc35)cc6ccccc16,CHEMBL550847,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 603nM,,11.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,6000,nM,,,,,=,6.219682688,pIC50,,radiometric,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,11,463.822,488.1767745,1,4,6,6,7.6448,42.74,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CC4CCCCC4C3)C2)CC1,agonist,,agonist,partial agonist,238
10569,5740,19394832,39,Q13133,LXRA,Homo sapiens,{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}-[(1-methyl-1H-indol-7-yl)methyl]amine,Cn1ccc2cccc(CNc3cccc(c3)c4c(Cc5ccccc5)cnc6c(cccc46)C(F)(F)F)c12,CHEMBL558496,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 34nM,agonist,75.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,4170,nM,,,,,=,7.468521083,pIC50,B,radiometric,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,75,495.378,521.2078825,1,3,6,6,8.6152,29.85,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCC43)C2)CC1,agonist,agonist,agonist,agonist,240
10570,5740,19394832,39,Q13133,LXRA,Homo sapiens,{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}-[(1-methyl-1H-indol-7-yl)methyl]amine,Cn1ccc2cccc(CNc3cccc(c3)c4c(Cc5ccccc5)cnc6c(cccc46)C(F)(F)F)c12,CHEMBL558496,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1415nM,,15.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,12000,nM,,,,,=,5.84924356,pIC50,,radiometric,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,15,495.378,521.2078825,1,3,6,6,8.6152,29.85,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCC43)C2)CC1,agonist,,agonist,agonist,240
10575,5743,19394832,35,Q13133,LXRA,Homo sapiens,3-Benzyl-4-{3-[(1-methyl-1H-indol-7-yl)methoxy]-phenyl}-8-(trifluoromethyl)cinnoline,Cn1ccc2cccc(COc3cccc(c3)c4c(Cc5ccccc5)nnc6c(cccc46)C(F)(F)F)c12,CHEMBL554508,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,partial agonist,67.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,1160,nM,,,,,=,7.853871964,pIC50,B,radiometric,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,67,499.366,523.187147,0,4,6,6,7.9771,39.94,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,240
10576,5743,19394832,35,Q13133,LXRA,Homo sapiens,3-Benzyl-4-{3-[(1-methyl-1H-indol-7-yl)methoxy]-phenyl}-8-(trifluoromethyl)cinnoline,Cn1ccc2cccc(COc3cccc(c3)c4c(Cc5ccccc5)nnc6c(cccc46)C(F)(F)F)c12,CHEMBL554508,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 1000nM,,23.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,8320,nM,,,,,>,6,pIC50,,radiometric,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,23,499.366,523.187147,0,4,6,6,7.9771,39.94,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCC43)C2)CC1,agonist,,agonist,partial agonist,240
10579,5745,20345102,18,P55055,LXRB,Homo sapiens,N-(2-chloro-6-fluorobenzyl)-1-methyl-N-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)-1H-imidazole-4-sulfonamide,Cn1cnc(c1)S(=O)(=O)N(Cc2ccc(cc2)c3cccc(c3)S(=O)(=O)C)Cc4c(F)cccc4Cl,CHEMBL1092952,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.0,agonist,100.00%,agonist,Compound 2,,,,,,,PEC50,=,7.1,,,,,,=,8,pIC50,B,radiometric,Cn1cnc(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c1,100,524.877,547.0802541,0,6,8,4,4.6742,89.34,CC(C)(C1CCCC1)C(CC1CCCCC1)CC1CCC(C2CCCCC2)CC1,agonist,agonist,agonist,agonist,971
10609,5762,19394832,33,Q13133,LXRA,Homo sapiens,3-Benzyl-4-(3-{[2-chloro-3-(trifluoromethyl)benzyl]oxy}-phenyl)-8-(trifluoromethyl)cinnoline,FC(F)(F)c1cccc(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(cccc35)C(F)(F)F)c1Cl,CHEMBL561449,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 43nM,partial agonist,52.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,8600,nM,,,,,=,7.366531544,pIC50,B,radiometric,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,52,553.784,572.1090102,0,3,6,5,9.1576,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,331
10610,5762,19394832,33,Q13133,LXRA,Homo sapiens,3-Benzyl-4-(3-{[2-chloro-3-(trifluoromethyl)benzyl]oxy}-phenyl)-8-(trifluoromethyl)cinnoline,FC(F)(F)c1cccc(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(cccc35)C(F)(F)F)c1Cl,CHEMBL561449,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2927nM,,5.50%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,18100,nM,,,,,=,5.533577278,pIC50,,radiometric,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,5.5,553.784,572.1090102,0,3,6,5,9.1576,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,,agonist,partial agonist,331
10613,5764,19394832,22,Q13133,LXRA,Homo sapiens,3-Benzyl-8-chloro-4-(3-{[2-chloro-3-(trifluoromethyl)-benzyl]oxy}phenyl)cinnoline,FC(F)(F)c1cccc(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(Cl)cccc35)c1Cl,CHEMBL550983,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,partial agonist,54.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,6540,nM,,,,,=,7.619788758,pIC50,B,radiometric,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,54,520.232,538.0826532,0,3,6,5,8.7922,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,331
10614,5764,19394832,22,Q13133,LXRA,Homo sapiens,3-Benzyl-8-chloro-4-(3-{[2-chloro-3-(trifluoromethyl)-benzyl]oxy}phenyl)cinnoline,FC(F)(F)c1cccc(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(Cl)cccc35)c1Cl,CHEMBL550983,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 837nM,,6.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,15300,nM,,,,,=,6.077274542,pIC50,,radiometric,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,6,520.232,538.0826532,0,3,6,5,8.7922,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,,agonist,partial agonist,331
10615,5765,18973288,19,P55055,LXRB,Homo sapiens,2-(2-Chlorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2Hindazole,FC(F)(F)c1cccc2c(c3ccc(Cl)cc3)n(Cc4ccccc4Cl)nc12,CHEMBL488174,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 40nM,partial agonist,67.00%,agonist,T0901317,,T0901317,,,,,EC50,=,10200,nM,,,,,=,7.397940009,pIC50,B,radiometric,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,67,408.145,420.0407884,0,2,3,4,7.0772,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10616,5765,18973288,19,Q13133,LXRA,Homo sapiens,2-(2-Chlorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2Hindazole,FC(F)(F)c1cccc2c(c3ccc(Cl)cc3)n(Cc4ccccc4Cl)nc12,CHEMBL488174,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 379nM,partial agonist,36.00%,agonist,T0901317,,T0901317,,,,,EC50,=,15210,nM,,,,,=,6.42136079,pIC50,,radiometric,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,36,408.145,420.0407884,0,2,3,4,7.0772,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10619,5767,18973288,5,P55055,LXRB,Homo sapiens,2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole,FC(F)(F)c1cccc2c(c3ccccc3)n(Cc4ccccc4)nc12,CHEMBL464189,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,53.00%,agonist,T0901317,,T0901317,,,,,EC50,=,990,nM,,,,,=,8,pIC50,B,radiometric,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,53,337.239,352.1187331,0,2,3,4,5.7704,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10620,5767,18973288,5,Q13133,LXRA,Homo sapiens,2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole,FC(F)(F)c1cccc2c(c3ccccc3)n(Cc4ccccc4)nc12,CHEMBL464189,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 78nM,partial agonist,31.00%,agonist,T0901317,,T0901317,,,,,EC50,=,1810,nM,,,,,=,7.107905397,pIC50,B,radiometric,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,31,337.239,352.1187331,0,2,3,4,5.7704,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10621,5768,18973288,21,P55055,LXRB,Homo sapiens,3-(4-Chlorophenyl)-7-(trifluoromethyl)-2-[2-(trifluoromethyl)-benzyl]-2H-indazole,FC(F)(F)c1ccccc1Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F,CHEMBL486955,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 48nM,partial agonist,38.00%,agonist,T0901317,,T0901317,,,,,EC50,=,15460,nM,,,,,=,7.318758763,pIC50,B,radiometric,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,38,441.697,454.0671454,0,2,3,4,7.4426,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10628,5770,18973288,17,P55055,LXRB,Homo sapiens,2-(4-Chloro-2-fluorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1cc(Cl)ccc1Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F,CHEMBL488173,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,agonist,104.00%,agonist,T0901317,,T0901317,,,,,EC50,=,9800,nM,,,,,=,7.420216403,pIC50,B,radiometric,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,104,427.143,438.0313666,0,2,3,4,7.2163,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,219
10629,5770,18973288,17,Q13133,LXRA,Homo sapiens,2-(4-Chloro-2-fluorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1cc(Cl)ccc1Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F,CHEMBL488173,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 260nM,partial agonist,64.00%,agonist,T0901317,,T0901317,,,,,EC50,=,13280,nM,,,,,=,6.585026652,pIC50,,radiometric,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,64,427.143,438.0313666,0,2,3,4,7.2163,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10630,5771,18973288,16,P55055,LXRB,Homo sapiens,2-(4-Chlorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccc(Cl)cc4)C(F)(F)F,CHEMBL458597,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 58nM,partial agonist,74.00%,agonist,T0901317,,T0901317,,,,,EC50,=,9050,nM,,,,,=,7.236572006,pIC50,B,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,74,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10631,5771,18973288,16,Q13133,LXRA,Homo sapiens,2-(4-Chlorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccc(Cl)cc4)C(F)(F)F,CHEMBL458597,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 401nM,partial agonist,35.00%,agonist,T0901317,,T0901317,,,,,EC50,=,12770,nM,,,,,=,6.396855627,pIC50,,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,35,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10632,5772,18973288,"12, WAY-252623",P55055,LXRB,Homo sapiens,2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccc(F)cc4Cl)C(F)(F)F,CHEMBL456237,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24nM,partial agonist,73.00%,agonist,T0901317,,T0901317,,,,,EC50,=,3670,nM,,,,,=,7.619788758,pIC50,B,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,73,410.688,422.0609172,0,2,3,4,6.702,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10633,5772,18973288,"12, WAY-252623",Q13133,LXRA,Homo sapiens,2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccc(F)cc4Cl)C(F)(F)F,CHEMBL456237,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 179nM,partial agonist,53.00%,agonist,T0901317,,T0901317,,,,,EC50,=,6660,nM,,,,,=,6.747146969,pIC50,,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,53,410.688,422.0609172,0,2,3,4,6.702,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10634,5773,18973288,14,P55055,LXRB,Homo sapiens,2-(2-Chlorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccccc4Cl)C(F)(F)F,CHEMBL514428,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 32nM,partial agonist,54.00%,agonist,T0901317,,T0901317,,,,,EC50,=,2890,nM,,,,,=,7.494850022,pIC50,B,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,54,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10635,5773,18973288,14,Q13133,LXRA,Homo sapiens,2-(2-Chlorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccccc4Cl)C(F)(F)F,CHEMBL514428,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 297nM,partial agonist,32.00%,agonist,T0901317,,T0901317,,,,,EC50,=,5020,nM,,,,,=,6.527243551,pIC50,,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,32,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10636,5774,18973288,"13, WAY-214950",P55055,LXRB,Homo sapiens,2-(2-Fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccccc4F)C(F)(F)F,CHEMBL457977,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 33nM,partial agonist,64.00%,agonist,T0901317,,T0901317,,,,,EC50,=,4150,nM,,,,,=,7.48148606,pIC50,B,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,64,375.235,388.0998895,0,2,3,4,6.0486,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10637,5774,18973288,"13, WAY-214950",Q13133,LXRA,Homo sapiens,2-(2-Fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(cc1)c2c3cccc(c3nn2Cc4ccccc4F)C(F)(F)F,CHEMBL457977,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 248nM,partial agonist,35.00%,agonist,T0901317,,T0901317,,,,,EC50,=,6100,nM,,,,,=,6.605548319,pIC50,,radiometric,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,35,375.235,388.0998895,0,2,3,4,6.0486,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10656,5782,19394832,31,Q13133,LXRA,Homo sapiens,3-Benzyl-4-(3-{[5-fluoro-2-(trifluoromethyl)benzyl]oxy}-phenyl)-8-(trifluoromethyl)cinnoline,Fc1ccc(c(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(cccc35)C(F)(F)F)c1)C(F)(F)F,CHEMBL550568,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 38nM,partial agonist,61.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,3650,nM,,,,,=,7.420216403,pIC50,B,radiometric,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,61,537.329,556.1385608,0,3,6,5,8.6433,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,331
10657,5782,19394832,31,Q13133,LXRA,Homo sapiens,3-Benzyl-4-(3-{[5-fluoro-2-(trifluoromethyl)benzyl]oxy}-phenyl)-8-(trifluoromethyl)cinnoline,Fc1ccc(c(COc2cccc(c2)c3c(Cc4ccccc4)nnc5c(cccc35)C(F)(F)F)c1)C(F)(F)F,CHEMBL550568,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1194nM,,9.50%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,8410,nM,,,,,=,5.922995673,pIC50,,radiometric,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,9.5,537.329,556.1385608,0,3,6,5,8.6433,35.01,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,,agonist,partial agonist,331
10662,5785,22746350,5g',P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-4,5,6,6a-tetrahydro-3aHcyclopenta[d]isoxazole",Fc1ccc(C2=NOC3CCCC23)c(c1)C(F)(F)F,CHEMBL2159565,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.81,partial antagonist,37.40%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.81,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,37.4,262.141,273.0776769,0,2,1,1,3.7475,21.59,C1CCC(C2CCC3CCCC32)CC1,,partial antagonist,,partial antagonist,105
10663,5785,22746350,5g,P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-4,5,6,6a-tetrahydro-3aHcyclopenta[d]isoxazole",Fc1ccc(C2=NOC3CCCC23)c(c1)C(F)(F)F,CHEMBL2159565,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.87,,23.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.87,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,23.2,262.141,273.0776769,0,2,1,1,3.7475,21.59,C1CCC(C2CCC3CCCC32)CC1,,,,partial antagonist,105
10664,5786,22746350,5f,P10275,AR,Homo sapiens,"rac-3-(4-Fluoro-3-(trifluoromethyl)phenyl)-4,5,6,6a-tetrahydro-3aHcyclopenta[d]isoxazole",Fc1ccc(cc1C(F)(F)F)C2=NOC3CCCC23,CHEMBL2159564,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.83,partial antagonist,54.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.83,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCC23)cc1C(F)(F)F,54.6,262.141,273.0776769,0,2,1,1,3.7475,21.59,C1CCC(C2CCC3CCCC32)CC1,,partial antagonist,,partial antagonist,105
10665,5787,22746350,6g,P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-3a,4,5,6,7,7ahexahydrobenzo[d]isoxazole",Fc1ccc(C2=NOC3CCCCC23)c(c1)C(F)(F)F,CHEMBL2159573,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.94,partial antagonist,49.70%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.94,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,49.7,274.152,287.0933269,0,2,1,1,4.1376,21.59,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,partial antagonist,111
10666,5787,22746350,6g',P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-3a,4,5,6,7,7ahexahydrobenzo[d]isoxazole",Fc1ccc(C2=NOC3CCCCC23)c(c1)C(F)(F)F,CHEMBL2159573,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.01,partial antagonist,27.00%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.01,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,27,274.152,287.0933269,0,2,1,1,4.1376,21.59,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,partial antagonist,111
10667,5788,22746350,6f,P10275,AR,Homo sapiens,"rac-3-(4-Fluoro-3-(trifluoromethyl)phenyl)-3a,4,5,6,7,7ahexahydrobenzo[d]isoxazole",Fc1ccc(cc1C(F)(F)F)C2=NOC3CCCCC23,CHEMBL2159572,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.96,partial antagonist,53.40%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.96,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCC23)cc1C(F)(F)F,53.4,274.152,287.0933269,0,2,1,1,4.1376,21.59,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,partial antagonist,111
10668,5789,22746350,7g,P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-4,5,6,7,8,8a-hexahydro-3aH-cyclohepta[d]-isoxazole",Fc1ccc(C2=NOC3CCCCCC23)c(c1)C(F)(F)F,CHEMBL2159544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.09,partial antagonist,28.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.09,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,28.8,286.163,301.108977,0,2,1,1,4.5277,21.59,C1CCC(C2CCC3CCCCCC32)CC1,,partial antagonist,,partial antagonist,126
10669,5789,22746350,7g',P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-4,5,6,7,8,8a-hexahydro-3aH-cyclohepta[d]-isoxazole",Fc1ccc(C2=NOC3CCCCCC23)c(c1)C(F)(F)F,CHEMBL2159544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.18,,15.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.18,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,15.6,286.163,301.108977,0,2,1,1,4.5277,21.59,C1CCC(C2CCC3CCCCCC32)CC1,,,,partial antagonist,126
10672,5790,22746350,7f,P10275,AR,Homo sapiens,"rac-3-(4-Fluoro-3-(trifluoromethyl)phenyl)-4,5,6,7,8,8a-hexahydro-3aH-cyclohepta[d]-isoxazole",Fc1ccc(cc1C(F)(F)F)C2=NOC3CCCCCC23,CHEMBL2159543,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 4.96,partial antagonist,43.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,4.96,pIC50,NB,radiometric,Fc1ccc(C2=NOC3CCCCCC23)cc1C(F)(F)F,43.8,286.163,301.108977,0,2,1,1,4.5277,21.59,C1CCC(C2CCC3CCCCCC32)CC1,,partial antagonist,,partial antagonist,126
10673,5791,22746350,8g',P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-2-(trifluoromethyl)phenyl)-3a,4,5,6,7,8,9,9aoctahydrocycloocta[d]-isoxazole",Fc1ccc(C2=NOC3CCCCCCC23)c(c1)C(F)(F)F,CHEMBL2159550,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 4.88,partial antagonist,35.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,4.88,pIC50,NB,radiometric,Fc1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,35.6,298.174,315.124627,0,2,1,1,4.9178,21.59,C1CCCC2C(CC1)CCC2C1CCCCC1,,partial antagonist,,partial antagonist,78
10674,5792,22746350,8f,P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-3-(trifluoromethyl)phenyl)-3a,4,5,6,7,8,9,9aoctahydrocycloocta[d]isoxazole",Fc1ccc(cc1C(F)(F)F)C2=NOC3CCCCCCC23,CHEMBL2159549,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.23,partial antagonist,57.70%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.23,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,57.7,298.174,315.124627,0,2,1,1,4.9178,21.59,C1CCCC2C(CC1)CCC2C1CCCCC1,,partial antagonist,,partial antagonist,78
10675,5792,22746350,8f',P10275,AR,Homo sapiens,"cis-3-(4-Fluoro-3-(trifluoromethyl)phenyl)-3a,4,5,6,7,8,9,9aoctahydrocycloocta[d]isoxazole",Fc1ccc(cc1C(F)(F)F)C2=NOC3CCCCCCC23,CHEMBL2159549,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.55,partial antagonist,56.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.55,pIC50,,radiometric,Fc1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,56.6,298.174,315.124627,0,2,1,1,4.9178,21.59,C1CCCC2C(CC1)CCC2C1CCCCC1,,partial antagonist,,partial antagonist,78
10682,5799,18973288,18,P55055,LXRB,Homo sapiens,2-(2-Chloro-4-fluorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1ccc(Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F)c(Cl)c1,CHEMBL521398,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,77.00%,agonist,T0901317,,T0901317,,,,,EC50,=,11220,nM,,,,,=,7.522878745,pIC50,B,radiometric,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,77,427.143,438.0313666,0,2,3,4,7.2163,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,219
10683,5799,18973288,18,Q13133,LXRA,Homo sapiens,2-(2-Chloro-4-fluorobenzyl)-3-(4-chlorophenyl)-7-(trifluoromethyl)-2H-indazole,Fc1ccc(Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F)c(Cl)c1,CHEMBL521398,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 252nM,partial agonist,45.00%,agonist,T0901317,,T0901317,,,,,EC50,=,14400,nM,,,,,=,6.598599459,pIC50,,radiometric,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,45,427.143,438.0313666,0,2,3,4,7.2163,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10685,58,15125928,1,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[3,5-Di-tert-butyl-2-(3-fluoro-propoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",C\C(=C/C(=O)O)\C=C\C=C(\C)/c1cc(cc(c1OCCCF)C(C)(C)C)C(C)(C)C,CHEMBL92243,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.7nM,antagonist,84.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,6.4,nM,=,8.568636236,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)(C)C)cc(C(C)(C)C)c1OCCCF,84,379.281,416.2726733,1,2,8,1,7.0104,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
10686,580,16153845,34,P37231,PPARG,Homo sapiens,"1-(4-tert-Butyl-phenyl)-3-[4-(4-trifluoromethyl-1H-pyrrol-2-yl)-phenoxy]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid",CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3ccc(cc3)c4cc(c[nH]4)C(F)(F)F)c5cccnc25,CHEMBL426105,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 251nM,partial agonist,56.00%,agonist,maximal activation (no details),,,,,,,EC50,=,34,nM,,,,,=,6.600326279,pIC50,,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3ccc(-c4cc(C(F)(F)F)c[nH]4)cc3)c3cccnc32)cc1,56,495.331,519.1769763,2,4,5,5,7.8274,80.14,C1CCC(C2CC(CC3CCC(C4CCCC4)CC3)C3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,142
10688,5800,18973288,15,P55055,LXRB,Homo sapiens,2-(4-Fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(Cn2nc3c(cccc3c2c4ccc(F)cc4)C(F)(F)F)cc1,CHEMBL515852,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 49nM,partial agonist,66.00%,agonist,T0901317,,T0901317,,,,,EC50,=,5720,nM,,,,,=,7.30980392,pIC50,B,radiometric,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,66,375.235,388.0998895,0,2,3,4,6.0486,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10689,5800,18973288,15,Q13133,LXRA,Homo sapiens,2-(4-Fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccc(Cn2nc3c(cccc3c2c4ccc(F)cc4)C(F)(F)F)cc1,CHEMBL515852,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 317nM,partial agonist,43.00%,agonist,T0901317,,T0901317,,,,,EC50,=,8400,nM,,,,,=,6.498940738,pIC50,,radiometric,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,43,375.235,388.0998895,0,2,3,4,6.0486,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10692,5802,18973288,20,P55055,LXRB,Homo sapiens,3-(4-Chlorophenyl)-2-(2-fluorobenzyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccccc1Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F,CHEMBL520883,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,partial agonist,68.00%,agonist,T0901317,,T0901317,,,,,EC50,=,7440,nM,,,,,=,7.420216403,pIC50,B,radiometric,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,68,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10693,5802,18973288,20,Q13133,LXRA,Homo sapiens,3-(4-Chlorophenyl)-2-(2-fluorobenzyl)-7-(trifluoromethyl)-2Hindazole,Fc1ccccc1Cn2nc3c(cccc3c2c4ccc(Cl)cc4)C(F)(F)F,CHEMBL520883,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 304nM,partial agonist,50.00%,agonist,T0901317,,T0901317,,,,,EC50,=,13440,nM,,,,,=,6.517126416,pIC50,,radiometric,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,50,391.69,404.070339,0,2,3,4,6.5629,17.82,C1CCC(CC2CC3CCCCC3C2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,219
10696,5804,19595590,16,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-(cyanomethyl)pyrrolidin-3-yl)amino)benzonitrile,Clc1ccccc1CN([C@H]2CCN(CC#N)C2)c3ccc(C#N)c(Cl)c3,CHEMBL539731,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,partial agonist,64.00%,agonist,progesterone,,,,,,,EC50,=,0.5,nM,,,,,=,8.096910013,pIC50,B,FPA,N#CCN1CC[C@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)C1,64,367.154,384.0908519,0,4,5,2,4.46956,54.06,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
10711,5811,25435151,3b,P55055,LXRB,Homo sapiens,"1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",Fc1ccc(CN2C(=O)C(=C(C=C2c3ccc(Oc4ccccc4)cc3)C(F)(F)F)C#N)c(F)c1,CHEMBL3360961,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,100.00%,agonist,compound 3b,,,,,,,EC50,=,20,nM,,,,,=,8.045757491,pIC50,B,radiometric,N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,100,467.288,482.1053688,0,4,5,4,6.52458,55.02,CC1CCCC(C2CCC(CC3CCCCC3)CC2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,746
10712,5811,25435151,3b,Q13133,LXRA,Homo sapiens,"1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",Fc1ccc(CN2C(=O)C(=C(C=C2c3ccc(Oc4ccccc4)cc3)C(F)(F)F)C#N)c(F)c1,CHEMBL3360961,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 26nM,agonist,100.00%,agonist,compound 3b,,,,,,,EC50,=,20,nM,,,,,=,7.585026652,pIC50,B,radiometric,N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,100,467.288,482.1053688,0,4,5,4,6.52458,55.02,CC1CCCC(C2CCC(CC3CCCCC3)CC2)C1CC1CCCCC1,agonist,agonist,agonist,agonist,746
10722,5816,20427184,"26, (-)-Enantiomer",P04150,GR,Homo sapiens,"2-fluoro-5-(2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)-1-hydroxyethyl)benzonitrile",OC(c1ccc(F)c(c1)C#N)(c2ccc3c(cnn3c4ccc(F)cc4)c2)C(F)(F)F,CHEMBL1096467,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 54nM,agonist,90.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,112,nM,,,,,=,7.26760624,pIC50,B,FPA,N#Cc1cc(C(O)(c2ccc3c(cnn3-c3ccc(F)cc3)c2)C(F)(F)F)ccc1F,90,417.252,429.0900531,1,4,3,4,4.97358,61.84,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
10765,5838,22746350,5b,P10275,AR,Homo sapiens,"rac-4-(4,5,6,6a-Tetrahydro-3aH-cyclopenta[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCC23)C#N,CHEMBL2159731,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.35,partial antagonist,29.30%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.35,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCC23)c(C(F)(F)F)c1,29.3,269.161,280.0823476,0,3,1,1,3.48008,45.38,C1CCC(C2CCC3CCCC32)CC1,,partial antagonist,,partial antagonist,105
10766,5839,22746350,6b,P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCC23)C#N,CHEMBL2159567,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.75,partial antagonist,27.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.75,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,27.5,281.172,294.0979977,0,3,1,1,3.87018,45.38,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,partial antagonist,111
10767,5839,22746350,6b',P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCC23)C#N,CHEMBL2159567,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.94,,20.30%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.94,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCC23)c(C(F)(F)F)c1,20.3,281.172,294.0979977,0,3,1,1,3.87018,45.38,C1CCC(C2CCC3CCCCC32)CC1,,,,partial antagonist,111
10771,5841,22746350,7b,P10275,AR,Homo sapiens,"cis-4-(4,5,6,7,8,8a-Hexahydro-3aH-cyclohepta[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCCC23)C#N,CHEMBL2159539,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.94,partial antagonist,29.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.94,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,29.8,293.183,308.1136478,0,3,1,1,4.26028,45.38,C1CCC(C2CCC3CCCCCC32)CC1,,partial antagonist,,partial antagonist,126
10772,5841,22746350,7b',P10275,AR,Homo sapiens,"cis-4-(4,5,6,7,8,8a-Hexahydro-3aH-cyclohepta[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCCC23)C#N,CHEMBL2159539,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.00,partial antagonist,27.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCCC23)c(C(F)(F)F)c1,27.2,293.183,308.1136478,0,3,1,1,4.26028,45.38,C1CCC(C2CCC3CCCCCC32)CC1,,partial antagonist,,partial antagonist,126
10774,5843,22746350,8b',P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,8,9,9a-Octahydrocycloocta[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCCCC23)C#N,CHEMBL2159546,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 5.75,partial antagonist,65.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,5.75,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,65.5,305.194,322.1292978,0,3,1,1,4.65038,45.38,C1CCCC2C(CC1)CCC2C1CCCCC1,,partial antagonist,,partial antagonist,78
10775,5843,22746350,8b,P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,8,9,9a-Octahydrocycloocta[d]isoxazol-3-yl)-3-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C2=NOC3CCCCCCC23)C#N,CHEMBL2159546,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.19,,9.40%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.19,pIC50,,radiometric,N#Cc1ccc(C2=NOC3CCCCCCC23)c(C(F)(F)F)c1,9.4,305.194,322.1292978,0,3,1,1,4.65038,45.38,C1CCCC2C(CC1)CCC2C1CCCCC1,,,,partial antagonist,78
10778,5846,22746350,5a,P10275,AR,Homo sapiens,"(S,S)-4-(4,5,6,6a-Tetrahydro-3aH-cyclopenta[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile",FC(F)(F)c1cc(ccc1C#N)C2=NO[C@H]3CCC[C@@H]23,CHEMBL2159729,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.21,partial antagonist,44.90%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.21,pIC50,,radiometric,N#Cc1ccc(C2=NO[C@H]3CCC[C@@H]23)cc1C(F)(F)F,44.9,269.161,280.0823476,0,3,1,1,3.48008,45.38,C1CCC(C2CCC3CCCC32)CC1,,partial antagonist,,partial antagonist,105
10782,5849,19595590,18,P06401,PR,Homo sapiens,(S)-2-(3-((3-chloro-4-cyanophenyl)(2-chlorobenzyl)amino)pyrrolidin-1-yl)acetamide,NC(=O)CN1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL560885,CV-1 cellscotransfected with the luciferase reporter plasmid ,,Fluorescence polarization (FP) competition binding assay,IC50 = 63nM,partial agonist,47.00%,agonist,progesterone,,,,,,,EC50,=,200,nM,,,,,=,7.200659451,pIC50,B,FPA,N#Cc1ccc(N(Cc2ccccc2Cl)[C@H]2CCN(CC(N)=O)C2)cc1Cl,47,383.153,402.1014166,1,4,6,2,3.43128,73.36,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
10783,585,16153845,17,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-5-chloro-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid,CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4cc(Cl)ccc24,CHEMBL198207,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 17nM,partial agonist,37.00%,agonist,maximal activation (no details),,,,,,,EC50,=,136,nM,,,,,=,7.769551079,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3cc(Cl)ccc32)cc1,37,466.737,487.1162059,1,3,4,4,8.0907,51.46,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
10786,5851,17181141,(+/-)-10b,P10275,AR,Homo sapiens,"4-(tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1-naphthalenecarbonitrile",OC1CCN2C1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL218914,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.5nM,agonist,101.00%,agonist,DHT,,DHT,,,,,EC50,=,6.3,nM,,,,,=,8.259637311,pKi,B,radiometric,N#Cc1ccc(N2C(=O)C3C(O)CCN3C2=O)c2ccccc12,101,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,agonist,agonist,agonist,473
10790,5855,17181141,(-)-10b,P10275,AR,Homo sapiens,"(7R,7aS)-4-(tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1-naphthalenecarbonitrile",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL425646,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,agonist,103.00%,agonist,DHT,,DHT,,,,,EC50,=,2.3,nM,,,,,=,8.494850022,pKi,B,radiometric,N#Cc1ccc(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)c2ccccc12,103,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,agonist,agonist,"agonist,partial agonist",473
10791,5855,17181141,(+)-10b,P10275,AR,Homo sapiens,"(7S,7aR)-4-(tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-1-naphthalenecarbonitrile",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL425646,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.3nM,partial agonist,49.00%,agonist,DHT,,DHT,,,,,EC50,=,1298,nM,,,,,=,8.27572413,pKi,B,radiometric,N#Cc1ccc(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)c2ccccc12,49,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",473
10792,5855,17292608,1,P10275,AR,Homo sapiens,"4-((7R,7aS)-7-hydroxy-1,3-dioxo-tetrahydro-1H-pyrrolo[1,2-e]imidazol-2(3H)-yl)-1-naphthonitrile",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL425646,-,,-,Ki = 3.2nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,2.3,nM,,,,,=,8.494850022,pKi,B,other,N#Cc1ccc(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)c2ccccc12,,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,,agonist,"agonist,partial agonist",473
10793,5855,17552509,7,P10275,AR,Homo sapiens,"4-((7R,7aS)-7-hydroxy-1,3-dioxo-tetrahydro-1H-pyrrolo[1,2-e]imidazol-2(3H)-yl)-1-naphthonitrile",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL425646,-,,-,Ki = 3.2nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,2.3,nM,,,,,=,8.494850022,pKi,B,other,N#Cc1ccc(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)c2ccccc12,,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,,agonist,"agonist,partial agonist",473
10794,5855,17574413,1,P10275,AR,Homo sapiens,"4-((7R,7aS)-7-hydroxy-1,3-dioxo-tetrahydro-1H-pyrrolo[1,2-e]imidazol-2(3H)-yl)-1-naphthonitrile",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(C#N)c4ccccc34,CHEMBL425646,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.2nM,agonist,no detail about the percentage act,,,,DHT,,,,,EC50,=,2.3,nM,,,,,=,8.494850022,pKi,B,radiometric,N#Cc1ccc(N2C(=O)[C@@H]3[C@H](O)CCN3C2=O)c2ccccc12,,294.205,307.0956913,1,4,1,2,1.61328,84.64,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,,agonist,"agonist,partial agonist",473
10811,587,16153845,28,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-3-(3-trifluoromethyl-phenoxy)-5-(4-trifluoromethyl-1H-pyrrol-2-yloxy)-1H-indole-2-carboxylic acid,CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4cc(Oc5cc(c[nH]5)C(F)(F)F)ccc24,CHEMBL370443,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,partial agonist,42.00%,agonist,maximal activation (no details),,,,,,,EC50,=,6,nM,,,,,=,8.301029996,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3cc(Oc4cc(C(F)(F)F)c[nH]4)ccc32)cc1,42,578.339,602.1640266,2,4,6,5,9.5765,76.48,C1CCC(CC2CC(C3CCCCC3)C3CCC(CC4CCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,244
10829,5881,24239186,5,P51449,RORG,Homo sapiens,"4-cyano-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccc(cc2)C#N)(C(F)(F)F)C(F)(F)F,CHEMBL3094367,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 50nM,inverse agonist,-96.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,61,nM,,,,,=,7.301029996,pIC50,B,radiometric,N#Cc1ccc(S(=O)(=O)N(CC(F)(F)F)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,-96,495.258,506.0346672,1,4,5,2,4.62808,81.4,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
10841,589,16153845,27,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-5-(1H-pyrrol-2-yloxy)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid,CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4cc(Oc5ccc[nH]5)ccc24,CHEMBL198269,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 11nM,partial agonist,32.00%,agonist,maximal activation (no details),,,,,,,EC50,=,126,nM,,,,,=,7.958607315,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3cc(Oc4ccc[nH]4)ccc32)cc1,32,509.334,534.1766419,2,4,6,5,8.5577,76.48,C1CCC(CC2CC(C3CCCCC3)C3CCC(CC4CCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,244
10855,5897,26048793,25,P37231,PPARG,Homo sapiens,"4-(3-(2-cyano-6-(trifluoromethyl)benzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(cccc3C(F)(F)F)C#N)n4CCCCc24,CHEMBL3596277,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 > 10000nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,220,nM,,,,,>,5,pIC50,NB,other,N#Cc1cccc(C(F)(F)F)c1C(=O)c1nc(-c2ccc(C(=O)O)cc2F)c2n1CCCC2,-99,442.263,457.1049542,1,5,4,3,4.84518,95.98,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
10857,5899,22746350,6c,P10275,AR,Homo sapiens,"cis-3-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile",FC(F)(F)c1c(cccc1C2=NOC3CCCCC23)C#N,CHEMBL2159568,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.10,antagonist,187.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,7.1,pIC50,B,radiometric,N#Cc1cccc(C2=NOC3CCCCC23)c1C(F)(F)F,187.8,281.172,294.0979977,0,3,1,1,3.87018,45.38,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
10858,5899,22746350,6c',P10275,AR,Homo sapiens,"cis-3-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile",FC(F)(F)c1c(cccc1C2=NOC3CCCCC23)C#N,CHEMBL2159568,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.19,,5.40%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,7.19,pIC50,B,radiometric,N#Cc1cccc(C2=NOC3CCCCC23)c1C(F)(F)F,5.4,281.172,294.0979977,0,3,1,1,3.87018,45.38,C1CCC(C2CCC3CCCCC32)CC1,,,,antagonist,111
10861,59,14592510,56,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-7-[2-(2,2-Difluoro-ethoxy)-5-isopropyl-biphenyl-3-yl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(\C(=C/C=C/C(=C/C(=O)O)/C)\C)c(OCC(F)F)c(c1)c2ccccc2,CHEMBL424639,,CV-1 cellscotransfected with the luciferase reporter plasmid ,radiometric binding assay monitoring the displacement of [3H]-(all E)-RA from the ligand-binding domain (LBD) ,Ki = 6.1nM,antagonist,83.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,57.9,nM,=,8.214670165,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)C)cc(-c2ccccc2)c1OCC(F)F,83,398.279,426.2006512,1,2,9,2,7.1113,46.53,C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,152
10864,590,16153845,15,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-6-chloro-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid,CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4ccc(Cl)cc24,CHEMBL381865,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 27nM,partial agonist,27.00%,agonist,maximal activation (no details),,,,,,,EC50,=,106,nM,,,,,=,7.568636236,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3ccc(Cl)cc32)cc1,27,466.737,487.1162059,1,3,4,4,8.0907,51.46,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
10867,5901,26048793,22,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-cyanobenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(Cl)cccc3C#N)n4CCCCc24,CHEMBL3596274,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 7700nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,250,nM,,,,,=,5.113509275,pIC50,,other,N#Cc1cccc(Cl)c1C(=O)c1nc(-c2ccc(C(=O)O)cc2F)c2n1CCCC2,-99,408.711,423.0785972,1,5,4,3,4.47978,95.98,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
10869,5903,24239186,4,P51449,RORG,Homo sapiens,"3-cyano-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2cccc(c2)C#N)(C(F)(F)F)C(F)(F)F,CHEMBL3094366,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 190nM,inverse agonist,-93.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,100,nM,,,,,=,6.721246399,pIC50,,radiometric,N#Cc1cccc(S(=O)(=O)N(CC(F)(F)F)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)c1,-93,495.258,506.0346672,1,4,5,2,4.62808,81.4,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
10874,5906,24239186,3,P51449,RORG,Homo sapiens,"2-cyano-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2C#N)(C(F)(F)F)C(F)(F)F,CHEMBL3094365,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 520nM,inverse agonist,-91.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,920,nM,,,,,=,6.283996656,pIC50,,radiometric,N#Cc1ccccc1S(=O)(=O)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-91,495.258,506.0346672,1,4,5,2,4.62808,81.4,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
10880,5910,17391964,20,P55055,LXRB,Homo sapiens,{4-[({3-[3-cyano-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl}acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C#N)cc1,CHEMBL387653,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 33.8nM,agonist,89.00%,agonist,T0901317,,T0901317,,,,,EC50,=,450,nM,,,,,=,7.4710833,pIC50,B,radiometric,N#Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,89,443.299,461.1351115,2,4,6,4,6.03148,86.01,C1CCC(CCC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,332
10889,5917,17391964,36,P55055,LXRB,Homo sapiens,2-{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl} acetamide,NC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL226049,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 1.4nM,agonist,85.00%,agonist,T0901317,,T0901317,,,,,EC50,=,316,nM,,,,,=,8.853871964,pIC50,B,radiometric,NC(=O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,85,515.365,539.1820617,2,4,8,5,6.7915,85.08,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
10893,592,16153845,5,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid,CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4ccccc24,CHEMBL373237,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,partial agonist,31.00%,agonist,maximal activation (no details),,,,,,,EC50,=,13,nM,,,,,=,7.920818754,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3ccccc32)cc1,31,431.284,453.1551782,1,3,4,4,7.4373,51.46,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
10906,593,16153845,33,P37231,PPARG,Homo sapiens,"1-(4-tert-Butyl-phenyl)-3-(3-trifluoromethyl-phenoxy)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid",CC(C)(C)c1ccc(cc1)n2c(C(=O)O)c(Oc3cccc(c3)C(F)(F)F)c4cccnc24,CHEMBL197848,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 75nM,partial agonist,30.00%,agonist,maximal activation (no details),,,,,,,EC50,=,464,nM,,,,,=,7.124938737,pIC50,B,radiometric,CC(C)(C)c1ccc(-n2c(C(=O)O)c(Oc3cccc(C(F)(F)F)c3)c3cccnc32)cc1,30,433.28,454.1504272,1,4,4,4,6.8323,64.35,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
10922,5938,23276448,"6, L-94901",P10827,TRA,Homo sapiens,"(S)-2-amino-3-(4-(3-benzyl-4-hydroxyphenoxy)-3,5-dibromophenyl)propanoic acid",N[C@@H](Cc1cc(Br)c(Oc2ccc(O)c(Cc3ccc(O)nn3)c2)c(Br)c1)C(=O)O,CHEMBL163228,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8.72nM,agonist,163.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.059483515,pKi,B,radiometric,N[C@@H](Cc1cc(Br)c(Oc2ccc(O)c(Cc3ccc(O)nn3)c2)c(Br)c1)C(=O)O,163,522.044,536.9534948,4,7,7,3,3.7503,138.79,CC1CCC(CC2CCCC(CC3CCCCC3)C2)CC1,,agonist,,agonist,750
10923,5938,23276448,"6, L-94901",P10828,TRB,Homo sapiens,"(S)-2-amino-3-(4-(3-benzyl-4-hydroxyphenoxy)-3,5-dibromophenyl)propanoic acid",N[C@@H](Cc1cc(Br)c(Oc2ccc(O)c(Cc3ccc(O)nn3)c2)c(Br)c1)C(=O)O,CHEMBL163228,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 238nM,agonist,121.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,6.623423043,pKi,,radiometric,N[C@@H](Cc1cc(Br)c(Oc2ccc(O)c(Cc3ccc(O)nn3)c2)c(Br)c1)C(=O)O,121,522.044,536.9534948,4,7,7,3,3.7503,138.79,CC1CCC(CC2CCCC(CC3CCCCC3)C2)CC1,,agonist,,agonist,750
10924,5939,12565933,T3,P10827,TRA,Homo sapiens,"(S)-2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.064nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,10.19382003,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,agonist,agonist,agonist,268
10925,5939,16099653,1,P10827,TRA,Homo sapiens,"(S)-2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.24nM,,,,,,T3,,,,,,,,,,,,,=,9.619788758,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10926,5939,17543524,1,P10827,TRA,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.24nM,,,,no detail ,,BRL-49653,,,,,,,,,,,,,=,9.619788758,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,92,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10927,5939,18975928,"1b, T3",P10827,TRA,Homo sapiens,"3,5,3'-triidodo-L-thyronine",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.33nM,,,,,,T3,,,,,,,,,,,,,=,9.48148606,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10928,5939,23276448,"1, T3",P10827,TRA,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.33nM,agonist,100.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.632644079,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,100,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,agonist,agonist,agonist,268
10929,5939,24290064,T3,P10827,TRA,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,CV-1 cellscotransfected with the luciferase reporter plasmid,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.2nM,agonist,no detail about the percentage act,,T3,,T3,,,,,EC50,=,2.1,nM,,,,,=,8.494850022,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,agonist,,agonist,agonist,268
10930,5939,12565933,T3,P10828,TRB,Homo sapiens,"(S)-2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.08nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,10.09691001,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,agonist,agonist,agonist,268
10931,5939,16099653,1,P10828,TRB,Homo sapiens,"(S)-2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.26nM,,,,,,T3,,,,,,,,,,,,,=,9.585026652,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10932,5939,17543524,1,P10828,TRB,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.26nM,,,,,,,,,,,,,,,,,,,=,9.585026652,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10933,5939,18975928,"1b, T3",P10828,TRB,Homo sapiens,"3,5,3'-triidodo-L-thyronine",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.68nM,,,,,,T3,,,,,,,,,,,,,=,9.167491087,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10934,5939,23276448,"1, T3",P10828,TRB,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.29nM,agonist,100.00%,agonist,T3,,T3,0.95nM,,,,,,,,,,,,=,8.640164518,pKi,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,100,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,agonist,agonist,agonist,268
10935,5939,24290064,T3,P10828,TRB,Homo sapiens,"(S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL1544,CV-1 cellscotransfected with the luciferase reporter plasmid,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.9nM,agonist,no detail about the percentage act,,T3,,T3,,,,,EC50,=,2,nM,,,,,=,8.537602002,pIC50,B,radiometric,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,agonist,,agonist,agonist,268
10939,5941,12699376,2,P10827,TRA,Homo sapiens,"2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.24nM,,,,,,T3,,Kd = 0.058nM,,,,,,,,,,,=,9.619788758,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10940,5941,16338239,2,P10827,TRA,Homo sapiens,"(R)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.24nM,agonist,100.00%,agonist,T3,,,,,,,EC50,=,1.3,nM,,,,,=,9.619788758,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,100,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
10941,5941,17467994,32,P10827,TRA,Homo sapiens,"(R)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 9.62,,,,,,,,,,,,,,,,,,,=,9.62,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10942,5941,12699376 12888625,2,P10827,TRA,Homo sapiens,"2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.24nM,,,,,,,,,,,,,,,,,,,=,9.619788758,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10943,5941,12699376,2,P10828,TRB,Homo sapiens,"2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.26nM,,,,,,T3,,Kd = 0.112nM,,,,,,,,,,,=,9.585026652,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10944,5941,16338239,2,P10828,TRB,Homo sapiens,"(R)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.26nM,agonist,100.00%,agonist,T3,,,,,,,EC50,=,3.5,nM,,,,,=,9.585026652,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,100,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
10945,5941,17467994,32,P10828,TRB,Homo sapiens,"(R)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 9.58,,,,,,,,,,,,,,,,,,,=,9.58,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10946,5941,12699376 12888625,2,P10828,TRB,Homo sapiens,"2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,CHEMBL557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.26nM,,,,,,,,,,,,,,,,,,,=,9.585026652,pIC50,B,radiometric,N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,,638.88,650.7900519,3,4,5,2,3.9527,92.78,C1CCC(CC2CCCCC2)CC1,,,agonist,agonist,268
10947,5942,17616395,23D1E1,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-cyclopentyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccc(F)cc2F)C(=O)NCC(O)(CC3(CCCc4ccccc34)C5CCCC5)C(F)(F)F,CHEMBL235205,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.02,antagonist,93.00%,antagonist,dexamethasone,,,,,,,PEC50,=,7.02,,,,,,=,8.02,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CC2(C3CCCC3)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccc(F)cc1F,93,531.335,562.2367173,3,5,7,3,5.6105,93.17,CC(CCCCC1(C2CCCC2)CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,agonist,antagonist,agonist,antagonist,1228
10948,5942,17616395,23D1E2,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-cyclopentyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(2,4-difluorophenyl)-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccc(F)cc2F)C(=O)NCC(O)(CC3(CCCc4ccccc34)C5CCCC5)C(F)(F)F,CHEMBL235205,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.68,,13.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.82,,,,,,=,7.68,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CC2(C3CCCC3)CCCc3ccccc32)C(F)(F)F)cnn1-c1ccc(F)cc1F,13,531.335,562.2367173,3,5,7,3,5.6105,93.17,CC(CCCCC1(C2CCCC2)CCCC2CCCCC21)C1CCC(C2CCCCC2)C1,agonist,,agonist,antagonist,1228
10949,5943,17616395,240,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-(2-chloro-5-fluorophenyl)cyclobutyl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-phenyl-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccccc2)C(=O)NCC(O)(CC3(CCC3)c4cc(F)ccc4Cl)C(F)(F)F,CHEMBL234988,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.37,agonist,104.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.82,,,,,,=,8.37,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CC2(c3cc(F)ccc3Cl)CCC2)C(F)(F)F)cnn1-c1ccccc1,104,487.735,510.1445665,3,5,7,3,4.7822,93.17,CC(CCCCC1(C2CCCCC2)CCC1)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1230
10950,5943,17616395,2400,P04150,GR,Homo sapiens,"5-amino-N-(2-((1-(2-chloro-5-fluorophenyl)cyclobutyl)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-phenyl-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccccc2)C(=O)NCC(O)(CC3(CCC3)c4cc(F)ccc4Cl)C(F)(F)F,CHEMBL234988,MMTV agonim,,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.32,agonist,99.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.76,,,,,,=,8.32,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CC2(c3cc(F)ccc3Cl)CCC2)C(F)(F)F)cnn1-c1ccccc1,99,487.735,510.1445665,3,5,7,3,4.7822,93.17,CC(CCCCC1(C2CCCCC2)CCC1)C1CCC(C2CCCCC2)C1,agonist,agonist,agonist,agonist,1230
10951,5944,19019676,16d,P04150,GR,Homo sapiens,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-(2-fluoroethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccc(F)cc2)C(=O)NCC(O)(CN(CCF)C(=O)c3c(F)cccc3F)C(F)(F)F,CHEMBL464245,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.7,agonist,105.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.7,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,105,527.271,547.145437,3,6,9,3,3.0069,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
10953,5945,19019676,16e,P04150,GR,Homo sapiens,"5-amino-N-(2-((2,6-difluoro-N-(2-hydroxyethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",Nc1c(cnn1c2ccc(F)cc2)C(=O)NCC(O)(CN(CCO)C(=O)c3c(F)cccc3F)C(F)(F)F,CHEMBL517933,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,agonist,119.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.3,,,,,,=,7.8,pIC50,B,FPA,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,119,524.272,545.1497735,4,7,9,3,2.0297,133.71,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
10958,5947,24215891,4,P04150,GR,Homo sapiens,"2-amino-4,6-dichloro-N-(1,1,1-trifluoro-3-(1H-indol-3-yl)propan-2-yl)benzenesulfonamide",Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NC(Cc2c[nH]c3ccccc23)C(F)(F)F,CHEMBL3093441,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,82.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,56,nM,,,,,=,8,pIC50,B,FPA,Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NC(Cc1c[nH]c2ccccc12)C(F)(F)F,82,438.173,451.0135877,3,3,5,3,4.5088,87.98,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,agonist,agonist,agonist,1240
10961,5948,16610787,1aai,P03372,ERA,Homo sapiens,5-amino-7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one,Nc1cc(O)cc2N=CN(C(=O)c12)c3ccc(O)cc3,CHEMBL206286,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 15512nM,partial agonist,32.00%,agonist,,,E1,11nM,,,,,,,,,,,,=,4.809332204,pIC50,NB,radiometric,Nc1cc(O)cc2ncn(-c3ccc(O)cc3)c(=O)c12,32,258.172,269.0800412,3,6,1,3,1.3791,101.37,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
10969,5950,17257838,8,P10275,AR,Homo sapiens,"7-amino-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",Nc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706876,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 407nM,partial agonist,58.00%,agonist,DHT,,,,,,,EC50,=,1300,nM,IC50,=,28,nM,=,6.390405591,pIC50,,radiometric,Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,58,221.117,228.0510475,2,2,0,2,2.1291,58.88,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
10970,5951,17034117,3,P10275,AR,Homo sapiens,6-amino-4-trifluoromethylquinolin-2(1H)-one,Nc1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL385509,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 10000nM,partial antagonist,28.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,26,nM,=,5,pKi,NB,radiometric,Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,28,221.117,228.0510475,2,3,0,2,2.5414,59.14,CC1CCC2CCCCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,651
10971,5951,17257838,13a,P10275,AR,Homo sapiens,"6-amino-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",Nc1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL385509,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,partial antagonist,28.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,26,nM,>,5,pIC50,NB,radiometric,Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,28,221.117,228.0510475,2,3,0,2,2.5414,59.14,CC1CCC2CCCCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,651
11028,598,16112571,12,P04150,GR,Homo sapiens,"2-(4-tert-Butyl-benzyl)-2-hydroxy-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(C)c1ccc(CC(O)(CC(C)(C)c2ccccc2)C(=O)Nc3ccc4C(=O)OCc4c3)cc1,CHEMBL196237,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 72nM,antagonist,90.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,760,nM,=,7.142667504,pIC50,B,FPA,CC(C)(C)c1ccc(CC(O)(CC(C)(C)c2ccccc2)C(=O)Nc2ccc3c(c2)COC3=O)cc1,90,450.344,485.2566086,2,4,7,3,5.9347,75.63,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,946
11064,5995,25993269,24g,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Bromophenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Br)cc4)c5ccc(O)cc5,CHEMBL3589699,,,,Ki > 5000nM,antagonist,101.00%,antagonist,E2,,,,,,,EC50,=,1140,nM,,,,,>,5.301029996,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Br)cc4)C2O3)cc1)NO,101,652.329,684.1140991,4,8,13,3,5.7985,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11065,5995,25993269,24g,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Bromophenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Br)cc4)c5ccc(O)cc5,CHEMBL3589699,,,,Ki = 2428.57nM,antagonist,91.00%,antagonist,E2,,,,,,,EC50,=,173,nM,,,,,=,5.614649374,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Br)cc4)C2O3)cc1)NO,91,652.329,684.1140991,4,8,13,3,5.7985,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11066,5996,25993269,24f,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Fluorophenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(F)cc4)c5ccc(O)cc5,CHEMBL3589698,,,,Ki > 5000nM,antagonist,135.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(F)cc4)C2O3)cc1)NO,135,591.423,624.1941652,4,8,13,3,5.1751,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11067,5996,25993269,24f,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 4-Fluorophenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(F)cc4)c5ccc(O)cc5,CHEMBL3589698,,,,Ki = 3400nM,antagonist,86.00%,antagonist,E2,,,,,,,EC50,=,2,nM,,,,,=,5.468521083,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(F)cc4)C2O3)cc1)NO,86,591.423,624.1941652,4,8,13,3,5.1751,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11070,5998,25993269,24h,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 1-Naphthalene Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4cccc5ccccc45)c6ccc(O)cc6,CHEMBL3589700,,,,Ki > 5000nM,antagonist,88.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4cccc5ccccc45)C2O3)cc1)NO,88,620.469,656.2192371,4,8,13,4,6.1892,151.26,CC(C)(CC1CCCC2CCCCC21)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1122
11071,5998,25993269,24h,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 1-Naphthalene Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4cccc5ccccc45)c6ccc(O)cc6,CHEMBL3589700,,,,Ki = 809.52nM,antagonist,94.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.091772417,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4cccc5ccccc45)C2O3)cc1)NO,94,620.469,656.2192371,4,8,13,4,6.1892,151.26,CC(C)(CC1CCCC2CCCCC21)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1122
11072,5999,25993269,24a,P03372,ERA,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Phenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4)c5ccc(O)cc5,CHEMBL3589369,,,,Ki > 5000nM,antagonist,77.00%,antagonist,E2,,,,,,,,,,,,,,,>,5.301029996,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4)C2O3)cc1)NO,77,572.425,606.203587,4,8,13,3,5.036,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11073,5999,25993269,24a,Q92731,ERB,Homo sapiens,(exo-rac)-6-(4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl)-5-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic Acid 2-Phenyl Ester,ONC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4)c5ccc(O)cc5,CHEMBL3589369,,,,Ki = 3090.9nM,antagonist,92.00%,antagonist,E2,,,,,,,EC50,=,2,nM,,,,,=,5.509915045,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4)C2O3)cc1)NO,92,572.425,606.203587,4,8,13,3,5.036,151.26,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11076,60,12801232,11e,P19793,RXRA,Homo sapiens,"7-[3,5-Diisopropyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)(F)F)c(c1)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL423503,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,87.00%,antagonist,,,9-Cis-RA,,,,,,,,,IC50,=,6,nM,=,8.522878745,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)C)cc(C(C)C)c1OCC(F)(F)F,87,381.244,410.2068794,1,2,8,1,6.8649,46.53,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
11077,600,15115388,36,P04150,GR,Homo sapiens,"(S)-2-(4-tert-Butyl-phenyl)-1-[(4aR,5S)-1-(4-fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-ethanol",CC(C)(C)c1ccc(C[C@H](O)[C@H]2CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)cc1,CHEMBL440877,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 16.6nM,partial agonist,48.80%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,24.2,nM,,,,,=,7.779891912,pIC50,B,radiometric,CC(C)(C)c1ccc(C[C@H](O)[C@H]2CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)cc1,48.8,423.341,458.273342,1,3,4,3,6.6584,38.05,C1CCC(CCC2CCCC3CC4C(CCC4C4CCCCC4)CC23)CC1,agonist,partial agonist,agonist,partial agonist,318
11078,6000,25993269,22,P03372,ERA,Homo sapiens,"4-(8-(Hydroxyamino)-8-oxooctanamido)phenyl5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonate",ONC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)cc1,CHEMBL3589351,,,,Ki = 147.62nM,antagonist,104.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.830854799,pKi,,other,O=C(CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)cc1)NO,104,588.424,622.1985017,5,9,13,3,4.7416,171.49,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11086,6003,17267219,6v,P10275,AR,Homo sapiens,"2,2,2-trifluoro-N-(2-oxo-4-(trifluoromethyl)-1,2,4a,8a-tetrahydroquinolin-6-yl)-N-(2,2,2-trifluoroethyl)acetamide",FC(F)(F)CN(C(=O)C(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL3706929,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1000nM,partial agonist,38.00%,agonist,DHT,,,,,,,EC50,=,22,nM,IC50,=,19,nM,=,6,pIC50,,radiometric,O=C(N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,38,399.148,406.0363814,1,2,2,2,4.0045,53.17,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
11089,6005,15125923,11c,P03372,ERA,Homo sapiens,"2,2,2-Trifluoro-1-{6-hydroxy-1-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-3,4-dihydro-1H-isoquinolin-2-yl}-ethanone",Oc1ccc2C(N(CCc2c1)C(=O)C(F)(F)F)c3ccc(OCCN4CCCC4)cc3,CHEMBL89994,,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28.7nM,antagonist,83.00%,antagonist,E2,,E2,0.5nM,,,,,,,,IC50,=,86.6,nM,=,7.542118103,pIC50,B,radiometric,O=C(N1CCc2cc(O)ccc2C1c1ccc(OCCN2CCCC2)cc1)C(F)(F)F,83,409.258,434.1817273,1,4,5,2,3.9032,53.01,C1CCC(CCCC2CCC(C3CCCC4CCCCC43)CC2)C1,antagonist,antagonist,antagonist,antagonist,385
11111,6019,21269824,1,Q96RI1,FXR,Homo sapiens,"(S)-2-(6-chloro-2-(4-chlorophenyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",Fc1cc2nc(c3ccc(Cl)cc3)n([C@@H](C4CCCCC4)C(=O)NC5CCCCC5)c2cc1Cl,CHEMBL1642362,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,partial agonist,42.00%,agonist,GW4064,,,,,,,EC50,=,100,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21,42,472.221,501.1749962,1,3,5,3,7.7195,46.92,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11115,6020,21269824,7a,Q96RI1,FXR,Homo sapiens,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",Fc1cc2nc(c3ccc(Cl)cc3)n([C@@H](C4CCCCC4)C(=O)NC5CCCCC5)c2cc1F,CHEMBL1668238,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,partial agonist,31.00%,agonist,GW4064,,,,,,,EC50,=,50,nM,,,,,=,8,pIC50,B,radiometric,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,31,455.766,485.2045467,1,3,5,3,7.2052,46.92,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11132,6030,20128594,10,Q03181,PPARB,Homo sapiens,N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)biphenyl-4-carboxamide,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c2ccc(cc2)c3ccccc3,CHEMBL598609,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.7,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.6,,=,6.7,pIC50,,radiometric,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(-c2ccccc2)cc1,100,417.303,434.0911981,1,4,6,3,3.9711,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCC(C2CCCCC2)CC1,antagonist,antagonist,antagonist,antagonist,1308
11135,6031,20128594,16,Q03181,PPARB,Homo sapiens,4-bromo-2-fluoro-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide,Fc1cc(Br)ccc1C(=O)NCCS(=O)(=O)c2ccc(cn2)C(F)(F)F,CHEMBL598371,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.3,antagonist,99.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,7.1,,=,7.3,pIC50,B,radiometric,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Br)cc1F,99,444.139,453.9609882,1,4,5,2,3.2057,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
11141,6033,20128594,14,Q03181,PPARB,Homo sapiens,3-bromo-4-chloro-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c2ccc(Cl)c(Br)c2,CHEMBL611073,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.9,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.6,,=,6.9,pIC50,,radiometric,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)c(Br)c1,100,460.594,469.9314377,1,4,5,2,3.72,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
11144,6034,20128594,"3, GSK-3787",Q03181,PPARB,Homo sapiens,4-chloro-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide,FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c2ccc(Cl)cc2,CHEMBL598608,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.7,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.9,,=,6.7,pIC50,,radiometric,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1,100,380.69,392.0209256,1,4,5,2,2.9575,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
11147,6035,20128594,13,Q03181,PPARB,Homo sapiens,"2,4-dichloro-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide",FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c2ccc(Cl)cc2Cl,CHEMBL598156,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.8,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.7,,=,6.8,pIC50,,radiometric,O=C(NCCS(=O)(=O)c1ccc(C(F)(F)F)cn1)c1ccc(Cl)cc1Cl,100,416.143,425.9819532,1,4,5,2,3.6109,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
11178,6059,21269824,7c,Q96RI1,FXR,Homo sapiens,"trans-4-((S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)cyclohexanecarboxylic acid",OC(=O)[C@@H]1CC[C@H](CC1)NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5,CHEMBL1668240,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 610nM,partial agonist,26.00%,agonist,GW4064,,,,,,,EC50,=,2700,nM,,,,,=,6.214670165,pIC50,,radiometric,O=C(N[C@H]1CC[C@H](C(=O)O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,26,499.775,529.1943759,2,4,6,3,6.5159,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11181,6061,21269824,7b,Q96RI1,FXR,Homo sapiens,"trans-(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(4-hydroxycyclohexyl)acetamide",O[C@@H]1CC[C@H](CC1)NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5,CHEMBL1668239,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 41nM,partial agonist,40.00%,agonist,GW4064,,,,,,,EC50,=,30,nM,,,,,=,7.387216143,pIC50,B,radiometric,O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,40,471.765,501.1994613,2,4,5,3,6.176,67.15,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11184,6063,18722772,8,Q03181,PPARB,Homo sapiens,"4-bromo-2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1ccc(Br)cc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3,CHEMBL484467,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.3,partial agonist,51.00%,agonist,GW501516,,,,,,,PEC50,=,6.8,,,,,,=,8.3,pIC50,B,radiometric,O=C(Nc1cc(Br)ccc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,51,496.233,514.0198048,2,4,5,3,4.1466,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11194,6068,18722772,5,Q03181,PPARB,Homo sapiens,"5-bromo-2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1cc(Br)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3,CHEMBL484266,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.1,partial agonist,48.00%,agonist,GW501516,,,,,,,PEC50,=,6.7,,,,,,=,8.1,pIC50,B,radiometric,O=C(Nc1ccc(Br)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,48,496.233,514.0198048,2,4,5,3,4.1466,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11199,6070,18722772,7,Q03181,PPARB,Homo sapiens,"2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)-5-(trifluoromethyl)benzoic acid",OC(=O)c1cc(ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3)C(F)(F)F,CHEMBL522619,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.3,partial agonist,55.00%,agonist,GW501516,,,,,,,PEC50,=,6.8,,,,,,=,8.3,pIC50,B,radiometric,O=C(Nc1ccc(C(F)(F)F)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,55,485.334,504.0966774,2,4,5,3,4.4029,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11205,6074,18722772,12,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(5-hydroxy-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1cc(Cl)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4c(O)cccc4C3,CHEMBL484466,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.7,partial agonist,63.00%,agonist,GW501516,,,,,,,PEC50,=,5.7,,,,,,=,7.7,pIC50,B,radiometric,O=C(Nc1ccc(Cl)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3c(O)cccc3C2)c1,63,467.781,486.065235,3,5,5,3,3.7431,124.01,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11208,6075,18722772,13,Q03181,PPARB,Homo sapiens,"2-(3-(2-carboxy-4-chlorophenylcarbamoyl)phenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxylic acid",OC(=O)c1cccc2CN(CCc12)S(=O)(=O)c3cccc(c3)C(=O)Nc4ccc(Cl)cc4C(=O)O,CHEMBL496136,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.4,partial agonist,45.00%,agonist,GW501516,,,,,,,PEC50,=,5.9,,,,,,=,8.4,pIC50,B,radiometric,O=C(Nc1ccc(Cl)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3c(cccc3C(=O)O)C2)c1,45,495.791,514.0601496,3,5,6,3,3.7357,141.08,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11211,6076,18722772,17,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(7-chloro-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1cc(Cl)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccc(Cl)cc4C3,CHEMBL496726,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.6,partial agonist,42.00%,agonist,GW501516,,,,,,,PEC50,=,6.1,,,,,,=,7.6,pIC50,B,radiometric,O=C(Nc1ccc(Cl)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccc(Cl)cc3C2)c1,42,487.235,504.031348,2,4,5,3,4.6909,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11214,6077,18722772,16,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1cc(Cl)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccc(F)cc4C3,CHEMBL498608,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.8,partial agonist,50.00%,agonist,GW501516,,,,,,,PEC50,=,6,,,,,,=,7.8,pIC50,B,radiometric,O=C(Nc1ccc(Cl)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccc(F)cc3C2)c1,50,470.78,488.0608986,2,4,5,3,4.1766,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11217,6078,18722772,4,Q03181,PPARB,Homo sapiens,"5-chloro-2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1cc(Cl)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3,CHEMBL485088,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.1,partial agonist,53.00%,agonist,GW501516,,,,,,,PEC50,=,6.9,,,,,,=,8.1,pIC50,B,radiometric,O=C(Nc1ccc(Cl)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,53,451.782,470.0703204,2,4,5,3,4.0375,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11220,6079,18722772,6,Q03181,PPARB,Homo sapiens,"2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)-5-fluorobenzoic acid",OC(=O)c1cc(F)ccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3,CHEMBL519345,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.6,partial agonist,50.00%,agonist,GW501516,,,,,,,PEC50,=,6.3,,,,,,=,7.6,pIC50,B,radiometric,O=C(Nc1ccc(F)cc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,50,435.327,454.0998709,2,4,5,3,3.5232,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11240,6089,26321361,6,P51449,RORG,Homo sapiens,"2,6-difluoro-N-(1-(4-fluorophenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzamide",Fc1ccc(cc1)S(=O)(=O)N2CCCc3ccc(NC(=O)c4c(F)cccc4F)cc23,CHEMBL3617295,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 50nM,inverse agonist,-99.00%,agonist,,,28-hydroxycholesterol,,,,,EC50,=,26,nM,,,,,=,7.301029996,pIC50,B,radiometric,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1F,-99,429.314,446.0911981,1,3,4,3,4.4977,66.48,CC(CC1CCC2CCCC(C(C)(C)C3CCCCC3)C2C1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,950
11242,6090,26321361,4,P51449,RORG,Homo sapiens,"2,6-difluoro-N-(1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzamide",Fc1cccc(F)c1C(=O)Nc2ccc3CCCN(c3c2)S(=O)(=O)c4ccccc4,CHEMBL3617293,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 180nM,inverse agonist,-91.00%,agonist,,,27-hydroxycholesterol,,,,,EC50,=,230,nM,,,,,=,6.744727495,pIC50,,radiometric,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccccc1)CCC2)c1c(F)cccc1F,-91,410.316,428.1006199,1,3,4,3,4.3586,66.48,CC(CC1CCC2CCCC(C(C)(C)C3CCCCC3)C2C1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,950
11243,6091,26321361,2,P51449,RORG,Homo sapiens,"2,6-difluoro-N-(1-(thiophen-2-ylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)benzamide",Fc1cccc(F)c1C(=O)Nc2ccc3CCCN(c3c2)S(=O)(=O)c4cccs4,CHEMBL1592140,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 1100nM,inverse agonist,-77.00%,agonist,,,25-hydroxycholesterol,,,,,EC50,=,2100,nM,,,,,=,5.958607315,pIC50,,radiometric,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1cccs1)CCC2)c1c(F)cccc1F,-77,418.361,434.0570408,1,4,4,3,4.4201,66.48,CC(CC1CCC2CCCC(C(C)(C)C3CCCC3)C2C1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,949
11249,6096,18722772,GW9371,Q03181,PPARB,Homo sapiens,"2-(3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)benzamido)benzoic acid",OC(=O)c1ccccc1NC(=O)c2cccc(c2)S(=O)(=O)N3CCc4ccccc4C3,CHEMBL523395,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.9,partial agonist,61.00%,agonist,GW501516,,,,,,,PEC50,=,5.9,,,,,,=,6.9,pIC50,,radiometric,O=C(Nc1ccccc1C(=O)O)c1cccc(S(=O)(=O)N2CCc3ccccc3C2)c1,61,416.329,436.1092927,2,4,5,3,3.3841,103.78,CC(CC1CCCCC1)C1CCCC(C(C)(C)C2CCC3CCCCC3C2)C1,agonist,partial agonist,agonist,partial agonist,1039
11255,61,12801232,11d,P19793,RXRA,Homo sapiens,"7-[2-(2,2-Difluoro-ethoxy)-3,5-diisopropyl-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL88931,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 2nM,partial antagonist,65.00%,antagonist,?,,9-Cis-RA,,,,,,,,,IC50,=,1,nM,=,8.698970004,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)C)cc(C(C)C)c1OCC(F)F,65,362.246,392.2163013,1,2,9,1,6.5677,46.53,C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,205
11298,6123,25993269,23m,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(6-(4-Bromophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Br)cc4)c5ccc(O)cc5,CHEMBL3589363,,,,Ki = 125.51nM,antagonist,75.00%,antagonist,E2,,,,,,,,,,,IC50,=,1700,nM,=,6.90132167,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Br)cc4)C2O3)cc1,75,638.322,669.1032001,3,7,13,3,6.3777,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1126
11299,6123,25993269,23m,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(4-Bromophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Br)cc4)c5ccc(O)cc5,CHEMBL3589363,,,,Ki = 60.5nM,antagonist,77.00%,antagonist,E2,,,,,,,,,,,IC50,=,250,nM,=,7.218244625,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Br)cc4)C2O3)cc1,77,638.322,669.1032001,3,7,13,3,6.3777,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1126
11300,6124,25993269,23n,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(4-(trifluoromethyl)-phenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(cc4)C(F)(F)F)c5ccc(O)cc5,CHEMBL3589364,,,,Ki = 1722.22nM,inverse agonist,-51.00%,agonist,E2,,,,,,,,,,,IC50,=,790,nM,=,5.763911372,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(C(F)(F)F)cc4)C2O3)cc1,-51,627.423,659.1800726,3,7,13,3,6.634,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,inverse agonist,antagonist,inverse agonist,1126
11301,6124,25993269,23n,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(4-(trifluoromethyl)-phenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(cc4)C(F)(F)F)c5ccc(O)cc5,CHEMBL3589364,,,,Ki = 255.64nM,antagonist,136.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.592371191,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(C(F)(F)F)cc4)C2O3)cc1,136,627.423,659.1800726,3,7,13,3,6.634,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11302,6125,25993269,23l,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(6-(4-Chlorophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Cl)cc4)c5ccc(O)cc5,CHEMBL3589362,,,,Ki = 126.02nM,antagonist,93.00%,antagonist,E2,,,,,,,EC50,=,790,nM,,,,,=,6.899560525,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Cl)cc4)C2O3)cc1,93,593.871,625.1537157,3,7,13,3,6.2686,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11303,6125,25993269,23l,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(4-Chlorophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(Cl)cc4)c5ccc(O)cc5,CHEMBL3589362,,,,Ki = 200.01nM,antagonist,188.00%,antagonist,E2,,,,,,,EC50,=,580,nM,,,,,=,6.69894829,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(Cl)cc4)C2O3)cc1,188,593.871,625.1537157,3,7,13,3,6.2686,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11304,6126,25993269,23j,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(6-(4-Fluorophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(F)cc4)c5ccc(O)cc5,CHEMBL3589360,,,,Ki = 92.26nM,antagonist,99.00%,antagonist,E2,,,,,,,EC50,=,18000,nM,,,,,=,7.03498655,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(F)cc4)C2O3)cc1,99,577.416,609.1832662,3,7,13,3,5.7543,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11305,6126,25993269,23j,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(4-Fluorophenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(F)cc4)c5ccc(O)cc5,CHEMBL3589360,,,,Ki = 49.78nM,antagonist,85.00%,antagonist,E2,,,,,,,,,,,IC50,=,280,nM,=,7.302945108,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(F)cc4)C2O3)cc1,85,577.416,609.1832662,3,7,13,3,5.7543,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1126
11306,6127,25993269,23h,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(6-(4-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(O)cc4)c5ccc(O)cc5,CHEMBL3589358,,,,Ki = 133.05nM,antagonist,99.00%,antagonist,E2,,,,,,,EC50,=,2420,nM,,,,,=,6.875985121,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(O)cc4)C2O3)cc1,99,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11307,6127,25993269,23h,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(4-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc(O)cc4)c5ccc(O)cc5,CHEMBL3589358,,,,Ki = 39.04nM,partial agonist,69.00%,agonist,E2,,,,,,,EC50,=,13400,nM,IC50,=,11700,nM,=,7.408490191,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc(O)cc4)C2O3)cc1,69,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,1126
11308,6128,25993269,23r,P03372,ERA,Homo sapiens,8-(4-(3-(4-Hydroxyphenyl)-6-(naphthalen-2-yloxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc5ccccc5c4)c6ccc(O)cc6,CHEMBL3589368,,,,Ki = 169.40nM,partial antagonist,45.00%,antagonist,E2,,,,,,,,,,,IC50,=,920,nM,=,6.771086594,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc5ccccc5c4)C2O3)cc1,45,606.462,641.2083381,3,7,13,4,6.7684,139.23,CC(C)(CC1CCC2CCCCC2C1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1111
11309,6128,25993269,23r,Q92731,ERB,Homo sapiens,8-(4-(3-(4-Hydroxyphenyl)-6-(naphthalen-2-yloxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccc5ccccc5c4)c6ccc(O)cc6,CHEMBL3589368,,,,Ki = 55.65nM,antagonist,94.00%,antagonist,E2,,,,,,,EC50,=,530,nM,,,,,=,7.254534831,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccc5ccccc5c4)C2O3)cc1,94,606.462,641.2083381,3,7,13,4,6.7684,139.23,CC(C)(CC1CCC2CCCCC2C1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1111
11310,6129,25993269,23g,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(6-(3-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4cccc(O)c4)c5ccc(O)cc5,CHEMBL3589357,,,,Ki = 81.36nM,antagonist,108.00%,antagonist,E2,,,,,,,EC50,=,3690,nM,,,,,=,7.08958906,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4cccc(O)c4)C2O3)cc1,108,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11311,6129,25993269,23g,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(3-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4cccc(O)c4)c5ccc(O)cc5,CHEMBL3589357,,,,Ki = 101.49nM,agonist,105.00%,agonist,E2,,,,,,,EC50,=,8100,nM,,,,,=,6.993576747,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4cccc(O)c4)C2O3)cc1,105,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,agonist,agonist,"agonist,antagonist",1126
11312,6129,25993269,23g,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(3-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4cccc(O)c4)c5ccc(O)cc5,CHEMBL3589357,,,,Ki = 101.49nM,antagonist,120.00%,antagonist,E2,,,,,,,EC50,=,8100,nM,,,,,=,6.993576747,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4cccc(O)c4)C2O3)cc1,120,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,"agonist,antagonist",1126
11316,6131,25993269,23a,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(phenoxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4)c5ccc(O)cc5,CHEMBL3588865,,,,Ki = 111.91nM,partial antagonist,36.00%,antagonist,E2,,,,,,,,,,,IC50,=,1210,nM,=,6.951131104,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4)C2O3)cc1,36,558.418,591.192688,3,7,13,3,5.6152,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1126
11317,6131,25993269,23a,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(phenoxysulfonyl)-7-oxabicyclo-[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4)c5ccc(O)cc5,CHEMBL3588865,,,,Ki = 653.85nM,antagonist,97.00%,antagonist,E2,,,,,,,EC50,=,930,nM,,,,,=,6.184521872,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4)C2O3)cc1,97,558.418,591.192688,3,7,13,3,5.6152,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11318,6132,25993269,23o,P03372,ERA,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(2-(trifluoromethyl)-phenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4C(F)(F)F)c5ccc(O)cc5,CHEMBL3589365,,,,Ki = 3875.00nM,partial antagonist,37.00%,antagonist,E2,,,,,,,,,,,IC50,=,640,nM,=,5.411728293,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4C(F)(F)F)C2O3)cc1,37,627.423,659.1800726,3,7,13,3,6.634,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1126
11319,6132,25993269,23o,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(3-(4-Hydroxyphenyl)-6-(2-(trifluoromethyl)-phenoxysulfonyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4C(F)(F)F)c5ccc(O)cc5,CHEMBL3589365,,,,Ki = 478.87nM,antagonist,102.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.31978237,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4C(F)(F)F)C2O3)cc1,102,627.423,659.1800726,3,7,13,3,6.634,139.23,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11321,6133,25993269,23k,Q92731,ERB,Homo sapiens,(exo-rac)-8-(4-(6-(2-Hydroxyphenoxysulfonyl)-3-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-2-en-2-yl)phenylamino)-8-oxooctanoic Acid,OC(=O)CCCCCCC(=O)Nc1ccc(cc1)C2=C(C3CC(C2O3)S(=O)(=O)Oc4ccccc4O)c5ccc(O)cc5,CHEMBL3589361,,,,Ki = 121.43nM,antagonist,87.00%,antagonist,E2,,,,,,,,,,,,,,,=,6.915674005,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(C2=C(c3ccc(O)cc3)C3CC(S(=O)(=O)Oc4ccccc4O)C2O3)cc1,87,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11323,6134,25993269,21a,Q92731,ERB,Homo sapiens,"8-(4-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-ylsulfonyloxy)phenylamino)-8-oxooctanoic Acid",OC(=O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)cc1,CHEMBL3589349,,,,Ki = 772.73nM,antagonist,89.00%,antagonist,E2,,,,,,,,,,,IC50,=,160,nM,=,6.111972227,pKi,,other,O=C(O)CCCCCCC(=O)Nc1ccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)cc1,89,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1126
11324,6135,25993269,21b,P03372,ERA,Homo sapiens,"8-(3-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-ylsulfonyloxy)phenylamino)-8-oxooctanoic Acid",OC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)c1,CHEMBL3589350,,,,Ki = 56.57nM,antagonist,122.00%,antagonist,E2,,,,,,,,,,,,,,,=,7.247413821,pKi,B,other,O=C(O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)c1,122,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,,antagonist,,antagonist,1126
11325,6135,25993269,21b,Q92731,ERB,Homo sapiens,"8-(3-(5,6-Bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-en-2-ylsulfonyloxy)phenylamino)-8-oxooctanoic Acid",OC(=O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(=C3c4ccc(O)cc4)c5ccc(O)cc5)c1,CHEMBL3589350,,,,Ki = 629.63nM,antagonist,102.00%,antagonist,E2,,,,,,,EC50,=,2100,nM,,,,,=,6.200914587,pKi,,other,O=C(O)CCCCCCC(=O)Nc1cccc(OS(=O)(=O)C2CC3OC2C(c2ccc(O)cc2)=C3c2ccc(O)cc2)c1,102,574.417,607.1876026,4,8,13,3,5.3208,159.46,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,agonist,antagonist,agonist,antagonist,1126
11376,6158,21269824,7s,Q96RI1,FXR,Homo sapiens,"trans-2-(4-((S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)cyclohexyloxy)acetic acid",OC(=O)CO[C@@H]1CC[C@H](CC1)NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)nc5,CHEMBL1668252,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 830nM,partial agonist,26.00%,agonist,GW4064,,,,,,,EC50,=,9900,nM,,,,,=,6.080921908,pIC50,,radiometric,O=C(O)CO[C@H]1CC[C@H](NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)nc3)nc3cc(F)c(F)cc32)CC1,26,529.781,560.2001896,2,6,8,3,5.6799,106.34,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11380,6161,17391964,29,P55055,LXRB,Homo sapiens,{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenoxy} acetic acid,OC(=O)COc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL225994,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 12.0nM,partial agonist,70.00%,agonist,T0901317,,T0901317,,,,,EC50,=,1271,nM,,,,,=,7.920818754,pIC50,B,radiometric,O=C(O)COc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,70,533.356,556.1609919,2,5,9,5,7.2271,88.52,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,851
11405,6171,19464171,24,Q03181,PPARB,Homo sapiens,"2-(4-(2-(5-hydroxypent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OCCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL499312,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 0.6nM,agonist,99.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,2000,nM,,,,,=,9.22184875,pKi,B,radiometric,O=C(O)COc1ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#CCCO)c2c1CCCC2,99,557.396,586.1636943,2,6,11,3,6.5424,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
11407,6172,19464171,23,P37231,PPARG,Homo sapiens,"2-(4-(2-(4-hydroxybut-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL525989,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 210nM,agonist,79.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,5900,nM,,,,,=,6.677780705,pKi,,other,O=C(O)COc1ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#CCO)c2c1CCCC2,79,545.385,572.1480442,2,6,10,3,6.1523,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
11408,6172,19464171,23,Q03181,PPARB,Homo sapiens,"2-(4-(2-(4-hydroxybut-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OCC#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL525989,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2nM,agonist,91.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,220,nM,,,,,=,8.698970004,pKi,B,radiometric,O=C(O)COc1ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#CCO)c2c1CCCC2,91,545.385,572.1480442,2,6,10,3,6.1523,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
11410,6173,19464171,28,P37231,PPARG,Homo sapiens,"2-(4-(2-(3-(pyridin-3-yl)prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OC(=O)COc1ccc(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#Cc4cccnc4)c5CCCCc15,CHEMBL508733,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 25nM,partial agonist,66.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,1600,nM,,,,,=,7.602059991,pKi,B,other,O=C(O)COc1ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#Cc2cccnc2)c2c1CCCC2,66,591.437,619.1640287,1,6,10,4,7.6033,77.88,C1CCC(CCCCC2CC(CCC3CCCCC3)CCC2CC2CCCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,444
11411,6173,19464171,28,Q03181,PPARB,Homo sapiens,"2-(4-(2-(3-(pyridin-3-yl)prop-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",OC(=O)COc1ccc(Sc2ccc(COc3ccc(cc3)C(F)(F)F)cc2OCC#Cc4cccnc4)c5CCCCc15,CHEMBL508733,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 16nM,agonist,99.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,680,nM,,,,,=,7.795880017,pKi,B,radiometric,O=C(O)COc1ccc(Sc2ccc(COc3ccc(C(F)(F)F)cc3)cc2OCC#Cc2cccnc2)c2c1CCCC2,99,591.437,619.1640287,1,6,10,4,7.6033,77.88,C1CCC(CCCCC2CC(CCC3CCCCC3)CCC2CC2CCCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,444
11417,6176,21269824,7r,Q96RI1,FXR,Homo sapiens,"trans-2-(4-((S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)cyclohexyl)acetic acid",OC(=O)C[C@@H]1CC[C@H](CC1)NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5,CHEMBL1668251,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 610nM,partial agonist,27.00%,agonist,GW4064,,,,,,,EC50,=,5000,nM,,,,,=,6.214670165,pIC50,,radiometric,O=C(O)C[C@H]1CC[C@H](NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)CC1,27,511.786,543.210026,2,4,7,3,6.906,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11458,62,12801232,11c,P19793,RXRA,Homo sapiens,"7-[2-(2-Fluoro-ethoxy)-3,5-diisopropyl-phenyl]-3-methyl-octa-2,4,6-trienoic acid",CC(C)c1cc(C(C)C)c(OCCF)c(c1)\C(=C/C=C/C(=C/C(=O)O)/C)\C,CHEMBL92430,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of [3H]-ATRA from the ligand-binding domain (LBD) ,Ki = 1nM,partial agonist,43.00%,agonist,?,,9-Cis-RA,,,,,EC50,=,7,nM,IC50,=,4,nM,=,9,pKi,B,radiometric,C/C(=C/C=C/C(C)=C/C(=O)O)c1cc(C(C)C)cc(C(C)C)c1OCCF,43,343.248,374.2257231,1,2,9,1,6.2721,46.53,C1CCCCC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,205
11470,6205,16099653,17,P10827,TRA,Homo sapiens,"[4-(5-Bromo-6-hydroxy-naphthalen-1-yl)-3,5-dichloro-phenyl]-acetic acid",OC(=O)Cc1cc(Cl)c(c(Cl)c1)c2cccc3c(Br)c(O)ccc23,CHEMBL195079,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 101nM,agonist,80.00%,agonist,T3,,T3,,,,,EC50,=,57,nM,,,,,=,6.995678626,pIC50,,radiometric,O=C(O)Cc1cc(Cl)c(-c2cccc3c(Br)c(O)ccc23)c(Cl)c1,80,415.005,423.9268617,2,2,3,3,5.9088,57.53,C1CCC(C2CCCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,143
11471,6205,16099653,17,P10828,TRB,Homo sapiens,"[4-(5-Bromo-6-hydroxy-naphthalen-1-yl)-3,5-dichloro-phenyl]-acetic acid",OC(=O)Cc1cc(Cl)c(c(Cl)c1)c2cccc3c(Br)c(O)ccc23,CHEMBL195079,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,92.00%,agonist,T3,,T3,,,,,EC50,=,40,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=C(O)Cc1cc(Cl)c(-c2cccc3c(Br)c(O)ccc23)c(Cl)c1,92,415.005,423.9268617,2,2,3,3,5.9088,57.53,C1CCC(C2CCCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,143
11514,6224,17391964,18,P55055,LXRB,Homo sapiens,{4-[({3-[3-phenyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl}acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)c5ccccc5)cc1,CHEMBL226461,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 3.7nM,agonist,101.00%,agonist,T0901317,,T0901317,,,,,EC50,=,44,nM,,,,,=,8.431798276,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,101,489.347,512.1711626,2,3,7,5,7.8268,62.22,C1CCC(CCC2CCCC(C3C4CCCCC4CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,329
11516,6225,17391964,16,P55055,LXRB,Homo sapiens,{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl}acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL226408,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 2.4nM,agonist,100.00%,agonist,T0901317,,T0901317,,,,,EC50,=,29,nM,,,,,=,8.619788758,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,100,517.357,540.1660773,2,4,8,5,7.3908,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11518,6226,17391964,26,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzoyl-8-chloroquinolin-4-yl)phenyl]amino}-methyl)phenyl]acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(Cl)cccc34)C(=O)c5ccccc5)cc1,CHEMBL225935,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 2.7nM,agonist,101.00%,agonist,T0901317,,T0901317,,,,,EC50,=,39,nM,,,,,=,8.568636236,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,101,483.805,506.1397203,2,4,8,5,7.0254,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11520,6227,17391964,24,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzoyl-8-fluoroquinolin-4-yl)phenyl]amino}-methyl)phenyl]acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4c(F)cccc34)C(=O)c5ccccc5)cc1,CHEMBL225878,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 17.0nM,agonist,142.00%,agonist,T0901317,,T0901317,,,,,EC50,=,700,nM,,,,,=,7.769551079,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(F)cccc34)c2)cc1,142,467.35,490.1692708,2,4,8,5,6.5111,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11522,6228,17391964,25,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzoylquinolin-4-yl)phenyl]amino}methyl)-phenyl]acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(cnc4ccccc34)C(=O)c5ccccc5)cc1,CHEMBL225879,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 154nM,agonist,110.00%,agonist,T0901317,,T0901317,,,,,EC50,=,1650,nM,,,,,=,6.812479279,pIC50,,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4ccccc34)c2)cc1,110,448.352,472.1786926,2,4,8,5,6.372,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11524,6229,17391964,19,P55055,LXRB,Homo sapiens,{4-[({3-[3-[hydroxy(phenyl)methyl]-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetic acid,OC(c1ccccc1)c2cnc3c(cccc3c2c4cccc(NCc5ccc(CC(=O)O)cc5)c4)C(F)(F)F,CHEMBL226462,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 56.4nM,partial agonist,68.00%,agonist,T0901317,,T0901317,,,,,EC50,=,812,nM,,,,,=,7.248720896,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,68,517.357,542.1817273,3,4,8,5,7.2415,82.45,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,331
11527,6230,17034119,16,P55055,LXRB,Homo sapiens,{4-[({3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl} acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.9nM,agonist,85.00%,agonist,T0901317,,,,,,,EC50,=,33,nM,,,,,=,8.721246399,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,85,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11528,6230,17391964,4,P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenylamino)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 1.9nM,agonist,85.00%,agonist,T0901317,,T0901317,,,,,EC50,=,33,nM,,,,,=,8.721246399,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,85,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11529,6230,18973288,4,P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenylamino)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 41nM,partial agonist,70.00%,agonist,T0901317,,T0901317,,,,,EC50,=,3260,nM,,,,,=,7.387216143,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,70,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",331
11530,6230,17034119,16,Q13133,LXRA,Homo sapiens,{4-[({3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl} acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 7.6nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,160,nM,,,,,=,8.119186408,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,,agonist,agonist,331
11531,6230,17391964,4,Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenylamino)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 7.6nM,,,,,,,,,,,,,,,,,,,=,8.119186408,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,,,agonist,agonist,331
11532,6230,18973288,4,Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenylamino)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL217118,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 279nM,agonist,82.00%,agonist,T0901317,,T0901317,,,,,EC50,=,4270,nM,,,,,=,6.554395797,pIC50,,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,82,501.358,526.1868127,2,3,8,5,7.7506,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,331
11533,6231,17391964,27,P55055,LXRB,Homo sapiens,[4-({[3-(3-benzyl-8-chloroquinolin-4-yl)phenyl]amino}-methyl)phenyl]acetic acid,OC(=O)Cc1ccc(CNc2cccc(c2)c3c(Cc4ccccc4)cnc5c(Cl)cccc35)cc1,CHEMBL225936,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 1.4nM,agonist,107.00%,agonist,T0901317,,T0901317,,,,,EC50,=,23,nM,,,,,=,8.853871964,pIC50,B,radiometric,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,107,467.806,492.1604557,2,3,8,5,7.3852,62.22,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,331
11535,6232,17034119,14,P55055,LXRB,Homo sapiens,[4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL386772,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5nM,agonist,77.00%,agonist,T0901317,,,,,,,EC50,=,143,nM,,,,,=,8.301029996,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,77,519.349,541.1500928,1,4,8,5,7.3577,76.49,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11537,6233,17034119,15,P55055,LXRB,Homo sapiens,[4-({3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,agonist,97.00%,agonist,T0901317,,,,,,,EC50,=,71,nM,,,,,=,8.677780705,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,97,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11538,6233,18023179,"4, WAY-254011",P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,-,IC50 = 2nM,partial agonist,63.00%,agonist,T0901317,,,,,,,EC50,=,90,nM,,,,,=,8.698970004,pIC50,B,other,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,63,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",331
11539,6233,18973288,"3, WAY-254011",P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,partial agonist,63.00%,agonist,T0901317,,T0901317,,,,,EC50,=,90,nM,,,,,=,8.698970004,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,63,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",331
11540,6233,19162487,"3, WAY-254011",P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,partial agonist,63.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,93,nM,,,,,=,8.677780705,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,63,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",331
11541,6233,19853462,"3, WAY-254011",P55055,LXRB,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-5-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.1nM,agonist,97.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,71,nM,,,,,=,8.677780705,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,97,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11542,6233,17034119,15,Q13133,LXRA,Homo sapiens,[4-({3-[3-benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.5nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,240,nM,,,,,=,8.022276395,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,,agonist,"agonist,partial agonist",331
11543,6233,18023179,"4, WAY-254011",Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,agonist,90.00%,agonist,T0901317,,,,,,,EC50,=,240,nM,,,,,=,8,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,90,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11544,6233,18973288,"3, WAY-254011",Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8nM,agonist,90.00%,agonist,T0901317,,T0901317,,,,,EC50,=,160,nM,,,,,=,8.096910013,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,90,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11545,6233,19162487,"3, WAY-254011",Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.5nM,agonist,90.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,238,nM,,,,,=,8.022276395,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,90,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11546,6233,19394832,4,Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,agonist,90.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,240,nM,,,,,=,8,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,90,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",331
11547,6233,19394832,"4, WAY-254011",Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2nM,partial agonist,63.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,90,nM,,,,,=,8.698970004,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,63,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",331
11548,6233,19853462,"3, WAY-254011",Q13133,LXRA,Homo sapiens,2-(4-((3-(3-benzyl-8-(trifluoromethyl)quinolin-5-yl)phenoxy)methyl)phenyl)acetic acid,OC(=O)Cc1ccc(COc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL214719,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.5nM,,,,,,,,,,,,,,,,,,,=,8.022276395,pIC50,B,radiometric,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,,503.35,527.1708283,1,3,8,5,7.7175,59.42,C1CCC(CCC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,,,agonist,"agonist,partial agonist",331
11565,6244,17391964,28,P55055,LXRB,Homo sapiens,{3-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl} acetic acid,OC(=O)Cc1cccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)c1,CHEMBL225937,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 6.0nM,agonist,88.00%,agonist,T0901317,,T0901317,,,,,EC50,=,141,nM,,,,,=,8.22184875,pIC50,B,radiometric,O=C(O)Cc1cccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,88,517.357,540.1660773,2,4,8,5,7.3908,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11567,6245,17034119,"2, GW-3965",P55055,LXRB,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,partial agonist,30.00%,agonist,T0901317,,,,,,,EC50,=,410,nM,,,,,=,7.920818754,pIC50,B,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,30,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,"partial agonist,agonist",471
11568,6245,18800767,"2, GW-3965",P55055,LXRB,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,,,,,,GW0438,,,,,,,,,,,,,=,7.522878745,pIC50,B,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,,,agonist,"partial agonist,agonist",471
11569,6245,18973288,"2, GW-3965",P55055,LXRB,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2nM,agonist,77.00%,agonist,T0901317,,T0901317,,,,,EC50,=,90,nM,,,,,=,8.698970004,pIC50,B,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,77,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,"partial agonist,agonist",471
11570,6245,19264481,"3, GW-3965",P55055,LXRB,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,reporter gene assay,,FRET ,IC50 = 78nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,130,nM,,,,,=,7.107905397,pIC50,B,other,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,,agonist,"partial agonist,agonist",471
11571,6245,20345102,2,P55055,LXRB,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.1,agonist,100.00%,agonist,Compound 2,,,,,,,PEC50,=,6.3,,,,,,=,8.1,pIC50,B,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,100,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,"partial agonist,agonist",471
11572,6245,17034119,2,Q13133,LXRA,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,,,,,,,,,,,,,,,,,,,=,7,pIC50,,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,,,agonist,partial agonist,471
11573,6245,18800767,"2, GW-3965",Q13133,LXRA,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 235nM,,,,,,GW0438,,,,,,,,,,,,,=,6.628932138,pIC50,,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,,,agonist,partial agonist,471
11574,6245,18973288,"2, GW-3965",Q13133,LXRA,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,58.00%,agonist,T0901317,,T0901317,,,,,EC50,=,240,nM,,,,,=,8,pIC50,B,radiometric,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,58,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,471
11575,6245,19264481,3,Q13133,LXRA,Homo sapiens,"2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL59030,reporter gene assay,,FRET ,IC50 = 280nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,310,nM,,,,,=,6.552841969,pIC50,,other,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,,550.814,581.1944562,1,3,13,4,8.0891,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,,agonist,partial agonist,471
11576,6246,18023179,33,P55055,LXRB,Homo sapiens,2-(5-(3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)benzylamino)naphthalen-1-yl)acetic acid,OC(=O)Cc1cccc2c(NCc3cccc(c3)c4c(Cc5ccccc5)cnc6c(cccc46)C(F)(F)F)cccc12,CHEMBL253311,Gal4 luciferase reporter gene assays,,-,IC50 = 5nM,partial agonist,48.00%,agonist,T0901317,,,,,,,EC50,=,355,nM,,,,,=,8.301029996,pIC50,B,other,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,48,549.402,576.2024628,2,3,8,6,8.9038,62.22,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,241
11577,6246,18023179,33,Q13133,LXRA,Homo sapiens,2-(5-(3-(3-benzyl-8-(trifluoromethyl)quinolin-4-yl)benzylamino)naphthalen-1-yl)acetic acid,OC(=O)Cc1cccc2c(NCc3cccc(c3)c4c(Cc5ccccc5)cnc6c(cccc46)C(F)(F)F)cccc12,CHEMBL253311,Gal4 luciferase reporter gene assays,,-,IC50 = 123nM,partial agonist,57.00%,agonist,T0901317,,,,,,,EC50,=,685,nM,,,,,=,6.910094889,pIC50,,other,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,57,549.402,576.2024628,2,3,8,6,8.9038,62.22,C1CCC(CC2CCC3CCCCC3C2C2CCCC(CCC3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,241
11578,6247,18023179,38,P55055,LXRB,Homo sapiens,2-(5-((3-(8-(trifluoromethyl)quinolin-4-yl)phenyl)methylamino)naphthalen-1-yl)acetic acid,OC(=O)Cc1cccc2c(NCc3cccc(c3)c4ccnc5c(cccc45)C(F)(F)F)cccc12,CHEMBL253731,Gal4 luciferase reporter gene assays,,-,IC50 = 15nM,partial agonist,32.00%,agonist,T0901317,,,,,,,EC50,=,622,nM,,,,,=,7.823908741,pIC50,B,other,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,32,465.325,486.1555126,2,3,6,5,7.313,62.22,C1CCC2C(C1)CCCC2CCC1CCCC(C2CCCC3CCCCC32)C1,agonist,partial agonist,agonist,partial agonist,25
11654,6275,16153845,1a,P37231,PPARG,Homo sapiens,5-Chloro-1-(4-chloro-benzyl)-3-phenylsulfanyl-1H-indole-2-carboxylic acid,OC(=O)c1c(Sc2ccccc2)c3cc(Cl)ccc3n1Cc4ccc(Cl)cc4,CHEMBL370152,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,partial agonist,31.00%,agonist,maximal activation (no details),,,,,,,EC50,=,55,nM,,,,,=,7.585026652,pIC50,B,radiometric,O=C(O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1,31,413.22,427.0200551,1,3,5,4,6.8458,42.23,C1CCC(CC2CC(CC3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,256
11656,6276,21269824,7l,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3,5-difluorobenzoic acid",OC(=O)c1cc(F)c(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)c(F)c1,CHEMBL1615154,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 4nM,partial agonist,48.00%,agonist,GW4064,,,,,,,EC50,=,1400,nM,,,,,=,8.397940009,pIC50,B,radiometric,O=C(O)c1cc(F)c(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1,48,537.771,559.1285821,2,4,6,4,7.3714,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11660,6279,26048793,18,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4CCCCc24,CHEMBL3596270,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 760nM,inverse agonist,-96.00%,agonist,,,,,,,,EC50,=,32,nM,,,,,=,6.119186408,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)c(F)c1,-96,451.698,466.0707329,1,4,4,3,5.6269,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11662,6280,26048793,3,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)benzoic acid",OC(=O)c1ccc(cc1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4CCCCc24,CHEMBL3598142,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 2100nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,58,nM,,,,,=,5.677780705,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)cc1,-99,432.7,448.0801547,1,4,4,3,5.4878,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11663,6281,26048793,10,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598149,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 320nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,9,nM,,,,,=,6.494850022,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)c(F)c1,-99,451.698,462.0394328,1,4,4,4,5.7418,71.67,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11664,6282,26048793,2,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)benzoic acid",OC(=O)c1ccc(cc1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598141,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 1500nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,10,nM,,,,,=,5.823908741,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1,-99,432.7,444.0488546,1,4,4,4,5.6027,71.67,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11665,6283,26048793,9,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)-2-hydroxybenzoic acid",OC(=O)c1ccc(cc1O)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598148,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 650nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,2,nM,,,,,=,6.187086643,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1O,-99,448.699,460.0437692,2,5,4,4,5.3083,91.9,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11666,6284,26048793,4,P37231,PPARG,Homo sapiens,"4-(6-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyrimidin-8-yl)benzoic acid",OC(=O)c1ccc(cc1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4cccnc24,CHEMBL3598143,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 4200nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,84,nM,,,,,=,5.37675071,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3cccnc23)cc1,-99,434.696,445.0441036,1,5,4,4,4.9977,84.56,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11667,6285,26048793,24,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-cyclopropylbenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(Cl)cccc3C4CC4)n5CCCCc25,CHEMBL3596276,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 1300nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,27,nM,,,,,=,5.886056648,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3c2CCCC3)c(F)c1,-99,418.726,438.1146484,1,4,5,3,5.4855,72.19,CC(C1CCCCC1C1CC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,839
11668,6286,26048793,28,P37231,PPARG,Homo sapiens,"4-(6-(2-chloro-6-cyclopropylbenzoyl)imidazo[1,5-a]pyrimidin-8-yl)-2-hydroxybenzoic acid",OC(=O)c1ccc(cc1O)c2nc(C(=O)c3c(Cl)cccc3C4CC4)n5cccnc25,CHEMBL3596279,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 3400nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,2,nM,,,,,=,5.468521083,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3cccnc23)cc1O,-99,417.723,433.0829337,2,6,5,4,4.5619,104.79,CC(C1CCCCC1C1CC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,839
11669,6287,26048793,21,P37231,PPARG,Homo sapiens,"4-(3-(2,6-dichlorobenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(Cl)cccc3Cl)n4CCCCc24,CHEMBL3596273,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 1100nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,77,nM,,,,,=,5.958607315,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3Cl)n3c2CCCC3)c(F)c1,-99,418.146,432.0443759,1,4,4,3,5.2615,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11670,6288,26048793,27,P37231,PPARG,Homo sapiens,"Benzoic acid, 4-??3-??(3,??-??ichloro-??-??yridinyl)??arbonyl]????,??,??,??-??etrahydroimidazo[1,??-??]??yridin-??-??l]????-??luoro- ",ClC=1C=NC=C(C1C(=O)C1=NC(=C2N1CCCC2)C2=C(C=C(C(=O)O)C=C2)F)Cl,,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 4200nM,inverse agonist,-98.00%,agonist,,,,,,,,EC50,=,510,nM,,,,,=,5.37675071,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cncc3Cl)n3c2CCCC3)c(F)c1,-98,420.142,433.0396249,1,5,4,3,4.6565,85.08,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11671,6289,26048793,20,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-fluorobenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)-3-fluorobenzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3c(F)cccc3Cl)n4CCCCc24,CHEMBL3596272,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 2900nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,190,nM,,,,,=,5.537602002,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3c(F)cccc3Cl)n3c2CCCC3)c(F)c1,-99,401.691,416.0739265,1,4,4,3,4.7472,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11672,629,20469868,20e,P04150,GR,Homo sapiens,"4-(1,1-Dimethylethyl)-N-[4-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)phenyl]benzenesulfonamide",CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1083784,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.3,partial antagonist,58.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5,,=,7.3,pIC50,B,FPA,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(-c3ccc4c(cnn4-c4ccc(F)cc4)c3)c(C(F)(F)F)c2)cc1,58,542.408,567.1603609,1,4,5,5,7.9487,63.99,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,antagonist,partial antagonist,antagonist,partial antagonist,1119
11675,6290,26048793,19,P37231,PPARG,Homo sapiens,"3-fluoro-4-(3-(2-(trifluoromethyl)benzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl)benzoic acid",OC(=O)c1ccc(c(F)c1)c2nc(C(=O)c3ccccc3C(F)(F)F)n4CCCCc24,CHEMBL3596271,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 5600nM,inverse agonist,-96.00%,agonist,,,,,,,,EC50,=,840,nM,,,,,=,5.251811973,pIC50,,other,O=C(O)c1ccc(-c2nc(C(=O)c3ccccc3C(F)(F)F)n3c2CCCC3)c(F)c1,-96,416.245,432.1097053,1,4,4,3,4.9735,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11676,6291,26048793,1,P37231,PPARG,Homo sapiens,4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid,OC(=O)c1ccc(cc1)c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c4ccccc24,CHEMBL3598140,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 130nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,16,nM,,,,,=,6.886056648,pIC50,,other,O=C(O)c1ccc(-c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc23)cc1,-99,432.7,444.0488546,1,4,3,4,5.7622,72.19,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11690,630,20005711,7g,P55055,LXRB,Homo sapiens,"2-tert-butyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CC(C)(C)c1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611467,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6.5nM,partial agonist,71.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,710,nM,,,,,=,8.187086643,pIC50,B,radiometric,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,71,465.347,488.1381483,0,5,4,4,6.5134,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
11691,630,20005711,7g,Q13133,LXRA,Homo sapiens,"2-tert-butyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CC(C)(C)c1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611467,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 222nM,partial agonist,55.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,2180,nM,,,,,=,6.653647026,pIC50,,radiometric,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,55,465.347,488.1381483,0,5,4,4,6.5134,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
11696,6304,17391964,31,P55055,LXRB,Homo sapiens,4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-benzoic acid,OC(=O)c1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL225996,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 138nM,partial agonist,34.00%,agonist,T0901317,,T0901317,,,,,EC50,=,365,nM,,,,,=,6.860120914,pIC50,,radiometric,O=C(O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,34,505.346,526.1504272,2,4,7,5,7.4619,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,851
11700,6306,17034119,10,P55055,LXRB,Homo sapiens,4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)benzoic acid,OC(=O)c1ccc(COc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL214074,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 67nM,partial agonist,40.00%,agonist,T0901317,,,,,,,EC50,=,160,nM,,,,,=,7.173925197,pIC50,B,radiometric,O=C(O)c1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,40,507.338,527.1344428,1,4,7,5,7.4288,76.49,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,851
11711,6314,21269824,7j,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-(trifluoromethyl)benzoic acid",OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)c(c1)C(F)(F)F,CHEMBL1668244,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8nM,partial agonist,59.00%,agonist,GW4064,,,,,,,EC50,=,50,nM,,,,,=,8.096910013,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(C(F)(F)F)c1,59,568.78,591.1348104,2,4,6,4,8.112,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11712,6315,21269824,7h,Q96RI1,FXR,Homo sapiens,"(S)-3-chloro-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)c(Cl)c1,CHEMBL1668243,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,partial agonist,54.00%,agonist,GW4064,,,,,,,EC50,=,300,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1,54,535.228,557.1084534,2,4,6,4,7.7466,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11713,6315,D3R,FXR_27,Q96RI1,FXR,Homo sapiens,,OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)c(Cl)c1,,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 8.7nM,,,,,,"2,N-dicyclohexyl-2-[2-(2,4-dimethoxy-phenyl)-benzoimidazol-1-yl]acetamide",,,,,,,,,,,,,=,8.060480747,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1,,535.228,557.1084534,2,4,6,4,7.7466,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,,,agonist,partial agonist,1052
11714,6316,21269824,7g,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-fluorobenzoic acid",OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)c(F)c1,CHEMBL1615152,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 37nM,partial agonist,30.00%,agonist,GW4064,,,,,,,EC50,=,300,nM,,,,,=,7.431798276,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1,30,518.773,541.1380039,2,4,6,4,7.2323,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11715,6316,D3R,FXR_58,Q96RI1,FXR,Homo sapiens,,OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(nc3cc(F)c(F)cc23)-c2ccc(Cl)cc2)c(F)c1,,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 35.7nM,,,,,,"2,N-dicyclohexyl-2-[2-(2,4-dimethoxy-phenyl)-benzoimidazol-1-yl]acetamide",,,,,,,,,,,,,=,7.447331784,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1,,518.773,541.1380039,2,4,6,4,7.2323,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,,,agonist,partial agonist,1052
11716,6317,21269824,7d,Q96RI1,FXR,Homo sapiens,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4cc(F)c(F)cc34)c5ccc(Cl)cc5)cc1,CHEMBL1615153,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 50nM,partial agonist,27.00%,agonist,GW4064,,,,,,,EC50,=,2500,nM,,,,,=,7.301029996,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1,27,499.775,523.1474257,2,4,6,4,7.0932,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11717,6317,D3R,FXR_53,Q96RI1,FXR,Homo sapiens,,OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(nc3cc(F)c(F)cc23)-c2ccc(Cl)cc2)cc1,,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 315nM,,,,,,"2,N-dicyclohexyl-2-[2-(2,4-dimethoxy-phenyl)-benzoimidazol-1-yl]acetamide",,,,,,,,,,,,,=,6.501689446,pIC50,,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1,,499.775,523.1474257,2,4,6,4,7.0932,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,,,agonist,partial agonist,1052
11719,6319,21269824,7z,Q96RI1,FXR,Homo sapiens,(S)-4-(2-(2-(4-chlorophenyl)-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-(trifluoromethyl)benzoic acid,OC(=O)c1ccc(NC(=O)[C@H](C2CCCCC2)n3c(nc4ccccc34)c5ccc(Cl)cc5)c(c1)C(F)(F)F,CHEMBL1668259,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 10nM,partial agonist,35.00%,agonist,GW4064,,,,,,,EC50,=,90,nM,,,,,=,8,pIC50,B,radiometric,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1,35,530.784,555.153654,2,4,6,4,7.8338,84.22,CC(CC1CCCCC1)C(C1CCCCC1)C1C2CCCCC2CC1C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1052
11720,632,16112571,1,P04150,GR,Homo sapiens,"4-(5-Fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(C(=O)Nc1ccc2C(=O)OCc2c1)C(F)(F)F)c3cc(F)ccc3O,CHEMBL194745,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 6.2nM,antagonist,100.00%,antagonist,RU486,,,,,,,EC50,=,45,nM,EC50,=,150,nM,=,8.207608311,pIC50,B,FPA,CC(C)(CC(O)(C(=O)Nc1ccc2c(c1)COC2=O)C(F)(F)F)c1cc(F)ccc1O,100,422.225,441.1199356,3,5,5,2,3.8015,95.86,CC(CCCC1CCCCC1)CC1CCC2C(C)CCC2C1,"antagonist,agonist",antagonist,"antagonist,agonist","antagonist,partial agonist",1218
11721,632,16112571,1,P04150,GR,Homo sapiens,"4-(5-Fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(C(=O)Nc1ccc2C(=O)OCc2c1)C(F)(F)F)c3cc(F)ccc3O,CHEMBL194745,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 6.2nM,partial agonist,59.00%,agonist,dexamethasone,,,,,,,EC50,=,45,nM,EC50,=,150,nM,=,8.207608311,pIC50,B,FPA,CC(C)(CC(O)(C(=O)Nc1ccc2c(c1)COC2=O)C(F)(F)F)c1cc(F)ccc1O,59,422.225,441.1199356,3,5,5,2,3.8015,95.86,CC(CCCC1CCCCC1)CC1CCC2C(C)CCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist","antagonist,partial agonist",1218
11744,633,16112571,2,P04150,GR,Homo sapiens,"2-Hydroxy-4-methyl-4-phenyl-2-trifluoromethyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(C(=O)Nc1ccc2C(=O)OCc2c1)C(F)(F)F)c3ccccc3,CHEMBL196067,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 79nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,150,nM,=,7.102372909,pIC50,B,FPA,CC(C)(CC(O)(C(=O)Nc1ccc2c(c1)COC2=O)C(F)(F)F)c1ccccc1,100,387.228,407.1344428,2,4,5,2,3.9568,75.63,CC(CCCC1CCCCC1)CC1CCC2C(C)CCC2C1,antagonist,antagonist,antagonist,antagonist,1218
11761,6337,26238323,2,P55055,LXRB,Homo sapiens,"3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)benzoic acid",OC(=O)c1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL3609361,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 160nM,partial agonist,72.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,100,nM,,,,,=,6.795880017,pKi,,FPA,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,72,538.803,567.1788061,1,3,12,4,8.1602,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,471
11762,6337,26238323,2,Q13133,LXRA,Homo sapiens,"3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)benzoic acid",OC(=O)c1cccc(OCCCN(CC(c2ccccc2)c3ccccc3)Cc4cccc(c4Cl)C(F)(F)F)c1,CHEMBL3609361,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 210nM,partial agonist,40.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,540,nM,,,,,=,6.677780705,pKi,,FPA,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,40,538.803,567.1788061,1,3,12,4,8.1602,49.77,C1CCC(CCCCC(CC2CCCCC2)CC(C2CCCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,471
11771,6343,26048793,11,P37231,PPARG,Homo sapiens,"4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)cyclohex-3-enecarboxylic acid",OC(=O)C1CCC(=CC1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598150,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 = 1800nM,inverse agonist,-99.00%,agonist,,,,,,,,EC50,=,100,nM,,,,,=,5.744727495,pIC50,,other,O=C(c1c(Cl)cccc1C(F)(F)F)c1nc(C2=CCC(C(=O)O)CC2)c2ccccn12,-99,432.7,448.0801547,1,4,4,3,5.5056,71.67,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11772,6344,26048793,14,P37231,PPARG,Homo sapiens,"1-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)piperidine-4-carboxylic acid",OC(=O)C1CCN(CC1)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598153,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 > 10000nM,inverse agonist,-94.00%,agonist,,,,,,,,EC50,=,400,nM,,,,,>,5,pIC50,NB,other,O=C(c1c(Cl)cccc1C(F)(F)F)c1nc(N2CCC(C(=O)O)CC2)c2ccccn12,-94,434.696,451.0910537,1,5,4,3,4.5385,74.91,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11773,6345,26048793,17,P37231,PPARG,Homo sapiens,"(trans)-1-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)-3-hydroxypiperidine-4-carboxylic acid",O[C@@H]1CN(CC[C@H]1C(=O)O)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3596269,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 > 10000nM,inverse agonist,-98.00%,agonist,,,,,,,,EC50,=,97,nM,,,,,>,5,pIC50,NB,other,O=C(c1c(Cl)cccc1C(F)(F)F)c1nc(N2CC[C@@H](C(=O)O)[C@H](O)C2)c2ccccn12,-98,450.695,467.0859684,2,6,4,3,3.5093,95.14,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11774,6346,26048793,16,P37231,PPARG,Homo sapiens,"(trans)-1-(3-(2-chloro-6-(trifluoromethyl)benzoyl)imidazo[1,5-a]pyridin-1-yl)-3-hydroxypiperidine-4-carboxylic acid",O[C@H]1CN(CC[C@@H]1C(=O)O)c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n4ccccc24,CHEMBL3598155,Inhibition of RORc-LBD recruitment of the SRC1 co-activator peptide,,displacement of a fluorescent probe,IC50 > 10000nM,inverse agonist,-95.00%,agonist,,,,,,,,EC50,=,440,nM,,,,,>,5,pIC50,NB,other,O=C(c1c(Cl)cccc1C(F)(F)F)c1nc(N2CC[C@H](C(=O)O)[C@@H](O)C2)c2ccccn12,-95,450.695,467.0859684,2,6,4,3,3.5093,95.14,CC(C1CCCCC1)C1CC(C2CCCCC2)C2CCCCC12,agonist,inverse agonist,agonist,inverse agonist,852
11776,6348,12565933,9f - (+/-exo),P10827,TRA,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 61.832nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,7.208786706,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11777,6348,12565933,9g - (+/-endo),P10827,TRA,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 5.152nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,8.288024146,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11778,6348,12565933,9h (R)-(+),P10827,TRA,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 18.389nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,7.735441887,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11779,6348,12565933,9f - (+/-exo),P10828,TRB,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.59nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,9.229147988,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11780,6348,12565933,9g - (+/-endo),P10828,TRB,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.16nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,9.795880017,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11781,6348,12565933,9h (R)-(+),P10828,TRB,Homo sapiens,"2-{4-[3-(2-Aza-bicyclo[2.2.1]heptane-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CC5CCC4C5,CHEMBL338602,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.37nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,9.431798276,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CC2CCC1C2,,471.171,488.065425,2,7,4,3,3.35,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CC5CCC4C5)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,709
11782,6349,12565933,9b,P10827,TRA,Homo sapiens,"2-{3,5-Dichloro-4-[4-hydroxy-3-(piperidine-1-carbonyl)-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CCCCC4,CHEMBL125242,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 41.958nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,7.377185221,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CCCCC1,,459.16,476.065425,2,7,4,3,3.3516,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CCCCC4)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,711
11783,6349,19900809,9,P10827,TRA,Homo sapiens,"2-(3,5-dichloro-4-(4-hydroxy-3-(piperidine-1-carbonyl)phenoxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CCCCC4,CHEMBL125242,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 20nM,,,,,,T3,0.4nM,,,,,,,,,,,,=,7.698970004,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CCCCC1,,459.16,476.065425,2,7,4,3,3.3516,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CCCCC4)C3)CC2)C(C)C1,,,,inverse agonist,711
11784,6349,12565933,9b,P10828,TRB,Homo sapiens,"2-{3,5-Dichloro-4-[4-hydroxy-3-(piperidine-1-carbonyl)-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CCCCC4,CHEMBL125242,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.63nM,,,T3,0.2nM,,,,,,,,,,,,,,,=,9.200659451,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CCCCC1,,459.16,476.065425,2,7,4,3,3.3516,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CCCCC4)C3)CC2)C(C)C1,,inverse agonist,,inverse agonist,711
11785,6349,19900809,9,P10828,TRB,Homo sapiens,"2-(3,5-dichloro-4-(4-hydroxy-3-(piperidine-1-carbonyl)phenoxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione",Oc1ccc(Oc2c(Cl)cc(cc2Cl)N3N=CC(=O)NC3=O)cc1C(=O)N4CCCCC4,CHEMBL125242,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1nM,,,,,,T3,0.4nM,,,,,,,,,,,,=,9,pKi,B,radiometric,O=C(c1cc(Oc2c(Cl)cc(-n3ncc(=O)[nH]c3=O)cc2Cl)ccc1O)N1CCCCC1,,459.16,476.065425,2,7,4,3,3.3516,117.52,CC1CCC(C2CCC(CC3CCCC(C(C)C4CCCCC4)C3)CC2)C(C)C1,,,,inverse agonist,711
11786,635,16112571,25,P04150,GR,Homo sapiens,"2-Cyclohexylmethyl-4-(5-fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc2ccc3C(=O)OCc3c2)c4cc(F)ccc4O,CHEMBL194802,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 20nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,130,nM,=,7.698970004,pIC50,B,FPA,CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc1ccc2c(c1)COC2=O)c1cc(F)ccc1O,100,437.297,469.2264513,3,5,7,2,5.2096,95.86,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,946
11805,636,16112571,6,P04150,GR,Homo sapiens,"2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc2ccc3C(=O)OCc3c2)c4ccccc4,CHEMBL363137,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,140,nM,=,8.045757491,pIC50,B,FPA,CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc1ccc2c(c1)COC2=O)c1ccccc1,100,402.3,435.2409585,2,4,7,2,5.3649,75.63,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,946
11806,636,16112571,7 (optically active enantiomer of 6),P04150,GR,Homo sapiens,"2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc2ccc3C(=O)OCc3c2)c4ccccc4,CHEMBL363137,,,Fluorescence polarization (FP) competition binding assay,IC50 = 320nM,,,,,,,,,,,,,,,,,,,=,6.494850022,pIC50,,FPA,CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc1ccc2c(c1)COC2=O)c1ccccc1,,402.3,435.2409585,2,4,7,2,5.3649,75.63,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,,,antagonist,antagonist,946
11807,636,16112571,8 (optically active enantiomer of 6),P04150,GR,Homo sapiens,"2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc2ccc3C(=O)OCc3c2)c4ccccc4,CHEMBL363137,,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,,,,,,,,,,,,,,,,,,,=,8.045757491,pIC50,B,FPA,CC(C)(CC(O)(CC1CCCCC1)C(=O)Nc1ccc2c(c1)COC2=O)c1ccccc1,,402.3,435.2409585,2,4,7,2,5.3649,75.63,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,,,antagonist,antagonist,946
11860,6383,1548683,4,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled estradiol",IC50 = 170nM,partial agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,6.769551079,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11861,6383,11356100,"2, Raloxifene",P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,luciferase reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,0.72,nM,=,8.397940009,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,914
11862,6383,11459665,estradiol,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 2.2nM,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,8.657577319,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11863,6383,11906280,raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 22nM,,,,,,E2,,,,,,,inactive,,,,,,=,7.657577319,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11864,6383,12565955,1,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,,,,,,,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11865,6383,12749895,raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.4nM,,,,,,E2,,,,,,,,,,,,,=,9.397940009,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11866,6383,12749898,1 (Raloxifene),P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7nM,,,,,,E2,2nM,,,,,,,,,,,,=,8.15490196,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11867,6383,15006374,raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.8nM,antagonist,96.00%,antagonist,,,E2,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,96,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,antagonist,"antagonist,agonist",antagonist,914
11868,6383,15084115,raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 1.8nM,,,,,,E2,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11869,6383,15109649,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,HEK-293 cells stably co-transfected with either human ER a or ER b and the alkaline phosphatase reporter gene,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.8nM,antagonist,no detail about the percentage act,,,,E2,,,,,,,,,IC50,=,4,nM,=,8.744727495,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,914
11870,6383,15177442,5,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,IL-6 production assay,,-,RBA = 35,agonist,no detail about the percentage act,,,,E2,,,,,IC50,=,3.1,nM,,,,,=,35,RBA,,other,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,agonist,,"antagonist,agonist",antagonist,914
11871,6383,15225686,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.3nM,,,,,,E2,,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11872,6383,15582421,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.8nM,,,,,,,,,,,,,,,,,,,=,8.744727495,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11873,6383,15658851,7,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,ERE assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 22nM,antagonist,no detail about the percentage act,,,,E2,8nM,,,,,,,,IC50,=,2.4,nM,=,7.657577319,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,914
11874,6383,15713417,1,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.73nM,,,,,,E2,,,,,,,,,,,,,=,9.13667714,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11875,6383,15911274,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 0.89nM,,,,,,E2,,,,,,,,,,,,,=,9.050609993,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11876,6383,15993065,Raloxifene,P03372,ERA,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.7nM,,,,,,E2,,,,,,,,,,,,,=,9.15490196,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11877,6383,16203138,2,P03372,ERA,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 3.0nM,,,,,,E2,,,,,,,,,,,,,=,8.522878745,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11878,6383,16722623,raloxifene,P03372,ERA,Homo sapiens,[6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.8nM,,,,,,,,,,,,,,,,,,,=,8.744727495,pIC50,B,FPA,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11879,6383,17489582,raloxifene,P03372,ERA,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 20.6nM,,,,,,E2,50nM,,,,,,,,,,,,=,7.68613278,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11880,6383,17489582,raloxifene,P03372,ERA,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",RBA = 91,,,,,,E2,50nM,,,,,,,,,,,,=,91,RBA,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11881,6383,18722117,Raloxifene,P03372,ERA,Homo sapiens,Raloxifene,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,,,,,,E2,,,,,,,,,,,,,=,8.698970004,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11882,6383,19366247,RAL,P03372,ERA,Homo sapiens,Raloxifene,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.8nM,,,,,,,,,,,,,,,,,,,=,8.744727495,pIC50,B,FPA,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,"antagonist,agonist",antagonist,914
11883,6383,1548683,4,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled estradiol",IC50 = 170nM,,,,,,,,,,,,,,,,,,,=,6.769551079,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11884,6383,11356100,"2, Raloxifene",Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,luciferase reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 43nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,0.72,nM,=,7.366531544,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,antagonist,antagonist,914
11885,6383,11459665,estradiol,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 3.5nM,agonist,no detail about the percentage act,,,,E2,1nM,,,,,,,,,,,,=,8.455931956,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11886,6383,11906280,raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 260nM,,,,,,E2,,,,,,,inactive,,,,,,=,6.585026652,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11887,6383,12565955,1,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM,,,,,,,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11888,6383,12749895,raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.3nM,,,,,,E2,,,,,,,,,,,,,=,8.366531544,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11889,6383,12749898,1 (Raloxifene),Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 470nM,,,,,,E2,4.8nM,,,,,,,,,,,,=,6.327902142,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11890,6383,15006374,raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,antagonist,96.00%,antagonist,,,E2,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,96,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,antagonist,antagonist,antagonist,914
11891,6383,15084115,raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 12nM,,,,,,E2,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11892,6383,15109649,Raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,HEK-293 cells stably co-transfected with either human ER a or ER b and the alkaline phosphatase reporter gene,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,antagonist,no detail about the percentage act,,,,E2,,,,,,,,,IC50,=,60,nM,=,7.920818754,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,antagonist,antagonist,914
11893,6383,15225686,Raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.1nM,,,,,,E2,,,,,,,,,,,,,=,8.958607315,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11894,6383,15582421,Raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 12nM ,,,,,,E2,,,,,,,,,,,,,=,7.920818754,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11895,6383,15658851,7,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,ERE assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 260nM,antagonist,no detail about the percentage act,,,,E2,8nM,,,,,,,,IC50,=,4454,nM,=,6.585026652,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,antagonist,,antagonist,antagonist,914
11896,6383,15713417,1,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 18.9nM,,,,,,E2,,,,,,,,,,,,,=,7.723538196,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11897,6383,15911274,Raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 11.6nM,,,,,,E2,,,,,,,,,,,,,=,7.935542011,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11898,6383,15993065,Raloxifene,Q92731,ERB,Homo sapiens,[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.9nM,,,,,,E2,,,,,,,,,,,,,=,8.721246399,pIC50,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11899,6383,16203138,2,Q92731,ERB,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 161nM,,,,,,E2,,,,,,,,,,,,,=,6.793174124,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11900,6383,16722623,raloxifene,Q92731,ERB,Homo sapiens,[6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,Fluorescence polarization (FP) competition binding assay,IC50 = 8.2nM,,,,,,,,,,,,,,,,,,,=,8.086186148,pIC50,B,FPA,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11901,6383,17489582,raloxifene,Q92731,ERB,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 557nM,,,,,,E2,50nM,,,,,,,,,,,,=,6.254144805,pIC50,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11902,6383,17489582,raloxifene,Q92731,ERB,Homo sapiens,(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",RBA = 3,,,,,,E2,50nM,,,,,,,,,,,,=,3,RBA,,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11903,6383,18722117,Raloxifene,Q92731,ERB,Homo sapiens,Raloxifene,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 23nM,,,,,,E2,,,,,,,,,,,,,=,7.638272164,pKi,B,radiometric,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11904,6383,19366247,RAL,Q92731,ERB,Homo sapiens,Raloxifene,Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL81,,,Fluorescence polarization (FP) competition binding assay,IC50 = 8.2nM,,,,,,,,,,,,,,,,,,,=,8.086186148,pIC50,B,FPA,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,,446.378,473.1660793,2,6,7,4,6.0752,70,CC(C1CCC(CCCC2CCCCC2)CC1)C1C2CCCCC2CC1C1CCCCC1,,,antagonist,antagonist,914
11910,6389,19162487,4e,P55055,LXRB,Homo sapiens,3-Benzyl-4-{3-[3-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCCC6)c4,CHEMBL502579,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.6nM,agonist,89.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,98,nM,,,,,=,8.585026652,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,89,525.38,552.2024628,0,3,6,5,8.5397,42.43,CC(C1CCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,827
11911,6389,19162487,4e,Q13133,LXRA,Homo sapiens,3-Benzyl-4-{3-[3-(pyrrolidin-1-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCCC6)c4,CHEMBL502579,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,agonist,75.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,435,nM,,,,,=,7.920818754,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,75,525.38,552.2024628,0,3,6,5,8.5397,42.43,CC(C1CCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,827
11916,6390,19162487,4f,P55055,LXRB,Homo sapiens,3-Benzyl-4-{3-[3-(piperidin-1-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCCCC6)c4,CHEMBL454596,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.9nM,agonist,85.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,170,nM,,,,,=,8.537602002,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,85,537.391,566.2181128,0,3,6,5,8.9298,42.43,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,896
11917,6390,19162487,4f,Q13133,LXRA,Homo sapiens,3-Benzyl-4-{3-[3-(piperidin-1-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCCCC6)c4,CHEMBL454596,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 20nM,agonist,99.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,477,nM,,,,,=,7.698970004,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,99,537.391,566.2181128,0,3,6,5,8.9298,42.43,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,896
11918,6391,19162487,4g,P55055,LXRB,Homo sapiens,3-Benzyl-4-{3-[3-(morpholin-4-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCOCC6)c4,CHEMBL450409,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.9nM,agonist,80.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,138,nM,,,,,=,8.721246399,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,80,541.379,568.1973774,0,4,6,5,7.7761,51.66,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,896
11919,6391,19162487,4g,Q13133,LXRA,Homo sapiens,3-Benzyl-4-{3-[3-(morpholin-4-ylcarbonyl)phenoxy]phenyl}-8-(trifluoromethyl)quinoline,FC(F)(F)c1cccc2c(c(Cc3ccccc3)cnc12)c4cccc(Oc5cccc(c5)C(=O)N6CCOCC6)c4,CHEMBL450409,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 15nM,agonist,90.00%,agonist,T0901317,,T0901317,-,,,,EC50,=,435,nM,,,,,=,7.823908741,pIC50,B,radiometric,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,90,541.379,568.1973774,0,4,6,5,7.7761,51.66,CC(C1CCCCC1)C1CCCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)C1,agonist,agonist,agonist,agonist,896
11920,6392,24239186,28,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzamide",OC(c1ccc(cc1)N(CC(F)(F)F)C(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL3094385,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 > 10000nM,inverse agonist,-79.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,4000,nM,,,,,>,5,pIC50,NB,radiometric,O=C(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-79,433.185,445.0724326,1,2,4,2,5.2079,40.54,CC(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1027
11946,641,21963986,32,P04150,GR,Homo sapiens,"rac-2-(2-hydroxy-4-methyl-4-(5-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)-2-(trifluoromethyl)pentyl)-1H-indole-5-carbonitrile",CC(C)(CC(O)(Cc1cc2cc(ccc2[nH]1)C#N)C(F)(F)F)c3cc(cc4CCOc34)S(=O)(=O)C,CHEMBL1911661,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,85.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,49,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(C#N)ccc2[nH]1)C(F)(F)F)c1cc(S(C)(=O)=O)cc2c1OCC2,85,481.346,506.1487129,2,5,6,3,4.58178,103.18,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
11958,6417,17391964,35,P55055,LXRB,Homo sapiens,{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)methyl]-phenyl} (difluoro)acetic acid,OC(=O)C(F)(F)c1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL376568,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 7.8nM,agonist,124.00%,agonist,T0901317,,T0901317,,,,,EC50,=,2395,nM,,,,,=,8.107905397,pIC50,B,radiometric,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(F)(F)C(=O)O)cc2)c1,124,555.353,576.1472336,2,4,8,5,7.9401,79.29,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11960,6418,17391964,34,P55055,LXRB,Homo sapiens,{4-[({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]-phenyl}amino)-methyl]phenyl} (hydroxy)acetic acid,OC(C(=O)O)c1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL226047,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 8.5nM,agonist,91.00%,agonist,T0901317,,T0901317,,,,,EC50,=,4003,nM,,,,,=,8.070581074,pIC50,B,radiometric,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(O)C(=O)O)cc2)c1,91,533.356,556.1609919,3,5,8,5,6.8817,99.52,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11962,6419,17391964,37,P55055,LXRB,Homo sapiens,[4-(3-{[4-(2-hydroxyethyl)benzyl]amino}phenyl)-8-(trifluoromethyl) quinolin-3-yl](phenyl)methanone,OCCc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL226096,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 5.4nM,agonist,102.00%,agonist,T0901317,,T0901317,,,,,EC50,=,795,nM,,,,,=,8.26760624,pIC50,B,radiometric,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CCO)cc2)c1,102,501.358,526.1868127,2,4,8,5,7.2985,62.22,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11964,642,25516791,22,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(4-fluorophenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4ccc(F)cc4,CHEMBL3358934,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 14nM,partial agonist,64.00%,agonist,dexamethasone,,,,,,,IC50,=,48,nM,,,,,=,7.853871964,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1,64,438.275,465.20394,2,4,6,3,4.7424,61.38,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,416
11965,6420,17391964,39,P55055,LXRB,Homo sapiens,[4-(3-{[4-(hydroxymethyl)benzyl]amino}phenyl)-8-(trifluoromethyl)-quinolin-3-yl](phenyl)methanone,OCc1ccc(CNc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)C(=O)c5ccccc5)cc1,CHEMBL226098,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 12.8nM,agonist,105.00%,agonist,T0901317,,T0901317,,,,,EC50,=,2304,nM,,,,,=,7.89279003,pIC50,B,radiometric,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CO)cc2)c1,105,489.347,512.1711626,2,4,7,5,7.256,62.22,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,agonist,agonist,agonist,851
11967,6421,17391964,38,P55055,LXRB,Homo sapiens,[4-[3-(benzylamino)phenyl]-8-(trifluoromethyl)quinolin-3-yl](phenyl)-methanone,FC(F)(F)c1cccc2c(c3cccc(NCc4ccccc4)c3)c(cnc12)C(=O)c5ccccc5,CHEMBL226097,,,radiometric binding assay monitoring the displacement of [3H]-T0901317 from the ligand-binding domain (LBD) ,IC50 = 45nM,partial agonist,26.00%,agonist,T0901317,,T0901317,,,,,EC50,=,770,nM,,,,,=,7.346787486,pIC50,B,radiometric,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccccc2)c1,26,461.337,482.160598,1,3,6,5,7.7637,41.99,CC(C1CCCCC1)C1CCC2CCCCC2C1C1CCCC(CCC2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,851
11985,643,25516791,28,P04150,GR,Homo sapiens,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4cccc(c4)C(=O)N,CHEMBL3358939,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 46nM,agonist,82.00%,agonist,dexamethasone,,,,,,,IC50,=,56,nM,,,,,=,7.337242168,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1,82,461.294,490.2191754,3,5,7,3,3.7022,104.47,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
11990,6432,17181141,(+/-)-10a,P10275,AR,Homo sapiens,"tetrahydro-7-hydroxy-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",OC1CCN2C1C(=O)N(C2=O)c3ccc(c4ccccc34)[N+](=O)[O-],CHEMBL374781,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3.5nM,agonist,96.00%,agonist,DHT,,DHT,,,,,EC50,=,4.4,nM,,,,,=,8.455931956,pKi,B,radiometric,O=C1C2C(O)CCN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,96,314.192,327.0855205,1,5,2,2,1.6498,103.99,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,agonist,agonist,agonist,473
11991,6433,17181141,7a,P10275,AR,Homo sapiens,"tetrahydro-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",[O-][N+](=O)c1ccc(N2C(=O)C3CCCN3C2=O)c4ccccc14,CHEMBL374121,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.7nM,partial agonist,63.00%,agonist,DHT,,DHT,,,,,EC50,=,270,nM,,,,,=,8.769551079,pKi,B,radiometric,O=C1C2CCCN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,63,298.193,311.0906059,0,4,2,2,2.679,83.76,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,473
11998,644,25516791,21,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-(3-fluorophenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4cccc(F)c4,CHEMBL3358933,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,agonist,89.00%,agonist,dexamethasone,,,,,,,IC50,=,18,nM,,,,,=,8.045757491,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1,89,438.275,465.20394,2,4,6,3,4.7424,61.38,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12011,645,25516791,24,P04150,GR,Homo sapiens,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)phenol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4cccc(O)c4,CHEMBL3358936,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 24nM,agonist,80.00%,agonist,dexamethasone,,,,,,,IC50,=,53,nM,,,,,=,7.619788758,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1,80,435.276,463.2082764,3,5,6,3,4.3089,81.61,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12032,646,25516791,29,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-methyl-4-(3-(methylsulfonyl)phenyl)-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4cccc(c4)S(=O)(=O)C,CHEMBL3358940,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 62nM,agonist,81.00%,agonist,dexamethasone,,,,,,,IC50,=,60,nM,,,,,=,7.20760831,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1,81,495.353,525.1909121,2,6,7,3,4.0068,95.52,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12039,6463,16730987,17,P03372,ERA,Homo sapiens,"(S)-6-bromo-9a-(2-cyclopropyl-ethyl)-8,9,9a,10-tetrahydro-3H-2,3-diaza-cyclopenta[a]fluoren-7-one",BrC1=C2c3ccc4[nH]ncc4c3C[C@]2(CCC5CC5)CCC1=O,CHEMBL211800,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 229nM,partial agonist,70.00%,agonist,E2,,E2,,,,,EC50,=,61,nM,,,,,=,6.640164518,pIC50,,radiometric,O=C1CC[C@@]2(CCC3CC3)Cc3c(ccc4[nH]ncc34)C2=C1Br,70,352.126,370.0680753,1,2,3,2,4.7645,45.75,CC1CCC2(CCC3CC3)CC3C4CCCC4CCC3C2C1,agonist,partial agonist,agonist,partial agonist,603
12040,6463,16730987,17,Q92731,ERB,Homo sapiens,"(S)-6-bromo-9a-(2-cyclopropyl-ethyl)-8,9,9a,10-tetrahydro-3H-2,3-diaza-cyclopenta[a]fluoren-7-one",BrC1=C2c3ccc4[nH]ncc4c3C[C@]2(CCC5CC5)CCC1=O,CHEMBL211800,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.6nM,agonist,76.00%,agonist,E2,,E2,,,,,EC50,=,0.9,nM,,,,,=,8.795880017,pIC50,B,radiometric,O=C1CC[C@@]2(CCC3CC3)Cc3c(ccc4[nH]ncc34)C2=C1Br,76,352.126,370.0680753,1,2,3,2,4.7645,45.75,CC1CCC2(CCC3CC3)CC3C4CCCC4CCC3C2C1,agonist,agonist,agonist,agonist,603
12049,647,25516791,30,P04150,GR,Homo sapiens,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzenesulfonamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4cccc(c4)S(=O)(=O)N,CHEMBL3358941,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 170nM,partial agonist,37.00%,agonist,dexamethasone,,,,,,,IC50,>,2000,nM,,,,,=,6.769551079,pIC50,,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1,37,497.349,526.1861611,3,6,7,3,3.2507,121.54,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,,partial agonist,,partial agonist,416
12078,648,25516791,20,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-4-phenylpentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4ccccc4,CHEMBL3358932,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,90.00%,agonist,dexamethasone,,,,,,,IC50,=,17,nM,,,,,=,8.096910013,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1,90,419.277,447.2133618,2,4,6,3,4.6033,61.38,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12101,649,25516791,25,P04150,GR,Homo sapiens,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4ccccc4C(=O)N,CHEMBL3352882,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 19nM,agonist,95.00%,agonist,dexamethasone,,,,,,,IC50,=,4,nM,,,,,=,7.721246399,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O,95,461.294,490.2191754,3,5,7,3,3.7022,104.47,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12124,650,25516791,26,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-methyl-4-(2-(methylsulfonyl)phenyl)-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)N3CCOCC3)C(F)(F)F)c4ccccc4S(=O)(=O)C,CHEMBL3358937,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 10nM,agonist,95.00%,agonist,dexamethasone,,,,,,,IC50,=,2,nM,,,,,=,8,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O,95,495.353,525.1909121,2,6,7,3,4.0068,95.52,C1CCC(CCCCC2CC3CCC(C4CCCCC4)CC3C2)CC1,agonist,agonist,agonist,agonist,416
12131,6506,17181141,(-)-10a,P10275,AR,Homo sapiens,"(7R,7aS)-tetrahydro-7-hydroxy-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(c4ccccc34)[N+](=O)[O-],CHEMBL220359,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.1nM,agonist,101.00%,agonist,DHT,,DHT,,,,,EC50,=,1.5,nM,,,,,=,8.677780705,pKi,B,radiometric,O=C1[C@@H]2[C@H](O)CCN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,101,314.192,327.0855205,1,5,2,2,1.6498,103.99,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,agonist,agonist,"agonist,partial agonist",473
12132,6506,17181141,(+)-10a,P10275,AR,Homo sapiens,"(7S,7aR)-tetrahydro-7-hydroxy-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",O[C@@H]1CCN2[C@@H]1C(=O)N(C2=O)c3ccc(c4ccccc34)[N+](=O)[O-],CHEMBL220359,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,partial agonist,63.00%,agonist,DHT,,DHT,,,,,EC50,=,281,nM,,,,,=,8.823908741,pKi,B,radiometric,O=C1[C@@H]2[C@H](O)CCN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,63,314.192,327.0855205,1,5,2,2,1.6498,103.99,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,partial agonist,agonist,"agonist,partial agonist",473
12136,6509,17181141,7b,P10275,AR,Homo sapiens,"(6R)-tetrahydro-6-hydroxy-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",O[C@@H]1C[C@H]2N(C1)C(=O)N(C2=O)c3ccc(c4ccccc34)[N+](=O)[O-],CHEMBL219198,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.5nM,partial agonist,65.00%,agonist,DHT,,DHT,,,,,EC50,=,320,nM,,,,,=,8.823908741,pKi,B,radiometric,O=C1[C@H]2C[C@@H](O)CN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,65,314.192,327.0855205,1,5,2,2,1.6498,103.99,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,473
12137,651,25516791,36,P04150,GR,Homo sapiens,"5-chloro-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)S(=O)(=O)C)C(F)(F)F)c3ccc(Cl)cc3C(=O)N,CHEMBL3358947,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,agonist,93.00%,agonist,dexamethasone,,,,,,,IC50,=,19,nM,,,,,=,7.397940009,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O,93,494.773,517.1049896,3,5,7,3,3.9225,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12138,6510,17181141,7c,P10275,AR,Homo sapiens,"(6S)-tetrahydro-6-hydroxy-2-(4-nitro-1-naphthalenyl)-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione",O[C@H]1C[C@H]2N(C1)C(=O)N(C2=O)c3ccc(c4ccccc34)[N+](=O)[O-],CHEMBL2096842,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 4.3nM,partial agonist,71.00%,agonist,DHT,,DHT,,,,,EC50,=,265,nM,,,,,=,8.366531544,pKi,B,radiometric,O=C1[C@H]2C[C@H](O)CN2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,71,314.192,327.0855205,1,5,2,2,1.6498,103.99,CC1C2CCCC2C(C)C1C1CCCC2CCCCC21,agonist,partial agonist,agonist,partial agonist,473
12139,6511,17181141,4a,P10275,AR,Homo sapiens,"(1S,6R,7R)-4-(4-nitro-1-naphthyl)-2,4-diazatricyclo[5.2.1.0~2,6~]decane-3,5-dione",[O-][N+](=O)c1ccc(N2C(=O)[C@H]3[C@@H]4CC[C@@H](C4)N3C2=O)c5ccccc15,CHEMBL384533,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.0nM,agonist,85.00%,agonist,DHT,,DHT,,,,,EC50,=,385,nM,,,,,=,9,pKi,B,radiometric,O=C1[C@H]2[C@@H]3CC[C@@H](C3)N2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,85,322.215,337.106256,0,4,2,2,3.0675,83.76,CC1C(C2CCCC3CCCCC32)C(C)C2C3CCC(C3)C12,agonist,agonist,agonist,agonist,510
12152,652,25516791,35,P04150,GR,Homo sapiens,"5-fluoro-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)S(=O)(=O)C)C(F)(F)F)c3ccc(F)cc3C(=O)N,CHEMBL3358946,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 120nM,agonist,90.00%,agonist,dexamethasone,,,,,,,IC50,=,59,nM,,,,,=,6.920818754,pIC50,,FPA,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O,90,478.318,501.1345401,3,5,7,3,3.4082,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12174,6530,15006374,6,P03372,ERA,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Oc1ccc(cc1)[C@H]2[C@H](Oc3cc(O)ccc3C2=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL286115,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 31nM,partial antagonist,50.00%,antagonist,,,E2,,,,,,,,,,,,,=,7.508638306,pIC50,B,radiometric,O=C1c2ccc(O)cc2O[C@H](c2ccc(OCCN3CCCCC3)cc2)[C@@H]1c1ccc(O)cc1,50,430.31,459.204573,2,6,6,3,5.0627,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,partial antagonist,,partial antagonist,493
12175,6530,15084115,1,P03372,ERA,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Oc1ccc(cc1)[C@H]2[C@H](Oc3cc(O)ccc3C2=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL286115,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 39nM,,,,,,E2,,,,,,,,,,,,,=,7.408935393,pIC50,B,radiometric,O=C1c2ccc(O)cc2O[C@H](c2ccc(OCCN3CCCCC3)cc2)[C@@H]1c1ccc(O)cc1,,430.31,459.204573,2,6,6,3,5.0627,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,,,partial antagonist,493
12176,6530,15006374,6,Q92731,ERB,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Oc1ccc(cc1)[C@H]2[C@H](Oc3cc(O)ccc3C2=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL286115,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2049nM,partial antagonist,50.00%,antagonist,,,E2,,,,,,,,,,,,,=,5.688458042,pIC50,,radiometric,O=C1c2ccc(O)cc2O[C@H](c2ccc(OCCN3CCCCC3)cc2)[C@@H]1c1ccc(O)cc1,50,430.31,459.204573,2,6,6,3,5.0627,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,partial antagonist,,partial antagonist,493
12177,6530,15084115,1,Q92731,ERB,Homo sapiens,"(2S,3S)-7-Hydroxy-3-(4-hydroxy-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-chroman-4-one",Oc1ccc(cc1)[C@H]2[C@H](Oc3cc(O)ccc3C2=O)c4ccc(OCCN5CCCCC5)cc4,CHEMBL286115,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-estradiol",IC50 = 2732nM,,,,,,E2,,,,,,,,,,,,,=,5.563519305,pIC50,,radiometric,O=C1c2ccc(O)cc2O[C@H](c2ccc(OCCN3CCCCC3)cc2)[C@@H]1c1ccc(O)cc1,,430.31,459.204573,2,6,6,3,5.0627,79.23,CC1C2CCCCC2CC(C2CCC(CCCC3CCCCC3)CC2)C1C1CCCCC1,,,,partial antagonist,493
12193,6539,18809325,1f,P37231,PPARG,Homo sapiens,"2,4,6-trichlorophenyl 2-phenylethenesulfonate",Clc1cc(Cl)c(OS(=O)(=O)\C=C\c2ccccc2)c(Cl)c1,CHEMBL451531,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49651",IC50 = 1439nM,partial agonist,60.90%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,5.841939206,pIC50,,radiometric,O=S(=O)(/C=C/c1ccccc1)Oc1c(Cl)cc(Cl)cc1Cl,60.9,354.577,361.9337982,0,3,4,2,5.0263,43.37,CC(C)(CCC1CCCCC1)CC1CCCCC1,,partial agonist,,partial agonist,1220
12194,654,25516791,31,P04150,GR,Homo sapiens,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)S(=O)(=O)C)C(F)(F)F)c3ccccc3C(=O)N,CHEMBL3358942,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 140nM,agonist,86.00%,agonist,dexamethasone,,,,,,,IC50,=,80,nM,,,,,=,6.853871964,pIC50,,FPA,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O,86,459.32,483.1439619,3,5,7,3,3.2691,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12197,6542,18809325,1b,P37231,PPARG,Homo sapiens,naphthalen-2-yl 2-phenylethenesulfonate,O=S(=O)(Oc1ccc2ccccc2c1)\C=C\c3ccccc3,CHEMBL469938,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49647",IC50 = 1088nM,partial agonist,25.80%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,5.963371105,pIC50,,radiometric,O=S(=O)(/C=C/c1ccccc1)Oc1ccc2ccccc2c1,25.8,296.262,310.0663653,0,3,4,3,4.2193,43.37,CC(C)(CCC1CCCCC1)CC1CCC2CCCCC2C1,,partial agonist,,partial agonist,1217
12198,6543,18809325,1l,P37231,PPARG,Homo sapiens,3-phenoxyphenyl 2-phenylethenesulfonate,O=S(=O)(Oc1cccc(Oc2ccccc2)c1)\C=C\c3ccccc3,CHEMBL513215,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49657",IC50 = 382nM,partial agonist,41.60%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,6.417936637,pIC50,,radiometric,O=S(=O)(/C=C/c1ccccc1)Oc1cccc(Oc2ccccc2)c1,41.6,336.283,352.07693,0,4,6,3,4.8584,52.6,CC(C)(CCC1CCCCC1)CC1CCCC(CC2CCCCC2)C1,,partial agonist,,partial agonist,1222
12199,6544,18809325,1a,P37231,PPARG,Homo sapiens,phenyl 2-phenylethenesulfonate,O=S(=O)(Oc1ccccc1)\C=C\c2ccccc2,CHEMBL443343,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled BRL49646",IC50 = 1326nM,partial agonist,33.40%,agonist,15d-PGJ2 ,,BRL49653,,,,,,,,,,,,,=,5.877456476,pIC50,,radiometric,O=S(=O)(/C=C/c1ccccc1)Oc1ccccc1,33.4,248.218,260.0507152,0,3,4,2,3.0661,43.37,CC(C)(CCC1CCCCC1)CC1CCCCC1,,partial agonist,,partial agonist,1220
12202,6547,20469868,23a,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-1-phenylmethanesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(NS(=O)(=O)Cc5ccccc5)cc4C(F)(F)F,CHEMBL1086484,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 8.0,agonist,92.00%,agonist,dexamethasone,,,,,,,PEC50,=,7.7,,,,,,=,8,pIC50,B,FPA,O=S(=O)(Cc1ccccc1)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,92,506.375,525.1134107,1,4,6,5,6.7923,63.99,CC(C)(CC1CCCCC1)CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,1146
12209,655,25516791,33,P04150,GR,Homo sapiens,"1,1,1-trifluoro-4-methyl-2-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-4-(2-(methylsulfonyl)phenyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)S(=O)(=O)C)C(F)(F)F)c3ccccc3S(=O)(=O)C,CHEMBL3358944,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,agonist,91.00%,agonist,dexamethasone,,,,,,,IC50,=,27,nM,,,,,=,7.468521083,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O,91,493.379,518.1156986,2,6,7,3,3.5737,117.19,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12210,6550,20469868,19d,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-(2-hydroxyethyl)-3-(trifluoromethyl)benzenesulfonamide,OCCNS(=O)(=O)c1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1086086,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,antagonist,90.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.7,,=,7.8,pIC50,B,FPA,O=S(=O)(NCCO)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,90,462.319,479.0926753,2,5,6,4,4.121,84.22,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,107
12213,6551,23294830,29,P37231,PPARG,Homo sapiens,"2,4-Dichloro-N-(4-(5-chloropyridin-3-yloxy)-3,5-bis(trifluoromethyl)phenyl)benzenesulfonamide",FC(F)(F)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc(c1Oc3cncc(Cl)c3)C(F)(F)F,CHEMBL2338478,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 31nM,partial agonist,55.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,100,nM,,,,,=,7.508638306,pIC50,B,radiometric,O=S(=O)(Nc1cc(C(F)(F)F)c(Oc2cncc(Cl)c2)c(C(F)(F)F)c1)c1ccc(Cl)cc1Cl,55,556.634,563.9303655,1,4,5,3,7.6725,68.29,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
12217,6555,23294830,26,P37231,PPARG,Homo sapiens,"2,4-Dichloro-N-(3-chloro-4-(5-chloropyridin-3-yloxy)-5-fluorophenyl)benzenesulfonamide",Fc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc(Cl)c1Oc3cncc(Cl)c3,CHEMBL2331771,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 18nM,partial agonist,45.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,20,nM,,,,,=,7.744727495,pIC50,B,radiometric,O=S(=O)(Nc1cc(F)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl,45,473.075,479.9072021,1,4,5,3,6.4274,68.29,CC(C)(CC1CCC(CC2CCCCC2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1167
12218,6556,20469868,23e,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-3-(trifluoromethyl)benzenesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(NS(=O)(=O)c5cccc(c5)C(F)(F)F)cc4C(F)(F)F,CHEMBL1084014,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.3,agonist,85.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.7,,,,,,=,7.3,pIC50,B,FPA,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1cccc(C(F)(F)F)c1,85,563.369,579.0851453,1,4,5,5,7.67,63.99,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,agonist,agonist,agonist,agonist,1119
12221,6557,20469868,23c,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-3-[(trifluoromethyl)oxy]benzenesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(NS(=O)(=O)c5cccc(OC(F)(F)F)c5)cc4C(F)(F)F,CHEMBL1085958,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.4,agonist,88.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.6,,,,,,=,7.4,pIC50,B,FPA,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1cccc(OC(F)(F)F)c1,88,579.368,595.0800599,1,5,6,5,7.5498,73.22,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,agonist,agonist,agonist,agonist,1119
12224,6558,20469868,20d,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]benzenesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(NS(=O)(=O)c5ccccc5)cc4C(F)(F)F,CHEMBL1083783,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,antagonist,84.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.8,,=,7.8,pIC50,B,FPA,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1ccccc1,84,494.364,511.0977607,1,4,5,5,6.6512,63.99,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1119
12227,6559,20469868,23f,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-3-thiophenesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(NS(=O)(=O)c5ccsc5)cc4C(F)(F)F,CHEMBL1082780,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,partial agonist,38.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.6,,,,,,=,7.9,pIC50,B,FPA,O=S(=O)(Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1)c1ccsc1,38,502.409,517.0541816,1,5,5,5,6.7127,63.99,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCC1,agonist,partial agonist,agonist,partial agonist,1118
12230,656,25516791,34,P04150,GR,Homo sapiens,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzenesulfonamide",CC(C)(CC(O)(Cc1cc2cc(ncc2[nH]1)S(=O)(=O)C)C(F)(F)F)c3ccccc3S(=O)(=O)N,CHEMBL3358945,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 180nM,agonist,77.00%,agonist,dexamethasone,,,,,,,IC50,=,200,nM,,,,,=,6.744727495,pIC50,,FPA,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O,77,495.375,519.1109475,3,6,7,3,2.8176,143.21,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12233,6562,23294830,34,P37231,PPARG,Homo sapiens,"2,4-dichloro-N-(3-chloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide",Clc1ccc(c(Cl)c1)S(=O)(=O)Nc2ccc(Oc3cnc4ccccc4c3)c(Cl)c2,CHEMBL2338472,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of [3H2]-radiolabeled rosiglitazone from the ligand-binding domain (LBD) ,IC50 = 18nM,partial agonist,30.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,100,nM,,,,,=,7.744727495,pIC50,B,radiometric,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,30,466.668,477.9712463,1,4,5,4,6.7881,68.29,CC(C)(CC1CCC(CC2CCC3CCCCC3C2)CC1)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1157
12239,6568,20469868,19b,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-phenyl-3-(trifluoromethyl)benzenesulfonamide,Fc1ccc(cc1)n2ncc3cc(ccc23)c4ccc(cc4C(F)(F)F)S(=O)(=O)Nc5ccccc5,CHEMBL1083149,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.6,partial antagonist,68.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.5,,=,7.6,pIC50,B,FPA,O=S(=O)(Nc1ccccc1)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,68,494.364,511.0977607,1,4,5,5,6.6512,63.99,CC(C)(CC1CCCCC1)C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,1134
12242,6569,25993269,OBHS,P03372,ERA,Homo sapiens,"(exo)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic acid phenyl ester",Oc1ccc(cc1)C2=C([C@H]3O[C@@H]2C[C@@H]3S(=O)(=O)Oc4ccccc4)c5ccc(O)cc5,CHEMBL3589346,,,,Ki = 21.53nM,partial antagonist,70.00%,antagonist,E2,,,,,,,EC50,=,95,nM,IC50,=,14,nM,=,7.66695597,pKi,B,other,O=S(=O)(Oc1ccccc1)[C@H]1C[C@H]2O[C@@H]1C(c1ccc(O)cc1)=C2c1ccc(O)cc1,70,416.325,436.0980594,2,6,5,3,3.9571,93.06,CC(C)(CC1CCCCC1)C1CC2CC1C(C1CCCCC1)C2C1CCCCC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,1126
12244,657,21963986,33,P04150,GR,Homo sapiens,"rac-2-(2-hydroxy-4-methyl-4-(5-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)-2-(trifluoromethyl)pentyl)-1H-indole-6-carbonitrile",CC(C)(CC(O)(Cc1cc2ccc(cc2[nH]1)C#N)C(F)(F)F)c3cc(cc4CCOc34)S(=O)(=O)C,CHEMBL1911662,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,89.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,39,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccc(C#N)cc2[nH]1)C(F)(F)F)c1cc(S(C)(=O)=O)cc2c1OCC2,89,481.346,506.1487129,2,5,6,3,4.58178,103.18,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12247,6570,16678409,3a,P06401,PR,Homo sapiens,"1-(5-bromothiophen-2-ylsulfonyl)-3-(3,4-dichlorophenyl)-4,5,6,7-tetrahydro-1H-1,2-diazepine",Clc1ccc(cc1Cl)C2=NN(CCCC2)S(=O)(=O)c3ccc(Br)s3,CHEMBL380305,,CV-1 cells ??reporter gene assay,Fluorescence polarization (FP) competition binding assay,PKi = 7.6,partial antagonist,60.00%,antagonist,progesterone,4nM,,,,,,,,,,PIC50,=,6.5,,=,7.6,pKi,B,FPA,O=S(=O)(c1ccc(Br)s1)N1CCCCC(c2ccc(Cl)c(Cl)c2)=N1,60,455.121,465.8978871,0,4,3,2,5.3963,49.74,CC(C)(C1CCCC1)C1CCCCC(C2CCCCC2)C1,antagonist,partial antagonist,antagonist,partial antagonist,955
12250,6573,15925510,10,P06401,PR,Homo sapiens,"1-(4-Chloro-benzenesulfonyl)-3-(3,4-dichloro-phenyl)-5-phenyl-4,5-dihydro-1H-pyrazole",Clc1ccc(cc1)S(=O)(=O)N2N=C(CC2c3ccccc3)c4ccc(Cl)c(Cl)c4,CHEMBL190900,,CV-1 cellscotransfected with the luciferase reporter plasmid ,Fluorescence polarization (FP) competition binding assay,PKi = 5.1,antagonist,75.00%,antagonist,mifepristone,,,,,,,,,,,PIC50,=,6.4,,=,5.1,pKi,,FPA,O=S(=O)(c1ccc(Cl)cc1)N1N=C(c2ccc(Cl)c(Cl)c2)CC1c1ccccc1,75,450.669,463.9919818,0,3,4,3,6.1868,49.74,CC(C)(C1CCCCC1)C1CC(C2CCCCC2)CC1C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1018
12251,6574,24239186,7,P51449,RORG,Homo sapiens,"4-fluoro-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccc(F)cc2)(C(F)(F)F)C(F)(F)F,CHEMBL3094369,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 34nM,inverse agonist,-99.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,19,nM,,,,,=,7.468521083,pIC50,B,radiometric,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-99,488.238,499.0299964,1,3,5,2,4.8955,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
12257,658,21963986,29,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-4-(5-bromo-2,3-dihydrobenzofuran-7-yl)-1,1,1-trifluoro-4-methylpentan-2-ol",CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c3cc(Br)cc4CCOc34,CHEMBL1911658,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 32nM,agonist,88.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,16,nM,,,,,=,7.494850022,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c1cc(Br)cc2c1OCC2,88,459.156,481.0864257,2,2,5,3,6.0691,45.25,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12262,6581,15125923,11i,P03372,ERA,Homo sapiens,"2-(Naphthalene-1-sulfonyl)-1-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol",Oc1ccc2C(N(CCc2c1)S(=O)(=O)c3cccc4ccccc34)c5ccc(OCCN6CCCC6)cc5,CHEMBL93230,,MCF-7 transient transfection assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.6nM,antagonist,96.00%,antagonist,E2,,E2,0.5nM,,,,,,,,IC50,=,51.3,nM,=,8.251811973,pIC50,B,radiometric,O=S(=O)(c1cccc2ccccc12)N1CCc2cc(O)ccc2C1c1ccc(OCCN2CCCC2)cc1,96,496.418,528.2082785,1,5,7,4,5.3564,70.08,CC(C)(C1CCCC2CCCCC21)C1CCC2CCCCC2C1C1CCC(CCCC2CCCC2)CC1,antagonist,antagonist,antagonist,antagonist,990
12268,6584,24239186,1,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 60nM,inverse agonist,-99.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,54,nM,,,,,=,7.22184875,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-99,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,"agonist,antagonist",inverse agonist,1138
12269,6584,25305688,T0901317,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,M1H assays,Fluorescence Resonance Energy Transfer (FRET),PIC50 = 7.9,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,447,nM,=,7.9,pIC50,B,other,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,antagonist,,"agonist,antagonist",inverse agonist,1138
12270,6584,16876993,T0901317,P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-(2,2,2-trifluoroethyl)phenyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 70nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,300,nM,,,,,=,7.15490196,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12271,6584,17034119,"3, TO901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,transfected hLXR reporter cell  line  (LAFb),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,16,nM,,,,,=,8,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12272,6584,18023179,"3, TO901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,-,IC50 = 9nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,178,nM,,,,,=,8.045757491,pIC50,B,other,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12273,6584,18800767,"3, T1317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,,,,,,GW0438,,,,,,,,,,,,,=,7.522878745,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12274,6584,18973288,"1, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,agonist,100.00%,agonist,T0901317,,T0901317,,,,,EC50,=,310,nM,,,,,=,7.920818754,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12275,6584,19264481,"2, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,FRET ,IC50 = 8nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,75,nM,,,,,=,8.096910013,pIC50,B,other,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,,agonist,agonist,1138
12276,6584,19853462,"1, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,agonist,100.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,16,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12277,6584,19932617,1,P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,agonist,100.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12278,6584,19962892,1 (TO901317),P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,agonist,100.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12279,6584,20005711,"1, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,agonist,100.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12280,6584,20006495,"1, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,,,,,,T0901317,,,,,,,,,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12281,6584,20345102,3,P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 7.7,agonist,110.00%,agonist,Compound 2,,,,,,,PEC50,=,7,,,,,,=,7.7,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,110,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12282,6584,20350005,1a,P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,100.00%,agonist,1a,170nM,,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12283,6584,20382019,"1, T0901317",P55055,LXRB,Homo sapiens,Tularik,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9nM,agonist,100.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,170,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12284,6584,22406115,"2, T0901317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 100nM,,,,,,Compound 1,,,,,,,,,,,,,=,7,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12285,6584,25435151,"1a, TO-091317",P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 26nM,agonist,140.00%,agonist,compound 3b,,,,,,,EC50,=,140,nM,,,,,=,7.585026652,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,140,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12286,6584,26238323,1,P55055,LXRB,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 220nM,agonist,100.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,130,nM,,,,,=,6.657577319,pKi,,FPA,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12287,6584,11090131,T0901317,Q13133,LXRA,Homo sapiens,,c1ccc(cc1)S(=O)(=O)N(CC(F)(F)F)c2ccc(cc2)C(C(F)(F)F)(C(F)(F)F)O, ZINC01550221,transcriptional potency ??luciferase reporter gene,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",IC50 = 20 nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,20,nM,,,,,=,7.698970004,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,,agonist,agonist,1138
12288,6584,16876993,T0901317,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-(2,2,2-trifluoroethyl)phenyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 30nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,250,nM,,,,,=,7.522878745,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12289,6584,17034119,3,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,,,,,,,,,,,,,,,,,,,=,8,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12290,6584,18023179,"3, TO901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,100.00%,agonist,T0901317,,,,,,,EC50,=,135,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12291,6584,18800767,"3, T1317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 75nM,,,,,,GW0438,,,,,,,,,,,,,=,7.124938737,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12292,6584,18973288,"1, T0901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 100nM,agonist,100.00%,agonist,T0901317,,T0901317,,,,,EC50,=,660,nM,,,,,=,7,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12293,6584,19264481,2,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,FRET ,IC50 = 10nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,85,nM,,,,,=,8,pIC50,B,other,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,,agonist,agonist,1138
12294,6584,19394832,3,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,agonist,100.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,135,nM,,,,,=,7.853871964,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12295,6584,19394832,"3, TO901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Transactivation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 9nM,agonist,100.00%,agonist,CHEMBL62136,14nM,,,,,,EC50,=,178,nM,,,,,=,8.045757491,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12296,6584,19853462,"1, T0901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,,,,,,,,,,,,,,,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12297,6584,19932617,1,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,,,,,,,,,,,,,,,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12298,6584,19962892,1 (TO901317),Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,100.00%,agonist,T0901317,140nM,T0901317,,,,,EC50,=,140,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12299,6584,20005711,"1, T0901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,agonist,100.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,135,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12300,6584,20006495,"1, T0901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,,,,,,T0901317,,,,,,,,,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12301,6584,20350005,1a,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 13nM,agonist,100.00%,agonist,1a,140nM,,,,,,EC50,=,140,nM,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12302,6584,20382019,"1, T0901317",Q13133,LXRA,Homo sapiens,Tularik,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 13nM,,,,,,,,,,,,,,,,,,,=,7.886056648,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12303,6584,22406115,"2, T0901317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 100nM,,,,,,Compound 1,,,,,,,,,,,,,=,7,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,,,agonist,agonist,1138
12304,6584,25435151,"1a, TO-091317",Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 31nM,agonist,100.00%,agonist,compound 3b,,,,,,,EC50,=,28,nM,,,,,=,7.508638306,pIC50,B,radiometric,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12305,6584,26238323,1,Q13133,LXRA,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL62136,Cell transfection assay (CTF),,Fluorescence polarization (FP) competition binding assay,Ki = 230nM,agonist,100.00%,agonist,,,T0901317,0.5nM,,,,EC50,=,30,nM,,,,,=,6.638272164,pKi,,FPA,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,100,469.24,481.0394182,1,3,5,2,4.7564,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,agonist,agonist,agonist,1138
12307,6586,24239186,18,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(3,3,3-trifluoropropyl)benzenesulfonamide",OC(c1ccc(cc1)N(CCC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,CHEMBL3094378,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 519nM,inverse agonist,-70.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,4000,nM,,,,,=,6.284832642,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(CCC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-70,481.251,495.0550683,1,3,6,2,5.1465,57.61,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
12308,6587,24239186,12,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxyethyl)benzenesulfonamide",OCCN(c1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c2ccccc2,CHEMBL3094373,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 4000nM,inverse agonist,-80.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,1000,nM,,,,,=,5.397940009,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(CCO)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-80,428.245,443.0625983,2,4,6,2,3.1864,77.84,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
12310,6589,24239186,19,P51449,RORG,Homo sapiens,"N-benzyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)benzenesulfonamide",OC(c1ccc(cc1)N(Cc2ccccc2)S(=O)(=O)c3ccccc3)(C(F)(F)F)C(F)(F)F,CHEMBL3094379,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 467nM,inverse agonist,-64.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,8000,nM,,,,,=,6.330683119,pIC50,,radiometric,O=S(=O)(c1ccccc1)N(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-64,472.301,489.0833337,1,3,6,3,5.3943,57.61,CC(C)(C1CCCCC1)C(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1067
12311,659,21963986,30,P04150,GR,Homo sapiens,"rac-7-(4-((1H-indol-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-2,3-dihydrobenzofuran-5-carbonitrile",CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c3cc(cc4CCOc34)C#N,CHEMBL1911659,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 15nM,partial agonist,65.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,104,nM,,,,,=,7.823908741,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c1cc(C#N)cc2c1OCC2,65,405.27,428.1711626,2,3,5,3,5.17828,69.04,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,975
12319,6595,24239186,26,P51449,RORG,Homo sapiens,"1,1,1,3,3,3-hexafluoro-2-(1-(phenylsulfonyl)indolin-5-yl)propan-2-ol",OC(c1ccc2N(CCc2c1)S(=O)(=O)c3ccccc3)(C(F)(F)F)C(F)(F)F,CHEMBL205937,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 883nM,inverse agonist,-76.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,5000,nM,,,,,=,6.054039296,pIC50,,radiometric,O=S(=O)(c1ccccc1)N1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,-76,412.246,425.0520336,1,3,3,2,3.7502,57.61,CC(C)(C1CCCCC1)C1CCC2CCCCC21,agonist,inverse agonist,agonist,inverse agonist,1014
12331,66,15006411,32,P19793,RXRA,Homo sapiens,"(E)-3-[4-(3,5-Di-tert-butyl-2-methyl-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid",C\C(=C/C(=O)O)\c1cc2c(cccc2s1)c3cc(cc(c3C)C(C)(C)C)C(C)(C)C,CHEMBL44420,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7nM,partial agonist,43.00%,agonist,,,ATRA,,,,,EC50,=,39,nM,,,,,=,8.15490196,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2c(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3C)cccc2s1,43,388.362,420.2123013,1,2,3,3,7.95962,37.3,C1CCC(C2CCCC3CCCC32)CC1,agonist,partial agonist,agonist,partial agonist,138
12334,660,21963986,27,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methylpentan-2-ol",CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c3cc(F)cc4CCOc34,CHEMBL1911656,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 8nM,agonist,90.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,21,nM,,,,,=,8.096910013,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c1cc(F)cc2c1OCC2,90,398.25,421.1664919,2,2,5,3,5.4457,45.25,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12337,6600,24239186,8,P51449,RORG,Homo sapiens,"N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)pyridine-3-sulfonamide",OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2cccnc2)(C(F)(F)F)C(F)(F)F,CHEMBL3094370,Inhibition of RORG LBD recruitment of the SRC1 co-activator peptide (negative percents?: denotes inverse agonism),,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 748nM,inverse agonist,-88.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,1000,nM,,,,,=,6.126098402,pIC50,,radiometric,O=S(=O)(c1cccnc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,-88,471.236,482.0346672,1,4,5,2,4.1514,70.5,CC(C)(CC1CCCCC1)C1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1138
12351,6609,22746350,8d,P10275,AR,Homo sapiens,"rac-3-(4-Nitro-3-(trifluoromethyl)phenyl)-3a,4,5,6,7,8,9,9aoctahydrocycloocta[d]isoxazole",[O-][N+](=O)c1ccc(cc1C(F)(F)F)C2=NOC3CCCCCCC23,CHEMBL2159547,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.15,partial antagonist,27.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.15,pIC50,,radiometric,O=[N+]([O-])c1ccc(C2=NOC3CCCCCCC23)cc1C(F)(F)F,27.8,325.181,342.1191271,0,4,2,1,4.6869,64.73,C1CCCC2C(CC1)CCC2C1CCCCC1,,partial antagonist,,partial antagonist,78
12352,661,21963986,31,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-1,1,1-trifluoro-4-methyl-4-(5-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c3cc(cc4CCOc34)S(=O)(=O)C,CHEMBL1911660,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 6nM,agonist,84.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,100,nM,,,,,=,8.22184875,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c1cc(S(C)(=O)=O)cc2c1OCC2,84,455.328,481.153464,2,4,6,3,4.7101,79.39,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12358,6613,22746350,7e',P10275,AR,Homo sapiens,"(S,S)-3-(4-Nitro-2-(trifluoromethyl)phenyl)-4,5,6,7,8,8a-hexahydro-3aH-cyclohepta[d]-isoxazole",[O-][N+](=O)c1ccc(C2=NO[C@H]3CCCCC[C@@H]23)c(c1)C(F)(F)F,CHEMBL2159542,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.41,partial antagonist,25.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.41,pIC50,,radiometric,O=[N+]([O-])c1ccc(C2=NO[C@H]3CCCCC[C@@H]23)c(C(F)(F)F)c1,25.5,313.17,328.103477,0,4,2,1,4.2968,64.73,C1CCC(C2CCC3CCCCCC32)CC1,,partial antagonist,,partial antagonist,126
12359,6614,22746350,6e',P10275,AR,Homo sapiens,"(S,S)-3-(4-Nitro-2-(trifluoromethy l)phenyl)-3a,4,5,6,7,7ahexahydrobenzo[d]isoxazole",[O-][N+](=O)c1ccc(C2=NO[C@H]3CCCC[C@@H]23)c(c1)C(F)(F)F,CHEMBL2159571,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.58,antagonist,75.90%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.58,pIC50,,radiometric,O=[N+]([O-])c1ccc(C2=NO[C@H]3CCCC[C@@H]23)c(C(F)(F)F)c1,75.9,301.159,314.0878269,0,4,2,1,3.9067,64.73,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
12365,662,21963986,26,P04150,GR,Homo sapiens,"rac-2-((1H-indol-2-yl)methyl)-4-(2,3-dihydrobenzofuran-7-yl)-1,1,1-trifluoro-4-methylpentan-2-ol",CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c3cccc4CCOc34,CHEMBL1911655,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 19nM,agonist,83.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,10,nM,,,,,=,7.721246399,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccccc2[nH]1)C(F)(F)F)c1cccc2c1OCC2,83,379.252,403.1759137,2,2,5,3,5.3066,45.25,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12378,663,20735001,38,P04150,GR,Homo sapiens,"3-[4,4,4-Trifluoro-3-hydroxy-1,1-dimethyl-3-(1H-pyrrolo-[2,3-c]pyridin-2-ylmethyl)butyl]biphenyl-4-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(ccc3O)c4ccccc4,CHEMBL1254265,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 11nM,agonist,88.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,15,nM,,,,,=,7.958607315,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(-c2ccccc2)ccc1O,88,429.292,454.1868127,3,3,6,4,6.1393,69.14,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
12394,664,20735001,39,P04150,GR,Homo sapiens,"2-(4-((1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-4-(pyridin-3-yl)phenol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(ccc3O)c4cccnc4,CHEMBL1254344,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 6.6nM,agonist,85.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,23,nM,,,,,=,8.180456064,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(-c2cccnc2)ccc1O,85,431.288,455.1820617,3,4,6,4,5.5343,82.03,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
12409,6648,11459643,genistein,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,"Ligand Screening System: Estrogen, Toyobo Co., Ltd., Osaka, Japa",Ki = 370nM,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,6.431798276,pKi,,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12410,6648,11906280,genistein,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3920nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,48,nM,,,,,=,5.406713933,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12411,6648,12502307,genistein,P03372,ERA,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,AP induction Ishikawa cells,,radiometric binding assay monitoring the displacement of [3H]-estradiol,IC50 = 300nM,agonist,no detail about the percentage act,,,,E2,,,,,IC50,=,510,nM,,,,,=,6.522878745,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12412,6648,12824043,genistein,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,-,IC50 = 395nM,,,,,,,,,,,,,,,,,,,=,6.403402904,pIC50,,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12413,6648,15006374,genistein,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 92nM,partial agonist,63.00%,agonist,,,E2,,,,,,,,,,,,,=,7.036212173,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,63,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,partial agonist,agonist,partial agonist,702
12414,6648,15081034,Genistein,P03372,ERA,Homo sapiens,"3-(3-Bromo-4-hydroxy-phenyl)-5,7-dihydroxy-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 =  390nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,200,nM,,,,,=,6.408935393,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12415,6648,15341953,1 (Genistein),P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 395nM,,,,,,E2,,,,,,,,,,,,,=,6.403402904,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12416,6648,15887952,genistein,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4660nM,,,,,,,,,,,,,,,,,,,=,5.331614083,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12417,6648,16098741,2,P03372,ERA,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 395nM,,,,,,,,,,,,,,,,,,,=,6.403402904,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12418,6648,16219463,2,P03372,ERA,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 29.4nM,,,,,,E2,0.5nM,,,,,,,,,,,,=,7.53165267,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12419,6648,16610787,genistein,P03372,ERA,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1973nM,agonist,no detail about the percentage act,,,,E1,11nM,,,,EC50,=,956,nM,,,,,=,5.704872915,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12420,6648,17049855,genistein,P03372,ERA,Homo sapiens,5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 395nM,,,,E2,,,,,,,,,,,,,,,=,6.403402904,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12421,6648,17149865,GEN,P03372,ERA,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1145nM,,,,,,E2,,,,,,,,,,,,,=,5.941194513,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12422,6648,17188490,3,P03372,ERA,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 395nM,,,,,,E2,,,,,,,,,,,,,=,6.403402904,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12423,6648,17482813,2,P03372,ERA,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 395nM,,,,,,,,,,,,,,,,,,,=,6.403402904,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12424,6648,17574424,genistein,P03372,ERA,Homo sapiens,"5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,Alpha-galactosidase activity,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 580nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,810,nM,,,,,=,6.236572006,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12425,6648,11459643,genistein,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,"Ligand Screening System: Estrogen, Toyobo Co., Ltd., Osaka, Japa",Ki = 24nM,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,7.619788758,pKi,B,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12426,6648,11906280,genistein,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 200nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,4.1,nM,,,,,=,6.698970004,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12427,6648,12502307,genistein,Q92731,ERB,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,AP induction Ishikawa cells,,radiometric binding assay monitoring the displacement of [3H]-estradiol,IC50 = 18nM,agonist,no detail about the percentage act,,,,E2,,,,,IC50,=,510,nM,,,,,=,7.744727495,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12428,6648,12824043,genistein,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,-,IC50 = 10nM,,,,,,,,,,,,,,,,,,,=,8,pIC50,B,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12429,6648,15006374,genistein,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4nM,partial agonist,63.00%,agonist,,,E2,,,,,,,,,,,,,=,8.397940009,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,63,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,partial agonist,agonist,partial agonist,702
12430,6648,15081034,Genistein,Q92731,ERB,Homo sapiens,"3-(3-Bromo-4-hydroxy-phenyl)-5,7-dihydroxy-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 =  6100nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,950,nM,,,,,=,5.214670165,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12431,6648,15341953,1 (Genistein),Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,,,,,,E2,,,,,,,,,,,,,=,8,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12432,6648,15887952,genistein,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 98.7nM,,,,,,,,,,,,,,,,,,,=,7.005682847,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12433,6648,16098741,2,Q92731,ERB,Homo sapiens,"5,7-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,,,,,,,,,,,,,,,,,,,=,8,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12434,6648,16219463,2,Q92731,ERB,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.30nM,,,,,,E2,0.5nM,,,,,,,,,,,,=,8.886056648,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12435,6648,16610787,"(+)-3,17-beta-estradiol",Q92731,ERB,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 11nM,partial agonist,no detail about the percentage act,,,,E1,11nM,,,,EC50,=,0.84,nM,,,,,=,7.958607315,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12436,6648,16610787,genistein,Q92731,ERB,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 61nM,partial agonist,no detail about the percentage act,,,,E1,11nM,,,,EC50,=,73,nM,,,,,=,7.214670165,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12437,6648,17049855,genistein,Q92731,ERB,Homo sapiens,5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.7nM,,,,E2,,,,,,,,,,,,,,,=,8.013228266,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12438,6648,17149865,GEN,Q92731,ERB,Homo sapiens,genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 25nM,,,,,,,,,,,,,,,,,,,=,7.602059991,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12439,6648,17188490,3,Q92731,ERB,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.7nM,,,,,,E2,,,,,,,,,,,,,=,8.013228266,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12440,6648,17482813,2,Q92731,ERB,Homo sapiens,Genistein,Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,,,,,,,,,,,,,,,,,,,=,8,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,,,agonist,partial agonist,702
12441,6648,17574424,genistein,Q92731,ERB,Homo sapiens,"5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one",Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,CHEMBL44,Alpha-galactosidase activity,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6.8nM,agonist,no detail about the percentage act,,,,E2,,,,,EC50,=,28,nM,,,,,=,8.167491087,pIC50,B,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,,260.16,270.0528234,3,5,1,3,2.5768,90.9,CC1CCCC2CCC(C3CCCCC3)CC12,agonist,,agonist,partial agonist,702
12442,6649,11459643,daidzen,P03372,ERA,Homo sapiens,7-Hydroxy-3-(4-hydroxy-phenyl)-chromen-4-one,Oc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,CHEMBL8145,,,"Ligand Screening System: Estrogen, Toyobo Co., Ltd., Osaka, Japa",Ki = 1800nM,agonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,5.744727495,pKi,,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,,244.161,254.0579088,2,4,1,3,2.8712,70.67,CC1C2CCCCC2CCC1C1CCCCC1,,,agonist,agonist,486
12443,6649,12502307,daidzen,P03372,ERA,Homo sapiens,daidzein,Oc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,CHEMBL8145,AP induction Ishikawa cells,,radiometric binding assay monitoring the displacement of [3H]-estradiol,IC50 = 17000nM,agonist,no detail about the percentage act,,,,E2,,,,,IC50,=,1200,nM,,,,,=,4.769551079,pIC50,NB,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,,244.161,254.0579088,2,4,1,3,2.8712,70.67,CC1C2CCCCC2CCC1C1CCCCC1,agonist,,agonist,agonist,486
12444,6649,15006374,daidzen,P03372,ERA,Homo sapiens,7-Hydroxy-3-(4-hydroxy-phenyl)-chromen-4-one,Oc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,CHEMBL8145,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2160nM,,,,,,E2,,,,,,,,,,,,,=,5.665546249,pIC50,,radiometric,O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,,244.161,254.0579088,2,4,1,3,2.8712,70.67,CC1C2CCCCC2CCC1C1CCCCC1,,,agonist,agonist,486
12445,6649,20669983,daidzein,P03372,ERA,Homo sapiens,7-O-glucosyl-40-hydroxyisoflavone,Oc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,CHEMBL8145,,,,RBA = 112,agonist,108.00%,agonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,112,RBA,,other,O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,108,244.161,254.0579088,2,4,1,3,2.8712,70.67,CC1C2CCCCC2CCC1C1CCCCC1,,agonist,agonist,agonist,486
12450,665,20735001,41,P04150,GR,Homo sapiens,"4-Pyrimidin-5-yl-2-[4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)butyl]phenol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(ccc3O)c4cncnc4,CHEMBL1254345,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 19nM,agonist,86.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,21,nM,,,,,=,7.721246399,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(-c2cncnc2)ccc1O,86,433.284,456.1773106,3,5,6,4,4.9293,94.92,C1CCC(C2CCCC(CCCCC3CC4CCCCC4C3)C2)CC1,agonist,agonist,agonist,agonist,204
12469,666,20735001,57,P04150,GR,Homo sapiens,"4-(5-Chloro-2,3-dihydrobenzofuran-7-yl)-1,1,1-trifluoro-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(Cl)cc4CCOc34,CHEMBL1254494,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,93.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,17,nM,,,,,=,8.15490196,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(Cl)cc2c1OCC2,93,416.701,438.1321903,2,3,5,3,5.355,58.14,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12490,667,20735001,56,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(F)cc4CCOc34,CHEMBL1254420,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.3nM,agonist,91.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,9.3,nM,,,,,=,8.638272164,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(F)cc2c1OCC2,91,400.246,422.1617408,2,3,5,3,4.8407,58.14,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12495,6671,16610787,1as,P03372,ERA,Homo sapiens,7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one,Oc1ccc(cc1)N2C=Nc3cc(O)ccc3C2=O,CHEMBL203370,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 53640nM,partial agonist,39.00%,agonist,,,E1,11nM,,,,,,,,,,,,=,4.270511231,pIC50,NB,radiometric,O=c1c2ccc(O)cc2ncn1-c1ccc(O)cc1,39,244.165,254.0691422,2,5,1,3,1.7969,75.35,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
12513,668,20735001,32,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-(3-fluorophenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]-pyridin-2-ylmethyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cccc(F)c3,CHEMBL1253987,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 23nM,partial agonist,73.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,99,nM,,,,,=,7.638272164,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cccc(F)c1,73,360.225,380.1511761,2,2,5,3,4.9058,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
12524,6684,17267219,7h,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-bromoquinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(Br)c2c1,CHEMBL238332,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.5nM,agonist,125.00%,agonist,DHT,,,,,,,EC50,=,1,nM,IC50,>,10000,nM,=,9.301029996,pIC50,B,radiometric,O=c1cc(Br)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,125,394.048,401.9802443,1,2,3,2,4.2216,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12526,6686,18442912,18b,P10275,AR,Homo sapiens,"10-hydroxy-4-(trifluoromethyl)-1H-chromeno[3,4-f]quinolin-2(5H)-one",Oc1cccc2OCc3c(ccc4NC(=O)C=C(c34)C(F)(F)F)c12,CHEMBL253535,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.3nM,agonist,138.00%,agonist,DHT,,,,,,,EC50,=,16,nM,IC50,>,10000,nM,=,8.886056648,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1c(O)cccc1OC3,138,323.185,333.0612778,2,3,0,3,3.8119,62.32,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,agonist,agonist,agonist,634
12527,6687,18442912,17a,P10275,AR,Homo sapiens,"4-(trifluoromethyl)-1H-isochromeno[3,4-f]quinolin-2(6H)-one",FC(F)(F)C1=CC(=O)Nc2ccc3c(OCc4ccccc34)c12,CHEMBL450334,reporter,reporter,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 8nM,partial agonist,34.00%,agonist,DHT,,,,,,,EC50,=,60,nM,IC50,>,10000,nM,=,8.096910013,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1ccccc1CO3,34,307.186,317.0663632,1,2,0,3,4.1063,42.09,CC1CCC2C(CCC3C4CCCCC4CCC23)C1,agonist,partial agonist,agonist,partial agonist,634
12528,6688,17267219,6o,P10275,AR,Homo sapiens,"6-((2,2-dichloroethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CN(CC(Cl)Cl)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL428026,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6.0nM,partial agonist,67.00%,agonist,DHT,,,,,,,EC50,=,1.6,nM,IC50,>,10000,nM,=,8.22184875,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(Cl)Cl)CC(F)(F)F)ccc2[nH]1,67,397.061,406.0074376,1,2,4,2,4.7193,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
12529,6689,17267219,6q,P10275,AR,Homo sapiens,"6-((2,2,3,3,3-pentafluoropropyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)C(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237681,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 31nM,agonist,94.00%,agonist,DHT,,,,,,,EC50,=,2.3,nM,IC50,>,10000,nM,=,7.508638306,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)C(F)(F)F)ccc2[nH]1,94,433.156,442.0539233,1,2,4,2,5.1132,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12530,669,20735001,55,P04150,GR,Homo sapiens,"4-(2,3-Dihydrobenzofuran-7-yl)-1,1,1-trifluoro-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cccc4CCOc34,CHEMBL1254419,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.5nM,agonist,88.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,15,nM,,,,,=,8.346787486,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cccc2c1OCC2,88,381.248,404.1711626,2,3,5,3,4.7016,58.14,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12533,6690,17034117,"4m, LGD2226",P10275,AR,Homo sapiens,"6-N,N-bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL436784,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.5nM,agonist,95.00%,agonist,DHT,,,,,,,EC50,=,0.2,nM,IC50,>,10000,nM,=,8.823908741,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,95,383.149,392.0571169,1,2,3,2,4.4779,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12534,6690,17267219,"2, LGD2226",P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL436784,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.5nM,agonist,95.00%,agonist,DHT,,,,,,,EC50,=,0.2,nM,IC50,>,10000,nM,=,8.823908741,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,95,383.149,392.0571169,1,2,3,2,4.4779,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12535,6690,17887661,7,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL436784,Luciferase reporter gene assay,,,Ki = 4.6nM,agonist,95.00%,agonist,DHT,,,,,,,EC50,=,0.2,nM,,,,,=,8.337242168,pKi,B,other,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,95,383.149,392.0571169,1,2,3,2,4.4779,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12536,6691,17267219,6d,P10275,AR,Homo sapiens,"6-((2-chloro-2,2-difluoroethyl)(2,2-difluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)CN(CC(F)(F)Cl)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL393664,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.3nM,agonist,110.00%,agonist,DHT,,,,,,,EC50,=,0.4,nM,IC50,>,10000,nM,=,8.638272164,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)(F)Cl)ccc2[nH]1,110,380.606,390.0369882,1,2,5,2,4.45,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12537,6692,17267219,6m,P10275,AR,Homo sapiens,"6-((2,2-difluoroethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL440980,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.7nM,agonist,84.00%,agonist,DHT,,,,,,,EC50,=,0.2,nM,IC50,>,10000,nM,=,8.769551079,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)(F)F)ccc2[nH]1,84,364.151,374.0665387,1,2,4,2,4.1807,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12538,6693,17267219,6c,P10275,AR,Homo sapiens,"6-(bis(2,2-difluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)CN(CC(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237045,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.5nM,partial agonist,74.00%,agonist,DHT,,,,,,,EC50,=,0.4,nM,IC50,>,10000,nM,=,9.301029996,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)F)ccc2[nH]1,74,345.153,356.0759605,1,2,5,2,3.8835,36.1,CC1CCC2CCCCC2C1,agonist,partial agonist,agonist,partial agonist,651
12539,6694,17267219,6p,P10275,AR,Homo sapiens,"6-((2,2,2-trifluoroethyl)(3,3,3-trifluoropropyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CCN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL391940,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 116nM,agonist,102.00%,agonist,DHT,,,,,,,EC50,=,46,nM,IC50,>,10000,nM,=,6.935542011,pIC50,,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CCC(F)(F)F)CC(F)(F)F)ccc2[nH]1,102,395.16,406.072767,1,2,4,2,4.868,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12540,6695,17267219,6n,P10275,AR,Homo sapiens,"6-((2-chloroethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",FC(F)(F)CN(CCCl)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237474,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.6nM,agonist,88.00%,agonist,DHT,,,,,,,EC50,=,0.5,nM,IC50,>,10000,nM,=,8.585026652,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CCCl)CC(F)(F)F)ccc2[nH]1,88,361.608,372.04641,1,2,4,2,4.1544,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12541,6696,17267219,6r,P10275,AR,Homo sapiens,"6-((2-hydroxyethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",OCCN(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237682,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 6.6nM,agonist,125.00%,agonist,DHT,,,,,,,EC50,=,7.9,nM,IC50,>,10000,nM,=,8.180456064,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(CCO)CC(F)(F)F)ccc2[nH]1,125,342.154,354.0802969,2,3,4,2,2.9079,56.33,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12542,6697,17267219,6s,P10275,AR,Homo sapiens,"6-(benzyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)CN(Cc1ccccc1)c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL3706926,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 79nM,partial agonist,71.00%,agonist,DHT,,,,,,,EC50,=,27,nM,IC50,>,10000,nM,=,7.102372909,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(Cc3ccccc3)CC(F)(F)F)ccc2[nH]1,71,386.21,400.1010324,1,2,4,3,5.1158,36.1,CC1CCC2CC(CCC3CCCCC3)CCC2C1,agonist,partial agonist,agonist,partial agonist,681
12543,6698,17267219,6t,P10275,AR,Homo sapiens,"6-((thiophen-2-ylmethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)CN(Cc1cccs1)c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL3706927,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 61nM,agonist,85.00%,agonist,DHT,,,,,,,EC50,=,12,nM,IC50,>,10000,nM,=,7.214670165,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(Cc3cccs3)CC(F)(F)F)ccc2[nH]1,85,394.255,406.0574533,1,3,4,3,5.1773,36.1,CC1CCC2CC(CCC3CCCC3)CCC2C1,agonist,agonist,agonist,agonist,676
12544,6699,17267219,6w,P10275,AR,Homo sapiens,"6-((furan-3-ylmethyl)(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)CN(Cc1cocc1)c2ccc3NC(=O)C=C(c3c2)C(F)(F)F,CHEMBL3706930,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,partial agonist,49.00%,agonist,DHT,,,,,,,EC50,=,2.8,nM,IC50,=,4.1,nM,=,7.853871964,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(N(Cc3ccoc3)CC(F)(F)F)ccc2[nH]1,49,378.187,390.0802969,1,3,4,3,4.7088,49.24,CC1CCC2CC(CCC3CCCC3)CCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,676
12548,67,15006411,36,P19793,RXRA,Homo sapiens,"(E)-3-{4-[3,5-Di-tert-butyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-benzo[b]thiophen-2-yl}-but-2-enoic acid",C\C(=C/C(=O)O)\c1cc2c(cccc2s1)c3cc(cc(c3OCC(F)(F)F)C(C)(C)C)C(C)(C)C,CHEMBL41260,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,93.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,14,nM,=,8.522878745,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2c(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3OCC(F)(F)F)cccc2s1,93,473.366,504.1946005,1,3,5,3,8.5923,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
12551,670,20735001,31,P04150,GR,Homo sapiens,"1,1,1-Trifluoro-4-methyl-4-phenyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3ccccc3,CHEMBL1253986,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 9.3nM,agonist,75.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,31,nM,,,,,=,8.031517051,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1ccccc1,75,341.227,362.160598,2,2,5,3,4.7667,48.91,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12554,6700,17887661,4a,P10275,AR,Homo sapiens,6-pyrrolidin-1-yl-4-trifluoromethyl-1H-quinolin-2-one,FC(F)(F)C1=CC(=O)Nc2ccc(cc12)N3CCCC3,CHEMBL446191,,Luciferase reporter gene assay,-,Ki = 1700nM,partial antagonist,58.00%,antagonist,DHT,,,,,,,,,,,IC50,=,25,nM,=,5.769551079,pKi,,other,O=c1cc(C(F)(F)F)c2cc(N3CCCC3)ccc2[nH]1,58,269.161,282.0979977,1,2,1,2,3.1471,36.1,CC1CCC2CC(C3CCCC3)CCC2C1,antagonist,partial antagonist,antagonist,partial antagonist,604
12555,6701,17257838,13e,P10275,AR,Homo sapiens,"6-(cyclopentylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2ccc(NC3CCCC3)cc12,CHEMBL3706909,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 74nM,antagonist,82.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,42,nM,=,7.13076828,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(NC3CCCC3)ccc2[nH]1,82,281.172,296.1136478,2,2,2,2,3.9014,44.89,CC1CCC2CC(CC3CCCC3)CCC2C1,antagonist,antagonist,antagonist,antagonist,645
12556,6702,17257838,13d,P10275,AR,Homo sapiens,"6-(2,2,3,3,3-pentafluoropropylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2ccc(NCC(F)(F)C(F)(F)F)cc12,CHEMBL3706908,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 78nM,agonist,89.00%,agonist,DHT,,,,,,,EC50,=,246,nM,IC50,=,17,nM,=,7.107905397,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)C(F)(F)F)ccc2[nH]1,89,352.14,360.0508886,2,2,3,2,4.1564,44.89,CC1CCC2CCCCC2C1,"antagonist,agonist",agonist,"antagonist,agonist",agonist,651
12557,6703,17257838,13c,P10275,AR,Homo sapiens,"6-(2,2,2-trifluoroethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)CNc1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL3706907,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 16nM,partial agonist,39.00%,agonist,DHT,,,,,,,EC50,=,108,nM,IC50,=,18,nM,=,7.795880017,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)F)ccc2[nH]1,39,302.133,310.0540822,2,2,2,2,3.5211,44.89,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
12561,6704,17439112,28,P10275,AR,Homo sapiens,"(+/-)-1,2,3,4,4a,5-hexahydro-11-(trifluoromethyl)-pyrido[1',2':4,5][1,4]oxazino[3,2-g]quinolin-9(8H)-one",FC(F)(F)C1=CC(=O)Nc2cc3OCC4CCCCN4c3cc12,CHEMBL226609,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 16nM,agonist,75.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,75,nM,IC50,>,10000,nM,=,7.795880017,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCC1CCCCN31,75,309.182,324.1085624,1,3,0,2,3.2982,45.33,CC1CCC2CC3C(CCC4CCCCC43)CC2C1,agonist,agonist,agonist,agonist,580
12562,6705,17439112,11a,P10275,AR,Homo sapiens,"9-(trifluoromethyl)-2,3-dihydro-1H-[1,4]oxazino[3,2-g]quinolin-7(6H)-one",FC(F)(F)C1=CC(=O)Nc2cc3OCCNc3cc12,CHEMBL390754,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki > 1000nM,partial antagonist,72.00%,antagonist,DHT,,DHT,0.3nM,,,,EC50,>,10000,nM,IC50,=,72,nM,>,6,pKi,,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3,72,261.138,270.0616122,2,3,0,2,2.3512,54.12,CC1CCC2CC3CCCCC3CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,586
12566,6706,17439112,10f,P10275,AR,Homo sapiens,"1,2,3,6-tetrahydro-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",FC(F)(F)CN1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL227783,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 4.0nM,agonist,88.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,88,nM,IC50,>,10000,nM,=,8.397940009,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3CC(F)(F)F,88,342.154,352.0646469,1,3,1,2,3.308,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
12570,6707,17439112,12a,P10275,AR,Homo sapiens,"1-cyclopropylmethyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",FC(F)(F)C1=CC(=O)Nc2cc3OCCN(CC4CC4)c3cc12,CHEMBL227784,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 1.6nM,partial agonist,68.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,68,nM,IC50,>,10000,nM,=,8.795880017,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3CC1CC1,68,309.182,324.1085624,1,3,2,2,3.1557,45.33,CC1CCC2CC3C(CC4CC4)CCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,574
12571,6708,17439112,12b,P10275,AR,Homo sapiens,"1-benzyl-1,2,3,6-tetrahydro-9-(trifluoromethyl)-7H-[1,4]oxazino-[3,2-g]quinolin-7-one",FC(F)(F)C1=CC(=O)Nc2cc3OCCN(Cc4ccccc4)c3cc12,CHEMBL390577,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 206nM,antagonist,90.00%,antagonist,DHT,,DHT,0.3nM,,,,EC50,>,10000,nM,IC50,=,90,nM,=,6.68613278,pKi,,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3Cc1ccccc1,90,345.215,360.1085624,1,3,2,3,3.9459,45.33,CC1CCC2CC3C(CC4CCCCC4)CCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,577
12572,6709,17439112,(R)-27,P10275,AR,Homo sapiens,"(R)-2,3,3a,4-tetrahydro-10-(trifluoromethyl)-1H-pyrrolo[1',2':4,5][1,4]oxazino[3,2-g]quinolin-8(7H)-one",FC(F)(F)C1=CC(=O)Nc2cc3OC[C@H]4CCCN4c3cc12,CHEMBL227749,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 27nM,partial agonist,46.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,46,nM,IC50,>,10000,nM,=,7.568636236,pKi,B,radiometric,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@H]1CCCN31,46,297.171,310.0929123,1,3,0,2,2.9081,45.33,CC1CCC2CC3C(CCC4CCCC43)CC2C1,agonist,partial agonist,agonist,partial agonist,579
12573,671,24506830,37,P04150,GR,Homo sapiens,"rac-4-(5-Chloro-2,3-dihydro-benzofuran-7-yl)-1,1,1-trifluoro-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c3cc(Cl)cc4CCOc34,CHEMBL3126945,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,87.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,13,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c1cc(Cl)cc2c1OCC2,87,418.697,439.1274393,2,4,5,3,4.75,71.03,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12576,6710,10230628,17,P10275,AR,Homo sapiens,"4-Trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",FC(F)(F)C1=CC(=O)Oc2cc3NCCCc3cc12,CHEMBL268098,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 1nM,partial agonist,68.00%,agonist,DHT,,,,,,,EC50,=,9,nM,,,inactive,,=,9,pIC50,B,other,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3,68,259.142,269.0663632,1,3,0,2,3.1699,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
12577,6711,10230628,21,P10275,AR,Homo sapiens,"4,5-Bis-trifluoromethyl-5,6,7,8-tetrahydro-1-oxa-8-aza-anthracen-2-one",FC(F)(F)C1CCNc2cc3OC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL267270,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,-,IC50 = 5nM,agonist,104.00%,agonist,DHT,,,,,,,EC50,=,2,nM,,,inactive,,=,8.301029996,pIC50,B,other,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3C(F)(F)F,104,328.147,337.0537478,1,3,0,2,4.2733,42.24,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
12578,6712,17257838,9i,P10275,AR,Homo sapiens,"7-(cyclobutylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2cc(NC3CCC3)ccc12,CHEMBL3706885,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 161nM,antagonist,89.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,43,nM,=,6.793174124,pIC50,,radiometric,O=c1cc(C(F)(F)F)c2ccc(NC3CCC3)cc2[nH]1,89,269.161,282.0979977,2,2,2,2,3.5113,44.89,CC1CCC2CCC(CC3CCC3)CC2C1,antagonist,antagonist,antagonist,antagonist,674
12579,6713,17257838,9j,P10275,AR,Homo sapiens,"7-(cyclopentylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2cc(NC3CCCC3)ccc12,CHEMBL3706886,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1000nM,antagonist,89.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,149,nM,=,6,pIC50,,radiometric,O=c1cc(C(F)(F)F)c2ccc(NC3CCCC3)cc2[nH]1,89,281.172,296.1136478,2,2,2,2,3.9014,44.89,CC1CCC2CCC(CC3CCCC3)CC2C1,antagonist,antagonist,antagonist,antagonist,675
12580,6714,17257838,9k,P10275,AR,Homo sapiens,"7-(cyclohexylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2cc(NC3CCCCC3)ccc12,CHEMBL3706887,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1000nM,antagonist,90.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,507,nM,=,6,pIC50,,radiometric,O=c1cc(C(F)(F)F)c2ccc(NC3CCCCC3)cc2[nH]1,90,293.183,310.1292978,2,2,2,2,4.2915,44.89,CC1CCC2CCC(CC3CCCCC3)CC2C1,antagonist,antagonist,antagonist,antagonist,679
12581,6715,17257838,9m,P10275,AR,Homo sapiens,"7-(2,2,3,3,3-pentafluoropropylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2cc(NCC(F)(F)C(F)(F)F)ccc12,CHEMBL3706889,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 36nM,antagonist,76.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,58,nM,=,7.443697499,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)C(F)(F)F)cc2[nH]1,76,352.14,360.0508886,2,2,3,2,4.1564,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
12582,6716,17257838,9l,P10275,AR,Homo sapiens,"7-(2,2,2-trifluoroethylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)CNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706888,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 15nM,partial antagonist,61.00%,antagonist,DHT,,,,,,,EC50,=,905,nM,IC50,=,21,nM,=,7.823908741,pIC50,B,radiometric,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)F)cc2[nH]1,61,302.133,310.0540822,2,2,2,2,3.5211,44.89,CC1CCC2CCCCC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,651
12583,6717,17257838,9o,P10275,AR,Homo sapiens,"7-(benzylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",FC(F)(F)C1=CC(=O)Nc2cc(NCc3ccccc3)ccc12,CHEMBL3706891,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 163nM,antagonist,94.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,294,nM,=,6.787812396,pIC50,,radiometric,O=c1cc(C(F)(F)F)c2ccc(NCc3ccccc3)cc2[nH]1,94,305.194,318.0979977,2,2,3,3,4.159,44.89,CC1CCC2CCC(CCC3CCCCC3)CC2C1,antagonist,antagonist,antagonist,antagonist,682
12584,6718,17267219,7f,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-(difluoromethyl)quinolin-2(1H)-one",FC(F)C1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL238330,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.4nM,agonist,97.00%,agonist,DHT,,,,,,,EC50,=,0.5,nM,IC50,>,10000,nM,=,9.397940009,pIC50,B,radiometric,O=c1cc(C(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,97,364.151,374.0665387,1,2,4,2,4.3967,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12585,6719,17267219,7g,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-chloroquinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=C(Cl)c2c1,CHEMBL238331,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 0.5nM,agonist,115.00%,agonist,DHT,,,,,,,EC50,=,0.89,nM,IC50,>,10000,nM,=,9.301029996,pIC50,B,radiometric,O=c1cc(Cl)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,115,349.597,358.0307599,1,2,3,2,4.1125,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
12586,672,24506830,36,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(5-fluoro-2,3-dihydro-benzofuran-7-yl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c3cc(F)cc4CCOc34,CHEMBL3126944,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,78.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,24,nM,,,,,=,8.15490196,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c1cc(F)cc2c1OCC2,78,402.242,423.1569898,2,4,5,3,4.2357,71.03,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
12589,6720,17267219,7j,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-hydroxyquinolin-2(1H)-one",OC1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL235126,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1000nM,partial agonist,43.00%,agonist,DHT,,,,,,,EC50,=,83,nM,IC50,=,7,nM,=,6,pIC50,,radiometric,O=c1cc(O)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,43,330.143,340.0646469,2,3,3,2,3.1647,56.33,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
12598,6723,17267219,7a,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)quinolin-2(1H)-one",FC(F)(F)CN(CC(F)(F)F)c1ccc2NC(=O)C=Cc2c1,CHEMBL391798,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 24nM,partial agonist,68.00%,agonist,DHT,,,,,,,EC50,=,57,nM,IC50,=,1,nM,=,7.619788758,pIC50,B,radiometric,O=c1ccc2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,68,314.144,324.0697323,1,2,3,2,3.4591,36.1,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
12611,673,24506830,41,P04150,GR,Homo sapiens,"rac-4-Fluoro-2-[4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(5Hpyrrolo[3,2-d]pyrimidin-6-ylmethyl)-butyl]-phenol",CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c3cc(F)ccc3O,CHEMBL3126941,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 7nM,agonist,91.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,11,nM,,,,,=,8.15490196,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c1cc(F)ccc1O,91,378.22,397.1413397,3,4,5,3,4.0064,82.03,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12628,6737,20427184,"25, (-)-Enantiomer",P04150,GR,Homo sapiens,"1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",OC(c1ccc(F)c(Cl)c1)(c2ccc3c(cnn3c4ccc(F)cc4)c2)C(F)(F)F,CHEMBL1094231,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 49nM,agonist,85.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,93,nM,,,,,=,7.30980392,pIC50,B,FPA,OC(c1ccc(F)c(Cl)c1)(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(F)(F)F,85,426.687,438.0558318,1,3,3,4,5.7553,38.05,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
12629,6737,20427184,18,P04150,GR,Homo sapiens,"1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",OC(c1ccc(F)c(Cl)c1)(c2ccc3c(cnn3c4ccc(F)cc4)c2)C(F)(F)F,CHEMBL1094231,,,Fluorescence polarization (FP) competition binding assay,IC50 = 117nM,,,,,,,,,,,,,,,,,,,=,6.931814138,pIC50,,FPA,OC(c1ccc(F)c(Cl)c1)(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(F)(F)F,,426.687,438.0558318,1,3,3,4,5.7553,38.05,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,,,agonist,agonist,235
12634,674,24506830,42,P04150,GR,Homo sapiens,"rac-5-Fluoro-2-[4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(5Hpyrrolo[3,2-d]pyrimidin-6-ylmethyl)-butyl]-phenol",CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c3ccc(F)cc3O,CHEMBL3126942,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,9,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c1ccc(F)cc1O,86,378.22,397.1413397,3,4,5,3,4.0064,82.03,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12637,6740,16876993,7,P55055,LXRB,Homo sapiens,"2-(4-(benzyl(2,2,2-trifluoroethyl)amino)-3-chlorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,CHEMBL384246,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3nM,partial agonist,55.00%,agonist,T0901317,,,,,,,EC50,=,20,nM,,,,,=,8.522878745,pIC50,B,radiometric,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,55,452.639,465.0541957,1,2,5,2,6.2211,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
12638,6740,16876993,7,Q13133,LXRA,Homo sapiens,"2-(4-(benzyl(2,2,2-trifluoroethyl)amino)-3-chlorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,CHEMBL384246,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1nM,agonist,89.00%,agonist,T0901317,,,,,,,EC50,=,100,nM,,,,,=,9,pIC50,B,radiometric,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,89,452.639,465.0541957,1,2,5,2,6.2211,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
12639,6741,16876993,6,P55055,LXRB,Homo sapiens,"2-(4-(benzyl(2,2,2-trifluoroethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",OC(c1ccc(cc1)N(Cc2ccccc2)CC(F)(F)F)(C(F)(F)F)C(F)(F)F,CHEMBL214777,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,79.00%,agonist,T0901317,,,,,,,EC50,=,200,nM,,,,,=,7.22184875,pIC50,B,radiometric,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,79,417.186,431.093168,1,2,5,2,5.5677,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
12640,6741,16876993,6,Q13133,LXRA,Homo sapiens,"2-(4-(benzyl(2,2,2-trifluoroethyl)amino)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol",OC(c1ccc(cc1)N(Cc2ccccc2)CC(F)(F)F)(C(F)(F)F)C(F)(F)F,CHEMBL214777,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 70nM,agonist,87.00%,agonist,T0901317,,,,,,,EC50,=,900,nM,,,,,=,7.15490196,pIC50,B,radiometric,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,87,417.186,431.093168,1,2,5,2,5.5677,23.47,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
12643,6743,20427184,"28, (+)-Enantiomer",P04150,GR,Homo sapiens,"(+)-1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",OC(c1ccc2c(cnn2c3ccc(F)cc3)c1)(c4cccc(Cl)c4Cl)C(F)(F)F,CHEMBL1094208,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 34nM,agonist,87.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,19,nM,,,,,=,7.468521083,pIC50,B,FPA,OC(c1ccc2c(cnn2-c2ccc(F)cc2)c1)(c1cccc(Cl)c1Cl)C(F)(F)F,87,443.142,454.0262812,1,3,3,4,6.2696,38.05,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
12644,6743,20427184,23,P04150,GR,Homo sapiens,"1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",OC(c1ccc2c(cnn2c3ccc(F)cc3)c1)(c4cccc(Cl)c4Cl)C(F)(F)F,CHEMBL1094208,,,Fluorescence polarization (FP) competition binding assay,IC50 = 87nM,,,,,,,,,,,,,,,,,,,=,7.060480747,pIC50,B,FPA,OC(c1ccc2c(cnn2-c2ccc(F)cc2)c1)(c1cccc(Cl)c1Cl)C(F)(F)F,,443.142,454.0262812,1,3,3,4,6.2696,38.05,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,,,agonist,agonist,235
12648,6747,20427184,"24, (-)-Enantiomer",P04150,GR,Homo sapiens,"1-(2-chloropyridin-4-yl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol",OC(c1ccnc(Cl)c1)(c2ccc3c(cnn3c4ccc(F)cc4)c2)C(F)(F)F,CHEMBL1094209,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 14nM,partial agonist,60.00%,agonist,dexamethasone,2nM,,,,,,EC50,=,627,nM,,,,,=,7.853871964,pIC50,B,FPA,OC(c1ccnc(Cl)c1)(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(F)(F)F,60,409.685,421.0605026,1,4,3,4,5.0112,50.94,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,235
12667,676,24506830,34,P04150,GR,Homo sapiens,"rac-1,1,1-Trifluoro-4-(2-methanesulfonyl-phenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)-pentan-2-ol",CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c3ccccc3S(=O)(=O)C,CHEMBL3126946,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 24nM,agonist,92.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,21,nM,,,,,=,7.619788758,pIC50,B,FPA,CC(C)(CC(O)(Cc1cc2ncncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O,92,419.299,441.1333972,2,5,6,3,3.5652,95.94,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
12682,6767,19853462,5d,P55055,LXRB,Homo sapiens,(4-{3-[3-Phenyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)methanol,OCc1ccc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)c5ccccc5)cc1,CHEMBL593960,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,agonist,80.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,646,nM,,,,,=,8,pIC50,B,radiometric,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,80,451.318,471.1446135,1,3,5,5,7.8722,42.35,C1CCC(CC2CCCC(C3C4CCCCC4CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,273
12684,6768,19853462,5e,P55055,LXRB,Homo sapiens,{4-[3-(8-Chloro-3-phenylquinolin-4-yl)phenoxy]phenyl}-methanol,OCc1ccc(Oc2cccc(c2)c3c(cnc4c(Cl)cccc34)c5ccccc5)cc1,CHEMBL596262,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.3nM,agonist,104.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,1010,nM,,,,,=,8.080921908,pIC50,B,radiometric,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,104,417.766,437.1182566,1,3,5,5,7.5068,42.35,C1CCC(CC2CCCC(C3C4CCCCC4CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,273
12686,6769,19853462,5c,P55055,LXRB,Homo sapiens,(3-{3-[3-Phenyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)methanol,OCc1cccc(Oc2cccc(c2)c3c(cnc4c(cccc34)C(F)(F)F)c5ccccc5)c1,CHEMBL603743,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 14nM,agonist,79.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,210,nM,,,,,=,7.853871964,pIC50,B,radiometric,OCc1cccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,79,451.318,471.1446135,1,3,5,5,7.8722,42.35,C1CCC(CC2CCCC(C3C4CCCCC4CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,273
12690,6770,19853462,5a,P55055,LXRB,Homo sapiens,(3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)methanol,OCc1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL604479,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 11.7nM,agonist,94.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,1030,nM,,,,,=,7.931814138,pIC50,B,radiometric,OCc1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,94,463.329,485.1602636,1,3,6,5,7.796,42.35,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
12705,6779,17034117,4l,P10275,AR,Homo sapiens,"6-N-(cyclopropylmethyl)-N-(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one",Oc1cc(c2cc(ccc2n1)N(CC3CC3)CC(F)(F)F)C(F)(F)F,CHEMBL267260,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 7.1nM,agonist,99.00%,agonist,DHT,,,,,,,EC50,=,2.8,nM,IC50,>,10000,nM,=,8.148741651,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc(N(CC3CC3)CC(F)(F)F)ccc2n1,99,350.177,364.1010324,1,3,4,2,4.7379,36.36,CC1CCC2CC(CCC3CC3)CCC2C1,agonist,agonist,agonist,agonist,673
12708,6780,17034117,4h,P10275,AR,Homo sapiens,"6-N,N-bis(cyclopropylmethyl)amino-4-trifluoromethylquinolin-2(1H)-one",Oc1cc(c2cc(ccc2n1)N(CC3CC3)CC4CC4)C(F)(F)F,CHEMBL217324,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 6.3nM,agonist,81.00%,agonist,DHT,,,,,,,EC50,=,1.9,nM,IC50,>,10000,nM,=,8.200659451,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc(N(CC3CC3)CC3CC3)ccc2n1,81,317.205,336.1449479,1,3,5,2,4.5856,36.36,CC1CCC2CC(C(CC3CC3)CC3CC3)CCC2C1,agonist,agonist,agonist,agonist,672
12710,6782,9871534,4,P10275,AR,Homo sapiens,"5-Trifluoromethyl-1,2,3,8-tetrahydro-pyrrolo[3,2-g]quinolin-7-one",Oc1cc(c2cc3CCNc3cc2n1)C(F)(F)F,CHEMBL166323,,,,Ki = 41nM,partial antagonist,71.00%,antagonist,DHT,,,,,,,EC50,=,1897,nM,IC50,=,23,nM,=,7.387216143,pKi,B,other,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCC3,71,245.139,254.0666976,2,3,0,2,2.9272,45.15,CC1CCC2CC3CCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,578
12711,6783,10340624,6a,P10275,AR,Homo sapiens,"4-Trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",Oc1cc(c2cc3CCCNc3cc2n1)C(F)(F)F,CHEMBL286684,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 19nM,partial agonist,35.00%,agonist,DHT,,DHT,,,,,EC50,=,317,nM,IC50,=,12,nM,=,7.721246399,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3,35,257.15,268.0823476,2,3,0,2,3.3173,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
12712,6784,10340624,6f,P10275,AR,Homo sapiens,"6-(3,5-Bis-trifluoromethyl-phenyl)-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",Oc1cc(c2cc3C(CCNc3cc2n1)c4cc(cc(c4)C(F)(F)F)C(F)(F)F)C(F)(F)F,CHEMBL285602,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki > 1000nM,partial antagonist,66.00%,antagonist,DHT,,DHT,,,,,,,,,IC50,=,251,nM,>,6,pKi,,radiometric,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3c1cc(C(F)(F)F)cc(C(F)(F)F)c1,66,467.226,480.088417,2,3,1,3,6.9443,45.15,CC1CCC2CC3C(CCCC3C3CCCCC3)CC2C1,antagonist,partial antagonist,antagonist,partial antagonist,585
12713,6785,10340624,17,P10275,AR,Homo sapiens,"Cis-(4aR,12bS)-11-Trifluoromethyl-2,3,4,4a,5,6,8,12b-octahydro-1H-6,8-diaza-benzo[a]anthracen-9-one",Oc1cc(c2cc3[C@H]4CCCC[C@H]4CNc3cc2n1)C(F)(F)F,CHEMBL431493,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2nM,agonist,107.00%,agonist,DHT,,DHT,,,,,EC50,=,3,nM,,,,,=,8.698970004,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC[C@@H]1CCCC[C@H]31,107,305.194,322.1292978,2,3,0,2,4.6585,45.15,CC1CCC2CC3C(CCC4CCCCC43)CC2C1,agonist,agonist,agonist,agonist,580
12714,6786,10340624,16,P10275,AR,Homo sapiens,"Cis-(3aR,11bS)-10-Trifluoromethyl-1,2,3,3a,4,5,7,11b-octahydro-5,7-diaza-cyclopenta[a]anthracen-8-one",Oc1cc(c2cc3[C@H]4CCC[C@H]4CNc3cc2n1)C(F)(F)F,CHEMBL27812,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 8nM,partial agonist,56.00%,agonist,DHT,,DHT,,,,,EC50,=,9,nM,,,,,=,8.096910013,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC[C@@H]1CCC[C@H]31,56,293.183,308.1136478,2,3,0,2,4.2684,45.15,CC1CCC2CC3C(CCC4CCCC43)CC2C1,agonist,partial agonist,agonist,partial agonist,579
12715,6787,10340624,21,P10275,AR,Homo sapiens,"Trans-11-Trifluoromethyl-2,3,4,4a,5,6,8,12b-octahydro-1H-6,8-diaza-benzo[a]anthracen-9-one",Oc1cc(c2cc3[C@H]4CCCC[C@@H]4CNc3cc2n1)C(F)(F)F,CHEMBL25802,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,agonist,86.00%,agonist,DHT,,DHT,,,,,EC50,=,2,nM,,,,,=,7.823908741,pKi,B,radiometric,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC[C@H]1CCCC[C@H]31,86,305.194,322.1292978,2,3,0,2,4.6585,45.15,CC1CCC2CC3C(CCC4CCCCC43)CC2C1,agonist,agonist,agonist,agonist,580
12716,6788,9871534,16,P10275,AR,Homo sapiens,"(5bR,9aR)-4-Trifluoromethyl-1,5b,6,7,8,9,9a,10-octahydro-pyrido[2,3-b]carbazol-2-one",Oc1cc(c2cc3[C@H]4CCCC[C@H]4Nc3cc2n1)C(F)(F)F,CHEMBL350932,,,,Ki = 5nM,agonist,91.00%,agonist,DHT,,,,,,,EC50,=,5,nM,,,inactive,,=,8.301029996,pKi,B,other,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)N[C@@H]1CCCC[C@H]31,91,293.183,308.1136478,2,3,0,2,4.4109,45.15,CC1CCC2CC3C(CC2C1)CC1CCCCC13,agonist,agonist,agonist,agonist,573
12751,68,15006411,35,P19793,RXRA,Homo sapiens,"(E)-3-{4-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-benzo[b]thiophen-2-yl}-but-2-enoic acid",C\C(=C/C(=O)O)\c1cc2c(cccc2s1)c3cc(cc(c3OCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL290761,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 12nM,antagonist,79.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,24,nM,=,7.920818754,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2c(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3OCC(F)F)cccc2s1,79,454.368,486.2040223,1,3,6,3,8.2951,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
12754,680,16112571,19,P04150,GR,Homo sapiens,"2-Benzyl-4-(5-fluoro-2-hydroxy-phenyl)-2-hydroxy-4-methyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(Cc1ccccc1)C(=O)Nc2ccc3C(=O)OCc3c2)c4cc(F)ccc4O,CHEMBL196051,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 60nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,420,nM,=,7.22184875,pIC50,B,FPA,CC(C)(CC(O)(Cc1ccccc1)C(=O)Nc1ccc2c(c1)COC2=O)c1cc(F)ccc1O,100,437.297,463.1795012,3,5,7,3,4.4819,95.86,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,946
12784,681,16112571,10,P04150,GR,Homo sapiens,"2-Benzyl-2-hydroxy-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)(CC(O)(Cc1ccccc1)C(=O)Nc2ccc3C(=O)OCc3c2)c4ccccc4,CHEMBL197161,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 13nM,antagonist,100.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,205,nM,=,7.886056648,pIC50,B,FPA,CC(C)(CC(O)(Cc1ccccc1)C(=O)Nc1ccc2c(c1)COC2=O)c1ccccc1,100,402.3,429.1940083,2,4,7,3,4.6372,75.63,CC(CC1CCC2C(C)CCC2C1)C(CCC1CCCCC1)CC1CCCCC1,antagonist,antagonist,antagonist,antagonist,946
12862,684,17181172,37,P04150,GR,Homo sapiens,1-[4-(4-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,CC(C)(CC(O)(CN1C=CC(=O)c2ccccc12)C(F)(F)F)c3ccc(F)cc3O,CHEMBL219207,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 3nM,agonist,88.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,3,nM,,,,,=,8.522878745,pIC50,B,FPA,CC(C)(CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F)c1ccc(F)cc1O,88,402.238,423.1457564,2,4,5,3,4.5075,62.46,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,agonist,agonist,agonist,807
12883,685,17181172,38,P04150,GR,Homo sapiens,"1-[4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one",CC(C)(CC(O)(CN1C=CC(=O)c2ccccc12)C(F)(F)F)c3cccc4CCOc34,CHEMBL373497,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 4nM,agonist,86.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,11,nM,,,,,=,8.397940009,pIC50,B,FPA,CC(C)(CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F)c1cccc2c1OCC2,86,407.262,431.1708283,1,4,5,3,4.5977,51.46,CC1CCC(CCCCC2CCCC3CCCC23)C2CCCCC12,agonist,agonist,agonist,agonist,806
12905,686,17181172,30,P04150,GR,Homo sapiens,1-(2-hydroxy-4-methyl-4-phenyl-2-(trifluoromethyl)pentyl)-1H-quinolin-4-one,CC(C)(CC(O)(CN1C=CC(=O)c2ccccc12)C(F)(F)F)c3ccccc3,CHEMBL219069,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 28nM,partial agonist,48.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,78,nM,,,,,=,7.552841969,pIC50,B,FPA,CC(C)(CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F)c1ccccc1,48,367.241,389.1602636,1,3,5,3,4.6628,42.23,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,partial agonist,agonist,partial agonist,807
12927,687,17181172,31,P04150,GR,Homo sapiens,1-[2-hydroxy-4-(2-hydroxyphenyl)-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one,CC(C)(CC(O)(CN1C=CC(=O)c2ccccc12)C(F)(F)F)c3ccccc3O,CHEMBL375838,IL-6 inhibition in HFF,,Fluorescence polarization (FP) competition binding assay,IC50 = 6nM,agonist,90.00%,agonist,dexamethasone,,dexamethasone,5nM,,,,IC50,=,6,nM,,,,,=,8.22184875,pIC50,B,FPA,CC(C)(CC(O)(Cn1ccc(=O)c2ccccc21)C(F)(F)F)c1ccccc1O,90,383.24,405.1551782,2,4,5,3,4.3684,62.46,CC1CCC(CCCCC2CCCCC2)C2CCCCC12,agonist,agonist,agonist,agonist,807
12930,6870,12459017,15,P03372,ERA,Homo sapiens,"4-(2-{4-[3-(4-Chloro-phenyl)-propylsulfanyl]-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",Oc1ccc(CCNc2nc(SCCCc3ccc(Cl)cc3)nc(n2)N4CCNCC4)cc1,CHEMBL346455,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 160nM,partial agonist,62.00%,agonist,E2,,E2,1nM,,,,EC50,=,160,nM,IC50,=,80,nM,=,6.795880017,pKi,,radiometric,Oc1ccc(CCNc2nc(SCCCc3ccc(Cl)cc3)nc(N3CCNCC3)n2)cc1,62,455.825,484.1812082,3,8,10,3,4.0197,86.2,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,450
12931,6870,12459017,15,Q92731,ERB,Homo sapiens,"4-(2-{4-[3-(4-Chloro-phenyl)-propylsulfanyl]-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino}-ethyl)-phenol",Oc1ccc(CCNc2nc(SCCCc3ccc(Cl)cc3)nc(n2)N4CCNCC4)cc1,CHEMBL346455,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 15nM,antagonist,103.00%,antagonist,E2,,E2,1nM,,,,,,inactive,,IC50,=,6,nM,=,7.823908741,pKi,B,radiometric,Oc1ccc(CCNc2nc(SCCCc3ccc(Cl)cc3)nc(N3CCNCC3)n2)cc1,103,455.825,484.1812082,3,8,10,3,4.0197,86.2,C1CCC(CCCCC2CC(CCCC3CCCCC3)CC(C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,450
12936,6873,19853462,9b,P55055,LXRB,Homo sapiens,4-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenol,Oc1ccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)cc1,CHEMBL592985,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 28nM,partial agonist,59.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,406,nM,,,,,=,7.552841969,pIC50,B,radiometric,Oc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,59,451.318,471.1446135,1,3,5,5,8.0093,42.35,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,278
13016,69,15006411,38,P19793,RXRA,Homo sapiens,"(E)-3-{4-[3,5-Di-tert-butyl-2-(3,3-difluoro-propoxy)-phenyl]-benzo[b]thiophen-2-yl}-but-2-enoic acid",C\C(=C/C(=O)O)\c1cc2c(cccc2s1)c3cc(cc(c3OCCC(F)F)C(C)(C)C)C(C)(C)C,CHEMBL43238,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 7nM,antagonist,94.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,16,nM,=,8.15490196,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2c(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3OCCC(F)F)cccc2s1,94,466.379,500.2196724,1,3,7,3,8.6852,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
13019,690,23916594,3c,P04150,GR,Homo sapiens,"(S)-3,3,3-trifluoro-N-(3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropyl)propanamide",CC(C)(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426124,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.81nM,partial agonist,65.00%,agonist,dexamethasone,,,,,,,EC50,=,129,nM,,,,,=,9.091514981,pIC50,B,FPA,CC(C)(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,65,458.309,483.1933753,1,3,7,4,6.3913,46.92,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,235
13133,694,23916594,4a,P04150,GR,Homo sapiens,"(S)-N-(3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropyl)methanesulfonamide",CC(C)(CNS(=O)(=O)C)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426114,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.53nM,partial agonist,32.00%,agonist,dexamethasone,,,,,,,EC50,=,148,nM,,,,,=,9.27572413,pIC50,B,FPA,CC(C)(CNS(C)(=O)=O)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,32,425.359,451.1729763,1,4,7,4,4.8719,63.99,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,235
13169,6954,15125923,6c,P03372,ERA,Homo sapiens,"1-Cyclohexyl-2-phenyl-1,2,3,4-tetrahydro-isoquinolin-6-ol",Oc1ccc2C(C3CCCCC3)N(CCc2c1)c4ccccc4,CHEMBL412907,MCF-7 transient transfection assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 29.8nM,agonist,93.00%,agonist,E2,,E2,0.5nM,,,,EC50,=,11.1,nM,,,,,=,7.525783736,pIC50,B,radiometric,Oc1ccc2c(c1)CCN(c1ccccc1)C2C1CCCCC1,93,282.237,307.1936144,1,2,2,2,5.0763,23.47,C1CCC(C2CCC3CCCCC3C2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,116
13216,697,21963986,(R)-33,P04150,GR,Homo sapiens,"(R)-2-(2-hydroxy-4-methyl-4-(5-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)-2-(trifluoromethyl)pentyl)-1H-indole-6-carbonitrile",CC(C)(C[C@@](O)(Cc1cc2ccc(cc2[nH]1)C#N)C(F)(F)F)c3cc(cc4CCOc34)S(=O)(=O)C,CHEMBL1911664,IL-6 repression,,Fluorescence polarization (FP) competition binding assay,IC50 = 2nM,agonist,88.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,28,nM,,,,,=,8.698970004,pIC50,B,FPA,CC(C)(C[C@@](O)(Cc1cc2ccc(C#N)cc2[nH]1)C(F)(F)F)c1cc(S(C)(=O)=O)cc2c1OCC2,88,481.346,506.1487129,2,5,6,3,4.58178,103.18,C(CCC1CCCC2CCCC12)CC1CC2CCCCC2C1,agonist,agonist,agonist,agonist,975
13240,698,20735001,(R)-16,P04150,GR,Homo sapiens,"4-Fluoro-2-[(R)-4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)butyl]phenol",CC(C)(C[C@@](O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c3cc(F)ccc3O,CHEMBL1253898,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.1nM,agonist,93.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,3.3,nM,,,,,=,8.677780705,pIC50,B,FPA,CC(C)(C[C@@](O)(Cc1cc2ccncc2[nH]1)C(F)(F)F)c1cc(F)ccc1O,93,376.224,396.1460908,3,3,5,3,4.6114,69.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
13263,699,20735001,(R)-17,P04150,GR,Homo sapiens,"4-Fluoro-2-[(R)-4,4,4-trifluoro-3-hydroxy-1,1-dimethyl-3-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)butyl]phenol",CC(C)(C[C@@](O)(Cc1cc2cnccc2[nH]1)C(F)(F)F)c3cc(F)ccc3O,CHEMBL1253899,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 4.7nM,agonist,94.00%,agonist,dexamethasone,0.51nM,dexamethasone,5nM,,,,IC50,=,3,nM,,,,,=,8.327902142,pIC50,B,FPA,CC(C)(C[C@@](O)(Cc1cc2cnccc2[nH]1)C(F)(F)F)c1cc(F)ccc1O,94,376.224,396.1460908,3,3,5,3,4.6114,69.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,agonist,agonist,agonist,420
13292,70,15006411,37,P19793,RXRA,Homo sapiens,"(E)-3-{4-[3,5-Di-tert-butyl-2-(3-fluoro-propoxy)-phenyl]-benzo[b]thiophen-2-yl}-but-2-enoic acid",C\C(=C/C(=O)O)\c1cc2c(cccc2s1)c3cc(cc(c3OCCCF)C(C)(C)C)C(C)(C)C,CHEMBL41146,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 3nM,antagonist,94.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,8,nM,=,8.522878745,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2c(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3OCCCF)cccc2s1,94,447.381,482.2290942,1,3,7,3,8.3896,46.53,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
13341,702,23953070,6a,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2-dimethyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)(Cc1ccc2c(cnn2c3ccc(F)cc3)c1)C(=O)Nc4nncs4,CHEMBL2426634,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 84nM,partial agonist,36.00%,agonist,,,,,,,,EC50,=,4322,nM,,,,,=,7.075720714,pKi,B,FPA,CC(C)(Cc1ccc2c(cnn2-c2ccc(F)cc2)c1)C(=O)Nc1nncs1,36,377.319,395.1216094,1,6,5,4,4.2235,72.7,CC(CCC1CCC2C(CCC2C2CCCCC2)C1)CC1CCCC1,agonist,partial agonist,agonist,partial agonist,1108
13362,703,19464171,22,P37231,PPARG,Homo sapiens,"2-(4-(2-(4-hydroxy-4-methylpent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CC(C)(O)C#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL506419,Gal4 luciferase reporter gene assays,,filtration assay,Ki = 84nM,agonist,81.00%,agonist,rosiglitazone,,rosiglitazone,20nM,,,,EC50,=,2200,nM,,,,,=,7.075720714,pKi,B,other,CC(C)(O)C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,81,569.407,600.1793444,2,6,10,3,6.9309,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
13363,703,19464171,22,Q03181,PPARB,Homo sapiens,"2-(4-(2-(4-hydroxy-4-methylpent-2-ynyloxy)-4-((4-(trifluoromethyl)phenoxy)methyl)phenylthio)-5,6,7,8-tetrahydronaphthalen-1-yloxy)acetic acid",CC(C)(O)C#CCOc1cc(COc2ccc(cc2)C(F)(F)F)ccc1Sc3ccc(OCC(=O)O)c4CCCCc34,CHEMBL506419,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 22nM,agonist,89.00%,agonist,GW501516,,GW501516,10nM,,,,EC50,=,1400,nM,,,,,=,7.657577319,pKi,B,radiometric,CC(C)(O)C#CCOc1cc(COc2ccc(C(F)(F)F)cc2)ccc1Sc1ccc(OCC(=O)O)c2c1CCCC2,89,569.407,600.1793444,2,6,10,3,6.9309,85.22,C1CCC(CCC2CCC(CC3CCCC4CCCCC43)CC2)CC1,agonist,agonist,agonist,agonist,334
13385,704,9484511,2b,P10275,AR,Homo sapiens,2-Hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,luciferase reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 27nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,15,nM,=,7.568636236,pKi,B,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,205
13386,704,10743937,1b (2-Hydroxyflutamide),P10275,AR,Homo sapiens,2-Hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,cotransfection,hAR transfected into COS-1 cells,Ki = 34nM,antagonist,97.00%,antagonist,maximal inhibition,,,,,,,,,,,IC50,=,43,nM,=,7.468521083,pKi,B,other,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,97,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,antagonist,antagonist,"antagonist,agonist",antagonist,205
13387,704,16129672,hydroxyflutamide,P10275,AR,Homo sapiens,,CC(C)(C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-])O, ZINC04655055,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 25 nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,,,,,=,7.602059991,pKi,B,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,,,"antagonist,agonist",antagonist,205
13388,704,17804229,"2, hydroxyflutamide",P10275,AR,Homo sapiens,2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 200nM,antagonist,no detail about the percentage act,,,,mibolerone,,,,,FI5,=,1000,nM,IC50,=,31,nM,=,6.698970004,pIC50,,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,"antagonist,agonist",,"antagonist,agonist",antagonist,205
13389,704,18291644,"5, hydroxyflutamide",P10275,AR,Homo sapiens,2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,"transiently transfected reporter assay system utilizing the secreted alkaline phosphatase reporter gene driven by the AR-dependent, PSA promoter",radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 43nM,antagonist,no detail about the percentage act,,,,DHT,,,,,,,,,IC50,=,26,nM,=,7.366531544,pKi,B,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,205
13390,704,18571420,"5, hydroxyflutamide",P10275,AR,Homo sapiens,2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,SC-3 growth-inhibitory activity ,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 430nM,antagonist,no detail about the percentage act,,,,testosterone,1nM,,,,,,,,IC50,=,350,nM,=,6.366531544,pKi,,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,205
13391,704,22746350,2,P10275,AR,Homo sapiens,hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.65,,13.00%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,=,6.65,pIC50,,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,13,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,,,"antagonist,agonist",antagonist,205
13392,704,26295173,3,P10275,AR,Homo sapiens,Hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CHEMBL491,,inhibition of SC-3 cell proliferation,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of [3H]-radiolabeled methyltrienolone",IC50 = 7690nM,antagonist,no detail about the percentage act,,,,,,,,,,,,,IC50,=,180,nM,=,5.11407366,pIC50,,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,,281.125,292.0670915,2,4,3,1,2.323,92.47,C1CCCCC1,antagonist,,"antagonist,agonist",antagonist,205
13413,705,10230629,2-hydroxyflutamide,P10275,AR,Homo sapiens,N-(2-Hydroxy-4-nitro-3-trifluoromethyl-phenyl)-isobutyramide,CC(C)(O)C(=O)Nc1ccc(c(c1O)C(F)(F)F)[N+](=O)[O-],CHEMBL2112349,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 27nM,antagonist,83.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,15,nM,=,7.568636236,pKi,B,radiometric,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1O,83,297.124,308.0620061,3,5,3,1,2.0286,112.7,C1CCCCC1,antagonist,antagonist,antagonist,antagonist,205
13435,706,15115388,28,P04150,GR,Homo sapiens,"2-[(4aR,5S)-1-(4-Fluoro-phenyl)-4a-methyl-4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazol-5-yl]-propan-2-ol",CC(C)(O)[C@H]1CCCC2=Cc3c(C[C@]12C)cnn3c4ccc(F)cc4,CHEMBL312041,IL-6 production assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1.9nM,agonist,86.70%,agonist,dexamethasone,,dexamethasone,2.5nM,,,,EC50,=,3,nM,,,,,=,8.721246399,pIC50,B,radiometric,CC(C)(O)[C@H]1CCCC2=Cc3c(cnn3-c3ccc(F)cc3)C[C@@]21C,86.7,315.242,340.1950916,1,3,2,2,4.5282,38.05,C1CCC(C2CCC3CC4CCCCC4CC32)CC1,agonist,agonist,agonist,agonist,97
13458,707,25435151,10,P55055,LXRB,Homo sapiens,2-(1-(2-chlorophenyl)-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-1H-pyrazol-3-yl)propan-2-ol,CC(C)(O)c1cc(c2ccc(s2)c3cccc(c3)S(=O)(=O)C)n(n1)c4ccccc4Cl,CHEMBL3360969,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 83nM,partial agonist,43.00%,agonist,compound 3b,,,,,,,EC50,=,620,nM,,,,,=,7.080921908,pIC50,B,radiometric,CC(C)(O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,43,451.851,472.0682122,1,6,5,4,5.5521,72.19,C1CCC(C2CCC(C3CCCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,139
13484,709,24980053,37,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)(O)c1ccc(cn1)c2ccc3[C@H](c4cccc(F)c4Oc3n2)C(C)(C)C(=O)NC(=O)N,CHEMBL3315069,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 4.0nM,partial agonist,49.00%,agonist,dexamethasone,,,,,,,EC50,=,107.4,nM,,,,,=,8.397940009,pKi,B,FPA,CC(C)(O)c1ccc(-c2ccc3c(n2)Oc2c(F)cccc2[C@@H]3C(C)(C)C(=O)NC(N)=O)cn1,49,439.297,464.1859835,3,6,4,3,3.9688,127.43,C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,98
13498,71,15006411,59,P19793,RXRA,Homo sapiens,"(E)-3-{7-[3,5-Diisopropyl-2-(2,2,2-trifluoro-ethoxy)-phenyl]-benzofuran-2-yl}-but-2-enoic acid",CC(C)c1cc(C(C)C)c(OCC(F)(F)F)c(c1)c2cccc3cc(oc23)\C(=C\C(=O)O)\C,CHEMBL39206,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 198nM,antagonist,76.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,347,nM,=,6.70333481,pKi,,radiometric,C/C(=C\C(=O)O)c1cc2cccc(-c3cc(C(C)C)cc(C(C)C)c3OCC(F)(F)F)c2o1,76,433.276,460.186144,1,3,7,3,7.7756,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
13501,710,19853462,5b,P55055,LXRB,Homo sapiens,2-(3-{3-[3-Benzyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}-phenyl)propan-2-ol,CC(C)(O)c1cccc(Oc2cccc(c2)c3c(Cc4ccccc4)cnc5c(cccc35)C(F)(F)F)c1,CHEMBL595124,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.3nM,agonist,106.00%,agonist,T0901317,16nM,T0901317,,,,,EC50,=,31,nM,,,,,=,8.48148606,pIC50,B,radiometric,CC(C)(O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,106,487.351,513.1915637,1,3,6,5,8.5311,42.35,C1CCC(CC2CCCC(C3C(CC4CCCCC4)CCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,278
13514,711,25435151,15,P55055,LXRB,Homo sapiens,"2-(2-(2,6-dichlorophenyl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol",CC(C)(O)c1cn(c2ccc(cc2)c3cccc(c3)S(=O)(=O)C)c(n1)c4c(Cl)cccc4Cl,CHEMBL3360972,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 54nM,partial agonist,44.00%,agonist,compound 3b,,,,,,,EC50,=,670,nM,,,,,=,7.26760624,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2c(Cl)cccc2Cl)n1,44,479.259,500.0728189,1,5,5,4,6.144,72.19,C1CCC(C2CCC(C3CCCC3C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,140
13539,712,25435151,14,P55055,LXRB,Homo sapiens,2-(2-(2-chlorophenyl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c2ccc(cc2)c3cccc(c3)S(=O)(=O)C)c(n1)c4ccccc4Cl,CHEMBL3360971,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 59nM,partial agonist,32.00%,agonist,compound 3b,,,,,,,EC50,=,600,nM,,,,,=,7.229147988,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2ccccc2Cl)n1,32,443.806,466.1117913,1,5,5,4,5.4906,72.19,C1CCC(C2CCC(C3CCCC3C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,140
13561,713,25435151,18,P55055,LXRB,Homo sapiens,2-(2-(2-(2-chlorophenyl)propan-2-yl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c2ccc(cc2)c3cccc(c3)S(=O)(=O)C)c(n1)C(C)(C)c4ccccc4Cl,CHEMBL3360975,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 14nM,partial agonist,72.00%,agonist,compound 3b,,,,,,,EC50,=,250,nM,,,,,=,7.853871964,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,72,479.839,508.1587415,1,5,6,4,6.1495,72.19,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,246
13562,713,25435151,18,Q13133,LXRA,Homo sapiens,2-(2-(2-(2-chlorophenyl)propan-2-yl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c2ccc(cc2)c3cccc(c3)S(=O)(=O)C)c(n1)C(C)(C)c4ccccc4Cl,CHEMBL3360975,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 68nM,partial agonist,38.00%,agonist,compound 3b,,,,,,,EC50,=,230,nM,,,,,=,7.167491087,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,38,479.839,508.1587415,1,5,6,4,6.1495,72.19,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,246
13583,714,25435151,16,P55055,LXRB,Homo sapiens,2-(1-(3'-(methylsulfonyl)biphenyl-4-yl)-2-(2-(trifluoromethyl)benzyl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c(Cc2ccccc2C(F)(F)F)n1)c3ccc(cc3)c4cccc(c4)S(=O)(=O)C,CHEMBL3360973,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 7nM,partial agonist,43.00%,agonist,compound 3b,,,,,,,EC50,=,140,nM,,,,,=,8.15490196,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2C(F)(F)F)n1,43,489.369,514.1537983,1,5,6,4,5.7798,72.19,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,246
13607,715,25435151,17,P55055,LXRB,Homo sapiens,2-(2-(2-chlorobenzyl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c(Cc2ccccc2Cl)n1)c3ccc(cc3)c4cccc(c4)S(=O)(=O)C,CHEMBL3360974,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 1nM,partial agonist,55.00%,agonist,compound 3b,,,,,,,EC50,=,66,nM,,,,,=,9,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,55,455.817,480.1274413,1,5,6,4,5.4144,72.19,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,246
13608,715,25435151,17,Q13133,LXRA,Homo sapiens,2-(2-(2-chlorobenzyl)-1-(3'-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol,CC(C)(O)c1cn(c(Cc2ccccc2Cl)n1)c3ccc(cc3)c4cccc(c4)S(=O)(=O)C,CHEMBL3360974,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 25nM,partial agonist,28.00%,agonist,compound 3b,,,,,,,EC50,=,85,nM,,,,,=,7.602059991,pIC50,B,radiometric,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,28,455.817,480.1274413,1,5,6,4,5.4144,72.19,C1CCC(CC2CCCC2C2CCC(C3CCCCC3)CC2)CC1,agonist,partial agonist,agonist,partial agonist,246
13639,716,11405642,3,Q07869,PPARA,Homo sapiens,2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 68000nM,,,,reference compound (?),,,,,,,Eff,<,20%,,,,,,=,4.167491087,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,,,agonist,"partial agonist,agonist",869
13640,716,12951090,13 (Fenofibric acid),Q07869,PPARA,Homo sapiens,2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 35000nM,,,,,,,,,,,,,,,,,,,=,4.455931956,pKi,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,,,agonist,"partial agonist,agonist",869
13641,716,14613314,2 - Fenofibric acid,Q07869,PPARA,Homo sapiens,2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 24000nM,agonist,no detail about the percentage act,,,,,,,,,EC50,=,13000,nM,,,,,=,4.619788758,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,agonist,,agonist,"partial agonist,agonist",869
13642,716,15582409,fenofibric acid,Q07869,PPARA,Homo sapiens,2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,CTF assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,,75.00%,,standard,,,,,,,EC50,>,10000,nM,,,,,>,5,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,75,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,,,agonist,"partial agonist,agonist",869
13643,716,15771468,Fenofibric acid,Q07869,PPARA,Homo sapiens,2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Transactivation assay (SEAP/CMV containing pIRSNeo vector),,Fluorescence polarization (FP) competition binding assay,IC50 > 10000nM,partial agonist,30.00%,agonist,GW2331,,,,,,,EC50,>,10000,nM,,,,,>,5,pIC50,NB,FPA,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,30,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,,partial agonist,agonist,"partial agonist,agonist",869
13644,716,17005393,fenofibric acid,Q07869,PPARA,Homo sapiens,2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 10000nM,agonist,75.00%,agonist,ref agonist,,,,,,,EC50,>,10000,nM,,,,,>,5,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,75,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,,agonist,agonist,"partial agonist,agonist",869
13645,716,17005394,"1b, Fenofibric acid",Q07869,PPARA,Homo sapiens,2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 > 10000nM,partial agonist,35.00%,agonist,"2-(4-{2-[3-(2,4-difluoro-phenyl)-1-heptyl- ureido]-ethyl}-phenoxy)-2- methyl-butyric acid",,,,,,,EC50,=,2646,nM,,,,,>,5,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,35,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,agonist,partial agonist,agonist,"partial agonist,agonist",869
13646,716,19349176,Fenofibric acid,Q07869,PPARA,Homo sapiens,Fenofibric acid,CC(C)(Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2)C(=O)O,CHEMBL981,Luciferase reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 106000nM,,11.00%,agonist,Farglitazar,284nM,Farglitazar,,,,,EC50,=,69000,nM,,,,,=,3.974694135,pIC50,NB,radiometric,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,11,303.636,318.0658866,1,3,5,2,3.813,63.6,CC(C1CCCCC1)C1CCCCC1,agonist,,agonist,"partial agonist,agonist",869
13694,7175,19019676,13d,P04150,GR,Homo sapiens,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3Cl,CHEMBL517440,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,nd,agonist,113.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,8.2,,,,,,,,NEG,NB,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,113,505.73,527.1347301,3,6,8,3,3.4325,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,"agonist,partial agonist",1316
13695,7175,19019676,13e,P04150,GR,Homo sapiens,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ccccc3Cl,CHEMBL517440,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,nd,partial agonist,70.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,6.5,,,,,,,,NEG,NB,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,70,505.73,527.1347301,3,6,8,3,3.4325,113.48,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,partial agonist,agonist,"agonist,partial agonist",1316
13699,7176,19019676,14b,P04150,GR,Homo sapiens,"N-(2-((5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-3-chloro-N-ethylpicolinamide",CCN(CC(O)(CNC(=O)c1cnn(c1N)c2ccc(F)cc2)C(F)(F)F)C(=O)c3ncccc3Cl,CHEMBL520276,MMTV agonism,,Fluorescence polarization (FP) competition binding assay,nd,agonist,93.00%,agonist,dexamethasone,,dexamethasone,,,,,PEC50,=,7.4,,,,,,,,NEG,NB,FPA,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl,93,507.726,528.1299791,3,7,8,3,2.8275,126.37,CC(CCCCCC(C)C1CCC(C2CCCCC2)C1)C1CCCCC1,agonist,agonist,agonist,agonist,1316
13761,72,15006411,61,P19793,RXRA,Homo sapiens,"(E)-3-{7-[2-(2,2-Difluoro-ethoxy)-3,5-diisopropyl-phenyl]-benzofuran-2-yl}-but-2-enoic acid",CC(C)c1cc(C(C)C)c(OCC(F)F)c(c1)c2cccc3cc(oc23)\C(=C\C(=O)O)\C,CHEMBL265051,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 161nM,partial antagonist,67.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,300,nM,=,6.793174124,pKi,,radiometric,C/C(=C\C(=O)O)c1cc2cccc(-c3cc(C(C)C)cc(C(C)C)c3OCC(F)F)c2o1,67,414.278,442.1955658,1,3,8,3,7.4784,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,partial antagonist,antagonist,partial antagonist,138
13764,720,12781197,10,P06401,PR,Homo sapiens,"9-Fluoro-2,2,4-trimethyl-5-((Z)-3-methyl-but-2-enylidene)-2,5-dihydro-1H-6-oxa-1-aza-chrysene",CC(=C\C=C\1/Oc2ccc(F)cc2c3ccc4NC(C)(C)C=C(C)c4c13)C,CHEMBL65690,co-transaction assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 2.5nM,agonist,172.00%,agonist,progesterone,,dexamethasone,2.5nM,,,,EC50,=,1.7,nM,,,,,=,8.602059991,pKi,B,radiometric,CC(C)=C/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,172,337.268,361.1841926,1,2,1,2,6.7996,21.26,CC1CC2CCCCC2C2CCC3CCCCC3C12,agonist,agonist,agonist,agonist,515
13811,722,22579420,APH 5,P37231,PPARG,Homo sapiens,"4-(4-((E)-3,7-dimethylocta-2,6-dienyl)-3,5-dihydroxystyryl)benzonitrile",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(cc2)C#N)cc1O)\C)C,CHEMBL2031859,,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 1200nM,partial agonist,41.00%,agonist,Troglitazone,,,,,,,,,,,,,,,=,5.920818754,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(C#N)cc2)cc1O,41,346.28,373.2041791,2,3,7,2,6.37508,64.25,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
13812,722,22579420,APH 5,Q07869,PPARA,Homo sapiens,"4-(4-((E)-3,7-dimethylocta-2,6-dienyl)-3,5-dihydroxystyryl)benzonitrile",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(cc2)C#N)cc1O)\C)C,CHEMBL2031859,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 3470nM,partial agonist,54.00%,agonist,Wy14643,,,,,,,EC50,=,20000,nM,,,,,=,5.459670525,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(C#N)cc2)cc1O,54,346.28,373.2041791,2,3,7,2,6.37508,64.25,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
13831,7229,23586645,2a,P03372,ERA,Homo sapiens,"2,5-Bis-(4-hydroxyphenyl)thiophene",Oc1ccc(cc1)c2ccc(s2)c3ccc(O)cc3,CHEMBL204010,,,,RBA = 0.040,agonist,125.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,2350,nM,,,,,=,0.04,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3)s2)cc1,125,256.241,268.0558006,2,3,2,3,4.4933,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13832,7229,23586645,2a,Q92731,ERB,Homo sapiens,"2,5-Bis-(4-hydroxyphenyl)thiophene",Oc1ccc(cc1)c2ccc(s2)c3ccc(O)cc3,CHEMBL204010,,,,RBA = 0.79,agonist,198.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1540,nM,,,,,=,0.79,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3)s2)cc1,198,256.241,268.0558006,2,3,2,3,4.4933,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13835,7230,23586645,2b,P03372,ERA,Homo sapiens,"2,5-Bis(4-hydroxy-2-methylphenyl)thiophene",Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3C,CHEMBL2332602,,,,RBA = 1.43,agonist,78.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,,,,,,,,,=,1.43,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2C)s1,78,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13836,7230,23586645,2b,Q92731,ERB,Homo sapiens,"2,5-Bis(4-hydroxy-2-methylphenyl)thiophene",Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3C,CHEMBL2332602,,,,RBA = 1.74,agonist,87.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,6600,nM,,,,,=,1.74,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2C)s1,87,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13841,7233,23586645,2e,P03372,ERA,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2ccc(s2)c3ccc(O)cc3F,CHEMBL2332593,,,,RBA = 2.03,agonist,181.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,,,,,,,,,=,2.03,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3F)s2)c(F)c1,181,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13842,7233,23586645,2e,Q92731,ERB,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2ccc(s2)c3ccc(O)cc3F,CHEMBL2332593,,,,RBA = 33.1,agonist,336.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,33.1,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3F)s2)c(F)c1,336,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13843,7234,23586645,2f,P03372,ERA,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2ccc(s2)c3ccc(O)cc3Cl,CHEMBL2332594,,,,RBA = 6.7,agonist,111.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,2180,nM,,,,,=,6.7,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3Cl)s2)c(Cl)c1,111,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13844,7234,23586645,2f,Q92731,ERB,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2ccc(s2)c3ccc(O)cc3Cl,CHEMBL2332594,,,,RBA = 10.0,agonist,169.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1940,nM,,,,,=,10,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3Cl)s2)c(Cl)c1,169,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13855,724,22579420,APH 9,P37231,PPARG,Homo sapiens,"4-(4-((E)-3,7-dimethylocta-2,6-dienyl)-3,5-dihydroxystyryl)benzaldehyde",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(C=O)cc2)cc1O)\C)C,CHEMBL2031954,,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 890nM,partial agonist,27.00%,agonist,Troglitazone,,,,,,,,,,,,,,,=,6.050609993,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(C=O)cc2)cc1O,27,348.272,376.2038448,2,3,8,2,6.3159,57.53,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
13856,724,22579420,APH 9,Q07869,PPARA,Homo sapiens,"4-(4-((E)-3,7-dimethylocta-2,6-dienyl)-3,5-dihydroxystyryl)benzaldehyde",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(C=O)cc2)cc1O)\C)C,CHEMBL2031954,,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 2820nM,partial agonist,35.00%,agonist,Wy14643,,,,,,,,,,,,,,,=,5.549750892,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(C=O)cc2)cc1O,35,348.272,376.2038448,2,3,8,2,6.3159,57.53,C1CCC(CCC2CCCCC2)CC1,,partial agonist,,partial agonist,326
13857,7240,23586645,2l,P03372,ERA,Homo sapiens,2-(2-Fluoro-4-hydroxyphenyl)-5-(4-hydroxy-2-methylphenyl)-thiophene,Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3F,CHEMBL2332600,,,,RBA = 0.97,agonist,117.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,470,nM,,,,,=,0.97,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2F)s1,117,287.25,300.0620289,2,3,2,3,4.94082,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13858,7240,23586645,2l,Q92731,ERB,Homo sapiens,2-(2-Fluoro-4-hydroxyphenyl)-5-(4-hydroxy-2-methylphenyl)-thiophene,Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3F,CHEMBL2332600,,,,RBA = 0.91,agonist,277.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,610,nM,,,,,=,0.91,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2F)s1,277,287.25,300.0620289,2,3,2,3,4.94082,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13859,7241,23586645,2m,P03372,ERA,Homo sapiens,2-(2-Chloro-4-hydroxyphenyl)-5-(4-hydroxy-2-methylphenyl)-thiophene,Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3Cl,CHEMBL2332601,,,,RBA = 4.29,agonist,78.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,1910,nM,,,,,=,4.29,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2Cl)s1,78,303.705,316.0324783,2,3,2,3,5.45512,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13860,7241,23586645,2m,Q92731,ERB,Homo sapiens,2-(2-Chloro-4-hydroxyphenyl)-5-(4-hydroxy-2-methylphenyl)-thiophene,Cc1cc(O)ccc1c2ccc(s2)c3ccc(O)cc3Cl,CHEMBL2332601,,,,RBA = 5.89,agonist,111.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1920,nM,,,,,=,5.89,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2Cl)s1,111,303.705,316.0324783,2,3,2,3,5.45512,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13861,7242,23586645,4a,P03372,ERA,Homo sapiens,"3,4-Bis(4-hydroxyphenyl)thiophene",Oc1ccc(cc1)c2cscc2c3ccc(O)cc3,CHEMBL2031540,,,,RBA = 0.57,partial agonist,69.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,2250,nM,,,,,=,0.57,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2)cc1,69,256.241,268.0558006,2,3,2,3,4.4933,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13862,7242,23586645,4a,Q92731,ERB,Homo sapiens,"3,4-Bis(4-hydroxyphenyl)thiophene",Oc1ccc(cc1)c2cscc2c3ccc(O)cc3,CHEMBL2031540,,,,RBA = 1.69,partial agonist,73.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1270,nM,,,,,=,1.69,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2)cc1,73,256.241,268.0558006,2,3,2,3,4.4933,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13863,7243,23586645,4b,P03372,ERA,Homo sapiens,"3,4-Bis(4-hydroxy-2-methylphenyl)thiophene",Cc1cc(O)ccc1c2cscc2c3ccc(O)cc3C,CHEMBL2031541,,,,RBA = 2.16,agonist,97.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,3150,nM,,,,,=,2.16,RBA,,other,Cc1cc(O)ccc1-c1cscc1-c1ccc(O)cc1C,97,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13864,7243,23586645,4b,Q92731,ERB,Homo sapiens,"3,4-Bis(4-hydroxy-2-methylphenyl)thiophene",Cc1cc(O)ccc1c2cscc2c3ccc(O)cc3C,CHEMBL2031541,,,,RBA = 4.9,partial agonist,67.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1870,nM,,,,,=,4.9,RBA,,other,Cc1cc(O)ccc1-c1cscc1-c1ccc(O)cc1C,67,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13865,7244,23586645,4c,P03372,ERA,Homo sapiens,"3,4-Bis(4-hydroxy-3-methylphenyl)thiophene",Cc1cc(ccc1O)c2cscc2c3ccc(O)c(C)c3,CHEMBL2031542,,,,RBA = 0.830,partial agonist,73.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,,,,,,,,,=,0.83,RBA,,other,Cc1cc(-c2cscc2-c2ccc(O)c(C)c2)ccc1O,73,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,,partial agonist,,partial agonist,128
13866,7244,23586645,4c,Q92731,ERB,Homo sapiens,"3,4-Bis(4-hydroxy-3-methylphenyl)thiophene",Cc1cc(ccc1O)c2cscc2c3ccc(O)c(C)c3,CHEMBL2031542,,,,RBA = 0.297,partial agonist,70.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,0.297,RBA,,other,Cc1cc(-c2cscc2-c2ccc(O)c(C)c2)ccc1O,70,280.263,296.0871008,2,3,2,3,5.11014,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,,partial agonist,,partial agonist,128
13869,7246,23586645,4e,P03372,ERA,Homo sapiens,"3,4-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2cscc2c3ccc(O)cc3F,CHEMBL2332569,,,,RBA = 3.03,agonist,79.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,120,nM,,,,,=,3.03,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2F)c(F)c1,79,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13870,7246,23586645,4e,Q92731,ERB,Homo sapiens,"3,4-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2cscc2c3ccc(O)cc3F,CHEMBL2332569,,,,RBA = 9.1,partial agonist,29.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,780,nM,,,,,=,9.1,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2F)c(F)c1,29,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13871,7247,23586645,4f,P03372,ERA,Homo sapiens,"3,4-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2cscc2c3ccc(O)cc3Cl,CHEMBL2331567,,,,RBA = 13.07,agonist,90.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,45,nM,,,,,=,13.07,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2Cl)c(Cl)c1,90,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13872,7247,23586645,4f,Q92731,ERB,Homo sapiens,"3,4-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2cscc2c3ccc(O)cc3Cl,CHEMBL2331567,,,,RBA = 17.5,partial agonist,57.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,203,nM,,,,,=,17.5,RBA,,other,Oc1ccc(-c2cscc2-c2ccc(O)cc2Cl)c(Cl)c1,57,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13873,7248,23586645,6a,P03372,ERA,Homo sapiens,"2,4-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2csc(c2)c3ccc(O)cc3F,CHEMBL2332570,,,,RBA = 1.22,agonist,123.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,1060,nM,,,,,=,1.22,RBA,,other,Oc1ccc(-c2csc(-c3ccc(O)cc3F)c2)c(F)c1,123,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13874,7248,23586645,6a,Q92731,ERB,Homo sapiens,"2,4-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2csc(c2)c3ccc(O)cc3F,CHEMBL2332570,,,,RBA = 10.4,agonist,177.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1340,nM,,,,,=,10.4,RBA,,other,Oc1ccc(-c2csc(-c3ccc(O)cc3F)c2)c(F)c1,177,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13875,7249,23586645,6b,P03372,ERA,Homo sapiens,"2,4-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2csc(c2)c3ccc(O)cc3Cl,CHEMBL2332571,,,,RBA = 4.21,agonist,87.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,563,nM,,,,,=,4.21,RBA,,other,Oc1ccc(-c2csc(-c3ccc(O)cc3Cl)c2)c(Cl)c1,87,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13876,7249,23586645,6b,Q92731,ERB,Homo sapiens,"2,4-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2csc(c2)c3ccc(O)cc3Cl,CHEMBL2332571,,,,RBA = 25.6,agonist,117.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,660,nM,,,,,=,25.6,RBA,,other,Oc1ccc(-c2csc(-c3ccc(O)cc3Cl)c2)c(Cl)c1,117,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13879,7250,23586645,8a,P03372,ERA,Homo sapiens,"2,3-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2ccsc2c3ccc(O)cc3F,CHEMBL2332572,,,,RBA = 1.22,partial agonist,69.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,65900,nM,,,,,=,1.22,RBA,,other,Oc1ccc(-c2ccsc2-c2ccc(O)cc2F)c(F)c1,69,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13880,7250,23586645,8a,Q92731,ERB,Homo sapiens,"2,3-Bis(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2ccsc2c3ccc(O)cc3F,CHEMBL2332572,,,,RBA = 2.54,partial agonist,33.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,2.54,RBA,,other,Oc1ccc(-c2ccsc2-c2ccc(O)cc2F)c(F)c1,33,294.237,304.036957,2,3,2,3,4.7715,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,,partial agonist,,partial agonist,128
13881,7251,23586645,8b,P03372,ERA,Homo sapiens,"2,3-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2ccsc2c3ccc(O)cc3Cl,CHEMBL2332573,,,,RBA = 6.5,agonist,82.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,1160,nM,,,,,=,6.5,RBA,,other,Oc1ccc(-c2ccsc2-c2ccc(O)cc2Cl)c(Cl)c1,82,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13882,7251,23586645,8b,Q92731,ERB,Homo sapiens,"2,3-Bis(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2ccsc2c3ccc(O)cc3Cl,CHEMBL2332573,,,,RBA = 7.73,agonist,116.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,5700,nM,,,,,=,7.73,RBA,,other,Oc1ccc(-c2ccsc2-c2ccc(O)cc2Cl)c(Cl)c1,116,327.147,335.9778559,2,3,2,3,5.8001,40.46,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13883,7252,23586645,10a,P03372,ERA,Homo sapiens,"2,5-Bis(4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2)c3ccc(O)cc3,CHEMBL2332574,,,,RBA = 0.95,agonist,116.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,1520,nM,,,,,=,0.95,RBA,,other,Cc1cc(-c2ccc(O)cc2)sc1-c1ccc(O)cc1,116,268.252,282.0714507,2,3,2,3,4.80172,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13884,7252,23586645,10a,Q92731,ERB,Homo sapiens,"2,5-Bis(4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2)c3ccc(O)cc3,CHEMBL2332574,,,,RBA = 1.6,agonist,200.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,1230,nM,,,,,=,1.6,RBA,,other,Cc1cc(-c2ccc(O)cc2)sc1-c1ccc(O)cc1,200,268.252,282.0714507,2,3,2,3,4.80172,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13885,7253,23586645,10b,P03372,ERA,Homo sapiens,"2,5-Bis(4-hydroxy-2-methylphenyl)-3-methylthiophene",Cc1cc(O)ccc1c2cc(C)c(s2)c3ccc(O)cc3C,CHEMBL2332575,,,,RBA = 5.15,partial agonist,70.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,439,nM,,,,,=,5.15,RBA,,other,Cc1cc(O)ccc1-c1cc(C)c(-c2ccc(O)cc2C)s1,70,292.274,310.1027508,2,3,2,3,5.41856,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,146
13886,7253,23586645,10b,Q92731,ERB,Homo sapiens,"2,5-Bis(4-hydroxy-2-methylphenyl)-3-methylthiophene",Cc1cc(O)ccc1c2cc(C)c(s2)c3ccc(O)cc3C,CHEMBL2332575,,,,RBA = 4.8,agonist,106.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,2460,nM,,,,,=,4.8,RBA,,other,Cc1cc(O)ccc1-c1cc(C)c(-c2ccc(O)cc2C)s1,106,292.274,310.1027508,2,3,2,3,5.41856,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13887,7254,23586645,10c,P03372,ERA,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2F)c3ccc(O)cc3F,CHEMBL2332576,,,,RBA = 9.3,agonist,149.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,447,nM,,,,,=,9.3,RBA,,other,Cc1cc(-c2ccc(O)cc2F)sc1-c1ccc(O)cc1F,149,306.248,318.0526071,2,3,2,3,5.07992,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13888,7254,23586645,10c,Q92731,ERB,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2F)c3ccc(O)cc3F,CHEMBL2332576,,,,RBA = 20.6,agonist,284.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,10800,nM,,,,,=,20.6,RBA,,other,Cc1cc(-c2ccc(O)cc2F)sc1-c1ccc(O)cc1F,284,306.248,318.0526071,2,3,2,3,5.07992,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13889,7255,23586645,10d,P03372,ERA,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2Cl)c3ccc(O)cc3Cl,CHEMBL2332577,,,,RBA = 10.4,agonist,82.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,101,nM,,,,,=,10.4,RBA,,other,Cc1cc(-c2ccc(O)cc2Cl)sc1-c1ccc(O)cc1Cl,82,339.158,349.993506,2,3,2,3,6.10852,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13890,7255,23586645,10d,Q92731,ERB,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)-3-methylthiophene",Cc1cc(sc1c2ccc(O)cc2Cl)c3ccc(O)cc3Cl,CHEMBL2332577,,,,RBA = 5.41,agonist,113.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,295,nM,,,,,=,5.41,RBA,,other,Cc1cc(-c2ccc(O)cc2Cl)sc1-c1ccc(O)cc1Cl,113,339.158,349.993506,2,3,2,3,6.10852,40.46,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13891,7256,23586645,12a,P03372,ERA,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)-3-phenylthiophene",Oc1ccc(c(F)c1)c2cc(c3ccccc3)c(s2)c4ccc(O)cc4F,CHEMBL2332578,,,,RBA = 1.88,partial agonist,70.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,615,nM,,,,,=,1.88,RBA,,other,Oc1ccc(-c2cc(-c3ccccc3)c(-c3ccc(O)cc3F)s2)c(F)c1,70,366.303,380.0682571,2,3,3,4,6.4385,40.46,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,123
13892,7256,23586645,12a,Q92731,ERB,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)-3-phenylthiophene",Oc1ccc(c(F)c1)c2cc(c3ccccc3)c(s2)c4ccc(O)cc4F,CHEMBL2332578,,,,RBA = 2.02,partial agonist,39.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,2.02,RBA,,other,Oc1ccc(-c2cc(-c3ccccc3)c(-c3ccc(O)cc3F)s2)c(F)c1,39,366.303,380.0682571,2,3,3,4,6.4385,40.46,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,,partial agonist,,partial agonist,123
13893,7257,23586645,12b,P03372,ERA,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)-3-phenylthiophene",Oc1ccc(c(Cl)c1)c2cc(c3ccccc3)c(s2)c4ccc(O)cc4Cl,CHEMBL2332579,,,,RBA = 3.65,partial agonist,72.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,66,nM,,,,,=,3.65,RBA,,other,Oc1ccc(-c2cc(-c3ccccc3)c(-c3ccc(O)cc3Cl)s2)c(Cl)c1,72,399.213,412.009156,2,3,3,4,7.4671,40.46,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,123
13895,7258,23586645,14a,P03372,ERA,Homo sapiens,"2,3,5-Tris(4-hydroxyphenyl)thiophene",Oc1ccc(cc1)c2cc(c3ccc(O)cc3)c(s2)c4ccc(O)cc4,CHEMBL2332580,,,,RBA = 1.79,agonist,82.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,485,nM,,,,,=,1.79,RBA,,other,Oc1ccc(-c2cc(-c3ccc(O)cc3)c(-c3ccc(O)cc3)s2)cc1,82,344.306,360.0820154,3,4,3,4,5.8659,60.69,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,123
13897,7259,23586645,14b,P03372,ERA,Homo sapiens,"2,3,5-Tris(2-fluoro-4-hydroxyphenyl)thiophene",Oc1ccc(c(F)c1)c2cc(c3ccc(O)cc3F)c(s2)c4ccc(O)cc4F,CHEMBL2332581,,,,RBA = 6.35,agonist,84.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,387,nM,,,,,=,6.35,RBA,,other,Oc1ccc(-c2cc(-c3ccc(O)cc3F)c(-c3ccc(O)cc3F)s2)c(F)c1,84,401.3,414.0537499,3,4,3,4,6.2832,60.69,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,123
13899,726,22579420,APH 6,P37231,PPARG,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-(4-fluorostyryl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(F)cc2)cc1O)\C)C,CHEMBL2031860,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 2320nM,partial agonist,68.00%,agonist,Troglitazone,,,,,,,EC50,=,11000,nM,,,,,=,5.634512015,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(F)cc2)cc1O,68,339.26,366.1995083,2,2,7,2,6.6425,40.46,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
13900,726,22579420,APH 6,Q07869,PPARA,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-(4-fluorostyryl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccc(F)cc2)cc1O)\C)C,CHEMBL2031860,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 2480nM,agonist,88.00%,agonist,Wy14643,,,,,,,EC50,=,6000,nM,,,,,=,5.605548319,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccc(F)cc2)cc1O,88,339.26,366.1995083,2,2,7,2,6.6425,40.46,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
13901,7260,23586645,14c,P03372,ERA,Homo sapiens,"2,3,5-Tris(2-chloro-4-hydroxyphenyl)thiophene",Oc1ccc(c(Cl)c1)c2cc(c3ccc(O)cc3Cl)c(s2)c4ccc(O)cc4Cl,CHEMBL2332582,,,,RBA = 85.7,partial agonist,52.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,9,nM,,,,,=,85.7,RBA,,other,Oc1ccc(-c2cc(-c3ccc(O)cc3Cl)c(-c3ccc(O)cc3Cl)s2)c(Cl)c1,52,450.665,461.9650983,3,4,3,4,7.8261,60.69,C1CCC(C2CC(C3CCCCC3)C(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,123
13903,7261,23586645,16a,P03372,ERA,Homo sapiens,"2,5-Bis(4-hydroxyphenyl)furan",Oc1ccc(cc1)c2oc(cc2)c3ccc(O)cc3,CHEMBL2332583,,,,RBA = 0.082,partial agonist,62.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,,,,,,,,,=,0.082,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3)o2)cc1,62,240.173,252.0786442,2,3,2,3,4.0248,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,partial agonist,,partial agonist,146
13904,7261,23586645,16a,Q92731,ERB,Homo sapiens,"2,5-Bis(4-hydroxyphenyl)furan",Oc1ccc(cc1)c2oc(cc2)c3ccc(O)cc3,CHEMBL2332583,,,,RBA = 0.34,agonist,94.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,0.34,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3)o2)cc1,94,240.173,252.0786442,2,3,2,3,4.0248,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13905,7262,23586645,16b,P03372,ERA,Homo sapiens,"2,5-Bis(4-hydroxy-2-methylphenyl)furan",Cc1cc(O)ccc1c2oc(cc2)c3ccc(O)cc3C,CHEMBL2332584,,,,RBA = 0.78,partial agonist,36.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,3790,nM,,,,,=,0.78,RBA,,other,Cc1cc(O)ccc1-c1ccc(-c2ccc(O)cc2C)o1,36,264.195,280.1099444,2,3,2,3,4.64164,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,146
13907,7263,23586645,16c,P03372,ERA,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)furan",Oc1ccc(c(F)c1)c2oc(cc2)c3ccc(O)cc3F,CHEMBL2332585,,,,RBA = 6.92,agonist,154.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,,,,,,,,,=,6.92,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3F)o2)c(F)c1,154,278.169,288.0598006,2,3,2,3,4.303,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13908,7263,23586645,16c,Q92731,ERB,Homo sapiens,"2,5-Bis(2-fluoro-4-hydroxyphenyl)furan",Oc1ccc(c(F)c1)c2oc(cc2)c3ccc(O)cc3F,CHEMBL2332585,,,,RBA = 32.2,agonist,159.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,32.2,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3F)o2)c(F)c1,159,278.169,288.0598006,2,3,2,3,4.303,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13909,7264,23586645,16d,P03372,ERA,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)furan",Oc1ccc(c(Cl)c1)c2oc(cc2)c3ccc(O)cc3Cl,CHEMBL2332586,,,,RBA = 2.73,agonist,82.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,3890,nM,,,,,=,2.73,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3Cl)o2)c(Cl)c1,82,311.079,320.0006995,2,3,2,3,5.3316,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,146
13910,7264,23586645,16d,Q92731,ERB,Homo sapiens,"2,5-Bis(2-chloro-4-hydroxyphenyl)furan",Oc1ccc(c(Cl)c1)c2oc(cc2)c3ccc(O)cc3Cl,CHEMBL2332586,,,,RBA = 6.9,agonist,106.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,6.9,RBA,,other,Oc1ccc(-c2ccc(-c3ccc(O)cc3Cl)o2)c(Cl)c1,106,311.079,320.0006995,2,3,2,3,5.3316,53.6,C1CCC(C2CCC(C3CCCCC3)C2)CC1,,agonist,,agonist,146
13911,7265,23586645,18a,P03372,ERA,Homo sapiens,"4,4'-(Furan-3,4-diyl)diphenol",Oc1ccc(cc1)c2cocc2c3ccc(O)cc3,CHEMBL2332587,,,,RBA = 0.22,agonist,81.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,10600,nM,,,,,=,0.22,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2)cc1,81,240.173,252.0786442,2,3,2,3,4.0248,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13912,7265,23586645,18a,Q92731,ERB,Homo sapiens,"4,4'-(Furan-3,4-diyl)diphenol",Oc1ccc(cc1)c2cocc2c3ccc(O)cc3,CHEMBL2332587,,,,RBA = 0.69,partial agonist,37.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,0.69,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2)cc1,37,240.173,252.0786442,2,3,2,3,4.0248,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,,partial agonist,,partial agonist,128
13913,7266,23586645,18b,P03372,ERA,Homo sapiens,"3,4-Bis(4-hydroxy-2-methylphenyl)furan",Cc1cc(O)ccc1c2cocc2c3ccc(O)cc3C,CHEMBL2332588,,,,RBA = 0.79,agonist,97.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,944,nM,,,,,=,0.79,RBA,,other,Cc1cc(O)ccc1-c1cocc1-c1ccc(O)cc1C,97,264.195,280.1099444,2,3,2,3,4.64164,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13914,7266,23586645,18b,Q92731,ERB,Homo sapiens,"3,4-Bis(4-hydroxy-2-methylphenyl)furan",Cc1cc(O)ccc1c2cocc2c3ccc(O)cc3C,CHEMBL2332588,,,,RBA = 2.28,partial agonist,56.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,5110,nM,,,,,=,2.28,RBA,,other,Cc1cc(O)ccc1-c1cocc1-c1ccc(O)cc1C,56,264.195,280.1099444,2,3,2,3,4.64164,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13915,7267,23586645,18c,P03372,ERA,Homo sapiens,"3,4-Bis(2-fluoro-4-hydroxyphenyl)furan",Oc1ccc(c(F)c1)c2cocc2c3ccc(O)cc3F,CHEMBL2332589,,,,RBA = 1.19,partial agonist,73.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,3640,nM,,,,,=,1.19,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2F)c(F)c1,73,278.169,288.0598006,2,3,2,3,4.303,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13916,7267,23586645,18c,Q92731,ERB,Homo sapiens,"3,4-Bis(2-fluoro-4-hydroxyphenyl)furan",Oc1ccc(c(F)c1)c2cocc2c3ccc(O)cc3F,CHEMBL2332589,,,,RBA = 5.41,agonist,85.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,,,,,,,,,=,5.41,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2F)c(F)c1,85,278.169,288.0598006,2,3,2,3,4.303,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,,agonist,,agonist,128
13917,7268,23586645,18d,P03372,ERA,Homo sapiens,"3,4-Bis(2-chloro-4-hydroxyphenyl)furan",Oc1ccc(c(Cl)c1)c2cocc2c3ccc(O)cc3Cl,CHEMBL2332590,,,,RBA = 2.99,agonist,86.00%,agonist,E2,,estradiol,2nM,Kd = 0.2nM,,,EC50,=,266,nM,,,,,=,2.99,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2Cl)c(Cl)c1,86,311.079,320.0006995,2,3,2,3,5.3316,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,agonist,agonist,agonist,128
13918,7268,23586645,18d,Q92731,ERB,Homo sapiens,"3,4-Bis(2-chloro-4-hydroxyphenyl)furan",Oc1ccc(c(Cl)c1)c2cocc2c3ccc(O)cc3Cl,CHEMBL2332590,,,,RBA = 5.44,partial agonist,54.00%,agonist,E2,,estradiol,2nM,Kd = 0.5nM,,,EC50,=,17500,nM,,,,,=,5.44,RBA,,other,Oc1ccc(-c2cocc2-c2ccc(O)cc2Cl)c(Cl)c1,54,311.079,320.0006995,2,3,2,3,5.3316,53.6,C1CCC(C2CCCC2C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,128
13965,729,22579420,APH-1,P37231,PPARG,Homo sapiens,Amorphastilbol,CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccccc2)cc1O)\C)C,CHEMBL500257,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 850nM,agonist,83.00%,agonist,Troglitazone,,,,,,,EC50,=,5000,nM,,,,,=,6.070581074,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccccc2)cc1O,83,320.262,348.2089301,2,2,7,2,6.5034,40.46,C1CCC(CCC2CCCCC2)CC1,agonist,agonist,agonist,agonist,326
13966,729,22579420,APH-1,Q07869,PPARA,Homo sapiens,Amorphastilbol,CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccccc2)cc1O)\C)C,CHEMBL500257,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 1520nM,partial agonist,66.00%,agonist,Wy14643,,,,,,,EC50,=,12000,nM,,,,,=,5.818156412,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccccc2)cc1O,66,320.262,348.2089301,2,2,7,2,6.5034,40.46,C1CCC(CCC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,326
13990,73,15006411,60,P19793,RXRA,Homo sapiens,"(E)-3-{7-[2-(3-Fluoro-propoxy)-3,5-diisopropyl-phenyl]-benzofuran-2-yl}-but-2-enoic acid",CC(C)c1cc(C(C)C)c(OCCCF)c(c1)c2cccc3cc(oc23)\C(=C\C(=O)O)\C,CHEMBL290399,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 47nM,antagonist,84.00%,antagonist,,,ATRA,,,,,,,,,IC50,=,194,nM,=,7.327902142,pKi,B,radiometric,C/C(=C\C(=O)O)c1cc2cccc(-c3cc(C(C)C)cc(C(C)C)c3OCCCF)c2o1,84,407.291,438.2206377,1,3,9,3,7.5729,59.67,C1CCC(C2CCCC3CCCC32)CC1,antagonist,antagonist,antagonist,antagonist,138
13991,730,22579420,APH 11,P37231,PPARG,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-((E)-2-(furan-3-yl)vinyl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2cocc2)cc1O)\C)C,CHEMBL2031956,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 650nM,agonist,98.00%,agonist,Troglitazone,,,,,,,EC50,=,5000,nM,,,,,=,6.187086643,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccoc2)cc1O,98,312.239,338.1881947,2,3,7,2,6.0964,53.6,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
13992,730,22579420,APH 11,Q07869,PPARA,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-((E)-2-(furan-3-yl)vinyl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2cocc2)cc1O)\C)C,CHEMBL2031956,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 2030nM,agonist,87.00%,agonist,Wy14643,,,,,,,EC50,=,6000,nM,,,,,=,5.692503962,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccoc2)cc1O,87,312.239,338.1881947,2,3,7,2,6.0964,53.6,C1CCC(CCC2CCCC2)CC1,agonist,agonist,agonist,agonist,316
14007,731,22579420,APH 12,P37231,PPARG,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-((E)-2-(thiophen-3-yl)vinyl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccsc2)cc1O)\C)C,CHEMBL2031957,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 1010nM,partial agonist,68.00%,agonist,Troglitazone,,,,,,,EC50,=,6000,nM,,,,,=,5.995678626,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccsc2)cc1O,68,328.307,354.1653511,2,3,7,2,6.5649,40.46,C1CCC(CCC2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,316
14008,731,22579420,APH 12,Q07869,PPARA,Homo sapiens,"2-((E)-3,7-dimethylocta-2,6-dienyl)-5-((E)-2-(thiophen-3-yl)vinyl)benzene-1,3-diol",CC(=CCC\C(=C\Cc1c(O)cc(\C=C\c2ccsc2)cc1O)\C)C,CHEMBL2031957,luciferase reporter gene assays,,TR-FRET (time-resolved fluorescence resonance energy transfer),IC50 = 5410nM,partial agonist,56.00%,agonist,Wy14643,,,,,,,EC50,=,14000,nM,,,,,=,5.266802735,pIC50,,other,CC(C)=CCC/C(C)=C/Cc1c(O)cc(/C=C/c2ccsc2)cc1O,56,328.307,354.1653511,2,3,7,2,6.5649,40.46,C1CCC(CCC2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,316
14015,7316,9703470,10,P10276,RARA,Homo sapiens,"(2E,4E,6E)-7-(1-Isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-octa-2,4,6-trienoic acid",CC(C)N1CCCc2cc(ccc12)\C(=C\C=C\C(=C\C(=O)O)\C)\C,CHEMBL109539,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 372,agonist,93.00%,agonist,ATRA,,ATRA,10nM,,,,EC30,=,21,nM,,,,,=,372,RBA,,radiometric,CC(/C=C/C=C(\C)c1ccc2c(c1)CCCN2C(C)C)=C\C(=O)O,93,298.236,325.2041791,1,2,5,1,4.838,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14016,7316,9703470,10,P10826,RARB,Homo sapiens,"(2E,4E,6E)-7-(1-Isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-octa-2,4,6-trienoic acid",CC(C)N1CCCc2cc(ccc12)\C(=C\C=C\C(=C\C(=O)O)\C)\C,CHEMBL109539,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 432,agonist,104.00%,agonist,ATRA,,ATRA,10nM,,,,EC30,=,11,nM,,,,,=,432,RBA,,radiometric,CC(/C=C/C=C(\C)c1ccc2c(c1)CCCN2C(C)C)=C\C(=O)O,104,298.236,325.2041791,1,2,5,1,4.838,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14017,7316,9703470,10,P13631,RARG,Homo sapiens,"(2E,4E,6E)-7-(1-Isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-octa-2,4,6-trienoic acid",CC(C)N1CCCc2cc(ccc12)\C(=C\C=C\C(=C\C(=O)O)\C)\C,CHEMBL109539,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 187,agonist,100.00%,agonist,ATRA,,ATRA,10nM,,,,EC30,=,25,nM,,,,,=,187,RBA,,radiometric,CC(/C=C/C=C(\C)c1ccc2c(c1)CCCN2C(C)C)=C\C(=O)O,100,298.236,325.2041791,1,2,5,1,4.838,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14018,7316,9703470,10,P19793,RXRA,Homo sapiens,"(2E,4E,6E)-7-(1-Isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-octa-2,4,6-trienoic acid",CC(C)N1CCCc2cc(ccc12)\C(=C\C=C\C(=C\C(=O)O)\C)\C,CHEMBL109539,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 12.7,agonist,125.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,3.3,nM,,,,,=,12.7,RBA,,radiometric,CC(/C=C/C=C(\C)c1ccc2c(c1)CCCN2C(C)C)=C\C(=O)O,125,298.236,325.2041791,1,2,5,1,4.838,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14019,7317,9703470,14a,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-6-Fluoro-7-(1-isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-octa-2,4,6-trienoic acid",CC(C)N1CCCc2cc(ccc12)\C(=C(/F)\C=C\C(=C\C(=O)O)\C)\C,CHEMBL109785,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 4.7,agonist,158.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,0.081,nM,,,,,=,4.7,RBA,,radiometric,C/C(=C(F)\C=C\C(C)=C\C(=O)O)c1ccc2c(c1)CCCN2C(C)C,158,317.234,343.1947573,1,2,5,1,5.1352,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14020,7318,9703470,14b,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-6-Fluoro-7-(1-isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-nona-2,4,6-trienoic acid",CC\C(=C(\F)/C=C/C(=C/C(=O)O)/C)\c1ccc2N(CCCc2c1)C(C)C,CHEMBL110002,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 6.6,agonist,233.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,0.033,nM,,,,,=,6.6,RBA,,radiometric,CC/C(=C(F)\C=C\C(C)=C\C(=O)O)c1ccc2c(c1)CCCN2C(C)C,233,329.245,357.2104074,1,2,6,1,5.5253,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14021,7319,9703470,14c,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-6-Fluoro-7-(1-isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-deca-2,4,6-trienoic acid",CCC\C(=C(\F)/C=C/C(=C/C(=O)O)/C)\c1ccc2N(CCCc2c1)C(C)C,CHEMBL109993,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 9.0,agonist,205.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,0.3,nM,,,,,=,9,RBA,,radiometric,CCC/C(=C(F)\C=C\C(C)=C\C(=O)O)c1ccc2c(c1)CCCN2C(C)C,205,341.256,371.2260574,1,2,7,1,5.9154,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14022,732,21115247,10,P04150,GR,Homo sapiens,"5-chloro-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-4-(3-methylbut-2-enyl)-1,2-dihydroquinolin-3(4H)-one",CC(=CCC1(C)C(=O)C(C)(C)Nc2c(C)cc(c(Cl)c12)c3cccc4cc[nH]c34)C,CHEMBL1644757,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 6.0nM,agonist,174.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,215,nM,,,,,=,8.22184875,pIC50,B,radiometric,CC(C)=CCC1(C)C(=O)C(C)(C)Nc2c(C)cc(-c3cccc4cc[nH]c34)c(Cl)c21,174,391.752,420.1968412,2,2,3,3,7.18392,44.89,CC1CCC2CCC(C3CCCC4CCCC43)CC2C1,agonist,agonist,agonist,agonist,646
14024,7320,9703470,14d,P19793,RXRA,Homo sapiens,"(2E,4E,6Z)-6-Fluoro-7-(1-isopropyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-methyl-undeca-2,4,6-trienoic acid",CCCC\C(=C(\F)/C=C/C(=C/C(=O)O)/C)\c1ccc2N(CCCc2c1)C(C)C,CHEMBL109283,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 121,agonist,92.00%,agonist,9-Cis-RA,,9-Cis-RA,15nM,,,,EC30,=,32,nM,,,,,=,121,RBA,,radiometric,CCCC/C(=C(F)\C=C\C(C)=C\C(=O)O)c1ccc2c(c1)CCCN2C(C)C,92,353.267,385.2417075,1,2,8,1,6.3055,40.54,C1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,41
14092,735,20144545,2,P11473,VDR,Homo sapiens,"(S)-8-amino-2-isobutyl-4-isopentyl-7-(2-methylprop-1-enyl)-4,5-dihydro-1H-benzo[e][1,4]diazepin-3(2H)-one",CC(C)CCN1Cc2cc(C=C(C)C)c(N)cc2N[C@@H](CC(C)C)C1=O,CHEMBL1086744,,reporter gene assay,TR-FRET,IC50 = 20000nM,partial agonist,68.00%,agonist,"1,25-(OH)2D3",3nM,"1,25-(OH)2D3",10nM,,,,,,,,IC50,=,17000,nM,=,4.698970004,pIC50,NB,other,CC(C)=Cc1cc2c(cc1N)N[C@@H](CC(C)C)C(=O)N(CCC(C)C)C2,68,322.262,357.2780127,2,3,6,1,4.9069,58.36,CC1CCC2CCCCC2CC1,antagonist,partial agonist,antagonist,partial agonist,659
14101,7355,12699377,9,P03372,ERA,Homo sapiens,4-[Bicyclo[3.3.1]non-9-ylidene-(4-fluoro-phenyl)-methyl]-phenol,Oc1ccc(cc1)C(=C2C3CCCC2CCC3)c4ccc(F)cc4,CHEMBL43246,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 40,partial agonist,65.00%,agonist,,,E2,,,,,,,,,,,,,=,40,RBA,,radiometric,Oc1ccc(C(=C2C3CCCC2CCC3)c2ccc(F)cc2)cc1,65,299.239,322.1732936,1,1,2,2,5.9334,20.23,C1CCC(C(C2CCCCC2)C2C3CCCC2CCC3)CC1,,partial agonist,,partial agonist,259
14103,7356,12699377,10,P03372,ERA,Homo sapiens,4-(Bicyclo[3.3.1]non-9-ylidene-phenyl-methyl)-phenol,Oc1ccc(cc1)C(=C2C3CCCC2CCC3)c4ccccc4,CHEMBL296018,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 31,agonist,83.00%,agonist,,,E2,,,,,,,,,,,,,=,31,RBA,,radiometric,Oc1ccc(C(=C2C3CCCC2CCC3)c2ccccc2)cc1,83,280.241,304.1827154,1,1,2,2,5.7943,20.23,C1CCC(C(C2CCCCC2)C2C3CCCC2CCC3)CC1,,agonist,,agonist,259
14105,7357,12699377,11,P03372,ERA,Homo sapiens,"4-[Bicyclo[3.3.1]non-9-ylidene-(4-hydroxy-phenyl)-methyl]-benzene-1,2-diol",Oc1ccc(cc1)C(=C2C3CCCC2CCC3)c4ccc(O)c(O)c4,CHEMBL43636,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 108,partial agonist,38.00%,agonist,,,E2,,,,,,,,,,,,,=,108,RBA,,radiometric,Oc1ccc(C(=C2C3CCCC2CCC3)c2ccc(O)c(O)c2)cc1,38,312.239,336.1725446,3,3,2,2,5.2055,60.69,C1CCC(C(C2CCCCC2)C2C3CCCC2CCC3)CC1,,partial agonist,,partial agonist,259
14111,736,19926282,32,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-isobutyrylpyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CC(C)C(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL589624,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 25nM,partial agonist,35.00%,agonist,progesterone,,,,,,,EC50,=,290,nM,,,,,=,7.602059991,pIC50,B,other,CC(C)C(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,35,426.72,449.1481747,0,3,5,2,5.49398,47.34,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
14112,7360,12699377,16,P03372,ERA,Homo sapiens,4-[bicyclo[2.2.1]hept-2-ylidene(4-hydroxyphenyl)methyl]phenol,Oc1ccc(cc1)C(=C2CC3CCC2C3)c4ccc(O)cc4,CHEMBL288955,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 47,partial agonist,32.00%,agonist,,,E2,,,,,,,,,,,,,=,47,RBA,,radiometric,Oc1ccc(C(=C2CC3CCC2C3)c2ccc(O)cc2)cc1,32,272.218,292.1463299,2,2,2,2,4.7197,40.46,C1CCC(C(C2CCCCC2)C2CC3CCC2C3)CC1,,partial agonist,,partial agonist,261
14114,7361,12699377,18,P03372,ERA,Homo sapiens,"4-[(4-hydroxyphenyl)(tricyclo[5.2.1.0~2,6~]dec-8-ylidene)methyl]phenol",Oc1ccc(cc1)C(=C2CC3CC2C4CCCC34)c5ccc(O)cc5,CHEMBL40747,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 97,partial agonist,35.00%,agonist,,,E2,,,,,,,,,,,,,=,97,RBA,,radiometric,Oc1ccc(C(=C2CC3CC2C2CCCC32)c2ccc(O)cc2)cc1,35,308.251,332.17763,2,2,2,2,5.3558,40.46,C1CCC(C(C2CCCCC2)C2CC3CC2C2CCCC32)CC1,,partial agonist,,partial agonist,260
14116,7362,12699377,21,P03372,ERA,Homo sapiens,"4-{4-hydroxyphenyl[2,2,6,7,7-pentamethyl-(1R,6R,8S)-tricyclo[6.2.1.01,6]undec-4-yliden]methyl}phenol",CC1(C)CC(=C(c2ccc(O)cc2)c3ccc(O)cc3)C[C@]4(C)C(C)(C)[C@H]5CC[C@@]14C5,CHEMBL416798,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 9,partial agonist,30.00%,agonist,,,E2,,,,,,,,,,,,,=,9,RBA,,radiometric,CC1(C)[C@H]2CC[C@@]3(C2)C(C)(C)CC(=C(c2ccc(O)cc2)c2ccc(O)cc2)C[C@]13C,30,380.317,416.2715304,2,2,2,2,7.5523,40.46,C1CCC(C(C2CCCCC2)C2CCC34CCC(CC3C2)C4)CC1,,partial agonist,,partial agonist,264
14122,7365,12699377,34,P03372,ERA,Homo sapiens,4-[bicyclo[3.3.1]non-9-yl(4-hydroxyphenyl)methyl]phenol,Oc1ccc(cc1)C(C2C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL40512,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 15,partial agonist,40.00%,agonist,,,E2,,,,,,,,,,,,,=,15,RBA,,radiometric,Oc1ccc(C(c2ccc(O)cc2)C2C3CCCC2CCC3)cc1,40,296.24,322.1932801,2,2,3,2,5.4461,40.46,C1CCC(C(C2CCCCC2)C2C3CCCC2CCC3)CC1,,partial agonist,,partial agonist,259
14123,7365,12699377,34,Q92731,ERB,Homo sapiens,4-[bicyclo[3.3.1]non-9-yl(4-hydroxyphenyl)methyl]phenol,Oc1ccc(cc1)C(C2C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL40512,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 13,partial agonist,55.00%,agonist,,,E2,,,,,,,,,,,,,=,13,RBA,,radiometric,Oc1ccc(C(c2ccc(O)cc2)C2C3CCCC2CCC3)cc1,55,296.24,322.1932801,2,2,3,2,5.4461,40.46,C1CCC(C(C2CCCCC2)C2C3CCCC2CCC3)CC1,,partial agonist,,partial agonist,259
14124,7366,12699377,35,P03372,ERA,Homo sapiens,4-[9-(4-hydroxyphenyl)bicyclo[3.3.1]non-9-yl]phenol,Oc1ccc(cc1)C2(C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL290759,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 0.31,partial agonist,43.00%,agonist,,,E2,,,,,,,,,,,,,=,0.31,RBA,,radiometric,Oc1ccc(C2(c3ccc(O)cc3)C3CCCC2CCC3)cc1,43,284.229,308.17763,2,2,2,2,4.9841,40.46,C1CCC(C2(C3CCCCC3)C3CCCC2CCC3)CC1,,partial agonist,,partial agonist,47
14125,7366,14643352,25,P03372,ERA,Homo sapiens,4-[9-(4-hydroxyphenyl)bicyclo[3.3.1]non-9-yl]phenol,Oc1ccc(cc1)C2(C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL290759,,,-,RBA = 0.31,,,,,,E2,,,,,,,,,,,,,=,0.31,RBA,,other,Oc1ccc(C2(c3ccc(O)cc3)C3CCCC2CCC3)cc1,,284.229,308.17763,2,2,2,2,4.9841,40.46,C1CCC(C2(C3CCCCC3)C3CCCC2CCC3)CC1,,,,partial agonist,47
14126,7366,12699377,35,Q92731,ERB,Homo sapiens,4-[9-(4-hydroxyphenyl)bicyclo[3.3.1]non-9-yl]phenol,Oc1ccc(cc1)C2(C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL290759,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,RBA = 0.25,agonist,78.00%,agonist,,,E2,,,,,,,,,,,,,=,0.25,RBA,,radiometric,Oc1ccc(C2(c3ccc(O)cc3)C3CCCC2CCC3)cc1,78,284.229,308.17763,2,2,2,2,4.9841,40.46,C1CCC(C2(C3CCCCC3)C3CCCC2CCC3)CC1,,agonist,,agonist,47
14127,7366,14643352,25,Q92731,ERB,Homo sapiens,4-[9-(4-hydroxyphenyl)bicyclo[3.3.1]non-9-yl]phenol,Oc1ccc(cc1)C2(C3CCCC2CCC3)c4ccc(O)cc4,CHEMBL290759,,,-,RBA = 0.25,,,,,,E2,,,,,,,,,,,,,=,0.25,RBA,,other,Oc1ccc(C2(c3ccc(O)cc3)C3CCCC2CCC3)cc1,,284.229,308.17763,2,2,2,2,4.9841,40.46,C1CCC(C2(C3CCCCC3)C3CCCC2CCC3)CC1,,,,agonist,47
14134,737,20584610,20,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Isobutyryl-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CC(C)C(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1209905,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 39nM,antagonist,98.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,215,nM,=,7.408935393,pKi,B,radiometric,CC(C)C(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,98,427.253,449.1562408,0,5,2,1,2.72848,90.71,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
14192,74,15125928,15,P19793,RXRA,Homo sapiens,"(E)-3-{3-[3,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-phenyl]-1H-indol-5-yl}-but-2-enoic acid",C\C(=C/C(=O)O)\c1ccc2[nH]cc(c3cc(cc(c3OCC(F)F)C(C)(C)C)C(C)(C)C)c2c1,CHEMBL430651,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 1.6nM,partial antagonist,41.00%,antagonist,LGD1069,,9-Cis-RA,,,,,EC50,=,65,nM,IC50,=,66.3,nM,=,8.795880017,pKi,B,radiometric,C/C(=C\C(=O)O)c1ccc2[nH]cc(-c3cc(C(C)(C)C)cc(C(C)(C)C)c3OCC(F)F)c2c1,41,436.308,469.2428504,2,2,6,3,7.5617,62.32,C1CCC(C2CCC3CCCCC32)CC1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,111
14209,7405,16644222,Ia,P04150,GR,Homo sapiens,"1-[(1R,2R,10aR,11S,12aS)-7-(6-fluoro-pyridin-3-yl)-1,11-dihydroxy-2,10a,12a-trimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-2-hydroxy-ethanone",C[C@@H]1CC2C3CCC4=Cc5c(C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO)cnn5c6ccc(F)nc6,CHEMBL208811,,,-,RBA = 250,agonist,237.00%,agonist,dexamethasone,,,,,,,,,,,,,,,=,250,RBA,,other,C[C@@H]1CC2C3CCC4=Cc5c(cnn5-c5ccc(F)nc5)C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,237,461.323,495.2533348,3,7,3,2,3.0978,108.47,C1CCC(C2CCC3CC4C(CCC5C6CCCC6CCC45)CC32)CC1,,agonist,,agonist,93
14210,7406,16644222,Ib,P04150,GR,Homo sapiens,"1-[(1R,2R,10aR,11S,12aS)-7-(2-fluoro-pyridin-3-yl)-1,11-dihydroxy-2,10a,12a-trimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl]-2-hydroxy-ethanone",C[C@@H]1CC2C3CCC4=Cc5c(C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO)cnn5c6cccnc6F,CHEMBL210657,,,-,RBA = 93,agonist,121.00%,agonist,dexamethasone,,,,,,,,,,,,,,,=,93,RBA,,other,C[C@@H]1CC2C3CCC4=Cc5c(cnn5-c5cccnc5F)C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,121,461.323,495.2533348,3,7,3,2,3.0978,108.47,C1CCC(C2CCC3CC4C(CCC5C6CCCC6CCC45)CC32)CC1,,agonist,,agonist,93
14211,7407,16644222,II,P04150,GR,Homo sapiens,"2'-(2-fluoro-4-pyridyl)-11beta,17,21-trihydroxy-16alpha-methyl-20-oxo-pregn-4-eno[3,2-c]-pyrazole",C[C@@H]1CC2C3CCC4=Cc5c(C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO)cnn5c6ccnc(F)c6,CHEMBL379610,,,-,RBA = 129,partial agonist,35.00%,agonist,dexamethasone,,,,,,,,,,,,,,,=,129,RBA,,other,C[C@@H]1CC2C3CCC4=Cc5c(cnn5-c5ccnc(F)c5)C[C@]4(C)C3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,35,461.323,495.2533348,3,7,3,2,3.0978,108.47,C1CCC(C2CCC3CC4C(CCC5C6CCCC6CCC45)CC32)CC1,,partial agonist,,partial agonist,93
14214,741,16112571,5,P04150,GR,Homo sapiens,"2-Hydroxy-2-isopropyl-4-methyl-4-phenyl-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide",CC(C)C(O)(CC(C)(C)c1ccccc1)C(=O)Nc2ccc3C(=O)OCc3c2,CHEMBL196373,IL-6 production assay,MMTV transactivation in HeLa cells,Fluorescence polarization (FP) competition binding assay,IC50 = 200nM,antagonist,95.00%,antagonist,RU486,,,,,,,,,inactive,,EC50,=,620,nM,=,6.698970004,pIC50,,FPA,CC(C)C(O)(CC(C)(C)c1ccccc1)C(=O)Nc1ccc2c(c1)COC2=O,95,354.256,381.1940083,2,4,6,2,4.0505,75.63,CC(CCCC1CCCCC1)CC1CCC2C(C)CCC2C1,antagonist,antagonist,antagonist,antagonist,1218
14239,743,23953070,6d,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2,4-trimethyl-N-(1,3,4-thiadiazol-2-yl)pentanamide",CC(C)C(c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)C(=O)Nc4nncs4,CHEMBL2426637,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 2.4nM,partial agonist,29.00%,agonist,,,,,,,,EC50,=,81,nM,,,,,=,8.619788758,pKi,B,FPA,CC(C)C(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)C(=O)Nc1nncs1,29,413.352,437.1685596,1,6,6,4,5.4206,72.7,CC(CCC1CCC2C(CCC2C2CCCCC2)C1)CC1CCCC1,agonist,partial agonist,agonist,partial agonist,1108
14250,744,19376703,27,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)amino)-2-chlorobenzonitrile",CC(C)C(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL552156,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 32nM,agonist,76.00%,agonist,progesterone,,,,,,,EC50,=,4.7,nM,,,,,=,7.494850022,pIC50,B,FPA,CC(C)C(c1nncn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,76,393.172,413.117401,0,5,6,3,5.39748,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,agonist,agonist,agonist,361
14303,747,10340624,6d,P10275,AR,Homo sapiens,"6-Isopropyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC(C)C1CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL27276,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 13nM,agonist,81.00%,agonist,DHT,,DHT,,,,,EC50,=,3,nM,,,,,=,7.886056648,pKi,B,radiometric,CC(C)C1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,81,293.183,310.1292978,2,3,1,2,4.5144,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,agonist,agonist,agonist,586
14332,7484,20669983,2,P03372,ERA,Homo sapiens,"3-(4-Hydroxyphenyl)-8,8-dimethyl-8H-pyrano[2,3-f]-chromen-4-one",CC1(C)Oc2ccc3C(=O)C(=COc3c2C=C1)c4ccc(O)cc4,CHEMBL1214836,,,,RBA = 44.1,antagonist,100.00%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,44.1,RBA,,other,CC1(C)C=Cc2c(ccc3c(=O)c(-c4ccc(O)cc4)coc23)O1,100,304.216,320.104859,1,4,1,3,4.3498,59.67,CC1C(C2CCCCC2)CCC2C3CCCCC3CCC12,,antagonist,,antagonist,536
14333,7485,20669983,3a,P03372,ERA,Homo sapiens,3-(4-Hydroxyphenyl)-7-methoxychromen-4-one,COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL453280,,,,RBA = 82.7,partial agonist,68.50%,agonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,82.7,RBA,,other,COc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,68.5,256.172,268.0735589,1,4,2,3,3.1742,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,partial agonist,,partial agonist,486
14334,7486,20669983,3b,P03372,ERA,Homo sapiens,3-(4-Hydroxyphenyl)-7-ethoxychromen-4-one,CCOc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL115092,,,,RBA = 66.6,agonist,79.00%,agonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,66.6,RBA,,other,CCOc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,79,268.183,282.0892089,1,4,3,3,3.5643,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,agonist,,agonist,486
14335,7487,20669983,3c,P03372,ERA,Homo sapiens,3-(4-Hydroxyphenyl)-7-propoxychromen-4-one,CCCOc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL1214837,,,,RBA = 44.9,partial antagonist,41.10%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,44.9,RBA,,other,CCCOc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,41.1,280.194,296.104859,1,4,4,3,3.9544,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,partial antagonist,,partial antagonist,486
14336,7488,20669983,3d,P03372,ERA,Homo sapiens,3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one,CC(C)Oc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL115109,,,,RBA = 42.9,partial antagonist,68.00%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,42.9,RBA,,other,CC(C)Oc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,68,280.194,296.104859,1,4,3,3,3.9528,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,partial antagonist,,partial antagonist,486
14337,7489,20669983,3e,P03372,ERA,Homo sapiens,7-Butoxy-3-(4-hydroxyphenyl)Chromen-4-one,CCCCOc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL1214900,,,,RBA = 81.9,partial antagonist,49.80%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,81.9,RBA,,other,CCCCOc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,49.8,292.205,310.1205091,1,4,5,3,4.3445,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,partial antagonist,,partial antagonist,486
14339,7490,20669983,3f,P03372,ERA,Homo sapiens,3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one,CC(C)COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL1214901,,,,RBA = 38.3,antagonist,91.30%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,38.3,RBA,,other,CC(C)COc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,91.3,292.205,310.1205091,1,4,4,3,4.2004,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,antagonist,,antagonist,486
14340,7491,20669983,3g,P03372,ERA,Homo sapiens,7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one,Oc1ccc(cc1)C2=COc3cc(OC4CCCC4)ccc3C2=O,CHEMBL1214902,,,,RBA = 19.2,antagonist,89.80%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,19.2,RBA,,other,O=c1c(-c2ccc(O)cc2)coc2cc(OC3CCCC3)ccc12,89.8,304.216,322.1205091,1,4,3,3,4.487,59.67,CC1C(C2CCCCC2)CCC2CC(CC3CCCC3)CCC21,,antagonist,,antagonist,540
14341,7492,20669983,3h,P03372,ERA,Homo sapiens,7-Hexyloxy-3-(4-hydroxyphenyl)chromen-4-one,CCCCCCOc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3,CHEMBL110472,,,,RBA = 88.5,partial antagonist,46.40%,antagonist,E2,0.1nM,ES2,3nM,,,,,,,,,,,,=,88.5,RBA,,other,CCCCCCOc1ccc2c(=O)c(-c3ccc(O)cc3)coc2c1,46.4,316.227,338.1518092,1,4,7,3,5.1247,59.67,CC1C2CCCCC2CCC1C1CCCCC1,,partial antagonist,,partial antagonist,486
14357,75,15125928,6,P19793,RXRA,Homo sapiens,"(E)-3-[3-(2-Hydroxy-3,5-diisopropyl-phenyl)-benzo[b]thiophen-5-yl]-but-2-enoic acid",CC(C)c1cc(C(C)C)c(O)c(c1)c2csc3ccc(cc23)\C(=C\C(=O)O)\C,CHEMBL93571,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 131nM,partial agonist,37.40%,agonist,LGD1069,,9-Cis-RA,,,,,EC50,=,1438,nM,,,,,=,6.882728704,pKi,,radiometric,C/C(=C\C(=O)O)c1ccc2scc(-c3cc(C(C)C)cc(C(C)C)c3O)c2c1,37.4,368.328,394.1602657,2,3,5,3,7.0086,57.53,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
14358,750,23953070,6e,P04150,GR,Homo sapiens,"rac-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2,5-trimethyl-N-(1,3,4-thiadiazol-2-yl)hexanamide",CC(C)CC(c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)C(=O)Nc4nncs4,CHEMBL2426638,reporter gene assay (AP-1),,Fluorescence polarization (FP) competition binding assay,Ki = 7.5nM,partial agonist,60.00%,agonist,,,,,,,,EC50,=,29,nM,,,,,=,8.124938737,pKi,B,FPA,CC(C)CC(c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)C(=O)Nc1nncs1,60,425.363,451.1842097,1,6,7,4,5.8107,72.7,CC(CCC1CCC2C(CCC2C2CCCCC2)C1)CC1CCCC1,agonist,partial agonist,agonist,partial agonist,1108
14420,753,19376703,28,P06401,PR,Homo sapiens,"4-((2-chlorobenzyl)(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)butyl)amino)-2-chlorobenzonitrile",CC(C)CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nncn3C,CHEMBL552107,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 25nM,partial agonist,58.00%,agonist,progesterone,,,,,,,EC50,=,157,nM,,,,,=,7.602059991,pIC50,B,FPA,CC(C)CC(c1nncn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,58,405.183,427.1330511,0,5,7,3,5.78758,57.74,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
14428,7534,22746350,6h,P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)benzonitrile",N#Cc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159727,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,110.70%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,N#Cc1ccc(C2=NOC3CCCCC23)cc1,110.7,212.167,226.1106131,0,3,1,1,2.85138,45.38,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14429,7534,22746350,6h',P10275,AR,Homo sapiens,"cis-4-(3a,4,5,6,7,7a-Hexahydrobenzo[d]isoxazol-3-yl)benzonitrile",N#Cc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159727,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,115.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,N#Cc1ccc(C2=NOC3CCCCC23)cc1,115.8,212.167,226.1106131,0,3,1,1,2.85138,45.38,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14430,7535,22746350,6i,P10275,AR,Homo sapiens,"rac-3-(4-Nitrophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",[O-][N+](=O)c1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159728,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,partial antagonist,48.00%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,O=[N+]([O-])c1ccc(C2=NOC3CCCCC23)cc1,48,232.154,246.1004423,0,4,2,1,2.8879,64.73,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,partial antagonist,111
14431,7536,22746350,6j,P10275,AR,Homo sapiens,"cis-3-(4-Fluorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Fc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159551,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,101.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Fc1ccc(C2=NOC3CCCCC23)cc1,101.6,205.147,219.1059423,0,2,1,1,3.1188,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14432,7536,22746350,6j',P10275,AR,Homo sapiens,"cis-3-(4-Fluorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Fc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159551,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,99.30%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Fc1ccc(C2=NOC3CCCCC23)cc1,99.3,205.147,219.1059423,0,2,1,1,3.1188,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14433,7537,22746350,6k,P10275,AR,Homo sapiens,"rac-3-(3-Fluorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Fc1cccc(c1)C2=NOC3CCCCC23,CHEMBL2159552,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,100.30%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Fc1cccc(C2=NOC3CCCCC23)c1,100.3,205.147,219.1059423,0,2,1,1,3.1188,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14434,7538,22746350,6l,P10275,AR,Homo sapiens,"cis-3-(2-Fluorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Fc1ccccc1C2=NOC3CCCCC23,CHEMBL2158018,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,101.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Fc1ccccc1C1=NOC2CCCCC12,101.2,205.147,219.1059423,0,2,1,1,3.1188,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14435,7538,22746350,6l',P10275,AR,Homo sapiens,"cis-3-(2-Fluorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Fc1ccccc1C2=NOC3CCCCC23,CHEMBL2158018,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,103.60%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Fc1ccccc1C1=NOC2CCCCC12,103.6,205.147,219.1059423,0,2,1,1,3.1188,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14436,7539,22746350,6m',P10275,AR,Homo sapiens,"cis-3-(4-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159553,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,91.40%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1ccc(C2=NOC3CCCCC23)cc1,91.4,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,"antagonist,partial antagonist",111
14437,7539,22746350,6m,P10275,AR,Homo sapiens,"cis-3-(4-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159553,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,partial antagonist,40.90%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1ccc(C2=NOC3CCCCC23)cc1,40.9,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,partial antagonist,,"antagonist,partial antagonist",111
14438,754,19376703,19,P06401,PR,Homo sapiens,2-chloro-4-(isobutyl(3-methyl-1-(1-methyl-1H-tetrazol-5-yl)butyl)amino)benzonitrile,CC(C)CC(N(CC(C)C)c1ccc(C#N)c(Cl)c1)c2nnnn2C,CHEMBL541973,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 16nM,partial agonist,47.00%,agonist,progesterone,,,,,,,EC50,=,9.5,nM,,,,,=,7.795880017,pIC50,B,FPA,CC(C)CC(c1nnnn1C)N(CC(C)C)c1ccc(C#N)c(Cl)c1,47,335.693,360.1829225,0,6,7,2,3.98498,70.63,C1CCC(CCC2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,316
14439,7540,22746350,6n,P10275,AR,Homo sapiens,"cis-3-(3-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1cccc(c1)C2=NOC3CCCCC23,CHEMBL2159554,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,95.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1cccc(C2=NOC3CCCCC23)c1,95.2,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14440,7540,22746350,6n',P10275,AR,Homo sapiens,"cis-3-(3-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1cccc(c1)C2=NOC3CCCCC23,CHEMBL2159554,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,106.70%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1cccc(C2=NOC3CCCCC23)c1,106.7,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14441,7541,22746350,6o,P10275,AR,Homo sapiens,"cis-3-(2-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1ccccc1C2=NOC3CCCCC23,CHEMBL2159555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,101.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1ccccc1C1=NOC2CCCCC12,101.5,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14442,7541,22746350,6o',P10275,AR,Homo sapiens,"cis-3-(2-Chlorophenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",Clc1ccccc1C2=NOC3CCCCC23,CHEMBL2159555,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,101.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,Clc1ccccc1C1=NOC2CCCCC12,101.2,221.602,235.0763917,0,2,1,1,3.6331,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14443,7542,22746350,6p,P10275,AR,Homo sapiens,"cis-3-(4-Methoxyphenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",COc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159556,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,100.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,COc1ccc(C2=NOC3CCCCC23)cc1,100.5,214.159,231.1259288,0,3,2,1,2.9883,30.82,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14444,7542,22746350,6p',P10275,AR,Homo sapiens,"cis-3-(4-Methoxyphenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",COc1ccc(cc1)C2=NOC3CCCCC23,CHEMBL2159556,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,99.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,COc1ccc(C2=NOC3CCCCC23)cc1,99.2,214.159,231.1259288,0,3,2,1,2.9883,30.82,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14445,7543,22746350,6q,P10275,AR,Homo sapiens,"cis-3-(3-Methoxyphenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",COc1cccc(c1)C2=NOC3CCCCC23,CHEMBL2159557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,101.80%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,COc1cccc(C2=NOC3CCCCC23)c1,101.8,214.159,231.1259288,0,3,2,1,2.9883,30.82,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14446,7543,22746350,6q',P10275,AR,Homo sapiens,"cis-3-(3-Methoxyphenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",COc1cccc(c1)C2=NOC3CCCCC23,CHEMBL2159557,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,102.70%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,COc1cccc(C2=NOC3CCCCC23)c1,102.7,214.159,231.1259288,0,3,2,1,2.9883,30.82,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14447,7544,22746350,6r,P10275,AR,Homo sapiens,"rac-3-(2-Methoxyphenyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",COc1ccccc1C2=NOC3CCCCC23,CHEMBL2159558,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,100.00%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,COc1ccccc1C1=NOC2CCCCC12,100,214.159,231.1259288,0,3,2,1,2.9883,30.82,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14448,7545,22746350,6s,P10275,AR,Homo sapiens,"cis-3-Phenyl-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",C1CCC2C(C1)ON=C2c3ccccc3,CHEMBL2159559,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,103.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,c1ccc(C2=NOC3CCCCC23)cc1,103.2,186.149,201.1153641,0,2,1,1,2.9797,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14449,7545,22746350,6s',P10275,AR,Homo sapiens,"cis-3-Phenyl-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",C1CCC2C(C1)ON=C2c3ccccc3,CHEMBL2159559,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,100.50%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,c1ccc(C2=NOC3CCCCC23)cc1,100.5,186.149,201.1153641,0,2,1,1,2.9797,21.59,C1CCC(C2CCC3CCCCC32)CC1,,antagonist,,antagonist,111
14450,7546,22746350,6t',P10275,AR,Homo sapiens,"cis-3-Naphthalen-1-yl-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",C1CCC2C(C1)ON=C2c3cccc4ccccc34,CHEMBL2159560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,antagonist,103.30%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,c1ccc2c(C3=NOC4CCCCC34)cccc2c1,103.3,234.193,251.1310142,0,2,1,2,4.1329,21.59,C1CCC2C(C1)CCCC2C1CCC2CCCCC21,,antagonist,,"antagonist,partial antagonist",22
14451,7546,22746350,6t,P10275,AR,Homo sapiens,"cis-3-Naphthalen-1-yl-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole",C1CCC2C(C1)ON=C2c3cccc4ccccc34,CHEMBL2159560,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,negligeable,partial antagonist,40.20%,antagonist,Testosterone,10000nM,R1881,1.34 nM,,,,,,,,,,,,,,NEG,NB,radiometric,c1ccc2c(C3=NOC4CCCCC34)cccc2c1,40.2,234.193,251.1310142,0,2,1,2,4.1329,21.59,C1CCC2C(C1)CCCC2C1CCC2CCCCC21,,partial antagonist,,"antagonist,partial antagonist",22
14458,755,19376703,20,P06401,PR,Homo sapiens,2-chloro-4-((cyclobutylmethyl)(3-methyl-1-(1-methyl-1H-tetrazol-5-yl)butyl)amino)benzonitrile,CC(C)CC(N(CC1CCC1)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL551972,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 40nM,partial agonist,31.00%,agonist,progesterone,,,,,,,EC50,=,11,nM,,,,,=,7.397940009,pIC50,B,FPA,CC(C)CC(c1nnnn1C)N(CC1CCC1)c1ccc(C#N)c(Cl)c1,31,347.704,372.1829225,0,6,7,2,4.12908,70.63,C1CCC(C(CC2CCCC2)CC2CCC2)CC1,agonist,partial agonist,agonist,partial agonist,317
14479,756,19376703,18,P06401,PR,Homo sapiens,4-((2-(trifluoromethyl)benzyl)(3-methyl-1-(1-methyl-1H-tetrazol-5-yl)butyl)amino)-2-chlorobenzonitrile,CC(C)CC(N(Cc1ccccc1C(F)(F)F)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL551305,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 25nM,partial agonist,56.00%,agonist,progesterone,,,,,,,EC50,=,139,nM,,,,,=,7.602059991,pIC50,B,FPA,CC(C)CC(c1nnnn1C)N(Cc1ccccc1C(F)(F)F)c1ccc(C#N)c(Cl)c1,56,440.731,462.154657,0,6,7,3,5.54798,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
14500,757,19376703,15,P06401,PR,Homo sapiens,4-((2-chlorobenzyl)(3-methyl-1-(1-methyl-1H-tetrazol-5-yl)butyl)amino)-2-chlorobenzonitrile,CC(C)CC(N(Cc1ccccc1Cl)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL561713,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,partial agonist,60.00%,agonist,progesterone,,,,,,,EC50,=,1.3,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(C)CC(c1nnnn1C)N(Cc1ccccc1Cl)c1ccc(C#N)c(Cl)c1,60,407.179,428.1283001,0,6,7,3,5.18258,70.63,C1CCC(CC(CC2CCCC2)C2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,361
14541,759,10340624,6e,P10275,AR,Homo sapiens,"6-Isobutyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC(C)CC1CCNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL282813,CV-1 cells ??reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 22nM,partial agonist,61.00%,agonist,DHT,,DHT,,,,,EC50,=,25,nM,,,,,=,7.657577319,pKi,B,radiometric,CC(C)CC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,61,305.194,324.1449479,2,3,2,2,4.9045,45.15,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
14555,76,15125928,7,P19793,RXRA,Homo sapiens,"(E)-3-{3-[2-(3-Fluoro-propoxy)-3,5-diisopropyl-phenyl]-benzo[b]thiophen-5-yl}-but-2-enoic acid",CC(C)c1cc(C(C)C)c(OCCCF)c(c1)c2csc3ccc(cc23)\C(=C\C(=O)O)\C,CHEMBL264746,,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 394nM,partial antagonist,48.00%,antagonist,LGD1069,,9-Cis-RA,,,,,,,,,IC50,=,4154,nM,=,6.404503778,pKi,,radiometric,C/C(=C\C(=O)O)c1ccc2scc(-c3cc(C(C)C)cc(C(C)C)c3OCCCF)c2c1,48,423.359,454.1977941,1,3,9,3,8.0414,46.53,C1CCC(C2CCC3CCCCC32)CC1,antagonist,partial antagonist,antagonist,partial antagonist,111
14557,7600,21391689,7,O00482,LRH-1,Homo sapiens,"(3aS,6aR)-5-hexyl-N,4-diphenyl-1,2,3,3a,6,6a-hexahydropentalen-3a-amine",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)Nc4ccccc4,CHEMBL384153,,,TR-FRET,PEC50 = 7.5,,38.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.5,pEC50,B,other,CCCCCCC1=C(c2ccccc2)[C@]2(Nc3ccccc3)CCC[C@@H]2C1,38,326.293,359.2613001,1,1,8,2,7.4653,12.03,C1CCC(CC23CCCC2CCC3C2CCCCC2)CC1,,partial agonist,,partial agonist,1320
14558,7600,21391689,7,Q13285,SF-1,Homo sapiens,"(3aS,6aR)-5-hexyl-N,4-diphenyl-1,2,3,3a,6,6a-hexahydropentalen-3a-amine",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)Nc4ccccc4,CHEMBL384153,,,TR-FRET,PEC50 = 7.4,,70.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.4,pEC50,B,other,CCCCCCC1=C(c2ccccc2)[C@]2(Nc3ccccc3)CCC[C@@H]2C1,70,326.293,359.2613001,1,1,8,2,7.4653,12.03,C1CCC(CC23CCCC2CCC3C2CCCCC2)CC1,,partial agonist,,partial agonist,1320
14560,7601,21391689,19,Q13285,SF-1,Homo sapiens,"rac-(3aR,7aR)-2-hexyl-3-phenyl-3a-(1-phenylvinyl)-3a,4,5,6,7,7a-hexahydro-1H-indene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765956,,,TR-FRET,PEC50 = 7.2,,42.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.2,pEC50,B,other,C=C(c1ccccc1)[C@@]12CCCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,42,348.319,384.2817012,0,0,8,2,8.7043,0,CC(C1CCCCC1)C12CCCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1321
14562,7602,21391689,12b,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-1-Ethoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCC,CHEMBL1765926,,,TR-FRET,PEC50 = 6.3,,55.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.3,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCC)CCC[C@@H]2C1,55,280.241,312.2453156,0,1,8,1,6.3897,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14564,7603,21391689,12c,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-3-Hexyl-2-phenyl-1-propoxy-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCCC,CHEMBL1765927,,,TR-FRET,PEC50 = 6.7,,67.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCCC)CCC[C@@H]2C1,67,292.252,326.2609657,0,1,9,1,6.7798,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14566,7604,21391689,12d,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-3-Hexyl-1-isopropoxy-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OC(C)C,CHEMBL1765928,,,TR-FRET,PEC50 = 6.4,,49.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.4,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OC(C)C)CCC[C@@H]2C1,49,292.252,326.2609657,0,1,8,1,6.7782,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14567,7605,21391689,12e,O00482,LRH-1,Homo sapiens,"rac-(1S,5R)-1-Butoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCCCC,CHEMBL1765929,,,TR-FRET,PEC50 = 5.3,,39.00%,agonist,RJW100,,,,,,,,,,,,,,,=,5.3,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCCCC)CCC[C@@H]2C1,39,304.263,340.2766158,0,1,10,1,7.1699,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,1325
14568,7605,21391689,12e,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-1-Butoxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCCCC,CHEMBL1765929,,,TR-FRET,PEC50 = 6.6,,62.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.6,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCCCC)CCC[C@@H]2C1,62,304.263,340.2766158,0,1,10,1,7.1699,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14570,7606,21391689,12f,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-3-Hexyl-1-(2-methylbutoxy)-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCC(C)CC,CHEMBL1765930,,,TR-FRET,PEC50 = 6.7,,56.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCC(C)CC)CCC[C@@H]2C1,56,316.274,354.2922658,0,1,10,1,7.4159,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14571,7607,21391689,12g,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-3-Hexyl-1-pentyloxy-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OCCCCC,CHEMBL1765923,,,TR-FRET,PEC50 = 6.4,,43.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.4,pEC50,,other,CCCCCCC1=C(c2ccccc2)[C@]2(OCCCCC)CCC[C@@H]2C1,43,316.274,354.2922658,0,1,11,1,7.56,9.23,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14573,7608,21391689,12i,Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-1-Cyclohexyloxy-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)OC4CCCCC4,CHEMBL1765931,,,TR-FRET,PEC50 = 7.1,,66.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.1,pEC50,B,other,CCCCCCC1=C(c2ccccc2)[C@]2(OC3CCCCC3)CCC[C@@H]2C1,66,328.285,366.2922658,0,1,8,1,7.7025,9.23,C1CCC(CC23CCCC2CCC3C2CCCCC2)CC1,,partial agonist,,partial agonist,1320
14575,7609,21391689,18a,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Hexyl-2-phenyl-1-(1-phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765933,,,TR-FRET,PEC50 = 7.2,,78.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.2,pEC50,B,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,78,336.308,370.2660511,0,0,8,2,8.3142,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14578,7610,21391689,18b,Q13285,SF-1,Homo sapiens,"rac-(3aR,6aR)-5-hexyl-6a-(1-(3-methoxyphenyl)vinyl)-6-phenyl-1,2,3,3a,4,6a-hexahydropentalene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4cccc(OC)c4,CHEMBL1765934,,,TR-FRET,PEC50 = 7.2,,28.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.2,pEC50,B,other,C=C(c1cccc(OC)c1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,28,364.318,400.2766158,0,1,9,2,8.3228,9.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14580,7611,21391689,18d,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Hexyl-1-(4-methylphenyl)vinyl)-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccc(C)cc4,CHEMBL1765936,,,TR-FRET,PEC50 = 6.8,,28.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.8,pEC50,,other,C=C(c1ccc(C)cc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,28,348.319,384.2817012,0,0,8,2,8.62262,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14582,7612,21391689,18i,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Hexyl-1-(pent-1-en-2-yl)-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)CCC,CHEMBL1765941,,,TR-FRET,PEC50 = 6.8,,66.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.8,pEC50,,other,C=C(CCC)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,66,300.275,336.2817012,0,0,9,1,7.9571,0,C1CCC(C2CCC3CCCC32)CC1,,partial agonist,,partial agonist,105
14584,7613,21391689,"18j, RJW102",Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-1-(Hex-1-en-2-yl)-3-hexyl-2-phenyl-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)CCCC,CHEMBL1765942,,,TR-FRET,PEC50 = 6.7,,76.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,C=C(CCCC)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1ccccc1,76,312.286,350.2973512,0,0,10,1,8.3472,0,C1CCC(C2CCC3CCCC32)CC1,,agonist,,agonist,105
14586,7614,21391689,18m,Q13285,SF-1,Homo sapiens,"rac-(3aR,6aR)-5-hexyl-6-(3-methoxyphenyl)-6a-(1-phenylvinyl)-1,2,3,3a,4,6a-hexahydropentalene",CCCCCCC1=C(c2cccc(OC)c2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765945,,,TR-FRET,PEC50 = 6.9,,42.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.9,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2c1cccc(OC)c1,42,364.318,400.2766158,0,1,9,2,8.3228,9.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14587,7615,21391689,18o,Q13285,SF-1,Homo sapiens,"rac-(3aR,6aS)-5-hexyl-6a-(1-phenylvinyl)-6-propyl-1,2,3,3a,4,6a-hexahydropentalene",CCCCCCC1=C(CCC)[C@@]2(CCC[C@@H]2C1)C(=C)c3ccccc3,CHEMBL1765947,,,TR-FRET,PEC50 = 6.4,,56.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.4,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2CCC,56,300.275,336.2817012,0,0,9,1,7.9571,0,CC(C1CCCCC1)C12CCCC1CCC2,,partial agonist,,partial agonist,1323
14588,7616,21391689,18p,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-2-Butyl-3-hexyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(CCCC)[C@@]2(CCC[C@@H]2C1)C(=C)c3ccccc3,CHEMBL1765948,,,TR-FRET,PEC50 = 6.6,,59.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.6,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2CCCC,59,312.286,350.2973512,0,0,10,1,8.3472,0,CC(C1CCCCC1)C12CCCC1CCC2,,partial agonist,,partial agonist,1323
14590,7617,21391689,18r,Q13285,SF-1,Homo sapiens,"rac-(3aR,6aR)-6-cyclohexyl-5-hexyl-6a-(1-phenylvinyl)-1,2,3,3a,4,6a-hexahydropentalene",CCCCCCC1=C(C2CCCCC2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765950,,,TR-FRET,PEC50 = 6.7,,59.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2C1CCCCC1,59,336.308,376.3130013,0,0,8,1,8.7373,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14591,7618,21391689,18u,O00482,LRH-1,Homo sapiens,"rac-(1R,5R)-3-Butyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765953,,,TR-FRET,PEC50 = 6.7,,54.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCC)=C2c1ccccc1,54,312.286,342.234751,0,0,6,2,7.534,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14592,7618,21391689,18u,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Butyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765953,,,TR-FRET,PEC50 = 7.4,,86.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.4,pEC50,B,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCC)=C2c1ccccc1,86,312.286,342.234751,0,0,6,2,7.534,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14594,7619,21391689,18v,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Octyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCCCC1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765954,,,TR-FRET,PEC50 = 6.8,,67.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.8,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCCCC)=C2c1ccccc1,67,360.33,398.2973512,0,0,10,2,9.0944,0,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14595,762,20144545,1a,P11473,VDR,Homo sapiens,"8-amino-2,7-diisobutyl-4-isopentyl-4,5-dihydro-1H-benzo[e][1,4]diazepin-3(2H)-one",CC(C)CCN1Cc2cc(CC(C)C)c(N)cc2N[C@@H](CC(C)C)C1=O,CHEMBL1087253,,reporter gene assay,TR-FRET,IC50 > 30000nM,partial agonist,47.00%,agonist,"1,25-(OH)2D3",3nM,"1,25-(OH)2D3",10nM,,,,,,,,IC50,>,30000,nM,>,4.522878745,pIC50,NB,other,CC(C)CCN1Cc2cc(CC(C)C)c(N)cc2N[C@@H](CC(C)C)C1=O,47,322.262,359.2936628,2,3,7,1,4.6822,58.36,CC1CCC2CCCCC2CC1,,partial agonist,,partial agonist,659
14596,7620,21391689,18w,O00482,LRH-1,Homo sapiens,"rac-(1R,5R)-3-Dimethyl(phenyl)silane-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",C[Si](C)(C1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4)c5ccccc5,CHEMBL1765955,,,TR-FRET,PEC50 = 6.8,,53.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.8,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC([Si](C)(C)c1ccccc1)=C2c1ccccc1,53,388.416,420.2273276,0,0,5,3,7.4986,0,CC(C1CCCCC1)C12CCCC1CC(CC1CCCCC1)C2C1CCCCC1,,partial agonist,,partial agonist,1324
14597,7620,21391689,18w,Q13285,SF-1,Homo sapiens,"rac-(1R,5R)-3-Dimethyl(phenyl)silane-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",C[Si](C)(C1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)C(=C)c4ccccc4)c5ccccc5,CHEMBL1765955,,,TR-FRET,PEC50 = 7.2,,33.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.2,pEC50,B,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC([Si](C)(C)c1ccccc1)=C2c1ccccc1,33,388.416,420.2273276,0,0,5,3,7.4986,0,CC(C1CCCCC1)C12CCCC1CC(CC1CCCCC1)C2C1CCCCC1,,partial agonist,,partial agonist,1324
14599,7621,21391689,"20a, RJW103",Q13285,SF-1,Homo sapiens,"rac-(1S,5R)-3-Hexyl-2-phenyl-1-(phenylvinyl)-7-methylaza-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CN(C)C[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765957,,,TR-FRET,PEC50 = 6.5,,49.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.5,pEC50,,other,C=C(c1ccccc1)[C@@]12CN(C)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,49,350.315,385.2769501,0,1,8,2,7.0757,3.24,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14600,7622,21391689,24-endo,O00482,LRH-1,Homo sapiens,"rac-(1R,5R,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CC[C@H](O)[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765960,,,TR-FRET,PEC50 = 6.4,,67.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.4,pEC50,,other,C=C(c1ccccc1)[C@@]12CC[C@H](O)[C@@H]1CC(CCCCCC)=C2c1ccccc1,67,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14601,7622,21391689,24-endo,Q13285,SF-1,Homo sapiens,"rac-(1R,5R,6S)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CC[C@H](O)[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765960,,,TR-FRET,PEC50 = 7.2,,77.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.2,pEC50,B,other,C=C(c1ccccc1)[C@@]12CC[C@H](O)[C@@H]1CC(CCCCCC)=C2c1ccccc1,77,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14602,7623,21391689,"24-exo, RJW100",O00482,LRH-1,Homo sapiens,"rac-(1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CC[C@@H](O)[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765959,,,TR-FRET,PEC50 = 6.6,,100.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.6,pEC50,,other,C=C(c1ccccc1)[C@@]12CC[C@@H](O)[C@@H]1CC(CCCCCC)=C2c1ccccc1,100,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14603,7623,21391689,"24-exo, RJW100",Q13285,SF-1,Homo sapiens,"rac-(1R,5R,6R)-3-Hexyl-6-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CC[C@@H](O)[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765959,,,TR-FRET,PEC50 = 7.5,,100.00%,agonist,RJW100,,,,,,,,,,,,,,,=,7.5,pEC50,B,other,C=C(c1ccccc1)[C@@]12CC[C@@H](O)[C@@H]1CC(CCCCCC)=C2c1ccccc1,100,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14604,7624,21391689,25-endo,O00482,LRH-1,Homo sapiens,"rac-(1R,5R,6S)-6-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(CC[C@H](OC(=O)C)[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765962,,,TR-FRET,PEC50 = 6.6,,67.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.6,pEC50,,other,C=C(c1ccccc1)[C@@]12CC[C@H](OC(C)=O)[C@@H]1CC(CCCCCC)=C2c1ccccc1,67,392.328,428.2715304,0,2,9,2,7.8558,26.3,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14609,7626,21391689,29-endo,Q13285,SF-1,Homo sapiens,"rac-(1R,5R,7S)-3-hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(C[C@H](O)C[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765964,,,TR-FRET,PEC50 = 6.5,,95.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.5,pEC50,,other,C=C(c1ccccc1)[C@@]12C[C@H](O)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,95,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,agonist,,agonist,1322
14610,7627,21391689,29-exo,O00482,LRH-1,Homo sapiens,"rac-(1R,5R,7R)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(C[C@@H](O)C[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765963,,,TR-FRET,PEC50 = 6.0,,53.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6,pEC50,,other,C=C(c1ccccc1)[C@@]12C[C@@H](O)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,53,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14611,7627,21391689,29-exo,Q13285,SF-1,Homo sapiens,"rac-(1R,5R,7R)-3-Hexyl-7-hydroxy-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(C[C@@H](O)C[C@@H]3C1)C(=C)c4ccccc4,CHEMBL1765963,,,TR-FRET,PEC50 = 6.6,,49.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.6,pEC50,,other,C=C(c1ccccc1)[C@@]12C[C@@H](O)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,49,352.307,386.2609657,1,1,8,2,7.285,20.23,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14612,7628,21391689,30-endo,O00482,LRH-1,Homo sapiens,"rac-(1R,5R,7S)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(C[C@@H](C[C@@H]3C1)OC(=O)C)C(=C)c4ccccc4,CHEMBL1765966,,,TR-FRET,PEC50 = 6.3,,33.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.3,pEC50,,other,C=C(c1ccccc1)[C@@]12C[C@H](OC(C)=O)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,33,392.328,428.2715304,0,2,9,2,7.8558,26.3,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14613,7628,21391689,30-endo,Q13285,SF-1,Homo sapiens,"rac-(1R,5R,7S)-7-Acetoxy-3-hexyl-2-phenyl-1-(phenylvinyl)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(c2ccccc2)[C@@]3(C[C@@H](C[C@@H]3C1)OC(=O)C)C(=C)c4ccccc4,CHEMBL1765966,,,TR-FRET,PEC50 = 6.7,,34.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.7,pEC50,,other,C=C(c1ccccc1)[C@@]12C[C@H](OC(C)=O)C[C@@H]1CC(CCCCCC)=C2c1ccccc1,34,392.328,428.2715304,0,2,9,2,7.8558,26.3,CC(C1CCCCC1)C12CCCC1CCC2C1CCCCC1,,partial agonist,,partial agonist,1322
14615,7629,21391689,"5, GSK-8470",Q13285,SF-1,Homo sapiens,"(3aS,6aR)-5-((E)-oct-4-en-4-yl)-N,4-diphenyl-1,2,3,3a,6,6a-hexahydropentalen-3a-amine",CCC\C=C(/CCC)\C1=C(c2ccccc2)[C@@]3(CCC[C@@H]3C1)Nc4ccccc4,CHEMBL385911,,,TR-FRET,PEC50 = 6.8,,36.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.8,pEC50,,other,CCC/C=C(\CCC)C1=C(c2ccccc2)[C@]2(Nc3ccccc3)CCC[C@@H]2C1,36,350.315,385.2769501,1,1,8,2,8.0215,12.03,C1CCC(CC23CCCC2CCC3C2CCCCC2)CC1,,partial agonist,,partial agonist,1320
14619,7632,21391689,"18s, RJW101",O00482,LRH-1,Homo sapiens,"rac-(1R,5R)-3-Hexyl-1-(phenylvinyl)-2-(propan-3-ol)-bicyclo[3.3.0]oct-2-ene",CCCCCCC1=C(CCCO)[C@@]2(CCC[C@@H]2C1)C(=C)c3ccccc3,CHEMBL1765951,,,TR-FRET,PEC50 = 6.1,,38.00%,agonist,RJW100,,,,,,,,,,,,,,,=,6.1,pEC50,,other,C=C(c1ccccc1)[C@@]12CCC[C@@H]1CC(CCCCCC)=C2CCCO,38,316.274,352.2766158,1,1,10,1,6.9295,20.23,CC(C1CCCCC1)C12CCCC1CCC2,,partial agonist,,partial agonist,1323
14654,773,23953070,5o,P04150,GR,Homo sapiens,"rac-3-(1-isopentyl-1H-indazol-5-yl)-2,2-dimethyl-3-phenyl-N-(1,3,4-thiadiazol-2-yl)propanamide",CC(C)CCn1ncc2cc(ccc12)C(c3ccccc3)C(C)(C)C(=O)Nc4nncs4,CHEMBL2426656,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,Ki = 5.7nM,partial agonist,66.00%,agonist,dexamethasone,,,,,,,EC50,=,132,nM,,,,,=,8.244125144,pKi,B,FPA,CC(C)CCn1ncc2cc(C(c3ccccc3)C(C)(C)C(=O)Nc3nncs3)ccc21,66,418.376,447.2092815,1,6,8,4,5.7307,72.7,CC(CC1CCCC1)CC(C1CCCCC1)C1CCC2CCCC2C1,agonist,partial agonist,agonist,partial agonist,965
14660,778,24685544,27,P51449,RORG,Homo sapiens,4'-((N-isobutyl-1-phenylmethylsulfonamido)methyl)biphenyl-4-carboxamide,CC(C)CN(Cc1ccc(cc1)c2ccc(cc2)C(=O)N)S(=O)(=O)Cc3ccccc3,CHEMBL3263716,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 33nM,inverse agonist,-90.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,40,nM,,,,,=,7.48148606,pIC50,B,radiometric,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,-90,408.353,436.1820638,1,3,9,3,4.4405,80.47,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14661,779,24685544,11,P51449,RORG,Homo sapiens,4-(5-((N-isobutyl-1-phenylmethylsulfonamido)methyl)thiophen-2-yl)benzamide,CC(C)CN(Cc1ccc(s1)c2ccc(cc2)C(=O)N)S(=O)(=O)Cc3ccccc3,CHEMBL3263700,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 160nM,inverse agonist,-69.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,130,nM,,,,,=,6.795880017,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,-69,416.398,442.1384847,1,4,9,3,4.502,80.47,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14665,780,24685544,29,P51449,RORG,Homo sapiens,2-(4'-((N-isobutyl-1-phenylmethylsulfonamido)methyl)biphenyl-4-yl)acetamide,CC(C)CN(Cc1ccc(cc1)c2ccc(CC(=O)N)cc2)S(=O)(=O)Cc3ccccc3,CHEMBL3264011,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 1800nM,inverse agonist,-84.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,1200,nM,,,,,=,5.744727495,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(CC(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,-84,420.364,450.1977138,1,3,10,3,4.3694,80.47,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14668,783,24685544,25,P51449,RORG,Homo sapiens,N-isobutyl-N-((4'-(methylsulfonamido)biphenyl-4-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(cc1)c2ccc(NS(=O)(=O)C)cc2)S(=O)(=O)Cc3ccccc3,CHEMBL3263714,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 46nM,inverse agonist,-95.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,32,nM,,,,,=,7.337242168,pIC50,B,radiometric,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,-95,456.419,486.1646994,1,4,10,3,4.7131,83.55,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14669,784,24685544,10,P51449,RORG,Homo sapiens,N-isobutyl-N-((5-(4-(methylsulfonamido)phenyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(s1)c2ccc(NS(=O)(=O)C)cc2)S(=O)(=O)Cc3ccccc3,CHEMBL3263699,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 71nM,inverse agonist,-83.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,150,nM,,,,,=,7.148741651,pIC50,B,radiometric,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,-83,464.464,492.1211204,1,5,10,3,4.7746,83.55,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14670,785,24685544,21,P51449,RORG,Homo sapiens,N-isobutyl-N-((4'-(methylsulfonyl)biphenyl-4-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(cc1)c2ccc(cc2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263710,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 32nM,inverse agonist,-94.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,21,nM,,,,,=,7.494850022,pIC50,B,radiometric,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,-94,442.412,471.1538004,0,4,9,3,4.7451,71.52,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14671,786,24685544,7,P51449,RORG,Homo sapiens,N-isobutyl-N-((5-(4-(methylsulfonyl)phenyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(s1)c2ccc(cc2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263696,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 130nM,inverse agonist,-72.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,460,nM,,,,,=,6.886056648,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,-72,450.457,477.1102213,0,5,9,3,4.8066,71.52,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14672,787,24685544,23,P51449,RORG,Homo sapiens,N-isobutyl-N-(4-(5-(methylsulfonyl)pyridin-2-yl)benzyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(cc1)c2ccc(cn2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263712,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 1400nM,inverse agonist,-79.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,1100,nM,,,,,=,5.853871964,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cn2)cc1)S(=O)(=O)Cc1ccccc1,-79,444.408,472.1490494,0,5,9,3,4.1401,84.41,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14673,788,24685544,22,P51449,RORG,Homo sapiens,N-isobutyl-N-(4-(6-(methylsulfonyl)pyridin-3-yl)benzyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(cc1)c2ccc(nc2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263711,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 650nM,inverse agonist,-79.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,360,nM,,,,,=,6.187086643,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)nc2)cc1)S(=O)(=O)Cc1ccccc1,-79,444.408,472.1490494,0,5,9,3,4.1401,84.41,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14674,789,24685544,26,P51449,RORG,Homo sapiens,4'-((N-isobutyl-1-phenylmethylsulfonamido)methyl)biphenyl-4-sulfonamide,CC(C)CN(Cc1ccc(cc1)c2ccc(cc2)S(=O)(=O)N)S(=O)(=O)Cc3ccccc3,CHEMBL3263715,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 120nM,inverse agonist,-94.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,140,nM,,,,,=,6.920818754,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccc(S(N)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,-94,444.408,472.1490494,1,4,9,3,3.989,97.54,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14678,790,24685544,30,P51449,RORG,Homo sapiens,2-(4'-((N-isobutyl-1-phenylmethylsulfonamido)methyl)biphenyl-3-yl)acetamide,CC(C)CN(Cc1ccc(cc1)c2cccc(CC(=O)N)c2)S(=O)(=O)Cc3ccccc3,CHEMBL3264012,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 91nM,inverse agonist,-94.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,200,nM,,,,,=,7.040958608,pIC50,B,radiometric,CC(C)CN(Cc1ccc(-c2cccc(CC(N)=O)c2)cc1)S(=O)(=O)Cc1ccccc1,-94,420.364,450.1977138,1,3,10,3,4.3694,80.47,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14679,791,24685544,9,P51449,RORG,Homo sapiens,N-isobutyl-N-((5-(3-(methylsulfonamido)phenyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(s1)c2cccc(NS(=O)(=O)C)c2)S(=O)(=O)Cc3ccccc3,CHEMBL3263698,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 920nM,inverse agonist,-56.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,4900,nM,,,,,=,6.036212173,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2cccc(NS(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,-56,464.464,492.1211204,1,5,10,3,4.7746,83.55,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14680,792,24685544,2,P51449,RORG,Homo sapiens,1N-isobutyl-N-((5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(s1)c2cccc(c2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263695,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 370nM,inverse agonist,-60.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,360,nM,,,,,=,6.431798276,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,-60,450.457,477.1102213,0,5,9,3,4.8066,71.52,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14681,793,24685544,8,P51449,RORG,Homo sapiens,N-isobutyl-N-((5-(2-(methylsulfonamido)phenyl)thiophen-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1ccc(s1)c2ccccc2NS(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263697,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 1100nM,inverse agonist,-76.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,1600,nM,,,,,=,5.958607315,pIC50,,radiometric,CC(C)CN(Cc1ccc(-c2ccccc2NS(C)(=O)=O)s1)S(=O)(=O)Cc1ccccc1,-76,464.464,492.1211204,1,5,10,3,4.7746,83.55,CC(C)(CCC1CCC(C2CCCCC2)C1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1202
14685,797,24685544,24,P51449,RORG,Homo sapiens,N-isobutyl-N-((5-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)methyl)-1-phenylmethanesulfonamide,CC(C)CN(Cc1cnc(cn1)c2ccc(cc2)S(=O)(=O)C)S(=O)(=O)Cc3ccccc3,CHEMBL3263713,Activation or inhibition of RORG-LBD recruitment of the SRC1 coactivator,,radiometric binding assay monitoring the displacement of [3H2]25??ydroxycholesterol from the ligand-binding domain (LBD) ,IC50 = 5500nM,inverse agonist,-67.00%,agonist,basal activity,,25-hydroxycholesterol,,,,,EC50,=,3800,nM,,,,,=,5.259637311,pIC50,,radiometric,CC(C)CN(Cc1cnc(-c2ccc(S(C)(=O)=O)cc2)cn1)S(=O)(=O)Cc1ccccc1,-67,446.404,473.1442983,0,6,9,3,3.5351,97.3,CC(C)(CCC1CCC(C2CCCCC2)CC1)CC1CCCCC1,agonist,inverse agonist,agonist,inverse agonist,1204
14723,824,17439112,10d,P10275,AR,Homo sapiens,"1,2,3,6-tetrahydro-1-isobutyl-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC(C)CN1CCOc2cc3NC(=O)C=C(c3cc12)C(F)(F)F,CHEMBL227645,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 17nM,partial agonist,70.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,70,nM,IC50,=,27,nM,=,7.769551079,pKi,B,radiometric,CC(C)CN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,70,309.182,326.1242124,1,3,2,2,3.4017,45.33,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,586
14727,828,20469868,19f,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-(2-methylpropyl)-3-(trifluoromethyl)benzenesulfonamide,CC(C)CNS(=O)(=O)c1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1085381,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.4,partial antagonist,74.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.5,,=,7.4,pIC50,B,FPA,CC(C)CNS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,74,470.342,491.1290608,1,4,6,4,5.7847,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,partial antagonist,antagonist,partial antagonist,107
14730,829,17257838,13f,P10275,AR,Homo sapiens,"6-(isobutylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)CNc1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL3706910,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 59nM,partial agonist,61.00%,agonist,DHT,,,,,,,EC50,=,404,nM,IC50,=,22,nM,=,7.229147988,pIC50,B,radiometric,CC(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,61,269.161,284.1136478,2,2,3,2,3.6148,44.89,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
14732,830,17257838,9e,P10275,AR,Homo sapiens,"7-(isobutylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)CNc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706881,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 65nM,antagonist,86.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,74,nM,=,7.187086643,pIC50,B,radiometric,CC(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,86,269.161,284.1136478,2,2,3,2,3.6148,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
14737,833,16153845,26,P37231,PPARG,Homo sapiens,1-(4-tert-Butyl-phenyl)-5-isobutoxy-3-(3-trifluoromethyl-phenoxy)-1H-indole-2-carboxylic acid,CC(C)COc1ccc2c(c1)c(Oc3cccc(c3)C(F)(F)F)c(C(=O)O)n2c4ccc(cc4)C(C)(C)C,CHEMBL198091,Transactivation assay ,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 18nM,partial agonist,34.00%,agonist,maximal activation (no details),,,,,,,EC50,=,91,nM,,,,,=,7.744727495,pIC50,B,radiometric,CC(C)COc1ccc2c(c1)c(Oc1cccc(C(F)(F)F)c1)c(C(=O)O)n2-c1ccc(C(C)(C)C)cc1,34,495.327,525.2126931,1,4,7,4,8.4721,60.69,C1CCC(CC2CC(C3CCCCC3)C3CCCCC23)CC1,agonist,partial agonist,agonist,partial agonist,243
14739,834,19926282,12,P06401,PR,Homo sapiens,(S)-2-chloro-4-((1-(isobutylsulfonyl)pyrrolidin-3-yl)(2-(trifluoromethyl)benzyl)amino)benzonitrile,CC(C)CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2C(F)(F)F)c3ccc(C#N)c(Cl)c3,CHEMBL602851,,,,IC50 = 80nM,partial agonist,65.00%,agonist,,,,,,,,EC50,=,10,nM,,,,,=,7.096910013,pIC50,B,other,CC(C)CS(=O)(=O)N1CC[C@H](N(Cc2ccccc2C(F)(F)F)c2ccc(C#N)c(Cl)c2)C1,65,474.786,499.1308104,0,4,7,2,5.29718,64.41,C1CCC(CC(C2CCCCC2)C2CCCC2)CC1,agonist,partial agonist,agonist,partial agonist,323
14740,835,23916594,3g,P04150,GR,Homo sapiens,"(S)-3,3,3-trifluoro-N-(3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2,5-trimethylhexyl)propanamide",CC(C)C[C@@H](c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)CNC(=O)CC(F)(F)F,CHEMBL2426128,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.3nM,agonist,81.00%,agonist,dexamethasone,,,,,,,EC50,=,262,nM,,,,,=,8.886056648,pIC50,B,FPA,CC(C)C[C@@H](c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)CNC(=O)CC(F)(F)F,81,434.287,463.2246754,1,3,8,3,6.3891,46.92,C1CCC(C2CCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,111
14741,836,23916594,3m,P04150,GR,Homo sapiens,"(S)-1-tert-butyl-3-(3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2,5-trimethylhexyl)urea",CC(C)C[C@@H](c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)CNC(=O)NC(C)(C)C,CHEMBL2426113,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 3.6nM,agonist,86.00%,agonist,dexamethasone,,,,,,,EC50,=,126,nM,,,,,=,8.443697499,pIC50,B,FPA,CC(C)C[C@@H](c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)CNC(=O)NC(C)(C)C,86,415.322,452.29514,2,3,7,3,6.4182,58.95,C1CCC(C2CCC3CCCCC32)CC1,agonist,agonist,agonist,agonist,111
14742,837,23916594,3k,P04150,GR,Homo sapiens,"(S)-1-(3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2,2,5-trimethylhexyl)-3-(2,2,2-trifluoroethyl)urea",CC(C)C[C@@H](c1ccc2c(cnn2c3ccc(F)cc3)c1)C(C)(C)CNC(=O)NCC(F)(F)F,CHEMBL2426111,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.42nM,partial agonist,58.00%,agonist,dexamethasone,,,,,,,EC50,=,501,nM,,,,,=,8.847711656,pIC50,B,FPA,CC(C)C[C@@H](c1ccc2c(cnn2-c2ccc(F)cc2)c1)C(C)(C)CNC(=O)NCC(F)(F)F,58,448.294,478.2355745,2,3,8,3,6.182,58.95,C1CCC(C2CCC3CCCCC32)CC1,agonist,partial agonist,agonist,partial agonist,111
14743,838,19376703,21,P06401,PR,Homo sapiens,(S)-2-chloro-4-((cyclobutylmethyl)(3-methyl-1-(1-methyl-1H-tetrazol-5-yl)butyl)amino)benzonitrile,CC(C)C[C@H](N(CC1CCC1)c2ccc(C#N)c(Cl)c2)c3nnnn3C,CHEMBL560248,T47D-based alkaline phosphatase PR agonist assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 16nM,partial agonist,38.00%,agonist,progesterone,,,,,,,EC50,=,6.8,nM,,,,,=,7.795880017,pIC50,B,FPA,CC(C)C[C@@H](c1nnnn1C)N(CC1CCC1)c1ccc(C#N)c(Cl)c1,38,347.704,372.1829225,0,6,7,2,4.12908,70.63,C1CCC(C(CC2CCCC2)CC2CCC2)CC1,agonist,partial agonist,agonist,partial agonist,317
14744,839,17439112,(R)-16h,P10275,AR,Homo sapiens,"(2R)-1,2,3,6-tetrahydro-2-isobutyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC(C)C[C@@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL227695,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 109nM,partial agonist,65.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,65,nM,IC50,>,10000,nM,=,6.962573502,pKi,,radiometric,CC(C)C[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,65,390.198,408.1272471,1,3,3,2,4.7227,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
14746,840,20047280,51,P04150,GR,Homo sapiens,"(R)-2-((5aR,6S)-1-(4-Fluorophenyl)-5a-methyl-5,5a,6,7,8,9-hexahydroimidazo[1,5-b]isoquinolin-6-yl)-4-methylpentan-2-ol",CC(C)C[C@@](C)(O)[C@H]1CCCC2=Cc3c(ncn3C[C@]12C)c4ccc(F)cc4,CHEMBL567237,Transactivation assay in NP-1 HeLa cells,,Fluorescence polarization (FP) competition binding assay,IC50 = 9nM,partial agonist,26.00%,agonist,dexamethasone,4.5nM,,,,,,EC50,=,876,nM,,,,,=,8.045757491,pIC50,B,FPA,CC(C)C[C@@](C)(O)[C@H]1CCCC2=Cc3c(-c4ccc(F)cc4)ncn3C[C@@]21C,26,351.275,382.2420418,1,3,4,2,5.6897,38.05,C1CCC(C2CCC3CC4CCCCC4CC32)CC1,agonist,partial agonist,agonist,partial agonist,97
14750,843,10340624,6o,P10275,AR,Homo sapiens,"Trans-6-Isobutyl-7-methyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC(C)C[C@@H]1[C@@H](C)CNc2cc3nc(O)cc(c3cc12)C(F)(F)F,CHEMBL2113248,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 72nM,partial antagonist,55.00%,antagonist,DHT,,DHT,,,,,EC50,=,56,nM,IC50,=,29,nM,=,7.142667504,pKi,B,radiometric,CC(C)C[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,55,317.205,338.160598,2,3,2,2,5.1505,45.15,CC1CCC2CC3CCCCC3CC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,586
14758,847,20128594,12,Q03181,PPARB,Homo sapiens,4-isobutyl-N-(2-(5-(trifluoromethyl)pyridin-2-ylsulfonyl)ethyl)benzamide,CC(C)Cc1ccc(cc1)C(=O)NCCS(=O)(=O)c2ccc(cn2)C(F)(F)F,CHEMBL598155,,Gal4 luciferase reporter gene assays,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 6.5,antagonist,100.00%,antagonist,GW501516,2nM,,,,,,,,,,PIC50,=,6.7,,=,6.5,pIC50,,radiometric,CC(C)Cc1ccc(C(=O)NCCS(=O)(=O)c2ccc(C(F)(F)F)cn2)cc1,100,393.281,414.1224982,1,4,7,2,3.5026,76.13,CC(CCCC(C)(C)C1CCCCC1)C1CCCCC1,antagonist,antagonist,antagonist,antagonist,1309
14769,852,17267219,6i,P10275,AR,Homo sapiens,"6-(isopropyl(2,2,2-trifluoroethyl)amino)-4-(trifluoromethyl)quinolin-2(1H)-one",CC(C)N(CC(F)(F)F)c1ccc2NC(=O)C=C(c2c1)C(F)(F)F,CHEMBL237262,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 2.9nM,agonist,107.00%,agonist,DHT,,,,,,,EC50,=,0.9,nM,IC50,>,10000,nM,=,8.537602002,pIC50,B,radiometric,CC(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,107,338.166,352.1010324,1,2,3,2,4.324,36.1,CC1CCC2CCCCC2C1,agonist,agonist,agonist,agonist,651
14776,857,20469868,21d,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-(1-methylethyl)-N-phenyl-3-(trifluoromethyl)benzenesulfonamide,CC(C)N(c1ccccc1)S(=O)(=O)c2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1086260,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.8,partial agonist,44.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.9,,,,,,=,7.8,pIC50,B,FPA,CC(C)N(c1ccccc1)S(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,44,530.397,553.1447109,0,4,6,5,7.4541,55.2,CC(C)(CC1CCCCC1)C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,1134
14779,858,20584610,15,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Isopropyl-1,7-dimethyl-3,5,8,10-tetraoxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CC(C)N1C(=O)[C@@]2(C)O[C@](C)([C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C1=O,CHEMBL1210908,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 14nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,32,nM,=,7.853871964,pKi,B,radiometric,CC(C)N1C(=O)[C@@]2(C)O[C@@](C)(C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,431.241,449.1198553,0,6,2,1,2.00748,107.78,CC1CC(C)C2CC1C1C(C)C(C3CCCCC3)C(C)C21,antagonist,antagonist,antagonist,antagonist,690
14782,86,15026058,12,P04150,GR,Homo sapiens,"5-But-2-enyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(C\C=C\C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL47742,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.6nM,partial agonist,53.00%,agonist,dexamethasone,,,,,,,IC50,=,150,nM,,,,,=,9.22184875,pIC50,B,radiometric,C/C=C/CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,53,334.269,361.2041791,1,3,3,2,6.3693,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
14786,861,19616429,20,P06401,PR,Homo sapiens,(S)-2-chloro-4-((2-chlorobenzyl)(1-isopropyl-5-oxopyrrolidin-3-yl)amino)benzonitrile,CC(C)N1C[C@H](CC1=O)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,CHEMBL559327,T47D-based alkaline phosphatase PR agonist assay,,-,IC50 = 10nM,partial agonist,63.00%,agonist,progesterone,,,,,,,EC50,=,0.3,nM,,,,,=,8,pIC50,B,other,CC(C)N1C[C@@H](N(Cc2ccccc2Cl)c2ccc(C#N)c(Cl)c2)CC1=O,63,381.157,401.1061677,0,3,5,2,4.88098,47.34,CC1CCC(C(CC2CCCCC2)C2CCCCC2)C1,agonist,partial agonist,agonist,partial agonist,779
14787,862,20584610,27,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid isopropylamide",CC(C)NC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1209971,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 98nM,antagonist,88.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,876,nM,=,7.008773924,pKi,B,radiometric,CC(C)NC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,88,441.26,464.1671399,1,5,2,1,2.66388,102.74,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
14788,863,21349714,(+/-)-10,P04150,GR,Homo sapiens,"(+/-)-(3R,4S)-6-(3-chloro-1H-indol-7-yl)-5,7-difluoro-2,2,4-trimethyl-1,2,3,4-tetrahydroquinolin-3-yl isopropylcarbamate",CC(C)NC(=O)O[C@@H]1[C@@H](C)c2c(F)c(c(F)cc2NC1(C)C)c3cccc4c(Cl)c[nH]c34,CHEMBL1684343,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 110nM,agonist,110.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,89,nM,,,,,=,6.958607315,pKi,,radiometric,CC(C)NC(=O)O[C@@H]1[C@@H](C)c2c(cc(F)c(-c3cccc4c(Cl)c[nH]c34)c2F)NC1(C)C,110,435.732,461.1681612,3,3,3,3,6.5773,66.15,C1CCC2CC(C3CCCC4CCCC43)CCC2C1,agonist,agonist,agonist,agonist,37
14800,870,20469868,19a,P04150,GR,Homo sapiens,4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-N-(1-methylethyl)-3-(trifluoromethyl)benzenesulfonamide,CC(C)NS(=O)(=O)c1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1082837,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,antagonist,102.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,=,5.9,,=,7.9,pIC50,B,FPA,CC(C)NS(=O)(=O)c1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,102,458.331,477.1134107,1,4,5,4,5.5371,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,antagonist,antagonist,antagonist,antagonist,107
14803,871,17257838,9d,P10275,AR,Homo sapiens,"7-(isopropylamino)-4-(trifluoromethyl)-1,8a-dihydroquinolin-2(4aH)-one",CC(C)Nc1ccc2C(=CC(=O)Nc2c1)C(F)(F)F,CHEMBL3706880,,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 79nM,antagonist,87.00%,antagonist,DHT,,,,,,,EC50,>,10000,nM,IC50,=,56,nM,=,7.102372909,pIC50,B,radiometric,CC(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,87,257.15,270.0979977,2,2,2,2,3.3672,44.89,CC1CCC2CCCCC2C1,antagonist,antagonist,antagonist,antagonist,651
14804,872,17034117,4b,P10275,AR,Homo sapiens,6-N-isopropylamino-4-trifluoromethylquinolin-2(1H)-one,CC(C)Nc1ccc2nc(O)cc(c2c1)C(F)(F)F,CHEMBL217428,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 58nM,partial antagonist,61.00%,antagonist,DHT,,,,,,,EC50,=,106,nM,IC50,=,16.5,nM,=,7.236572006,pKi,B,radiometric,CC(C)Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,61,257.15,270.0979977,2,3,2,2,3.7795,45.15,CC1CCC2CCCCC2C1,"antagonist,agonist",partial antagonist,"antagonist,agonist",partial antagonist,651
14805,873,20584610,25,P10275,AR,Homo sapiens,"(1S,2S,6R,7R)-4-(4-Cyano-3-trifluoromethyl-phenyl)-1,7-dimethyl-3,5-dioxo-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undecane-9-carboxylic acid isopropyl ester",CC(C)OC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F,CHEMBL1210842,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 11nM,antagonist,99.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,12,nM,=,7.958607315,pKi,B,radiometric,CC(C)OC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,99,443.252,465.1511555,0,6,2,1,3.09088,99.94,CC1C(C2CCCCC2)C(C)C2C3CCCC(C3)C12,antagonist,antagonist,antagonist,antagonist,535
14807,875,24980053,38,P04150,GR,Homo sapiens,"(S)-N-carbamoyl-2-(9-fluoro-2-(6-isopropoxypyridin-3-yl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamide",CC(C)Oc1ccc(cn1)c2ccc3[C@H](c4cccc(F)c4Oc3n2)C(C)(C)C(=O)NC(=O)N,CHEMBL3315070,GR transactivation NP-1 assay,,Fluorescence polarization (FP) competition binding assay,Ki = 0.7nM,partial agonist,54.00%,agonist,dexamethasone,,,,,,,EC50,=,59.2,nM,,,,,=,9.15490196,pKi,B,FPA,CC(C)Oc1ccc(-c2ccc3c(n2)Oc2c(F)cccc2[C@@H]3C(C)(C)C(=O)NC(N)=O)cn1,54,439.297,464.1859835,2,6,5,3,4.5286,116.43,C1CCC(C2CCC3CC4CCCCC4CC3C2)CC1,agonist,partial agonist,agonist,partial agonist,98
14809,876,21899328,27,P04150,GR,Homo sapiens,"[(5S)-2-[3-Fluoro-4-(1-methylethoxy)phenyl]-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)Oc1ccc(cc1F)c2ccc3[C@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911157,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 3.9nM,antagonist,91.00%,antagonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,496,nM,IC50,=,162,nM,=,8.408935393,pKi,B,FPA,CC(C)Oc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@@H]3C(C)(C)C(=O)Nc2nncs2)cc1F,91,479.387,504.1631399,1,7,6,4,6.4289,86.23,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",antagonist,"antagonist,agonist",antagonist,956
14810,877,21899328,22,P04150,GR,Homo sapiens,"[(5S)-a,a-Dimethyl-2-[(4-methylethooxy)phenyl]-N-1,3,4-thiadiazol-2-yl-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide",CC(C)Oc1ccc(cc1)c2ccc3[C@@H](c4ccccc4Oc3n2)C(C)(C)C(=O)Nc5nncs5,CHEMBL1911152,Gal4 luciferase reporter gene assays,Gal4 luciferase reporter gene assays,Fluorescence polarization (FP) competition binding assay,Ki = 1.6nM,partial agonist,56.00%,agonist,dexamethasone,,,,Kd = 0.3nM,,,EC50,=,135,nM,IC50,=,77,nM,=,8.795880017,pKi,B,FPA,CC(C)Oc1ccc(-c2ccc3c(n2)Oc2ccccc2[C@H]3C(C)(C)C(=O)Nc2nncs2)cc1,56,460.389,486.1725617,1,7,6,4,6.2898,86.23,CC(CC1CCCC1)CC1C2CCCCC2CC2CC(C3CCCCC3)CCC21,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,956
14816,88,15911283,29m,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4',5'-di[(E)-1-propenyl]-(4'R,4aS,5'R)-spiro[1,4,4a,5,6,7-hexahydrocyclopenta[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C\C=C\[C@H]1OC2(CCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1\C=C\C,CHEMBL444286,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.7nM,agonist,93.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,6.5,nM,,,,,=,8.568636236,pIC50,B,radiometric,C/C=C/[C@H]1OC2(CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1/C=C/C,93,379.285,406.2056563,0,4,3,2,5.3835,36.28,C1CCC(C2CCC3CC4C(CCC45CCCC5)CC32)CC1,agonist,agonist,agonist,agonist,91
14818,881,20469868,23b,P04150,GR,Homo sapiens,N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-2-propanesulfonamide,CC(C)S(=O)(=O)Nc1ccc(c2ccc3c(cnn3c4ccc(F)cc4)c2)c(c1)C(F)(F)F,CHEMBL1083709,reporter gene assay(MMTV),,Fluorescence polarization (FP) competition binding assay,PIC50 = 7.9,partial agonist,39.00%,agonist,dexamethasone,,,,,,,PEC50,=,6.8,,,,,,=,7.9,pIC50,B,FPA,CC(C)S(=O)(=O)Nc1ccc(-c2ccc3c(cnn3-c3ccc(F)cc3)c2)c(C(F)(F)F)c1,39,458.331,477.1134107,1,4,5,4,6.0005,63.99,C1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,partial agonist,107
14821,882,25516791,40,P04150,GR,Homo sapiens,"5-fluoro-2-(5,5,5-trifluoro-4-hydroxy-4-((5-(isopropylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-2-methylpentan-2-yl)benzamide",CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(=O)N)C(F)(F)F)[nH]c2cn1,CHEMBL3358951,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 370nM,partial agonist,66.00%,agonist,dexamethasone,,,,,,,IC50,=,570,nM,,,,,=,6.431798276,pIC50,,FPA,CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,66,502.34,529.1658402,3,5,8,3,4.1868,126.14,C1CCC(CCCCC2CC3CCCCC3C2)CC1,agonist,partial agonist,agonist,partial agonist,420
14828,886,19932617,7l,P55055,LXRB,Homo sapiens,4-(3-(3-(isopropylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)quinoline,CC(C)S(=O)(=O)c1cccc(Oc2cccc(c2)c3ccnc4c(cccc34)C(F)(F)F)c1,CHEMBL595344,reporter gene assay,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.4nM,partial agonist,44.00%,agonist,Compound 1,170nM,T0901317,,,,,EC50,=,299,nM,,,,,=,8.619788758,pIC50,B,radiometric,CC(C)S(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,44,451.34,471.1115992,0,4,5,4,6.895,56.26,C1CCC(CC2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,280
14835,89,15911283,23m,P04150,GR,Homo sapiens,"1-(4-fluorophenyl)-4a-methyl-4',5'-di[(E)-1-propenyl]-(4'R,4aS,5'R)-spiro[4,4a,5,6,7,8-hexahydro-1H-benzo[f]indazole-5,2'-(dihydro[1,3]dioxolane)]",C\C=C\[C@H]1OC2(CCCC3=Cc4c(C[C@]23C)cnn4c5ccc(F)cc5)O[C@@H]1\C=C\C,CHEMBL196185,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.5nM,partial agonist,67.00%,agonist,dexamethasone,,dexamethasone,,,,,EC50,=,7.8,nM,,,,,=,8.602059991,pIC50,B,radiometric,C/C=C/[C@H]1OC2(CCCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@@]32C)O[C@@H]1/C=C/C,67,391.296,420.2213064,0,4,3,2,5.7736,36.28,C1CCC(C2CCC3CC4C(CCCC45CCCC5)CC32)CC1,agonist,partial agonist,agonist,partial agonist,95
14840,892,10230629,11,P10275,AR,Homo sapiens,"(S)-8-Isopropyl-4-trifluoromethyl-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one",CC(C)[C@@H]1CCc2cc3c(cc(O)nc3cc2N1)C(F)(F)F,CHEMBL267850,CV-1 cells ??reporter gene assay,CV-1 cells ??reporter gene assay,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,Ki = 109nM,antagonist,82.00%,antagonist,DHT,,DHT,,,,,,,inactive,,IC50,=,25,nM,=,6.962573502,pKi,,radiometric,CC(C)[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,82,293.183,310.1292978,2,3,1,2,4.3419,45.15,CC1CCC2CC3CCCCC3CC2C1,antagonist,antagonist,antagonist,antagonist,586
14841,893,17439112,(R)-16g,P10275,AR,Homo sapiens,"(2R)-1,2,3,6-tetrahydro-2-isopropyl-1-(2,2,2-trifluoroethyl)-9-(trifluoromethyl)-7H-[1,4]oxazino[3,2-g]quinolin-7-one",CC(C)[C@@H]1COc2cc3NC(=O)C=C(c3cc2N1CC(F)(F)F)C(F)(F)F,CHEMBL226559,reporter,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 51nM,partial agonist,46.00%,agonist,DHT,,DHT,0.3nM,,,,EC50,=,46,nM,IC50,>,10000,nM,=,7.292429824,pKi,B,radiometric,CC(C)[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,46,378.187,394.1115971,1,3,2,2,4.3326,45.33,CC1CCC2CC3CCCCC3CC2C1,agonist,partial agonist,agonist,partial agonist,586
14848,896,16107159,41,P37231,PPARG,Homo sapiens,"(R)-5-[2-(2-Chloro-4-trifluoromethoxy-phenoxy)-ethoxy]-2-isopropyl-2,3-dihydro-benzofuran-2-carboxylic acid",CC(C)[C@]1(Cc2cc(OCCOc3ccc(OC(F)(F)F)cc3Cl)ccc2O1)C(=O)O,CHEMBL363006,Gal4 luciferase reporter gene assays,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 > 50000nM,partial agonist,40.00%,agonist,ref compound,,,,,,,EC50,>,3000,nM,,,,,>,4.301029996,pIC50,NB,radiometric,CC(C)[C@@]1(C(=O)O)Cc2cc(OCCOc3ccc(OC(F)(F)F)cc3Cl)ccc2O1,40,440.672,460.0900507,1,5,8,2,5.1107,74.22,C1CCC(CCCCC2CCC3CCCC3C2)CC1,,partial agonist,,partial agonist,421
14859,9,17890084,9,Q92731,ERB,Homo sapiens,"(8R,9S,10S,13S,14S,17S)-17-ethynyl-3,13-dimethyl-10-vinyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol",CC1=CC2=CC[C@H]3[C@@H]4CC[C@@](O)(C#C)[C@@]4(C)CC[C@@H]3[C@]2(CC1)C=C,CHEMBL249904,reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 72nM,agonist,80.00%,agonist,E2,,E2,,,,,EC50,=,31,nM,,,,,=,7.142667504,pIC50,B,radiometric,C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4C=C(C)CC[C@]4(C=C)[C@H]3CC[C@@]21C,80,292.252,322.2296656,1,1,1,0,5.0358,20.23,C1CCC2C(C1)CCC1C3CCCC3CCC21,agonist,agonist,agonist,agonist,15
14871,905,20584610,14,P10275,AR,Homo sapiens,"4-((1S,2S,6R,7R)-9-Isopropyl-1,7-dimethyl-3,5,8,10-tetraoxo-9-oxy-11-oxa-4,9-diaza-tricyclo[5.3.1.0*2,6*]undec-4-yl)-2-trifluoromethyl-benzonitrile",CC(C)[N+]1([O-])C(=O)[C@@]2(C)O[C@](C)([C@H]3[C@@H]2C(=O)N(C3=O)c4ccc(C#N)c(c4)C(F)(F)F)C1=O,CHEMBL1210843,,transiently transfected reporter system utilizing a secreted alkaline phosphatase (SEAP) reporter construct and a PSA AR promoter domain,radiometric binding assay monitoring the displacement of [3H]-radiolabeled DHT from the ligand-binding domain (LBD) ,Ki = 3600nM,partial antagonist,58.00%,antagonist,DHT,1nM,DHT,,,,,,,,,IC50,=,3900,nM,=,5.443697499,pKi,,radiometric,CC(C)[N+]1([O-])C(=O)[C@@]2(C)O[C@@](C)(C1=O)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,58,447.24,465.11477,0,7,2,1,2.02008,127.6,CC1CC(C)C2CC1C1C(C)C(C3CCCCC3)C(C)C21,antagonist,partial antagonist,antagonist,partial antagonist,690
14873,907,17267219,7e,P10275,AR,Homo sapiens,"6-(bis(2,2,2-trifluoroethyl)amino)-4-isopropylquinolin-2(1H)-one",CC(C)C1=CC(=O)Nc2ccc(cc12)N(CC(F)(F)F)CC(F)(F)F,CHEMBL238124,reporter gene assay,reporter gene assay,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 21nM,partial agonist,26.00%,agonist,DHT,,,,,,,EC50,=,9.1,nM,IC50,=,2,nM,=,7.677780705,pIC50,B,radiometric,CC(C)c1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,26,350.177,366.1166825,1,2,4,2,4.5825,36.1,CC1CCC2CCCCC2C1,"antagonist,agonist",partial agonist,"antagonist,agonist",partial agonist,651
14874,908,20469868,20f,P04150,GR,Homo sapiens,"N-[4-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-3-(trifluoromethyl)-phenyl]-2,4,6-tris(1-methylethyl)benzenesulfonamide",CC(C)c1cc(C(C)C)c(c(c1)C(C)C)S(=O)(=O)Nc2ccc(c3ccc4c(cnn4c5ccc(F)cc5)c3)c(c2)C(F)(F)F,CHEMBL1084716,,reporter gene assay(MMTV),Fluorescence polarization (FP) competition binding assay,PIC50 = 6.6,partial antagonist,52.00%,antagonist,dexamethasone,,,,,,,,,,,PIC50,<,5,,=,6.6,pIC50,,FPA,CC(C)c1cc(C(C)C)c(S(=O)(=O)Nc2ccc(-c3ccc4c(cnn4-c4ccc(F)cc4)c3)c(C(F)(F)F)c2)c(C(C)C)c1,52,602.463,637.2386112,1,4,8,5,10.0214,63.99,CC(C)(CC1CCC(C2CCC3C(CCC3C3CCCCC3)C2)CC1)C1CCCCC1,,partial antagonist,,partial antagonist,1119
14898,915,17543524,3a,P10827,TRA,Homo sapiens,"2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)acetic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)NCC(=O)O)cc2Br)ccc1O,CHEMBL236080,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,agonist,75.00%,agonist,compound 2b,,,,,,,EC50,=,103,nM,,,,,=,7.585026652,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)NCC(=O)O)cc2Br)ccc1O,75,482.019,498.9629969,3,4,7,2,4.5762,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14899,915,17543524,3a,P10828,TRB,Homo sapiens,"2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)acetic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)NCC(=O)O)cc2Br)ccc1O,CHEMBL236080,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.7nM,agonist,85.00%,agonist,compound 2b,,,,,,,EC50,=,42,nM,,,,,=,8.568636236,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)NCC(=O)O)cc2Br)ccc1O,85,482.019,498.9629969,3,4,7,2,4.5762,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14900,916,17543524,3e,P10827,TRA,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@@H](NC(=O)Cc1cc(Br)c(Oc2ccc(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL391512,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 9.8nM,agonist,88.00%,agonist,compound 2b,,,,,,,EC50,=,2.3,nM,,,,,=,8.008773924,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)C(C)C)cc2Br)ccc1O,88,518.052,541.0099471,3,4,8,2,5.6008,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14901,916,17543524,3e,P10828,TRB,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@@H](NC(=O)Cc1cc(Br)c(Oc2ccc(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL391512,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.71nM,agonist,100.00%,agonist,compound 2b,,,,,,,EC50,=,1.2,nM,,,,,=,9.148741651,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)C(C)C)cc2Br)ccc1O,100,518.052,541.0099471,3,4,8,2,5.6008,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14902,917,17543524,3g,P10827,TRA,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-2-phenylacetic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)c3ccccc3)cc2Br)ccc1O,CHEMBL236291,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.5nM,partial agonist,65.00%,agonist,compound 2b,,,,,,,EC50,=,1.5,nM,,,,,=,8.259637311,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)c3ccccc3)cc2Br)ccc1O,65,554.085,574.994297,3,4,8,3,6.3175,95.86,CC(CCC1CCCCC1)CC1CCC(CC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,1149
14903,917,17543524,3g,P10828,TRB,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-2-phenylacetic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)c3ccccc3)cc2Br)ccc1O,CHEMBL236291,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.6nM,agonist,85.00%,agonist,compound 2b,,,,,,,EC50,=,0.73,nM,,,,,=,9.22184875,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C(=O)O)c3ccccc3)cc2Br)ccc1O,85,554.085,574.994297,3,4,8,3,6.3175,95.86,CC(CCC1CCCCC1)CC1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,1149
14904,918,17543524,3b,P10827,TRA,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)propanoic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C)C(=O)O)cc2Br)ccc1O,CHEMBL391367,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,agonist,81.00%,agonist,compound 2b,,,,,,,EC50,=,7.2,nM,,,,,=,8,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C)C(=O)O)cc2Br)ccc1O,81,494.03,512.978647,3,4,7,2,4.9647,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14905,918,17543524,3b,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)propanoic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C)C(=O)O)cc2Br)ccc1O,CHEMBL391367,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.3nM,agonist,92.00%,agonist,compound 2b,,,,,,,EC50,=,2.6,nM,,,,,=,8.886056648,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](C)C(=O)O)cc2Br)ccc1O,92,494.03,512.978647,3,4,7,2,4.9647,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14906,919,17543524,4a,P10827,TRA,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)succinic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,CHEMBL391513,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 460nM,partial agonist,72.00%,agonist,compound 2b,,,,,,,EC50,=,1500,nM,,,,,=,6.337242168,pIC50,,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,72,538.039,556.9684762,4,5,9,2,4.4195,133.16,C1CCC(CC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,268
14907,919,17543524,4a,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)succinic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,CHEMBL391513,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 290nM,agonist,84.00%,agonist,compound 2b,,,,,,,EC50,=,1300,nM,,,,,=,6.537602002,pIC50,,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,84,538.039,556.9684762,4,5,9,2,4.4195,133.16,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14911,920,17543524,9,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(3-chloro-4-hydroxy-5-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2cc(Cl)c(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL393201,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1400nM,partial agonist,31.00%,agonist,compound 2b,,,,,,,EC50,=,210,nM,,,,,=,5.853871964,pIC50,,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)cc(Cl)c1O,31,553.505,574.9709747,3,4,8,2,6.2542,95.86,C1CCC(CC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,268
14912,921,17543524,7,P10827,TRA,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(3-fluoro-4-hydroxy-5-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2cc(F)c(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL236499,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 88nM,agonist,78.00%,agonist,compound 2b,,,,,,,EC50,=,17,nM,,,,,=,7.055517328,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)cc(F)c1O,78,537.05,559.0005253,3,4,8,2,5.7399,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14913,921,17543524,7,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(3-fluoro-4-hydroxy-5-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2cc(F)c(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL236499,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 12nM,agonist,88.00%,agonist,compound 2b,,,,,,,EC50,=,11,nM,,,,,=,7.920818754,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)cc(F)c1O,88,537.05,559.0005253,3,4,8,2,5.7399,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14914,922,17543524,3d,P10827,TRA,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2ccc(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL236289,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.3nM,agonist,78.00%,agonist,compound 2b,,,,,,,EC50,=,1.4,nM,,,,,=,8.366531544,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)ccc1O,78,518.052,541.0099471,3,4,8,2,5.6008,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14915,922,17543524,3d,P10828,TRB,Homo sapiens,"(S)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)-3-methylbutanoic acid",CC(C)[C@H](NC(=O)Cc1cc(Br)c(Oc2ccc(O)c(c2)C(C)C)c(Br)c1)C(=O)O,CHEMBL236289,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.27nM,agonist,92.00%,agonist,compound 2b,,,,,,,EC50,=,0.77,nM,,,,,=,9.568636236,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C(=O)O)C(C)C)cc2Br)ccc1O,92,518.052,541.0099471,3,4,8,2,5.6008,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14918,924,17543524,3c,P10827,TRA,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)propanoic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C)C(=O)O)cc2Br)ccc1O,CHEMBL440975,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 83nM,agonist,83.00%,agonist,compound 2b,,,,,,,EC50,=,15,nM,,,,,=,7.080921908,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C)C(=O)O)cc2Br)ccc1O,83,494.03,512.978647,3,4,7,2,4.9647,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14919,924,17543524,3c,P10828,TRB,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)propanoic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C)C(=O)O)cc2Br)ccc1O,CHEMBL440975,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 5.9nM,agonist,100.00%,agonist,compound 2b,,,,,,,EC50,=,7.6,nM,,,,,=,8.229147988,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](C)C(=O)O)cc2Br)ccc1O,100,494.03,512.978647,3,4,7,2,4.9647,95.86,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14920,925,17543524,4b,P10827,TRA,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)succinic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,CHEMBL236498,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 168nM,agonist,74.00%,agonist,compound 2b,,,,,,,EC50,=,66,nM,,,,,=,6.774690718,pIC50,,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,74,538.039,556.9684762,4,5,9,2,4.4195,133.16,C1CCC(CC2CCCCC2)CC1,agonist,partial agonist,agonist,partial agonist,268
14921,925,17543524,4b,P10828,TRB,Homo sapiens,"(R)-2-(2-(3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)acetamido)succinic acid",CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,CHEMBL236498,alkaline phos-phatase reporter gene downstream thyroid response element,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 26nM,agonist,88.00%,agonist,compound 2b,,,,,,,EC50,=,38,nM,,,,,=,7.585026652,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc(CC(=O)N[C@H](CC(=O)O)C(=O)O)cc2Br)ccc1O,88,538.039,556.9684762,4,5,9,2,4.4195,133.16,C1CCC(CC2CCCCC2)CC1,agonist,agonist,agonist,agonist,268
14947,933,16338239,6a,P10827,TRA,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3[nH]c(cc3c2Br)C(=O)O)ccc1O,CHEMBL425939,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.5nM,agonist,85.00%,agonist,T3,,,,,,,EC50,=,10,nM,,,,,=,8.602059991,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3[nH]c(C(=O)O)cc3c2Br)ccc1O,85,454.009,466.9367822,3,3,4,3,6.0124,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14948,933,17467994,48,P10827,TRA,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3[nH]c(cc3c2Br)C(=O)O)ccc1O,CHEMBL425939,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.6,,,,,,,,,,,,,,,,,,,=,8.6,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3[nH]c(C(=O)O)cc3c2Br)ccc1O,,454.009,466.9367822,3,3,4,3,6.0124,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,,,agonist,agonist,234
14949,933,16338239,6a,P10828,TRB,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3[nH]c(cc3c2Br)C(=O)O)ccc1O,CHEMBL425939,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 0.28nM,agonist,96.00%,agonist,T3,,,,,,,EC50,=,4.2,nM,,,,,=,9.552841969,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3[nH]c(C(=O)O)cc3c2Br)ccc1O,96,454.009,466.9367822,3,3,4,3,6.0124,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14950,933,17467994,48,P10828,TRB,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3[nH]c(cc3c2Br)C(=O)O)ccc1O,CHEMBL425939,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 9.55,,,,,,,,,,,,,,,,,,,=,9.55,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3[nH]c(C(=O)O)cc3c2Br)ccc1O,,454.009,466.9367822,3,3,4,3,6.0124,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,,,agonist,agonist,234
14951,934,16338239,10,P10827,TRA,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-2,3-dihydro-1H-indene-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3CC(Cc3c2Br)C(=O)O)ccc1O,CHEMBL203828,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 38nM,agonist,95.00%,agonist,T3,,,,,,,EC50,=,4.1,nM,,,,,=,7.420216403,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3c(c2Br)CC(C(=O)O)C3)ccc1O,95,452.013,467.9571833,2,3,4,2,5.6323,66.76,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14952,934,16338239,10,P10828,TRB,Homo sapiens,"4,6-dibromo-5-(4-hydroxy-3-isopropylphenoxy)-2,3-dihydro-1H-indene-2-carboxylic acid",CC(C)c1cc(Oc2c(Br)cc3CC(Cc3c2Br)C(=O)O)ccc1O,CHEMBL203828,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 8.5nM,agonist,97.00%,agonist,T3,,,,,,,EC50,=,4.3,nM,,,,,=,8.070581074,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Br)cc3c(c2Br)CC(C(=O)O)C3)ccc1O,97,452.013,467.9571833,2,3,4,2,5.6323,66.76,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14993,943,16338239,6b,P10827,TRA,Homo sapiens,"4,6-dichloro-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Cl)cc3[nH]c(cc3c2Cl)C(=O)O)ccc1O,CHEMBL203777,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 1.4nM,agonist,80.00%,agonist,T3,,,,,,,EC50,=,10,nM,,,,,=,8.853871964,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Cl)cc3[nH]c(C(=O)O)cc3c2Cl)ccc1O,80,365.107,379.0378133,3,3,4,3,5.7942,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14994,943,17467994,49,P10827,TRA,Homo sapiens,"4,6-dichloro-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Cl)cc3[nH]c(cc3c2Cl)C(=O)O)ccc1O,CHEMBL203777,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 8.85,,,,,,,,,,,,,,,,,,,=,8.85,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Cl)cc3[nH]c(C(=O)O)cc3c2Cl)ccc1O,,365.107,379.0378133,3,3,4,3,5.7942,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,,,agonist,agonist,234
14995,943,16338239,6b,P10828,TRB,Homo sapiens,"4,6-dichloro-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Cl)cc3[nH]c(cc3c2Cl)C(=O)O)ccc1O,CHEMBL203777,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 60nM,agonist,83.00%,agonist,T3,,,,,,,EC50,=,4.7,nM,,,,,=,7.22184875,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Cl)cc3[nH]c(C(=O)O)cc3c2Cl)ccc1O,83,365.107,379.0378133,3,3,4,3,5.7942,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,agonist,agonist,agonist,agonist,234
14996,943,17467994,49,P10828,TRB,Homo sapiens,"4,6-dichloro-5-(4-hydroxy-3-isopropylphenoxy)-1H-indole-2-carboxylic acid",CC(C)c1cc(Oc2c(Cl)cc3[nH]c(cc3c2Cl)C(=O)O)ccc1O,CHEMBL203777,,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,PIC50 = 10.22,,,,,,,,,,,,,,,,,,,=,10.22,pIC50,B,radiometric,CC(C)c1cc(Oc2c(Cl)cc3[nH]c(C(=O)O)cc3c2Cl)ccc1O,,365.107,379.0378133,3,3,4,3,5.7942,82.55,C1CCC(CC2CCC3CCCC3C2)CC1,,,agonist,agonist,234
15012,95,19606870,17,P10275,AR,Homo sapiens,16-(Methylmethylidene)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one,C\C=C\1/C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,CHEMBL557116,transactivation assay of hAR (TAMAR),,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 35nM,agonist,92.00%,agonist,R1871,100nM,methyltrienolone,,,,,EC50,=,17,nM,,,,,=,7.455931956,pIC50,B,radiometric,C/C=C1\C[C@H]2[C@@H]3CC[C@H]4N(C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]2(C)[C@H]1O,92,298.236,329.2354792,1,2,0,0,3.5429,40.54,CC1CCC2C(CCC3C4CC(C)CC4CCC23)C1,agonist,agonist,agonist,agonist,633
15031,959,20382019,8i,P55055,LXRB,Homo sapiens,3-isopropyl-4-(3'-(methylsulfonyl)biphenyl-3-yl)-8-(trifluoromethyl)quinoline,CC(C)c1cnc2c(cccc2c1c3cccc(c3)c4cccc(c4)S(=O)(=O)C)C(F)(F)F,CHEMBL1097799,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 4.1nM,agonist,97.00%,agonist,T0901317,170nM,T0901317,,,,,EC50,=,91,nM,,,,,=,8.387216143,pIC50,B,radiometric,CC(C)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,97,447.352,469.1323346,0,3,4,4,7.1145,47.03,C1CCC(C2CCCC(C3CCCC4CCCCC43)C2)CC1,agonist,agonist,agonist,agonist,162
15032,96,11728194,15,P04150,GR,Homo sapiens,"10-Methoxy-2,2,4-trimethyl-5-propenyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(\C=C/C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL138197,GRE activation,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",Ki = 18nM,partial agonist,27.00%,agonist,dexamethasone,,dexamethasone,,0.8nM,,,EC50,=,460,nM,,,,,=,7.744727495,pKi,B,radiometric,C/C=C\C1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,27,322.258,347.188529,1,3,2,2,5.9792,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
15034,960,20005711,7q,P55055,LXRB,Homo sapiens,"2-isopropyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)imidazo[1,2-a]pyridine-8-carbonitrile",CC(C)c1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C#N,CHEMBL596157,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 43nM,partial agonist,44.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,1680,nM,,,,,=,7.366531544,pIC50,B,radiometric,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,44,410.349,431.1303625,0,6,5,4,5.19218,84.46,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
15044,965,20005711,7z,P55055,LXRB,Homo sapiens,"2-isopropyl-3-(3-(3-(methylsulfonyl)benzyloxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CC(C)c1nc2c(cccn2c1c3cccc(OCc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL596381,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 89nM,partial agonist,26.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,3240,nM,,,,,=,7.050609993,pIC50,B,radiometric,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,26,465.347,488.1381483,0,5,6,4,6.126,60.67,C1CCC(CCC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,330
15050,968,20005711,7f,P55055,LXRB,Homo sapiens,"2-isopropyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CC(C)c1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611466,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 3.5nM,partial agonist,68.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,950,nM,,,,,=,8.455931956,pIC50,B,radiometric,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,68,453.336,474.1224982,0,5,5,4,6.3393,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
15051,968,20005711,7f,Q13133,LXRA,Homo sapiens,"2-isopropyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine",CC(C)c1nc2c(cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3)C(F)(F)F,CHEMBL611466,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 137nM,partial agonist,44.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1860,nM,,,,,=,6.863279433,pIC50,,radiometric,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,44,453.336,474.1224982,0,5,5,4,6.3393,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
15054,97,15026058,10a,P04150,GR,Homo sapiens,"5-But-2-enyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene",COc1cccc2OC(C\C=C/C)c3c(ccc4NC(C)(C)C=C(C)c34)c12,CHEMBL49386,GRE activation,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 2.9nM,partial agonist,46.00%,agonist,dexamethasone,,,,,,,IC50,=,39,nM,,,,,=,8.537602002,pIC50,B,radiometric,C/C=C\CC1Oc2cccc(OC)c2-c2ccc3c(c21)C(C)=CC(C)(C)N3,46,334.269,361.2041791,1,3,3,2,6.3693,30.49,C1CCC2C(C1)CCC1C3CCCCC3CCC21,agonist,partial agonist,agonist,partial agonist,16
15056,970,20005711,7p,P55055,LXRB,Homo sapiens,"8-chloro-2-isopropyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)imidazo[1,2-a]pyridine",CC(C)c1nc2c(Cl)cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3,CHEMBL603956,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 10nM,partial agonist,50.00%,agonist,T0901317,9nM,T0901317,,,,,EC50,=,540,nM,,,,,=,8,pIC50,B,radiometric,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,50,419.784,440.0961412,0,5,5,4,5.9739,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
15057,970,20005711,7p,Q13133,LXRA,Homo sapiens,"8-chloro-2-isopropyl-3-(3-(3-(methylsulfonyl)phenoxy)phenyl)imidazo[1,2-a]pyridine",CC(C)c1nc2c(Cl)cccn2c1c3cccc(Oc4cccc(c4)S(=O)(=O)C)c3,CHEMBL603956,Gal4 luciferase reporter gene assays,,radiometric binding assay monitoring the displacement of a radiolabeled ligand from the ligand-binding domain (LBD) ,IC50 = 304nM,partial agonist,53.00%,agonist,T0901317,13nM,T0901317,,,,,EC50,=,1660,nM,,,,,=,6.517126416,pIC50,,radiometric,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,53,419.784,440.0961412,0,5,5,4,5.9739,60.67,C1CCC(CC2CCCC(C3CCC4CCCCC43)C2)CC1,agonist,partial agonist,agonist,partial agonist,276
15064,974,21269824,GW-4064,Q96RI1,FXR,Homo sapiens,"3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid",CC(C)c1onc(c1COc2ccc(\C=C\c3cccc(c3)C(=O)O)c(Cl)c2)c4c(Cl)cccc4Cl,CHEMBL318457,Luciferase reporter gene assay,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 112nM,agonist,99.00%,agonist,GW4064,,,,,,,EC50,=,910,nM,,,,,=,6.950781977,pIC50,,radiometric,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,99,520.67,541.0614412,1,4,8,4,8.8728,72.56,C1CCC(CCC2CCC(CCC3CCCC3C3CCCCC3)CC2)CC1,agonist,agonist,agonist,agonist,342
15076,981,23916594,"3i, more active stereoisomer",P04150,GR,Homo sapiens,"3,3,3-trifluoro-N-((3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenylpropyl)propanamide",CC(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426109,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.4nM,agonist,102.00%,agonist,dexamethasone,,,,,,,EC50,=,20.7,nM,,,,,=,8.619788758,pIC50,B,FPA,CC(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,102,446.298,469.1777252,1,3,7,4,6.0012,46.92,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,"agonist,partial agonist",235
15077,981,23916594,"3h, less active stereoisomer",P04150,GR,Homo sapiens,"3,3,3-trifluoro-N-((3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenylpropyl)propanamide",CC(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426109,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 2.3nM,partial agonist,52.00%,agonist,dexamethasone,,,,,,,EC50,=,374,nM,,,,,=,8.638272164,pIC50,B,FPA,CC(CNC(=O)CC(F)(F)F)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,52,446.298,469.1777252,1,3,7,4,6.0012,46.92,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,partial agonist,agonist,"agonist,partial agonist",235
15079,982,16125384,20,Q13133,LXRA,Homo sapiens,"(1S,4aS,10aR)-1,4a-Dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid (2,2-diphenyl-propyl)-amide",CC(CNC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CCc3ccccc23)(c4ccccc4)c5ccccc5,CHEMBL365750,Transactivation assay ,,"scintillation proximity assays (SPA), results reported as IC50 values for displacement of radiolabeled reference compound",IC50 = 490nM,partial agonist,42.00%,agonist,maximal inhibition (no details),,,,,,,,,,,,,,,=,6.30980392,pIC50,,radiometric,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,42,414.358,451.2875148,1,1,5,3,6.8193,29.1,CC(CCC(C1CCCCC1)C1CCCCC1)C1CCCC2C3CCCCC3CCC12,,partial agonist,,partial agonist,1211
15080,983,23916594,4f,P04150,GR,Homo sapiens,"2,2,2-trifluoro-N-((3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenylpropyl)ethanesulfonamide",CC(CNS(=O)(=O)CC(F)(F)F)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426119,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 1.34nM,agonist,112.00%,agonist,dexamethasone,,,,,,,EC50,=,26,nM,,,,,=,8.872895202,pIC50,B,FPA,CC(CNS(=O)(=O)CC(F)(F)F)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,112,482.353,505.1447109,1,4,8,4,5.4143,63.99,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
15081,984,23916594,4g,P04150,GR,Homo sapiens,N-((3S)-3-(1-(4-fluorophenyl)-1H-indazol-5-yl)-2-methyl-3-phenylpropyl)methanesulfonamide,CC(CNS(=O)(=O)C)[C@@H](c1ccccc1)c2ccc3c(cnn3c4ccc(F)cc4)c2,CHEMBL2426120,NP-1 agonism,,Fluorescence polarization (FP) competition binding assay,IC50 = 0.93nM,agonist,101.00%,agonist,dexamethasone,,,,,,,EC50,=,24,nM,,,,,=,9.031517051,pIC50,B,FPA,CC(CNS(C)(=O)=O)[C@@H](c1ccccc1)c1ccc2c(cnn2-c2ccc(F)cc2)c1,101,413.348,437.1573262,1,4,7,4,4.4818,63.99,C1CCC(CC2CCC3C(CCC3C3CCCCC3)C2)CC1,agonist,agonist,agonist,agonist,235
15095,989,24215891,3,P04150,GR,Homo sapiens,"N-(1-(1H-indol-3-yl)propan-2-yl)-2-amino-4,6-dichlorobenzenesulfonamide",CC(Cc1c[nH]c2ccccc12)NS(=O)(=O)c3c(N)cc(Cl)cc3Cl,CHEMBL3093440,IL-6 assay,,Fluorescence polarization (FP) competition binding assay,IC50 = 5nM,partial agonist,59.00%,agonist,dexamethasone,,mifepristone,,,,,EC50,=,120,nM,,,,,=,8.301029996,pIC50,B,FPA,CC(Cc1c[nH]c2ccccc12)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,59,381.179,397.0418531,3,3,5,3,3.9664,87.98,CC(C)(CCCC1CCC2CCCCC21)C1CCCCC1,agonist,partial agonist,agonist,partial agonist,1240
